0	CPRFalse	Binding of dimemorfan to @CHEMICAL$ and its anticonvulsant and locomotor effects in mice, compared with @GENE$ and dextrorphan.
1	CPRFalse	Binding of @CHEMICAL$ to @GENE$ and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan.
2	CPRFalse	Binding of dimemorfan to @CHEMICAL$ and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and @GENE$.
3	CPRFalse	This study therefore characterized the binding of @CHEMICAL$ to the @GENE$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR.
4	CPRFalse	This study therefore characterized the binding of DF to the @CHEMICAL$ and @GENE$-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR.
5	CPRFalse	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked @GENE$ sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR.
6	CPRFalse	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of @GENE$ in mice in comparison with those of DM and DR.
7	CPRFalse	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of @GENE$ and DR.
8	CPRFalse	This study therefore characterized the binding of DF to the @CHEMICAL$ and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and @GENE$.
9	CPRFalse	We found that @CHEMICAL$, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at @GENE$ (Ki=4-11 microM).
10	CPRFalse	We found that @CHEMICAL$, DM, and DR were relative high-affinity ligands at @GENE$ (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).
11	CPRFalse	We found that DF, @CHEMICAL$, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at @GENE$ (Ki=4-11 microM).
12	CPRFalse	We found that DF, @CHEMICAL$, and DR were relative high-affinity ligands at @GENE$ (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).
13	CPRFalse	We found that DF, DM, and @CHEMICAL$ were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at @GENE$ (Ki=4-11 microM).
14	CPRFalse	We found that DF, DM, and @CHEMICAL$ were relative high-affinity ligands at @GENE$ (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).
15	CPRFalse	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of @GENE$ at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.
16	CPRFalse	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of DF at @GENE$ sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.
17	CPRFalse	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of DF at PCP sites may suggest that acting on the @GENE$ sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.
18	CPRFalse	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to @CHEMICAL$, the very low affinity of DF at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these @GENE$ analogs.
19	CPRFalse	@CHEM-GENE$ blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
20	CPRFalse	@CHEMICAL$ receptor blockade in normotensive subjects: A direct comparison of three @GENE$ antagonists.
21	CPRFalse	Use of @CHEM-GENE$ antagonists for treatment of hypertension is rapidly increasing, yet direct comparisons of the relative efficacy of antagonists to block the renin-angiotensin system in humans are lacking.
22	CPRFalse	Use of @CHEM-GENE$ antagonists for treatment of hypertension is rapidly increasing, yet direct comparisons of the relative efficacy of antagonists to block the renin-angiotensin system in humans are lacking.
23	CPRFalse	In this study, the @CHEM-GENE$ blockade induced by the recommended starting dose of 3 antagonists was evaluated in normotensive subjects in a double-blind, placebo-controlled, randomized, 4-way crossover study.
24	CPRFalse	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @GENE$ assay, and reactive changes in plasma Ang II levels.
25	CPRFalse	Blockade of the @CHEMICAL$-@GENE$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.
26	CPRFalse	Blockade of the renin-@CHEM-GENE$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.
27	CPRFalse	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.
28	CPRFalse	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.
29	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro @GENE$ assay, and reactive changes in plasma Ang II levels.
30	CPRFalse	Blockade of the @CHEMICAL$-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.
31	CPRFalse	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.
32	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEM-GENE$, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.
33	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.
34	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @CHEM-GENE$ assay, and reactive changes in plasma Ang II levels.
35	CPRFalse	Blockade of the @CHEMICAL$-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @GENE$ receptor assay, and reactive changes in plasma Ang II levels.
36	CPRFalse	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @GENE$ receptor assay, and reactive changes in plasma Ang II levels.
37	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro @GENE$ receptor assay, and reactive changes in plasma Ang II levels.
38	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @CHEMICAL$ receptor assay, and reactive changes in plasma @GENE$ levels.
39	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro @CHEMICAL$ assay, and reactive changes in plasma @GENE$ levels.
40	CPRFalse	Blockade of the @CHEMICAL$-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.
41	CPRFalse	Blockade of the renin-@CHEMICAL$ system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.
42	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous @CHEMICAL$, in vitro Ang II receptor assay, and reactive changes in plasma @GENE$ levels.
43	CPRFalse	Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma @CHEM-GENE$ levels.
44	CPRFalse	At 4 hours, losartan blocked 43% of the @CHEM-GENE$-induced systolic blood pressure increase; valsartan, 51%; and irbesartan, 88% (P<0.01 between drugs).
45	CPR:4	At 4 hours, losartan blocked 43% of the @CHEMICAL$-induced systolic blood pressure increase; @GENE$, 51%; and irbesartan, 88% (P<0.01 between drugs).
46	CPR:4	At 4 hours, losartan blocked 43% of the @CHEMICAL$-induced systolic blood pressure increase; valsartan, 51%; and @GENE$, 88% (P<0.01 between drugs).
47	CPRFalse	Similar results were obtained when @CHEM-GENE$ blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma Ang II levels.
48	CPRFalse	Similar results were obtained when @CHEMICAL$ receptor blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma @GENE$ levels.
49	CPRFalse	Similar results were obtained when @CHEMICAL$ blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma @GENE$ levels.
50	CPRFalse	Similar results were obtained when Ang II receptor blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma @CHEM-GENE$ levels.
51	CPR:4	This study thus demonstrates that the first administration of the recommended starting dose of @CHEMICAL$ induces a greater and longer lasting @GENE$ blockade than that of valsartan and losartan in normotensive subjects.
52	CPRFalse	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting @CHEM-GENE$ blockade than that of valsartan and losartan in normotensive subjects.
53	CPR:4	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting @CHEMICAL$ blockade than that of @GENE$ and losartan in normotensive subjects.
54	CPR:4	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting @CHEMICAL$ blockade than that of valsartan and @GENE$ in normotensive subjects.
55	CPRFalse	Characterisation of the @CHEM-GENE$ binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
56	CPRFalse	Characterisation of the @CHEMICAL$ receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at @GENE$ and 5-HT1D receptors.
57	CPRFalse	Characterisation of the @CHEMICAL$ receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and @GENE$ receptors.
58	CPRFalse	Characterisation of the @CHEMICAL$ binding profile of @GENE$ and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
59	CPRFalse	Characterisation of the 5-HT receptor binding profile of @CHEMICAL$ and kinetics of [3H]eletriptan binding at @GENE$ and 5-HT1D receptors.
60	CPRFalse	Characterisation of the 5-HT receptor binding profile of @CHEMICAL$ and kinetics of [3H]eletriptan binding at human 5-HT1B and @GENE$ receptors.
61	CPRFalse	Characterisation of the @CHEMICAL$ binding profile of eletriptan and kinetics of @GENE$ binding at human 5-HT1B and 5-HT1D receptors.
62	CPRFalse	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of @CHEMICAL$ binding at @GENE$ and 5-HT1D receptors.
63	CPRFalse	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of @CHEMICAL$ binding at human 5-HT1B and @GENE$ receptors.
64	CPRFalse	The affinity of eletriptan ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of @CHEM-GENE$ was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.
65	CPRFalse	The affinity of eletriptan ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of @CHEMICAL$ receptors was compared to values obtained for other @GENE$ receptor agonists known to be effective in the treatment of migraine.
66	CPRFalse	The affinity of @CHEMICAL$ ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of @GENE$ was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.
67	CPRFalse	The affinity of @CHEMICAL$ ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of 5-HT receptors was compared to values obtained for other @GENE$ receptor agonists known to be effective in the treatment of migraine.
68	CPRFalse	The affinity of eletriptan (@CHEMICAL$) for a range of @GENE$ was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.
69	CPRFalse	The affinity of eletriptan (@CHEMICAL$) for a range of 5-HT receptors was compared to values obtained for other @GENE$ receptor agonists known to be effective in the treatment of migraine.
70	CPRFalse	Eletriptan, like sumatriptan, zolmitriptan, @CHEMICAL$ and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.
71	CPRFalse	Eletriptan, like sumatriptan, zolmitriptan, @CHEMICAL$ and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.
72	CPRFalse	Eletriptan, like sumatriptan, zolmitriptan, @CHEMICAL$ and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.
73	CPRFalse	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and @CHEMICAL$ had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.
74	CPRFalse	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and @CHEMICAL$ had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.
75	CPRFalse	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and @CHEMICAL$ had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.
76	CPRFalse	@CHEMICAL$, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.
77	CPRFalse	@CHEMICAL$, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.
78	CPRFalse	@CHEMICAL$, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.
79	CPRFalse	Eletriptan, like @CHEMICAL$, zolmitriptan, naratriptan and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.
80	CPRFalse	Eletriptan, like @CHEMICAL$, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.
81	CPRFalse	Eletriptan, like @CHEMICAL$, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.
82	CPRFalse	Eletriptan, like sumatriptan, @CHEMICAL$, naratriptan and rizatriptan had highest affinity for the @GENE$, 5-HT1D and putative 5-ht1f receptor.
83	CPRFalse	Eletriptan, like sumatriptan, @CHEMICAL$, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, @GENE$ and putative 5-ht1f receptor.
84	CPRFalse	Eletriptan, like sumatriptan, @CHEMICAL$, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative @GENE$ receptor.
85	CPRFalse	Kinetic studies comparing the binding of @CHEMICAL$ and [3H]sumatriptan to the @GENE$ and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.
86	CPRFalse	Kinetic studies comparing the binding of @CHEMICAL$ and [3H]sumatriptan to the human recombinant 5-HT1B and @GENE$ receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.
87	CPRFalse	Kinetic studies comparing the binding of [3H]eletriptan and @CHEMICAL$ to the @GENE$ and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.
88	CPRFalse	Kinetic studies comparing the binding of [3H]eletriptan and @CHEMICAL$ to the human recombinant 5-HT1B and @GENE$ receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.
89	CPRFalse	However, @CHEMICAL$ had over 6-fold higher affinity than [3H]sumatriptan at the @GENE$ receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).
90	CPRFalse	However, @CHEMICAL$ had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the @GENE$ receptor (K(D): 3.14 and 11.07 nM, respectively).
91	CPRFalse	However, [3H]eletriptan had over 6-fold higher affinity than @CHEMICAL$ at the @GENE$ receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).
92	CPRFalse	However, [3H]eletriptan had over 6-fold higher affinity than @CHEMICAL$ at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the @GENE$ receptor (K(D): 3.14 and 11.07 nM, respectively).
93	CPRFalse	However, [3H]eletriptan had over 6-fold higher affinity than [3H]sumatriptan at the @CHEMICAL$ receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than @GENE$ at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).
94	CPRFalse	However, [3H]eletriptan had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than @CHEMICAL$ at the @GENE$ receptor (K(D): 3.14 and 11.07 nM, respectively).
95	CPRFalse	Association and dissociation rates for both radioligands could only be accurately determined at the @CHEMICAL$ receptor and then only at 4 degrees C. At this temperature, @GENE$ had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than [3H]sumatriptan (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for [3H]sumatriptan).
96	CPRFalse	Association and dissociation rates for both radioligands could only be accurately determined at the @CHEMICAL$ receptor and then only at 4 degrees C. At this temperature, [3H]eletriptan had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than @GENE$ (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for [3H]sumatriptan).
97	CPRFalse	Association and dissociation rates for both radioligands could only be accurately determined at the @CHEMICAL$ receptor and then only at 4 degrees C. At this temperature, [3H]eletriptan had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than [3H]sumatriptan (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for @GENE$).
98	CPRFalse	Pharmacological profile of @CHEMICAL$ at @GENE$.
99	CPRFalse	Pharmacological profile of neuroleptics at @CHEM-GENE$.
100	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 @CHEMICAL$ and one metabolite of a neuroleptic (haloperidol metabolite) for the @GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.
101	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (@CHEMICAL$ metabolite) for the @GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.
102	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEM-GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.
103	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEM-GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.
104	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEM-GENE$ with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.
105	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEMICAL$ with @GENE$, [3H]nisoxetine, and [3H]WIN35428, respectively.
106	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEMICAL$ with [3H]imipramine, @GENE$, and [3H]WIN35428, respectively.
107	CPRFalse	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the @CHEMICAL$ with [3H]imipramine, [3H]nisoxetine, and @GENE$, respectively.
108	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEM-GENE$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
109	CPRFalse	Among neuroleptics, the four most potent compounds at the human @CHEMICAL$ transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
110	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were @GENE$, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
111	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were @CHEMICAL$, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
112	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, @GENE$, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
113	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, @CHEMICAL$, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
114	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, @GENE$, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
115	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, @CHEMICAL$, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
116	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and @GENE$ (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
117	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and @CHEMICAL$ (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
118	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$ transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
119	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEM-GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
120	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, @GENE$, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
121	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, @GENE$, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
122	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, @GENE$, chlorprothixene, and promazine (K(D) 19-25 nM).
123	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, chlorpromazine, @GENE$, chlorprothixene, and promazine (K(D) 19-25 nM).
124	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, @GENE$, and promazine (K(D) 19-25 nM).
125	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, chlorpromazine, zotepine, @GENE$, and promazine (K(D) 19-25 nM).
126	CPRFalse	Among neuroleptics, the four most potent compounds at the @CHEMICAL$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and @GENE$ (K(D) 19-25 nM).
127	CPRFalse	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @CHEMICAL$, chlorpromazine, zotepine, chlorprothixene, and @GENE$ (K(D) 19-25 nM).
128	CPRFalse	Among @CHEMICAL$, the four most potent compounds at the @GENE$ were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
129	CPRFalse	Among @CHEMICAL$, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the @GENE$, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).
130	CPRFalse	At the @CHEM-GENE$, only pimozide (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.
131	CPRFalse	At the @CHEMICAL$, only @GENE$ (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.
132	CPRFalse	At the @CHEMICAL$, only pimozide (K(D) = 69+/-3) @GENE$ (K(D) = 76+/-5) had notable potency.
133	CPRFalse	@CHEMICAL$ does not prevent terbutaline-induced desensitization of @GENE$-mediated cardiovascular in vivo functions in human volunteers.
134	CPRFalse	Disodium cromoglycate does not prevent @CHEMICAL$-induced desensitization of @GENE$-mediated cardiovascular in vivo functions in human volunteers.
135	CPRFalse	In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of @CHEMICAL$-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug @GENE$.
136	CPRFalse	In humans, prolonged administration of the @CHEMICAL$ agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug @GENE$.
137	CPRFalse	In humans, prolonged administration of the beta 2-adrenoceptor agonist @CHEMICAL$ leads to a desensitization of @GENE$-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.
138	CPR:5	In humans, prolonged administration of the @CHEMICAL$ agonist @GENE$ leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.
139	CPRFalse	This study investigated the effect of @CHEMICAL$, another antiallergic drug, on terbutaline-induced desensitization of @GENE$-mediated cardiovascular and noncardiovascular responses.
140	CPRFalse	This study investigated the effect of disodium cromoglycate, another antiallergic drug, on @CHEMICAL$-induced desensitization of @GENE$-mediated cardiovascular and noncardiovascular responses.
141	CPR:5	beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective @CHEMICAL$ agonist @GENE$; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.
142	CPRFalse	@CHEMICAL$ cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist @GENE$; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.
143	CPRFalse	beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist @CHEMICAL$; @GENE$ cardiovascular function was assessed by exercise-induced tachycardia.
144	CPRFalse	@CHEMICAL$ affected neither the rightward shift of @GENE$-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of terbutaline.
145	CPRFalse	@CHEMICAL$ affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in @GENE$-mediated exercise tachycardia after 2 weeks' administration of terbutaline.
146	CPRFalse	Disodium cromoglycate affected neither the rightward shift of @CHEMICAL$-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of @GENE$.
147	CPRFalse	Disodium cromoglycate affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in @CHEMICAL$-mediated exercise tachycardia after 2 weeks' administration of @GENE$.
148	CPRFalse	Tremulousness observed during the first few days of @CHEMICAL$ administration disappeared after 4 to 8 days, indicating development of desensitization of @GENE$-mediated noncardiovascular responses.
149	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @CHEMICAL$, on reperfusion induced by @GENE$ (TPA) in patients with acute myocardial infarction (AMI).
150	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @CHEMICAL$, on reperfusion induced by tissue plasminogen activator (@GENE$) in patients with acute myocardial infarction (AMI).
151	CPR:4	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct @CHEMICAL$ inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
152	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (@CHEMICAL$) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
153	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and @CHEMICAL$ (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
154	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to @CHEMICAL$ (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, @GENE$, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
155	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by @GENE$ (TPA) in patients with acute myocardial infarction (AMI).
156	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (@GENE$) in patients with acute myocardial infarction (AMI).
157	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct @GENE$ inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
158	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (@CHEMICAL$) in acute myocardial infarction: myocardial infarction with @GENE$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
159	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with @CHEMICAL$ and @GENE$ (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
160	CPRFalse	A multicenter, randomized study of argatroban versus heparin as adjunct to @CHEMICAL$ (TPA) in acute myocardial infarction: myocardial infarction with @GENE$ and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
161	CPRFalse	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by @GENE$ (TPA) in patients with acute myocardial infarction (AMI).
162	CPRFalse	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (@GENE$) in patients with acute myocardial infarction (AMI).
163	CPRFalse	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct @GENE$ inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
164	CPRFalse	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (@GENE$) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
165	CPRFalse	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and @GENE$ (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
166	CPRFalse	A multicenter, randomized study of @CHEMICAL$ versus heparin as adjunct to @GENE$ (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
167	CPR:4	In vitro and in vivo studies have shown that @CHEMICAL$ has advantages over heparin for the inhibition of clot-bound @GENE$ and for the enhancement of thrombolysis with TPA.
168	CPRFalse	In vitro and in vivo studies have shown that @CHEMICAL$ has advantages over heparin for the inhibition of clot-bound thrombin and for the enhancement of thrombolysis with @GENE$.
169	CPRFalse	METHODS: One hundred and twenty-five patients with AMI within 6 h were randomized to heparin, low-dose @CHEMICAL$ or high-dose argatroban in addition to @GENE$.
170	CPRFalse	METHODS: One hundred and twenty-five patients with AMI within 6 h were randomized to heparin, low-dose argatroban or high-dose @CHEMICAL$ in addition to @GENE$.
171	CPRFalse	CONCLUSIONS: @CHEMICAL$, as compared with heparin, appears to enhance reperfusion with @GENE$ in patients with AMI, particularly in those patients with delayed presentation.
172	CPRFalse	The functional inhibitory characteristics of the @CHEM-GENE$ blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.
173	CPR:4	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; @GENE$; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.
174	CPR:4	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) @GENE$; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.
175	CPR:4	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; irbesartan; and @GENE$ and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.
176	CPR:4	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite @GENE$ (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.
177	CPR:4	The functional inhibitory characteristics of the @CHEMICAL$ blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (@GENE$) were studied in rabbit aortic strips and rat portal vein preparations in vitro.
178	CPR:4	In both vascular preparations, @CHEMICAL$ caused a marked decrease in the maximal contractile response of the @GENE$ (Ang II) concentration-response curve.
179	CPR:4	In both vascular preparations, @CHEMICAL$ caused a marked decrease in the maximal contractile response of the angiotensin II (@GENE$) concentration-response curve.
180	CPRFalse	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the @CHEM-GENE$ (Ang II) concentration-response curve.
181	CPRFalse	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the @CHEMICAL$ (@GENE$) concentration-response curve.
182	CPRFalse	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the @CHEMICAL$ (@GENE$) concentration-response curve.
183	CPRFalse	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the angiotensin II (@CHEM-GENE$) concentration-response curve.
184	CPRFalse	@CHEMICAL$, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to @GENE$.
185	CPRFalse	Losartan, @CHEMICAL$, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to @GENE$.
186	CPRFalse	Losartan, EXP, and @CHEMICAL$ caused a rightward parallel shift without any major effects on the maximal response to @GENE$.
187	CPRFalse	Losartan, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to @CHEM-GENE$.
188	CPRFalse	Cooling of the rat portal vein preparations to 4 degrees C before administration of @CHEMICAL$ prevented the persistent inhibition of @GENE$ response seen at 37 degrees C.
189	CPRFalse	Cooling of the rat portal vein preparations to 4 degrees C before administration of candesartan prevented the persistent inhibition of @CHEM-GENE$ response seen at 37 degrees C.
190	CPRFalse	For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the @CHEM-GENE$ response were independent of the incubation temperature before washing.
191	CPRFalse	In addition, when candesartan was given to conscious rats, the inhibitory effect on @CHEMICAL$-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of @GENE$ at 24 hours.
192	CPR:4	In addition, when @CHEMICAL$ was given to conscious rats, the inhibitory effect on @GENE$-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.
193	CPRFalse	In addition, when candesartan was given to conscious rats, the inhibitory effect on @CHEM-GENE$-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.
194	CPR:4	At clinically relevant concentrations, @CHEMICAL$ is an insurmountable and long-lasting antagonist of the vascular contractile responses to @GENE$.
195	CPRFalse	At clinically relevant concentrations, candesartan is an insurmountable and long-lasting antagonist of the vascular contractile responses to @CHEM-GENE$.
196	CPR:4	Dose-dependent inhibition of platelet @CHEMICAL$ and monocyte cyclooxygenase-2 by @GENE$ in healthy subjects.
197	CPR:4	Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte @CHEMICAL$ by @GENE$ in healthy subjects.
198	CPRFalse	We evaluated whether therapeutic blood levels of @CHEMICAL$ are associated with selective inhibition of monocyte @GENE$ in vitro and ex vivo.
199	CPR:4	Concentration-response curves for the inhibition of monocyte @CHEMICAL$ and platelet COX-1 were obtained in vitro after the incubation of @GENE$ with whole blood samples.
200	CPR:4	Concentration-response curves for the inhibition of monocyte COX-2 and platelet @CHEMICAL$ were obtained in vitro after the incubation of @GENE$ with whole blood samples.
201	CPR:9	Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and @CHEMICAL$ was measured in plasma as an index of monocyte @GENE$ activity.
202	CPR:9	The production of @CHEMICAL$ in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet @GENE$ activity.
203	CPR:4	In contrast, the administration of 7.5 and 15 mg of @CHEMICAL$ caused dose-dependent reductions in monocyte @GENE$ activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.
204	CPR:4	In contrast, the administration of 7.5 and 15 mg of @CHEMICAL$ caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet @GENE$ activity by 25% and 35%, respectively.
205	CPR:4	Although the IC50 value of @CHEMICAL$ for inhibition of @GENE$ was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.
206	CPR:4	Although the IC50 value of @CHEMICAL$ for inhibition of COX-1 was 10-fold higher than the IC50 value of @GENE$ in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.
207	CPRFalse	Although the IC50 value of meloxicam for inhibition of @CHEMICAL$ was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of @GENE$ on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.
208	CPRFalse	Although the IC50 value of meloxicam for inhibition of COX-1 was 10-fold higher than the IC50 value of @CHEMICAL$ in vitro, this biochemical selectivity was inadequate to clearly separate the effects of @GENE$ on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.
209	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by @CHEMICAL$ alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.
210	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by @CHEMICAL$ alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.
211	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with @CHEMICAL$ reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.
212	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with @CHEMICAL$ reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.
213	CPRFalse	Modulation of dialysate levels of @CHEMICAL$, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.
214	CPRFalse	Modulation of dialysate levels of @CHEMICAL$, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.
215	CPRFalse	Modulation of dialysate levels of dopamine, @CHEMICAL$, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.
216	CPRFalse	Modulation of dialysate levels of dopamine, @CHEMICAL$, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.
217	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and @CHEMICAL$ (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.
218	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and @CHEMICAL$ (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.
219	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (@CHEMICAL$) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, @GENE$ and 5-HT1B receptors.
220	CPRFalse	Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (@CHEMICAL$) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and @GENE$ receptors.
221	CPRFalse	@CHEMICAL$, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @GENE$, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
222	CPRFalse	@CHEMICAL$, which possesses significant affinity for 5-HT1A, 5-HT1B, and @GENE$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
223	CPRFalse	@CHEMICAL$, which possesses significant affinity for @GENE$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
224	CPRFalse	@CHEMICAL$, which possesses significant affinity for 5-HT1A, @GENE$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
225	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
226	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
227	CPRFalse	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
228	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of @GENE$ (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
229	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
230	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
231	CPRFalse	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
232	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (@GENE$) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
233	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
234	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
235	CPRFalse	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
236	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and @GENE$ (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
237	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
238	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
239	CPRFalse	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
240	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (@GENE$) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
241	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors @CHEMICAL$, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
242	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and @CHEMICAL$ (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
243	CPRFalse	(-)-Pindolol, which possesses significant affinity for @CHEMICAL$, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
244	CPRFalse	(-)-Pindolol, which possesses significant affinity for 5-HT1A, @CHEMICAL$, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus @GENE$, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.
245	CPR:6	In distinction, the preferential @CHEMICAL$ antagonist, @GENE$, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.
246	CPRFalse	In distinction, the preferential beta 1-AR antagonist, @CHEMICAL$, and the preferential @GENE$ antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.
247	CPRFalse	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, @GENE$, did not increase basal levels of DA, NAD, or 5-HT.
248	CPR:6	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, @GENE$, did not increase basal levels of DA, NAD, or 5-HT.
249	CPRFalse	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of @GENE$, NAD, or 5-HT.
250	CPRFalse	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, ICI118,551, did not increase basal levels of @GENE$, NAD, or 5-HT.
251	CPRFalse	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, @GENE$, or 5-HT.
252	CPRFalse	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, ICI118,551, did not increase basal levels of DA, @GENE$, or 5-HT.
253	CPRFalse	In distinction, the preferential @CHEMICAL$ antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or @GENE$.
254	CPRFalse	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential @CHEMICAL$ antagonist, ICI118,551, did not increase basal levels of DA, NAD, or @GENE$.
255	CPR:6	The selective @CHEMICAL$ receptor antagonist, @GENE$, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.
256	CPRFalse	The selective 5-HT1A receptor antagonist, @CHEMICAL$, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.
257	CPRFalse	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the @GENE$-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.
258	CPRFalse	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the @CHEMICAL$-induced increase in DA and NAD levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.
259	CPRFalse	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in @GENE$ and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.
260	CPRFalse	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in @CHEMICAL$ and NAD levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.
261	CPRFalse	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and @GENE$ levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.
262	CPRFalse	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and @CHEMICAL$ levels, while the selective @GENE$ antagonist, SB224,289, was ineffective.
263	CPRFalse	The selective @CHEMICAL$ receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, @GENE$, was ineffective.
264	CPR:6	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective @CHEMICAL$ antagonist, @GENE$, was ineffective.
265	CPRFalse	These data suggest that @CHEMICAL$ facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of @GENE$ and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas 5-HT1B receptors are not involved.
266	CPRFalse	These data suggest that @CHEMICAL$ facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas @GENE$ receptors are not involved.
267	CPRFalse	These data suggest that @CHEMICAL$ facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of @GENE$ receptors, whereas 5-HT1B receptors are not involved.
268	CPRFalse	In conclusion, @CHEMICAL$ modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at @GENE$, 5-HT1A, and 5-HT1B receptors.
269	CPRFalse	In conclusion, @CHEMICAL$ modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, @GENE$, and 5-HT1B receptors.
270	CPRFalse	In conclusion, @CHEMICAL$ modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and @GENE$ receptors.
271	CPRFalse	In conclusion, (-)-pindolol modulates, both alone and together with @CHEMICAL$ reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at @GENE$, 5-HT1A, and 5-HT1B receptors.
272	CPRFalse	In conclusion, (-)-pindolol modulates, both alone and together with @CHEMICAL$ reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, @GENE$, and 5-HT1B receptors.
273	CPRFalse	In conclusion, (-)-pindolol modulates, both alone and together with @CHEMICAL$ reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and @GENE$ receptors.
274	CPRFalse	UNLABELLED: Entacapone is a potent and specific peripheral @CHEM-GENE$ (COMT) inhibitor.
275	CPRFalse	UNLABELLED: Entacapone is a potent and specific peripheral @CHEMICAL$-O-methyltransferase (@GENE$) inhibitor.
276	CPRFalse	UNLABELLED: Entacapone is a potent and specific peripheral @CHEM-GENE$ (COMT) inhibitor.
277	CPRFalse	UNLABELLED: Entacapone is a potent and specific peripheral catechol-@CHEMICAL$-methyltransferase (@GENE$) inhibitor.
278	CPR:4	UNLABELLED: @CHEMICAL$ is a potent and specific peripheral @GENE$ (COMT) inhibitor.
279	CPR:4	UNLABELLED: @CHEMICAL$ is a potent and specific peripheral catechol-O-methyltransferase (@GENE$) inhibitor.
280	CPRFalse	It has been shown to improve the clinical benefits of levodopa plus an @CHEMICAL$ inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to @GENE$ (the 'wearing off' phenomenon).
281	CPRFalse	It has been shown to improve the clinical benefits of levodopa plus an aromatic L-amino acid decarboxylase inhibitor (@CHEMICAL$) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to @GENE$ (the 'wearing off' phenomenon).
282	CPRFalse	It has been shown to improve the clinical benefits of @CHEMICAL$ plus an @GENE$ inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).
283	CPRFalse	It has been shown to improve the clinical benefits of @CHEMICAL$ plus an aromatic L-amino acid decarboxylase inhibitor (@GENE$) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).
284	CPRFalse	It has been shown to improve the clinical benefits of levodopa plus an @CHEM-GENE$ inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).
285	CPRFalse	It has been shown to improve the clinical benefits of levodopa plus an @CHEMICAL$ decarboxylase inhibitor (@GENE$) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).
286	CPRFalse	In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with @CHEMICAL$ (200 mg with each dose of levodopa/@GENE$ inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.
287	CPRFalse	In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with entacapone (200 mg with each dose of @CHEMICAL$/@GENE$ inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.
288	CPRFalse	@CHEMICAL$ also provided benefits when given with controlled release levodopa/ @GENE$ inhibitor or with standard levodopa/AADC inhibitor and selegiline in small trials.
289	CPRFalse	@CHEMICAL$ also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard levodopa/@GENE$ inhibitor and selegiline in small trials.
290	CPRFalse	Entacapone also provided benefits when given with controlled release @CHEMICAL$/ @GENE$ inhibitor or with standard levodopa/AADC inhibitor and selegiline in small trials.
291	CPRFalse	Entacapone also provided benefits when given with controlled release @CHEMICAL$/ AADC inhibitor or with standard levodopa/@GENE$ inhibitor and selegiline in small trials.
292	CPRFalse	Entacapone also provided benefits when given with controlled release levodopa/ @CHEMICAL$ inhibitor or with standard @GENE$/AADC inhibitor and selegiline in small trials.
293	CPRFalse	Entacapone also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard @CHEMICAL$/@GENE$ inhibitor and selegiline in small trials.
294	CPRFalse	Entacapone also provided benefits when given with controlled release levodopa/ @CHEMICAL$ inhibitor or with standard levodopa/AADC inhibitor and @GENE$ in small trials.
295	CPRFalse	Entacapone also provided benefits when given with controlled release levodopa/ AADC inhibitor or with standard levodopa/@CHEMICAL$ inhibitor and @GENE$ in small trials.
296	CPRFalse	CONCLUSIONS: The efficacy and tolerability of entacapone administered with @CHEMICAL$/@GENE$ inhibitor have not yet been compared with those of other strategies for the treatment of Parkinson's disease.
297	CPR:3	@CHEMICAL$ evokes @GENE$ activation in bovine aortic endothelial cell cultures.
298	CPRFalse	5-hydroxytryptamine evokes @CHEM-GENE$ activation in bovine aortic endothelial cell cultures.
299	CPR:9	Activation of @CHEMICAL$ (eNOS) results in the production of @GENE$ (NO) that mediates the vasorelaxing properties of endothelial cells.
300	CPR:9	Activation of endothelial nitric oxide synthase (@CHEMICAL$) results in the production of @GENE$ (NO) that mediates the vasorelaxing properties of endothelial cells.
301	CPR:9	Activation of @CHEMICAL$ (eNOS) results in the production of nitric oxide (@GENE$) that mediates the vasorelaxing properties of endothelial cells.
302	CPR:9	Activation of endothelial nitric oxide synthase (@CHEMICAL$) results in the production of nitric oxide (@GENE$) that mediates the vasorelaxing properties of endothelial cells.
303	CPRFalse	Activation of @CHEM-GENE$ (eNOS) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.
304	CPRFalse	Activation of endothelial @CHEMICAL$ synthase (@GENE$) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.
305	CPRFalse	The goal of this project was to address the possibility that @CHEMICAL$ (5-HT) stimulates @GENE$ activity in bovine aortic endothelial cell (BAEC) cultures.
306	CPRFalse	The goal of this project was to address the possibility that 5-hydroxytryptamine (@CHEMICAL$) stimulates @GENE$ activity in bovine aortic endothelial cell (BAEC) cultures.
307	CPRFalse	Here, we tested the hypothesis that @CHEM-GENE$ mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures.
308	CPRFalse	Here, we tested the hypothesis that @CHEMICAL$ receptors mediate @GENE$ activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures.
309	CPRFalse	Here, we tested the hypothesis that @CHEMICAL$ mediate eNOS activation by measuring agonist-stimulated @GENE$ ([3H]L-Cit) formation in BAEC cultures.
310	CPR:9	Here, we tested the hypothesis that 5-HT receptors mediate @CHEMICAL$ activation by measuring agonist-stimulated @GENE$ ([3H]L-Cit) formation in BAEC cultures.
311	CPRFalse	Here, we tested the hypothesis that @CHEMICAL$ mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline (@GENE$) formation in BAEC cultures.
312	CPR:9	Here, we tested the hypothesis that 5-HT receptors mediate @CHEMICAL$ activation by measuring agonist-stimulated [3H]L-citrulline (@GENE$) formation in BAEC cultures.
313	CPR:3	We found that @CHEMICAL$ stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating @GENE$ activation.
314	CPR:9	We found that 5-HT stimulated the conversion of @CHEMICAL$ ([3H]L-Arg) to [3H]L-Cit, indicating @GENE$ activation.
315	CPR:9	We found that 5-HT stimulated the conversion of [3H]L-arginine (@CHEMICAL$) to [3H]L-Cit, indicating @GENE$ activation.
316	CPR:9	We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to @CHEMICAL$, indicating @GENE$ activation.
317	CPR:5	The high affinity @CHEMICAL$ receptor agonist, @GENE$ (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.
318	CPRFalse	The high affinity @CHEMICAL$ receptor agonist, 5-nonyloxytryptamine (5-NOT)-stimulated @GENE$ turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.
319	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
320	CPR:6	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
321	CPRFalse	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
322	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): @GENE$ (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
323	CPR:6	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, @GENE$, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
324	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, @CHEMICAL$, and the @GENE$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
325	CPRFalse	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, @GENE$, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
326	CPR:6	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, @GENE$, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).
327	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).
328	CPR:6	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).
329	CPRFalse	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).
330	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (@GENE$) and L-N omega-iminoethyl-L-ornithine (L-NIO).
331	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).
332	CPR:6	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).
333	CPRFalse	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).
334	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and @GENE$ (L-NIO).
335	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/@CHEMICAL$ antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).
336	CPR:6	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the @CHEMICAL$ selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).
337	CPRFalse	These responses were effectively blocked by the @CHEMICAL$ receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).
338	CPRFalse	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the @CHEMICAL$/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (@GENE$).
339	CPRFalse	These findings lend evidence of a @CHEMICAL$ receptor/eNOS pathway, accounting in part for the activation of eNOS by @GENE$.
340	CPRFalse	These findings lend evidence of a 5-HT1B receptor/@CHEMICAL$ pathway, accounting in part for the activation of eNOS by @GENE$.
341	CPR:3	These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of @CHEMICAL$ by @GENE$.
342	CPRFalse	Further investigation is needed to determine the role of other vascular @CHEM-GENE$ in the stimulation of eNOS activity.
343	CPRFalse	Further investigation is needed to determine the role of other vascular @CHEMICAL$ receptors in the stimulation of @GENE$ activity.
344	CPR:4	@CHEMICAL$ inhibits the checkpoint @GENE$ ATM.
345	CPR:4	@CHEMICAL$ inhibits the checkpoint kinase @GENE$.
346	CPRFalse	We report that the radiation-induced activation of the @CHEMICAL$ Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by @GENE$ in vitro.
347	CPR:4	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM @CHEMICAL$ activity is directly inhibited by @GENE$ in vitro.
348	CPRFalse	We report that the radiation-induced activation of the kinase @CHEMICAL$ [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by @GENE$ in vitro.
349	CPRFalse	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as @CHEMICAL$ [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by @GENE$ in vitro.
350	CPR:4	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that @CHEMICAL$ kinase activity is directly inhibited by @GENE$ in vitro.
351	CPR:4	We report that the radiation-induced activation of the @CHEMICAL$ Cds1 [4] (also known as Chk2 [5]) is inhibited by @GENE$ in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.
352	CPRFalse	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by @CHEMICAL$ in vivo and that ATM @GENE$ activity is directly inhibited by caffeine in vitro.
353	CPR:4	We report that the radiation-induced activation of the kinase @CHEMICAL$ [4] (also known as Chk2 [5]) is inhibited by @GENE$ in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.
354	CPR:4	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as @CHEMICAL$ [5]) is inhibited by @GENE$ in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.
355	CPRFalse	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by @CHEMICAL$ in vivo and that @GENE$ kinase activity is directly inhibited by caffeine in vitro.
356	CPR:4	Inhibition of @CHEMICAL$ provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of @GENE$-treated cells [6] [7] [8].
357	CPRFalse	@CHEM-GENE$ production and degradation rates: studies with RTI-76.
358	CPRFalse	@CHEMICAL$ production and degradation rates: studies with @GENE$.
359	CPRFalse	The objective of this study was to examine the turnover of the @CHEM-GENE$ (SERT) by determining its production rate (r), degradation rate constant (k) and half-life of recovery (t1/2).
360	CPRFalse	The objective of this study was to examine the turnover of the @CHEMICAL$ transporter (@GENE$) by determining its production rate (r), degradation rate constant (k) and half-life of recovery (t1/2).
361	CPR:4	The turnover of @CHEMICAL$ was determined from the rate of recovery of binding after administration of @GENE$, an irreversible inhibitor of ligand binding.
362	CPR:4	In preliminary studies, in vitro incubation of rat cerebral cortex with @CHEMICAL$ produced a wash and temperature resistant inhibition of @GENE$ binding densities (Bmax).
363	CPRFalse	@CHEMICAL$ protected against the RTI-76-induced inhibition of @GENE$ binding.
364	CPR:4	Citalopram protected against the @CHEMICAL$-induced inhibition of @GENE$ binding.
365	CPRFalse	Following 6 h of in vivo intracerebroventricular injections of 100 nmol of @CHEMICAL$, there was a dose- and time-dependent reduction (- 60%) of @GENE$ binding in hippocampus and striatum, without a change in the Kd.
366	CPR:9	The decrease and recovery of @CHEMICAL$ uptake correlated highly (r = 0.93) with the recovery of @GENE$ binding.
367	CPRFalse	Pharmacological properties of @CHEM-GENE$ antagonists.
368	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-@GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
369	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEM-GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
370	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the @GENE$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
371	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
372	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ inhibitors.
373	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
374	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-angiotensin-@GENE$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
375	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-@GENE$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
376	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@CHEMICAL$ system at the level of the @GENE$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
377	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@CHEMICAL$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
378	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@CHEMICAL$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ inhibitors.
379	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-@GENE$ system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
380	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
381	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
382	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the @CHEMICAL$ receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
383	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @CHEM-GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
384	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @CHEMICAL$, and avoid the nonspecificity of the @GENE$ inhibitors.
385	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
386	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @CHEMICAL$-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.
387	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@CHEMICAL$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.
388	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the @CHEMICAL$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.
389	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @CHEMICAL$, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.
390	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @CHEM-GENE$ inhibitors.
391	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ converting enzyme inhibitors.
392	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the @GENE$-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
393	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-@GENE$-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
394	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the @GENE$ receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
395	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of @GENE$, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
396	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEMICAL$ type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the @GENE$ inhibitors.
397	CPRFalse	The availability of selective, potent, orally active and long acting nonpeptide @CHEM-GENE$ antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.
398	CPR:6	@CHEMICAL$ was the first, but by no means remained the only, @GENE$ receptor antagonist.
399	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of @GENE$) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.
400	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, @GENE$ 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.
401	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: @GENE$ 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.
402	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, @GENE$ 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.
403	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, @GENE$ (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.
404	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, @GENE$ 50, eprosartan 100 and the prodrug candesartan cilexetil 280.
405	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, @GENE$ 100 and the prodrug candesartan cilexetil 280.
406	CPR:6	Among the current @CHEMICAL$ receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug @GENE$ 280.
407	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, @GENE$, zolasartan, irbesartan, valsartan, telmisartan, E3174).
408	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, @GENE$, irbesartan, valsartan, telmisartan, E3174).
409	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, @GENE$, valsartan, telmisartan, E3174).
410	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, @GENE$, telmisartan, E3174).
411	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, @GENE$, E3174).
412	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, @GENE$).
413	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (@GENE$, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).
414	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, @GENE$, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).
415	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, @GENE$) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).
416	CPR:6	The mode of (functional) @CHEMICAL$ receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (@GENE$, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).
417	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and @GENE$ inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
418	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and @GENE$ inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
419	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and @GENE$ inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
420	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question mark@GENE$; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
421	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question mark@GENE$; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
422	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question mark@GENE$; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
423	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEM-GENE$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
424	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ receptor (@GENE$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
425	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ receptor (ER)-positive or @GENE$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
426	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (@GENE$, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
427	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (@GENE$, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
428	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (@GENE$, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
429	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, @GENE$, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
430	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, @GENE$, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
431	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, @GENE$, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
432	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and @GENE$ inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
433	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and @GENE$ inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
434	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and @GENE$ inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
435	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with @CHEMICAL$ (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus @GENE$ and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
436	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (@CHEMICAL$)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus @GENE$ and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
437	CPRFalse	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or @CHEMICAL$-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus @GENE$ and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.
438	CPRFalse	Characterization and partial purification of microsomal @CHEM-GENE$.
439	CPRFalse	Characterization and partial purification of microsomal @CHEM-GENE$.
440	CPRFalse	@CHEM-GENE$ are flavoproteins that catalyze two-electron reduction and detoxification of quinones.
441	CPR:9	@CHEMICAL$ are flavoproteins that catalyze two-electron reduction and detoxification of @GENE$.
442	CPRFalse	Two cytosolic forms of @CHEMICAL$ [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:@GENE$ oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
443	CPRFalse	Two cytosolic forms of quinone oxidoreductases @CHEMICAL$ (NQO1) and NRH:@GENE$ oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
444	CPRFalse	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (@CHEMICAL$) and NRH:@GENE$ oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
445	CPRFalse	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and @CHEM-GENE$ (NQO2)] were previously identified, purified, and cloned.
446	CPRFalse	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:@CHEMICAL$ oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.
447	CPRFalse	Two cytosolic forms of @CHEM-GENE$ [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
448	CPRFalse	Two cytosolic forms of @CHEMICAL$ oxidoreductases @GENE$ (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
449	CPRFalse	Two cytosolic forms of @CHEMICAL$ oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (@GENE$) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
450	CPRFalse	Two cytosolic forms of @CHEMICAL$ oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and @GENE$ (NQO2)] were previously identified, purified, and cloned.
451	CPRFalse	Two cytosolic forms of @CHEMICAL$ oxidoreductases [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.
452	CPRFalse	Two cytosolic forms of @CHEMICAL$ [@GENE$:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
453	CPRFalse	Two cytosolic forms of quinone oxidoreductases @CHEM-GENE$ (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
454	CPRFalse	Two cytosolic forms of quinone oxidoreductases [@CHEMICAL$:quinone oxidoreductase 1 (@GENE$) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
455	CPRFalse	Two cytosolic forms of quinone oxidoreductases [@CHEMICAL$:quinone oxidoreductase 1 (NQO1) and @GENE$ (NQO2)] were previously identified, purified, and cloned.
456	CPRFalse	Two cytosolic forms of quinone oxidoreductases [@CHEMICAL$:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.
457	CPRFalse	Two cytosolic forms of @CHEMICAL$ [NAD(P)H:@GENE$ oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
458	CPRFalse	Two cytosolic forms of quinone oxidoreductases @CHEM-GENE$ (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
459	CPRFalse	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:@CHEMICAL$ oxidoreductase 1 (@GENE$) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.
460	CPRFalse	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:@CHEMICAL$ oxidoreductase 1 (NQO1) and @GENE$ (NQO2)] were previously identified, purified, and cloned.
461	CPRFalse	Two cytosolic forms of quinone oxidoreductases [NAD(P)H:@CHEMICAL$ oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (@GENE$)] were previously identified, purified, and cloned.
462	CPR:9	A role of cytosolic @CHEMICAL$ in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of @GENE$ was established.
463	CPRFalse	The @CHEMICAL$ activity showed significantly higher affinity for @GENE$ than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione.
464	CPRFalse	The @CHEMICAL$ activity showed significantly higher affinity for NADH than @GENE$ as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione.
465	CPR:9	The @CHEMICAL$ activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of @GENE$ and menadione.
466	CPR:9	The @CHEMICAL$ activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and @GENE$.
467	CPRFalse	The @CHEMICAL$ activity was insensitive to @GENE$, a potent inhibitor of cytosolic NQO1.
468	CPR:4	The mNQO activity was insensitive to @CHEMICAL$, a potent inhibitor of cytosolic @GENE$.
469	CPRFalse	The @CHEMICAL$ activity was partially purified by solubilization of microsomes with detergent Chaps, @GENE$ fractionation, and DEAE-Sephacel column chromatography.
470	CPRFalse	The @CHEMICAL$ activity was partially purified by solubilization of microsomes with detergent Chaps, ammonium sulfate fractionation, and @GENE$-Sephacel column chromatography.
471	CPRFalse	The microsomal @CHEMICAL$ proteins are expected to provide additional protection after cytosolic NQOs against @GENE$ toxicity and mutagenicity.
472	CPRFalse	The microsomal mNQO proteins are expected to provide additional protection after cytosolic @CHEMICAL$ against @GENE$ toxicity and mutagenicity.
473	CPRFalse	The affinity and functional profile of opioids possessing activity at the @CHEMICAL$ was determined using [3H]nociceptin and nociceptin-stimulated @GENE$ binding.
474	CPR:5	The @CHEMICAL$-selective agonist @GENE$ potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).
475	CPR:5	@CHEMICAL$ exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant @GENE$ receptors (EC(50) 50 nM).
476	CPRFalse	Lofentanil exhibited full agonism for enhancement of @CHEMICAL$ binding to human recombinant @GENE$ receptors (EC(50) 50 nM).
477	CPRFalse	The related piperidines ohmefentanyl and @CHEMICAL$ and the nonselective @GENE$ agonist etorphine were less potent nociceptin receptor agonists.
478	CPR:5	The related piperidines ohmefentanyl and @CHEMICAL$ and the nonselective opioid receptor agonist etorphine were less potent @GENE$ agonists.
479	CPR:5	The related piperidines ohmefentanyl and sufentanil and the nonselective @CHEMICAL$ agonist @GENE$ were less potent nociceptin receptor agonists.
480	CPR:5	The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist @CHEMICAL$ were less potent @GENE$ agonists.
481	CPRFalse	The related @CHEMICAL$ ohmefentanyl and sufentanil and the nonselective @GENE$ agonist etorphine were less potent nociceptin receptor agonists.
482	CPR:5	The related @CHEMICAL$ ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent @GENE$ agonists.
483	CPRFalse	The related piperidines @CHEMICAL$ and sufentanil and the nonselective @GENE$ agonist etorphine were less potent nociceptin receptor agonists.
484	CPR:5	The related piperidines @CHEMICAL$ and sufentanil and the nonselective opioid receptor agonist etorphine were less potent @GENE$ agonists.
485	CPR:6	The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist @CHEMICAL$ was a pure antagonist at both rat brain and human @GENE$ receptors.
486	CPR:6	The kappa(1)+kappa(3)-opioid receptor agonist/@CHEMICAL$ antagonist @GENE$ was a pure antagonist at both rat brain and human ORL1 receptors.
487	CPR:5	The nonselective @CHEMICAL$ partial agonist @GENE$ and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.
488	CPRFalse	The nonselective opioid receptor partial agonist @CHEMICAL$ and the nonselective @GENE$ antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.
489	CPRFalse	The nonselective opioid receptor partial agonist @CHEMICAL$ and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at @GENE$ receptors.
490	CPRFalse	The nonselective @CHEMICAL$ partial agonist buprenorphine and the nonselective opioid receptor antagonist @GENE$ exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.
491	CPR:6	The nonselective opioid receptor partial agonist buprenorphine and the nonselective @CHEMICAL$ antagonist @GENE$ exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.
492	CPR:5	The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist @CHEMICAL$ exhibited pure antagonism at rat brain receptors, but displayed partial agonism at @GENE$ receptors.
493	CPRFalse	In addition, the stereospecificity required at @CHEMICAL$ appears to be retained at the nociceptin receptor, since @GENE$ is inactive at both receptors.
494	CPRFalse	In addition, the stereospecificity required at opioid receptors appears to be retained at the @CHEMICAL$, since @GENE$ is inactive at both receptors.
495	CPRFalse	@CHEM-GENE$ and thymidine kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.
496	CPRFalse	@CHEMICAL$ synthase and @GENE$ are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.
497	CPR:9	@CHEMICAL$ and thymidine kinase are key enzymes involved in the de novo and salvage pathways for @GENE$ synthesis, respectively.
498	CPR:9	Thymidylate synthase and @CHEMICAL$ are key enzymes involved in the de novo and salvage pathways for @GENE$ synthesis, respectively.
499	CPRFalse	@CHEMICAL$ and @GENE$ kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.
500	CPRFalse	Thymidylate synthase and @CHEM-GENE$ are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.
501	CPRFalse	@CHEM-GENE$ is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular folate.
502	CPR:4	@CHEMICAL$ is inhibited by @GENE$, forming an inactive ternary complex with intracellular folate.
503	CPRFalse	@CHEMICAL$ is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular @GENE$.
504	CPR:4	Thirty-week administration of @CHEMICAL$ with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @GENE$ inhibition and the decrease of thymidine kinase activity in the tumor cells.
505	CPR:4	Thirty-week administration of @CHEMICAL$ with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of @GENE$ activity in the tumor cells.
506	CPR:4	Thirty-week administration of UFT with or without @CHEMICAL$ markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @GENE$ inhibition and the decrease of thymidine kinase activity in the tumor cells.
507	CPR:4	Thirty-week administration of UFT with or without @CHEMICAL$ markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of @GENE$ activity in the tumor cells.
508	CPRFalse	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @CHEM-GENE$ inhibition and the decrease of thymidine kinase activity in the tumor cells.
509	CPRFalse	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @CHEMICAL$ synthase inhibition and the decrease of @GENE$ activity in the tumor cells.
510	CPRFalse	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of @CHEMICAL$ inhibition and the decrease of @GENE$ kinase activity in the tumor cells.
511	CPRFalse	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of @CHEM-GENE$ activity in the tumor cells.
512	CPRFalse	@CHEMICAL$ is rapidly induced in growth-stimulated mouse fibroblasts and releases @GENE$ decarboxylase from antizyme suppression.
513	CPRFalse	Antizyme inhibitor is rapidly induced in growth-stimulated mouse fibroblasts and releases @CHEMICAL$ decarboxylase from @GENE$ suppression.
514	CPRFalse	Antizyme inhibitor is rapidly induced in growth-stimulated mouse fibroblasts and releases @CHEM-GENE$ from antizyme suppression.
515	CPRFalse	@CHEMICAL$ decarboxylase (@GENE$) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine.
516	CPRFalse	@CHEM-GENE$ (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine.
517	CPR:9	Ornithine decarboxylase (@CHEMICAL$) catalyses the first step in the synthesis of the polyamines putrescine, @GENE$ and spermine.
518	CPR:9	@CHEMICAL$ (ODC) catalyses the first step in the synthesis of the polyamines putrescine, @GENE$ and spermine.
519	CPR:9	Ornithine decarboxylase (@CHEMICAL$) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and @GENE$.
520	CPR:9	@CHEMICAL$ (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and @GENE$.
521	CPR:9	Ornithine decarboxylase (@CHEMICAL$) catalyses the first step in the synthesis of the polyamines @GENE$, spermidine and spermine.
522	CPR:9	@CHEMICAL$ (ODC) catalyses the first step in the synthesis of the polyamines @GENE$, spermidine and spermine.
523	CPRFalse	In untransfected CHL cells, @CHEMICAL$ had no effect at concentrations up to 100 microM. In @GENE$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).
524	CPR:5	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was @GENE$ (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).
525	CPR:5	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>@GENE$ (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).
526	CPR:5	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>@GENE$ (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).
527	CPR:5	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>@GENE$ (7.05)>noradrenaline (6.92).
528	CPR:5	In untransfected CHL cells, noradrenaline had no effect at concentrations up to 100 microM. In @CHEMICAL$ transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>@GENE$ (6.92).
529	CPRFalse	3. The selective @CHEMICAL$ ligand @GENE$ antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43.
530	CPRFalse	3. The selective @CHEMICAL$ ligand rauwolscine antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against @GENE$ was 8.43.
531	CPRFalse	The selective @CHEMICAL$ ligands @GENE$ and doxazosin (each 3 microM) had no effect on noradrenaline responses.
532	CPRFalse	The selective @CHEMICAL$ ligands prazosin and @GENE$ (each 3 microM) had no effect on noradrenaline responses.
533	CPRFalse	The selective @CHEMICAL$ ligands prazosin and doxazosin (each 3 microM) had no effect on @GENE$ responses.
534	CPR:3	@CHEMICAL$ were activated by @GENE$ as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.
535	CPR:6	The @CHEMICAL$ antagonist @GENE$ (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.
536	CPRFalse	The glucocorticoid receptor antagonist @CHEMICAL$ (mifepristone) significantly counteracted the effect of dexamethasone on @GENE$ activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.
537	CPRFalse	The glucocorticoid receptor antagonist @CHEMICAL$ (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the @GENE$.
538	CPR:6	The @CHEMICAL$ antagonist RU-486 (@GENE$) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.
539	CPRFalse	The glucocorticoid receptor antagonist RU-486 (@CHEMICAL$) significantly counteracted the effect of dexamethasone on @GENE$ activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.
540	CPRFalse	The glucocorticoid receptor antagonist RU-486 (@CHEMICAL$) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the @GENE$.
541	CPRFalse	The @CHEMICAL$ antagonist RU-486 (mifepristone) significantly counteracted the effect of @GENE$ on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.
542	CPRFalse	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of @CHEMICAL$ on @GENE$ activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.
543	CPRFalse	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of @CHEMICAL$ on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the @GENE$.
544	CPRFalse	The @CHEMICAL$ antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the @GENE$ effect is specific and is mediated through the glucocorticoid receptor.
545	CPRFalse	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on @CHEMICAL$ activation, indicating that the @GENE$ effect is specific and is mediated through the glucocorticoid receptor.
546	CPRFalse	The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the @CHEMICAL$ effect is specific and is mediated through the @GENE$.
547	CPRFalse	The presence of @CHEMICAL$ confers their responsiveness to glucocorticoids and indicates that the airway epithelium may be a target for the anti-inflammatory effects of inhaled @GENE$.
548	CPRFalse	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. @CHEMICAL$, CD15 and CD120b) and increased expression of aminopeptidase-@GENE$ (CD13).
549	CPRFalse	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, @CHEMICAL$ and CD120b) and increased expression of aminopeptidase-@GENE$ (CD13).
550	CPRFalse	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, CD15 and @CHEMICAL$) and increased expression of aminopeptidase-@GENE$ (CD13).
551	CPRFalse	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, CD15 and CD120b) and increased expression of @CHEM-GENE$ (CD13).
552	CPRFalse	Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. CD16, CD15 and CD120b) and increased expression of aminopeptidase-@CHEMICAL$ (@GENE$).
553	CPRFalse	A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high @CHEM-GENE$ occupancy.
554	CPRFalse	A positron emission tomography study of @CHEMICAL$ in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high @GENE$ occupancy.
555	CPRFalse	As such, relatively little has been published regarding its in vivo effects at the @CHEM-GENE$ (D2) and serotonin type 2a (5-HT2a) receptor systems.
556	CPRFalse	As such, relatively little has been published regarding its in vivo effects at the @CHEMICAL$ type 2 (@GENE$) and serotonin type 2a (5-HT2a) receptor systems.
557	CPRFalse	As such, relatively little has been published regarding its in vivo effects at the @CHEMICAL$ type 2 (D2) and @GENE$ systems.
558	CPRFalse	As such, relatively little has been published regarding its in vivo effects at the @CHEMICAL$ (D2) and @GENE$ type 2a (5-HT2a) receptor systems.
559	CPRFalse	As such, relatively little has been published regarding its in vivo effects at the dopamine type 2 (@CHEMICAL$) and @GENE$ type 2a (5-HT2a) receptor systems.
560	CPRFalse	As such, relatively little has been published regarding its in vivo effects at the dopamine type 2 (D2) and @CHEM-GENE$ systems.
561	CPR:3	RESULTS: @CHEMICAL$ was an effective antipsychotic and improved the extrapyramidal symptoms and @GENE$ level elevation noted at baseline.
562	CPRFalse	Study of the additional subjects revealed that @CHEMICAL$ does give rise to transiently high (58%-64%) @GENE$ occupancy 2 to 3 hours after a single dose that then decreases to minimal levels in 12 hours.
563	CPRFalse	CONCLUSIONS: @CHEMICAL$ shows a transiently high @GENE$ occupancy, which decreases to very low levels by the end of the dosing interval.
564	CPRFalse	In this study, we compared the @CHEMICAL$ and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
565	CPRFalse	In this study, we compared the insulin and @CHEMICAL$ binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
566	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of @CHEMICAL$ aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
567	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp @CHEMICAL$), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
568	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), @CHEMICAL$ lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
569	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro @CHEMICAL$), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
570	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), @CHEMICAL$ glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
571	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg @CHEMICAL$), insulin detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
572	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), @CHEMICAL$ detemir (NN304) [B29Lys(@GENE$), desB30 human insulin], and reference insulin analogs.
573	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@CHEMICAL$), desB30 human @GENE$], and reference insulin analogs.
574	CPRFalse	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(@CHEMICAL$), desB30 human insulin], and reference @GENE$ analogs.
575	CPRFalse	The attachment of a @CHEMICAL$ chain to LysB29 provided @GENE$ detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies.
576	CPRFalse	@CHEMICAL$, an inactivating 2P domain @GENE$ channel.
577	CPRFalse	TWIK-2, an inactivating @CHEM-GENE$.
578	CPRFalse	We cloned human and rat @CHEMICAL$ and expressed this novel 2P domain @GENE$ channel in transiently transfected COS cells.
579	CPRFalse	We cloned human and rat TWIK-2 and expressed this novel @CHEM-GENE$ in transiently transfected COS cells.
580	CPRFalse	@CHEMICAL$ currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological @GENE$ gradient and mild inward rectification in symmetrical K(+) conditions.
581	CPRFalse	Rat TWIK-2 currents are about 15 times larger than @CHEMICAL$ currents, but both exhibit outward rectification in a physiological @GENE$ gradient and mild inward rectification in symmetrical K(+) conditions.
582	CPRFalse	@CHEMICAL$ currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical @GENE$ conditions.
583	CPRFalse	Rat TWIK-2 currents are about 15 times larger than @CHEMICAL$ currents, but both exhibit outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical @GENE$ conditions.
584	CPRFalse	In a physiological @CHEMICAL$ gradient, @GENE$ is half inhibited by 0.1 mm Ba(2+), quinine, and quinidine.
585	CPR:4	In a physiological K(+) gradient, @CHEMICAL$ is half inhibited by 0.1 mm @GENE$, quinine, and quinidine.
586	CPR:4	In a physiological K(+) gradient, @CHEMICAL$ is half inhibited by 0.1 mm Ba(2+), @GENE$, and quinidine.
587	CPR:4	In a physiological K(+) gradient, @CHEMICAL$ is half inhibited by 0.1 mm Ba(2+), quinine, and @GENE$.
588	CPRFalse	Finally, @CHEMICAL$ 53 in the @GENE$ is required for functional expression of TWIK-2 but is not critical for subunit self-assembly.
589	CPRFalse	Finally, @CHEMICAL$ 53 in the M1P1 external loop is required for functional expression of @GENE$ but is not critical for subunit self-assembly.
590	CPRFalse	TWIK-2 is the first reported @CHEM-GENE$ that inactivates.
591	CPRFalse	@CHEMICAL$ is the first reported 2P domain @GENE$ channel that inactivates.
592	CPRFalse	The base-line, transient, and delayed activities of @CHEMICAL$ suggest that this novel 2P domain @GENE$ channel may play an important functional role in cell electrogenesis.
593	CPRFalse	The base-line, transient, and delayed activities of TWIK-2 suggest that this novel @CHEM-GENE$ may play an important functional role in cell electrogenesis.
594	CPR:4	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of @CHEMICAL$ (EPA) blocked @GENE$ activity, the terminal enzymatic step in AA synthesis.
595	CPR:4	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (@CHEMICAL$) blocked @GENE$ activity, the terminal enzymatic step in AA synthesis.
596	CPRFalse	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA) blocked @CHEMICAL$ activity, the terminal enzymatic step in @GENE$ synthesis.
597	CPRFalse	Effects of a @CHEM-GENE$ opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.
598	CPR:3	BACKGROUND: This study examines the effects of @CHEMICAL$, a @GENE$ opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).
599	CPRFalse	BACKGROUND: This study examines the effects of nicorandil, a @CHEM-GENE$ opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).
600	CPR:4	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, @CHEMICAL$ (100 micromol/L) to block @GENE$ (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).
601	CPR:4	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, @CHEMICAL$ (100 micromol/L) to block I(Kr) (LQT2 model), and @GENE$ (20 nmol/L) to augment late I(Na) (LQT3 model).
602	CPRFalse	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block @CHEMICAL$ (LQT2 model), and ATX-II (20 nmol/L) to augment late I(@GENE$) (LQT3 model).
603	CPRFalse	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and @CHEMICAL$ (20 nmol/L) to augment late I(@GENE$) (LQT3 model).
604	CPR:4	@CHEMICAL$ (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block @GENE$ (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).
605	CPR:4	@CHEMICAL$ (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and @GENE$ (20 nmol/L) to augment late I(Na) (LQT3 model).
606	CPRFalse	@CHEMICAL$+chromanol 293B, d-sotalol, and @GENE$ produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).
607	CPRFalse	Isoproterenol+@CHEMICAL$, d-sotalol, and @GENE$ produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).
608	CPRFalse	Isoproterenol+chromanol 293B, @CHEMICAL$, and @GENE$ produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).
609	CPRFalse	@CHEMICAL$ 20 micromol/L reversed only 50% of the effect of @GENE$ and failed to completely suppress TdP in the LQT3 model (5/6 to 3/6).
610	CPRFalse	CONCLUSIONS: Our data suggest that @CHEM-GENE$ openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or I(Ks) but less so when it is due to augmented late I(Na).
611	CPRFalse	CONCLUSIONS: Our data suggest that @CHEMICAL$ channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced @GENE$ or I(Ks) but less so when it is due to augmented late I(Na).
612	CPRFalse	CONCLUSIONS: Our data suggest that @CHEMICAL$ channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or @GENE$ but less so when it is due to augmented late I(Na).
613	CPRFalse	CONCLUSIONS: Our data suggest that @CHEMICAL$ openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or I(Ks) but less so when it is due to augmented late I(@GENE$).
614	CPRFalse	CONCLUSIONS: Our data suggest that K(+) channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced @CHEMICAL$ or I(Ks) but less so when it is due to augmented late I(@GENE$).
615	CPRFalse	CONCLUSIONS: Our data suggest that K(+) channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or @CHEMICAL$ but less so when it is due to augmented late I(@GENE$).
616	CPR:9	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. @CHEMICAL$ (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
617	CPR:9	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (@CHEMICAL$) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
618	CPRFalse	@CHEMICAL$ (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
619	CPRFalse	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase @CHEMICAL$ mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
620	CPRFalse	Peroxisome proliferator-activated receptor alpha (@CHEMICAL$) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for @GENE$ ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
621	CPRFalse	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, @CHEMICAL$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. @GENE$ (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
622	CPRFalse	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, @CHEMICAL$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (@GENE$) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
623	CPR:3	@CHEMICAL$ (PPARalpha) activators, @GENE$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
624	CPR:3	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, @CHEMICAL$ and Wy-14,643, increase @GENE$ mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
625	CPR:3	Peroxisome proliferator-activated receptor alpha (@CHEMICAL$) activators, @GENE$ and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
626	CPRFalse	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and @CHEMICAL$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. @GENE$ (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
627	CPRFalse	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and @CHEMICAL$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (@GENE$) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
628	CPR:3	@CHEMICAL$ (PPARalpha) activators, bezafibrate and @GENE$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
629	CPR:3	Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and @CHEMICAL$, increase @GENE$ mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
630	CPR:3	Peroxisome proliferator-activated receptor alpha (@CHEMICAL$) activators, bezafibrate and @GENE$, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.
631	CPRFalse	We have studied the effects of two fibrates, @CHEMICAL$ and Wy-14,643, on @GENE$ and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.
632	CPRFalse	We have studied the effects of two fibrates, @CHEMICAL$ and Wy-14,643, on UCP-3 and @GENE$ mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.
633	CPRFalse	We have studied the effects of two fibrates, bezafibrate and @CHEMICAL$, on @GENE$ and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.
634	CPRFalse	We have studied the effects of two fibrates, bezafibrate and @CHEMICAL$, on UCP-3 and @GENE$ mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.
635	CPR:3	Thus, @CHEMICAL$ treatment resulted in an 8-fold induction in @GENE$ mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes.
636	CPRFalse	In contrast to @CHEMICAL$, UCP-2 mRNA levels were only slightly modified by @GENE$ in adipocytes.
637	CPRFalse	In contrast to UCP-3, @CHEMICAL$ mRNA levels were only slightly modified by @GENE$ in adipocytes.
638	CPR:3	The induction in @CHEMICAL$ expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after @GENE$ or Wy-14,643 treatment.
639	CPR:3	The induction in @CHEMICAL$ expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or @GENE$ treatment.
640	CPRFalse	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after @GENE$ and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.
641	CPR:3	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after @GENE$ and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.
642	CPRFalse	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and @GENE$ treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.
643	CPR:3	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after bezafibrate and @GENE$ treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.
644	CPRFalse	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of @GENE$, limiting their availability to be stored as triglycerides.
645	CPRFalse	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of @GENE$, limiting their availability to be stored as triglycerides.
646	CPRFalse	Since it has been proposed that @CHEMICAL$ could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as @GENE$.
647	CPRFalse	Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the @CHEMICAL$ induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as @GENE$.
648	CPRFalse	@CHEMICAL$ protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
649	CPR:3	@CHEMICAL$ protects against menadione-induced hepatotoxicity by enhancing @GENE$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
650	CPRFalse	Schisandrin B protects against @CHEMICAL$-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
651	CPRFalse	Schisandrin B protects against @CHEMICAL$-induced hepatotoxicity by enhancing @GENE$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
652	CPR:4	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against @CHEMICAL$-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
653	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against @GENE$-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
654	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with @CHEMICAL$ (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
655	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with @GENE$ (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
656	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @CHEMICAL$ activity (78%) and hepatic @GENE$ level (70%), when compared with the menadione intoxicated control.
657	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic @GENE$ level (70%), when compared with the menadione intoxicated control.
658	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (@CHEMICAL$), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @GENE$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
659	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (@GENE$), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.
660	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma @CHEMICAL$ activity (78%) and hepatic malondialdehyde level (70%), when compared with the @GENE$ intoxicated control.
661	CPRFalse	Schisandrin B protects against menadione-induced hepatotoxicity by enhancing @CHEMICAL$ activity. Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the @GENE$ intoxicated control.
662	CPRFalse	In order to define the biochemical mechanism involved in the hepatoprotection afforded by @CHEMICAL$ pretreatment, we examined the activity of @GENE$ (DTD) in hepatocytes isolated from Sch B pretreated rats.
663	CPRFalse	In order to define the biochemical mechanism involved in the hepatoprotection afforded by @CHEMICAL$ pretreatment, we examined the activity of DT-diaphorase (@GENE$) in hepatocytes isolated from Sch B pretreated rats.
664	CPRFalse	In order to define the biochemical mechanism involved in the hepatoprotection afforded by Sch B pretreatment, we examined the activity of @CHEMICAL$ (DTD) in hepatocytes isolated from @GENE$ pretreated rats.
665	CPRFalse	In order to define the biochemical mechanism involved in the hepatoprotection afforded by Sch B pretreatment, we examined the activity of DT-diaphorase (@CHEMICAL$) in hepatocytes isolated from @GENE$ pretreated rats.
666	CPR:3	Hepatocytes isolated from @CHEMICAL$ pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in @GENE$ activity.
667	CPRFalse	The increase in @CHEMICAL$ activity was associated with the enhanced rate of @GENE$ elimination in the hepatocyte culture.
668	CPR:3	The ensemble of results suggests that the ability of @CHEMICAL$ pretreatment to enhance hepatocellular @GENE$ activity may at least in part be attributed to the protection against menadione hepatotoxicity.
669	CPRFalse	The ensemble of results suggests that the ability of Sch B pretreatment to enhance hepatocellular @CHEMICAL$ activity may at least in part be attributed to the protection against @GENE$ hepatotoxicity.
670	CPRFalse	This study was designed to investigate the delayed effects of @CHEMICAL$ and treadmill exercise on @GENE$ activity, lipid peroxidation and histology of peripheral tissues of mice.
671	CPR:4	The group treated with @CHEMICAL$ alone showed decreased plasma @GENE$ (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.
672	CPR:4	The group treated with @CHEMICAL$ alone showed decreased plasma butyrylcholinesterase (@GENE$) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.
673	CPRFalse	The group treated with @CHEMICAL$ alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the @GENE$ activity (79% of control), indicating an interactive effect of the combination.
674	CPRFalse	The group treated with pyridostigmine alone showed decreased plasma @CHEMICAL$ (BChE) activity (87% of control), whereas @GENE$ plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.
675	CPRFalse	The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (@CHEMICAL$) activity (87% of control), whereas @GENE$ plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.
676	CPR:4	The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas @CHEMICAL$ plus exercise significantly decreased the @GENE$ activity (79% of control), indicating an interactive effect of the combination.
677	CPR:4	However, @CHEMICAL$ activity in triceps muscle decreased significantly (78% of control) in the group treated with @GENE$ plus exercise.
678	CPRFalse	@CHEM-GENE$ activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.
679	CPR:3	@CHEMICAL$ activity in plasma increased slightly (compared to control, @GENE$ or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.
680	CPR:3	@CHEMICAL$ activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with @GENE$ plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.
681	CPRFalse	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as @CHEMICAL$ and GnRH agonist, exert direct regulatory action on @GENE$ (MCP-1) expression by endometrial epithelial cells.
682	CPRFalse	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as @CHEMICAL$ and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (@GENE$) expression by endometrial epithelial cells.
683	CPRFalse	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as @CHEMICAL$ and @GENE$ agonist, exert direct regulatory action on monocyte chemotactic protein-1 (MCP-1) expression by endometrial epithelial cells.
684	CPRFalse	DESIGN: Primary cultures of epithelial cells isolated from human endometrium were exposed to different concentrations of @CHEMICAL$ and @GENE$ hormone analogs.
685	CPRFalse	RESULT(S): Buserelin acetate, a @CHEMICAL$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas @GENE$ (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
686	CPRFalse	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @CHEMICAL$ expression, whereas @GENE$ (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
687	CPR:4	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas @CHEMICAL$ (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.
688	CPRFalse	RESULT(S): Buserelin acetate, a @CHEMICAL$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a @GENE$ analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
689	CPRFalse	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @CHEMICAL$ expression, whereas danazol (10(-7)-10(-5) M), a @GENE$ analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
690	CPR:4	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a @CHEMICAL$ analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.
691	CPRFalse	RESULT(S): Buserelin acetate, a @CHEMICAL$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and @GENE$, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
692	CPRFalse	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @CHEMICAL$ expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and @GENE$, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
693	CPR:4	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and @CHEMICAL$, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.
694	CPR:5	RESULT(S): @CHEMICAL$, a @GENE$ agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
695	CPRFalse	RESULT(S): @CHEMICAL$, a GnRH agonist (0.1-10 ng/mL), had no significant effect on @GENE$ expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.
696	CPRFalse	RESULT(S): @CHEMICAL$, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on @GENE$ expression.
697	CPRFalse	Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of @CHEMICAL$ receptor and @GENE$ agonists.
698	CPRFalse	Pharmacological modulation of @CHEMICAL$ synthesis: a mechanistic comparison of @GENE$ receptor and beta(2)-adrenoceptor agonists.
699	CPRFalse	Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of @CHEM-GENE$ and beta(2)-adrenoceptor agonists.
700	CPRFalse	The present studies were undertaken to compare two compounds, a @CHEMICAL$ analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting @GENE$ agonist, both of which induce NGF synthesis in vivo.
701	CPR:4	The present studies were undertaken to compare two compounds, a @CHEMICAL$ analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce @GENE$ synthesis in vivo.
702	CPRFalse	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (@CHEMICAL$) with minimal calcaemic effects, and clenbuterol, a long-acting @GENE$ agonist, both of which induce NGF synthesis in vivo.
703	CPR:3	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (@CHEMICAL$) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce @GENE$ synthesis in vivo.
704	CPR:5	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and @CHEMICAL$, a long-acting @GENE$ agonist, both of which induce NGF synthesis in vivo.
705	CPR:3	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and @CHEMICAL$, a long-acting beta(2)-adrenoceptor agonist, both of which induce @GENE$ synthesis in vivo.
706	CPR:3	@CHEMICAL$ caused significant increases in both @GENE$ mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.
707	CPRFalse	Effects of clenbuterol on @CHEMICAL$ mRNA were antagonized by @GENE$.
708	CPRFalse	Effects of @CHEMICAL$ on @GENE$ mRNA were antagonized by propranolol.
709	CPRFalse	Mobility shift assays on whole cell extracts showed that @CHEMICAL$ increased @GENE$ binding in 3T3 cells prior to increasing NGF synthesis.
710	CPR:3	Mobility shift assays on whole cell extracts showed that @CHEMICAL$ increased AP1 binding in 3T3 cells prior to increasing @GENE$ synthesis.
711	CPRFalse	@CHEMICAL$ was without effect on @GENE$ mRNA levels in L929 cells, whereas CB1093 caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells.
712	CPRFalse	@CHEMICAL$ was without effect on NGF mRNA levels in L929 cells, whereas CB1093 caused significant increases in both @GENE$ mRNA and protein levels in both 3T3 and L929 cells.
713	CPRFalse	Clenbuterol was without effect on @CHEMICAL$ mRNA levels in L929 cells, whereas @GENE$ caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells.
714	CPR:3	Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas @CHEMICAL$ caused significant increases in both @GENE$ mRNA and protein levels in both 3T3 and L929 cells.
715	CPRFalse	Binding to the @CHEM-GENE$ (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.
716	CPRFalse	Binding to the @CHEMICAL$ nuclear receptor (@GENE$), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.
717	CPRFalse	Binding to the @CHEMICAL$ nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased @GENE$ binding preceded increased NGF mRNA.
718	CPRFalse	Binding to the @CHEMICAL$ nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased VDR binding preceded increased @GENE$ mRNA.
719	CPRFalse	Binding to the @CHEMICAL$ (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @GENE$ and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.
720	CPRFalse	Binding to the vitamin D nuclear receptor (@CHEMICAL$), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @GENE$ and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.
721	CPRFalse	Binding to the vitamin D nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @CHEMICAL$ and maintained up to 24 h. Increased @GENE$ binding preceded increased NGF mRNA.
722	CPRFalse	Binding to the vitamin D nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of @CHEMICAL$ and maintained up to 24 h. Increased VDR binding preceded increased @GENE$ mRNA.
723	CPR:3	This study demonstrates that @CHEMICAL$ and clenbuterol stimulate @GENE$ levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.
724	CPRFalse	This study demonstrates that @CHEMICAL$ and clenbuterol stimulate NGF levels in vitro and that @GENE$ binding could be a commonality between the mechanism of NGF induction of these two compounds.
725	CPR:3	This study demonstrates that @CHEMICAL$ and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of @GENE$ induction of these two compounds.
726	CPR:3	This study demonstrates that CB1093 and @CHEMICAL$ stimulate @GENE$ levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.
727	CPRFalse	This study demonstrates that CB1093 and @CHEMICAL$ stimulate NGF levels in vitro and that @GENE$ binding could be a commonality between the mechanism of NGF induction of these two compounds.
728	CPR:3	This study demonstrates that CB1093 and @CHEMICAL$ stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of @GENE$ induction of these two compounds.
729	CPR:4	Protective effect of @CHEMICAL$ anesthesia on retinal light damage: inhibition of metabolic @GENE$ regeneration.
730	CPRFalse	PURPOSE: To determine whether the volatile anesthetic @CHEMICAL$ protects against light-induced @GENE$ degeneration in the rodent retina.
731	CPR:4	RESULTS: @CHEMICAL$ anesthesia reversibly inhibited metabolic @GENE$ regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.
732	CPR:4	RESULTS: @CHEMICAL$ anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented @GENE$ from absorbing high numbers of photons during light exposure.
733	CPRFalse	Consequently, @CHEMICAL$ of mice and rats anesthetized with @GENE$ were completely protected against degeneration induced by white light.
734	CPR:4	CONCLUSIONS: After the initial bleach, @CHEMICAL$ impeded photon absorption by rhodopsin by inhibiting metabolic @GENE$ regeneration.
735	CPRFalse	CONCLUSIONS: After the initial bleach, @CHEMICAL$ impeded photon absorption by @GENE$ by inhibiting metabolic rhodopsin regeneration.
736	CPRFalse	RATIONALE: A recent study suggested that selective @CHEMICAL$ reuptake inhibitors were inactive in 40-week-old male mice in the mouse forced swimming test, possibly because of alteration of @GENE$ receptors.
737	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@GENE$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
738	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [@GENE$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
739	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
740	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
741	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
742	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [@CHEMICAL$ (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
743	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@GENE$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
744	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@GENE$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
745	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
746	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
747	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
748	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (@CHEMICAL$), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
749	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @GENE$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
750	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @GENE$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
751	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
752	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
753	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
754	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), @CHEMICAL$ (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
755	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@GENE$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
756	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@GENE$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
757	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
758	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
759	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
760	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (@CHEMICAL$ reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
761	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @GENE$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
762	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @GENE$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
763	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
764	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
765	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
766	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), @CHEMICAL$ (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
767	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @GENE$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
768	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @GENE$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
769	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
770	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
771	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
772	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed @CHEMICAL$ and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
773	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @GENE$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
774	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @GENE$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
775	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
776	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
777	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
778	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and @CHEMICAL$ reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
779	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @GENE$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
780	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @GENE$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
781	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
782	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
783	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
784	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), @CHEMICAL$ and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
785	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @GENE$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
786	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @GENE$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
787	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
788	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
789	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
790	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and @CHEMICAL$ (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
791	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @GENE$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
792	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @GENE$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
793	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @GENE$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
794	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @GENE$ receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
795	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
796	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective @CHEMICAL$ reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
797	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
798	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
799	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @CHEMICAL$ and 5-HT1B receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
800	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @CHEMICAL$ receptor agonists [@GENE$ (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
801	CPR:5	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@CHEMICAL$ (partial @GENE$ agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.
802	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [@CHEMICAL$ (partial 5-HT1A agonist), anpirtoline (@GENE$ agonist)] in the mouse forced swimming test.
803	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of @CHEMICAL$ and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.
804	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and @CHEMICAL$ receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.
805	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with @CHEMICAL$ and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.
806	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and @CHEMICAL$ receptor agonists [buspirone (partial 5-HT1A agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.
807	CPRFalse	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial @CHEMICAL$ agonist), @GENE$ (5-HT1B agonist)] in the mouse forced swimming test.
808	CPR:5	OBJECTIVES: The present study was aimed at investigating the action of various antidepressant drugs in 4- and 40-week-old male mice using the mouse forced swimming test and determining the involvement of 5-HT1A and 5-HT1B receptors mediating the effects. METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), @CHEMICAL$ (@GENE$ agonist)] in the mouse forced swimming test.
809	CPRFalse	@CHEMICAL$, peroxisomal enzymes and @GENE$ cofactors in koala liver.
810	CPRFalse	We have examined hepatic levels of microsomal @CHEM-GENE$ activity and cyanide-insensitive palmitoyl coenzyme A oxidative activity in koala (Phascolarctos cinereus) and tammar wallaby (Macropus eugenii) and compared our results to those determined in rat.
811	CPRFalse	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the @CHEMICAL$ family led to the cloning of a partial, near full length, cDNA clone with approximately 70% nucleotide and deduced @GENE$ sequence identity to human CYP4A11.
812	CPRFalse	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the CYP4A family led to the cloning of a partial, near full length, cDNA clone with approximately 70% nucleotide and deduced @CHEMICAL$ sequence identity to @GENE$.
813	CPRFalse	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the @CHEMICAL$ family led to the cloning of a partial, near full length, cDNA clone with approximately 70% @GENE$ and deduced amino acid sequence identity to human CYP4A11.
814	CPRFalse	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the CYP4A family led to the cloning of a partial, near full length, cDNA clone with approximately 70% @CHEMICAL$ and deduced amino acid sequence identity to @GENE$.
815	CPR:4	@CHEMICAL$ (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.
816	CPR:4	@CHEMICAL$ (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @GENE$.
817	CPR:4	@CHEMICAL$ (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.
818	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @CHEM-GENE$, and glycinamide ribonucleotide formyl transferase.
819	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @CHEMICAL$ reductase, and @GENE$.
820	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$, @GENE$ reductase, and glycinamide ribonucleotide formyl transferase.
821	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @CHEMICAL$, and @GENE$ transferase.
822	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @CHEM-GENE$.
823	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$, dihydrofolate reductase, and @GENE$ transferase.
824	CPR:4	Pemetrexed disodium (@CHEMICAL$, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.
825	CPR:4	Pemetrexed disodium (@CHEMICAL$, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @GENE$.
826	CPR:4	Pemetrexed disodium (@CHEMICAL$, LY231514) is a novel, multitargeted antifolate that inhibits @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.
827	CPR:4	Pemetrexed disodium (Alimta, @CHEMICAL$) is a novel, multitargeted antifolate that inhibits thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.
828	CPR:4	Pemetrexed disodium (Alimta, @CHEMICAL$) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and @GENE$.
829	CPR:4	Pemetrexed disodium (Alimta, @CHEMICAL$) is a novel, multitargeted antifolate that inhibits @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.
830	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$ synthase, @GENE$, and glycinamide ribonucleotide formyl transferase.
831	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEMICAL$ synthase, dihydrofolate reductase, and @GENE$.
832	CPRFalse	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits @CHEM-GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.
833	CPR:3	To mechanistically evaluate this regional selectivity, we assessed @CHEMICAL$ (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and @GENE$-treated rats.
834	CPR:3	To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (@CHEMICAL$) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and @GENE$-treated rats.
835	CPRFalse	The striking distal predilection of @CHEMICAL$ may be, at least partially, explained by distal bowel over-expression of @GENE$ and PPAR-delta.
836	CPRFalse	The striking distal predilection of @CHEMICAL$ may be, at least partially, explained by distal bowel over-expression of COX-2 and @GENE$.
837	CPRFalse	Nuclear @CHEMICAL$ kinase-theta is activated in response to @GENE$.
838	CPRFalse	Nuclear @CHEM-GENE$ is activated in response to alpha-thrombin.
839	CPRFalse	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with @CHEMICAL$ leads to the production of two lipid second messengers in the nucleus: an increase in nuclear @GENE$ mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate phosphatidic acid.
840	CPRFalse	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with @CHEMICAL$ leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of @GENE$ to generate phosphatidic acid.
841	CPRFalse	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with @CHEMICAL$ leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate @GENE$.
842	CPRFalse	@CHEM-GENE$ (DGK) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component.
843	CPRFalse	@CHEMICAL$ kinase (@GENE$) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component.
844	CPR:9	@CHEMICAL$ (DGK) catalyzes the conversion of @GENE$ to phosphatidic acid, making it an attractive candidate for a signal transduction component.
845	CPR:9	Diacylglycerol kinase (@CHEMICAL$) catalyzes the conversion of @GENE$ to phosphatidic acid, making it an attractive candidate for a signal transduction component.
846	CPR:9	@CHEMICAL$ (DGK) catalyzes the conversion of diacylglycerol to @GENE$, making it an attractive candidate for a signal transduction component.
847	CPR:9	Diacylglycerol kinase (@CHEMICAL$) catalyzes the conversion of diacylglycerol to @GENE$, making it an attractive candidate for a signal transduction component.
848	CPR:4	We took advantage of the previous observations that @CHEMICAL$ inhibits @GENE$ (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol.
849	CPRFalse	Constitutively active @CHEMICAL$ inhibited the nuclear stimulated activity, whereas @GENE$ did not have an inhibitory effect.
850	CPR:4	@CHEMICAL$ (NDGA) has been shown to inhibit both 5-lipoxygenase and @GENE$ and is active against several cancer cell lines and at least one mouse tumor model.
851	CPR:4	@CHEMICAL$ (NDGA) has been shown to inhibit both @GENE$ and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.
852	CPR:4	Nordihydroguaiaretic acid (@CHEMICAL$) has been shown to inhibit both 5-lipoxygenase and @GENE$ and is active against several cancer cell lines and at least one mouse tumor model.
853	CPR:4	Nordihydroguaiaretic acid (@CHEMICAL$) has been shown to inhibit both @GENE$ and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.
854	CPRFalse	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and @CHEM-GENE$ and is active against several cancer cell lines and at least one mouse tumor model.
855	CPRFalse	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both @CHEMICAL$ and @GENE$ decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.
856	CPR:9	@CHEMICAL$ (CA) is a zinc enzyme that catalyses the reversible hydration reaction of @GENE$ and plays a major role in the acid-base balance.
857	CPR:9	Carbonic anhydrase (@CHEMICAL$) is a zinc enzyme that catalyses the reversible hydration reaction of @GENE$ and plays a major role in the acid-base balance.
858	CPRFalse	@CHEMICAL$ (CA) is a @GENE$ enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance.
859	CPRFalse	Carbonic anhydrase (@CHEMICAL$) is a @GENE$ enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance.
860	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
861	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
862	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
863	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, @CHEMICAL$, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
864	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEM-GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
865	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
866	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
867	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
868	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
869	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEM-GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
870	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
871	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
872	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, @GENE$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
873	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, @GENE$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
874	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, @CHEMICAL$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
875	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, @CHEMICAL$, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
876	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, @GENE$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
877	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, @GENE$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
878	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, @CHEMICAL$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
879	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, @CHEMICAL$, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
880	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, @GENE$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
881	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, @GENE$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
882	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, @CHEMICAL$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
883	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, @CHEMICAL$, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
884	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, @GENE$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
885	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, @GENE$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
886	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, @CHEMICAL$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
887	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, @CHEMICAL$, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
888	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, @GENE$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
889	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, @GENE$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
890	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, @CHEMICAL$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
891	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, @CHEMICAL$, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
892	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, @GENE$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
893	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, @GENE$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
894	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, @CHEMICAL$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
895	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, @CHEMICAL$, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
896	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @GENE$, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
897	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @GENE$, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
898	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @CHEMICAL$, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
899	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, @CHEMICAL$, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
900	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @GENE$, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
901	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @GENE$, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
902	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @CHEMICAL$, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
903	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, @CHEMICAL$, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
904	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @GENE$, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
905	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @GENE$, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
906	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @CHEMICAL$, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
907	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, @CHEMICAL$, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
908	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @GENE$ and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
909	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @GENE$ and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
910	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @CHEMICAL$ and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
911	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, @CHEMICAL$ and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
912	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @CHEMICAL$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @GENE$ on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
913	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @CHEMICAL$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @GENE$ on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
914	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @CHEMICAL$ on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
915	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and @CHEMICAL$ on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
916	CPRFalse	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
917	CPRFalse	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
918	CPRFalse	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
919	CPRFalse	We studied the in vitro effects of @CHEMICAL$, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
920	CPRFalse	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
921	CPRFalse	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
922	CPRFalse	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
923	CPRFalse	We studied the in vitro effects of noradrenaline, @CHEMICAL$, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
924	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, @GENE$, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
925	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, angiotensin II, @GENE$, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.
926	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified @GENE$ and vascular smooth muscle CA I isolated from rabbits.
927	CPRFalse	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, @CHEMICAL$, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle @GENE$ isolated from rabbits.
928	CPRFalse	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: @CHEMICAL$ (group 1), desmopressin (group 2), verapamil (group 3), irbesartan (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.
929	CPRFalse	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), @CHEMICAL$ (group 2), verapamil (group 3), irbesartan (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.
930	CPRFalse	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), desmopressin (group 2), @CHEMICAL$ (group 3), irbesartan (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.
931	CPRFalse	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), desmopressin (group 2), verapamil (group 3), @CHEMICAL$ (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.
932	CPRFalse	In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), desmopressin (group 2), verapamil (group 3), irbesartan (group 4), @CHEMICAL$ (group 5) and placebo (control group). Vascular smooth muscle @GENE$ activity and systolic blood pressure were determined and compared with those of the control group.
933	CPRFalse	Neuroparalysis and oxime efficacy in @CHEMICAL$ poisoning: a study of @GENE$.
934	CPRFalse	Neuroparalysis and @CHEMICAL$ efficacy in organophosphate poisoning: a study of @GENE$.
935	CPRFalse	The temporal profile of @CHEMICAL$ (BuChE) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 @GENE$-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.
936	CPRFalse	The temporal profile of butyrylcholinesterase (@CHEMICAL$) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 @GENE$-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.
937	CPRFalse	The temporal profile of butyrylcholinesterase (BuChE) and in vitro pralidoxime-reactivated @CHEMICAL$ was studied in a cohort of 25 @GENE$-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.
938	CPRFalse	The temporal profile of @CHEMICAL$ (BuChE) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of @GENE$ treatment.
939	CPRFalse	The temporal profile of butyrylcholinesterase (@CHEMICAL$) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of @GENE$ treatment.
940	CPRFalse	The temporal profile of butyrylcholinesterase (BuChE) and in vitro pralidoxime-reactivated @CHEMICAL$ was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of @GENE$ treatment.
941	CPRFalse	The temporal profile of @CHEMICAL$ (BuChE) and in vitro @GENE$-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.
942	CPRFalse	The temporal profile of butyrylcholinesterase (@CHEMICAL$) and in vitro @GENE$-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.
943	CPR:3	The temporal profile of butyrylcholinesterase (BuChE) and in vitro @CHEMICAL$-reactivated @GENE$ was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.
944	CPR:3	Reactivation potentials of @CHEMICAL$ (the difference between @GENE$-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.
945	CPR:4	Reactivation potentials of @CHEMICAL$ (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after @GENE$ ingestion.
946	CPR:4	Patients who received @CHEMICAL$ prior to hospitalization had a higher rate of intermediate syndrome and lower levels of @GENE$ at admission than those who had not.
947	CPRFalse	The study suggests that (i) @CHEMICAL$ reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BuChE; and (iii) the lack of @GENE$ efficacy in our patients maybe due to their severity of poisoning and the timing of oxime treatment.
948	CPRFalse	The study suggests that (i) BuChE reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of @CHEMICAL$; and (iii) the lack of @GENE$ efficacy in our patients maybe due to their severity of poisoning and the timing of oxime treatment.
949	CPRFalse	The study suggests that (i) @CHEMICAL$ reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BuChE; and (iii) the lack of oxime efficacy in our patients maybe due to their severity of poisoning and the timing of @GENE$ treatment.
950	CPRFalse	The study suggests that (i) BuChE reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of @CHEMICAL$; and (iii) the lack of oxime efficacy in our patients maybe due to their severity of poisoning and the timing of @GENE$ treatment.
951	CPRFalse	Potent @CHEMICAL$-mediated vasoconstriction by @GENE$ in porcine ciliary arteries.
952	CPR:5	The segments were contracted with the @CHEMICAL$ agonists @GENE$, apraclonidine, and oxymetazoline.
953	CPR:5	The segments were contracted with the @CHEMICAL$ agonists brimonidine, @GENE$, and oxymetazoline.
954	CPR:5	The segments were contracted with the @CHEMICAL$ agonists brimonidine, apraclonidine, and @GENE$.
955	CPRFalse	To determine which subtypes of the @CHEMICAL$ mediate this contraction, antagonists subselective for the different alpha(2)-adrenoceptors were added to the vessel bath before concentration-response curves for @GENE$ were obtained.
956	CPRFalse	To determine which subtypes of the alpha(2)-adrenoceptor mediate this contraction, antagonists subselective for the different @CHEMICAL$ were added to the vessel bath before concentration-response curves for @GENE$ were obtained.
957	CPRFalse	The following @CHEMICAL$ antagonists were applied: @GENE$ (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
958	CPR:6	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (@GENE$-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
959	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (@GENE$- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
960	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (alpha(2B)- and @GENE$-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
961	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (@GENE$- and alpha(2C)-selective).
962	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: @CHEMICAL$ (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and @GENE$-selective).
963	CPRFalse	The following @CHEMICAL$ antagonists were applied: BRL44408 (alpha(2A)-selective), @GENE$ (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
964	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (@CHEMICAL$-selective), @GENE$ (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
965	CPR:6	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (@GENE$- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
966	CPR:6	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (alpha(2B)- and @GENE$-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).
967	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (alpha(2B)- and alpha(2C)-selective), and prazosin (@GENE$- and alpha(2C)-selective).
968	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), @CHEMICAL$ (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and @GENE$-selective).
969	CPRFalse	The following @CHEMICAL$ antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).
970	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (@CHEMICAL$-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).
971	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (@CHEMICAL$- and alpha(2C)-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).
972	CPRFalse	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and @CHEMICAL$-selective), and @GENE$ (alpha(2B)- and alpha(2C)-selective).
973	CPR:6	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @CHEMICAL$ (@GENE$- and alpha(2C)-selective).
974	CPR:6	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and @CHEMICAL$ (alpha(2B)- and @GENE$-selective).
975	CPR:5	RESULTS: The @CHEMICAL$ agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: @GENE$ 2.11, oxymetazoline 5.26, and apraclonidine 13.0.
976	CPR:5	RESULTS: The @CHEMICAL$ agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, @GENE$ 5.26, and apraclonidine 13.0.
977	CPR:5	RESULTS: The @CHEMICAL$ agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and @GENE$ 13.0.
978	CPR:6	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for @CHEMICAL$ (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional @GENE$.
979	CPR:6	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), @CHEMICAL$ (5.8) and for prazosin (6.0) suggesting the presence of functional @GENE$.
980	CPR:6	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for @CHEMICAL$ (6.0) suggesting the presence of functional @GENE$.
981	CPRFalse	Schild analyses for the antagonists against @CHEMICAL$ yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional @GENE$.
982	CPR:5	CONCLUSIONS: The @CHEMICAL$ agonists @GENE$, apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.
983	CPR:5	CONCLUSIONS: The @CHEMICAL$ agonists brimonidine, @GENE$, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.
984	CPR:5	CONCLUSIONS: The @CHEMICAL$ agonists brimonidine, apraclonidine, and @GENE$ are potent vasoconstrictors in the porcine ciliary artery.
985	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three @CHEMICAL$-dependent enzymes, @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.
986	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three @CHEMICAL$-dependent enzymes, thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.
987	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three @CHEMICAL$-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @GENE$.
988	CPR:4	@CHEMICAL$ (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.
989	CPR:4	@CHEMICAL$ (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.
990	CPR:4	@CHEMICAL$ (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @GENE$.
991	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEM-GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.
992	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$ synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.
993	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$ synthase, dihydrofolate reductase, and @GENE$.
994	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$, @GENE$ reductase, and glycinamide ribonucleotide formyltransferase.
995	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @CHEM-GENE$, and glycinamide ribonucleotide formyltransferase.
996	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @CHEMICAL$ reductase, and @GENE$.
997	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @CHEMICAL$, dihydrofolate reductase, and @GENE$ formyltransferase.
998	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @CHEMICAL$, and @GENE$ formyltransferase.
999	CPRFalse	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @CHEM-GENE$.
1000	CPR:4	Pemetrexed disodium (@CHEMICAL$) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, @GENE$, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.
1001	CPR:4	Pemetrexed disodium (@CHEMICAL$) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, @GENE$, and glycinamide ribonucleotide formyltransferase.
1002	CPR:4	Pemetrexed disodium (@CHEMICAL$) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and @GENE$.
1003	CPRFalse	@CHEMICAL$ biosynthesis in plants: molecular and functional characterization of dihydrofolate synthetase and three isoforms of @GENE$ in Arabidopsis thaliana.
1004	CPRFalse	@CHEMICAL$ biosynthesis in plants: molecular and functional characterization of @GENE$ and three isoforms of folylpolyglutamate synthetase in Arabidopsis thaliana.
1005	CPRFalse	Tetrahydrofolate biosynthesis in plants: molecular and functional characterization of @CHEMICAL$ synthetase and three isoforms of @GENE$ in Arabidopsis thaliana.
1006	CPRFalse	Tetrahydrofolate biosynthesis in plants: molecular and functional characterization of @CHEM-GENE$ and three isoforms of folylpolyglutamate synthetase in Arabidopsis thaliana.
1007	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEM-GENE$ (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1008	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEMICAL$ synthetase (@GENE$) catalyze the attachment of glutamate residues to the folate molecule.
1009	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ (DHFS) and @GENE$ synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1010	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (@CHEMICAL$) and @GENE$ synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1011	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEMICAL$ (FPGS) catalyze the attachment of @GENE$ residues to the folate molecule.
1012	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (@CHEMICAL$) catalyze the attachment of @GENE$ residues to the folate molecule.
1013	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of @GENE$ residues to the folate molecule.
1014	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (@CHEMICAL$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of @GENE$ residues to the folate molecule.
1015	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and @CHEMICAL$ (FPGS) catalyze the attachment of glutamate residues to the @GENE$ molecule.
1016	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (@CHEMICAL$) catalyze the attachment of glutamate residues to the @GENE$ molecule.
1017	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the @GENE$ molecule.
1018	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (@CHEMICAL$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the @GENE$ molecule.
1019	CPRFalse	In organisms that synthesize @CHEMICAL$ de novo, dihydrofolate synthetase (DHFS) and @GENE$ (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1020	CPRFalse	In organisms that synthesize @CHEMICAL$ de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (@GENE$) catalyze the attachment of glutamate residues to the folate molecule.
1021	CPRFalse	In organisms that synthesize @CHEMICAL$ de novo, @GENE$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1022	CPRFalse	In organisms that synthesize @CHEMICAL$ de novo, dihydrofolate synthetase (@GENE$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1023	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ synthetase (DHFS) and @GENE$ (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1024	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ synthetase (DHFS) and folylpolyglutamate synthetase (@GENE$) catalyze the attachment of glutamate residues to the folate molecule.
1025	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, @CHEM-GENE$ (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1026	CPRFalse	In organisms that synthesize tetrahydrofolate de novo, @CHEMICAL$ synthetase (@GENE$) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.
1027	CPRFalse	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in @CHEMICAL$ or FPGS activity, and by measuring in vitro @GENE$ incorporation into dihydrofolate or tetrahydrofolate.
1028	CPRFalse	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or @CHEMICAL$ activity, and by measuring in vitro @GENE$ incorporation into dihydrofolate or tetrahydrofolate.
1029	CPRFalse	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in @CHEMICAL$ or FPGS activity, and by measuring in vitro glutamate incorporation into @GENE$ or tetrahydrofolate.
1030	CPRFalse	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or @CHEMICAL$ activity, and by measuring in vitro glutamate incorporation into @GENE$ or tetrahydrofolate.
1031	CPRFalse	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in @CHEMICAL$ or FPGS activity, and by measuring in vitro glutamate incorporation into dihydrofolate or @GENE$.
1032	CPRFalse	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or @CHEMICAL$ activity, and by measuring in vitro glutamate incorporation into dihydrofolate or @GENE$.
1033	CPR:9	@CHEMICAL$ is present exclusively in the mitochondria, making this compartment the sole site of synthesis of @GENE$ in the plant cell.
1034	CPRFalse	The compartmentation of FPGS isoforms is in agreement with the predominance of @CHEMICAL$ derivatives and the presence of @GENE$ and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.
1035	CPRFalse	The compartmentation of FPGS isoforms is in agreement with the predominance of @CHEMICAL$ derivatives and the presence of serine hydroxymethyltransferase and @GENE$ in the cytosol, the mitochondria, and the plastids.
1036	CPRFalse	The compartmentation of @CHEMICAL$ isoforms is in agreement with the predominance of @GENE$ derivatives and the presence of serine hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.
1037	CPRFalse	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @CHEM-GENE$ and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.
1038	CPRFalse	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @CHEMICAL$ hydroxymethyltransferase and @GENE$ in the cytosol, the mitochondria, and the plastids.
1039	CPRFalse	The compartmentation of @CHEMICAL$ isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @GENE$ hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.
1040	CPRFalse	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of @CHEMICAL$ and @GENE$ interconverting enzymes in the cytosol, the mitochondria, and the plastids.
1041	CPRFalse	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of serine hydroxymethyltransferase and @CHEM-GENE$ in the cytosol, the mitochondria, and the plastids.
1042	CPRFalse	The compartmentation of @CHEMICAL$ isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of serine hydroxymethyltransferase and @GENE$ interconverting enzymes in the cytosol, the mitochondria, and the plastids.
1043	CPRFalse	Thus, the combination of @CHEMICAL$ with these @GENE$-mediated reactions can supply each compartment with the polyglutamylated folate coenzymes required for the reactions of C1 metabolism.
1044	CPRFalse	Thus, the combination of @CHEMICAL$ with these folate-mediated reactions can supply each compartment with the polyglutamylated @GENE$ coenzymes required for the reactions of C1 metabolism.
1045	CPRFalse	Thus, the combination of @CHEMICAL$ with these folate-mediated reactions can supply each compartment with the polyglutamylated folate coenzymes required for the reactions of @GENE$ metabolism.
1046	CPRFalse	Also, the multicompartmentation of @CHEMICAL$ in the plant cell suggests that the transported forms of @GENE$ are unconjugated.
1047	CPR:4	UNLABELLED: @CHEMICAL$ is an inhibitor of the @GENE$.
1048	CPR:4	CONCLUSION: @CHEMICAL$ is a well tolerated @GENE$ inhibitor.
1049	CPRFalse	@CHEM-GENE$ suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
1050	CPRFalse	@CHEMICAL$ suppression in humans by the orally active @GENE$ inhibitor Aliskiren (SPP100): comparison with enalapril.
1051	CPRFalse	@CHEMICAL$ suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with @GENE$.
1052	CPRFalse	Angiotensin II suppression in humans by the orally active @CHEMICAL$ inhibitor Aliskiren (SPP100): comparison with @GENE$.
1053	CPR:4	@CHEMICAL$ suppression in humans by the orally active renin inhibitor @GENE$ (SPP100): comparison with enalapril.
1054	CPR:4	Angiotensin II suppression in humans by the orally active @CHEMICAL$ inhibitor @GENE$ (SPP100): comparison with enalapril.
1055	CPR:4	@CHEMICAL$ suppression in humans by the orally active renin inhibitor Aliskiren (@GENE$): comparison with enalapril.
1056	CPR:4	Angiotensin II suppression in humans by the orally active @CHEMICAL$ inhibitor Aliskiren (@GENE$): comparison with enalapril.
1057	CPRFalse	@CHEMICAL$ is the main determinant of @GENE$ levels.
1058	CPRFalse	Renin is the main determinant of @CHEM-GENE$ levels.
1059	CPRFalse	It, therefore, always appeared desirable to reduce @CHEM-GENE$ levels by direct inhibition of renin.
1060	CPRFalse	It, therefore, always appeared desirable to reduce @CHEMICAL$ levels by direct inhibition of @GENE$.
1061	CPR:4	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor @GENE$ (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.
1062	CPR:4	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor SPP100 (@GENE$, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.
1063	CPR:4	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor SPP100 (Aliskiren, an @GENE$ with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.
1064	CPRFalse	We tested the new orally active nonpeptidic @CHEMICAL$ inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d @GENE$ diet using a double-blind, 3-way crossover protocol.
1065	CPRFalse	There was a dose-dependent decrease in plasma @CHEMICAL$ activity, @GENE$, and Ang II following single doses of Aliskiren starting with 40 mg.
1066	CPRFalse	There was a dose-dependent decrease in plasma renin activity, @CHEM-GENE$, and Ang II following single doses of Aliskiren starting with 40 mg.
1067	CPRFalse	There was a dose-dependent decrease in plasma renin activity, @CHEMICAL$, and @GENE$ following single doses of Aliskiren starting with 40 mg.
1068	CPRFalse	There was a dose-dependent decrease in plasma @CHEMICAL$ activity, Ang I, and @GENE$ following single doses of Aliskiren starting with 40 mg.
1069	CPRFalse	There was a dose-dependent decrease in plasma renin activity, @CHEMICAL$, and @GENE$ following single doses of Aliskiren starting with 40 mg.
1070	CPRFalse	There was a dose-dependent decrease in plasma renin activity, Ang I, and @CHEM-GENE$ following single doses of Aliskiren starting with 40 mg.
1071	CPR:4	There was a dose-dependent decrease in plasma @CHEMICAL$ activity, Ang I, and Ang II following single doses of @GENE$ starting with 40 mg.
1072	CPR:4	There was a dose-dependent decrease in plasma renin activity, @CHEMICAL$, and Ang II following single doses of @GENE$ starting with 40 mg.
1073	CPR:4	There was a dose-dependent decrease in plasma renin activity, Ang I, and @CHEMICAL$ following single doses of @GENE$ starting with 40 mg.
1074	CPRFalse	Inhibition was still marked and significant after repeated dosing with maximal decreases in @CHEM-GENE$ levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.
1075	CPR:4	Inhibition was still marked and significant after repeated dosing with maximal decreases in @CHEMICAL$ levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of @GENE$ was compared with placebo.
1076	CPR:3	At the same time, mean plasma active @CHEMICAL$ was increased 16- and 34-fold at the highest dose of @GENE$.
1077	CPR:4	In conclusion, the @CHEMICAL$ inhibitor @GENE$ dose-dependently decreases Ang II levels in humans following oral administration.
1078	CPR:4	In conclusion, the renin inhibitor @CHEMICAL$ dose-dependently decreases @GENE$ levels in humans following oral administration.
1079	CPRFalse	In conclusion, the @CHEMICAL$ inhibitor Aliskiren dose-dependently decreases @GENE$ levels in humans following oral administration.
1080	CPRFalse	In conclusion, the renin inhibitor Aliskiren dose-dependently decreases @CHEM-GENE$ levels in humans following oral administration.
1081	CPR:6	@CHEMICAL$ has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and @GENE$ antagonists in therapy for hypertension and other cardiovascular and renal diseases.
1082	CPR:4	@CHEMICAL$ has the potential to become the first orally active @GENE$ inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.
1083	CPR:4	@CHEMICAL$ has the potential to become the first orally active renin inhibitor that provides a true alternative to @GENE$-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.
1084	CPRFalse	Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and @CHEM-GENE$ antagonists in therapy for hypertension and other cardiovascular and renal diseases.
1085	CPRFalse	Aliskiren has the potential to become the first orally active @CHEMICAL$ inhibitor that provides a true alternative to ACE-inhibitors and @GENE$ receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.
1086	CPRFalse	Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to @CHEMICAL$-inhibitors and @GENE$ receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.
1087	CPRFalse	Almost all patients with @CHEMICAL$ (38/41) or KIR6.2 (5/7) mutations were resistant to @GENE$.
1088	CPRFalse	Almost all patients with SUR1 (38/41) or @CHEMICAL$ (5/7) mutations were resistant to @GENE$.
1089	CPRFalse	Ten patients with hyperinsulinism-hyperammonaemia syndrome had a mutation in the @CHEM-GENE$ gene (three neonates and seven infants) after reverse transcriptase-polymerase chain reaction and sequence analysis of cDNA.
1090	CPR:4	The earliest known @CHEMICAL$ inhibitors, namely, @GENE$ and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).
1091	CPR:4	The earliest known @CHEMICAL$ inhibitors, namely, physostigmine and @GENE$, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).
1092	CPR:4	@CHEMICAL$ inaugurates a new class of @GENE$ inhibitors with longer and more selective action and with manageable adverse effects.
1093	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through @GENE$, but not CD2.
1094	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the @GENE$ that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1095	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact @GENE$ binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1096	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and @GENE$ to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1097	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase @GENE$ phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1098	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and @GENE$ and be mediated through CD16, but not CD2.
1099	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not @GENE$.
1100	CPRFalse	Experimentation using isoforms of @CHEMICAL$ engineered to have @GENE$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1101	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that @GENE$ mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1102	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing @GENE$ and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1103	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker @GENE$, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1104	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of @GENE$. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.
1105	CPRFalse	Experimentation using isoforms of alefacept engineered to have @CHEMICAL$ substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to @GENE$ and CD16 and be mediated through CD16, but not CD2.
1106	CPR:4	Thalidomide in multiple myeloma. @CHEMICAL$--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of @GENE$.
1107	CPRFalse	@CHEMICAL$ in multiple myeloma. Thalidomide--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of @GENE$.
1108	CPR:4	As a prodrug @CHEMICAL$ is completely converted to its active metabolite A 77 1726 (M1) which blocks the @GENE$, a key enzyme of the pyrimidine de novo synthesis.
1109	CPR:4	As a prodrug leflunomide is completely converted to its active metabolite @CHEMICAL$ (M1) which blocks the @GENE$, a key enzyme of the pyrimidine de novo synthesis.
1110	CPRFalse	As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the @CHEM-GENE$, a key enzyme of the pyrimidine de novo synthesis.
1111	CPRFalse	As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the @CHEMICAL$, a key enzyme of the @GENE$ de novo synthesis.
1112	CPRFalse	Endocrine therapy is first-line therapy for patients with @CHEM-GENE$-positive or progesterone receptor-positive metastatic breast cancer.
1113	CPRFalse	Endocrine therapy is first-line therapy for patients with @CHEMICAL$ receptor-positive or @GENE$-positive metastatic breast cancer.
1114	CPRFalse	Endocrine therapy is first-line therapy for patients with @CHEMICAL$-positive or @GENE$ receptor-positive metastatic breast cancer.
1115	CPRFalse	Endocrine therapy is first-line therapy for patients with estrogen receptor-positive or @CHEM-GENE$-positive metastatic breast cancer.
1116	CPRFalse	Commonly used endocrine therapies are @CHEMICAL$, megestrol acetate, and @GENE$ inhibitors.
1117	CPRFalse	Commonly used endocrine therapies are tamoxifen, @CHEMICAL$, and @GENE$ inhibitors.
1118	CPRFalse	The @CHEMICAL$ inhibitors are currently used as second-line therapy after @GENE$ failure.
1119	CPR:4	A recent study showed that @CHEMICAL$, an @GENE$ inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.
1120	CPRFalse	A recent study showed that anastrozole, an @CHEMICAL$ inhibitor, is as effective or even superior to @GENE$ when used as a first-line therapy.
1121	CPRFalse	A new class of drug, the @CHEM-GENE$ downregulators, has been developed.
1122	CPR:4	@CHEMICAL$, the first agent in this new class, not only induces the degradation of the @GENE$ but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.
1123	CPRFalse	Fulvestrant, the first agent in this new class, not only induces the degradation of the @CHEM-GENE$ but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.
1124	CPRFalse	Fulvestrant, the first agent in this new class, not only induces the degradation of the @CHEMICAL$ but also is an @GENE$ antagonist; further, its lack of agonist activity provides a better safety profile.
1125	CPRFalse	We recently identified @CHEM-GENE$, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of the head and neck squamous cell carcinomas (HNSCC) and cervical carcinomas (CC).
1126	CPRFalse	We recently identified @CHEM-GENE$, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of the head and neck squamous cell carcinomas (HNSCC) and cervical carcinomas (CC).
1127	CPR:4	@CHEMICAL$, a specific inhibitor of @GENE$, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.
1128	CPRFalse	Lovastatin, a specific inhibitor of @CHEM-GENE$, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.
1129	CPRFalse	These included @CHEM-GENE$/acyl-CoA-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1130	CPRFalse	These included @CHEMICAL$-binding inhibitor/@GENE$ the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1131	CPRFalse	These included @CHEMICAL$-binding inhibitor/acyl-CoA-binding protein, the @GENE$ and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1132	CPRFalse	These included @CHEMICAL$-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and @GENE$. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1133	CPRFalse	These included @CHEMICAL$/@GENE$-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1134	CPRFalse	These included diazepam-binding inhibitor/@CHEM-GENE$ the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1135	CPRFalse	These included diazepam-binding inhibitor/@CHEMICAL$-binding protein, the @GENE$ and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1136	CPRFalse	These included diazepam-binding inhibitor/@CHEMICAL$-binding protein, the activated transcription factor 4 and @GENE$. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1137	CPRFalse	These included @CHEMICAL$/acyl-CoA-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1138	CPRFalse	These included diazepam-binding inhibitor/@CHEMICAL$ the activated transcription factor 4 and rhoA. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1139	CPRFalse	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the @CHEMICAL$ and rhoA. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1140	CPRFalse	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and @CHEMICAL$. Because the biosynthesis of @GENE$ leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated.
1141	CPRFalse	These included @CHEMICAL$/acyl-CoA-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.
1142	CPRFalse	These included diazepam-binding inhibitor/@CHEMICAL$ the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.
1143	CPRFalse	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the @CHEMICAL$ and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.
1144	CPRFalse	These included diazepam-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and @CHEMICAL$. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in @GENE$-induced apoptosis was also evaluated.
1145	CPRFalse	Because @CHEMICAL$ requires @GENE$ for its function, this links the microarray and biochemical data and identifies rhoA as a potential mediator of the anticancer properties of lovastatin.
1146	CPRFalse	Because rhoA requires @CHEMICAL$ for its function, this links the microarray and biochemical data and identifies @GENE$ as a potential mediator of the anticancer properties of lovastatin.
1147	CPRFalse	Because @CHEMICAL$ requires GGPP for its function, this links the microarray and biochemical data and identifies rhoA as a potential mediator of the anticancer properties of @GENE$.
1148	CPRFalse	Because rhoA requires GGPP for its function, this links the microarray and biochemical data and identifies @CHEMICAL$ as a potential mediator of the anticancer properties of @GENE$.
1149	CPRFalse	Regulation of @CHEM-GENE$ abundance by catecholamines and desipramine in vivo.
1150	CPRFalse	Regulation of @CHEMICAL$ abundance by @GENE$ and desipramine in vivo.
1151	CPRFalse	Regulation of @CHEMICAL$ abundance by catecholamines and @GENE$ in vivo.
1152	CPRFalse	The norepinephrine transporter (NET) regulates @CHEMICAL$ signaling by controlling the availability of synaptic @GENE$ (NE), and it is a direct target for some classes of antidepressant drugs.
1153	CPRFalse	The norepinephrine transporter (@CHEMICAL$) regulates adrenoreceptor signaling by controlling the availability of synaptic @GENE$ (NE), and it is a direct target for some classes of antidepressant drugs.
1154	CPRFalse	The @CHEMICAL$ (NET) regulates adrenoreceptor signaling by controlling the availability of synaptic @GENE$ (NE), and it is a direct target for some classes of antidepressant drugs.
1155	CPRFalse	The norepinephrine transporter (NET) regulates @CHEMICAL$ signaling by controlling the availability of synaptic norepinephrine (@GENE$), and it is a direct target for some classes of antidepressant drugs.
1156	CPRFalse	The norepinephrine transporter (@CHEMICAL$) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (@GENE$), and it is a direct target for some classes of antidepressant drugs.
1157	CPRFalse	The @CHEMICAL$ (NET) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (@GENE$), and it is a direct target for some classes of antidepressant drugs.
1158	CPRFalse	The @CHEMICAL$ transporter (NET) regulates @GENE$ signaling by controlling the availability of synaptic norepinephrine (NE), and it is a direct target for some classes of antidepressant drugs.
1159	CPRFalse	The @CHEMICAL$ transporter (@GENE$) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (NE), and it is a direct target for some classes of antidepressant drugs.
1160	CPRFalse	The @CHEM-GENE$ (NET) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (NE), and it is a direct target for some classes of antidepressant drugs.
1161	CPRFalse	@CHEMICAL$ levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack @GENE$, demonstrating that the NET does not require endogenous NE for appropriate regulation under physiological conditions.
1162	CPRFalse	NET levels are normal in @CHEMICAL$ knockout (Dbh -/-) mice that lack @GENE$, demonstrating that the NET does not require endogenous NE for appropriate regulation under physiological conditions.
1163	CPRFalse	NET levels are normal in dopamine beta-hydroxylase knockout (@CHEMICAL$ -/-) mice that lack @GENE$, demonstrating that the NET does not require endogenous NE for appropriate regulation under physiological conditions.
1164	CPRFalse	NET levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack @CHEMICAL$, demonstrating that the @GENE$ does not require endogenous NE for appropriate regulation under physiological conditions.
1165	CPRFalse	@CHEMICAL$ levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack NE, demonstrating that the NET does not require endogenous @GENE$ for appropriate regulation under physiological conditions.
1166	CPRFalse	NET levels are normal in @CHEMICAL$ knockout (Dbh -/-) mice that lack NE, demonstrating that the NET does not require endogenous @GENE$ for appropriate regulation under physiological conditions.
1167	CPRFalse	NET levels are normal in dopamine beta-hydroxylase knockout (@CHEMICAL$ -/-) mice that lack NE, demonstrating that the NET does not require endogenous @GENE$ for appropriate regulation under physiological conditions.
1168	CPRFalse	NET levels are normal in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack NE, demonstrating that the @CHEMICAL$ does not require endogenous @GENE$ for appropriate regulation under physiological conditions.
1169	CPRFalse	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not @GENE$ per se.
1170	CPRFalse	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not @GENE$ per se.
1171	CPRFalse	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of @CHEMICAL$, suggesting that it is down-regulated by a complete absence of catecholamines and not @GENE$ per se.
1172	CPRFalse	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both @GENE$ and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1173	CPRFalse	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both @GENE$ and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1174	CPRFalse	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both @CHEMICAL$ and dopamine (DA) have reduced levels of @GENE$, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1175	CPRFalse	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and @GENE$ (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1176	CPRFalse	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and @GENE$ (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1177	CPRFalse	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and @CHEMICAL$ (DA) have reduced levels of @GENE$, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1178	CPRFalse	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and dopamine (@GENE$) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1179	CPRFalse	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and dopamine (@GENE$) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1180	CPRFalse	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (@CHEMICAL$) have reduced levels of @GENE$, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.
1181	CPRFalse	In contrast, @CHEMICAL$ knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of @GENE$ and not NE per se.
1182	CPRFalse	In contrast, tyrosine hydroxylase knockout (@CHEMICAL$ -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of @GENE$ and not NE per se.
1183	CPRFalse	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of @CHEMICAL$, suggesting that it is down-regulated by a complete absence of @GENE$ and not NE per se.
1184	CPR:4	Chronic treatment with the @CHEMICAL$ inhibitor, @GENE$ (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.
1185	CPR:4	Chronic treatment with the NET inhibitor, @CHEMICAL$ (DMI), reduced @GENE$ levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.
1186	CPRFalse	Chronic treatment with the NET inhibitor, @CHEMICAL$ (DMI), reduced NET levels in both control and @GENE$ -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.
1187	CPRFalse	Chronic treatment with the NET inhibitor, @CHEMICAL$ (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of @GENE$ by antidepressant drugs.
1188	CPRFalse	Chronic treatment with the @CHEMICAL$ inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that @GENE$ is not required for the regulation of NET by antidepressant drugs.
1189	CPRFalse	Chronic treatment with the NET inhibitor, desipramine (DMI), reduced @CHEMICAL$ levels in both control and Dbh -/- mice, demonstrating that @GENE$ is not required for the regulation of NET by antidepressant drugs.
1190	CPRFalse	Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and @CHEMICAL$ -/- mice, demonstrating that @GENE$ is not required for the regulation of NET by antidepressant drugs.
1191	CPRFalse	Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that @CHEMICAL$ is not required for the regulation of @GENE$ by antidepressant drugs.
1192	CPRFalse	@CHEM-GENE$ regulation of spinal norepinephrine release.
1193	CPRFalse	@CHEMICAL$ regulation of spinal @GENE$ release.
1194	CPRFalse	BACKGROUND: @CHEM-GENE$ (nAChR) agonists produce antinociception in animals.
1195	CPRFalse	BACKGROUND: Neuronal nicotinic @CHEMICAL$ receptor (@GENE$) agonists produce antinociception in animals.
1196	CPRFalse	This study tested whether @CHEMICAL$ agonists stimulate spinal release of the neurotransmitter @GENE$ either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce norepinephrine release.
1197	CPRFalse	This study tested whether @CHEMICAL$ agonists stimulate spinal release of the neurotransmitter norepinephrine either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce @GENE$ release.
1198	CPRFalse	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist @CHEMICAL$, or nicotine plus @GENE$ antagonists and norepinephrine measured in the microdialysates.
1199	CPR:5	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific @CHEMICAL$ agonist @GENE$, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.
1200	CPRFalse	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine, or @CHEMICAL$ plus @GENE$ antagonists and norepinephrine measured in the microdialysates.
1201	CPR:5	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific @CHEMICAL$ agonist metanicotine, or @GENE$ plus nAChR antagonists and norepinephrine measured in the microdialysates.
1202	CPRFalse	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine, or nicotine plus @CHEMICAL$ antagonists and @GENE$ measured in the microdialysates.
1203	CPRFalse	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific @CHEMICAL$ agonist metanicotine, or nicotine plus nAChR antagonists and @GENE$ measured in the microdialysates.
1204	CPRFalse	The effects of specific @CHEM-GENE$ antagonists and nitric oxide synthase inhibitors were also examined.
1205	CPRFalse	The effects of specific @CHEMICAL$ receptor antagonists and @GENE$ inhibitors were also examined.
1206	CPRFalse	The effects of specific @CHEMICAL$ antagonists and @GENE$ synthase inhibitors were also examined.
1207	CPRFalse	The effects of specific glutamate receptor antagonists and @CHEM-GENE$ inhibitors were also examined.
1208	CPRFalse	RESULTS: Both @CHEMICAL$ and metanicotine induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @GENE$ inhibitors.
1209	CPRFalse	RESULTS: Both nicotine and @CHEMICAL$ induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @GENE$ inhibitors.
1210	CPRFalse	RESULTS: Both nicotine and metanicotine induced @CHEMICAL$ release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @GENE$ inhibitors.
1211	CPRFalse	RESULTS: Both nicotine and metanicotine induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not @CHEMICAL$ antagonists or @GENE$ inhibitors.
1212	CPRFalse	RESULTS: Both nicotine and metanicotine induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or @CHEM-GENE$ inhibitors.
1213	CPRFalse	Both of the nicotinic agonists stimulated @CHEMICAL$ release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of alpha(4)beta(2*)- than alpha(7*)-preferring @GENE$ antagonists.
1214	CPRFalse	Both of the nicotinic agonists stimulated @CHEMICAL$ release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of @GENE$- than alpha(7*)-preferring nAChR antagonists.
1215	CPRFalse	Both of the nicotinic agonists stimulated @CHEMICAL$ release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of alpha(4)beta(2*)- than @GENE$-preferring nAChR antagonists.
1216	CPRFalse	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of @CHEMICAL$ was blocked at lower concentrations of alpha(4)beta(2*)- than alpha(7*)-preferring @GENE$ antagonists.
1217	CPRFalse	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of @CHEMICAL$ was blocked at lower concentrations of @GENE$- than alpha(7*)-preferring nAChR antagonists.
1218	CPRFalse	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of @CHEMICAL$ was blocked at lower concentrations of alpha(4)beta(2*)- than @GENE$-preferring nAChR antagonists.
1219	CPRFalse	CONCLUSION: These results suggest that one mechanism by which @CHEMICAL$ agonists act for analgesia is to stimulate spinal @GENE$ release.
1220	CPRFalse	They do so by actions on @CHEMICAL$, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating norepinephrine release through @GENE$ release or nitric oxide synthesis.
1221	CPRFalse	They do so by actions on @CHEMICAL$, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating norepinephrine release through glutamate release or @GENE$ synthesis.
1222	CPRFalse	They do so by actions on @CHEMICAL$, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating @GENE$ release through glutamate release or nitric oxide synthesis.
1223	CPRFalse	In addition, there is inhibition of @CHEMICAL$ uptake, eventually resulting in changes in cAMP levels, dependent on the type of @GENE$.
1224	CPRFalse	In addition, there is inhibition of adenosine uptake, eventually resulting in changes in @CHEMICAL$ levels, dependent on the type of @GENE$.
1225	CPRFalse	In addition, there is inhibition of adenosine uptake, eventually resulting in changes in cAMP levels, dependent on the type of @CHEM-GENE$.
1226	CPR:3	@CHEMICAL$ decreases levels of serum triglycerides and causes some increase in @GENE$-cholesterol levels.
1227	CPRFalse	Cilostazol decreases levels of serum triglycerides and causes some increase in @CHEMICAL$-@GENE$ levels.
1228	CPR:9	@CHEMICAL$ undergoes intensive and finally complete hepatic metabolism via the @GENE$ systems.
1229	CPRFalse	Identification of interaction sites of cyclic nucleotide @CHEMICAL$ with milrinone and @GENE$ using molecular modeling and site-directed mutagenesis.
1230	CPRFalse	Identification of interaction sites of cyclic @CHEMICAL$ @GENE$ with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.
1231	CPRFalse	Identification of interaction sites of cyclic nucleotide @CHEMICAL$ with @GENE$ and cilostazol using molecular modeling and site-directed mutagenesis.
1232	CPRFalse	To identify @CHEMICAL$ residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of @GENE$ using a model created on basis of homology to the PDE4B crystal structure.
1233	CPRFalse	To identify @CHEMICAL$ residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the @GENE$ crystal structure.
1234	CPRFalse	To identify @CHEMICAL$ residues involved in @GENE$-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the PDE4B crystal structure.
1235	CPRFalse	We changed the residues to @CHEMICAL$ using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of @GENE$.
1236	CPR:4	We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by @CHEMICAL$ and cilostazol, specific inhibitors of @GENE$.
1237	CPR:4	We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and @CHEMICAL$, specific inhibitors of @GENE$.
1238	CPR:4	Mutants @CHEMICAL$, D950A, and F1004A had reduced sensitivity to @GENE$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1239	CPR:4	Mutants Y751A, @CHEMICAL$, and F1004A had reduced sensitivity to @GENE$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1240	CPR:4	Mutants Y751A, D950A, and @CHEMICAL$ had reduced sensitivity to @GENE$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1241	CPR:4	Mutants Y751A, D950A, and F1004A had reduced sensitivity to @CHEMICAL$ (K(i) changed from 0.66 microM for the recombinant @GENE$ to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1242	CPRFalse	Mutants Y751A, D950A, and F1004A had reduced sensitivity to @CHEMICAL$ (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant @GENE$).
1243	CPRFalse	Mutants @CHEMICAL$, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1244	CPRFalse	Mutants Y751A, @CHEMICAL$, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1245	CPRFalse	Mutants Y751A, D950A, and @CHEMICAL$ had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1246	CPRFalse	Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant @CHEMICAL$ to 7.5 to 156 microM for the mutants), and diminished sensitivity to @GENE$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).
1247	CPR:4	Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to @CHEMICAL$ (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant @GENE$).
1248	CPR:4	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for @GENE$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1249	CPR:4	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for @GENE$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1250	CPR:4	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for @GENE$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1251	CPR:4	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for @CHEMICAL$ but no difference for milrinone from the recombinant @GENE$. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1252	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for @CHEMICAL$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the @GENE$ inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1253	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for @CHEMICAL$ but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.
1254	CPR:4	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for cilostazol but no difference for @GENE$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1255	CPR:4	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for cilostazol but no difference for @GENE$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1256	CPR:4	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for cilostazol but no difference for @GENE$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1257	CPR:4	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for @CHEMICAL$ from the recombinant @GENE$. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1258	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for @CHEMICAL$ from the recombinant PDE3A. Molecular models show that the @GENE$ inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1259	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for @CHEMICAL$ from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.
1260	CPRFalse	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1261	CPRFalse	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1262	CPRFalse	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1263	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant @CHEMICAL$. Molecular models show that the PDE3 inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1264	CPR:4	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the @CHEMICAL$ inhibitors @GENE$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1265	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors @CHEMICAL$ and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.
1266	CPRFalse	In contrast, the mutants @CHEMICAL$, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1267	CPRFalse	In contrast, the mutants T844A, @CHEMICAL$ and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1268	CPRFalse	In contrast, the mutants T844A, F972A and @CHEMICAL$ showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1269	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant @CHEMICAL$. Molecular models show that the PDE3 inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1270	CPR:4	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the @CHEMICAL$ inhibitors cilostazol and @GENE$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.
1271	CPRFalse	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and @CHEMICAL$ share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against @GENE$ active site.
1272	CPR:4	Our study implies that highly conserved residuals Y751, D950 and F1004 in the @CHEMICAL$ families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the @GENE$ selectivity of PDE3A. Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.
1273	CPR:4	Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the @CHEMICAL$ selectivity of @GENE$. Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.
1274	CPR:9	The bacterial enzyme @CHEMICAL$ (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as @GENE$ (Glc1P).
1275	CPR:9	The bacterial enzyme maltodextrin phosphorylase (@CHEMICAL$) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as @GENE$ (Glc1P).
1276	CPR:9	The bacterial enzyme @CHEMICAL$ (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (@GENE$).
1277	CPR:9	The bacterial enzyme maltodextrin phosphorylase (@CHEMICAL$) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (@GENE$).
1278	CPRFalse	The bacterial enzyme @CHEMICAL$ (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing @GENE$ residues of linear oligosaccharides as glucose-1-phosphate (Glc1P).
1279	CPRFalse	The bacterial enzyme maltodextrin phosphorylase (@CHEMICAL$) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing @GENE$ residues of linear oligosaccharides as glucose-1-phosphate (Glc1P).
1280	CPRFalse	The 2.0A crystal structure of the MalP/@CHEMICAL$ binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @GENE$, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.
1281	CPRFalse	The 2.0A crystal structure of the @CHEMICAL$/@GENE$ binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.
1282	CPRFalse	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the @CHEMICAL$ substrate adopts a conformation seen previously with both inactive and active forms of @GENE$, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.
1283	CPRFalse	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the @GENE$ substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.
1284	CPRFalse	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the @GENE$ group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.
1285	CPRFalse	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the @GENE$ group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.
1286	CPRFalse	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the phosphate group not in close contact with the @GENE$ group of the essential pyridoxal phosphate (PLP) cofactor.
1287	CPRFalse	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the @GENE$ group of the essential pyridoxal phosphate (PLP) cofactor.
1288	CPRFalse	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the phosphate group not in close contact with the 5'-phosphate group of the essential @GENE$ (PLP) cofactor.
1289	CPRFalse	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential @GENE$ (PLP) cofactor.
1290	CPRFalse	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of @CHEMICAL$, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (@GENE$) cofactor.
1291	CPRFalse	The 2.0A crystal structure of the @CHEMICAL$/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (@GENE$) cofactor.
1292	CPRFalse	In the active @CHEMICAL$ enzyme, the residue Arg569 stabilizes the negative-charged @GENE$, whereas in the inactive form of GP this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.
1293	CPRFalse	In the active MalP enzyme, the residue Arg569 stabilizes the negative-charged @CHEMICAL$, whereas in the inactive form of @GENE$ this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.
1294	CPRFalse	The comparison between @CHEMICAL$ structures shows that His377, through a hydrogen bond with the @GENE$ group of Glc1P substrate, triggers a conformational change of the 380s loop.
1295	CPRFalse	The comparison between @CHEMICAL$ structures shows that His377, through a hydrogen bond with the 6-hydroxyl group of @GENE$ substrate, triggers a conformational change of the 380s loop.
1296	CPRFalse	The structures solved after the diffusion of oligosaccharides (either @CHEMICAL$, G4 or maltopentaose, G5) into @GENE$/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.
1297	CPRFalse	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or @CHEMICAL$, G5) into @GENE$/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.
1298	CPRFalse	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into @CHEMICAL$/@GENE$ crystals show the formation of phosphate and elongation of the oligosaccharide chain.
1299	CPRFalse	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into @CHEMICAL$/Glc1P crystals show the formation of @GENE$ and elongation of the oligosaccharide chain.
1300	CPRFalse	The relatively large oligosaccharide substrates can diffuse quickly into the @CHEMICAL$/@GENE$ crystals and the enzymatic reaction can occur without significant crystal damage.
1301	CPRFalse	OBJECTIVE: @CHEMICAL$ is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to @GENE$.
1302	CPR:4	OBJECTIVE: @CHEMICAL$ is the first in a new class of synthetic @GENE$ inhibitors that binds reversibly with high affinity to antithrombin III.
1303	CPRFalse	Molecular analysis of @CHEMICAL$ gene in Korean patients with @GENE$ acidemia.
1304	CPRFalse	It is caused by a deficiency of @CHEM-GENE$ (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1305	CPRFalse	It is caused by a deficiency of @CHEMICAL$ carboxylase (@GENE$, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1306	CPRFalse	It is caused by a deficiency of @CHEMICAL$ carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1307	CPRFalse	It is caused by a deficiency of @CHEMICAL$ carboxylase (PCC, @GENE$), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1308	CPRFalse	It is caused by a deficiency of @CHEMICAL$ (PCC, EC 6.4.1.3), a @GENE$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1309	CPRFalse	It is caused by a deficiency of propionyl-CoA carboxylase (@CHEMICAL$, EC 6.4.1.3), a @GENE$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1310	CPRFalse	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a @CHEMICAL$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1311	CPRFalse	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, @CHEMICAL$), a @GENE$-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1312	CPR:9	It is caused by a deficiency of @CHEMICAL$ (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of @GENE$ to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1313	CPR:9	It is caused by a deficiency of propionyl-CoA carboxylase (@CHEMICAL$, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of @GENE$ to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1314	CPRFalse	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of @CHEMICAL$ to D-methylmalonyl-CoA. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1315	CPR:9	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, @CHEMICAL$), a biotin-dependent enzyme that catalyzes the carboxylation of @GENE$ to D-methylmalonyl-CoA. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1316	CPR:9	It is caused by a deficiency of @CHEMICAL$ (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @GENE$. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1317	CPR:9	It is caused by a deficiency of propionyl-CoA carboxylase (@CHEMICAL$, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @GENE$. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1318	CPRFalse	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @CHEMICAL$. @GENE$ is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1319	CPR:9	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, @CHEMICAL$), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to @GENE$. PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.
1320	CPRFalse	Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and @CHEMICAL$ release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.
1321	CPRFalse	Atypical antipsychotic drugs, @CHEMICAL$, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.
1322	CPRFalse	Atypical antipsychotic drugs, quetiapine, @CHEMICAL$, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.
1323	CPRFalse	Atypical antipsychotic drugs, quetiapine, iloperidone, and @CHEMICAL$, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.
1324	CPRFalse	Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase @CHEMICAL$ and acetylcholine release in rat medial prefrontal cortex: role of @GENE$ receptor agonism.
1325	CPR:5	Although only @CHEMICAL$ and ziprasidone are directly acting @GENE$ agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.
1326	CPRFalse	Although only @CHEMICAL$ and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective @GENE$ antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.
1327	CPR:4	Although only @CHEMICAL$ and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined @GENE$ and D(2) blockade.
1328	CPR:4	Although only @CHEMICAL$ and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and @GENE$ blockade.
1329	CPR:5	Although only clozapine and @CHEMICAL$ are directly acting @GENE$ agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.
1330	CPRFalse	Although only clozapine and @CHEMICAL$ are directly acting 5-HT(1A) agonists, WAY100635, a selective @GENE$ antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.
1331	CPR:4	Although only clozapine and @CHEMICAL$ are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined @GENE$ and D(2) blockade.
1332	CPR:4	Although only clozapine and @CHEMICAL$ are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and @GENE$ blockade.
1333	CPRFalse	Although only clozapine and ziprasidone are directly acting @CHEMICAL$ agonists, @GENE$, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.
1334	CPR:6	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, @CHEMICAL$, a selective @GENE$ antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.
1335	CPR:4	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, @CHEMICAL$, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined @GENE$ and D(2) blockade.
1336	CPR:4	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, @CHEMICAL$, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and @GENE$ blockade.
1337	CPRFalse	Although only clozapine and ziprasidone are directly acting @CHEMICAL$ agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical @GENE$ release that may be due to combined 5-HT(2A) and D(2) blockade.
1338	CPRFalse	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective @CHEMICAL$ antagonist, partially attenuates these atypical APD-induced increases in cortical @GENE$ release that may be due to combined 5-HT(2A) and D(2) blockade.
1339	CPRFalse	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical @CHEMICAL$ release that may be due to combined @GENE$ and D(2) blockade.
1340	CPRFalse	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical @CHEMICAL$ release that may be due to combined 5-HT(2A) and @GENE$ blockade.
1341	CPRFalse	The present study determined whether @CHEMICAL$, iloperidone and melperone, @GENE$/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1342	CPRFalse	The present study determined whether @CHEMICAL$, iloperidone and melperone, 5-HT(2A)/@GENE$ antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1343	CPRFalse	The present study determined whether @CHEMICAL$, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to @GENE$ agonism.
1344	CPRFalse	The present study determined whether quetiapine, @CHEMICAL$ and melperone, @GENE$/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1345	CPRFalse	The present study determined whether quetiapine, @CHEMICAL$ and melperone, 5-HT(2A)/@GENE$ antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1346	CPRFalse	The present study determined whether quetiapine, @CHEMICAL$ and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to @GENE$ agonism.
1347	CPRFalse	The present study determined whether quetiapine, iloperidone and @CHEMICAL$, @GENE$/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1348	CPRFalse	The present study determined whether quetiapine, iloperidone and @CHEMICAL$, 5-HT(2A)/@GENE$ antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1349	CPRFalse	The present study determined whether quetiapine, iloperidone and @CHEMICAL$, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to @GENE$ agonism.
1350	CPRFalse	The present study determined whether quetiapine, iloperidone and melperone, @CHEMICAL$/D(2) antagonist atypical APDs, also increase cortical @GENE$ and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1351	CPRFalse	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/@CHEMICAL$ antagonist atypical APDs, also increase cortical @GENE$ and ACh release, and whether these effects are related to 5-HT(1A) agonism.
1352	CPRFalse	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical @CHEMICAL$ and ACh release, and whether these effects are related to @GENE$ agonism.
1353	CPRFalse	The present study determined whether quetiapine, iloperidone and melperone, @CHEMICAL$/D(2) antagonist atypical APDs, also increase cortical DA and @GENE$ release, and whether these effects are related to 5-HT(1A) agonism.
1354	CPRFalse	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/@CHEMICAL$ antagonist atypical APDs, also increase cortical DA and @GENE$ release, and whether these effects are related to 5-HT(1A) agonism.
1355	CPRFalse	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and @CHEMICAL$ release, and whether these effects are related to @GENE$ agonism.
1356	CPRFalse	These results indicate that @CHEMICAL$, iloperidone and melperone preferentially increase DA release in the mPFC, compared to the NAC via a @GENE$-related mechanism.
1357	CPRFalse	These results indicate that quetiapine, @CHEMICAL$ and melperone preferentially increase DA release in the mPFC, compared to the NAC via a @GENE$-related mechanism.
1358	CPRFalse	These results indicate that quetiapine, iloperidone and @CHEMICAL$ preferentially increase DA release in the mPFC, compared to the NAC via a @GENE$-related mechanism.
1359	CPRFalse	These results indicate that quetiapine, iloperidone and melperone preferentially increase @CHEMICAL$ release in the mPFC, compared to the NAC via a @GENE$-related mechanism.
1360	CPR:5	However, @CHEMICAL$ agonism may be important only for @GENE$-induced ACh release.
1361	CPRFalse	However, @CHEMICAL$ agonism may be important only for quetiapine-induced @GENE$ release.
1362	CPRFalse	BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current @CHEMICAL$ channel opener for @GENE$ and KCNQ3/5 channels.
1363	CPRFalse	BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current @CHEMICAL$ channel opener for KCNQ2/3 and @GENE$ channels.
1364	CPRFalse	BACKGROUND: The novel antiepileptic drug retigabine is the first selective @CHEM-GENE$ opener for KCNQ2/3 and KCNQ3/5 channels.
1365	CPR:3	BACKGROUND: The novel antiepileptic drug @CHEMICAL$ is the first selective M-current potassium channel opener for @GENE$ and KCNQ3/5 channels.
1366	CPR:3	BACKGROUND: The novel antiepileptic drug @CHEMICAL$ is the first selective M-current potassium channel opener for KCNQ2/3 and @GENE$ channels.
1367	CPR:3	BACKGROUND: The novel antiepileptic drug @CHEMICAL$ is the first selective @GENE$ opener for KCNQ2/3 and KCNQ3/5 channels.
1368	CPR:4	OBJECTIVE: Because of these physiological effects and the widespread use of the selective @CHEMICAL$ inhibitor, @GENE$, we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing.
1369	CPRFalse	OBJECTIVE: Because of these physiological effects and the widespread use of the selective COX-2 inhibitor, @CHEMICAL$, we wanted to determine if inhibition of @GENE$ would affect incisional skin wound healing.
1370	CPR:4	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective @CHEMICAL$ inhibitor, @GENE$, with a selective COX-2 inhibitor, SC-791.
1371	CPRFalse	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of @CHEMICAL$ in the wound healing process by comparing the effects of a nonselective COX inhibitor, @GENE$, with a selective COX-2 inhibitor, SC-791.
1372	CPRFalse	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective COX inhibitor, @CHEMICAL$, with a selective @GENE$ inhibitor, SC-791.
1373	CPRFalse	Neither selective COX-2, nor nonselective @CHEMICAL$ inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas @GENE$ treatment resulted in epidermal and granulation tissue atrophy.
1374	CPRFalse	Neither selective @CHEMICAL$, nor nonselective COX inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas @GENE$ treatment resulted in epidermal and granulation tissue atrophy.
1375	CPRFalse	In addition, neither selective COX-2, nor nonselective @CHEMICAL$ inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas @GENE$ reduced the tensile strength of the wounds by 30-38% throughout the healing period.
1376	CPRFalse	In addition, neither selective @CHEMICAL$, nor nonselective COX inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas @GENE$ reduced the tensile strength of the wounds by 30-38% throughout the healing period.
1377	CPRFalse	Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the @CHEM-GENE$.
1378	CPRFalse	These radiotracers are close analogues of reboxetine, a potent and selective ligand for the @CHEM-GENE$ (NET).
1379	CPRFalse	These radiotracers are close analogues of reboxetine, a potent and selective ligand for the @CHEMICAL$ transporter (@GENE$).
1380	CPRFalse	These radiotracers are close analogues of @CHEMICAL$, a potent and selective ligand for the @GENE$ (NET).
1381	CPRFalse	These radiotracers are close analogues of @CHEMICAL$, a potent and selective ligand for the norepinephrine transporter (@GENE$).
1382	CPRFalse	In vitro autoradiography studies (rat brain slices) with @CHEMICAL$ produced a regional distribution pattern that was consistent with the reported distribution of @GENE$.
1383	CPRFalse	@CHEMICAL$ has the potential to be the first successful PET ligand to image @GENE$.
1384	CPRFalse	@CHEM-GENE$ antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
1385	CPRFalse	@CHEMICAL$ antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of @GENE$ and reduced haloperidol.
1386	CPRFalse	@CHEMICAL$ antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced @GENE$.
1387	CPR:6	@CHEMICAL$ antagonists, @GENE$ and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
1388	CPR:6	@CHEMICAL$ antagonists, promethazine and @GENE$, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
1389	CPRFalse	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @CHEMICAL$, on the steady-state plasma concentrations (Css) of @GENE$ and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1390	CPRFalse	The effects of @CHEMICAL$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of @GENE$ and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1391	CPRFalse	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @CHEMICAL$, on the steady-state plasma concentrations (Css) of haloperidol and reduced @GENE$ were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1392	CPRFalse	The effects of @CHEMICAL$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced @GENE$ were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1393	CPRFalse	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @CHEMICAL$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving @GENE$, 12 to 36 mg/d, for 2 to 29 weeks.
1394	CPRFalse	The effects of @CHEMICAL$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving @GENE$, 12 to 36 mg/d, for 2 to 29 weeks.
1395	CPR:4	The effects of histamine H1-receptor antagonists, @CHEMICAL$ and homochlorcyclizine, both of which are inhibitors of @GENE$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1396	CPR:6	The effects of @CHEMICAL$ antagonists, @GENE$ and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1397	CPR:4	The effects of histamine H1-receptor antagonists, promethazine and @CHEMICAL$, both of which are inhibitors of @GENE$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1398	CPR:6	The effects of @CHEMICAL$ antagonists, promethazine and @GENE$, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1399	CPRFalse	The effects of @CHEMICAL$ H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of @GENE$, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1400	CPRFalse	The effects of @CHEM-GENE$ antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.
1401	CPR:9	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @CHEMICAL$-catalyzed metabolism of haloperidol and reduced @GENE$.
1402	CPR:4	Thus, the current study suggests that coadministration of clinical doses of @CHEMICAL$ and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.
1403	CPR:4	Thus, the current study suggests that coadministration of clinical doses of promethazine and @CHEMICAL$ increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.
1404	CPRFalse	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of @CHEMICAL$ and reduced haloperidol via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.
1405	CPRFalse	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced @CHEMICAL$ via the inhibitory effects on the @GENE$-catalyzed metabolism of haloperidol and reduced haloperidol.
1406	CPR:9	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the @CHEMICAL$-catalyzed metabolism of @GENE$ and reduced haloperidol.
1407	CPRFalse	@CHEMICAL$ regulation, an enzyme-enzyme activity control: identification of residues of @GENE$ carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities.
1408	CPRFalse	Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of @CHEMICAL$ carbamoyltransferase and @GENE$ responsible for enzyme catalytic and regulatory activities.
1409	CPRFalse	Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of @CHEM-GENE$ and arginase responsible for enzyme catalytic and regulatory activities.
1410	CPRFalse	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of @GENE$ is inhibited whereas arginase remains catalytically active.
1411	CPRFalse	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas @GENE$ remains catalytically active.
1412	CPRFalse	In the presence of @CHEMICAL$ and arginine, @GENE$ (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1413	CPRFalse	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (@GENE$) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1414	CPRFalse	In the presence of @CHEMICAL$ and arginine, ornithine carbamoyltransferase (OTCase) and @GENE$ form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1415	CPRFalse	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of @GENE$ is inhibited whereas arginase remains catalytically active.
1416	CPRFalse	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas @GENE$ remains catalytically active.
1417	CPRFalse	In the presence of ornithine and @CHEMICAL$, @GENE$ (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1418	CPRFalse	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (@GENE$) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1419	CPRFalse	In the presence of ornithine and @CHEMICAL$, ornithine carbamoyltransferase (OTCase) and @GENE$ form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1420	CPRFalse	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of @GENE$ is inhibited whereas arginase remains catalytically active.
1421	CPRFalse	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas @GENE$ remains catalytically active.
1422	CPRFalse	In the presence of ornithine and arginine, @CHEM-GENE$ (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1423	CPRFalse	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (@GENE$) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1424	CPRFalse	In the presence of ornithine and arginine, @CHEMICAL$ carbamoyltransferase (OTCase) and @GENE$ form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.
1425	CPRFalse	In @CHEMICAL$, two @GENE$ at the C terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.
1426	CPRFalse	In arginase, two @CHEMICAL$ at the C terminus of the protein are crucial for its @GENE$ function but not for its catalytic activity and trimeric structure.
1427	CPRFalse	In @CHEMICAL$, two cysteines at the @GENE$ terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.
1428	CPRFalse	In arginase, two cysteines at the @CHEMICAL$ terminus of the protein are crucial for its @GENE$ function but not for its catalytic activity and trimeric structure.
1429	CPRFalse	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, @GENE$-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.
1430	CPRFalse	In OTCase, mutations of putative ornithine binding residues, Asp-182, @CHEMICAL$-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.
1431	CPRFalse	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, @GENE$-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.
1432	CPRFalse	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, @CHEMICAL$-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.
1433	CPRFalse	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, @GENE$-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.
1434	CPRFalse	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, @CHEMICAL$-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.
1435	CPRFalse	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and @GENE$-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.
1436	CPRFalse	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and @CHEMICAL$-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.
1437	CPRFalse	In @CHEMICAL$, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for @GENE$ and impaired the interaction with arginase.
1438	CPRFalse	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for @CHEMICAL$ and impaired the interaction with @GENE$.
1439	CPRFalse	In @CHEMICAL$, mutations of putative @GENE$ binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.
1440	CPRFalse	In OTCase, mutations of putative @CHEMICAL$ binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.
1441	CPRFalse	In @CHEMICAL$, mutations of putative ornithine binding residues, @GENE$-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.
1442	CPRFalse	In OTCase, mutations of putative ornithine binding residues, @CHEMICAL$-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with @GENE$.
1443	CPRFalse	The four @CHEMICAL$ residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1444	CPRFalse	The four @CHEMICAL$ residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1445	CPRFalse	The four lysine residues located in the SMG loop, @CHEMICAL$-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1446	CPRFalse	The four lysine residues located in the SMG loop, @CHEMICAL$-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1447	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, @CHEMICAL$-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1448	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, @CHEMICAL$-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1449	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, Lys-263, @CHEMICAL$-265, and Lys-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1450	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, Lys-263, @CHEMICAL$-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1451	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and @CHEMICAL$-268, also play an important role in mediating the sensitivity of @GENE$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1452	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and @CHEMICAL$-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1453	CPR:4	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @CHEMICAL$ to @GENE$ and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1454	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to @CHEMICAL$ and to @GENE$ and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.
1455	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of @CHEMICAL$ to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by @GENE$ for the closure of the catalytic domain.
1456	CPRFalse	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to @CHEMICAL$ and appear to be involved in transducing and enhancing the signal given by @GENE$ for the closure of the catalytic domain.
1457	CPRFalse	On the other hand, @CHEMICAL$ did not modify the eosinophil spontaneous adhesion to the resting or @GENE$ plus TNF-alpha-stimulated pulmonary endothelial cells.
1458	CPRFalse	On the other hand, @CHEMICAL$ did not modify the eosinophil spontaneous adhesion to the resting or IL-4 plus @GENE$-stimulated pulmonary endothelial cells.
1459	CPRFalse	Similarly, @CHEMICAL$ did not modulate @GENE$- or FMLP-activated eosinophil adhesion to the resting endothelial cells.
1460	CPRFalse	The @CHEM-GENE$ P-glycoprotein (P-gp) affects the absorption and disposition of many compounds.
1461	CPRFalse	The @CHEMICAL$-dependent drug efflux pump P-glycoprotein (@GENE$) affects the absorption and disposition of many compounds.
1462	CPRFalse	The @CHEMICAL$-dependent drug efflux pump @GENE$ (P-gp) affects the absorption and disposition of many compounds.
1463	CPRFalse	The assays included in @CHEMICAL$ predictions, inhibition assays (based on cellular uptake of rhodamine-123 or calcein AM), and functional assays (@GENE$ activity assay and transcellular transport assay, the latter for a subset of compounds).
1464	CPRFalse	The assays included in silico predictions, inhibition assays (based on cellular uptake of @CHEMICAL$ or calcein AM), and functional assays (@GENE$ activity assay and transcellular transport assay, the latter for a subset of compounds).
1465	CPRFalse	The assays included in silico predictions, inhibition assays (based on cellular uptake of rhodamine-123 or @CHEMICAL$), and functional assays (@GENE$ activity assay and transcellular transport assay, the latter for a subset of compounds).
1466	CPRFalse	@CHEMICAL$ was incorporated into a model target protein, @GENE$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.
1467	CPRFalse	@CHEMICAL$ was incorporated into a model target protein, murine dihydrofolate reductase (@GENE$), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.
1468	CPRFalse	5TFI was incorporated into a model target protein, @CHEM-GENE$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.
1469	CPRFalse	5TFI was incorporated into a model target protein, murine @CHEMICAL$ reductase (@GENE$), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.
1470	CPRFalse	5TFI was incorporated into a model target protein, @CHEMICAL$ (mDHFR), in an @GENE$ auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.
1471	CPRFalse	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (@CHEMICAL$), in an @GENE$ auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.
1472	CPRFalse	5TFI was incorporated into a model target protein, @CHEMICAL$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in @GENE$-supplemented minimal medium depleted of isoleucine.
1473	CPRFalse	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (@CHEMICAL$), in an isoleucine auxotrophic Escherichia coli host strain suspended in @GENE$-supplemented minimal medium depleted of isoleucine.
1474	CPRFalse	5TFI was incorporated into a model target protein, @CHEMICAL$ (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of @GENE$.
1475	CPRFalse	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (@CHEMICAL$), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of @GENE$.
1476	CPRFalse	Measurement of the rate of activation of @CHEMICAL$ by the @GENE$ (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.
1477	CPRFalse	Measurement of the rate of activation of @CHEMICAL$ by the E. coli isoleucyl-tRNA synthetase (@GENE$) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.
1478	CPRFalse	Measurement of the rate of activation of 5TFI by the @CHEM-GENE$ (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.
1479	CPRFalse	Measurement of the rate of activation of 5TFI by the E. coli @CHEMICAL$-tRNA synthetase (@GENE$) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.
1480	CPRFalse	Measurement of the rate of activation of 5TFI by the @CHEMICAL$ (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for @GENE$.
1481	CPRFalse	Measurement of the rate of activation of 5TFI by the E. coli isoleucyl-tRNA synthetase (@CHEMICAL$) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for @GENE$.
1482	CPRFalse	@CHEMICAL$ was successfully introduced into the @GENE$ murine interleukin-2 (mIL-2) at the encoded isoleucine positions.
1483	CPRFalse	@CHEMICAL$ was successfully introduced into the cytokine @GENE$ (mIL-2) at the encoded isoleucine positions.
1484	CPRFalse	@CHEMICAL$ was successfully introduced into the cytokine murine interleukin-2 (@GENE$) at the encoded isoleucine positions.
1485	CPRFalse	5TFI was successfully introduced into the @CHEMICAL$ murine interleukin-2 (mIL-2) at the encoded @GENE$ positions.
1486	CPRFalse	5TFI was successfully introduced into the cytokine @CHEMICAL$ (mIL-2) at the encoded @GENE$ positions.
1487	CPRFalse	5TFI was successfully introduced into the cytokine murine interleukin-2 (@CHEMICAL$) at the encoded @GENE$ positions.
1488	CPRFalse	@CHEMICAL$ yielded no evidence for in vivo incorporation into recombinant proteins, and no evidence for activation by @GENE$ in vitro.
1489	CPRFalse	This binding was not significantly inhibited by the @CHEMICAL$ analogue epsilon-amino caproic acid (EACA), indicating that @GENE$ binding was not just through lysine binding sites as suggested for other plasminogen binding sites.
1490	CPRFalse	This binding was not significantly inhibited by the @CHEMICAL$ analogue epsilon-amino caproic acid (EACA), indicating that plasminogen binding was not just through lysine binding sites as suggested for other @GENE$ binding sites.
1491	CPRFalse	This binding was not significantly inhibited by the lysine analogue @CHEMICAL$ (EACA), indicating that @GENE$ binding was not just through lysine binding sites as suggested for other plasminogen binding sites.
1492	CPRFalse	This binding was not significantly inhibited by the lysine analogue @CHEMICAL$ (EACA), indicating that plasminogen binding was not just through lysine binding sites as suggested for other @GENE$ binding sites.
1493	CPRFalse	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (@CHEMICAL$), indicating that @GENE$ binding was not just through lysine binding sites as suggested for other plasminogen binding sites.
1494	CPRFalse	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (@CHEMICAL$), indicating that plasminogen binding was not just through lysine binding sites as suggested for other @GENE$ binding sites.
1495	CPRFalse	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (EACA), indicating that @CHEMICAL$ binding was not just through @GENE$ binding sites as suggested for other plasminogen binding sites.
1496	CPRFalse	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (EACA), indicating that plasminogen binding was not just through @CHEMICAL$ binding sites as suggested for other @GENE$ binding sites.
1497	CPR:4	Inhibition of binding of both @CHEMICAL$ and plasmin to gp330 by @GENE$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.
1498	CPR:4	Inhibition of binding of both plasminogen and @CHEMICAL$ to gp330 by @GENE$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.
1499	CPRFalse	Inhibition of binding of both plasminogen and plasmin to @CHEMICAL$ by @GENE$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.
1500	CPRFalse	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of @GENE$ to gp330 slightly more than the binding of plasminogen to gp330.
1501	CPRFalse	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of plasmin to @GENE$ slightly more than the binding of plasminogen to gp330.
1502	CPRFalse	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of @GENE$ to gp330.
1503	CPRFalse	Inhibition of binding of both plasminogen and plasmin to gp330 by @CHEMICAL$ was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to @GENE$.
1504	CPRFalse	Inhibition of binding of both @CHEMICAL$ and plasmin to gp330 by benzamidine was similar, although @GENE$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.
1505	CPRFalse	Inhibition of binding of both plasminogen and @CHEMICAL$ to gp330 by benzamidine was similar, although @GENE$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.
1506	CPRFalse	Inhibition of binding of both plasminogen and plasmin to @CHEMICAL$ by benzamidine was similar, although @GENE$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.
1507	CPR:4	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of @GENE$ to gp330 slightly more than the binding of plasminogen to gp330.
1508	CPRFalse	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of plasmin to @GENE$ slightly more than the binding of plasminogen to gp330.
1509	CPR:4	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of plasmin to gp330 slightly more than the binding of @GENE$ to gp330.
1510	CPRFalse	Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although @CHEMICAL$ inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to @GENE$.
1511	CPRFalse	Involvement of @CHEMICAL$ was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, @GENE$ (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).
1512	CPR:6	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective @CHEMICAL$ antagonists, @GENE$ (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).
1513	CPRFalse	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, @CHEMICAL$ (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective @GENE$ antagonist, prazosin (0.3 mg/kg).
1514	CPRFalse	Involvement of @CHEMICAL$ was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and @GENE$ (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).
1515	CPR:6	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective @CHEMICAL$ antagonists, phentolamine (0.3-3 mg/kg) and @GENE$ (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).
1516	CPRFalse	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and @CHEMICAL$ (0.03-0.3 mg/kg), as well as by the selective @GENE$ antagonist, prazosin (0.3 mg/kg).
1517	CPRFalse	Involvement of @CHEMICAL$ was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, @GENE$ (0.3 mg/kg).
1518	CPRFalse	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective @CHEMICAL$ antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, @GENE$ (0.3 mg/kg).
1519	CPR:6	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective @CHEMICAL$ antagonist, @GENE$ (0.3 mg/kg).
1520	CPRFalse	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1521	CPR:6	The @CHEMICAL$ antagonist, @GENE$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1522	CPRFalse	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1523	CPRFalse	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1524	CPRFalse	The alpha(2)-adrenoceptor antagonist, @CHEMICAL$ (0.5 mg/kg), was without antagonistic effects. @GENE$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1525	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @CHEMICAL$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1526	CPRFalse	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @GENE$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1527	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @CHEMICAL$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1528	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, @CHEMICAL$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1529	CPR:6	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, @GENE$ (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1530	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@CHEMICAL$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1531	CPRFalse	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@GENE$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1532	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@CHEMICAL$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1533	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@CHEMICAL$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1534	CPR:6	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (@GENE$; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1535	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @CHEMICAL$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1536	CPRFalse	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @GENE$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1537	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @CHEMICAL$ (0.1-1 mg/kg), the @GENE$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1538	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @CHEMICAL$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1539	CPR:6	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and @GENE$ (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1540	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @CHEMICAL$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1541	CPRFalse	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @GENE$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1542	CPR:6	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, @GENE$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1543	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @CHEMICAL$ (L-765314; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1544	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, @GENE$ (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1545	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@CHEMICAL$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1546	CPRFalse	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@GENE$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1547	CPR:6	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@GENE$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1548	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@CHEMICAL$; 0.3-1 mg/kg), as well as the @GENE$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1549	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (@GENE$; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1550	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @CHEMICAL$ (BMY-7378; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1551	CPRFalse	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1552	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1553	CPR:6	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @CHEMICAL$ selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1554	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, @GENE$ (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1555	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@CHEMICAL$; 1 mg/kg), were used to delineate the @GENE$ subtypes involved.
1556	CPRFalse	The @CHEMICAL$ antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1557	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the @CHEMICAL$ selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1558	CPR:6	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the @CHEMICAL$ selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1559	CPRFalse	The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. @CHEMICAL$ selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (@GENE$; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.
1560	CPR:4	To further investigate this positive correlation and its possible therapeutic implications, a selective @CHEMICAL$ inhibitor, @GENE$, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.
1561	CPRFalse	To further investigate this positive correlation and its possible therapeutic implications, a selective COX-2 inhibitor, @CHEMICAL$, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and @GENE$ expression levels.
1562	CPRFalse	In human kidney, we found unique @CHEMICAL$-binding sites that were insensitive to phentolamine and were thus unlikely to be @GENE$.
1563	CPRFalse	In human kidney, we found unique prazosin-binding sites that were insensitive to @CHEMICAL$ and were thus unlikely to be @GENE$.
1564	CPRFalse	As the binding of @CHEMICAL$ to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1565	CPRFalse	As the binding of [(3)H]prazosin to @CHEMICAL$-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1566	CPRFalse	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM @CHEMICAL$, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1567	CPRFalse	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting @CHEMICAL$ binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1568	CPRFalse	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM @CHEMICAL$ from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1569	CPRFalse	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM @CHEMICAL$. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1570	CPRFalse	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. @CHEMICAL$ bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1571	CPRFalse	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the @CHEMICAL$-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1572	CPRFalse	As the binding of [(3)H]prazosin to phentolamine-insensitive sites was prevented by 100 microM guanabenz, the insensitive sites were evaluated by subtracting [(3)H]prazosin binding in the presence of 100 microM guanabenz from that in the presence of 10 microM phentolamine. [(3)H]Prazosin bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the @CHEMICAL$-sensitive @GENE$ (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).
1573	CPRFalse	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and @GENE$, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1574	CPRFalse	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and @GENE$, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1575	CPRFalse	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and noradrenaline, @GENE$ and propranolol were without effect on the [(3)H]prazosin binding.
1576	CPRFalse	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, @GENE$ and propranolol were without effect on the [(3)H]prazosin binding.
1577	CPRFalse	However, other alpha(1)-adrenoceptor antagonists (@CHEMICAL$, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @GENE$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1578	CPR:6	However, other @CHEMICAL$ antagonists (@GENE$, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1579	CPRFalse	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, @CHEMICAL$ and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @GENE$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1580	CPR:6	However, other @CHEMICAL$ antagonists (tamsulosin, @GENE$ and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1581	CPRFalse	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and @CHEMICAL$) did not inhibit the binding at a range of concentrations that generally exhibit @GENE$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1582	CPR:6	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and @GENE$) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.
1583	CPRFalse	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and noradrenaline, rauwolscine and @GENE$ were without effect on the [(3)H]prazosin binding.
1584	CPRFalse	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and @GENE$ were without effect on the [(3)H]prazosin binding.
1585	CPRFalse	However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit @CHEMICAL$ antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the @GENE$ binding.
1586	CPRFalse	However, other @CHEMICAL$ antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the @GENE$ binding.
1587	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, @GENE$ and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.
1588	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and @GENE$) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.
1589	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of @GENE$ to phentolamine-insensitive sites at micromolar concentrations.
1590	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to @GENE$-insensitive sites at micromolar concentrations.
1591	CPRFalse	On the other hand, ligands for the renal @CHEM-GENE$ (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.
1592	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (@GENE$ and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.
1593	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and @GENE$) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.
1594	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for @GENE$ recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.
1595	CPRFalse	On the other hand, ligands for the renal @CHEMICAL$ (amiloride and triamterene) and for imidazoline recognition sites (@GENE$, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.
1596	CPRFalse	Photoaffinity labeling with @CHEMICAL$ showed phentolamine-insensitive labeling at around 100 kDa, a molecular size larger than that of @GENE$ expressed in 293 cells (50-60 and 70-80 kDa, respectively) on electrophoresis.
1597	CPRFalse	Photoaffinity labeling with [(125)I]iodoarylazidoprazosin showed @CHEMICAL$-insensitive labeling at around 100 kDa, a molecular size larger than that of @GENE$ expressed in 293 cells (50-60 and 70-80 kDa, respectively) on electrophoresis.
1598	CPRFalse	In contrast, there was no detectable @CHEMICAL$-insensitive binding site but were phentolamine-sensitive @GENE$ in human liver (pK(d)=10.0+/-0.06, B(max)=44+/-6 fmol mg(-1) protein, n=3).
1599	CPRFalse	In contrast, there was no detectable phentolamine-insensitive binding site but were @CHEMICAL$-sensitive @GENE$ in human liver (pK(d)=10.0+/-0.06, B(max)=44+/-6 fmol mg(-1) protein, n=3).
1600	CPRFalse	chi-Conopeptide MrIA partially overlaps @CHEM-GENE$ on the human norepinephrine transporter.
1601	CPRFalse	chi-Conopeptide MrIA partially overlaps @CHEMICAL$ and cocaine binding sites on the @GENE$.
1602	CPRFalse	chi-Conopeptide MrIA partially overlaps @CHEM-GENE$ on the human norepinephrine transporter.
1603	CPRFalse	chi-Conopeptide MrIA partially overlaps desipramine and @CHEMICAL$ binding sites on the @GENE$.
1604	CPRFalse	chi-Conopeptide MrIA partially overlaps @CHEMICAL$ on the human @GENE$ transporter.
1605	CPRFalse	chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the @CHEM-GENE$.
1606	CPRFalse	The interactions of chi-conopeptide MrIA with the human @CHEMICAL$ transporter (hNET) were investigated by determining the effects of @GENE$ point mutations on the inhibitory potency of MrIA.
1607	CPRFalse	The interactions of chi-conopeptide MrIA with the @CHEM-GENE$ (hNET) were investigated by determining the effects of hNET point mutations on the inhibitory potency of MrIA.
1608	CPRFalse	The interactions of chi-conopeptide MrIA with the human @CHEMICAL$ transporter (@GENE$) were investigated by determining the effects of hNET point mutations on the inhibitory potency of MrIA.
1609	CPR:9	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of @GENE$ (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).
1610	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of @CHEMICAL$ (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the @GENE$ and serotonin transporter were not inhibited by MrIA (to 7 microM).
1611	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of @CHEMICAL$ (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and @GENE$ were not inhibited by MrIA (to 7 microM).
1612	CPR:9	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of [3H]norepinephrine (Ki 1.89 microM) than @GENE$ (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).
1613	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than @CHEMICAL$ (Ki 4.33 microM), and the @GENE$ and serotonin transporter were not inhibited by MrIA (to 7 microM).
1614	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than @CHEMICAL$ (Ki 4.33 microM), and the human dopamine transporter and @GENE$ were not inhibited by MrIA (to 7 microM).
1615	CPRFalse	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human @GENE$ transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).
1616	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the @CHEM-GENE$ and serotonin transporter were not inhibited by MrIA (to 7 microM).
1617	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human @CHEMICAL$ transporter and @GENE$ were not inhibited by MrIA (to 7 microM).
1618	CPRFalse	The potency of MrIA was greater for inhibition of uptake by @CHEMICAL$ of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and @GENE$ transporter were not inhibited by MrIA (to 7 microM).
1619	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the @CHEMICAL$ and @GENE$ transporter were not inhibited by MrIA (to 7 microM).
1620	CPRFalse	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and @CHEM-GENE$ were not inhibited by MrIA (to 7 microM).
1621	CPRFalse	Of 18 mutations where @CHEMICAL$ amino acid residues were exchanged with those of the human @GENE$ transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).
1622	CPRFalse	Of 18 mutations where hNET amino acid residues were exchanged with those of the @CHEM-GENE$, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).
1623	CPRFalse	Of 18 mutations where @CHEMICAL$ amino acid residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of @GENE$ uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).
1624	CPRFalse	Of 18 mutations where hNET amino acid residues were exchanged with those of the @CHEMICAL$, MrIA had increased potency for inhibition of @GENE$ uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).
1625	CPRFalse	Of 18 mutations where @CHEMICAL$ @GENE$ residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).
1626	CPRFalse	Of 18 mutations where hNET @CHEMICAL$ residues were exchanged with those of the @GENE$, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).
1627	CPRFalse	A comparison of the results with previous data for @CHEMICAL$ and cocaine inhibition of norepinephrine uptake by the mutant @GENE$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.
1628	CPRFalse	A comparison of the results with previous data for @CHEMICAL$ and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to @GENE$ occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.
1629	CPR:9	A comparison of the results with previous data for desipramine and cocaine inhibition of @CHEMICAL$ uptake by the mutant @GENE$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.
1630	CPRFalse	A comparison of the results with previous data for desipramine and cocaine inhibition of @CHEMICAL$ uptake by the mutant hNETs reveals that MrIA binding to @GENE$ occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.
1631	CPRFalse	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant @CHEMICAL$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for @GENE$ antidepressants and cocaine.
1632	CPRFalse	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to @CHEMICAL$ occurs at a site that is distinct from but overlaps with the binding sites for @GENE$ antidepressants and cocaine.
1633	CPRFalse	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant @CHEMICAL$ reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and @GENE$.
1634	CPRFalse	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to @CHEMICAL$ occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and @GENE$.
1635	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$ aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @GENE$ having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1636	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$ aminohydrolase, @GENE$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1637	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$ aminohydrolase, ACY-1) [@GENE$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1638	CPRFalse	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (@GENE$ aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1639	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEM-GENE$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1640	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @CHEMICAL$ having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1641	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @CHEMICAL$) [EC 3.5.1.14], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1642	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@CHEMICAL$], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1643	CPRFalse	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1644	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two @GENE$ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1645	CPR:9	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @CHEMICAL$ having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1646	CPR:9	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @CHEMICAL$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1647	CPR:9	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@CHEMICAL$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1648	CPR:9	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1649	CPR:9	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of @GENE$ except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1650	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @CHEMICAL$ having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1651	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @CHEMICAL$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1652	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@CHEMICAL$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1653	CPRFalse	A cDNA encoding the complete amino acid sequence of @CHEMICAL$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1654	CPRFalse	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (@CHEMICAL$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except @GENE$, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1655	CPRFalse	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric @GENE$ having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1656	CPRFalse	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, @GENE$) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1657	CPRFalse	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [@GENE$], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1658	CPRFalse	A cDNA encoding the complete @CHEMICAL$ sequence of @GENE$ (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1659	CPRFalse	A cDNA encoding the complete @CHEMICAL$ sequence of aminoacylase 1 (@GENE$, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.
1660	CPRFalse	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that @CHEMICAL$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with @GENE$ at the N-terminus.
1661	CPRFalse	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that @CHEMICAL$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the @GENE$-terminus.
1662	CPRFalse	From sequence analysis of the cDNA and the @CHEMICAL$- and C-terminal amino acid analyses of the purified protein, it is deduced that @GENE$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.
1663	CPRFalse	From sequence analysis of the cDNA and the N- and @CHEMICAL$-terminal amino acid analyses of the purified protein, it is deduced that @GENE$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.
1664	CPRFalse	From sequence analysis of the cDNA and the N- and C-terminal @CHEMICAL$ analyses of the purified protein, it is deduced that @GENE$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.
1665	CPRFalse	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that @CHEMICAL$ consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 @GENE$ with acetylalanine at the N-terminus.
1666	CPRFalse	The @CHEMICAL$ sequence deduced from the nucleotide sequence of the cDNA from porcine liver was identical to that deduced for @GENE$.
1667	CPRFalse	The amino acid sequence deduced from the @CHEMICAL$ sequence of the cDNA from porcine liver was identical to that deduced for @GENE$.
1668	CPRFalse	Comparison of the @CHEMICAL$ sequence of porcine ACY-1 with those of other @GENE$ showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.
1669	CPRFalse	Comparison of the @CHEMICAL$ sequence of @GENE$ with those of other Zn2+-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.
1670	CPRFalse	Comparison of the amino acid sequence of porcine ACY-1 with those of other @CHEM-GENE$ showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.
1671	CPRFalse	Comparison of the amino acid sequence of @CHEMICAL$ with those of other @GENE$-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.
1672	CPRFalse	@CHEMICAL$ polymorphisms and antihypertensive response to @GENE$.
1673	CPRFalse	OBJECTIVES: Marked interpatient variability exists in blood pressure response to beta-blocker monotherapy. We tested the hypothesis that 2 common polymorphisms in the gene for @CHEMICAL$ are associated with antihypertensive response to @GENE$ in patients with uncomplicated hypertension.
1674	CPRFalse	CONCLUSIONS: Our data suggest that @CHEMICAL$ polymorphisms are important determinants of antihypertensive response to @GENE$.
1675	CPRFalse	In the future, codon 49 and 389 genotypes or @CHEMICAL$ haplotypes might be used to predict the diastolic blood pressure response to @GENE$ in patients with hypertension.
1676	CPRFalse	Patients stable on @CHEMICAL$ therapy and concurrently taking a @GENE$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.
1677	CPRFalse	Patients stable on @CHEMICAL$ therapy and concurrently taking a cyclooxygenase-2 (@GENE$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.
1678	CPR:4	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, @GENE$, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.
1679	CPR:4	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, @GENE$, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.
1680	CPR:4	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or @GENE$) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.
1681	CPR:4	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or @GENE$) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.
1682	CPR:4	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received @GENE$ 200 mg/day or rofecoxib 25 mg/day for three weeks.
1683	CPR:4	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received @GENE$ 200 mg/day or rofecoxib 25 mg/day for three weeks.
1684	CPR:4	Patients stable on warfarin therapy and concurrently taking a @CHEMICAL$ (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or @GENE$ 25 mg/day for three weeks.
1685	CPR:4	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (@CHEMICAL$) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or @GENE$ 25 mg/day for three weeks.
1686	CPRFalse	Adverse drug reactions were similar for each @CHEMICAL$ inhibitor, but the rate of edema requiring medical intervention was higher in the @GENE$ group.
1687	CPR:6	@CHEMICAL$ antagonism by @GENE$ lowers heart rate variability and baroreflex gain.
1688	CPRFalse	INTRODUCTION: Blockade of the @CHEMICAL$-@GENE$ system (RAS) by ACE inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.
1689	CPRFalse	INTRODUCTION: Blockade of the renin-@CHEM-GENE$ system (RAS) by ACE inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.
1690	CPRFalse	INTRODUCTION: Blockade of the renin-@CHEMICAL$ system (RAS) by @GENE$ inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.
1691	CPRFalse	We sought to assess the effects of the @CHEM-GENE$ blocker eprosartan on HRV and BRG.
1692	CPR:4	We sought to assess the effects of the @CHEMICAL$ blocker @GENE$ on HRV and BRG.
1693	CPR:3	RESULTS: @CHEMICAL$ tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating @GENE$ levels (p<0.01).
1694	CPRFalse	RESULTS: Eprosartan tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating @CHEM-GENE$ levels (p<0.01).
1695	CPR:6	CONCLUSIONS: @CHEMICAL$ antagonism by @GENE$ lowers heart rate variability and baroreflex gain.
1696	CPRFalse	We speculate that these findings are due to the marked increase in circulating @CHEM-GENE$ (Ang II).
1697	CPRFalse	We speculate that these findings are due to the marked increase in circulating @CHEMICAL$ (@GENE$).
1698	CPRFalse	We speculate that these findings are due to the marked increase in circulating @CHEMICAL$ (@GENE$).
1699	CPRFalse	We speculate that these findings are due to the marked increase in circulating angiotensin II (@CHEM-GENE$).
1700	CPRFalse	Further studies are needed to clarify whether @CHEM-GENE$ (AT1) blockers with potential actions inside the blood-brain barrier (BBB) may have different effects on HRV and BRG.
1701	CPRFalse	Further studies are needed to clarify whether @CHEMICAL$ type 1 (@GENE$) blockers with potential actions inside the blood-brain barrier (BBB) may have different effects on HRV and BRG.
1702	CPRFalse	@CHEMICAL$ did not prevent or reverse that modulatory activity; moreover, pretreatment with the acetylated peptide did not change the pA2 value displayed by the antagonist at the @GENE$.
1703	CPR:5	The antinociceptive activity of the @CHEMICAL$ agonist @GENE$ was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).
1704	CPRFalse	The antinociceptive activity of the @CHEMICAL$ agonist clonidine was also increased in mice treated with alpha @GENE$ beta-endorphin-(1-31).
1705	CPRFalse	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon @CHEMICAL$- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of @GENE$/Go transducer proteins.
1706	CPRFalse	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon @CHEMICAL$- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of Gi/@GENE$ transducer proteins.
1707	CPRFalse	The reducing activity of alpha @CHEMICAL$ beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of @GENE$/Go transducer proteins.
1708	CPRFalse	The reducing activity of alpha @CHEMICAL$ beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of Gi/@GENE$ transducer proteins.
1709	CPRFalse	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or @CHEMICAL$, agents known to impair the function of @GENE$/Go transducer proteins.
1710	CPRFalse	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or @CHEMICAL$, agents known to impair the function of Gi/@GENE$ transducer proteins.
1711	CPRFalse	These results confirm and strengthen the idea of alpha @CHEMICAL$ beta-endorphin-(1-31) acting as a non-competitive regulator of mu opioid- and @GENE$-mediated supraspinal antinociception.
1712	CPRFalse	These results confirm and strengthen the idea of alpha @CHEMICAL$ beta-endorphin-(1-31) acting as a non-competitive regulator of @GENE$- and alpha 2-adrenoceptor-mediated supraspinal antinociception.
1713	CPR:4	@CHEMICAL$, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress @GENE$ and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.
1714	CPRFalse	@CHEMICAL$, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and cortisol levels in normal subjects, but not in patients with proven @GENE$-dependent Cushing's disease.
1715	CPRFalse	Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress @CHEMICAL$ and @GENE$ levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.
1716	CPRFalse	Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and @CHEMICAL$ levels in normal subjects, but not in patients with proven @GENE$-dependent Cushing's disease.
1717	CPR:4	In seven normal subjects, basal @CHEMICAL$ plasma levels were significantly suppressed 3 h after @GENE$ administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).
1718	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1719	CPRFalse	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms @GENE$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1720	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEM-GENE$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1721	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms @GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1722	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the @GENE$ peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1723	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1724	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1725	CPRFalse	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms GnRH, 100 micrograms @GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1726	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms @GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1727	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEM-GENE$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1728	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms TRH), the @GENE$ peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1729	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1730	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEM-GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1731	CPRFalse	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1732	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1733	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms @GENE$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1734	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEMICAL$), the @GENE$ peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1735	CPRFalse	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEMICAL$), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1736	CPR:4	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms @CHEMICAL$), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1737	CPR:4	After the combined pituitary stimulation test (100 micrograms @CHEMICAL$, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1738	CPR:4	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms @CHEMICAL$, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1739	CPR:4	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms @CHEMICAL$, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1740	CPR:4	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the @CHEMICAL$ peak (maximum increase at 30 min) was significantly blunted by @GENE$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1741	CPR:4	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by @CHEMICAL$ from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of @GENE$ from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).
1742	CPRFalse	In the @CHEMICAL$-hypoglycemia test (0.15 IU/kg BW), neither the ACTH peak nor the area under the curve of ACTH was affected by @GENE$.
1743	CPRFalse	In the insulin-hypoglycemia test (0.15 IU/kg BW), neither the @CHEMICAL$ peak nor the area under the curve of ACTH was affected by @GENE$.
1744	CPRFalse	In the insulin-hypoglycemia test (0.15 IU/kg BW), neither the ACTH peak nor the area under the curve of @CHEMICAL$ was affected by @GENE$.
1745	CPRFalse	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal @CHEMICAL$ and @GENE$ levels nor CRH-stimulated levels were influenced by loperamide.
1746	CPRFalse	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal ACTH and @CHEMICAL$ levels nor @GENE$-stimulated levels were influenced by loperamide.
1747	CPRFalse	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal @CHEMICAL$ and cortisol levels nor CRH-stimulated levels were influenced by @GENE$.
1748	CPRFalse	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal ACTH and cortisol levels nor @CHEMICAL$-stimulated levels were influenced by @GENE$.
1749	CPRFalse	In four cultured human corticotropic adenomas, @CHEMICAL$ was not able to reduce basal and @GENE$-induced ACTH secretion.
1750	CPRFalse	In four cultured human corticotropic adenomas, @CHEMICAL$ was not able to reduce basal and CRH-induced @GENE$ secretion.
1751	CPR:4	In summary, @CHEMICAL$ is able to reduce basal and @GENE$-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.
1752	CPR:4	In summary, @CHEMICAL$ is able to reduce basal and CRH-induced @GENE$ and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.
1753	CPRFalse	In summary, loperamide is able to reduce basal and @CHEMICAL$-induced ACTH and @GENE$ levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.
1754	CPRFalse	In summary, loperamide is able to reduce basal and CRH-induced @CHEMICAL$ and @GENE$ levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.
1755	CPRFalse	Loperamide has no significant effect on @CHEMICAL$-hypoglycemia-induced ACTH and @GENE$ levels and, therefore, no effect on stress-induced elevation of cortisol levels.
1756	CPRFalse	Loperamide has no significant effect on insulin-hypoglycemia-induced @CHEMICAL$ and @GENE$ levels and, therefore, no effect on stress-induced elevation of cortisol levels.
1757	CPRFalse	@CHEMICAL$ has no significant effect on @GENE$-hypoglycemia-induced ACTH and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.
1758	CPRFalse	@CHEMICAL$ has no significant effect on insulin-hypoglycemia-induced @GENE$ and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.
1759	CPR:6	We also examined the effects of @CHEMICAL$, a @GENE$ antagonist, in parallel.
1760	CPR:9	The unique role of the enzyme @CHEMICAL$ (5-LO) in the production of @GENE$ (LTs) makes it a likely target for biochemical manipulation.
1761	CPR:9	The unique role of the enzyme 5-lipoxygenase (@CHEMICAL$) in the production of @GENE$ (LTs) makes it a likely target for biochemical manipulation.
1762	CPR:9	The unique role of the enzyme @CHEMICAL$ (5-LO) in the production of leukotrienes (@GENE$) makes it a likely target for biochemical manipulation.
1763	CPR:9	The unique role of the enzyme 5-lipoxygenase (@CHEMICAL$) in the production of leukotrienes (@GENE$) makes it a likely target for biochemical manipulation.
1764	CPRFalse	The rationale for using @CHEMICAL$ inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of @GENE$ in the inflamed mucosa, LTB4 being the most potent chemotactic and chemokinetic metabolite of arachidonic acid.
1765	CPRFalse	The rationale for using @CHEMICAL$ inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of LTs in the inflamed mucosa, @GENE$ being the most potent chemotactic and chemokinetic metabolite of arachidonic acid.
1766	CPRFalse	The rationale for using @CHEMICAL$ inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of LTs in the inflamed mucosa, LTB4 being the most potent chemotactic and chemokinetic metabolite of @GENE$.
1767	CPRFalse	Furthermore, conventional drugs, such as corticosteroids, @CHEMICAL$, and 5-aminosalicylic acid, inhibit LT production and specific @GENE$ inhibition accelerates healing in animal models of acute colitis.
1768	CPRFalse	Furthermore, conventional drugs, such as corticosteroids, sulphasalazine, and @CHEMICAL$, inhibit LT production and specific @GENE$ inhibition accelerates healing in animal models of acute colitis.
1769	CPRFalse	Furthermore, conventional drugs, such as corticosteroids, sulphasalazine, and 5-aminosalicylic acid, inhibit @CHEMICAL$ production and specific @GENE$ inhibition accelerates healing in animal models of acute colitis.
1770	CPRFalse	The compounds identified as @CHEMICAL$ inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where @GENE$ are potent and more selective inhibitors of 5-LO.
1771	CPR:4	The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where @CHEMICAL$ are potent and more selective inhibitors of @GENE$.
1772	CPR:4	The @CHEMICAL$, zileuton, is the first selective @GENE$ inhibitor evaluated for the treatment of patients with IBD.
1773	CPR:4	The benzothiophene hydroxyurea, @CHEMICAL$, is the first selective @GENE$ inhibitor evaluated for the treatment of patients with IBD.
1774	CPRFalse	The proof that any putative @CHEMICAL$ inhibitor is blocking @GENE$ production is an important stage in assessing any such drug.
1775	CPRFalse	Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun @CHEMICAL$-terminal kinase-1 is critical for @GENE$-induced p21WAF1/CIP1 promoter activity independent of p53.
1776	CPRFalse	Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun @CHEMICAL$-terminal kinase-1 is critical for PDGF-induced @GENE$ activity independent of p53.
1777	CPRFalse	@CHEMICAL$-activated c-Jun @GENE$-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53.
1778	CPRFalse	Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun @CHEMICAL$-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of @GENE$.
1779	CPRFalse	Platelet-derived growth factor (PDGF) receptor-alpha-activated @CHEM-GENE$ is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53.
1780	CPRFalse	We showed previously that @CHEMICAL$ antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @GENE$-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.
1781	CPRFalse	We showed previously that alpha-PDGFR antagonizes @CHEMICAL$-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @GENE$-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.
1782	CPRFalse	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of @CHEMICAL$/c-Jun @GENE$-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.
1783	CPRFalse	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/@CHEM-GENE$, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.
1784	CPRFalse	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @CHEMICAL$-terminal kinase-1, whereas both @GENE$ and beta-PDGFR induce mitogenic signals.
1785	CPRFalse	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun @CHEMICAL$-terminal kinase-1, whereas both alpha-PDGFR and @GENE$ induce mitogenic signals.
1786	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, @GENE$, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1787	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, von Willebrand factor, @GENE$, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1788	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, von Willebrand factor, anti-thrombin III, @GENE$-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1789	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine @CHEMICAL$/creatinine, von Willebrand factor, anti-thrombin III, t-plasminogen activator-@GENE$-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1790	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, @GENE$, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1791	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, von Willebrand factor, @GENE$, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1792	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, von Willebrand factor, anti-thrombin III, @GENE$-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1793	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/@CHEMICAL$, von Willebrand factor, anti-thrombin III, t-plasminogen activator-@GENE$-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.
1794	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, @CHEMICAL$, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.
1795	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, @CHEMICAL$, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.
1796	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, anti-thrombin III, @CHEMICAL$-plasminogen activator inhibitor 1-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.
1797	CPRFalse	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, anti-thrombin III, t-plasminogen activator-@CHEMICAL$-complex, hematocrit, blood @GENE$ and blood pressure in the morning and at midnight during a duty day and in the following morning.
1798	CPRFalse	The human @CHEMICAL$ reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant @GENE$.
1799	CPRFalse	The @CHEM-GENE$ complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
1800	CPRFalse	The human @CHEMICAL$ reductase subunit hRRM2 complements @GENE$ in response to UV-induced DNA repair in cells with mutant p53.
1801	CPRFalse	@CHEMICAL$ reductase (@GENE$) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.
1802	CPRFalse	@CHEM-GENE$ (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.
1803	CPR:9	Ribonucleotide reductase (@CHEMICAL$) is responsible for the de novo conversion of the ribonucleoside diphosphates to @GENE$, which are essential for DNA synthesis and repair.
1804	CPR:9	@CHEMICAL$ (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to @GENE$, which are essential for DNA synthesis and repair.
1805	CPR:9	Ribonucleotide reductase (@CHEMICAL$) is responsible for the de novo conversion of the @GENE$ to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.
1806	CPR:9	@CHEMICAL$ (RR) is responsible for the de novo conversion of the @GENE$ to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.
1807	CPRFalse	In this study, we investigated the expression and function of @CHEMICAL$ and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated @GENE$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.
1808	CPRFalse	In this study, we investigated the expression and function of p53R2 and @CHEMICAL$ after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated @GENE$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.
1809	CPRFalse	In this study, we investigated the expression and function of p53R2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant @CHEMICAL$ with a truncated @GENE$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.
1810	CPRFalse	In this study, we investigated the expression and function of p53R2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated @CHEMICAL$-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type @GENE$.
1811	CPR:4	In PC3 cells, @CHEMICAL$ inhibited @GENE$ and resulted in increased sensitivity to UV irradiation.
1812	CPR:4	In addition, @CHEMICAL$ treatment significantly reduced the specific @GENE$ activity after SCI as compared to that of vehicle control.
1813	CPR:3	Furthermore, RT-PCR analyses revealed that @CHEMICAL$ treatment increased expression of @GENE$ mRNA but decreased tumor necrosis factor-alpha expression.
1814	CPR:4	Furthermore, RT-PCR analyses revealed that @CHEMICAL$ treatment increased expression of interleukin-10 mRNA but decreased @GENE$ expression.
1815	CPRFalse	These data suggest that, after SCI, @CHEMICAL$ treatment modulated expression of @GENE$, attenuated cell death and the size of lesions, and improved functional recovery in the injured rat.
1816	CPRFalse	Likewise, the Rif(r) mutant possessed a mutation in the rpoB gene (encoding the @CHEMICAL$ subunit). Increased productivity of @GENE$ in the Str(r) mutant (containing the K88R mutation in the S12 protein) may be a result of an aberrant protein synthesis mechanism.
1817	CPRFalse	Likewise, the Rif(r) mutant possessed a mutation in the rpoB gene (encoding the RNA polymerase beta subunit). Increased productivity of @CHEMICAL$ in the Str(r) mutant (containing the @GENE$ mutation in the S12 protein) may be a result of an aberrant protein synthesis mechanism.
1818	CPRFalse	Likewise, the Rif(r) mutant possessed a mutation in the @CHEMICAL$ gene (encoding the RNA polymerase beta subunit). Increased productivity of @GENE$ in the Str(r) mutant (containing the K88R mutation in the S12 protein) may be a result of an aberrant protein synthesis mechanism.
1819	CPRFalse	Likewise, the Rif(r) mutant possessed a mutation in the rpoB gene (encoding the RNA polymerase beta subunit). Increased productivity of @CHEMICAL$ in the Str(r) mutant (containing the K88R mutation in the @GENE$ protein) may be a result of an aberrant protein synthesis mechanism.
1820	CPRFalse	The @CHEMICAL$ mutant ribosome was characterized by increased 70S complex stability in low @GENE$ concentrations.
1821	CPRFalse	The K88R mutant ribosome was characterized by increased @CHEMICAL$ stability in low @GENE$ concentrations.
1822	CPRFalse	We conclude that this aberrant protein synthesis ability in the Str(r) mutant, which is a result of increased stability of the @CHEMICAL$, is responsible for the remarkable @GENE$ production enhancement obtained.
1823	CPRFalse	[The effects of @CHEMICAL$ on @GENE$ of liver and sexual glands in burned rats].
1824	CPRFalse	OBJECTIVE: To assess the effects of @CHEMICAL$ (NP) on @GENE$ (AR) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.
1825	CPRFalse	OBJECTIVE: To assess the effects of @CHEMICAL$ (NP) on androgen receptor (@GENE$) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.
1826	CPRFalse	OBJECTIVE: To assess the effects of nandrolone phenylpropionate (@CHEMICAL$) on @GENE$ (AR) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.
1827	CPRFalse	OBJECTIVE: To assess the effects of nandrolone phenylpropionate (@CHEMICAL$) on androgen receptor (@GENE$) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.
1828	CPR:3	RESULTS: The density of @CHEMICAL$ in liver tissue in @GENE$ group was higher than that in control group (P < 0.05).
1829	CPRFalse	The density of @CHEMICAL$ in testis and ovary tissues showed no significant difference between @GENE$ group and control group at every time-point (P > 0.05).
1830	CPR:3	CONCLUSION: @CHEMICAL$ up-regulated the density of @GENE$ in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.
1831	CPRFalse	CONCLUSION: @CHEMICAL$ up-regulated the density of AR in liver tissue, whereas it had no significant effects on the density of @GENE$ in testis and ovary tissues.
1832	CPRFalse	@CHEM-GENE$ loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.
1833	CPRFalse	@CHEMICAL$ loss of function mutation in a patient with @GENE$-associated primary pulmonary hypertension.
1834	CPRFalse	A mouse model incriminates the @CHEM-GENE$ but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via nitric oxide production.
1835	CPRFalse	A mouse model incriminates the @CHEMICAL$ but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via @GENE$ production.
1836	CPRFalse	CONCLUSION: Loss of @CHEMICAL$ @GENE$ function may predispose to fenfluramine-associated PPH in man.
1837	CPRFalse	CONCLUSION: Loss of serotonin @CHEMICAL$ function may predispose to @GENE$-associated PPH in man.
1838	CPRFalse	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (TBP) were disrupted on @CHEMICAL$ (CldAMP)-substituted @GENE$.
1839	CPRFalse	We demonstrated by in vitro gel-shift assays that binding interactions of the @CHEMICAL$ (TBP) were disrupted on @GENE$ (CldAMP)-substituted TATA box consensus sequences.
1840	CPRFalse	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (@CHEMICAL$) were disrupted on @GENE$ (CldAMP)-substituted TATA box consensus sequences.
1841	CPRFalse	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (TBP) were disrupted on 2-chlorodeoxyadenosine monophosphate (@CHEMICAL$)-substituted @GENE$.
1842	CPRFalse	We demonstrated by in vitro gel-shift assays that binding interactions of the @CHEMICAL$ (TBP) were disrupted on 2-chlorodeoxyadenosine monophosphate (@GENE$)-substituted TATA box consensus sequences.
1843	CPRFalse	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (@CHEMICAL$) were disrupted on 2-chlorodeoxyadenosine monophosphate (@GENE$)-substituted TATA box consensus sequences.
1844	CPRFalse	We hypothesized that @CHEMICAL$ (pol II) transcriptional processes would therefore be affected by @GENE$ (CldATP) incorporation into a promoter TATA element.
1845	CPRFalse	We hypothesized that human RNA polymerase II (@CHEMICAL$) transcriptional processes would therefore be affected by @GENE$ (CldATP) incorporation into a promoter TATA element.
1846	CPRFalse	We hypothesized that human RNA polymerase II (pol II) transcriptional processes would therefore be affected by @CHEMICAL$ (CldATP) incorporation into a promoter @GENE$.
1847	CPRFalse	We hypothesized that @CHEMICAL$ (pol II) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (@GENE$) incorporation into a promoter TATA element.
1848	CPRFalse	We hypothesized that human RNA polymerase II (@CHEMICAL$) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (@GENE$) incorporation into a promoter TATA element.
1849	CPRFalse	We hypothesized that human RNA polymerase II (pol II) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (@CHEMICAL$) incorporation into a promoter @GENE$.
1850	CPRFalse	With increasing amounts of HeLa extract, @CHEMICAL$ substitution for dAMP within the @GENE$ decreased in vitro pol II transcription by approximately 35% compared with control substrates.
1851	CPRFalse	With increasing amounts of HeLa extract, @CHEMICAL$ substitution for dAMP within the TATA box decreased in vitro @GENE$ transcription by approximately 35% compared with control substrates.
1852	CPRFalse	With increasing amounts of HeLa extract, CldAMP substitution for @CHEMICAL$ within the @GENE$ decreased in vitro pol II transcription by approximately 35% compared with control substrates.
1853	CPRFalse	With increasing amounts of HeLa extract, CldAMP substitution for @CHEMICAL$ within the TATA box decreased in vitro @GENE$ transcription by approximately 35% compared with control substrates.
1854	CPRFalse	In contrast, transcription on @CHEMICAL$-substituted @GENE$ reached a plateau after 20 min.
1855	CPRFalse	Furthermore, @CHEMICAL$-substituted promoter sequences trapped or sequestered TBP, preventing its dissociation from DNA and subsequent binding to additional @GENE$ to reinitiate transcription.
1856	CPRFalse	Blockade of @CHEMICAL$- and desensitization of beta 2-adrenoceptors reduce @GENE$-induced cardiac fibrosis.
1857	CPRFalse	Blockade of beta 1- and desensitization of @CHEMICAL$ reduce @GENE$-induced cardiac fibrosis.
1858	CPRFalse	The aim of the present study was to analyse the role of @CHEMICAL$ in the @GENE$-induced myocardial remodeling, especially the interstitial fibrosis.
1859	CPR:6	Rats received a concomitant treatment with the selective @CHEMICAL$ antagonist, @GENE$ (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.
1860	CPRFalse	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, @CHEMICAL$ (50 mg/kg/day p.o.) or were chronically pretreated with the selective @GENE$ agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.
1861	CPRFalse	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, @CHEMICAL$ (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce @GENE$ desensitization.
1862	CPRFalse	Rats received a concomitant treatment with the selective @CHEMICAL$ antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist @GENE$ (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.
1863	CPR:5	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective @CHEMICAL$ agonist @GENE$ (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.
1864	CPRFalse	Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist @CHEMICAL$ (40 microg/kg/h) for 1 week to induce @GENE$ desensitization.
1865	CPR:4	The pretreatment with @CHEMICAL$ induced a 59% down-regulation of left ventricular @GENE$ compared to control.
1866	CPRFalse	beta(1)-adrenoceptor blockade and beta(2)-adrenoceptors down-regulation provided similar protection against @CHEMICAL$-induced cardiac interstitial fibrosis suggesting that both @GENE$ are involved in such cardiac remodeling process.
1867	CPRFalse	beta(1)-adrenoceptor blockade and @CHEMICAL$ down-regulation provided similar protection against @GENE$-induced cardiac interstitial fibrosis suggesting that both beta-adrenoceptors are involved in such cardiac remodeling process.
1868	CPRFalse	@CHEMICAL$ blockade and beta(2)-adrenoceptors down-regulation provided similar protection against @GENE$-induced cardiac interstitial fibrosis suggesting that both beta-adrenoceptors are involved in such cardiac remodeling process.
1869	CPRFalse	Characterization of the @CHEM-GENE$ TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. 1.
1870	CPRFalse	Characterization of the mouse cold-@CHEMICAL$ receptor @GENE$ and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. 1.
1871	CPRFalse	Characterization of the mouse cold-@CHEMICAL$ receptor TRPM8 and @GENE$ VR1 using a fluorometric imaging plate reader (FLIPR) assay. 1.
1872	CPRFalse	Characterization of the mouse cold-@CHEMICAL$ receptor TRPM8 and vanilloid receptor type-1 @GENE$ using a fluorometric imaging plate reader (FLIPR) assay. 1.
1873	CPRFalse	TRPM8 (CMR1) is a @CHEM-GENE$, which can be activated by low temperatures, menthol, eucalyptol and icilin.
1874	CPRFalse	TRPM8 (@CHEMICAL$) is a @GENE$-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.
1875	CPRFalse	@CHEMICAL$ (CMR1) is a @GENE$-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.
1876	CPR:3	TRPM8 (CMR1) is a @CHEMICAL$, which can be activated by low temperatures, menthol, @GENE$ and icilin.
1877	CPR:3	TRPM8 (@CHEMICAL$) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, @GENE$ and icilin.
1878	CPR:3	@CHEMICAL$ (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, @GENE$ and icilin.
1879	CPR:3	TRPM8 (CMR1) is a @CHEMICAL$, which can be activated by low temperatures, @GENE$, eucalyptol and icilin.
1880	CPR:3	TRPM8 (@CHEMICAL$) is a Ca(2+)-permeable channel, which can be activated by low temperatures, @GENE$, eucalyptol and icilin.
1881	CPR:3	@CHEMICAL$ (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, @GENE$, eucalyptol and icilin.
1882	CPR:3	TRPM8 (CMR1) is a @CHEMICAL$, which can be activated by low temperatures, menthol, eucalyptol and @GENE$.
1883	CPR:3	TRPM8 (@CHEMICAL$) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and @GENE$.
1884	CPR:3	@CHEMICAL$ (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and @GENE$.
1885	CPRFalse	We tested whether substances which are structurally related to @CHEMICAL$, or which produce a cooling sensation, could activate @GENE$, and compared the responses of TRPM8 and VR1 to these ligands.
1886	CPRFalse	We tested whether substances which are structurally related to @CHEMICAL$, or which produce a cooling sensation, could activate TRPM8, and compared the responses of @GENE$ and VR1 to these ligands.
1887	CPRFalse	We tested whether substances which are structurally related to @CHEMICAL$, or which produce a cooling sensation, could activate TRPM8, and compared the responses of TRPM8 and @GENE$ to these ligands.
1888	CPRFalse	The effects of 70 odorants and @CHEMICAL$-related substances on recombinant @GENE$ (mTRPM8), expressed in HEK293 cells, were examined using a FLIPR assay.
1889	CPRFalse	The effects of 70 odorants and @CHEMICAL$-related substances on recombinant mouse TRPM8 (@GENE$), expressed in HEK293 cells, were examined using a FLIPR assay.
1890	CPR:6	Known @CHEMICAL$ antagonists (@GENE$, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1891	CPR:4	Known VR1 antagonists (@CHEMICAL$, thio-BCTC and capsazepine) were also able to block the response of @GENE$ to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1892	CPR:6	Known @CHEMICAL$ antagonists (BCTC, @GENE$ and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1893	CPR:4	Known VR1 antagonists (BCTC, @CHEMICAL$ and capsazepine) were also able to block the response of @GENE$ to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1894	CPR:6	Known @CHEMICAL$ antagonists (BCTC, thio-BCTC and @GENE$) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1895	CPR:4	Known VR1 antagonists (BCTC, thio-BCTC and @CHEMICAL$) were also able to block the response of @GENE$ to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1896	CPRFalse	Known @CHEMICAL$ antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to @GENE$ (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1897	CPR:3	Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of @CHEMICAL$ to @GENE$ (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).
1898	CPRFalse	The @CHEMICAL$ response of @GENE$-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH.
1899	CPRFalse	The @CHEMICAL$ response of hVR1-transfected HEK293 cells to the endogenous @GENE$ agonist N-arachidonoyl-dopamine was potentiated by low pH.
1900	CPR:3	The Ca(2+) response of @CHEMICAL$-transfected HEK293 cells to the endogenous VR1 agonist @GENE$ was potentiated by low pH.
1901	CPR:5	The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous @CHEMICAL$ agonist @GENE$ was potentiated by low pH.
1902	CPR:3	In contrast, @CHEMICAL$- and icilin-activated @GENE$ currents were suppressed by low pH. 6.
1903	CPR:3	In contrast, menthol- and @CHEMICAL$-activated @GENE$ currents were suppressed by low pH. 6.
1904	CPRFalse	Inhibitory effects of the @CHEM-GENE$ inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.
1905	CPRFalse	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the @GENE$ enzymes CYP2C19, CYP2C9, and CYP2D6.
1906	CPRFalse	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes @GENE$, CYP2C9, and CYP2D6.
1907	CPRFalse	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, @GENE$, and CYP2D6.
1908	CPRFalse	Inhibitory effects of the @CHEMICAL$ oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and @GENE$.
1909	CPR:4	Inhibitory effects of the @CHEMICAL$ inhibitor @GENE$ on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.
1910	CPRFalse	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the @GENE$ enzymes CYP2C19, CYP2C9, and CYP2D6.
1911	CPRFalse	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the cytochrome P450 enzymes @GENE$, CYP2C9, and CYP2D6.
1912	CPRFalse	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the cytochrome P450 enzymes CYP2C19, @GENE$, and CYP2D6.
1913	CPRFalse	Inhibitory effects of the monoamine oxidase inhibitor @CHEMICAL$ on the cytochrome P450 enzymes CYP2C19, CYP2C9, and @GENE$.
1914	CPRFalse	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three @GENE$ (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1915	CPRFalse	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (@GENE$) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1916	CPR:4	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of @GENE$ (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1917	CPR:4	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (@GENE$), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1918	CPRFalse	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely @GENE$, CYP2C19, and CYP2D6, have been evaluated in vitro.
1919	CPRFalse	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, @GENE$, and CYP2D6, have been evaluated in vitro.
1920	CPRFalse	The inhibitory effects of @CHEMICAL$, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and @GENE$, have been evaluated in vitro.
1921	CPRFalse	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three @GENE$ (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1922	CPRFalse	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (@GENE$) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1923	CPRFalse	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEM-GENE$ (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1924	CPRFalse	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (@GENE$), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.
1925	CPRFalse	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely @GENE$, CYP2C19, and CYP2D6, have been evaluated in vitro.
1926	CPRFalse	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, @GENE$, and CYP2D6, have been evaluated in vitro.
1927	CPRFalse	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and @GENE$, have been evaluated in vitro.
1928	CPRFalse	A range of substrate concentrations was coincubated with a range of @CHEMICAL$ concentrations in the presence of each of the @GENE$ enzymes at 37 degrees C for a predetermined period of time.
1929	CPR:4	The results demonstrated that @CHEMICAL$ is a competitive inhibitor of @GENE$ (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).
1930	CPR:4	The results demonstrated that @CHEMICAL$ is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and @GENE$ (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).
1931	CPR:4	The results demonstrated that @CHEMICAL$ is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of @GENE$ (Ki = 56 microM).
1932	CPRFalse	However, in certain situations such as high dose tranylcypromine therapy, or in poor metabolizers of @CHEMICAL$ substrates, clinically significant interactions might occur, particularly when @GENE$ is coadministered with drugs with a narrow therapeutic index.
1933	CPRFalse	However, in certain situations such as high dose @CHEMICAL$ therapy, or in poor metabolizers of @GENE$ substrates, clinically significant interactions might occur, particularly when tranylcypromine is coadministered with drugs with a narrow therapeutic index.
1934	CPRFalse	Organization and expression of the @CHEM-GENE$ genes.
1935	CPRFalse	The @CHEMICAL$ gene, which encodes the lysosomal @GENE$ transporter LYAAT1/PAT1, generates multiple alternative mRNAs, some of which encode truncated proteins.
1936	CPRFalse	The human SLC36A1 gene, which encodes the @CHEM-GENE$/PAT1, generates multiple alternative mRNAs, some of which encode truncated proteins.
1937	CPRFalse	The human SLC36A1 gene, which encodes the lysosomal @CHEMICAL$ transporter LYAAT1/@GENE$, generates multiple alternative mRNAs, some of which encode truncated proteins.
1938	CPRFalse	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @CHEM-GENE$ tramdorinl/PAT2, is most abundant in kidney and muscle.
1939	CPRFalse	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @CHEMICAL$ transporter @GENE$/PAT2, is most abundant in kidney and muscle.
1940	CPRFalse	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @CHEMICAL$ transporter tramdorinl/@GENE$, is most abundant in kidney and muscle.
1941	CPRFalse	@CHEMICAL$ is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the @GENE$ transporter tramdorinl/PAT2, is most abundant in kidney and muscle.
1942	CPRFalse	SLC36A1 is expressed in numerous tissues, whereas expression of @CHEMICAL$, which encodes the @GENE$ transporter tramdorinl/PAT2, is most abundant in kidney and muscle.
1943	CPRFalse	@CHEMICAL$ mutants were hypersensitive to @GENE$ (HU), aphidicolin, and UV-B light but only mildly sensitive to gamma-radiation.
1944	CPRFalse	@CHEMICAL$ mutants were hypersensitive to hydroxyurea (@GENE$), aphidicolin, and UV-B light but only mildly sensitive to gamma-radiation.
1945	CPRFalse	@CHEMICAL$ mutants were hypersensitive to hydroxyurea (HU), @GENE$, and UV-B light but only mildly sensitive to gamma-radiation.
1946	CPRFalse	G2 arrest also was observed in wild-type plants in response to @CHEMICAL$ but was defective in @GENE$ mutants, resulting in compaction of nuclei and subsequent cell death.
1947	CPRFalse	The current report describes progress in development of a selective @CHEM-GENE$ modulator, GC-1.
1948	CPRFalse	This compound binds selectively to the @CHEM-GENE$, and its uptake into the heart is relatively low.
1949	CPRFalse	Studies in rats, mice and monkeys show that GC-1 lowers @CHEMICAL$ with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of triglyceride and @GENE$, and induces loss of fat.
1950	CPRFalse	Studies in rats, mice and monkeys show that GC-1 lowers @CHEMICAL$ with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @GENE$. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat.
1951	CPRFalse	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than @CHEMICAL$, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of triglyceride and @GENE$, and induces loss of fat.
1952	CPR:4	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than @CHEMICAL$, a compound that blocks @GENE$. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat.
1953	CPRFalse	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @CHEMICAL$ reductase. GC-1 also decreases plasma levels of triglyceride and @GENE$, and induces loss of fat.
1954	CPRFalse	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @CHEM-GENE$. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat.
1955	CPRFalse	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of @CHEMICAL$ and @GENE$, and induces loss of fat.
1956	CPRFalse	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks @CHEMICAL$. GC-1 also decreases plasma levels of @GENE$ and lipoprotein (a), and induces loss of fat.
1957	CPRFalse	@CHEM-GENE$ as a drug target in leukemia.
1958	CPRFalse	The @CHEM-GENE$ (Flk2, STK1) has recently received much attention as a potential drug target.
1959	CPRFalse	The hematopoietic class III receptor @CHEMICAL$ kinase (RTK) Flt3 (@GENE$, STK1) has recently received much attention as a potential drug target.
1960	CPRFalse	The hematopoietic class III receptor @CHEMICAL$ kinase (RTK) Flt3 (Flk2, @GENE$) has recently received much attention as a potential drug target.
1961	CPRFalse	Signal transduction of Flt3 involves activation of several conserved pathways, including the @CHEMICAL$/MAP-Kinase and the @GENE$-3-kinase/Akt signaling cascades.
1962	CPRFalse	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/@CHEMICAL$ and the @GENE$-3-kinase/Akt signaling cascades.
1963	CPRFalse	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/MAP-Kinase and the @CHEM-GENE$/Akt signaling cascades.
1964	CPRFalse	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/MAP-Kinase and the @CHEMICAL$-3-kinase/@GENE$ signaling cascades.
1965	CPRFalse	Signal transduction of @CHEMICAL$ involves activation of several conserved pathways, including the RAS/MAP-Kinase and the @GENE$-3-kinase/Akt signaling cascades.
1966	CPRFalse	Selective inhibitors of Flt3 @CHEM-GENE$ activity have the potential to suppress aberrant Flt3 signaling.
1967	CPRFalse	Selective inhibitors of @CHEMICAL$ @GENE$ kinase activity have the potential to suppress aberrant Flt3 signaling.
1968	CPRFalse	Selective inhibitors of Flt3 @CHEMICAL$ kinase activity have the potential to suppress aberrant @GENE$ signaling.
1969	CPRFalse	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the @GENE$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1970	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the @CHEMICAL$ STI571 (Gleevec, Imatinib), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.
1971	CPRFalse	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the @GENE$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1972	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the @CHEMICAL$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.
1973	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the @CHEMICAL$ STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.
1974	CPRFalse	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the phenylaminopyrimidine @GENE$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1975	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine @CHEMICAL$ (Gleevec, Imatinib), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.
1976	CPRFalse	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the phenylaminopyrimidine @GENE$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1977	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine @CHEMICAL$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.
1978	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine @CHEMICAL$ (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.
1979	CPRFalse	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the phenylaminopyrimidine STI571 (@GENE$, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1980	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (@CHEMICAL$, Imatinib), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.
1981	CPRFalse	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the phenylaminopyrimidine STI571 (@GENE$, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1982	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (@CHEMICAL$, Imatinib), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.
1983	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (@CHEMICAL$, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.
1984	CPRFalse	Although highly homologous to other @CHEMICAL$, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @GENE$), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1985	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @CHEMICAL$), a potent inhibitor of other @GENE$ in the family, such as the PDGFbeta-receptor or c-Kit.
1986	CPRFalse	Although highly homologous to other class III RTKs, @CHEMICAL$ is resistant to the phenylaminopyrimidine STI571 (Gleevec, @GENE$), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.
1987	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @CHEMICAL$), a potent inhibitor of other RTKs in the family, such as the @GENE$ or c-Kit.
1988	CPR:4	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, @CHEMICAL$), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or @GENE$.
1989	CPRFalse	@CHEMICAL$ binding to @GENE$ is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.
1990	CPRFalse	@CHEMICAL$ binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding @GENE$ mutant sensitive to STI571.
1991	CPRFalse	STI571 binding to @CHEMICAL$ is prevented by the @GENE$ 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.
1992	CPRFalse	STI571 binding to Flt3 is prevented by the @CHEMICAL$ 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding @GENE$ mutant sensitive to STI571.
1993	CPRFalse	STI571 binding to @CHEMICAL$ is prevented by the phenylalanine 691 side-chain in the @GENE$ binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.
1994	CPRFalse	STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the @CHEMICAL$ binding center and mutating this site to threonine renders the corresponding @GENE$ mutant sensitive to STI571.
1995	CPRFalse	STI571 binding to @CHEMICAL$ is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to @GENE$ renders the corresponding Flt3 mutant sensitive to STI571.
1996	CPRFalse	STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to @CHEMICAL$ renders the corresponding @GENE$ mutant sensitive to STI571.
1997	CPRFalse	STI571 binding to @CHEMICAL$ is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to @GENE$.
1998	CPR:4	STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding @CHEMICAL$ mutant sensitive to @GENE$.
1999	CPR:4	Compounds of several other structural families, including the @CHEMICAL$ AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2000	CPR:4	Compounds of several other structural families, including the @CHEMICAL$ AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2001	CPR:4	Compounds of several other structural families, including the quinoxaline @CHEMICAL$, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2002	CPR:4	Compounds of several other structural families, including the quinoxaline @CHEMICAL$, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2003	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the @CHEMICAL$ D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2004	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the @CHEMICAL$ D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2005	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone @CHEMICAL$, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2006	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone @CHEMICAL$, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2007	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the @CHEMICAL$ SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2008	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the @CHEMICAL$ SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2009	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones @CHEMICAL$ and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2010	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones @CHEMICAL$ and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2011	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and @CHEMICAL$, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2012	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and @CHEMICAL$, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2013	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the @CHEMICAL$ PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2014	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the @CHEMICAL$ PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2015	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles @CHEMICAL$ and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2016	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles @CHEMICAL$ and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2017	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and @CHEMICAL$, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 @GENE$.
2018	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and @CHEMICAL$, and the piperazonyl quinazoline CT53518, are potent inhibitors of @GENE$ kinase.
2019	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the @CHEMICAL$ CT53518, are potent inhibitors of Flt3 @GENE$.
2020	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the @CHEMICAL$ CT53518, are potent inhibitors of @GENE$ kinase.
2021	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline @CHEMICAL$, are potent inhibitors of Flt3 @GENE$.
2022	CPR:4	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline @CHEMICAL$, are potent inhibitors of @GENE$ kinase.
2023	CPRFalse	Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of @CHEM-GENE$.
2024	CPRFalse	Novel mechanism of action for hydralazine: induction of @CHEMICAL$, vascular endothelial growth factor, and angiogenesis by inhibition of @GENE$ hydroxylases.
2025	CPRFalse	Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, @CHEMICAL$, and angiogenesis by inhibition of @GENE$ hydroxylases.
2026	CPR:4	Novel mechanism of action for @CHEMICAL$: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of @GENE$.
2027	CPR:3	Novel mechanism of action for @CHEMICAL$: induction of @GENE$, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.
2028	CPR:3	Novel mechanism of action for @CHEMICAL$: induction of hypoxia-inducible factor-1alpha, @GENE$, and angiogenesis by inhibition of prolyl hydroxylases.
2029	CPRFalse	@CHEM-GENE$ is a known target of hydralazine.
2030	CPRFalse	@CHEMICAL$ is a known target of @GENE$.
2031	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the @CHEMICAL$ (HIF)-regulating @GENE$-dependent prolyl hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.
2032	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (@CHEMICAL$)-regulating @GENE$-dependent prolyl hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.
2033	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating @CHEMICAL$-dependent @GENE$ (PHD) enzymes, could represent a novel mechanism of action.
2034	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating @CHEMICAL$-dependent prolyl hydroxylase domain (@GENE$) enzymes, could represent a novel mechanism of action.
2035	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the @CHEMICAL$ (HIF)-regulating O2-dependent @GENE$ hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.
2036	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (@CHEMICAL$)-regulating O2-dependent @GENE$ hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.
2037	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating O2-dependent @CHEM-GENE$ (PHD) enzymes, could represent a novel mechanism of action.
2038	CPRFalse	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating O2-dependent @CHEMICAL$ hydroxylase domain (@GENE$) enzymes, could represent a novel mechanism of action.
2039	CPR:3	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of @GENE$ (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.
2040	CPR:3	@CHEMICAL$ induced rapid and transient expression of @GENE$ and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.
2041	CPR:3	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (@GENE$, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.
2042	CPR:3	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, @GENE$, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.
2043	CPR:3	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, @GENE$, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.
2044	CPR:3	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and @GENE$ [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.
2045	CPR:3	@CHEMICAL$ induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [@GENE$]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.
2046	CPR:4	@CHEMICAL$ dose-dependently inhibited @GENE$ activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.
2047	CPRFalse	@CHEMICAL$ dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for @GENE$ stabilization specifically by inhibition of PHD enzyme activity.
2048	CPR:4	@CHEMICAL$ dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of @GENE$ enzyme activity.
2049	CPR:3	@CHEMICAL$ dose-dependently inhibited PHD activity and induced nonhydroxylated @GENE$, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.
2050	CPR:3	In vivo, @CHEMICAL$ induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma @GENE$ levels.
2051	CPR:3	In vivo, @CHEMICAL$ induced @GENE$ and VEGF protein in tissue extracts and elevated plasma VEGF levels.
2052	CPR:3	In vivo, @CHEMICAL$ induced HIF-1alpha and @GENE$ protein in tissue extracts and elevated plasma VEGF levels.
2053	CPR:3	Thus, @CHEMICAL$ activates the @GENE$ pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.
2054	CPR:4	Thus, @CHEMICAL$ activates the HIF pathway through inhibition of @GENE$ activity and initiates a pro-angiogenic phenotype.
2055	CPRFalse	This represents a novel mechanism of action for @CHEMICAL$ and presents @GENE$ as a potential target for treatment of ischemic disease.
2056	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, @CHEMICAL$, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2057	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, @CHEMICAL$, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2058	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, @CHEMICAL$, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2059	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, @CHEMICAL$, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2060	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, @CHEMICAL$, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2061	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, @CHEMICAL$, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2062	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and @CHEMICAL$ had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2063	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and @CHEMICAL$ had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2064	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and @CHEMICAL$ had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2065	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas @GENE$, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2066	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas @CHEMICAL$, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2067	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas @CHEMICAL$, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2068	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, @GENE$, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2069	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, @CHEMICAL$, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2070	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, @CHEMICAL$, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2071	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, carprofen, @GENE$, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2072	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, @CHEMICAL$, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2073	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, @CHEMICAL$, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2074	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, carprofen, tolfenamic acid, @GENE$, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2075	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, @CHEMICAL$, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2076	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, @CHEMICAL$, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2077	CPRFalse	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @CHEMICAL$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and @GENE$ had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2078	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and @CHEMICAL$ had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2079	CPR:4	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and @CHEMICAL$ had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2080	CPRFalse	RESULTS: @CHEMICAL$, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2081	CPRFalse	RESULTS: @CHEMICAL$, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2082	CPRFalse	RESULTS: @CHEMICAL$, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2083	CPRFalse	RESULTS: Aspirin, @CHEMICAL$, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2084	CPRFalse	RESULTS: Aspirin, @CHEMICAL$, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2085	CPRFalse	RESULTS: Aspirin, @CHEMICAL$, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2086	CPRFalse	RESULTS: Aspirin, diclofenac, @CHEMICAL$, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward @GENE$ isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.
2087	CPRFalse	RESULTS: Aspirin, diclofenac, @CHEMICAL$, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting @GENE$ than COX-1.
2088	CPRFalse	RESULTS: Aspirin, diclofenac, @CHEMICAL$, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than @GENE$.
2089	CPR:4	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by @GENE$, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.
2090	CPRFalse	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by @CHEMICAL$, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.
2091	CPR:4	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, @GENE$, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.
2092	CPRFalse	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, @CHEMICAL$, and NS398; tolfenamic acid and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.
2093	CPR:4	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, nimesulide, and @GENE$; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.
2094	CPRFalse	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and @CHEMICAL$; tolfenamic acid and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.
2095	CPRFalse	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, nimesulide, and NS398; @GENE$ and carprofen also appeared to be preferential COX-2 inhibitors in dogs.
2096	CPR:4	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; @CHEMICAL$ and carprofen also appeared to be preferential @GENE$ inhibitors in dogs.
2097	CPRFalse	CONCLUSIONS AND CLINICAL RELEVANCE: @CHEMICAL$ was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and @GENE$ also appeared to be preferential COX-2 inhibitors in dogs.
2098	CPR:4	CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and @CHEMICAL$ also appeared to be preferential @GENE$ inhibitors in dogs.
2099	CPRFalse	@CHEMICAL$ binds to the @GENE$.
2100	CPRFalse	Ketoconazole binds to the @CHEM-GENE$.
2101	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @GENE$ (SSBG), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.
2102	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (@GENE$), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.
2103	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to @GENE$ (AR) in vitro was also examined.
2104	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of @CHEMICAL$ for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (@GENE$) in vitro was also examined.
2105	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for @GENE$ (SSBG), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.
2106	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for sex steroid binding globulin (@GENE$), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.
2107	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for sex steroid binding globulin (SSBG), the binding of ketoconazole to @GENE$ (AR) in vitro was also examined.
2108	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and @CHEMICAL$ and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (@GENE$) in vitro was also examined.
2109	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @CHEM-GENE$ (SSBG), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.
2110	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex @CHEMICAL$ binding globulin (@GENE$), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.
2111	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex @CHEMICAL$ binding globulin (SSBG), the binding of ketoconazole to @GENE$ (AR) in vitro was also examined.
2112	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex @CHEMICAL$ binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (@GENE$) in vitro was also examined.
2113	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @CHEMICAL$ (SSBG), the binding of @GENE$ to human androgen receptors (AR) in vitro was also examined.
2114	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (@CHEMICAL$), the binding of @GENE$ to human androgen receptors (AR) in vitro was also examined.
2115	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of @CHEMICAL$ to @GENE$ (AR) in vitro was also examined.
2116	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of @CHEMICAL$ to human androgen receptors (@GENE$) in vitro was also examined.
2117	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for @CHEMICAL$ (SSBG), the binding of ketoconazole to human @GENE$ receptors (AR) in vitro was also examined.
2118	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (@CHEMICAL$), the binding of ketoconazole to human @GENE$ receptors (AR) in vitro was also examined.
2119	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to @CHEM-GENE$ (AR) in vitro was also examined.
2120	CPRFalse	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human @CHEMICAL$ receptors (@GENE$) in vitro was also examined.
2121	CPRFalse	@CHEMICAL$ competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.
2122	CPRFalse	Ketoconazole competition with @CHEMICAL$ (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.
2123	CPRFalse	Ketoconazole competition with [3H]methyltrienolone (@CHEMICAL$) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.
2124	CPRFalse	Ketoconazole competition with [3H]methyltrienolone (R1881) for @CHEMICAL$ binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.
2125	CPRFalse	Ketoconazole competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of @CHEMICAL$ binding to @GENE$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.
2126	CPRFalse	Ketoconazole competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to @CHEMICAL$ was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M @GENE$.
2127	CPRFalse	Additional binding studies performed with @CHEMICAL$ in the presence of increasing amounts of [3H]R1881 showed that the interaction of ketoconazole with @GENE$ was competitive when the data were analyzed by the Scatchard method.
2128	CPRFalse	Additional binding studies performed with ketoconazole in the presence of increasing amounts of [3H]R1881 showed that the interaction of @CHEMICAL$ with @GENE$ was competitive when the data were analyzed by the Scatchard method.
2129	CPRFalse	Additional binding studies performed with ketoconazole in the presence of increasing amounts of @CHEMICAL$ showed that the interaction of ketoconazole with @GENE$ was competitive when the data were analyzed by the Scatchard method.
2130	CPRFalse	It should be noted, however, that the dose of @CHEMICAL$ required for 50% occupancy of the @GENE$ is not likely to be achieved in vivo, at least in plasma.
2131	CPRFalse	It should be noted, however, that the dose of ketoconazole required for 50% occupancy of the @CHEM-GENE$ is not likely to be achieved in vivo, at least in plasma.
2132	CPRFalse	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only @CHEMICAL$ appears to interact with the @GENE$.
2133	CPRFalse	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @CHEM-GENE$.
2134	CPRFalse	Finally, @CHEMICAL$ binding studies performed with other imidazoles, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.
2135	CPRFalse	Finally, androgen binding studies performed with other @CHEMICAL$, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.
2136	CPRFalse	Finally, androgen binding studies performed with other imidazoles, such as @CHEMICAL$, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.
2137	CPRFalse	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, @CHEMICAL$, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.
2138	CPRFalse	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and @CHEMICAL$, revealed that in this class of compounds only ketoconazole appears to interact with the @GENE$.
2139	CPRFalse	@CHEMICAL$ appears to be the first example of a non-steroidal compound which binds competitively to both SSBG and multiple @GENE$, suggesting that the ligand binding sites of these proteins share some features in common.
2140	CPRFalse	@CHEMICAL$ appears to be the first example of a non-steroidal compound which binds competitively to both @GENE$ and multiple steroid hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.
2141	CPRFalse	Ketoconazole appears to be the first example of a non-@CHEMICAL$ compound which binds competitively to both SSBG and multiple @GENE$, suggesting that the ligand binding sites of these proteins share some features in common.
2142	CPRFalse	Ketoconazole appears to be the first example of a non-@CHEMICAL$ compound which binds competitively to both @GENE$ and multiple steroid hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.
2143	CPRFalse	Ketoconazole appears to be the first example of a non-steroidal compound which binds competitively to both SSBG and multiple @CHEM-GENE$, suggesting that the ligand binding sites of these proteins share some features in common.
2144	CPRFalse	Ketoconazole appears to be the first example of a non-steroidal compound which binds competitively to both @CHEMICAL$ and multiple @GENE$ hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.
2145	CPRFalse	BACKGROUND: Extracellular @CHEMICAL$ (ATP, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.
2146	CPRFalse	BACKGROUND: Extracellular @CHEMICAL$ (ATP, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.
2147	CPRFalse	BACKGROUND: Extracellular nucleotides (@CHEMICAL$, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.
2148	CPRFalse	BACKGROUND: Extracellular nucleotides (@CHEMICAL$, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.
2149	CPRFalse	BACKGROUND: Extracellular nucleotides (ATP, @CHEMICAL$, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.
2150	CPRFalse	BACKGROUND: Extracellular nucleotides (ATP, @CHEMICAL$, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.
2151	CPRFalse	BACKGROUND: Extracellular nucleotides (ATP, ADP, @CHEMICAL$ and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.
2152	CPRFalse	BACKGROUND: Extracellular nucleotides (ATP, ADP, @CHEMICAL$ and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.
2153	CPRFalse	BACKGROUND: Extracellular nucleotides (ATP, ADP, UTP and @CHEMICAL$) exert a wide range of biological effects in blood cells mediated by multiple ionotropic @GENE$ receptors and G protein-coupled P2Y receptors.
2154	CPRFalse	BACKGROUND: Extracellular nucleotides (ATP, ADP, UTP and @CHEMICAL$) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and @GENE$.
2155	CPRFalse	CONCLUSIONS: The most interesting findings were the high mRNA expression of @CHEMICAL$ receptors in lymphocytes potentially explaining the anti-inflammatory effects of @GENE$, P2Y13 receptors in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes.
2156	CPRFalse	CONCLUSIONS: The most interesting findings were the high mRNA expression of P2Y12 receptors in lymphocytes potentially explaining the anti-inflammatory effects of @CHEMICAL$, @GENE$ receptors in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes.
2157	CPRFalse	CONCLUSIONS: The most interesting findings were the high mRNA expression of P2Y12 receptors in lymphocytes potentially explaining the anti-inflammatory effects of @CHEMICAL$, P2Y13 receptors in monocytes and a previously unrecognised expression of @GENE$ in lymphocytes and monocytes.
2158	CPR:4	@CHEMICAL$ served as inhibitor of an interfering @GENE$ present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.
2159	CPRFalse	A disorder to order transition accompanies catalysis in @CHEM-GENE$.
2160	CPRFalse	@CHEM-GENE$ (RalDH2) converts retinal to the transcriptional regulator retinoic acid in the developing embryo.
2161	CPRFalse	@CHEMICAL$ dehydrogenase II (@GENE$) converts retinal to the transcriptional regulator retinoic acid in the developing embryo.
2162	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @GENE$ this region forms a well defined wall of the substrate access channel.
2163	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEM-GENE$ of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.
2164	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @GENE$ is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.
2165	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-@CHEMICAL$ span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @GENE$ this region forms a well defined wall of the substrate access channel.
2166	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ of the same enzyme superfamily; a 20-@GENE$ span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.
2167	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-@CHEMICAL$ span in the substrate access channel in @GENE$ is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.
2168	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @CHEMICAL$ dehydrogenase II is disordered, whereas in other @GENE$ this region forms a well defined wall of the substrate access channel.
2169	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @GENE$ dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.
2170	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @CHEM-GENE$ is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.
2171	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @CHEM-GENE$ this region forms a well defined wall of the substrate access channel.
2172	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other @CHEMICAL$ of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other @GENE$ dehydrogenases this region forms a well defined wall of the substrate access channel.
2173	CPRFalse	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in @CHEMICAL$ is disordered, whereas in other @GENE$ dehydrogenases this region forms a well defined wall of the substrate access channel.
2174	CPRFalse	Effects of @CHEMICAL$ on @GENE$ concentration and symptoms in patients with heart failure and preserved ejection fraction.
2175	CPR:4	After 12 months of treatment, @CHEMICAL$ significantly improved all end points (plasma concentration of @GENE$ [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).
2176	CPR:4	After 12 months of treatment, @CHEMICAL$ significantly improved all end points (plasma concentration of B-type natriuretic peptide [@GENE$] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).
2177	CPRFalse	After 12 months of treatment, @CHEMICAL$ significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (@GENE$ concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).
2178	CPR:4	Univariate regression analyses showed that only the use of @CHEMICAL$ was correlated with the decrease in @GENE$ concentration (p <0.03).
2179	CPRFalse	Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of BNP (p <0.02), left ventricular dilation (p <0.03), and use of @CHEMICAL$ (p <0.04) at baseline were predictive of a decrease in plasma concentration of @GENE$.
2180	CPRFalse	Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of @CHEMICAL$ (p <0.02), left ventricular dilation (p <0.03), and use of @GENE$ (p <0.04) at baseline were predictive of a decrease in plasma concentration of BNP.
2181	CPRFalse	Psychopharmacology of anticonvulsants: @CHEMICAL$ as a @GENE$ modulator.
2182	CPRFalse	@CHEMICAL$ binds selectively and with high affinity to a @GENE$ known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.
2183	CPRFalse	@CHEMICAL$ binds selectively and with high affinity to a synaptic vesicle protein known as @GENE$, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.
2184	CPR:4	@CHEMICAL$: mode of action and properties of the @GENE$ inhibition.
2185	CPRFalse	Terbinafine: mode of action and properties of the @CHEM-GENE$ inhibition.
2186	CPR:4	@CHEMICAL$ (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of @GENE$ inhibition.
2187	CPRFalse	Terbinafine (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of @CHEM-GENE$ inhibition.
2188	CPR:4	Terbinafine (@CHEMICAL$) has primarily fungicidal action against many fungi as a result of its specific mechanism of @GENE$ inhibition.
2189	CPR:4	@CHEMICAL$ is a potent non-competitive inhibitor of @GENE$ from Candida (Ki = 30 nM).
2190	CPRFalse	Terbinafine is a potent non-competitive inhibitor of @CHEM-GENE$ from Candida (Ki = 30 nM).
2191	CPRFalse	In contrast, inhibition of @CHEM-GENE$ only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with squalene.
2192	CPR:4	In contrast, inhibition of @CHEMICAL$ only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with @GENE$.
2193	CPRFalse	@CHEMICAL$ epoxidase is not an enzyme of the @GENE$ type, thereby avoiding potential inhibition of this class of enzymes.
2194	CPRFalse	@CHEM-GENE$ is not an enzyme of the cytochrome P-450 type, thereby avoiding potential inhibition of this class of enzymes.
2195	CPRFalse	@CHEMICAL$ decreased the stability of @GENE$-mRNA and COX-2 mRNA.
2196	CPRFalse	@CHEMICAL$ decreased the stability of TNF-mRNA and @GENE$ mRNA.
2197	CPRFalse	Although @CHEMICAL$ inhibits PG biosynthesis, most do not affect the @GENE$ activity of COX, which can generate proximate carcinogens.
2198	CPRFalse	Although @CHEMICAL$ inhibits PG biosynthesis, most do not affect the peroxidase activity of @GENE$, which can generate proximate carcinogens.
2199	CPRFalse	Because @CHEMICAL$ does not completely inhibit @GENE$ expression or PG biosynthesis, a therapeutic strategy combining celecoxib with thalidomide might be more effective than using either agent alone.
2200	CPRFalse	Because thalidomide does not completely inhibit @CHEMICAL$ expression or PG biosynthesis, a therapeutic strategy combining @GENE$ with thalidomide might be more effective than using either agent alone.
2201	CPRFalse	Because thalidomide does not completely inhibit @CHEMICAL$ expression or PG biosynthesis, a therapeutic strategy combining celecoxib with @GENE$ might be more effective than using either agent alone.
2202	CPRFalse	Effect of @CHEMICAL$ on @GENE$ production in HepG2 cell.
2203	CPRFalse	There are few reports describing the mechanism of @CHEMICAL$-elevating action of @GENE$ reductase inhibitors (statins).
2204	CPRFalse	There are few reports describing the mechanism of HDL-elevating action of @CHEM-GENE$ inhibitors (statins).
2205	CPRFalse	Each statin induced @CHEMICAL$ expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction @GENE$ (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).
2206	CPR:3	Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the @CHEMICAL$ induction @GENE$ (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).
2207	CPRFalse	Each statin induced @CHEMICAL$ expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>@GENE$ (10 microM)>atorvastatin (30 microM).
2208	CPR:3	Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the @CHEMICAL$ induction pitavastatin (3 microM)>@GENE$ (10 microM)>atorvastatin (30 microM).
2209	CPRFalse	Each statin induced @CHEMICAL$ expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>@GENE$ (30 microM).
2210	CPR:3	Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the @CHEMICAL$ induction pitavastatin (3 microM)>simvastatin (10 microM)>@GENE$ (30 microM).
2211	CPR:4	The induction of @CHEMICAL$ by statins disappeared with addition of @GENE$, which indicates that the effect is HMG-CoA reductase inhibition-dependent.
2212	CPRFalse	The induction of apoA-I by statins disappeared with addition of @CHEMICAL$, which indicates that the effect is @GENE$ inhibition-dependent.
2213	CPRFalse	The induction of @CHEMICAL$ by statins disappeared with addition of mevalonate, which indicates that the effect is @GENE$ reductase inhibition-dependent.
2214	CPRFalse	The induction of apoA-I by statins disappeared with addition of mevalonate, which indicates that the effect is @CHEM-GENE$ inhibition-dependent.
2215	CPRFalse	Based on @CHEMICAL$ inhibition, pitavastatin-induced apoA-I more efficiently than @GENE$ and atorvastatin.
2216	CPR:3	Based on HMG-CoA reductase inhibition, pitavastatin-induced @CHEMICAL$ more efficiently than @GENE$ and atorvastatin.
2217	CPRFalse	Based on @CHEMICAL$ inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and @GENE$.
2218	CPR:3	Based on HMG-CoA reductase inhibition, pitavastatin-induced @CHEMICAL$ more efficiently than simvastatin and @GENE$.
2219	CPRFalse	Based on @CHEM-GENE$ inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and atorvastatin.
2220	CPRFalse	Based on @CHEMICAL$ reductase inhibition, pitavastatin-induced @GENE$ more efficiently than simvastatin and atorvastatin.
2221	CPRFalse	Based on @CHEMICAL$ inhibition, @GENE$-induced apoA-I more efficiently than simvastatin and atorvastatin.
2222	CPR:3	Based on HMG-CoA reductase inhibition, @CHEMICAL$-induced @GENE$ more efficiently than simvastatin and atorvastatin.
2223	CPRFalse	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that @GENE$ and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2224	CPRFalse	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and @GENE$ inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2225	CPR:3	Further study revealed that @CHEMICAL$ increased @GENE$ mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2226	CPRFalse	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in @GENE$-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2227	CPRFalse	Further study revealed that @CHEMICAL$ increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased @GENE$ production in the HepG2 cells.
2228	CPRFalse	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$ reductase-dependent manner and that @GENE$ and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2229	CPRFalse	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$ reductase-dependent manner and that Rho and @GENE$ inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2230	CPRFalse	Further study revealed that pitavastatin increased @CHEMICAL$ mRNA in @GENE$ reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2231	CPRFalse	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEM-GENE$-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.
2232	CPRFalse	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$ reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased @GENE$ production in the HepG2 cells.
2233	CPR:4	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that @CHEMICAL$ and Rho kinase inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.
2234	CPR:4	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and @CHEMICAL$ inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.
2235	CPRFalse	Further study revealed that pitavastatin increased @CHEMICAL$ mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.
2236	CPRFalse	Further study revealed that pitavastatin increased ABCA1 mRNA in @CHEMICAL$-dependent manner and that Rho and Rho kinase inhibitor (C3T and @GENE$) increased apoA-I production in the HepG2 cells.
2237	CPR:3	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and @CHEMICAL$) increased @GENE$ production in the HepG2 cells.
2238	CPR:4	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of @GENE$ activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2239	CPR:3	These results suggest that @CHEMICAL$ efficiently increases @GENE$ in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2240	CPR:3	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting @GENE$ production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2241	CPR:4	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @GENE$ and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2242	CPRFalse	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting @GENE$ from catabolism through ABCA1 induction and lipidation of apoA-I.
2243	CPR:3	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through @GENE$ induction and lipidation of apoA-I.
2244	CPR:3	These results suggest that @CHEMICAL$ efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of @GENE$.
2245	CPRFalse	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of @GENE$ activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2246	CPRFalse	These results suggest that pitavastatin efficiently increases @CHEMICAL$ in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @GENE$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2247	CPRFalse	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting @CHEMICAL$ production through inhibition of @GENE$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2248	CPRFalse	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEM-GENE$ and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
2249	CPRFalse	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of Rho activity and by protecting @GENE$ from catabolism through ABCA1 induction and lipidation of apoA-I.
2250	CPRFalse	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through @GENE$ induction and lipidation of apoA-I.
2251	CPRFalse	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of @CHEMICAL$ reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of @GENE$.
2252	CPRFalse	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two @CHEM-GENE$ inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
2253	CPRFalse	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor @CHEMICAL$ kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or @GENE$ inhibition.
2254	CPRFalse	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor @CHEMICAL$ kinase inhibitors, imatinib and SU11248, were used to disrupt @GENE$-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
2255	CPR:4	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two @CHEMICAL$ inhibitors, @GENE$ and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
2256	CPR:4	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, @CHEMICAL$ and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or @GENE$ inhibition.
2257	CPR:4	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, @CHEMICAL$ and SU11248, were used to disrupt @GENE$-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
2258	CPR:4	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two @CHEMICAL$ inhibitors, imatinib and @GENE$, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
2259	CPR:4	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and @CHEMICAL$, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or @GENE$ inhibition.
2260	CPR:4	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and @CHEMICAL$, were used to disrupt @GENE$-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
2261	CPR:4	RESULTS: @CHEMICAL$, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or @GENE$ inhibition.
2262	CPRFalse	Synovitis in horses is frequently treated by administration of non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs), which inhibit @GENE$ isoforms (COX-1 and COX-2).
2263	CPRFalse	Synovitis in horses is frequently treated by administration of non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase isoforms (@GENE$ and COX-2).
2264	CPRFalse	Synovitis in horses is frequently treated by administration of non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase isoforms (COX-1 and @GENE$).
2265	CPR:4	The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective @CHEMICAL$ inhibitor @GENE$ in horses with lipopolysaccharide (LPS)-induced synovitis.
2266	CPRFalse	The objective of the present study was to compare the anti-inflammatory effects of the preferential @CHEMICAL$ inhibitor etodolac with the non-selective COX inhibitor @GENE$ in horses with lipopolysaccharide (LPS)-induced synovitis.
2267	CPRFalse	In addition, both drugs significantly reduced @CHEMICAL$ levels (P<0.05) 6-h following LPS injection, whereas the probable @GENE$ prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.
2268	CPRFalse	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ @GENE$ TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.
2269	CPRFalse	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ prostanoid @GENE$ was significantly reduced by phenylbutazone (P<0.05), but not etodolac.
2270	CPR:4	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ prostanoid TXB2 was significantly reduced by @GENE$ (P<0.05), but not etodolac.
2271	CPRFalse	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable @CHEMICAL$ prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not @GENE$.
2272	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @GENE$ and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2273	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @GENE$; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2274	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @GENE$; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2275	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2276	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [@GENE$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2277	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (@GENE$) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2278	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @GENE$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2279	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (@GENE$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2280	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2281	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in @CHEMICAL$-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2282	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) @GENE$ and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2283	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and @GENE$; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2284	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @GENE$; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2285	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2286	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEM-GENE$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2287	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (@GENE$) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2288	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; @GENE$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2289	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (@GENE$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2290	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2291	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2292	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @CHEMICAL$ and A1298C; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2293	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @CHEMICAL$; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2294	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) @GENE$; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2295	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) A2756G; methionine synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2296	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ (MTHFR) C677T and A1298C; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2297	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (@CHEMICAL$) C677T and A1298C; @GENE$ synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2298	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEM-GENE$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2299	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (@GENE$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2300	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) A2756G; @GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2301	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ synthase (MS) A2756G; methionine synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2302	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @CHEMICAL$ and A1298C; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2303	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @CHEMICAL$; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2304	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @CHEMICAL$; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2305	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEMICAL$ synthase reductase (MTRR) @GENE$] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2306	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2307	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (@CHEMICAL$) C677T and A1298C; methionine synthase (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2308	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ (MS) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2309	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (@CHEMICAL$) A2756G; @GENE$ synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2310	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEM-GENE$ (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2311	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEMICAL$ synthase reductase (@GENE$) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2312	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) @CHEMICAL$ and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2313	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and @CHEMICAL$; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2314	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) @CHEMICAL$; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2315	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) @CHEMICAL$] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2316	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [@CHEMICAL$ (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2317	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (@CHEMICAL$) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2318	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; @CHEMICAL$ (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2319	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (@CHEMICAL$) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2320	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; @CHEMICAL$ (MTRR) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2321	CPRFalse	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (@CHEMICAL$) A66G] in relation to total plasma @GENE$ levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.
2322	CPRFalse	However, MS A2756G was significantly associated with @CHEMICAL$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR @GENE$ (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).
2323	CPRFalse	However, MS @CHEMICAL$ was significantly associated with @GENE$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).
2324	CPRFalse	However, MS A2756G was significantly associated with @CHEMICAL$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was @GENE$ A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).
2325	CPRFalse	However, @CHEMICAL$ A2756G was significantly associated with @GENE$ levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).
2326	CPRFalse	Differences in @CHEMICAL$ and folate levels with the MTRR @GENE$ and MS A2756G polymorphisms were noted.
2327	CPRFalse	Differences in @CHEMICAL$ and folate levels with the MTRR A66G and MS @GENE$ polymorphisms were noted.
2328	CPRFalse	Differences in @CHEMICAL$ and folate levels with the @GENE$ A66G and MS A2756G polymorphisms were noted.
2329	CPRFalse	Differences in @CHEMICAL$ and folate levels with the MTRR A66G and @GENE$ A2756G polymorphisms were noted.
2330	CPR:6	Effect of @CHEMICAL$ (@GENE$/ETB receptor antagonist) on metabolic changes during stress and diabetes.
2331	CPR:6	Effect of @CHEMICAL$ (ETA/@GENE$ receptor antagonist) on metabolic changes during stress and diabetes.
2332	CPR:6	To test this, we studied the possible effect of the @CHEMICAL$ antagonist, @GENE$ (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.
2333	CPRFalse	To test this, we studied the possible effect of the endothelin receptor antagonist, @CHEMICAL$ (50 and 100 mg kg(-1)) on serum glucose and @GENE$ levels as well as on liver glycogen contents in normoglycemic stressed animals.
2334	CPRFalse	To test this, we studied the possible effect of the @CHEMICAL$ antagonist, bosentan (50 and 100 mg kg(-1)) on serum @GENE$ and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.
2335	CPRFalse	To test this, we studied the possible effect of the endothelin receptor antagonist, bosentan (50 and 100 mg kg(-1)) on serum @CHEMICAL$ and @GENE$ levels as well as on liver glycogen contents in normoglycemic stressed animals.
2336	CPRFalse	In addition, the effect of @CHEMICAL$ on serum glucose and @GENE$ levels in both mild and severely diabetic rats and its effect on insulin-induced hypoglycemia were also determined.
2337	CPRFalse	In addition, the effect of @CHEMICAL$ on serum glucose and insulin levels in both mild and severely diabetic rats and its effect on @GENE$-induced hypoglycemia were also determined.
2338	CPRFalse	In addition, the effect of bosentan on serum @CHEMICAL$ and @GENE$ levels in both mild and severely diabetic rats and its effect on insulin-induced hypoglycemia were also determined.
2339	CPRFalse	In addition, the effect of bosentan on serum @CHEMICAL$ and insulin levels in both mild and severely diabetic rats and its effect on @GENE$-induced hypoglycemia were also determined.
2340	CPRFalse	@CHEMICAL$ partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in @GENE$ level in normoglycemic stressed rats.
2341	CPRFalse	@CHEMICAL$ also decreased serum glucose level without any effect on @GENE$ secretion in mild diabetic rats and potentiated the hypoglycemic action of insulin.
2342	CPRFalse	@CHEMICAL$ also decreased serum glucose level without any effect on insulin secretion in mild diabetic rats and potentiated the hypoglycemic action of @GENE$.
2343	CPRFalse	Bosentan also decreased serum @CHEMICAL$ level without any effect on @GENE$ secretion in mild diabetic rats and potentiated the hypoglycemic action of insulin.
2344	CPRFalse	Bosentan also decreased serum @CHEMICAL$ level without any effect on insulin secretion in mild diabetic rats and potentiated the hypoglycemic action of @GENE$.
2345	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2346	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2347	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2348	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2349	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2350	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), @CHEMICAL$ reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2351	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2352	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2353	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2354	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2355	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2356	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), @CHEMICAL$, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2357	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEM-GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2358	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2359	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2360	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2361	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2362	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2363	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$ (complex-I), @GENE$-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2364	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@CHEMICAL$), @GENE$-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2365	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEM-GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2366	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2367	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2368	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2369	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @CHEMICAL$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2370	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@CHEMICAL$), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2371	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @CHEMICAL$ (complex I/II), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2372	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@CHEMICAL$), @GENE$-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2373	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @CHEM-GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2374	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @CHEMICAL$-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2375	CPRFalse	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2376	CPRFalse	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2377	CPRFalse	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2378	CPRFalse	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2379	CPRFalse	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2380	CPRFalse	Levels of @CHEMICAL$ anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2381	CPRFalse	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2382	CPRFalse	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2383	CPRFalse	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2384	CPRFalse	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2385	CPRFalse	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2386	CPRFalse	Levels of superoxide anion (@CHEMICAL$), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2387	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2388	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2389	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2390	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2391	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2392	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized @CHEMICAL$ (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2393	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2394	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2395	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2396	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2397	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2398	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (@CHEMICAL$ or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2399	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, @GENE$ (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2400	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (@GENE$), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2401	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), @GENE$ (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2402	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (@GENE$), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2403	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), @GENE$ (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2404	CPRFalse	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or @CHEMICAL$), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (@GENE$) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.
2405	CPR:3	Pre-irradiation administration of RP-1 enhanced levels of @CHEMICAL$ induced increase in @GENE$ (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).
2406	CPR:3	Pre-irradiation administration of RP-1 enhanced levels of @CHEMICAL$ induced increase in complex I (upto 16 h), @GENE$ (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).
2407	CPR:3	Pre-irradiation administration of RP-1 enhanced levels of @CHEMICAL$ induced increase in complex I (upto 16 h), complex I/III (4 h) @GENE$ activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).
2408	CPRFalse	Effects of @CHEMICAL$ on @GENE$-mediated fulminant hepatitis in mice. 1.
2409	CPRFalse	We investigated the effects of @CHEMICAL$ on fulminant hepatitis in C57BL/6J mice induced by lethal challenge of the activating anti-@GENE$ antibody, Jo2.
2410	CPRFalse	Intraperitoneal injection of Jo2 (0.6 microg g(-1)) to mice resulted in fulminant hepatitis, as evidenced by increase of @CHEM-GENE$ activities and histopathological alterations in liver sections, as well as animal death.
2411	CPRFalse	Intraperitoneal injection of Jo2 (0.6 microg g(-1)) to mice resulted in fulminant hepatitis, as evidenced by increase of @CHEM-GENE$ activities and histopathological alterations in liver sections, as well as animal death.
2412	CPRFalse	Jo2-induced activation of caspase-3 or -9 in liver tissues was inhibited by @CHEMICAL$ pretreatment, and yet the direct addition of minocycline to liver extracts from Jo2-challenged mice failed to block @GENE$ activation in vitro.
2413	CPRFalse	Jo2-induced activation of @CHEMICAL$ in liver tissues was inhibited by @GENE$ pretreatment, and yet the direct addition of minocycline to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.
2414	CPRFalse	Jo2-induced activation of caspase-3 or -9 in liver tissues was inhibited by minocycline pretreatment, and yet the direct addition of @CHEMICAL$ to liver extracts from Jo2-challenged mice failed to block @GENE$ activation in vitro.
2415	CPRFalse	Jo2-induced activation of @CHEMICAL$ in liver tissues was inhibited by minocycline pretreatment, and yet the direct addition of @GENE$ to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.
2416	CPR:4	Moreover, @CHEMICAL$ efficiently suppressed the release of @GENE$ from mitochondria of the liver tissues from Jo2-challenged mice.
2417	CPRFalse	In contrast, @CHEMICAL$ activation and Bid truncation triggered by Jo2 were not diminished by @GENE$ pretreatment in mouse livers.
2418	CPRFalse	In contrast, caspase-8 activation and @CHEMICAL$ truncation triggered by Jo2 were not diminished by @GENE$ pretreatment in mouse livers.
2419	CPR:4	Our results suggest that easing of Fas-triggered fulminant hepatitis by @CHEMICAL$ may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream @GENE$ activation.
2420	CPRFalse	Our results suggest that easing of @CHEMICAL$-triggered fulminant hepatitis by @GENE$ may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation.
2421	CPR:4	Our results suggest that easing of Fas-triggered fulminant hepatitis by @CHEMICAL$ may involve a mitochondrial apoptotic pathway, probably through preventing @GENE$ release and thereby blocking downstream caspase activation.
2422	CPR:9	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2423	CPR:9	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2424	CPR:9	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2425	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize @CHEMICAL$ as substrate to form H2S. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2426	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize @CHEMICAL$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2427	CPR:9	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize @GENE$ as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2428	CPR:9	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2429	CPR:9	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2430	CPR:9	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2431	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @CHEMICAL$. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2432	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @CHEMICAL$. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2433	CPR:9	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form @GENE$. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2434	CPRFalse	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2435	CPRFalse	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2436	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2437	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @CHEM-GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2438	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @CHEMICAL$-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2439	CPRFalse	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2440	CPRFalse	Cystathionine-gamma-lyase (@CHEMICAL$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.
2441	CPRFalse	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.
2442	CPRFalse	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (@CHEMICAL$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.
2443	CPR:9	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @CHEMICAL$ (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.
2444	CPR:9	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@CHEMICAL$) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.
2445	CPRFalse	@CHEMICAL$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms @GENE$ in the cardiovascular system.
2446	CPRFalse	@CHEMICAL$-gamma-lyase (@GENE$) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2447	CPRFalse	@CHEMICAL$-gamma-lyase (CSE) and @GENE$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2448	CPRFalse	@CHEMICAL$-gamma-lyase (CSE) and cystathionine-beta-synthase (@GENE$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2449	CPRFalse	@CHEMICAL$-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2450	CPRFalse	@CHEMICAL$-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2451	CPRFalse	@CHEM-GENE$ (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2452	CPRFalse	Cystathionine-gamma-lyase (@CHEMICAL$) and @GENE$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2453	CPRFalse	Cystathionine-gamma-lyase (CSE) and @CHEM-GENE$ (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2454	CPRFalse	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$-beta-synthase (@GENE$) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2455	CPRFalse	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, @GENE$ (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2456	CPRFalse	Cystathionine-gamma-lyase (CSE) and @CHEMICAL$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (@GENE$) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2457	CPRFalse	@CHEMICAL$ (CSE) and @GENE$-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.
2458	CPRFalse	In this paper, we report the presence of @CHEMICAL$ synthesizing enzyme activity and @GENE$ (as determined by mRNA signal) in the pancreas.
2459	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2460	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2461	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2462	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; @GENE$, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2463	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2464	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2465	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2466	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2467	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, @CHEMICAL$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @GENE$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2468	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, @CHEMICAL$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2469	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, @CHEMICAL$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2470	CPR:4	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, @GENE$ (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2471	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (@CHEMICAL$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @GENE$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2472	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (@CHEMICAL$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2473	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (@CHEMICAL$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2474	CPR:4	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (@GENE$), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2475	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @CHEMICAL$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @GENE$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2476	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @CHEMICAL$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2477	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @CHEMICAL$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2478	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of @GENE$-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2479	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @GENE$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2480	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @CHEMICAL$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2481	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @CHEMICAL$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2482	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; @GENE$, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2483	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @GENE$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2484	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @CHEMICAL$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2485	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @CHEMICAL$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2486	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; @GENE$, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2487	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2488	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @CHEMICAL$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @GENE$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2489	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @CHEMICAL$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@GENE$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2490	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2491	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2492	CPR:3	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2493	CPR:3	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2494	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; @GENE$, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2495	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2496	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2497	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2498	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; @GENE$, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2499	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2500	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2501	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2502	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 @GENE$ c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2503	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma @CHEMICAL$ (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2504	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic @CHEMICAL$ (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2505	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (@CHEMICAL$) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2506	CPRFalse	Also, prophylactic, as well as therapeutic, treatment with the @CHEMICAL$ inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; @GENE$, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.
2507	CPRFalse	These effects of @CHEMICAL$ blockade suggest an important proinflammatory role of @GENE$ in regulating the severity of pancreatitis and associated lung injury and raise the possibility that H2S may exert similar activity in other forms of inflammation.
2508	CPRFalse	These effects of @CHEMICAL$ blockade suggest an important proinflammatory role of H2S in regulating the severity of pancreatitis and associated lung injury and raise the possibility that @GENE$ may exert similar activity in other forms of inflammation.
2509	CPRFalse	Atypical and typical antipsychotic drug interactions with the @CHEM-GENE$.
2510	CPRFalse	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics @GENE$ and loxapine, and the atypical antipsychotics clozapine and melperone.
2511	CPRFalse	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and @GENE$, and the atypical antipsychotics clozapine and melperone.
2512	CPRFalse	A model of the @CHEM-GENE$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and melperone.
2513	CPRFalse	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics @GENE$ and melperone.
2514	CPRFalse	A model of the @CHEMICAL$ was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and @GENE$.
2515	CPRFalse	A model of the @CHEMICAL$ was used to study the receptor interactions of @GENE$, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and melperone.
2516	CPRFalse	At doses ranging from 0.02 to 0.2 microg/kg, exenatide dose-dependently reduced postprandial plasma @CHEMICAL$ excursion by insulinotropism, suppression of plasma @GENE$, and slowing of gastric emptying.
2517	CPRFalse	@CHEM-GENE$: targets of natural sterols and new lipid lowering drugs.
2518	CPRFalse	@CHEMICAL$: targets of natural @GENE$ and new lipid lowering drugs.
2519	CPRFalse	Recent insights in the role of @CHEM-GENE$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2520	CPRFalse	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of @GENE$ (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2521	CPRFalse	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@GENE$) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2522	CPRFalse	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters @GENE$ and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2523	CPRFalse	Recent insights in the role of @CHEMICAL$-binding cassette (ABC) transporters ABCG5 and @GENE$, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2524	CPRFalse	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of @GENE$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2525	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of @CHEMICAL$, the first approved direct cholesterol absorption inhibitor, as well as the identification of @GENE$ (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2526	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of @CHEMICAL$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@GENE$) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2527	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of @GENE$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2528	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of @GENE$, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2529	CPRFalse	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct @GENE$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2530	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct @CHEMICAL$ absorption inhibitor, as well as the identification of @GENE$ (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2531	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct @CHEMICAL$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@GENE$) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2532	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of ezetimibe, the first approved direct @GENE$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2533	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of ezetimibe, the first approved direct @GENE$ absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2534	CPRFalse	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2535	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of @CHEMICAL$ (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2536	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@CHEMICAL$) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2537	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2538	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as @GENE$ transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.
2539	CPRFalse	Recent insights in the role of @CHEMICAL$ ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.
2540	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of @CHEMICAL$ (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.
2541	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (@CHEMICAL$) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.
2542	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters @CHEMICAL$ and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.
2543	CPRFalse	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and @CHEMICAL$, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on @GENE$ transport processes in the small intestine and the liver.
2544	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEM-GENE$ regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2545	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2546	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.
2547	CPRFalse	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @GENE$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2548	CPRFalse	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as @GENE$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2549	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. @GENE$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2550	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and @GENE$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2551	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal @GENE$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2552	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2553	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.
2554	CPRFalse	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @GENE$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2555	CPRFalse	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @GENE$ absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2556	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. @GENE$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2557	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal @CHEMICAL$ absorption and the hepatic sterol output. ABCG5 and @GENE$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2558	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal sterol absorption and the hepatic @GENE$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2559	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2560	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.
2561	CPRFalse	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @GENE$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2562	CPRFalse	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @GENE$ output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2563	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. @GENE$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2564	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic @CHEMICAL$ output. ABCG5 and @GENE$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2565	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2566	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @CHEMICAL$ via @GENE$ (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2567	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @CHEMICAL$ via liver X receptors (@GENE$), which are also activated by oxysterols and some derivatives of plant sterols.
2568	CPRFalse	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2569	CPRFalse	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2570	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. @CHEMICAL$ and ABCG8 themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2571	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and @CHEMICAL$ themselves are regulated by @GENE$ via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.
2572	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as @CHEMICAL$ regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.
2573	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via @CHEMICAL$ (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.
2574	CPR:3	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (@CHEMICAL$), which are also activated by oxysterols and some derivatives of plant @GENE$.
2575	CPRFalse	The identification of defective structures in the @CHEMICAL$ or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.
2576	CPRFalse	The identification of defective structures in the ABCG5 or @CHEMICAL$ transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.
2577	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. @CHEMICAL$ and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.
2578	CPRFalse	The identification of defective structures in the ABCG5 or ABCG8 transporters in patients with the rare disease of sitosterolemia elucidated their role as sterol efflux pumps regulating at least in parts the intestinal sterol absorption and the hepatic sterol output. ABCG5 and @CHEMICAL$ themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant @GENE$.
2579	CPRFalse	NPC1L1 could recently be identified as a major @CHEM-GENE$ for the intestinal uptake of cholesterol as well as plant sterols.
2580	CPRFalse	@CHEMICAL$ could recently be identified as a major @GENE$ transporter for the intestinal uptake of cholesterol as well as plant sterols.
2581	CPR:9	NPC1L1 could recently be identified as a major @CHEMICAL$ for the intestinal uptake of @GENE$ as well as plant sterols.
2582	CPR:9	@CHEMICAL$ could recently be identified as a major sterol transporter for the intestinal uptake of @GENE$ as well as plant sterols.
2583	CPR:9	NPC1L1 could recently be identified as a major @CHEMICAL$ for the intestinal uptake of cholesterol as well as plant @GENE$.
2584	CPR:9	@CHEMICAL$ could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant @GENE$.
2585	CPRFalse	Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of @CHEMICAL$ and that @GENE$ might also be involved in the mechanism of action of ezetimibe.
2586	CPRFalse	Studies in @CHEMICAL$ knockout mice indicate that this transporter is essential for the intestinal uptake of @GENE$ and that NPC1L1 might also be involved in the mechanism of action of ezetimibe.
2587	CPRFalse	Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that @CHEMICAL$ might also be involved in the mechanism of action of @GENE$.
2588	CPRFalse	Studies in @CHEMICAL$ knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that NPC1L1 might also be involved in the mechanism of action of @GENE$.
2589	CPRFalse	[Change of @CHEM-GENE$ activity (DAT) during the action of bupropion (in depression)].
2590	CPRFalse	[Change of @CHEMICAL$ transporter activity (@GENE$) during the action of bupropion (in depression)].
2591	CPRFalse	[Change of @CHEMICAL$ activity (DAT) during the action of @GENE$ (in depression)].
2592	CPRFalse	[Change of dopamine transporter activity (@CHEMICAL$) during the action of @GENE$ (in depression)].
2593	CPR:4	@CHEMICAL$ has an antidepressant effect through blocking the @GENE$.
2594	CPRFalse	Bupropion has an antidepressant effect through blocking the @CHEM-GENE$.
2595	CPRFalse	After 3 weeks' @CHEMICAL$ treatment we studied the change in @GENE$ activity, which corresponds to the occupancy of bupropion.
2596	CPRFalse	After 3 weeks' bupropion treatment we studied the change in @CHEMICAL$ activity, which corresponds to the occupancy of @GENE$.
2597	CPRFalse	The average occupancy of @CHEMICAL$ on @GENE$ was similar to the international findings at 20.84% in 9 depressed patients.
2598	CPRFalse	In vitro studies demonstrated that the @CHEMICAL$ (RXR) retinoid, @GENE$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.
2599	CPRFalse	In vitro studies demonstrated that the retinoid X receptor (@CHEMICAL$) retinoid, @GENE$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.
2600	CPR:3	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, @CHEMICAL$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the @GENE$ and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.
2601	CPR:3	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, @CHEMICAL$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the @GENE$ and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.
2602	CPR:3	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, @CHEMICAL$, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and @GENE$ subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.
2603	CPRFalse	Modulation of @CHEMICAL$ expression was observed at or above a @GENE$ dose of 150 mg/day.
2604	CPRFalse	Our results demonstrate that the combination of denileukin diftitox and @CHEMICAL$ is well tolerated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of @GENE$ expression on circulating leukemia cells.
2605	CPR:3	Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of @CHEMICAL$ are capable of in vivo upregulation of @GENE$ expression on circulating leukemia cells.
2606	CPRFalse	PSMA acts as a @CHEM-GENE$ (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2607	CPRFalse	@CHEMICAL$ acts as a @GENE$ carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2608	CPRFalse	PSMA acts as a @CHEMICAL$ carboxypeptidase (@GENE$) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2609	CPR:9	PSMA acts as a @CHEMICAL$ (GCPII) on small molecule substrates, including @GENE$, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2610	CPR:9	@CHEMICAL$ acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including @GENE$, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2611	CPR:9	PSMA acts as a glutamate carboxypeptidase (@CHEMICAL$) on small molecule substrates, including @GENE$, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2612	CPR:9	PSMA acts as a @CHEMICAL$ (GCPII) on small molecule substrates, including folate, the anticancer drug @GENE$, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2613	CPR:9	@CHEMICAL$ acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug @GENE$, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2614	CPR:9	PSMA acts as a glutamate carboxypeptidase (@CHEMICAL$) on small molecule substrates, including folate, the anticancer drug @GENE$, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.
2615	CPR:9	PSMA acts as a @CHEMICAL$ (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide @GENE$.
2616	CPR:9	@CHEMICAL$ acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide @GENE$.
2617	CPRFalse	PSMA acts as a glutamate carboxypeptidase (@CHEMICAL$) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide @GENE$.
2618	CPRFalse	Here we present the 3.5-A crystal structure of the @CHEMICAL$, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for @GENE$-loaded transferrin that lacks protease activity.
2619	CPRFalse	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to @CHEMICAL$, a receptor for @GENE$-loaded transferrin that lacks protease activity.
2620	CPRFalse	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for @CHEMICAL$-loaded transferrin that lacks @GENE$ activity.
2621	CPRFalse	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for @CHEMICAL$-loaded @GENE$ that lacks protease activity.
2622	CPRFalse	Unlike @CHEMICAL$, the protease domain of PSMA contains a binuclear @GENE$ site, catalytic residues, and a proposed substrate-binding arginine patch.
2623	CPRFalse	Unlike transferrin receptor, the @CHEMICAL$ of PSMA contains a binuclear @GENE$ site, catalytic residues, and a proposed substrate-binding arginine patch.
2624	CPRFalse	Unlike transferrin receptor, the protease domain of @CHEMICAL$ contains a binuclear @GENE$ site, catalytic residues, and a proposed substrate-binding arginine patch.
2625	CPRFalse	Unlike @CHEMICAL$, the protease domain of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding @GENE$ patch.
2626	CPRFalse	Unlike transferrin receptor, the @CHEMICAL$ of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding @GENE$ patch.
2627	CPRFalse	Unlike transferrin receptor, the protease domain of @CHEMICAL$ contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding @GENE$ patch.
2628	CPR:9	Elucidation of the @CHEMICAL$ structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate @GENE$.
2629	CPRFalse	Conversion of @CHEM-GENE$ into a more active enzyme by linking the two subunits: spectroscopic and kinetic properties.
2630	CPRFalse	The two active sites of dimeric @CHEMICAL$ (ALAS), a pyridoxal 5'-phosphate (@GENE$)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.
2631	CPRFalse	The two active sites of dimeric 5-aminolevulinate synthase (@CHEMICAL$), a pyridoxal 5'-phosphate (@GENE$)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.
2632	CPRFalse	The two active sites of dimeric @CHEMICAL$ (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential @GENE$ from each subunit.
2633	CPRFalse	The two active sites of dimeric 5-aminolevulinate synthase (@CHEMICAL$), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential @GENE$ from each subunit.
2634	CPRFalse	The two active sites of dimeric @CHEM-GENE$ (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.
2635	CPRFalse	The two active sites of dimeric @CHEMICAL$ synthase (@GENE$), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.
2636	CPRFalse	The two active sites of dimeric @CHEMICAL$ (ALAS), a @GENE$ (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.
2637	CPRFalse	The two active sites of dimeric 5-aminolevulinate synthase (@CHEMICAL$), a @GENE$ (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.
2638	CPRFalse	Transient kinetic analysis of the formation and decay of the @CHEMICAL$ intermediate EQ(2) indicated that, although their rates were similar in @GENE$ and 2XALAS, accumulation of this intermediate was greater in the 2XALAS-catalyzed reaction.
2639	CPRFalse	Transient kinetic analysis of the formation and decay of the @CHEMICAL$ intermediate EQ(2) indicated that, although their rates were similar in ALAS and @GENE$, accumulation of this intermediate was greater in the 2XALAS-catalyzed reaction.
2640	CPRFalse	Transient kinetic analysis of the formation and decay of the @CHEMICAL$ intermediate EQ(2) indicated that, although their rates were similar in ALAS and 2XALAS, accumulation of this intermediate was greater in the @GENE$-catalyzed reaction.
2641	CPRFalse	Collectively, these results suggest that @CHEMICAL$ is the active form of the coenzyme and forms a more prominent coenzyme structure in @GENE$ than in ALAS at pH approximately 7.5.
2642	CPRFalse	Collectively, these results suggest that @CHEMICAL$ is the active form of the coenzyme and forms a more prominent coenzyme structure in 2XALAS than in @GENE$ at pH approximately 7.5.
2643	CPRFalse	@CHEMICAL$ (PAD) convert protein-bound arginine residues into citrulline residues in a @GENE$ ion-dependent manner.
2644	CPRFalse	Peptidylarginine deiminases (@CHEMICAL$) convert protein-bound arginine residues into citrulline residues in a @GENE$ ion-dependent manner.
2645	CPRFalse	@CHEMICAL$ (PAD) convert protein-bound @GENE$ residues into citrulline residues in a Ca(2+) ion-dependent manner.
2646	CPRFalse	Peptidylarginine deiminases (@CHEMICAL$) convert protein-bound @GENE$ residues into citrulline residues in a Ca(2+) ion-dependent manner.
2647	CPRFalse	@CHEMICAL$ (PAD) convert protein-bound arginine residues into @GENE$ residues in a Ca(2+) ion-dependent manner.
2648	CPRFalse	Peptidylarginine deiminases (@CHEMICAL$) convert protein-bound arginine residues into @GENE$ residues in a Ca(2+) ion-dependent manner.
2649	CPRFalse	Activator of G protein signaling 3 regulates opiate activation of @CHEMICAL$ signaling and relapse of @GENE$-seeking behavior.
2650	CPRFalse	@CHEMICAL$ regulates opiate activation of protein kinase A signaling and relapse of @GENE$-seeking behavior.
2651	CPRFalse	Galpha(i) inhibits @CHEMICAL$ production, but betagamma regulates several molecular pathways, including protein kinase A (@GENE$).
2652	CPRFalse	@CHEMICAL$ inhibits @GENE$ production, but betagamma regulates several molecular pathways, including protein kinase A (PKA).
2653	CPRFalse	Galpha(i) inhibits @CHEMICAL$ production, but betagamma regulates several molecular pathways, including @GENE$ (PKA).
2654	CPRFalse	In rats self-administering @CHEMICAL$, @GENE$ antisense in the NAc core, but not shell, eliminates reinstatement of heroin-seeking behavior, a model of human relapse.
2655	CPRFalse	In rats self-administering heroin, @CHEMICAL$ antisense in the NAc core, but not shell, eliminates reinstatement of @GENE$-seeking behavior, a model of human relapse.
2656	CPRFalse	Thus, @CHEMICAL$/AGS3 appears to mediate mu opiate receptor activation of PKA signaling as well as @GENE$-seeking behavior.
2657	CPRFalse	Thus, Galpha(i3)/betagamma/AGS3 appears to mediate mu opiate receptor activation of @CHEMICAL$ signaling as well as @GENE$-seeking behavior.
2658	CPRFalse	Thus, Galpha(i3)/betagamma/@CHEMICAL$ appears to mediate mu opiate receptor activation of PKA signaling as well as @GENE$-seeking behavior.
2659	CPRFalse	Thus, Galpha(i3)/betagamma/AGS3 appears to mediate @CHEMICAL$ activation of PKA signaling as well as @GENE$-seeking behavior.
2660	CPRFalse	@CHEMICAL$ (A-381393), a selective @GENE$ antagonist.
2661	CPRFalse	2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (@CHEMICAL$), a selective @GENE$ antagonist.
2662	CPRFalse	2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective @CHEM-GENE$ antagonist.
2663	CPRFalse	@CHEMICAL$ (A-381393) was identified as a potent @GENE$ antagonist with excellent receptor selectivity.
2664	CPRFalse	2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole (@CHEMICAL$) was identified as a potent @GENE$ antagonist with excellent receptor selectivity.
2665	CPRFalse	2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393) was identified as a potent @CHEM-GENE$ antagonist with excellent receptor selectivity.
2666	CPRFalse	@CHEMICAL$ competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant @GENE$ (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).
2667	CPRFalse	[3H]-spiperone competition binding assays showed that @CHEMICAL$ potently bound to membrane from cells expressing recombinant @GENE$ (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).
2668	CPRFalse	[3H]-spiperone competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant @CHEM-GENE$ (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).
2669	CPRFalse	[3H]-spiperone competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant @CHEMICAL$ (Ki=1.5 nM), which was 20-fold higher than that of @GENE$ (Ki=30.4 nM).
2670	CPRFalse	@CHEMICAL$ exhibited highly selective binding for the @GENE$ (>2700-fold) when compared to D1, D2, D3 and D5 dopamine receptors.
2671	CPRFalse	@CHEMICAL$ exhibited highly selective binding for the dopamine D4.4 receptor (>2700-fold) when compared to @GENE$.
2672	CPRFalse	A-381393 exhibited highly selective binding for the @CHEM-GENE$ (>2700-fold) when compared to D1, D2, D3 and D5 dopamine receptors.
2673	CPRFalse	A-381393 exhibited highly selective binding for the @CHEMICAL$ D4.4 receptor (>2700-fold) when compared to @GENE$.
2674	CPRFalse	A-381393 exhibited highly selective binding for the @CHEMICAL$ (>2700-fold) when compared to D1, D2, D3 and D5 @GENE$ receptors.
2675	CPRFalse	A-381393 exhibited highly selective binding for the dopamine D4.4 receptor (>2700-fold) when compared to @CHEM-GENE$.
2676	CPRFalse	Furthermore, in comparison to @CHEMICAL$ and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2677	CPRFalse	Furthermore, in comparison to @CHEMICAL$ and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.
2678	CPRFalse	Furthermore, in comparison to @CHEMICAL$ and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @GENE$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2679	CPRFalse	Furthermore, in comparison to clozapine and @CHEMICAL$, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2680	CPRFalse	Furthermore, in comparison to clozapine and @CHEMICAL$, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.
2681	CPRFalse	Furthermore, in comparison to clozapine and @CHEMICAL$, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @GENE$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2682	CPRFalse	Furthermore, in comparison to clozapine and L-745870, @CHEMICAL$ exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2683	CPRFalse	Furthermore, in comparison to clozapine and L-745870, @CHEMICAL$ exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.
2684	CPRFalse	Furthermore, in comparison to clozapine and L-745870, @CHEMICAL$ exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @GENE$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2685	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). @CHEMICAL$ potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2686	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). @CHEMICAL$ potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.
2687	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). @GENE$ potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2688	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced @CHEMICAL$-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2689	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced @CHEMICAL$-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.
2690	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced @GENE$-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2691	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM @CHEMICAL$ induced-Ca2+ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2692	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM @CHEMICAL$ induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.
2693	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM @GENE$ induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2694	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-@CHEMICAL$ flux in @GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2695	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-@CHEMICAL$ flux in human dopamine D4.4 receptor expressing cells, but not in @GENE$ cells.
2696	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-@GENE$ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2697	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @CHEM-GENE$ expressing cells, but not in human dopamine D2L or D3 receptor cells.
2698	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human @CHEMICAL$ D4.4 receptor expressing cells, but not in @GENE$ cells.
2699	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human @GENE$ D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.
2700	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in @CHEMICAL$ expressing cells, but not in human @GENE$ D2L or D3 receptor cells.
2701	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in @CHEM-GENE$ cells.
2702	CPRFalse	Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for @CHEMICAL$ (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human @GENE$ D2L or D3 receptor cells.
2703	CPRFalse	In contrast to @CHEMICAL$, A-381393 did not exhibit any significant intrinsic activity in a @GENE$.
2704	CPRFalse	In contrast to L-745870, @CHEMICAL$ did not exhibit any significant intrinsic activity in a @GENE$.
2705	CPRFalse	Thus, A-381393 is a novel selective D4 antagonist that will enhance the ability to study @CHEM-GENE$ both in vitro and in vivo.
2706	CPRFalse	Thus, @CHEMICAL$ is a novel selective D4 antagonist that will enhance the ability to study @GENE$ both in vitro and in vivo.
2707	CPR:6	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and @GENE$.
2708	CPR:6	A number of selective @CHEMICAL$ antagonists have been developed including @GENE$, granisetron, tropisetron renzapride and zacopride.
2709	CPR:6	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, @GENE$, tropisetron renzapride and zacopride.
2710	CPR:6	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, granisetron, @GENE$ renzapride and zacopride.
2711	CPR:6	A number of selective @CHEMICAL$ antagonists have been developed including ondansetron, granisetron, tropisetron @GENE$ and zacopride.
2712	CPR:4	While the substituted @CHEMICAL$ prokinetics (for example, metoclopramide, cisapride) also block @GENE$ receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.
2713	CPR:5	While the substituted @CHEMICAL$ prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative @GENE$ receptor.
2714	CPR:4	While the substituted benzamide prokinetics (for example, @CHEMICAL$, cisapride) also block @GENE$ receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.
2715	CPR:5	While the substituted benzamide prokinetics (for example, @CHEMICAL$, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative @GENE$ receptor.
2716	CPR:4	While the substituted benzamide prokinetics (for example, metoclopramide, @CHEMICAL$) also block @GENE$ receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.
2717	CPR:5	While the substituted benzamide prokinetics (for example, metoclopramide, @CHEMICAL$) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative @GENE$ receptor.
2718	CPRFalse	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, @CHEMICAL$, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a @GENE$ antagonist.
2719	CPR:6	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, @GENE$, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.
2720	CPR:5	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, @GENE$, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.
2721	CPRFalse	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, @CHEMICAL$) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a @GENE$ antagonist.
2722	CPR:6	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, @GENE$) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.
2723	CPR:5	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, @GENE$) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.
2724	CPRFalse	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, @CHEMICAL$, granisetron), while tropisetron in high concentrations is a @GENE$ antagonist.
2725	CPRFalse	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, @GENE$, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.
2726	CPRFalse	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, zacopride) and others do not (for example, @GENE$, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.
2727	CPRFalse	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, @CHEMICAL$), while tropisetron in high concentrations is a @GENE$ antagonist.
2728	CPRFalse	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, @GENE$), while tropisetron in high concentrations is a 5-HT4 antagonist.
2729	CPRFalse	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, @GENE$), while tropisetron in high concentrations is a 5-HT4 antagonist.
2730	CPR:6	Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while @CHEMICAL$ in high concentrations is a @GENE$ antagonist.
2731	CPRFalse	Some @CHEMICAL$ antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while @GENE$ in high concentrations is a 5-HT4 antagonist.
2732	CPRFalse	Some 5-HT3 antagonists have @CHEMICAL$ agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while @GENE$ in high concentrations is a 5-HT4 antagonist.
2733	CPRFalse	Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. A @CHEMICAL$ to @GENE$ (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.
2734	CPRFalse	Niacin mediates lipolysis in adipose tissue through its @CHEMICAL$. A G-protein coupled receptor to @GENE$ (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.
2735	CPRFalse	Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. A @CHEMICAL$ to niacin (@GENE$) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.
2736	CPRFalse	Niacin mediates lipolysis in adipose tissue through its @CHEMICAL$. A G-protein coupled receptor to niacin (@GENE$) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.
2737	CPRFalse	@CHEMICAL$ mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. A @GENE$ to niacin (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.
2738	CPRFalse	@CHEMICAL$ mediates lipolysis in adipose tissue through its @GENE$. A G-protein coupled receptor to niacin (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.
2739	CPR:3	We present our studies to demonstrate that HM74A, but not HM74, binds @CHEMICAL$ at high affinities and effectively mediates @GENE$ signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.
2740	CPRFalse	We present our studies to demonstrate that HM74A, but not HM74, binds @CHEMICAL$ at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing @GENE$.
2741	CPRFalse	We present our studies to demonstrate that @CHEMICAL$, but not HM74, binds @GENE$ at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.
2742	CPRFalse	We present our studies to demonstrate that HM74A, but not @CHEMICAL$, binds @GENE$ at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.
2743	CPRFalse	Furthermore, @CHEMICAL$, but not HM74, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by @GENE$.
2744	CPRFalse	Furthermore, HM74A, but not @CHEMICAL$, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by @GENE$.
2745	CPRFalse	Our results provided direct evidence indicating that @CHEMICAL$, but not HM74, was sufficient to mediate anti-lipolytic effect of @GENE$ in adipose tissue.
2746	CPRFalse	Our results provided direct evidence indicating that HM74A, but not @CHEMICAL$, was sufficient to mediate anti-lipolytic effect of @GENE$ in adipose tissue.
2747	CPRFalse	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the @GENE$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2748	CPRFalse	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the KGD1 (@GENE$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2749	CPRFalse	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @GENE$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2750	CPRFalse	When cultured in YPD medium containing 15% @CHEMICAL$ under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$) gene-disrupted mutant produced an increased level of succinate.
2751	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (@GENE$ dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2752	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEM-GENE$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2753	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$ dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @GENE$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2754	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$ dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$) gene-disrupted mutant produced an increased level of succinate.
2755	CPR:9	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of @GENE$ than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2756	CPR:9	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$) gene disrupted mutant produced a lower level of @GENE$ than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2757	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of @CHEMICAL$ than the wild-type strain, while the @GENE$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2758	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of @CHEMICAL$ than the wild-type strain, while the SDH1 (@GENE$) gene-disrupted mutant produced an increased level of succinate.
2759	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$ dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2760	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@GENE$ dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2761	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @CHEMICAL$ (@GENE$ dehydrogenase) gene-disrupted mutant produced an increased level of succinate.
2762	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@CHEM-GENE$) gene-disrupted mutant produced an increased level of succinate.
2763	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the @CHEMICAL$ (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of @GENE$.
2764	CPRFalse	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (@CHEMICAL$) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of @GENE$.
2765	CPR:9	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the @CHEMICAL$ (succinate dehydrogenase) gene-disrupted mutant produced an increased level of @GENE$.
2766	CPR:9	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (@CHEMICAL$) gene-disrupted mutant produced an increased level of @GENE$.
2767	CPR:9	On the other hand, the @CHEMICAL$ (fumarase) gene disrupted mutant produced significantly higher levels of @GENE$ but did not form malate at all.
2768	CPR:9	On the other hand, the FUM1 (@CHEMICAL$) gene disrupted mutant produced significantly higher levels of @GENE$ but did not form malate at all.
2769	CPRFalse	On the other hand, the @CHEMICAL$ (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form @GENE$ at all.
2770	CPRFalse	On the other hand, the FUM1 (@CHEMICAL$) gene disrupted mutant produced significantly higher levels of fumarate but did not form @GENE$ at all.
2771	CPR:9	When the growth condition was shifted from aerobic to anaerobic, the increased level of @CHEMICAL$ in @GENE$ disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.
2772	CPRFalse	When the growth condition was shifted from aerobic to anaerobic, the increased level of @CHEMICAL$ in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the @GENE$ diruptant was still observed.
2773	CPRFalse	When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in @CHEMICAL$ disruptants was no longer observed, whereas the decreased level of @GENE$ in the KGD1 diruptant was still observed.
2774	CPR:9	When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of @CHEMICAL$ in the @GENE$ diruptant was still observed.
2775	CPRFalse	A double mutant of the two @CHEM-GENE$ isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
2776	CPRFalse	A double mutant of the two @CHEMICAL$ reductase isozyme genes (@GENE$ and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
2777	CPRFalse	A double mutant of the two @CHEMICAL$ reductase isozyme genes (OSM1 and @GENE$) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
2778	CPR:9	A double mutant of the two @CHEMICAL$ isozyme genes (OSM1 and FRDS) showed a @GENE$ productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
2779	CPR:9	A double mutant of the two fumarate reductase isozyme genes (@CHEMICAL$ and FRDS) showed a @GENE$ productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
2780	CPR:9	A double mutant of the two fumarate reductase isozyme genes (OSM1 and @CHEMICAL$) showed a @GENE$ productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
2781	CPRFalse	A double mutant of the two @CHEMICAL$ isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in @GENE$-buffered solution.
2782	CPRFalse	A double mutant of the two fumarate reductase isozyme genes (@CHEMICAL$ and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in @GENE$-buffered solution.
2783	CPRFalse	A double mutant of the two fumarate reductase isozyme genes (OSM1 and @CHEMICAL$) showed a succinate productivity of 50% as compared to the parent when cells were incubated in @GENE$-buffered solution.
2784	CPRFalse	As examples, @CHEMICAL$, flurbiprofen, ketoprofen and indomethacin have increased @GENE$ selectivity when compared with naproxen and ibuprofen.
2785	CPRFalse	As examples, ketorolac, @CHEMICAL$, ketoprofen and indomethacin have increased @GENE$ selectivity when compared with naproxen and ibuprofen.
2786	CPRFalse	As examples, ketorolac, flurbiprofen, @CHEMICAL$ and indomethacin have increased @GENE$ selectivity when compared with naproxen and ibuprofen.
2787	CPRFalse	As examples, ketorolac, flurbiprofen, ketoprofen and @CHEMICAL$ have increased @GENE$ selectivity when compared with naproxen and ibuprofen.
2788	CPRFalse	As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased @CHEMICAL$ selectivity when compared with @GENE$ and ibuprofen.
2789	CPRFalse	As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased @CHEMICAL$ selectivity when compared with naproxen and @GENE$.
2790	CPRFalse	Association of MTRR@CHEMICAL$ polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.
2791	CPRFalse	Association of MTRRA66G polymorphism (but not of MTHFR @CHEMICAL$ and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.
2792	CPRFalse	Association of MTRRA66G polymorphism (but not of MTHFR C677T and @CHEMICAL$, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.
2793	CPRFalse	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTR@CHEMICAL$, TCN C776G) with @GENE$ and coronary artery disease in the French population.
2794	CPRFalse	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, @CHEMICAL$ C776G) with @GENE$ and coronary artery disease in the French population.
2795	CPRFalse	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN @CHEMICAL$) with @GENE$ and coronary artery disease in the French population.
2796	CPRFalse	Association of @CHEMICAL$A66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.
2797	CPRFalse	Association of MTRRA66G polymorphism (but not of @CHEMICAL$ C677T and A1298C, MTRA2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.
2798	CPRFalse	Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, @CHEMICAL$A2756G, TCN C776G) with @GENE$ and coronary artery disease in the French population.
2799	CPRFalse	Methylenetetrahydrofolate reductase polymorphism (MTHFR @CHEMICAL$) is an established determinant of @GENE$ plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.
2800	CPRFalse	@CHEMICAL$ polymorphism (MTHFR C677T) is an established determinant of @GENE$ plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.
2801	CPRFalse	Methylenetetrahydrofolate reductase polymorphism (@CHEMICAL$ C677T) is an established determinant of @GENE$ plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.
2802	CPRFalse	@CHEMICAL$ reductase polymorphism (MTHFR @GENE$) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.
2803	CPRFalse	@CHEM-GENE$ polymorphism (MTHFR C677T) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.
2804	CPRFalse	@CHEMICAL$ reductase polymorphism (@GENE$ C677T) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.
2805	CPRFalse	Methylenetetrahydrofolate reductase polymorphism (MTHFR @CHEMICAL$) is an established determinant of homocysteine plasma level (t-@GENE$) while its association with coronary artery disease (CAD) seems to be more limited.
2806	CPRFalse	@CHEMICAL$ polymorphism (MTHFR C677T) is an established determinant of homocysteine plasma level (t-@GENE$) while its association with coronary artery disease (CAD) seems to be more limited.
2807	CPRFalse	Methylenetetrahydrofolate reductase polymorphism (@CHEMICAL$ C677T) is an established determinant of homocysteine plasma level (t-@GENE$) while its association with coronary artery disease (CAD) seems to be more limited.
2808	CPRFalse	In contrast, the association of the substitutions @CHEMICAL$ of @GENE$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2809	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), @GENE$ of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2810	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and @GENE$ of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2811	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of @GENE$ (TCN) to both t-Hcys and CAD needs to be evaluated further.
2812	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (@GENE$) to both t-Hcys and CAD needs to be evaluated further.
2813	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEM-GENE$ (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2814	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (@GENE$), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2815	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of @GENE$ (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2816	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ synthase (MTR), A66G of methionine synthase reductase (@GENE$) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2817	CPRFalse	In contrast, the association of the substitutions @CHEMICAL$ of methionine synthase (MTR), A66G of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2818	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), @CHEMICAL$ of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2819	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (MTRR) and @GENE$ of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2820	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (MTRR) and C776G of @GENE$ (TCN) to both t-Hcys and CAD needs to be evaluated further.
2821	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (MTRR) and C776G of transcobalamin (@GENE$) to both t-Hcys and CAD needs to be evaluated further.
2822	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ (MTR), A66G of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2823	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (@CHEMICAL$), A66G of @GENE$ synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2824	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEM-GENE$ (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2825	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ synthase reductase (@GENE$) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.
2826	CPRFalse	In contrast, the association of the substitutions @CHEMICAL$ of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2827	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), @CHEMICAL$ of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2828	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and @CHEMICAL$ of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2829	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of @CHEMICAL$ (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2830	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (@CHEMICAL$) to both t-@GENE$ and CAD needs to be evaluated further.
2831	CPRFalse	In contrast, the association of the substitutions A2756G of @CHEMICAL$ (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2832	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (@CHEMICAL$), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2833	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of @CHEMICAL$ (MTRR) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2834	CPRFalse	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (@CHEMICAL$) and C776G of transcobalamin (TCN) to both t-@GENE$ and CAD needs to be evaluated further.
2835	CPRFalse	t-@CHEMICAL$ was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of @GENE$AA and MTHFR 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).
2836	CPRFalse	t-@CHEMICAL$ was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of MTRRAA and @GENE$ 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).
2837	CPRFalse	In multivariate analysis, t-@CHEMICAL$ > median and @GENE$AA genotype were two significant independent predictors of CAD with respective odds ratios of 3.1 (95 % CI: 1.8-5.1, P < 0.0001) and 4.5 (95% CI: 1.5-13.1, P = 0.0051).
2838	CPRFalse	@CHEMICAL$ supplementation alters @GENE$-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol.
2839	CPRFalse	@CHEMICAL$ supplementation alters HDL-cholesterol concentration and @GENE$ activity in rabbits fed high-cholesterol diet: comparison with probucol.
2840	CPRFalse	Vitamin E supplementation alters @CHEMICAL$-cholesterol concentration and paraoxonase activity in rabbits fed high-@GENE$ diet: comparison with probucol.
2841	CPRFalse	Vitamin E supplementation alters HDL-cholesterol concentration and @CHEMICAL$ activity in rabbits fed high-@GENE$ diet: comparison with probucol.
2842	CPRFalse	Vitamin E supplementation alters @CHEMICAL$-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with @GENE$.
2843	CPRFalse	Vitamin E supplementation alters HDL-cholesterol concentration and @CHEMICAL$ activity in rabbits fed high-cholesterol diet: comparison with @GENE$.
2844	CPRFalse	Vitamin E supplementation alters @CHEMICAL$-@GENE$ concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol.
2845	CPRFalse	Vitamin E supplementation alters HDL-@CHEMICAL$ concentration and @GENE$ activity in rabbits fed high-cholesterol diet: comparison with probucol.
2846	CPR:4	@CHEMICAL$ and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and @GENE$ cholesterol compared to HC-control group.
2847	CPR:4	Vitamin E and @CHEMICAL$ significantly suppressed an increase in plasma total-cholesterol (total-C) and @GENE$ cholesterol compared to HC-control group.
2848	CPRFalse	Vitamin E and probucol significantly suppressed an increase in plasma total-@CHEMICAL$ (total-C) and @GENE$ cholesterol compared to HC-control group.
2849	CPRFalse	Vitamin E and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and @CHEMICAL$ @GENE$ compared to HC-control group.
2850	CPRFalse	However, plasma @CHEMICAL$-@GENE$ (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.
2851	CPRFalse	However, plasma high-density lipoprotein-@CHEMICAL$ (@GENE$-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.
2852	CPRFalse	However, plasma high-density lipoprotein-@CHEMICAL$ (HDL-C) and @GENE$-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.
2853	CPRFalse	However, plasma high-density lipoprotein-@CHEMICAL$ (HDL-C) and HDL-C/total-C ratio levels and plasma @GENE$ activity were only significantly higher in vitamin E group after 8 weeks.
2854	CPR:3	However, plasma @CHEMICAL$-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in @GENE$ group after 8 weeks.
2855	CPR:3	However, plasma high-density lipoprotein-cholesterol (@CHEMICAL$-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in @GENE$ group after 8 weeks.
2856	CPR:3	However, plasma high-density lipoprotein-cholesterol (HDL-C) and @CHEMICAL$-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in @GENE$ group after 8 weeks.
2857	CPR:3	However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma @CHEMICAL$ activity were only significantly higher in @GENE$ group after 8 weeks.
2858	CPR:4	Hepatic @CHEMICAL$ activity was significantly lower in both @GENE$ and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.
2859	CPRFalse	Hepatic ACAT activity was significantly lower in both @CHEMICAL$ and probucol groups than in HC-control group, while @GENE$ activity was the highest only in the probucol group.
2860	CPR:4	Hepatic @CHEMICAL$ activity was significantly lower in both vitamin E and @GENE$ groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.
2861	CPRFalse	Hepatic ACAT activity was significantly lower in both vitamin E and @CHEMICAL$ groups than in HC-control group, while @GENE$ activity was the highest only in the probucol group.
2862	CPRFalse	Hepatic @CHEMICAL$ activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while @GENE$ reductase activity was the highest only in the probucol group.
2863	CPRFalse	Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while @CHEM-GENE$ activity was the highest only in the probucol group.
2864	CPRFalse	Hepatic @CHEMICAL$ activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the @GENE$ group.
2865	CPR:3	Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while @CHEMICAL$ activity was the highest only in the @GENE$ group.
2866	CPR:4	Hepatic mRNA expressions of @CHEMICAL$ and apo C-III were significantly lower in @GENE$ group than in other groups.
2867	CPR:4	Hepatic mRNA expressions of apo B-100 and @CHEMICAL$ were significantly lower in @GENE$ group than in other groups.
2868	CPRFalse	@CHEMICAL$ supplementation was found to alter the plasma @GENE$-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL-C concentration.
2869	CPRFalse	@CHEMICAL$ supplementation was found to alter the plasma HDL-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma @GENE$-C concentration.
2870	CPRFalse	Vitamin E supplementation was found to alter the plasma @CHEMICAL$-C-related factors; meanwhile, @GENE$ supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL-C concentration.
2871	CPR:4	Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, @CHEMICAL$ supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma @GENE$-C concentration.
2872	CPRFalse	Vitamin E supplementation was found to alter the plasma @CHEMICAL$-C-related factors; meanwhile, probucol supplementation was very effective in enhancing @GENE$ metabolism, except for a negative effect that reduced plasma HDL-C concentration.
2873	CPRFalse	Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, probucol supplementation was very effective in enhancing @CHEMICAL$ metabolism, except for a negative effect that reduced plasma @GENE$-C concentration.
2874	CPR:6	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel @CHEMICAL$ antagonists, such as @GENE$ (UK-427,857).
2875	CPR:6	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel @CHEMICAL$ antagonists, such as maraviroc (@GENE$).
2876	CPRFalse	To do this we cloned and expressed @CHEMICAL$ from rhesus macaque and compared the binding properties of [@GENE$]-MIP-1beta and [3H]-maraviroc with human recombinant CCR5.
2877	CPRFalse	To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [@CHEMICAL$]-MIP-1beta and [3H]-maraviroc with @GENE$.
2878	CPRFalse	To do this we cloned and expressed @CHEMICAL$ from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and @GENE$ with human recombinant CCR5.
2879	CPRFalse	To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and @CHEMICAL$ with @GENE$.
2880	CPRFalse	[@CHEMICAL$]-MIP-1beta bound with similar high affinity to @GENE$ from macaque (K(d) = 0.24 +/- 0.05 nM) and human (K(d) = 0.23 +/- 0.05 nM) and with similar kinetic properties.
2881	CPRFalse	@CHEMICAL$ inhibited binding of [125I]-MIP-1beta to @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).
2882	CPR:6	@CHEMICAL$ inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).
2883	CPRFalse	Maraviroc inhibited binding of [@CHEMICAL$]-MIP-1beta to @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).
2884	CPRFalse	Maraviroc inhibited binding of [@CHEMICAL$]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).
2885	CPRFalse	Maraviroc inhibited binding of [125I]-MIP-1beta to @CHEMICAL$ from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular @GENE$ release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).
2886	CPRFalse	Maraviroc inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular @CHEMICAL$ release mediated through @GENE$ from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).
2887	CPRFalse	@CHEMICAL$ bound with high affinity to @GENE$ from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from macaque CCR5.
2888	CPRFalse	@CHEMICAL$ bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from @GENE$.
2889	CPR:6	However, as with the human receptor, @CHEMICAL$ was shown to be a high affinity, potent functional antagonist of @GENE$ thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.
2890	CPR:6	However, as with the human receptor, @CHEMICAL$ was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel @GENE$ antagonists.
2891	CPRFalse	To better understand the molecular mechanism of @CHEMICAL$ on tumor suppression, we utilized a complementary @GENE$ microarray composed of approximately 6,000 human cancer-related genes to determine the gene expression pattern altered by re-introduction of p75NTR into PC-3 prostate tumor cells.
2892	CPRFalse	To better understand the molecular mechanism of p75(NTR) on tumor suppression, we utilized a complementary @CHEMICAL$ microarray composed of approximately 6,000 human cancer-related genes to determine the gene expression pattern altered by re-introduction of @GENE$ into PC-3 prostate tumor cells.
2893	CPRFalse	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (@GENE$) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.
2894	CPRFalse	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (CRABPI) and @GENE$ protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.
2895	CPRFalse	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (CRABPI) and IGFBP5 protein levels and decreased level of @GENE$ protein with increasing p75NTR protein expression.
2896	CPRFalse	Immunoblot analysis further confirmed increased cellular @CHEMICAL$-binding protein I (CRABPI) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing @GENE$ protein expression.
2897	CPRFalse	Immunoblot analysis further confirmed increased @CHEM-GENE$ (CRABPI) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.
2898	CPRFalse	As @CHEMICAL$ was elevated far more than any other genes, we observed that the @GENE$, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2899	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the @CHEMICAL$, all-trans retinoic acid and 9-cis retinoic acid, that bind @GENE$, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2900	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the @CHEMICAL$, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.
2901	CPRFalse	As @CHEMICAL$ was elevated far more than any other genes, we observed that the retinoids, @GENE$ and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2902	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the retinoids, @CHEMICAL$ and 9-cis retinoic acid, that bind @GENE$, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2903	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the retinoids, @CHEMICAL$ and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.
2904	CPRFalse	As @CHEMICAL$ was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and @GENE$, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2905	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and @CHEMICAL$, that bind @GENE$, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2906	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and @CHEMICAL$, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.
2907	CPRFalse	As @CHEMICAL$ was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted @GENE$-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2908	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind @CHEMICAL$, promoted @GENE$-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.
2909	CPRFalse	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted @CHEMICAL$-associated functional cell differentiation in @GENE$ PC-3 cells, but not in neo control PC-3 cells.
2910	CPRFalse	Subsequent examination of the @CHEM-GENE$ (RARs) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.
2911	CPRFalse	Subsequent examination of the @CHEMICAL$ receptors @GENE$) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.
2912	CPRFalse	Subsequent examination of the @CHEMICAL$ receptors (RARs) expression levels demonstrated an absence of @GENE$ in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.
2913	CPRFalse	Subsequent examination of the @CHEMICAL$ receptors (RARs) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the @GENE$ expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.
2914	CPRFalse	Subsequent examination of the @CHEMICAL$ receptors (RARs) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where @GENE$ is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.
2915	CPRFalse	Hence, re-expression of the @CHEMICAL$ appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @GENE$ that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.
2916	CPR:3	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of @CHEMICAL$ for localized sequestration of @GENE$ that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.
2917	CPRFalse	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @CHEMICAL$ that are available to newly up-regulated @GENE$, RXR-alpha, and RXR-beta.
2918	CPRFalse	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @CHEMICAL$ that are available to newly up-regulated RAR-beta, @GENE$, and RXR-beta.
2919	CPRFalse	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of @CHEMICAL$ that are available to newly up-regulated RAR-beta, RXR-alpha, and @GENE$.
2920	CPRFalse	@CHEMICAL$ (PUMA-G/HM74A) mediates @GENE$-induced flushing.
2921	CPRFalse	GPR109A (PUMA-G/@CHEMICAL$) mediates @GENE$-induced flushing.
2922	CPRFalse	GPR109A (@CHEMICAL$/HM74A) mediates @GENE$-induced flushing.
2923	CPRFalse	Its special profile of actions, especially the rise in @CHEMICAL$-@GENE$ levels induced by nicotinic acid, is unique among the currently available pharmacological tools to treat lipid disorders.
2924	CPR:3	Its special profile of actions, especially the rise in @CHEMICAL$-cholesterol levels induced by @GENE$, is unique among the currently available pharmacological tools to treat lipid disorders.
2925	CPRFalse	Recently, a @CHEMICAL$, termed GPR109A (HM74A in humans, PUMA-G in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.
2926	CPRFalse	Recently, a G-protein-coupled receptor, termed @CHEMICAL$ (HM74A in humans, PUMA-G in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.
2927	CPRFalse	Recently, a G-protein-coupled receptor, termed GPR109A (@CHEMICAL$ in humans, PUMA-G in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.
2928	CPRFalse	Recently, a G-protein-coupled receptor, termed GPR109A (HM74A in humans, @CHEMICAL$ in mice), was described and shown to mediate the @GENE$-induced antilipolytic effects in adipocytes.
2929	CPRFalse	In the present study, we show that mice lacking @CHEMICAL$ did not show @GENE$-induced flushing.
2930	CPRFalse	In addition, flushing in response to @CHEMICAL$ was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @GENE$ had reduced flushing responses.
2931	CPRFalse	In addition, flushing in response to @CHEMICAL$ was also abrogated in the absence of @GENE$, and mice lacking prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.
2932	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.
2933	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking @GENE$ (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.
2934	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.
2935	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking prostaglandin D(2) (@GENE$) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.
2936	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.
2937	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking prostaglandin D(2) (PGD(2)) and @GENE$ (PGE(2)) receptors had reduced flushing responses.
2938	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of cyclooxygenase type 1, and mice lacking @CHEM-GENE$ had reduced flushing responses.
2939	CPRFalse	In addition, flushing in response to nicotinic acid was also abrogated in the absence of @CHEMICAL$, and mice lacking prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (@GENE$) receptors had reduced flushing responses.
2940	CPRFalse	The mouse orthologue of GPR109A, @CHEMICAL$, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated PUMA-G-deficient mice restored the @GENE$-induced flushing response.
2941	CPRFalse	The mouse orthologue of GPR109A, PUMA-G, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated @CHEMICAL$-deficient mice restored the @GENE$-induced flushing response.
2942	CPRFalse	The mouse orthologue of @CHEMICAL$, PUMA-G, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated PUMA-G-deficient mice restored the @GENE$-induced flushing response.
2943	CPRFalse	Our data clearly indicate that @CHEMICAL$ mediates @GENE$-induced flushing and that this effect involves release of PGE(2) and PGD(2), most likely from immune cells of the skin.
2944	CPRFalse	Our data clearly indicate that @CHEMICAL$ mediates nicotinic acid-induced flushing and that this effect involves release of @GENE$ and PGD(2), most likely from immune cells of the skin.
2945	CPRFalse	Our data clearly indicate that @CHEMICAL$ mediates nicotinic acid-induced flushing and that this effect involves release of PGE(2) and @GENE$, most likely from immune cells of the skin.
2946	CPRFalse	The @CHEMICAL$ beta1-adrenoceptor polymorphism and @GENE$ effects on plasma-renin activity.
2947	CPRFalse	The Arg389Gly @CHEMICAL$ polymorphism and @GENE$ effects on plasma-renin activity.
2948	CPRFalse	The Arg389Gly beta1-adrenoceptor polymorphism and @CHEMICAL$ effects on plasma-@GENE$ activity.
2949	CPRFalse	OBJECTIVES: The purpose of this research was to find out whether, in humans, @CHEMICAL$-induced hemodynamic effects and increase in plasma-@GENE$ activity (PRA) might be beta1-adrenoceptor (beta1AR) genotype-dependent.
2950	CPRFalse	OBJECTIVES: The purpose of this research was to find out whether, in humans, @CHEMICAL$-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be @GENE$ (beta1AR) genotype-dependent.
2951	CPRFalse	OBJECTIVES: The purpose of this research was to find out whether, in humans, @CHEMICAL$-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (@GENE$) genotype-dependent.
2952	CPRFalse	RESULTS: With regard to PRA, @CHEMICAL$ increased PRA more potently in Arg389-@GENE$ versus Gly389-beta1AR subjects.
2953	CPRFalse	RESULTS: With regard to PRA, @CHEMICAL$ increased PRA more potently in Arg389-beta1AR versus Gly389-@GENE$ subjects.
2954	CPRFalse	@CHEMICAL$ markedly suppressed the dobutamine-induced PRA increase in Arg389- but only marginally in Gly389-@GENE$ subjects.
2955	CPRFalse	Bisoprolol markedly suppressed the @CHEMICAL$-induced PRA increase in Arg389- but only marginally in Gly389-@GENE$ subjects.
2956	CPRFalse	With regard to hemodynamics, @CHEMICAL$ caused larger heart rate and contractility increases and diastolic blood pressure decreases in Arg389- versus Gly389-@GENE$ subjects.
2957	CPRFalse	@CHEMICAL$ reduced dobutamine-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-@GENE$ subjects.
2958	CPRFalse	Bisoprolol reduced @CHEMICAL$-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-@GENE$ subjects.
2959	CPR:4	@CHEMICAL$ selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by @GENE$: relevance to bipolar disorder.
2960	CPRFalse	Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by @CHEM-GENE$: relevance to bipolar disorder.
2961	CPR:9	Valproic acid selectively inhibits conversion of @CHEMICAL$ to arachidonoyl-CoA by @GENE$: relevance to bipolar disorder.
2962	CPR:9	Valproic acid selectively inhibits conversion of arachidonic acid to @CHEMICAL$ by @GENE$: relevance to bipolar disorder.
2963	CPRFalse	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not @CHEMICAL$, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.
2964	CPRFalse	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an @CHEMICAL$-selective @GENE$.
2965	CPR:4	RATIONALE: Several drugs used to treat bipolar disorder (@CHEMICAL$ and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.
2966	CPR:4	RATIONALE: Several drugs used to treat bipolar disorder (lithium and @CHEMICAL$), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.
2967	CPRFalse	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of @CHEMICAL$, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective @GENE$.
2968	CPRFalse	Although chronic @CHEMICAL$ produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter @GENE$ activity, suggesting that it targets a different enzyme in the turnover pathway.
2969	CPRFalse	Although chronic valproic acid produces similar effects on brain @CHEMICAL$ and docosahexaenoic acid turnover, it does not alter @GENE$ activity, suggesting that it targets a different enzyme in the turnover pathway.
2970	CPRFalse	Although chronic valproic acid produces similar effects on brain arachidonic acid and @CHEMICAL$ turnover, it does not alter @GENE$ activity, suggesting that it targets a different enzyme in the turnover pathway.
2971	CPRFalse	MATERIALS AND METHODS/RESULTS: By isolating @CHEM-GENE$ (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.
2972	CPRFalse	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal @CHEMICAL$ synthetases (@GENE$), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.
2973	CPRFalse	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal @CHEMICAL$ synthetases (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of @GENE$, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.
2974	CPRFalse	MATERIALS AND METHODS/RESULTS: By isolating @CHEMICAL$ (Acsl), we show in vitro that @GENE$ is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.
2975	CPRFalse	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (@CHEMICAL$), we show in vitro that @GENE$ is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.
2976	CPR:4	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that @CHEMICAL$ is a non-competitive inhibitor of @GENE$, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.
2977	CPRFalse	Furthermore, @CHEMICAL$ did not produce @GENE$. CONCLUSIONS: This study shows that valproic acid acts as a non-competitive inhibitor of brain microsomal Acsl, and that inhibition is substrate-selective.
2978	CPRFalse	Furthermore, brain microsomal Acsl did not produce @CHEMICAL$. CONCLUSIONS: This study shows that valproic acid acts as a non-competitive inhibitor of @GENE$, and that inhibition is substrate-selective.
2979	CPRFalse	Furthermore, @CHEMICAL$ did not produce valproyl-CoA. CONCLUSIONS: This study shows that @GENE$ acts as a non-competitive inhibitor of brain microsomal Acsl, and that inhibition is substrate-selective.
2980	CPR:4	Furthermore, brain microsomal Acsl did not produce valproyl-CoA. CONCLUSIONS: This study shows that @CHEMICAL$ acts as a non-competitive inhibitor of @GENE$, and that inhibition is substrate-selective.
2981	CPRFalse	This article summarizes some findings of a research that I have pursued for the past 25 years, whose roots are immersed in the field of inherited metabolic disorders, and deal with different aspects of the vitamin @CHEMICAL$, starting with a patient with multiple @GENE$ deficiency (MCD).
2982	CPR:3	On the other hand, holocarboxylase synthetase (@CHEMICAL$) mRNA levels were markedly low in the deficient animals, and increased upon @GENE$ injection.
2983	CPR:3	On the other hand, @CHEMICAL$ (HCS) mRNA levels were markedly low in the deficient animals, and increased upon @GENE$ injection.
2984	CPRFalse	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for @CHEMICAL$ effects on specific genes and proteins, such as HCS and @GENE$, and on their proteomes."
2985	CPRFalse	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for @CHEMICAL$ effects on specific genes and proteins, such as @GENE$ and hexokinases, and on their proteomes."
2986	CPRFalse	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for biotin effects on specific genes and proteins, such as @CHEMICAL$ and @GENE$, and on their proteomes."
2987	CPRFalse	"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for biotin effects on specific genes and proteins, such as @CHEM-GENE$ and hexokinases, and on their proteomes."
2988	CPR:9	Involvement of @CHEMICAL$ and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced @GENE$ production by microglia.
2989	CPR:9	Involvement of COX-1 and up-regulated @CHEMICAL$ in phosphatidylserine liposome-induced @GENE$ production by microglia.
2990	CPRFalse	Involvement of @CHEMICAL$ and up-regulated @GENE$ synthases in phosphatidylserine liposome-induced prostaglandin E2 production by microglia.
2991	CPRFalse	Involvement of COX-1 and up-regulated @CHEM-GENE$ in phosphatidylserine liposome-induced prostaglandin E2 production by microglia.
2992	CPRFalse	Involvement of @CHEMICAL$ and up-regulated prostaglandin E synthases in @GENE$ liposome-induced prostaglandin E2 production by microglia.
2993	CPRFalse	Involvement of COX-1 and up-regulated @CHEMICAL$ in @GENE$ liposome-induced prostaglandin E2 production by microglia.
2994	CPRFalse	The specific ligand for @CHEMICAL$ (SR-B), high density lipoprotein, significantly suppressed PS liposome-induced @GENE$ production.
2995	CPRFalse	The specific ligand for class B scavenger receptor (@CHEMICAL$), high density lipoprotein, significantly suppressed PS liposome-induced @GENE$ production.
2996	CPRFalse	The specific ligand for class B scavenger receptor (SR-B), @CHEMICAL$, significantly suppressed PS liposome-induced @GENE$ production.
2997	CPRFalse	@CHEMICAL$ (COX)-2 and membrane-bound @GENE$ synthase-1 (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.
2998	CPRFalse	Cyclooxygenase (COX)-2 and membrane-bound @CHEMICAL$ synthase-1 (@GENE$) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.
2999	CPRFalse	Cyclooxygenase @CHEMICAL$ and membrane-bound @GENE$ synthase-1 (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.
3000	CPRFalse	Cyclooxygenase (COX)-2 and membrane-bound @CHEM-GENE$ (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.
3001	CPRFalse	Furthermore, PS liposome-induced @CHEMICAL$ production was significantly suppressed by indomethacin, a preferential @GENE$ inhibitor, but not by NS-398, a selective COX-2 inhibitor.
3002	CPRFalse	Furthermore, PS liposome-induced @CHEMICAL$ production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by NS-398, a selective @GENE$ inhibitor.
3003	CPR:4	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by @CHEMICAL$, a preferential @GENE$ inhibitor, but not by NS-398, a selective COX-2 inhibitor.
3004	CPRFalse	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by @CHEMICAL$, a preferential COX-1 inhibitor, but not by NS-398, a selective @GENE$ inhibitor.
3005	CPRFalse	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential @CHEMICAL$ inhibitor, but not by @GENE$, a selective COX-2 inhibitor.
3006	CPR:4	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by @CHEMICAL$, a selective @GENE$ inhibitor.
3007	CPR:9	These observations strongly suggest that the up-regulation of terminal @CHEMICAL$ that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced @GENE$ production by microglia.
3008	CPR:9	These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with @CHEMICAL$, especially mPGES-2, plays the pivotal role in PS liposome-induced @GENE$ production by microglia.
3009	CPR:9	These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially @CHEMICAL$, plays the pivotal role in PS liposome-induced @GENE$ production by microglia.
3010	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other @GENE$, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.
3011	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly @GENE$, could also promote PGE2 production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.
3012	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/p42 @GENE$ after PS liposomes treatment.
3013	CPRFalse	Although @CHEMICAL$ plays an essential role in PS liposome-induced @GENE$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.
3014	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including @GENE$/p42 ERK after PS liposomes treatment.
3015	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced @CHEMICAL$ production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote PGE2 production by transducing intracellular signals including p44/@GENE$ ERK after PS liposomes treatment.
3016	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other @CHEMICAL$, possibly PS-specific receptor, could also promote @GENE$ production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.
3017	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly @CHEMICAL$, could also promote @GENE$ production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.
3018	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @CHEMICAL$ production by transducing intracellular signals including p44/p42 @GENE$ after PS liposomes treatment.
3019	CPRFalse	Although @CHEMICAL$ plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @GENE$ production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.
3020	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @CHEMICAL$ production by transducing intracellular signals including @GENE$/p42 ERK after PS liposomes treatment.
3021	CPRFalse	Although SR-BI plays an essential role in PS liposome-induced PGE2 production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote @CHEMICAL$ production by transducing intracellular signals including p44/@GENE$ ERK after PS liposomes treatment.
3022	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-@CHEMICAL$ inhibitors (MKIs) @GENE$, sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.
3023	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) @CHEMICAL$, sunitinib, and AG013736, which target multiple @GENE$ as well as PDGFR-beta.
3024	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) @CHEMICAL$, sunitinib, and AG013736, which target multiple VEGFRs as well as @GENE$.
3025	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-@CHEMICAL$ inhibitors (MKIs) sorafenib, @GENE$, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.
3026	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, @CHEMICAL$, and AG013736, which target multiple @GENE$ as well as PDGFR-beta.
3027	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, @CHEMICAL$, and AG013736, which target multiple VEGFRs as well as @GENE$.
3028	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-@CHEMICAL$ inhibitors (MKIs) sorafenib, sunitinib, and @GENE$, which target multiple VEGFRs as well as PDGFR-beta.
3029	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and @CHEMICAL$, which target multiple @GENE$ as well as PDGFR-beta.
3030	CPR:4	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and @CHEMICAL$, which target multiple VEGFRs as well as @GENE$.
3031	CPR:4	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of @GENE$ and PDGFR-beta.
3032	CPR:4	@CHEMICAL$ has the added advantage of inhibiting multiple different @GENE$ isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.
3033	CPR:4	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target @GENE$/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.
3034	CPR:4	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/@GENE$ signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.
3035	CPR:4	@CHEMICAL$ has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and @GENE$.
3036	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with @GENE$ and Ex1-1G>A).
3037	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and @GENE$).
3038	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (@GENE$) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3039	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @GENE$ activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3040	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic @GENE$ protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3041	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in @GENE$ gene (compound heterozygote with S225X and Ex1-1G>A).
3042	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma @CHEMICAL$ level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum @GENE$ (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3043	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with @GENE$ and Ex1-1G>A).
3044	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and @GENE$).
3045	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (@CHEMICAL$) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @GENE$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3046	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEM-GENE$ activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3047	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic @GENE$ protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3048	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @CHEMICAL$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in @GENE$ gene (compound heterozygote with S225X and Ex1-1G>A).
3049	CPRFalse	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum @CHEMICAL$ (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic @GENE$ synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).
3050	CPRFalse	Inhibition of @CHEMICAL$ binding to rat renal brush-border membrane by @GENE$ ligands and basic peptides.
3051	CPRFalse	Our previous studies showed that coadministration of cytochrome c and a 20-residue basic peptide, N-WASP181-200 (@CHEMICAL$, pI=10.87) inhibits renal accumulation of @GENE$.
3052	CPRFalse	Our previous studies showed that coadministration of @CHEMICAL$ and a 20-residue basic peptide, N-WASP181-200 (NISHTKEKKKGKAKKKRLTK, pI=10.87) inhibits renal accumulation of @GENE$.
3053	CPRFalse	In this study, we examined effects of ligands of @CHEMICAL$, an endocytic receptor involved in renal uptake of @GENE$, and basic peptides including N-WASP180-200 and its mutant peptides on gentamicin binding to isolated rat renal brush-border membrane (BBM).
3054	CPRFalse	In this study, we examined effects of ligands of @CHEMICAL$, an endocytic receptor involved in renal uptake of gentamicin, and basic peptides including N-WASP180-200 and its mutant peptides on @GENE$ binding to isolated rat renal brush-border membrane (BBM).
3055	CPRFalse	@CHEMICAL$ binding to BBM was inhibited by @GENE$ ligands, basic peptide fragments of cytochrome c, and N-WASP181-200 in a concentration-dependent manner.
3056	CPRFalse	@CHEMICAL$ binding to BBM was inhibited by megalin ligands, basic peptide fragments of @GENE$, and N-WASP181-200 in a concentration-dependent manner.
3057	CPRFalse	By substituting glycines for @CHEMICAL$ in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the @GENE$ content in the peptide.
3058	CPRFalse	By substituting glycines for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on @CHEMICAL$ binding to BBM was reduced, which may be related to a decrease in the @GENE$ content in the peptide.
3059	CPRFalse	By substituting @CHEMICAL$ for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the @GENE$ content in the peptide.
3060	CPRFalse	@CHEMICAL$ binding to BBM treated with @GENE$, in which megalin completely disappeared, was significantly but not completely decreased compared with the native BBM.
3061	CPRFalse	@CHEMICAL$ binding to BBM treated with trypsin, in which @GENE$ completely disappeared, was significantly but not completely decreased compared with the native BBM.
3062	CPRFalse	In addition, treatment of BBM with @CHEMICAL$ led to a decrease in the inhibitory effect of N-WASP181-200 on @GENE$ binding.
3063	CPRFalse	These observations support that @CHEMICAL$ ligands and basic peptides including N-WASP181-200 decrease renal accumulation of @GENE$ by inhibiting its binding to BBM of proximal tubule cells, partly interacting with megalin.
3064	CPRFalse	These observations support that megalin ligands and basic peptides including N-WASP181-200 decrease renal accumulation of @CHEMICAL$ by inhibiting its binding to BBM of proximal tubule cells, partly interacting with @GENE$.
3065	CPRFalse	In addition, the @CHEMICAL$ conformation may play an important role in the inhibitory effect of N-WASP181-200 on the binding of @GENE$ to BBM.
3066	CPRFalse	@CHEM-GENE$ expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
3067	CPRFalse	@CHEMICAL$ expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with @GENE$.
3068	CPRFalse	@CHEMICAL$ expression pattern, expression level and single @GENE$ polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
3069	CPRFalse	Several variables associated to @CHEMICAL$ (TS), the biological target of 5-fluorouracil (@GENE$) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.
3070	CPRFalse	Several variables associated to thymidylate synthase (@CHEMICAL$), the biological target of 5-fluorouracil (@GENE$) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.
3071	CPRFalse	Several variables associated to @CHEM-GENE$ (TS), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.
3072	CPRFalse	Several variables associated to @CHEMICAL$ synthase (@GENE$), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.
3073	CPRFalse	Several variables associated to @CHEMICAL$ (TS), the biological target of @GENE$ (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.
3074	CPRFalse	Several variables associated to thymidylate synthase (@CHEMICAL$), the biological target of @GENE$ (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.
3075	CPR:4	Low @CHEMICAL$ expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with @GENE$.
3076	CPRFalse	Leishmania species express three @CHEMICAL$ enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @GENE$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3077	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEM-GENE$ (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3078	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ phosphoribosyltransferase (@GENE$), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3079	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ phosphoribosyltransferase (APRT), and @GENE$ (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3080	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (@GENE$), which enable this genus to acquire purine nutrients from their hosts.
3081	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ (HGPRT), @GENE$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3082	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (@CHEMICAL$), @GENE$ phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3083	CPRFalse	Leishmania species express three @CHEMICAL$ enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3084	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3085	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (@CHEMICAL$), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3086	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @CHEM-GENE$ (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3087	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @CHEMICAL$ phosphoribosyltransferase (@GENE$), which enable this genus to acquire purine nutrients from their hosts.
3088	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ (HGPRT), adenine phosphoribosyltransferase (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3089	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (@CHEMICAL$), adenine phosphoribosyltransferase (APRT), and @GENE$ phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3090	CPRFalse	Leishmania species express three @CHEMICAL$ enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.
3091	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), @CHEMICAL$ (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.
3092	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (@CHEMICAL$), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.
3093	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @CHEMICAL$ (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.
3094	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (@CHEMICAL$), which enable this genus to acquire @GENE$ nutrients from their hosts.
3095	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.
3096	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (@CHEMICAL$), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire @GENE$ nutrients from their hosts.
3097	CPRFalse	Leishmania species express three @CHEMICAL$ enzymes, @GENE$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3098	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), @GENE$ (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3099	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (@GENE$), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3100	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and @GENE$ (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3101	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (@GENE$), which enable this genus to acquire purine nutrients from their hosts.
3102	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEM-GENE$ (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3103	CPRFalse	Leishmania species express three phosphoribosyltransferase enzymes, @CHEMICAL$ phosphoribosyltransferase (@GENE$), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.
3104	CPRFalse	These data support the hypothesis that none of the three @CHEMICAL$ is essential for @GENE$ salvage or viability by itself and that purine salvage occurs through multiple anabolic routes in both parasite life cycle stages.
3105	CPRFalse	These data support the hypothesis that none of the three @CHEMICAL$ is essential for purine salvage or viability by itself and that @GENE$ salvage occurs through multiple anabolic routes in both parasite life cycle stages.
3106	CPRFalse	In addition these studies revealed the presence of an @CHEM-GENE$ enzyme in L. donovani axenic amastigotes, an activity previously thought to be restricted to promastigotes.
3107	CPRFalse	In mammalian mitochondria the translational machinery is of dual origin with tRNAs encoded by a simplified and rapidly evolving mitochondrial (mt) genome and @CHEM-GENE$ (aaRS) coded by the nuclear genome, and imported.
3108	CPRFalse	In mammalian mitochondria the translational machinery is of dual origin with tRNAs encoded by a simplified and rapidly evolving mitochondrial (mt) genome and @CHEMICAL$-tRNA synthetases (@GENE$) coded by the nuclear genome, and imported.
3109	CPRFalse	We have explored here the human mt-@CHEMICAL$ system in which a @GENE$, highly similar to the Escherichia coli enzyme, recognizes a bizarre tRNA(Asp).
3110	CPRFalse	This position is otherwise known as the site of a universally conserved major @CHEMICAL$ identity element, @GENE$, also known as a primordial identity signal.
3111	CPRFalse	Sequence alignments of various AspRSs allowed placing @CHEMICAL$-269 at a position occupied by Asp-220, the residue contacting @GENE$ in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.
3112	CPRFalse	Sequence alignments of various @CHEMICAL$ allowed placing @GENE$-269 at a position occupied by Asp-220, the residue contacting G73 in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.
3113	CPRFalse	Sequence alignments of various AspRSs allowed placing @CHEMICAL$-269 at a position occupied by Asp-220, the residue contacting G73 in the crystallographic structure of @GENE$-tRNA(Asp) complex.
3114	CPRFalse	Sequence alignments of various AspRSs allowed placing Gly-269 at a position occupied by @CHEMICAL$-220, the residue contacting @GENE$ in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.
3115	CPRFalse	Sequence alignments of various @CHEMICAL$ allowed placing Gly-269 at a position occupied by @GENE$-220, the residue contacting G73 in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.
3116	CPRFalse	Sequence alignments of various AspRSs allowed placing Gly-269 at a position occupied by @CHEMICAL$-220, the residue contacting G73 in the crystallographic structure of @GENE$-tRNA(Asp) complex.
3117	CPRFalse	Replacing this @CHEMICAL$ by an aspartate renders human mt-AspRS more discriminative to @GENE$.
3118	CPRFalse	Replacing this @CHEMICAL$ by an aspartate renders @GENE$ more discriminative to G73.
3119	CPRFalse	Replacing this glycine by an @CHEMICAL$ renders human mt-AspRS more discriminative to @GENE$.
3120	CPRFalse	Replacing this glycine by an @CHEMICAL$ renders @GENE$ more discriminative to G73.
3121	CPRFalse	Metabolic syndrome: @CHEM-GENE$ and malonyl coenzyme A. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by insulin resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.
3122	CPRFalse	Metabolic syndrome: @CHEMICAL$-activated protein kinase and malonyl coenzyme A. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by @GENE$ resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.
3123	CPRFalse	Metabolic syndrome: @CHEMICAL$ and @GENE$. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by insulin resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.
3124	CPRFalse	Metabolic syndrome: adenosine monophosphate-activated protein kinase and @CHEMICAL$. The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by @GENE$ resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases.
3125	CPRFalse	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the @CHEM-GENE$ (AMPK)/malonyl coenzyme A (CoA) fuel-sensing and signaling mechanism.
3126	CPRFalse	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the @CHEMICAL$-activated protein kinase (@GENE$)/malonyl coenzyme A (CoA) fuel-sensing and signaling mechanism.
3127	CPRFalse	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the @CHEMICAL$ (AMPK)/@GENE$ (CoA) fuel-sensing and signaling mechanism.
3128	CPRFalse	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the adenosine monophosphate-activated protein kinase (@CHEMICAL$)/@GENE$ (CoA) fuel-sensing and signaling mechanism.
3129	CPRFalse	Such dysregulation could be reflected by isolated increases in @CHEMICAL$ or by concurrent changes in malonyl CoA and @GENE$, both of which would alter intracellular fatty acid partitioning.
3130	CPRFalse	Such dysregulation could be reflected by isolated increases in malonyl CoA or by concurrent changes in @CHEMICAL$ and @GENE$, both of which would alter intracellular fatty acid partitioning.
3131	CPRFalse	The possibility is also raised that pharmacological agents and other factors that activate @CHEMICAL$ and/or decrease @GENE$ could be therapeutic targets.
3132	CPRFalse	Chronic effect of @CHEMICAL$ on @GENE$.
3133	CPRFalse	In previous studies, we have demonstrated that chronic @CHEMICAL$ or [D-Ala2,D-Leu5]enkephalin (DADLE) treatment of rats results in the reduction of @GENE$ binding activities as tolerance develops.
3134	CPRFalse	In previous studies, we have demonstrated that chronic etorphine or @CHEMICAL$ (DADLE) treatment of rats results in the reduction of @GENE$ binding activities as tolerance develops.
3135	CPRFalse	In previous studies, we have demonstrated that chronic etorphine or [D-Ala2,D-Leu5]enkephalin (@CHEMICAL$) treatment of rats results in the reduction of @GENE$ binding activities as tolerance develops.
3136	CPRFalse	As both @CHEMICAL$ and DADLE are relatively non-specific opioid ligands, interacting with both @GENE$, these studies could not determine whether down-regulation of a specific receptor type occurs.
3137	CPRFalse	As both etorphine and @CHEMICAL$ are relatively non-specific opioid ligands, interacting with both @GENE$, these studies could not determine whether down-regulation of a specific receptor type occurs.
3138	CPR:5	Therefore, in the present studies, animals were rendered tolerant to the @CHEMICAL$-selective agonist [D-Pen2,D-Pen5]enkephalin (@GENE$), and receptor binding activities were measured.
3139	CPR:5	Therefore, in the present studies, animals were rendered tolerant to the @CHEMICAL$-selective agonist @GENE$ (DPDPE), and receptor binding activities were measured.
3140	CPRFalse	When @CHEMICAL$ binding was determined by using @GENE$, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.
3141	CPRFalse	When @CHEMICAL$ binding was determined by using [3H]DPDPE, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of @GENE$ treatment.
3142	CPRFalse	To our surprise, when @CHEMICAL$ binding was determined by using @GENE$ (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.
3143	CPRFalse	To our surprise, when @CHEMICAL$ binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (@GENE$), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.
3144	CPRFalse	To our surprise, when @CHEMICAL$ binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of @GENE$ treatment.
3145	CPR:4	Our conclusion is that chronic @CHEMICAL$ treatment preferentially reduces @GENE$ binding activity.
3146	CPRFalse	In vitro binding studies showed that both @CHEMICAL$ and amitriptyline interact in the nanomolar range with @GENE$ receptors labelled by [3H]ketanserin in cortical membranes.
3147	CPRFalse	In vitro binding studies showed that both amoxapine and @CHEMICAL$ interact in the nanomolar range with @GENE$ receptors labelled by [3H]ketanserin in cortical membranes.
3148	CPRFalse	In vitro binding studies showed that both amoxapine and amitriptyline interact in the nanomolar range with @CHEMICAL$ receptors labelled by @GENE$ in cortical membranes.
3149	CPRFalse	By contrast, neither amoxapine nor @CHEMICAL$ can be considered as possible ligands of @GENE$ and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).
3150	CPRFalse	By contrast, neither amoxapine nor @CHEMICAL$ can be considered as possible ligands of 5-HT1A and @GENE$ receptors because their affinities for these sites are in the micromolar range (or even worse).
3151	CPRFalse	By contrast, neither @CHEMICAL$ nor amitriptyline can be considered as possible ligands of @GENE$ and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).
3152	CPRFalse	By contrast, neither @CHEMICAL$ nor amitriptyline can be considered as possible ligands of 5-HT1A and @GENE$ receptors because their affinities for these sites are in the micromolar range (or even worse).
3153	CPRFalse	Interestingly, @CHEMICAL$ binds with a good affinity (IC50 = 0.30 microM) to @GENE$ receptors labelled by [3H]zacopride in cortical membranes.
3154	CPRFalse	Interestingly, amoxapine binds with a good affinity (IC50 = 0.30 microM) to @CHEMICAL$ receptors labelled by @GENE$ in cortical membranes.
3155	CPRFalse	Complementary experiments using the @CHEMICAL$-dependent Bezold-Jarisch reflex confirmed that @GENE$ really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors.
3156	CPR:6	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that @CHEMICAL$ really acts in vivo as a @GENE$ antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors.
3157	CPRFalse	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that @CHEMICAL$ really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on @GENE$ receptors.
3158	CPRFalse	Complementary experiments using the @CHEMICAL$-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas @GENE$ is essentially inactive on 5-HT3 receptors.
3159	CPRFalse	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a @CHEMICAL$ antagonist (IC50 = 50 micrograms/kg i.v.), whereas @GENE$ is essentially inactive on 5-HT3 receptors.
3160	CPRFalse	Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms/kg i.v.), whereas @CHEMICAL$ is essentially inactive on @GENE$ receptors.
3161	CPRFalse	The second part of this study consisted of looking for possible changes in central @CHEMICAL$ 24 h after either a single or a repeated (for 14 days) treatment with @GENE$ (10 mg/kg i.p.
3162	CPRFalse	Finally we explored whether acute and/or chronic administration of @CHEMICAL$ or amitriptyline affected the levels of opioid peptides and the @GENE$ in various regions of the brain and the spinal cord.(ABSTRACT TRUNCATED AT 250 WORDS)
3163	CPRFalse	Finally we explored whether acute and/or chronic administration of amoxapine or @CHEMICAL$ affected the levels of opioid peptides and the @GENE$ in various regions of the brain and the spinal cord.(ABSTRACT TRUNCATED AT 250 WORDS)
3164	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the @CHEM-GENE$ (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3165	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human @CHEMICAL$ (5-HT) transporter (@GENE$) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3166	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human @CHEMICAL$ (5-HT) transporter (hSERT) or @GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3167	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human @CHEMICAL$ (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3168	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the @CHEM-GENE$ (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3169	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (@CHEMICAL$) transporter (@GENE$) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3170	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (@CHEMICAL$) transporter (hSERT) or @GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3171	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (@CHEMICAL$) transporter (hSERT) or norepinephrine (NE) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3172	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the @CHEMICAL$ (hSERT) or @GENE$ (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3173	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (@CHEMICAL$) or @GENE$ (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3174	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEM-GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3175	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEMICAL$ (NE) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3176	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the @CHEMICAL$ (hSERT) or norepinephrine (@GENE$) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3177	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (@CHEMICAL$) or norepinephrine (@GENE$) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3178	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEM-GENE$ (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3179	CPRFalse	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (@CHEMICAL$) transporter (@GENE$) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3180	CPR:4	Competitive radioligand binding assays were performed using cells expressing either the @CHEMICAL$ (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3181	CPR:4	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (@CHEMICAL$) or norepinephrine (NE) transporter (hNET) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3182	CPR:4	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or @CHEMICAL$ (hNET) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3183	CPR:4	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (@CHEMICAL$) with K(i) values for @GENE$ of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.
3184	CPRFalse	@CHEMICAL$ showed weak binding affinity (62% inhibition at 100 microM) at the @GENE$.
3185	CPRFalse	DVS showed weak binding affinity (62% inhibition at 100 microM) at the @CHEM-GENE$.
3186	CPRFalse	DVS showed weak binding affinity (62% inhibition at 100 microM) at the @CHEM-GENE$.
3187	CPR:9	Inhibition of @CHEMICAL$ or [3H]NE uptake by DVS for the @GENE$ or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.
3188	CPRFalse	Inhibition of @CHEMICAL$ or [3H]NE uptake by DVS for the hSERT or @GENE$ produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.
3189	CPRFalse	Inhibition of [3H]5-HT or @CHEMICAL$ uptake by DVS for the @GENE$ or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.
3190	CPR:9	Inhibition of [3H]5-HT or @CHEMICAL$ uptake by DVS for the hSERT or @GENE$ produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.
3191	CPRFalse	Inhibition of [3H]5-HT or [3H]NE uptake by @CHEMICAL$ for the @GENE$ or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.
3192	CPRFalse	Inhibition of [3H]5-HT or [3H]NE uptake by @CHEMICAL$ for the hSERT or @GENE$ produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.
3193	CPRFalse	To mimic chronic selective @CHEMICAL$ reuptake inhibitor treatment and to block the inhibitory @GENE$ autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).
3194	CPRFalse	To mimic chronic selective @CHEMICAL$ reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @GENE$ antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).
3195	CPRFalse	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory @CHEMICAL$ autoreceptors, a 5-HT(1A) antagonist, @GENE$ (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).
3196	CPR:6	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @CHEMICAL$ antagonist, @GENE$ (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).
3197	CPRFalse	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory @CHEMICAL$ autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (@GENE$) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).
3198	CPR:6	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @CHEMICAL$ antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (@GENE$) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).
3199	CPRFalse	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory @CHEMICAL$ autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with @GENE$ (30 mg/kg orally).
3200	CPRFalse	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a @CHEMICAL$ antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with @GENE$ (30 mg/kg orally).
3201	CPRFalse	The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal @CHEMICAL$ exposure or dose because of a narrow therapeutic index, nonlinear pharmacokinetics, variabilities in administration rates and metabolism, and in targets like @GENE$.
3202	CPRFalse	The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal fluorouracil exposure or dose because of a narrow therapeutic index, nonlinear pharmacokinetics, variabilities in administration rates and metabolism, and in targets like @CHEM-GENE$.
3203	CPRFalse	To individualise @CHEMICAL$ administration before the first dose, assessment of the individual @GENE$ (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.
3204	CPRFalse	To individualise @CHEMICAL$ administration before the first dose, assessment of the individual dihydropyrimidine dehydrogenase (@GENE$) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.
3205	CPRFalse	To individualise fluorouracil administration before the first dose, assessment of the individual @CHEM-GENE$ (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.
3206	CPRFalse	To individualise fluorouracil administration before the first dose, assessment of the individual @CHEMICAL$ dehydrogenase (@GENE$) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.
3207	CPRFalse	To individualise fluorouracil administration before the first dose, assessment of the individual @CHEMICAL$ (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of @GENE$ elimination.
3208	CPRFalse	To individualise fluorouracil administration before the first dose, assessment of the individual dihydropyrimidine dehydrogenase (@CHEMICAL$) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of @GENE$ elimination.
3209	CPRFalse	A complete or partial loss of @CHEMICAL$ activity in 0.1 and 3-5% of Caucasians, respectively, leads to increased @GENE$ exposure and toxicity.
3210	CPRFalse	Several methods to assess @CHEMICAL$ activity in patients have been proposed (genotyping, various phenotyping methods), but each of them has limitations, as has the @GENE$ test dose approach.
3211	CPRFalse	Whether an adaptation of the fluorouracil starting dose to the results of two @CHEMICAL$ activity tests before fluorouracil administration a priori, and the adaptation of doses to @GENE$ exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.
3212	CPRFalse	Whether an adaptation of the @CHEMICAL$ starting dose to the results of two @GENE$ activity tests before fluorouracil administration a priori, and the adaptation of doses to fluorouracil exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.
3213	CPRFalse	Whether an adaptation of the fluorouracil starting dose to the results of two @CHEMICAL$ activity tests before @GENE$ administration a priori, and the adaptation of doses to fluorouracil exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.
3214	CPRFalse	Expression of @CHEMICAL$ correlates with resistance to @GENE$ in human patient tumors.
3215	CPRFalse	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between @CHEMICAL$ expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.
3216	CPRFalse	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that @CHEMICAL$ expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.
3217	CPRFalse	BACKGROUND: Preclinical results indicate @CHEMICAL$ (aFGF) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.
3218	CPRFalse	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (@CHEMICAL$) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.
3219	CPRFalse	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and @CHEMICAL$ (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.
3220	CPRFalse	BACKGROUND: Preclinical results indicate acidic fibroblast growth factor (aFGF) and basic FGF (@CHEMICAL$) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. We investigated the relationship between FGF expression and @GENE$ activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.
3221	CPRFalse	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, @GENE$ (Pgp), p53, and bcl-2.
3222	CPRFalse	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (@GENE$), p53, and bcl-2.
3223	CPRFalse	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of @GENE$, bFGF, P-glycoprotein (Pgp), p53, and bcl-2.
3224	CPRFalse	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, @GENE$, P-glycoprotein (Pgp), p53, and bcl-2.
3225	CPRFalse	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), @GENE$, and bcl-2.
3226	CPRFalse	Bladder tumors were treated with @CHEMICAL$ for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of paclitaxel were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), p53, and @GENE$.
3227	CPRFalse	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, @GENE$ (Pgp), p53, and bcl-2.
3228	CPRFalse	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (@GENE$), p53, and bcl-2.
3229	CPRFalse	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of @GENE$, bFGF, P-glycoprotein (Pgp), p53, and bcl-2.
3230	CPRFalse	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, @GENE$, P-glycoprotein (Pgp), p53, and bcl-2.
3231	CPRFalse	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), @GENE$, and bcl-2.
3232	CPRFalse	Bladder tumors were treated with paclitaxel for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of @CHEMICAL$ were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), p53, and @GENE$.
3233	CPRFalse	@CHEMICAL$ expression did not correlate with tumor sensitivity to @GENE$, whereas bFGF expression showed an inverse correlation (p < 0.01).
3234	CPRFalse	aFGF expression did not correlate with tumor sensitivity to @CHEMICAL$, whereas @GENE$ expression showed an inverse correlation (p < 0.01).
3235	CPRFalse	bFGF expression was a stronger predictor of @CHEMICAL$ resistance compared to @GENE$, p53, or Bcl-2.
3236	CPRFalse	@CHEMICAL$ expression was a stronger predictor of @GENE$ resistance compared to Pgp, p53, or Bcl-2.
3237	CPRFalse	bFGF expression was a stronger predictor of @CHEMICAL$ resistance compared to Pgp, @GENE$, or Bcl-2.
3238	CPRFalse	bFGF expression was a stronger predictor of @CHEMICAL$ resistance compared to Pgp, p53, or @GENE$.
3239	CPRFalse	CONCLUSION: These results support a role of @CHEMICAL$ in @GENE$ resistance in human patient tumors.
3240	CPRFalse	@CHEM-GENE$ expression in the obligatory paedomorphic salamander Necturus maculosus.
3241	CPRFalse	These hormones induce metamorphosis by controlling gene expression through binding to @CHEM-GENE$ (TRs).
3242	CPRFalse	These hormones induce metamorphosis by controlling gene expression through binding to @CHEMICAL$ receptors (@GENE$).
3243	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine @GENE$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3244	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @GENE$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3245	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (@GENE$)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3246	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3247	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.
3248	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to @CHEMICAL$, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.
3249	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two @GENE$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3250	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: @GENE$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3251	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (@GENE$)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3252	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3253	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.
3254	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two @CHEMICAL$-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.
3255	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @GENE$-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3256	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @CHEM-GENE$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3257	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (@GENE$)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3258	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (CTHBP)-@GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3259	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.
3260	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic @CHEMICAL$-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.
3261	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-@GENE$ kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3262	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @CHEMICAL$ (CTHBP)-M2-@GENE$ kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3263	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (@CHEMICAL$)-M2-@GENE$ kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3264	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@CHEM-GENE$, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3265	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-@CHEMICAL$ kinase, a gene encoding a @GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.
3266	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-@CHEMICAL$ kinase, a gene encoding a cytosolic TH binding protein and @GENE$, a direct TH target gene in Xenopus laevis.
3267	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine @CHEMICAL$ gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3268	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: @CHEMICAL$ (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3269	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (@CHEMICAL$)-M2-pyruvate kinase, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3270	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-@CHEMICAL$, a gene encoding a cytosolic @GENE$ binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.
3271	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a @CHEM-GENE$ and stromelysin 3, a direct TH target gene in Xenopus laevis.
3272	CPRFalse	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic @CHEMICAL$ binding protein and @GENE$, a direct TH target gene in Xenopus laevis.
3273	CPRFalse	The tissue @CHEMICAL$ level is maintained through a cascade of metabolic reactions where @GENE$ (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.
3274	CPRFalse	The tissue @CHEMICAL$ level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (@GENE$) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.
3275	CPRFalse	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEM-GENE$ (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.
3276	CPRFalse	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEMICAL$ dehydrogenases (@GENE$) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step.
3277	CPR:9	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEMICAL$ (RALDHs) catalyze the terminal reaction of @GENE$ biosynthesis from retinal, a rate-limiting step.
3278	CPR:9	The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (@CHEMICAL$) catalyze the terminal reaction of @GENE$ biosynthesis from retinal, a rate-limiting step.
3279	CPR:9	The tissue RA level is maintained through a cascade of metabolic reactions where @CHEMICAL$ (RALDHs) catalyze the terminal reaction of RA biosynthesis from @GENE$, a rate-limiting step.
3280	CPR:9	The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (@CHEMICAL$) catalyze the terminal reaction of RA biosynthesis from @GENE$, a rate-limiting step.
3281	CPRFalse	We showed that dietary supplement of cholesterol enhanced the expression of @CHEMICAL$ genes and the cellular @GENE$ content in vital organs such as brain, kidney, liver and heart.
3282	CPRFalse	We showed that dietary supplement of @CHEMICAL$ enhanced the expression of @GENE$ genes and the cellular RA content in vital organs such as brain, kidney, liver and heart.
3283	CPRFalse	Consistently, the @CHEMICAL$-lowering agent (pravastatin sodium) downregulated the expression of @GENE$ genes in several organs especially the liver and in cultured liver cells.
3284	CPRFalse	Consistently, the cholesterol-lowering agent (@CHEMICAL$) downregulated the expression of @GENE$ genes in several organs especially the liver and in cultured liver cells.
3285	CPRFalse	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for @GENE$ (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.
3286	CPRFalse	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (@GENE$), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.
3287	CPR:3	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @GENE$ (SREBP-1c) that bound to the regulatory regions of these genes.
3288	CPR:3	Further, @CHEMICAL$ metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (@GENE$) that bound to the regulatory regions of these genes.
3289	CPRFalse	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for @GENE$ (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.
3290	CPRFalse	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for liver X receptor (@GENE$), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.
3291	CPR:3	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @GENE$ (SREBP-1c) that bound to the regulatory regions of these genes.
3292	CPR:3	Further, cholesterol metabolites, predominantly the @CHEMICAL$, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (@GENE$) that bound to the regulatory regions of these genes.
3293	CPRFalse	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for @CHEMICAL$ (LXR), induced these genes via upregulation of @GENE$ regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.
3294	CPRFalse	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (@CHEMICAL$), induced these genes via upregulation of @GENE$ regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.
3295	CPRFalse	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @CHEM-GENE$ (SREBP-1c) that bound to the regulatory regions of these genes.
3296	CPRFalse	Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of @CHEMICAL$ regulatory element binding protein-1c (@GENE$) that bound to the regulatory regions of these genes.
3297	CPRFalse	Brain abnormalities in +/rl are similar to psychotic brain and include a reduction in @CHEM-GENE$ (GAD67), dendritic arbors and spine density in cortex and hippocampus, and abnormalities in synaptic function including long-term potentiation (LTP).
3298	CPRFalse	Brain abnormalities in +/rl are similar to psychotic brain and include a reduction in @CHEMICAL$ de carboxylase 67 (@GENE$), dendritic arbors and spine density in cortex and hippocampus, and abnormalities in synaptic function including long-term potentiation (LTP).
3299	CPR:3	Hypermethlyation of @CHEMICAL$ can be induced by treating mice with @GENE$, and these mice display brain and behavioral abnormalities similar to +/rl.
3300	CPR:6	Functional and bioenergetic consequences of @CHEMICAL$ antagonist @GENE$ in hearts with postinfarction LV remodeling.
3301	CPRFalse	The structural left ventricular (LV) remodeling and contractile dysfunction of hearts with postinfarction LV remodeling are benefited by @CHEMICAL$ type 1 receptor (@GENE$) blocker.
3302	CPRFalse	The structural left ventricular (LV) remodeling and contractile dysfunction of hearts with postinfarction LV remodeling are benefited by @CHEM-GENE$ (AT1) blocker.
3303	CPRFalse	Animals with heart failure demonstrated reductions in both mitochondrial @CHEMICAL$ expression and myocardial high-energy @GENE$ levels.
3304	CPR:6	Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the @CHEMICAL$ antagonist @GENE$.
3305	CPRFalse	Regulation of @CHEM-GENE$ and retinoid X receptor alpha after sciatic nerve injury.
3306	CPRFalse	Regulation of @CHEMICAL$ receptors alpha, beta and @GENE$ after sciatic nerve injury.
3307	CPRFalse	Regulation of @CHEMICAL$ and @GENE$ X receptor alpha after sciatic nerve injury.
3308	CPRFalse	Regulation of retinoic acid receptors alpha, beta and @CHEM-GENE$ after sciatic nerve injury.
3309	CPRFalse	Since the effect of @CHEMICAL$ is mediated via @GENE$ and retinoid X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.
3310	CPRFalse	Since the effect of @CHEMICAL$ is mediated via retinoic acid receptors and @GENE$, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.
3311	CPRFalse	Since the effect of retinoic acid is mediated via @CHEM-GENE$ and retinoid X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.
3312	CPRFalse	Since the effect of retinoic acid is mediated via @CHEMICAL$ receptors and @GENE$, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.
3313	CPRFalse	Since the effect of retinoic acid is mediated via @CHEMICAL$ and @GENE$ X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.
3314	CPRFalse	Since the effect of retinoic acid is mediated via retinoic acid receptors and @CHEM-GENE$, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.
3315	CPRFalse	Seven days after crush injury, transcript concentrations of all @CHEMICAL$ and of @GENE$ X receptor alpha were significantly higher than in non-lesioned nerves.
3316	CPRFalse	Seven days after crush injury, transcript concentrations of all retinoic acid receptors and of @CHEM-GENE$ were significantly higher than in non-lesioned nerves.
3317	CPRFalse	Seven days after crush injury, transcript concentrations of all @CHEM-GENE$ and of retinoid X receptor alpha were significantly higher than in non-lesioned nerves.
3318	CPRFalse	Seven days after crush injury, transcript concentrations of all @CHEMICAL$ receptors and of @GENE$ were significantly higher than in non-lesioned nerves.
3319	CPRFalse	Protein levels of @CHEM-GENE$, retinoic acid receptor beta and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.
3320	CPRFalse	Protein levels of @CHEMICAL$ receptor alpha, @GENE$ and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.
3321	CPRFalse	Protein levels of @CHEMICAL$ receptor alpha, retinoic acid receptor beta and @GENE$ were upregulated 4, 7 and 14 days after injury.
3322	CPRFalse	Protein levels of @CHEMICAL$, @GENE$ receptor beta and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.
3323	CPRFalse	Protein levels of retinoic acid receptor alpha, @CHEM-GENE$ and retinoid X receptor alpha were upregulated 4, 7 and 14 days after injury.
3324	CPRFalse	Protein levels of retinoic acid receptor alpha, @CHEMICAL$ receptor beta and @GENE$ were upregulated 4, 7 and 14 days after injury.
3325	CPRFalse	Protein levels of @CHEMICAL$, retinoic acid receptor beta and @GENE$ X receptor alpha were upregulated 4, 7 and 14 days after injury.
3326	CPRFalse	Protein levels of retinoic acid receptor alpha, @CHEMICAL$ and @GENE$ X receptor alpha were upregulated 4, 7 and 14 days after injury.
3327	CPRFalse	Protein levels of retinoic acid receptor alpha, retinoic acid receptor beta and @CHEM-GENE$ were upregulated 4, 7 and 14 days after injury.
3328	CPRFalse	In degenerating nerves a significant increase of @CHEM-GENE$ was detected 7 and 14 days, and of retinoic acid receptor beta 14 and 21 days after complete transection.
3329	CPRFalse	In degenerating nerves a significant increase of @CHEMICAL$ receptor alpha was detected 7 and 14 days, and of @GENE$ 14 and 21 days after complete transection.
3330	CPRFalse	In degenerating nerves a significant increase of @CHEMICAL$ was detected 7 and 14 days, and of @GENE$ receptor beta 14 and 21 days after complete transection.
3331	CPRFalse	In degenerating nerves a significant increase of retinoic acid receptor alpha was detected 7 and 14 days, and of @CHEM-GENE$ 14 and 21 days after complete transection.
3332	CPRFalse	Immunohistochemical staining of @CHEM-GENE$ revealed their expression in Schwann cells and macrophages.
3333	CPRFalse	In addition, we observed that @CHEM-GENE$ and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.
3334	CPRFalse	In addition, we observed that @CHEMICAL$ receptor alpha and @GENE$ appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.
3335	CPRFalse	In addition, we observed that @CHEMICAL$ receptor alpha and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$-staining co-localized with some regenerating axons.
3336	CPRFalse	In addition, we observed that @CHEMICAL$ and @GENE$ X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.
3337	CPRFalse	In addition, we observed that retinoic acid receptor alpha and @CHEM-GENE$ appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that retinoid X receptor alpha-staining co-localized with some regenerating axons.
3338	CPRFalse	In addition, we observed that retinoic acid receptor alpha and @CHEMICAL$ X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$-staining co-localized with some regenerating axons.
3339	CPRFalse	In addition, we observed that @CHEMICAL$ and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$ X receptor alpha-staining co-localized with some regenerating axons.
3340	CPRFalse	In addition, we observed that retinoic acid receptor alpha and @CHEMICAL$ appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @GENE$ X receptor alpha-staining co-localized with some regenerating axons.
3341	CPRFalse	In addition, we observed that retinoic acid receptor alpha and retinoid X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that @CHEM-GENE$-staining co-localized with some regenerating axons.
3342	CPRFalse	Experiments with Schwann cell primary cultures revealed an effect of @CHEMICAL$ on the expression of the @GENE$ ErbB3, suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.
3343	CPRFalse	Experiments with Schwann cell primary cultures revealed an effect of @CHEMICAL$ on the expression of the neuregulin receptor @GENE$, suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.
3344	CPRFalse	Experiments with Schwann cell primary cultures revealed an effect of retinoic acid on the expression of the @CHEMICAL$ ErbB3, suggesting that one function of @GENE$ consists in the regulation of neuroglial interactions after peripheral nerve injury.
3345	CPRFalse	Experiments with Schwann cell primary cultures revealed an effect of retinoic acid on the expression of the neuregulin receptor @CHEMICAL$, suggesting that one function of @GENE$ consists in the regulation of neuroglial interactions after peripheral nerve injury.
3346	CPRFalse	Cellular effects of @CHEMICAL$ on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated @GENE$ mutations.
3347	CPRFalse	BACKGROUND: Activating mutations in the RET gene, which encodes a @CHEM-GENE$, often cause medullary thyroid carcinoma (MTC).
3348	CPRFalse	BACKGROUND: Activating mutations in the @CHEMICAL$ gene, which encodes a @GENE$ kinase receptor, often cause medullary thyroid carcinoma (MTC).
3349	CPR:4	We evaluated @CHEMICAL$, a @GENE$ inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.
3350	CPRFalse	We evaluated @CHEMICAL$, a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant @GENE$.
3351	CPRFalse	We evaluated imatinib, a @CHEM-GENE$ inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.
3352	CPRFalse	We evaluated imatinib, a @CHEMICAL$ kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant @GENE$.
3353	CPR:4	RESULTS: @CHEMICAL$ inhibited RET @GENE$ phosphorylation in a dose-dependent manner after 1.5 hours of exposure.
3354	CPR:4	RESULTS: @CHEMICAL$ inhibited @GENE$ Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.
3355	CPR:4	CONCLUSIONS: @CHEMICAL$ inhibits @GENE$-mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner.
3356	CPR:4	CONCLUSIONS: @CHEMICAL$ inhibits RET-mediated MTC cell growth affecting @GENE$ protein levels in vitro in a dose-dependent manner.
3357	CPR:4	The concentration of @CHEMICAL$ necessary to inhibit @GENE$ in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.
3358	CPRFalse	The concentration of imatinib necessary to inhibit @CHEMICAL$ in vitro, however, makes it impossible to conclude that @GENE$ monotherapy will be a good option for systemic therapy of MTC.
3359	CPRFalse	With the exception of @CHEMICAL$, where @GENE$ is a constituent of the FeMo-cofactor, Mo is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.
3360	CPRFalse	With the exception of @CHEMICAL$, where Mo is a constituent of the @GENE$-cofactor, Mo is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.
3361	CPRFalse	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, @GENE$ is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.
3362	CPRFalse	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a @GENE$, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.
3363	CPRFalse	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a pterin, thus forming the @GENE$ cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.
3364	CPRFalse	With the exception of @CHEMICAL$, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other @GENE$-enzymes.
3365	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @CHEM-GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3366	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$ reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3367	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$ reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3368	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$ reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3369	CPRFalse	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3370	CPRFalse	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) @GENE$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3371	CPRFalse	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3372	CPRFalse	In eukaryotes, the most prominent @CHEMICAL$-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3373	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of @CHEMICAL$-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3374	CPR:9	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of @GENE$-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3375	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of @CHEMICAL$-containing amino acids and is involved in detoxifying excess sulfite, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3376	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of @CHEMICAL$-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3377	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @CHEMICAL$, which catalyzes the key step in inorganic @GENE$ assimilation.
3378	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic @GENE$ assimilation.
3379	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic @GENE$ assimilation.
3380	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic @GENE$ assimilation.
3381	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing @CHEMICAL$ and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3382	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing @GENE$ and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3383	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing @CHEMICAL$ and is involved in detoxifying excess sulfite, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3384	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing @CHEMICAL$ and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3385	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @CHEMICAL$, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3386	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @GENE$, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3387	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @CHEMICAL$, (2) @GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3388	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess @CHEMICAL$, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3389	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$ dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3390	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @GENE$ dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3391	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEM-GENE$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3392	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$ dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3393	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in @CHEMICAL$ catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3394	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in @GENE$ catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3395	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in @GENE$ catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3396	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in @CHEMICAL$ catabolism and reactive oxygen production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3397	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive @CHEMICAL$ production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3398	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive @GENE$ production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3399	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive @GENE$ production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3400	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive @CHEMICAL$ production, (3) @GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3401	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$ oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3402	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$ oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3403	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) @GENE$ oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3404	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEM-GENE$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3405	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of @CHEMICAL$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3406	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of @GENE$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3407	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of @GENE$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3408	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of @GENE$ and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3409	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @CHEMICAL$, and in autotrophic organisms also (4) @GENE$, which catalyzes the key step in inorganic nitrogen assimilation.
3410	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) @CHEMICAL$, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @GENE$, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3411	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) @CHEMICAL$, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @GENE$, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3412	CPRFalse	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) @CHEMICAL$, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone @GENE$, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.
3413	CPRFalse	All @CHEMICAL$-enzymes, except @GENE$, need at least one more redox active center, many of them involving iron in electron transfer.
3414	CPRFalse	All Mo-enzymes, except @CHEM-GENE$, need at least one more redox active center, many of them involving iron in electron transfer.
3415	CPRFalse	All Mo-enzymes, except @CHEMICAL$, need at least one more redox active center, many of them involving @GENE$ in electron transfer.
3416	CPRFalse	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEMICAL$ oxidase and @GENE$, require the post-translational sulfuration of their Mo-site for becoming active.
3417	CPRFalse	@CHEMICAL$ and aldehyde oxidase, but not @GENE$ oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3418	CPRFalse	Xanthine dehydrogenase and @CHEMICAL$, but not @GENE$ oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3419	CPRFalse	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEM-GENE$ and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3420	CPRFalse	Xanthine dehydrogenase and aldehyde oxidase, but not sulfite oxidase and @CHEM-GENE$, require the post-translational sulfuration of their Mo-site for becoming active.
3421	CPRFalse	@CHEMICAL$ and aldehyde oxidase, but not sulfite oxidase and @GENE$ reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3422	CPRFalse	Xanthine dehydrogenase and @CHEMICAL$, but not sulfite oxidase and @GENE$ reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3423	CPRFalse	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEMICAL$ and @GENE$ reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3424	CPRFalse	Xanthine dehydrogenase and aldehyde oxidase, but not sulfite oxidase and @CHEMICAL$, require the post-translational sulfuration of their @GENE$-site for becoming active.
3425	CPRFalse	@CHEMICAL$ and aldehyde oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their @GENE$-site for becoming active.
3426	CPRFalse	Xanthine dehydrogenase and @CHEMICAL$, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their @GENE$-site for becoming active.
3427	CPRFalse	Xanthine dehydrogenase and aldehyde oxidase, but not @CHEMICAL$ and nitrate reductase, require the post-translational sulfuration of their @GENE$-site for becoming active.
3428	CPRFalse	@CHEMICAL$ dehydrogenase and aldehyde oxidase, but not sulfite oxidase and @GENE$, require the post-translational sulfuration of their Mo-site for becoming active.
3429	CPRFalse	@CHEM-GENE$ and aldehyde oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3430	CPRFalse	@CHEMICAL$ dehydrogenase and @GENE$, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3431	CPRFalse	@CHEMICAL$ dehydrogenase and aldehyde oxidase, but not @GENE$ and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3432	CPRFalse	Xanthine dehydrogenase and @CHEMICAL$ oxidase, but not sulfite oxidase and @GENE$, require the post-translational sulfuration of their Mo-site for becoming active.
3433	CPRFalse	@CHEMICAL$ and @GENE$ oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3434	CPRFalse	Xanthine dehydrogenase and @CHEM-GENE$, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3435	CPRFalse	Xanthine dehydrogenase and @CHEMICAL$ oxidase, but not @GENE$ and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.
3436	CPRFalse	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes @CHEMICAL$ from l-cysteine in a pyridoxal phosphate-dependent manner as typical for @GENE$.
3437	CPRFalse	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes @GENE$ from l-cysteine in a pyridoxal phosphate-dependent manner as typical for cysteine desulfurases.
3438	CPRFalse	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from @CHEMICAL$ in a pyridoxal phosphate-dependent manner as typical for @GENE$.
3439	CPRFalse	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes sulfur from @GENE$ in a pyridoxal phosphate-dependent manner as typical for cysteine desulfurases.
3440	CPRFalse	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from l-cysteine in a @CHEMICAL$-dependent manner as typical for @GENE$.
3441	CPRFalse	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes sulfur from l-cysteine in a @GENE$-dependent manner as typical for cysteine desulfurases.
3442	CPRFalse	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from l-cysteine in a pyridoxal phosphate-dependent manner as typical for @CHEM-GENE$.
3443	CPRFalse	This final maturation step is catalyzed by a @CHEMICAL$ enzyme, which mobilizes sulfur from l-cysteine in a pyridoxal phosphate-dependent manner as typical for @GENE$ desulfurases.
3444	CPRFalse	@CHEMICAL$ is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and @GENE$), members of nuclear hormone receptor superfamily.
3445	CPR:3	@CHEMICAL$ is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of @GENE$ superfamily.
3446	CPR:3	@CHEMICAL$ is a collective term for compounds which bind to and activate @GENE$ (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.
3447	CPRFalse	@CHEMICAL$ is a collective term for compounds which bind to and activate retinoic acid receptors (@GENE$ and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.
3448	CPRFalse	The most important endogeneous @CHEMICAL$ is all-trans-retinoic acid (ATRA) which is an @GENE$ ligand.
3449	CPRFalse	The most important endogeneous retinoid is @CHEMICAL$ (ATRA) which is an @GENE$ ligand.
3450	CPRFalse	The most important endogeneous retinoid is all-trans-retinoic acid (@CHEMICAL$) which is an @GENE$ ligand.
3451	CPRFalse	Among them, @CHEMICAL$ (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and @GENE$-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3452	CPRFalse	Among them, @CHEMICAL$ (Am80) is an @GENE$- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3453	CPRFalse	Among them, @CHEMICAL$ (Am80) is an RARalpha- and @GENE$-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3454	CPRFalse	Among them, @CHEMICAL$ (Am80) is an RARalpha- and RARbeta-specific (but @GENE$- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3455	CPRFalse	Among them, tamibarotene (@CHEMICAL$) is an RARalpha- and RARbeta-specific (but RARgamma- and @GENE$-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3456	CPRFalse	Among them, tamibarotene (@CHEMICAL$) is an @GENE$- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3457	CPRFalse	Among them, tamibarotene (@CHEMICAL$) is an RARalpha- and @GENE$-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3458	CPRFalse	Among them, tamibarotene (@CHEMICAL$) is an RARalpha- and RARbeta-specific (but @GENE$- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.
3459	CPRFalse	Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and @CHEMICAL$-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.
3460	CPRFalse	Among them, tamibarotene (Am80) is an @CHEMICAL$- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.
3461	CPRFalse	Among them, tamibarotene (Am80) is an RARalpha- and @CHEMICAL$-specific (but RARgamma- and RXRs-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.
3462	CPRFalse	Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but @CHEMICAL$- and RXRs-nonbinding) synthetic @GENE$ that is effective in the treatment of psoriasis patients and relapsed APL.
3463	CPRFalse	@CHEMICAL$ regulates non-neuronal cholinergic activity in T lymphocytes via @GENE$-mediated pathways.
3464	CPRFalse	We previously showed that @CHEMICAL$ stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in @GENE$ (ACh) synthesis and choline acetyltransferase (ChAT) mRNA expression.
3465	CPRFalse	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via @CHEMICAL$-mediated pathways, as evidenced by increases in @GENE$ (ACh) synthesis and choline acetyltransferase (ChAT) mRNA expression.
3466	CPRFalse	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in @CHEMICAL$ (ACh) synthesis and @GENE$ (ChAT) mRNA expression.
3467	CPRFalse	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in @CHEMICAL$ (ACh) synthesis and choline acetyltransferase (@GENE$) mRNA expression.
3468	CPRFalse	We previously showed that @CHEMICAL$ stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (@GENE$) synthesis and choline acetyltransferase (ChAT) mRNA expression.
3469	CPRFalse	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via @CHEMICAL$-mediated pathways, as evidenced by increases in acetylcholine (@GENE$) synthesis and choline acetyltransferase (ChAT) mRNA expression.
3470	CPRFalse	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (@CHEMICAL$) synthesis and @GENE$ (ChAT) mRNA expression.
3471	CPRFalse	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (@CHEMICAL$) synthesis and choline acetyltransferase (@GENE$) mRNA expression.
3472	CPRFalse	The @CHEMICAL$-lowering drug simvastatin inhibits @GENE$ signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.
3473	CPRFalse	The @CHEMICAL$-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on @GENE$ (LFA-1 alpha chain), which leads to immunomodulation.
3474	CPRFalse	The @CHEMICAL$-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (@GENE$), which leads to immunomodulation.
3475	CPR:4	The cholesterol-lowering drug @CHEMICAL$ inhibits @GENE$ signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.
3476	CPRFalse	The cholesterol-lowering drug @CHEMICAL$ inhibits LFA-1 signaling by binding to an allosteric site on @GENE$ (LFA-1 alpha chain), which leads to immunomodulation.
3477	CPRFalse	The cholesterol-lowering drug @CHEMICAL$ inhibits LFA-1 signaling by binding to an allosteric site on CD11a (@GENE$), which leads to immunomodulation.
3478	CPRFalse	We found that anti-@CHEMICAL$ monoclonal antibody (mAb) increased ChAT activity, @GENE$ synthesis and release, and expression of ChAT and M5 muscarinic ACh receptor mRNA in MOLT-3 cells, a human leukemic T cell line.
3479	CPRFalse	We found that anti-CD11a monoclonal antibody (mAb) increased @CHEMICAL$ activity, @GENE$ synthesis and release, and expression of ChAT and M5 muscarinic ACh receptor mRNA in MOLT-3 cells, a human leukemic T cell line.
3480	CPRFalse	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, @CHEMICAL$ synthesis and release, and expression of @GENE$ and M5 muscarinic ACh receptor mRNA in MOLT-3 cells, a human leukemic T cell line.
3481	CPRFalse	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and @GENE$ mRNA in MOLT-3 cells, a human leukemic T cell line.
3482	CPRFalse	We found that anti-@CHEMICAL$ monoclonal antibody (mAb) increased ChAT activity, ACh synthesis and release, and expression of ChAT and M5 muscarinic @GENE$ receptor mRNA in MOLT-3 cells, a human leukemic T cell line.
3483	CPRFalse	We found that anti-CD11a monoclonal antibody (mAb) increased @CHEMICAL$ activity, ACh synthesis and release, and expression of ChAT and M5 muscarinic @GENE$ receptor mRNA in MOLT-3 cells, a human leukemic T cell line.
3484	CPRFalse	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, ACh synthesis and release, and expression of @CHEMICAL$ and M5 muscarinic @GENE$ receptor mRNA in MOLT-3 cells, a human leukemic T cell line.
3485	CPRFalse	We found that anti-CD11a monoclonal antibody (mAb) increased ChAT activity, ACh synthesis and release, and expression of ChAT and @CHEM-GENE$ mRNA in MOLT-3 cells, a human leukemic T cell line.
3486	CPR:4	@CHEMICAL$ abolished these anti-@GENE$ mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.
3487	CPRFalse	Simvastatin abolished these anti-@CHEMICAL$ mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its @GENE$-lowering activity.
3488	CPRFalse	These results indicate that @CHEMICAL$ contributes to the regulation of lymphocytic cholinergic activity via CD11a-mediated pathways, and suggest that @GENE$ exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.
3489	CPRFalse	These results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via @CHEMICAL$-mediated pathways, and suggest that @GENE$ exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.
3490	CPR:3	@CHEMICAL$, popularly known for its cooling effect, activates TRPM8--a cold-activated @GENE$.
3491	CPR:3	@CHEMICAL$, popularly known for its cooling effect, activates @GENE$--a cold-activated thermoTRP ion channel.
3492	CPRFalse	However, human physiological studies demonstrate a paradoxical role of @CHEMICAL$ in modulation of warm sensation, and here, we show that menthol also activates heat-activated @GENE$.
3493	CPR:3	However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that @CHEMICAL$ also activates heat-activated @GENE$.
3494	CPR:4	We further show that @CHEMICAL$ inhibits @GENE$, potentially explaining the use of menthol as an analgesic.
3495	CPRFalse	We further show that menthol inhibits @CHEMICAL$, potentially explaining the use of @GENE$ as an analgesic.
3496	CPRFalse	Similar to @CHEMICAL$, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other @GENE$.
3497	CPR:3	Similar to @CHEMICAL$, both camphor and cinnamaldehyde (initially reported to be specific activators of @GENE$ and TRPA1, respectively) also modulate other thermoTRPs.
3498	CPR:3	Similar to @CHEMICAL$, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and @GENE$, respectively) also modulate other thermoTRPs.
3499	CPRFalse	Similar to menthol, both @CHEMICAL$ and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other @GENE$.
3500	CPR:3	Similar to menthol, both @CHEMICAL$ and cinnamaldehyde (initially reported to be specific activators of @GENE$ and TRPA1, respectively) also modulate other thermoTRPs.
3501	CPR:3	Similar to menthol, both @CHEMICAL$ and cinnamaldehyde (initially reported to be specific activators of TRPV3 and @GENE$, respectively) also modulate other thermoTRPs.
3502	CPRFalse	Similar to menthol, both camphor and @CHEMICAL$ (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other @GENE$.
3503	CPR:3	Similar to menthol, both camphor and @CHEMICAL$ (initially reported to be specific activators of @GENE$ and TRPA1, respectively) also modulate other thermoTRPs.
3504	CPR:3	Similar to menthol, both camphor and @CHEMICAL$ (initially reported to be specific activators of TRPV3 and @GENE$, respectively) also modulate other thermoTRPs.
3505	CPRFalse	These PCSCs possessed @CHEM-GENE$ and KGFR, but not androgen receptor as determined by RT-PCR and Western blot, respectively.
3506	CPRFalse	These PCSCs possessed @CHEMICAL$ receptors and @GENE$, but not androgen receptor as determined by RT-PCR and Western blot, respectively.
3507	CPRFalse	These PCSCs possessed @CHEMICAL$ receptors and KGFR, but not @GENE$ as determined by RT-PCR and Western blot, respectively.
3508	CPRFalse	These PCSCs possessed @CHEMICAL$ and KGFR, but not @GENE$ receptor as determined by RT-PCR and Western blot, respectively.
3509	CPRFalse	These PCSCs possessed estrogen receptors and @CHEMICAL$, but not @GENE$ receptor as determined by RT-PCR and Western blot, respectively.
3510	CPRFalse	These PCSCs possessed estrogen receptors and KGFR, but not @CHEM-GENE$ as determined by RT-PCR and Western blot, respectively.
3511	CPRFalse	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and @GENE$ expression.
3512	CPRFalse	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, @GENE$ prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.
3513	CPRFalse	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated @GENE$ triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.
3514	CPRFalse	Cell proliferation analysis indicated that @CHEMICAL$ or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating @GENE$ and phospho-Akt expression.
3515	CPRFalse	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and @GENE$ expression.
3516	CPRFalse	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, @GENE$ prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.
3517	CPRFalse	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated @GENE$ triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.
3518	CPRFalse	Cell proliferation analysis indicated that tamoxifen or @CHEMICAL$ reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating @GENE$ and phospho-Akt expression.
3519	CPR:9	The glutamate-aspartate transporter @CHEMICAL$ mediates @GENE$ uptake at inner hair cell afferent synapses in the mammalian cochlea.
3520	CPR:9	The @CHEMICAL$ GLAST mediates @GENE$ uptake at inner hair cell afferent synapses in the mammalian cochlea.
3521	CPRFalse	Focal application of the transporter substrate @CHEMICAL$ elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated @GENE$ and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate.
3522	CPR:6	Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated @CHEMICAL$ and blocked by the transporter antagonist @GENE$.
3523	CPRFalse	These currents were produced by @CHEM-GENE$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3524	CPRFalse	These currents were produced by @CHEMICAL$-aspartate transporters (@GENE$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3525	CPRFalse	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (@GENE$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3526	CPRFalse	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3527	CPRFalse	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.
3528	CPRFalse	These currents were produced by @CHEMICAL$-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.
3529	CPRFalse	These currents were produced by @CHEM-GENE$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3530	CPRFalse	These currents were produced by glutamate-@CHEMICAL$ transporters (@GENE$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3531	CPRFalse	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (@GENE$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3532	CPRFalse	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3533	CPRFalse	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.
3534	CPRFalse	These currents were produced by glutamate-@CHEMICAL$ transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.
3535	CPRFalse	These currents were produced by @CHEMICAL$ (GLAST) (excitatory @GENE$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3536	CPRFalse	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory @GENE$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3537	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEM-GENE$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3538	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory @CHEMICAL$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3539	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory @CHEMICAL$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.
3540	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory @CHEMICAL$ transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.
3541	CPR:4	These currents were produced by @CHEMICAL$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @GENE$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3542	CPR:4	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory amino acid transporter 1) because they were weakly inhibited by @GENE$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3543	CPR:4	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEMICAL$) because they were weakly inhibited by @GENE$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3544	CPR:6	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @CHEMICAL$, an antagonist of @GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3545	CPR:6	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @CHEMICAL$, an antagonist of glutamate transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.
3546	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by @CHEMICAL$, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.
3547	CPRFalse	These currents were produced by @CHEMICAL$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3548	CPRFalse	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3549	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEMICAL$) because they were weakly inhibited by dihydrokainate, an antagonist of @GENE$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3550	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEM-GENE$ (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3551	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEMICAL$ transporter-1 (@GENE$) and were absent from IPCs in GLAST-/- cochleas.
3552	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEMICAL$ transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in @GENE$-/- cochleas.
3553	CPRFalse	These currents were produced by @CHEMICAL$ (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3554	CPRFalse	These currents were produced by glutamate-aspartate transporters (@CHEMICAL$) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3555	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (@CHEMICAL$) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3556	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of @CHEMICAL$ (excitatory @GENE$ transporter 2) and were absent from IPCs in GLAST-/- cochleas.
3557	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (@CHEM-GENE$) and were absent from IPCs in GLAST-/- cochleas.
3558	CPRFalse	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory @CHEMICAL$ transporter 2) and were absent from IPCs in @GENE$-/- cochleas.
3559	CPRFalse	Furthermore, @CHEMICAL$-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of @GENE$, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.
3560	CPRFalse	Furthermore, @CHEMICAL$-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of GLAST, and examination of cochlea from @GENE$-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.
3561	CPR:9	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by @CHEMICAL$, a prominent feature of @GENE$, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.
3562	CPRFalse	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by @CHEMICAL$, a prominent feature of GLAST, and examination of cochlea from @GENE$-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.
3563	CPRFalse	The @CHEMICAL$ blocking activities of @GENE$ and its RR-SR (50:50) stereoisomers. 1.
3564	CPRFalse	We compared the @CHEMICAL$ blocking potencies of @GENE$ with those of its two stereoisomers (RR and SR) in pithed rats and in homogenized rat cerebral cortex and heart.
3565	CPRFalse	@CHEMICAL$ 4 and 20 micrograms kg-1 body wt. and propranolol 1 and 5 mg kg-1 body wt., were given intravenously for comparison studies of potency at @GENE$, respectively.
3566	CPRFalse	Prazosin 4 and 20 micrograms kg-1 body wt. and @CHEMICAL$ 1 and 5 mg kg-1 body wt., were given intravenously for comparison studies of potency at @GENE$, respectively.
3567	CPRFalse	Following both oral and intravenous dosing, the RR-SR combination was twice potent as @CHEMICAL$ in terms of @GENE$ antagonism at equivalent doses.
3568	CPRFalse	@CHEMICAL$ and the enantiomers lacked affinity at @GENE$ while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than labetalol.
3569	CPRFalse	@CHEMICAL$ and the enantiomers lacked affinity at alpha 2-adrenoceptors while at @GENE$ the order of potency was prazosin much greater than RR-SR greater than labetalol.
3570	CPRFalse	Labetalol and the enantiomers lacked affinity at @CHEMICAL$ while at alpha 1-adrenoceptors the order of potency was @GENE$ much greater than RR-SR greater than labetalol.
3571	CPRFalse	Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at @CHEMICAL$ the order of potency was @GENE$ much greater than RR-SR greater than labetalol.
3572	CPRFalse	Labetalol and the enantiomers lacked affinity at @CHEMICAL$ while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than @GENE$.
3573	CPRFalse	Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at @CHEMICAL$ the order of potency was prazosin much greater than RR-SR greater than @GENE$.
3574	CPRFalse	At @CHEMICAL$, the affinity of the compound RR-SR was about 3 times that of @GENE$.5.
3575	CPRFalse	As @CHEMICAL$ is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of @GENE$ actions), the combination of RR and SR may be a valuable substitute for labetalol in the treatment of systemic hypertension.
3576	CPRFalse	As labetalol is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of @CHEMICAL$ actions), the combination of RR and SR may be a valuable substitute for @GENE$ in the treatment of systemic hypertension.
3577	CPRFalse	Overexpression of @CHEM-GENE$ induces proline-dependent and mitochondria-mediated apoptosis.
3578	CPR:9	Overexpression of @CHEMICAL$ induces @GENE$-dependent and mitochondria-mediated apoptosis.
3579	CPRFalse	@CHEM-GENE$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C).
3580	CPRFalse	@CHEMICAL$ oxidase (@GENE$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C).
3581	CPR:9	@CHEMICAL$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of @GENE$ to pyrroline- 5-carboxylate (P5C).
3582	CPR:9	Proline oxidase (@CHEMICAL$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of @GENE$ to pyrroline- 5-carboxylate (P5C).
3583	CPR:9	@CHEMICAL$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to @GENE$ (P5C).
3584	CPR:9	Proline oxidase (@CHEMICAL$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to @GENE$ (P5C).
3585	CPR:9	@CHEMICAL$ (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (@GENE$).
3586	CPR:9	Proline oxidase (@CHEMICAL$), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (@GENE$).
3587	CPRFalse	Previously we showed that overexpression of @CHEMICAL$ is associated with generation of reactive @GENE$ species (ROS) and apoptosis in POX-inducible colorectal cancer cells, DLD-1.POX.
3588	CPRFalse	Previously we showed that overexpression of POX is associated with generation of reactive @CHEMICAL$ species (ROS) and apoptosis in @GENE$-inducible colorectal cancer cells, DLD-1.POX.
3589	CPRFalse	Previously we showed that overexpression of POX is associated with generation of reactive @CHEMICAL$ species (ROS) and apoptosis in POX-inducible colorectal cancer cells, DLD-1.@GENE$.
3590	CPRFalse	To further investigate the molecular basis of @CHEMICAL$-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an @GENE$-dependent apoptotic response.
3591	CPRFalse	To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.@CHEMICAL$ cells to show that cells overproducing POX exhibit an @GENE$-dependent apoptotic response.
3592	CPR:9	To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing @CHEMICAL$ exhibit an @GENE$-dependent apoptotic response.
3593	CPRFalse	The apoptotic effect is specific for @CHEMICAL$, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of L-proline to cells with maximally induced @GENE$.
3594	CPR:9	The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of @CHEMICAL$ to cells with maximally induced @GENE$.
3595	CPR:9	We conclude that in the presence of @CHEMICAL$, high @GENE$ activity is sufficient to induce mitochondria-mediated apoptosis.
3596	CPRFalse	The effects of @CHEM-GENE$ inactivation on locomotor activity in mice.
3597	CPRFalse	Because @CHEMICAL$ is an important regulator of spontaneous locomotor activity, we speculated that @GENE$ blockade contributes to the effects of some antidepressants on spontaneous locomotor activity.
3598	CPRFalse	Because norepinephrine is an important regulator of spontaneous locomotor activity, we speculated that @CHEM-GENE$ blockade contributes to the effects of some antidepressants on spontaneous locomotor activity.
3599	CPRFalse	METHODS: Antidepressant drugs (@CHEMICAL$, desipramine, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.
3600	CPRFalse	METHODS: Antidepressant drugs (reboxetine, @CHEMICAL$, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.
3601	CPRFalse	METHODS: Antidepressant drugs (reboxetine, desipramine, @CHEMICAL$, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.
3602	CPRFalse	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, @CHEMICAL$, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.
3603	CPRFalse	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, venlafaxine, @CHEMICAL$) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.
3604	CPRFalse	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and @CHEM-GENE$ knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.
3605	CPRFalse	RESULTS: Acute treatment with most @CHEM-GENE$-blocking antidepressants decreased spontaneous locomotor activity in a novel environment, whereas chronic treatment decreased spontaneous locomotor activity in both novel and familiar environments.
3606	CPR:4	The exception was @CHEMICAL$, a dual @GENE$/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.
3607	CPR:4	The exception was @CHEMICAL$, a dual norepinephrine transporter/@GENE$ blocker, which tended to increase spontaneous locomotor activity.
3608	CPRFalse	The exception was bupropion, a dual @CHEM-GENE$/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.
3609	CPRFalse	The exception was bupropion, a dual @CHEMICAL$ transporter/@GENE$ blocker, which tended to increase spontaneous locomotor activity.
3610	CPRFalse	The exception was bupropion, a dual @CHEMICAL$/@GENE$ transporter blocker, which tended to increase spontaneous locomotor activity.
3611	CPRFalse	The exception was bupropion, a dual norepinephrine transporter/@CHEM-GENE$ blocker, which tended to increase spontaneous locomotor activity.
3612	CPRFalse	Coadministration of @CHEMICAL$ and the @GENE$ blocker GBR 12909 also increased spontaneous locomotor activity.
3613	CPRFalse	Coadministration of reboxetine and the @CHEM-GENE$ blocker GBR 12909 also increased spontaneous locomotor activity.
3614	CPR:4	Coadministration of reboxetine and the @CHEMICAL$ blocker @GENE$ also increased spontaneous locomotor activity.
3615	CPRFalse	@CHEMICAL$ knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in @GENE$ transporter knockout mice.
3616	CPRFalse	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in @CHEM-GENE$ knockout mice.
3617	CPRFalse	@CHEM-GENE$ knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in norepinephrine transporter knockout mice.
3618	CPRFalse	@CHEMICAL$ transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in @GENE$ knockout mice.
3619	CPRFalse	@CHEMICAL$ knockout mice had low basal spontaneous locomotor activity, which was increased by @GENE$, whereas reboxetine had no effect in norepinephrine transporter knockout mice.
3620	CPRFalse	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by @CHEMICAL$, whereas reboxetine had no effect in @GENE$ knockout mice.
3621	CPRFalse	@CHEMICAL$ knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas @GENE$ had no effect in norepinephrine transporter knockout mice.
3622	CPRFalse	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas @CHEMICAL$ had no effect in @GENE$ knockout mice.
3623	CPRFalse	CONCLUSIONS: Acute or chronic inactivation of the @CHEM-GENE$ decreases spontaneous locomotor activity in novel and familiar environments unless coupled with dopamine transporter blockade.
3624	CPRFalse	CONCLUSIONS: Acute or chronic inactivation of the @CHEMICAL$ transporter decreases spontaneous locomotor activity in novel and familiar environments unless coupled with @GENE$ blockade.
3625	CPRFalse	CONCLUSIONS: Acute or chronic inactivation of the @CHEMICAL$ decreases spontaneous locomotor activity in novel and familiar environments unless coupled with @GENE$ transporter blockade.
3626	CPRFalse	CONCLUSIONS: Acute or chronic inactivation of the norepinephrine transporter decreases spontaneous locomotor activity in novel and familiar environments unless coupled with @CHEM-GENE$ blockade.
3627	CPRFalse	Treatment of Postmenopausal Breast Cancer with Selective @CHEM-GENE$ Modulators (SERMs).
3628	CPRFalse	Endocrine therapy that targets the @CHEMICAL$ receptor (ER) is a standard of care for the treatment of postmenopausal women with @GENE$-positive breast cancer.
3629	CPRFalse	Endocrine therapy that targets the @CHEM-GENE$ (ER) is a standard of care for the treatment of postmenopausal women with ER-positive breast cancer.
3630	CPRFalse	Endocrine therapy that targets the @CHEMICAL$ receptor (@GENE$) is a standard of care for the treatment of postmenopausal women with ER-positive breast cancer.
3631	CPRFalse	The selective @CHEMICAL$ modulator (SERM) @GENE$ has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of ER-positive disease.
3632	CPRFalse	The selective ER modulator (SERM) @CHEMICAL$ has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of @GENE$-positive disease.
3633	CPRFalse	@CHEMICAL$ blocks the action of estrogen by binding to the @GENE$, and possesses both ER-agonist and antagonist properties.
3634	CPR:6	@CHEMICAL$ blocks the action of estrogen by binding to the ER, and possesses both @GENE$-agonist and antagonist properties.
3635	CPR:5	@CHEMICAL$ blocks the action of estrogen by binding to the ER, and possesses both @GENE$-agonist and antagonist properties.
3636	CPRFalse	Tamoxifen blocks the action of @CHEMICAL$ by binding to the @GENE$, and possesses both ER-agonist and antagonist properties.
3637	CPRFalse	Tamoxifen blocks the action of @CHEMICAL$ by binding to the ER, and possesses both @GENE$-agonist and antagonist properties.
3638	CPRFalse	"The subsequent development of the @CHEMICAL$ inhibitors (AIs) is an important therapeutic advance by creating a ""no @GENE$"" environment."
3639	CPR:6	@CHEMICAL$ is a novel @GENE$ antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.
3640	CPR:4	@CHEMICAL$ is a novel ER antagonist that destroys the @GENE$ and its signaling pathway and is not associated with tamoxifen-like agonist effects.
3641	CPRFalse	Fulvestrant is a novel @CHEMICAL$ antagonist that destroys the ER and its signaling pathway and is not associated with @GENE$-like agonist effects.
3642	CPRFalse	Fulvestrant is a novel ER antagonist that destroys the @CHEMICAL$ and its signaling pathway and is not associated with @GENE$-like agonist effects.
3643	CPRFalse	It produces high response rates compared with other SERMs and is not cross-resistant to @CHEMICAL$ or @GENE$ inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant tamoxifen therapy.
3644	CPRFalse	It produces high response rates compared with other SERMs and is not cross-resistant to tamoxifen or @CHEMICAL$ inhibitors and is equally as effective as the AI @GENE$ in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant tamoxifen therapy.
3645	CPRFalse	It produces high response rates compared with other SERMs and is not cross-resistant to tamoxifen or @CHEMICAL$ inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant @GENE$ therapy.
3646	CPRFalse	A 46-amino acid segment in phosphodiesterase-5 @CHEMICAL$ provides for high vardenafil potency over @GENE$ and tadalafil and is involved in phosphodiesterase-5 dimerization.
3647	CPRFalse	A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over @CHEMICAL$ and tadalafil and is involved in @GENE$ dimerization.
3648	CPRFalse	A 46-amino acid segment in @CHEMICAL$ GAF-B domain provides for high vardenafil potency over @GENE$ and tadalafil and is involved in phosphodiesterase-5 dimerization.
3649	CPRFalse	A 46-amino acid segment in phosphodiesterase-5 @CHEMICAL$ provides for high vardenafil potency over sildenafil and @GENE$ and is involved in phosphodiesterase-5 dimerization.
3650	CPRFalse	A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and @CHEMICAL$ and is involved in @GENE$ dimerization.
3651	CPRFalse	A 46-amino acid segment in @CHEMICAL$ GAF-B domain provides for high vardenafil potency over sildenafil and @GENE$ and is involved in phosphodiesterase-5 dimerization.
3652	CPRFalse	A 46-@CHEMICAL$ segment in phosphodiesterase-5 @GENE$ provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
3653	CPRFalse	A 46-@CHEMICAL$ segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in @GENE$ dimerization.
3654	CPRFalse	A 46-@CHEMICAL$ segment in @GENE$ GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
3655	CPRFalse	A 46-amino acid segment in phosphodiesterase-5 @CHEMICAL$ provides for high @GENE$ potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
3656	CPRFalse	A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high @CHEMICAL$ potency over sildenafil and tadalafil and is involved in @GENE$ dimerization.
3657	CPRFalse	A 46-amino acid segment in @CHEMICAL$ GAF-B domain provides for high @GENE$ potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
3658	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two @CHEMICAL$, Anabaena @GENE$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3659	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, Escherichia coli FhlAs @GENE$ and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3660	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$ (cNPKs).
3661	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (@GENE$).
3662	CPRFalse	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @GENE$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3663	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, @CHEM-GENE$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3664	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @CHEMICAL$ cyclases, @GENE$ (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3665	CPRFalse	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena @GENE$ cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3666	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two @CHEMICAL$, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).
3667	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs @CHEMICAL$ and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).
3668	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @CHEM-GENE$ (cNPKs).
3669	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @CHEMICAL$-dependent protein kinases (@GENE$).
3670	CPRFalse	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).
3671	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, @CHEMICAL$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).
3672	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, @CHEMICAL$ (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).
3673	CPRFalse	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$-dependent protein kinases (cNPKs).
3674	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two @GENE$, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3675	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs @GENE$ and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3676	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$ (cNPKs).
3677	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (@GENE$).
3678	CPR:9	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes @GENE$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3679	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, @GENE$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3680	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes @CHEMICAL$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, @GENE$ (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3681	CPR:9	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes @GENE$ and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3682	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two @CHEM-GENE$, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3683	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs @GENE$ and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3684	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for @GENE$ (cNPKs).
3685	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (@GENE$).
3686	CPRFalse	@CHEMICAL$ (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @GENE$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3687	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, @GENE$, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3688	CPRFalse	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @CHEMICAL$-binding phosphodiesterase, Anabaena adenylyl cyclases, @GENE$ (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3689	CPRFalse	Phosphodiesterase-5 (@CHEMICAL$) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian @GENE$-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).
3690	CPRFalse	Binding of @CHEMICAL$ to @GENE$ increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.
3691	CPR:3	Binding of @CHEMICAL$ to GAF-A increases @GENE$ phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.
3692	CPR:3	Binding of @CHEMICAL$ to GAF-A increases cNPK phosphorylation of @GENE$ and improves catalytic site affinity for cGMP or inhibitors.
3693	CPRFalse	Binding of cGMP to @CHEMICAL$ increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for @GENE$ or inhibitors.
3694	CPRFalse	Binding of cGMP to GAF-A increases @CHEMICAL$ phosphorylation of PDE5 and improves catalytic site affinity for @GENE$ or inhibitors.
3695	CPRFalse	Binding of cGMP to GAF-A increases cNPK phosphorylation of @CHEMICAL$ and improves catalytic site affinity for @GENE$ or inhibitors.
3696	CPRFalse	@CHEMICAL$ contributes to dimerization of PDE5, inhibition of @GENE$ binding to GAF-A, and sequestration of the phosphorylation site.
3697	CPRFalse	GAF-B contributes to dimerization of PDE5, inhibition of @CHEMICAL$ binding to @GENE$, and sequestration of the phosphorylation site.
3698	CPRFalse	GAF-B contributes to dimerization of @CHEMICAL$, inhibition of @GENE$ binding to GAF-A, and sequestration of the phosphorylation site.
3699	CPRFalse	To probe potential @CHEMICAL$ effects on catalytic site affinity for certain inhibitors, four @GENE$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3700	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained @GENE$, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3701	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between @GENE$; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3702	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained @GENE$; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3703	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of @GENE$; and PDE5Delta1-534 contained only C domain.
3704	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: @GENE$ contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3705	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; @GENE$ contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3706	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; @GENE$ contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3707	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four @CHEMICAL$-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and @GENE$ contained only C domain.
3708	CPRFalse	To probe potential @CHEMICAL$ effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3709	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained @CHEMICAL$, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3710	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between @CHEMICAL$; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3711	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained @CHEMICAL$; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3712	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @CHEMICAL$-terminal portion of @GENE$; and PDE5Delta1-534 contained only C domain.
3713	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: @CHEMICAL$ contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3714	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; @CHEMICAL$ contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3715	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; @CHEMICAL$ contained the C domain and the @GENE$-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.
3716	CPRFalse	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the @CHEMICAL$-terminal portion of GAF-B; and @GENE$ contained only C domain.
3717	CPRFalse	Truncated proteins with a complete @CHEMICAL$ were dimers, but those lacking the @GENE$-terminal 46 amino acids of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.
3718	CPRFalse	Truncated proteins with a complete GAF-B were dimers, but those lacking the @CHEMICAL$-terminal 46 amino acids of @GENE$ were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.
3719	CPRFalse	Truncated proteins with a complete GAF-B were dimers, but those lacking the @CHEMICAL$-terminal 46 amino acids of GAF-B were monomers, indicating that these residues are vital for @GENE$-mediated PDE5 dimerization.
3720	CPRFalse	Truncated proteins with a complete GAF-B were dimers, but those lacking the @CHEMICAL$-terminal 46 amino acids of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated @GENE$ dimerization.
3721	CPRFalse	Truncated proteins with a complete @CHEMICAL$ were dimers, but those lacking the N-terminal 46 @GENE$ of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.
3722	CPRFalse	Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 @CHEMICAL$ of @GENE$ were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.
3723	CPRFalse	Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 @CHEMICAL$ of GAF-B were monomers, indicating that these residues are vital for @GENE$-mediated PDE5 dimerization.
3724	CPRFalse	Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 @CHEMICAL$ of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated @GENE$ dimerization.
3725	CPR:9	K(m) values of the mutants for @CHEMICAL$ were similar to that of full-length @GENE$.
3726	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the @GENE$-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3727	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @CHEMICAL$. This indicated that the @GENE$-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3728	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the @CHEMICAL$-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.
3729	CPRFalse	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the @GENE$-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3730	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 @GENE$ in GAF-B are required for high vardenafil potency.
3731	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @CHEMICAL$. This indicated that the N-terminal 46 @GENE$ in GAF-B are required for high vardenafil potency.
3732	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 @CHEMICAL$ in @GENE$ are required for high vardenafil potency.
3733	CPRFalse	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 @GENE$ in GAF-B are required for high vardenafil potency.
3734	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high @GENE$ potency.
3735	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @CHEMICAL$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high @GENE$ potency.
3736	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @CHEMICAL$ are required for high @GENE$ potency.
3737	CPRFalse	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high @GENE$ potency.
3738	CPRFalse	All PDE5 constructs had similar affinities for @CHEMICAL$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3739	CPRFalse	All PDE5 constructs had similar affinities for @CHEMICAL$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3740	CPRFalse	All PDE5 constructs had similar affinities for @CHEMICAL$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.
3741	CPRFalse	All @CHEMICAL$ constructs had similar affinities for @GENE$, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3742	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, @CHEMICAL$, tadalafil, and UK-122764, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3743	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, @CHEMICAL$, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3744	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, @CHEMICAL$, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.
3745	CPRFalse	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, @GENE$, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3746	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @CHEMICAL$, and UK-122764, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3747	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @CHEMICAL$, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3748	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @CHEMICAL$, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.
3749	CPRFalse	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, @GENE$, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3750	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @CHEMICAL$, but mutants containing a complete @GENE$ had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3751	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @CHEMICAL$, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3752	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @CHEMICAL$, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.
3753	CPRFalse	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and @GENE$, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3754	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete @CHEMICAL$ had 7- to 18-fold higher affinity for @GENE$-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3755	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for @CHEMICAL$-based compounds compared with those lacking a complete @GENE$. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3756	CPRFalse	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for @CHEMICAL$-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in @GENE$ are required for high vardenafil potency.
3757	CPRFalse	All @CHEMICAL$ constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for @GENE$-based compounds compared with those lacking a complete GAF-B. This indicated that the N-terminal 46 amino acids in GAF-B are required for high vardenafil potency.
3758	CPR:4	@CHEMICAL$ downregulates @GENE$ through activation of peroxisome proliferator-activated receptor gamma.
3759	CPR:3	@CHEMICAL$ downregulates angiotensin II type 1 receptor through activation of @GENE$.
3760	CPR:5	OBJECTIVE: @CHEMICAL$, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of @GENE$ (PPARgamma).
3761	CPR:5	OBJECTIVE: @CHEMICAL$, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (@GENE$).
3762	CPR:6	OBJECTIVE: @CHEMICAL$, an @GENE$ (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).
3763	CPR:6	OBJECTIVE: @CHEMICAL$, an angiotensin II type 1 receptor (@GENE$) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).
3764	CPRFalse	Since previous studies have demonstrated that @CHEMICAL$ activators suppressed AT1R expression, we examined whether @GENE$ affects AT1R expression in vascular smooth muscle cells.
3765	CPRFalse	Since previous studies have demonstrated that PPARgamma activators suppressed @CHEMICAL$ expression, we examined whether @GENE$ affects AT1R expression in vascular smooth muscle cells.
3766	CPRFalse	Since previous studies have demonstrated that PPARgamma activators suppressed AT1R expression, we examined whether @CHEMICAL$ affects @GENE$ expression in vascular smooth muscle cells.
3767	CPR:4	RESULTS: @CHEMICAL$ decreased the expression of @GENE$ at the mRNA and protein levels in a dose- and time-dependent manner.
3768	CPRFalse	Decreased @CHEMICAL$ activity with unchanged mRNA stability suggested that @GENE$ suppressed AT1R gene expression at the transcriptional level.
3769	CPR:4	Decreased AT1R promoter activity with unchanged mRNA stability suggested that @CHEMICAL$ suppressed @GENE$ gene expression at the transcriptional level.
3770	CPRFalse	However, the expression of @CHEMICAL$ was not suppressed by other AT1R antagonists such as @GENE$ or olmesartan.
3771	CPR:6	However, the expression of AT1R was not suppressed by other @CHEMICAL$ antagonists such as @GENE$ or olmesartan.
3772	CPRFalse	However, the expression of @CHEMICAL$ was not suppressed by other AT1R antagonists such as candesartan or @GENE$.
3773	CPR:6	However, the expression of AT1R was not suppressed by other @CHEMICAL$ antagonists such as candesartan or @GENE$.
3774	CPR:3	Since the suppression of @CHEMICAL$ expression was prevented by pretreatment with @GENE$, a PPARgamma antagonist, PPARgamma should have participated in the process.
3775	CPR:6	Since the suppression of AT1R expression was prevented by pretreatment with @CHEMICAL$, a @GENE$ antagonist, PPARgamma should have participated in the process.
3776	CPRFalse	Since the suppression of AT1R expression was prevented by pretreatment with @CHEMICAL$, a PPARgamma antagonist, @GENE$ should have participated in the process.
3777	CPR:4	The deletion and mutation analysis of the AT1R gene promoter indicated that a @CHEMICAL$ located in the proximal promoter region is responsible for the @GENE$-induced downregulation.
3778	CPR:4	The deletion and mutation analysis of the @CHEMICAL$ gene promoter indicated that a GC box located in the proximal promoter region is responsible for the @GENE$-induced downregulation.
3779	CPRFalse	CONCLUSION: Our data provides a novel insight into an effect of @CHEMICAL$: telmisartan inhibits @GENE$ gene expression through PPARgamma activation.
3780	CPRFalse	CONCLUSION: Our data provides a novel insight into an effect of @CHEMICAL$: telmisartan inhibits AT1R gene expression through @GENE$ activation.
3781	CPR:4	CONCLUSION: Our data provides a novel insight into an effect of telmisartan: @CHEMICAL$ inhibits @GENE$ gene expression through PPARgamma activation.
3782	CPR:3	CONCLUSION: Our data provides a novel insight into an effect of telmisartan: @CHEMICAL$ inhibits AT1R gene expression through @GENE$ activation.
3783	CPRFalse	Upon differentiation, osteoclasts express @CHEM-GENE$ (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons.
3784	CPRFalse	Upon differentiation, osteoclasts express vesicular @CHEMICAL$ transporter 1 (@GENE$), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons.
3785	CPR:9	Upon differentiation, osteoclasts express @CHEMICAL$ (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of @GENE$ in neurons.
3786	CPR:9	Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (@CHEMICAL$), which is essential for vesicular storage and subsequent exocytosis of @GENE$ in neurons.
3787	CPR:9	@CHEMICAL$ is localized in transcytotic vesicles and accumulates @GENE$.
3788	CPRFalse	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a @CHEMICAL$-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.
3789	CPRFalse	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. @CHEMICAL$- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.
3790	CPRFalse	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. KCl- and @CHEMICAL$-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.
3791	CPRFalse	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of @CHEMICAL$ was absent in osteoclasts prepared from @GENE$-/- knockout mice.
3792	CPRFalse	Osteoclasts secrete @CHEMICAL$ and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.
3793	CPRFalse	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with @CHEMICAL$ or ATP in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.
3794	CPRFalse	Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or @CHEMICAL$ in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from @GENE$-/- knockout mice.
3795	CPRFalse	Osteoclasts express mGluR8, a @CHEM-GENE$.
3796	CPRFalse	Osteoclasts express @CHEMICAL$, a class III metabotropic @GENE$ receptor.
3797	CPR:4	Synthesis, @CHEMICAL$ inhibition, antitumor testing, and molecular modeling study of some new @GENE$ analogs.
3798	CPRFalse	Synthesis, @CHEM-GENE$ inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.
3799	CPR:4	In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble @CHEMICAL$ (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of @GENE$ activity.
3800	CPR:4	In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (@CHEMICAL$, 1) structure features and fitted with functional groups believed to enhance inhibition of @GENE$ activity.
3801	CPR:4	In order to produce potent new leads for anticancer drugs, a new series of @CHEMICAL$ analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of @GENE$ activity.
3802	CPRFalse	@CHEMICAL$ receptor mutant mice consume more food, which leads to late-onset obesity and impaired @GENE$ tolerance.
3803	CPRFalse	Administration of @CHEMICAL$ and fenfluramine, both of which induce anorexic effects via @GENE$ receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.
3804	CPRFalse	Administration of @CHEMICAL$ and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or @GENE$ receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.
3805	CPRFalse	Administration of m-chlorophenylpiperazine and @CHEMICAL$, both of which induce anorexic effects via @GENE$ receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.
3806	CPRFalse	Administration of m-chlorophenylpiperazine and @CHEMICAL$, both of which induce anorexic effects via 5-HT2C receptors and/or @GENE$ receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.
3807	CPRFalse	"When treatment is started, LHRH agonists initially stimulate the release of @CHEMICAL$, causing a surge in serum @GENE$ that can precipitate a ""flare"" phenomenon or worsening of disease, particularly in patients with bone metastatic disease."
3808	CPRFalse	"When treatment is started, @CHEMICAL$ agonists initially stimulate the release of LH, causing a surge in serum @GENE$ that can precipitate a ""flare"" phenomenon or worsening of disease, particularly in patients with bone metastatic disease."
3809	CPRFalse	Results from 1 phase II and 3 phase III clinical trials demonstrate that abarelix produces medical castration more quickly and without causing @CHEMICAL$ surge, as compared with @GENE$ agonists with or without a nonsteroidal antagonist.
3810	CPRFalse	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of delta-6 desaturase (@GENE$) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3811	CPRFalse	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of delta-6 desaturase (D6D) and @GENE$ (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3812	CPRFalse	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of delta-6 desaturase (D6D) and delta-5 desaturase (@GENE$) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3813	CPRFalse	AIM: To compare the composition of @CHEMICAL$ (FAs) in diet, and the expression of @GENE$ (D6D) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3814	CPRFalse	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of delta-6 desaturase (@GENE$) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3815	CPRFalse	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of delta-6 desaturase (D6D) and @GENE$ (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3816	CPRFalse	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of delta-6 desaturase (D6D) and delta-5 desaturase (@GENE$) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3817	CPRFalse	AIM: To compare the composition of fatty acids (@CHEMICAL$) in diet, and the expression of @GENE$ (D6D) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.
3818	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of @CHEMICAL$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC @GENE$ and D5D genes.
3819	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of @CHEMICAL$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and @GENE$ genes.
3820	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of @GENE$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.
3821	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of @GENE$ (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.
3822	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (@CHEMICAL$) and alpha-linolenic acid (LNA) and the expression of PBMC @GENE$ and D5D genes.
3823	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (@CHEMICAL$) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and @GENE$ genes.
3824	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (@GENE$) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.
3825	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of linoleic acid (@GENE$) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes.
3826	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @CHEMICAL$ (LNA) and the expression of PBMC @GENE$ and D5D genes.
3827	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @CHEMICAL$ (LNA) and the expression of PBMC D6D and @GENE$ genes.
3828	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @GENE$ (LNA) and the expression of PBMC D6D and D5D genes.
3829	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and @GENE$ (LNA) and the expression of PBMC D6D and D5D genes.
3830	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@CHEMICAL$) and the expression of PBMC @GENE$ and D5D genes.
3831	CPR:4	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@CHEMICAL$) and the expression of PBMC D6D and @GENE$ genes.
3832	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC @CHEMICAL$ and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@GENE$) and the expression of PBMC D6D and D5D genes.
3833	CPRFalse	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and @CHEMICAL$ genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (@GENE$) and the expression of PBMC D6D and D5D genes.
3834	CPR:3	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC @GENE$ and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.
3835	CPR:3	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC D6D and @GENE$ genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.
3836	CPRFalse	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC @GENE$ and D5D genes.
3837	CPRFalse	CONCLUSION: Intake of high @CHEMICAL$ and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and @GENE$ genes.
3838	CPR:3	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC @GENE$ and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.
3839	CPR:3	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC D6D and @GENE$ genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.
3840	CPRFalse	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC @GENE$ and D5D genes.
3841	CPRFalse	CONCLUSION: Intake of high SFAs and @CHEMICAL$ appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and @GENE$ genes.
3842	CPRFalse	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC @CHEMICAL$ and D5D genes, whilst high @GENE$ intake appears to decrease expression of PBMC D6D and D5D genes.
3843	CPRFalse	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and @CHEMICAL$ genes, whilst high @GENE$ intake appears to decrease expression of PBMC D6D and D5D genes.
3844	CPR:4	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high @CHEMICAL$ intake appears to decrease expression of PBMC @GENE$ and D5D genes.
3845	CPR:4	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high @CHEMICAL$ intake appears to decrease expression of PBMC D6D and @GENE$ genes.
3846	CPRFalse	A follow-up study of the expression of @CHEMICAL$ and D5D genes in Chinese who live in European countries with high @GENE$ and MUFA diets would be of interest.
3847	CPRFalse	A follow-up study of the expression of D6D and @CHEMICAL$ genes in Chinese who live in European countries with high @GENE$ and MUFA diets would be of interest.
3848	CPRFalse	A follow-up study of the expression of @CHEMICAL$ and D5D genes in Chinese who live in European countries with high SFA and @GENE$ diets would be of interest.
3849	CPRFalse	A follow-up study of the expression of D6D and @CHEMICAL$ genes in Chinese who live in European countries with high SFA and @GENE$ diets would be of interest.
3850	CPRFalse	The evolution of @CHEM-GENE$ ligands.
3851	CPRFalse	@CHEMICAL$ is one of the first @GENE$ hormones to be described functionally and subsequently approached as a drug target.
3852	CPRFalse	Because @CHEMICAL$ (1) affects both menstruation and gestation via the @GENE$ (PR), research aimed at modulating its activity is usually surrounded by controversy.
3853	CPRFalse	Because @CHEMICAL$ (1) affects both menstruation and gestation via the progesterone receptor (@GENE$), research aimed at modulating its activity is usually surrounded by controversy.
3854	CPRFalse	Because progesterone (1) affects both menstruation and gestation via the @CHEM-GENE$ (PR), research aimed at modulating its activity is usually surrounded by controversy.
3855	CPRFalse	Because progesterone (1) affects both menstruation and gestation via the @CHEMICAL$ receptor (@GENE$), research aimed at modulating its activity is usually surrounded by controversy.
3856	CPRFalse	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like @GENE$ that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3857	CPRFalse	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like @CHEMICAL$ that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3858	CPRFalse	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of @GENE$; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3859	CPRFalse	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of @CHEMICAL$; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3860	CPRFalse	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like @GENE$ with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3861	CPRFalse	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like @CHEMICAL$ with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3862	CPRFalse	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from @GENE$ and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3863	CPRFalse	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from @CHEMICAL$ and expanded therapeutic applications; and (3) non-steroidal @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3864	CPRFalse	However, ligands for @CHEMICAL$ were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-@GENE$ PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3865	CPRFalse	However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-@CHEMICAL$ @GENE$ ligands with improved selectivity and modulator properties and further expanded therapeutic applications.
3866	CPR:4	@CHEMICAL$ inhibits @GENE$ and has shown therapeutic effects in patients with hematologic malignancies.
3867	CPRFalse	We investigated the activity and expression of @CHEM-GENE$ in isolated rat Sertoli cells, peritubular cells, pachytene spermatocytes, and early spermatids.
3868	CPRFalse	We assessed the @CHEMICAL$ uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of @GENE$, and studied the expression of the genes encoding them by RT-PCR.
3869	CPRFalse	We assessed the l-arginine uptake kinetics, @CHEMICAL$ dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of @GENE$, and studied the expression of the genes encoding them by RT-PCR.
3870	CPRFalse	We assessed the l-arginine uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral @CHEMICAL$, and sensitivity to trans stimulation of @GENE$, and studied the expression of the genes encoding them by RT-PCR.
3871	CPRFalse	We assessed the l-arginine uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of @CHEM-GENE$, and studied the expression of the genes encoding them by RT-PCR.
3872	CPR:9	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (@GENE$/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.
3873	CPRFalse	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/@GENE$) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.
3874	CPRFalse	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (@GENE$ and SLC7A2), with system B(0+) making a minor contribution.
3875	CPRFalse	Our data suggest that @CHEMICAL$ is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (SLC7A1 and @GENE$), with system B(0+) making a minor contribution.
3876	CPRFalse	By contrast, system B(0+), associated with system y(+)L (@CHEMICAL$/SLC7A7 and SLC7A6), made a major contribution to the transport of cationic @GENE$ in pachytene spermatocytes and early spermatids.
3877	CPRFalse	By contrast, system B(0+), associated with system y(+)L (SLC3A2/@CHEMICAL$ and SLC7A6), made a major contribution to the transport of cationic @GENE$ in pachytene spermatocytes and early spermatids.
3878	CPRFalse	By contrast, system B(0+), associated with system y(+)L (SLC3A2/SLC7A7 and @CHEMICAL$), made a major contribution to the transport of cationic @GENE$ in pachytene spermatocytes and early spermatids.
3879	CPRFalse	Furthermore, whereas @CHEMICAL$ induce nitric oxide (@GENE$) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by cytokines was observed in these cells.
3880	CPRFalse	Furthermore, whereas cytokines induce nitric oxide (@CHEMICAL$) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by @GENE$ was observed in these cells.
3881	CPRFalse	Furthermore, whereas @CHEMICAL$ induce nitric oxide (NO) production in peritubular and Sertoli cells, little or no upregulation of @GENE$ transport by cytokines was observed in these cells.
3882	CPRFalse	Furthermore, whereas cytokines induce nitric oxide (NO) production in peritubular and Sertoli cells, little or no upregulation of @CHEMICAL$ transport by @GENE$ was observed in these cells.
3883	CPRFalse	Furthermore, whereas @CHEMICAL$ induce @GENE$ (NO) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by cytokines was observed in these cells.
3884	CPRFalse	Furthermore, whereas cytokines induce @CHEMICAL$ (NO) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by @GENE$ was observed in these cells.
3885	CPRFalse	Transition-state structure of @CHEM-GENE$.
3886	CPRFalse	Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of @CHEM-GENE$ (MTAP).
3887	CPRFalse	Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human @CHEMICAL$ phosphorylase (@GENE$).
3888	CPR:9	KIEs were measured on the arsenolysis of @CHEMICAL$ (MTA) catalyzed by @GENE$ and were corrected for the forward commitment to catalysis.
3889	CPR:9	KIEs were measured on the arsenolysis of 5'-methylthioadenosine (@CHEMICAL$) catalyzed by @GENE$ and were corrected for the forward commitment to catalysis.
3890	CPRFalse	The primary intrinsic KIEs (@CHEMICAL$ and 9-(15)N) suggest that @GENE$ has a dissociative S(N)1 transition state with its cationic center at the anomeric carbon and insignificant bond order to the leaving group.
3891	CPRFalse	The primary intrinsic KIEs (1'-(14)C and @CHEMICAL$) suggest that @GENE$ has a dissociative S(N)1 transition state with its cationic center at the anomeric carbon and insignificant bond order to the leaving group.
3892	CPRFalse	The primary intrinsic KIEs (1'-(14)C and 9-(15)N) suggest that @CHEMICAL$ has a dissociative S(N)1 transition state with its cationic center at the anomeric @GENE$ and insignificant bond order to the leaving group.
3893	CPRFalse	@CHEMICAL$ is characterized by a late S(N)1 transition state with significant participation of the @GENE$ nucleophile.
3894	CPRFalse	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a @CHEM-GENE$ (Lratb).
3895	CPRFalse	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a @CHEMICAL$:retinol acyltransferase (@GENE$).
3896	CPRFalse	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a @CHEM-GENE$ (Lratb).
3897	CPRFalse	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a leci-thin:@CHEMICAL$ acyltransferase (@GENE$).
3898	CPRFalse	During embryogenesis, @CHEMICAL$ is expressed in mostly non-overlapping domains opposite to @GENE$ dehydrogenase 2 (raldh2), the key enzyme for retinoic acid synthesis.
3899	CPRFalse	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to @CHEM-GENE$ (raldh2), the key enzyme for retinoic acid synthesis.
3900	CPRFalse	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to @CHEMICAL$ dehydrogenase 2 (@GENE$), the key enzyme for retinoic acid synthesis.
3901	CPRFalse	During embryogenesis, @CHEMICAL$ is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2), the key enzyme for @GENE$ synthesis.
3902	CPR:9	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to @CHEMICAL$ (raldh2), the key enzyme for @GENE$ synthesis.
3903	CPR:9	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (@CHEMICAL$), the key enzyme for @GENE$ synthesis.
3904	CPR:9	Blocking @CHEMICAL$ formation by a targeted knock down of @GENE$ results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.
3905	CPRFalse	Blocking retinyl ester formation by a targeted knock down of @CHEMICAL$ results in significantly increased @GENE$ levels, which lead to severe embryonic patterning defects.
3906	CPRFalse	Thus, we provide evidence that a balanced competition between @CHEMICAL$ and Raldh2 for yolk @GENE$ defines embryonic compartments either for retinyl ester or retinoic acid synthesis.
3907	CPRFalse	Thus, we provide evidence that a balanced competition between Lratb and @CHEMICAL$ for yolk @GENE$ defines embryonic compartments either for retinyl ester or retinoic acid synthesis.
3908	CPRFalse	Thus, we provide evidence that a balanced competition between @CHEMICAL$ and Raldh2 for yolk vitamin A defines embryonic compartments either for @GENE$ or retinoic acid synthesis.
3909	CPRFalse	Thus, we provide evidence that a balanced competition between Lratb and @CHEMICAL$ for yolk vitamin A defines embryonic compartments either for @GENE$ or retinoic acid synthesis.
3910	CPRFalse	Thus, we provide evidence that a balanced competition between @CHEMICAL$ and Raldh2 for yolk vitamin A defines embryonic compartments either for retinyl ester or @GENE$ synthesis.
3911	CPRFalse	Thus, we provide evidence that a balanced competition between Lratb and @CHEMICAL$ for yolk vitamin A defines embryonic compartments either for retinyl ester or @GENE$ synthesis.
3912	CPRFalse	@CHEMICAL$ are a class of cell surface receptors for @GENE$ that prefer ATP or ADP over adenosine.
3913	CPRFalse	@CHEMICAL$ are a class of cell surface receptors for purines that prefer @GENE$ or ADP over adenosine.
3914	CPRFalse	@CHEMICAL$ are a class of cell surface receptors for purines that prefer ATP or @GENE$ over adenosine.
3915	CPRFalse	@CHEMICAL$ are a class of cell surface receptors for purines that prefer ATP or ADP over @GENE$.
3916	CPRFalse	The surface receptors for extracellular @CHEMICAL$ are called @GENE$.
3917	CPR:3	@CHEMICAL$ initiates platelet aggregation by 'simultaneous activation of two @GENE$, P2Y1 and P2Y12.
3918	CPR:3	@CHEMICAL$ initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, @GENE$ and P2Y12.
3919	CPR:3	@CHEMICAL$ initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and @GENE$.
3920	CPRFalse	@CHEMICAL$ has been shown to be the target of the @GENE$ drugs, ticlopidine and clopidogrel.
3921	CPRFalse	@CHEMICAL$ has been shown to be the target of the thienopyridine drugs, @GENE$ and clopidogrel.
3922	CPRFalse	@CHEMICAL$ has been shown to be the target of the thienopyridine drugs, ticlopidine and @GENE$.
3923	CPRFalse	Here, the active sites of @CHEMICAL$ for @GENE$ as well as ADP are predicted by bioinformatics and molecular modeling.
3924	CPRFalse	Here, the active sites of @CHEMICAL$ for ATP as well as @GENE$ are predicted by bioinformatics and molecular modeling.
3925	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEM-GENE$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3926	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (@GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3927	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3928	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."
3929	CPRFalse	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (@GENE$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3930	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (@GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3931	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEM-GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3932	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3933	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."
3934	CPRFalse	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@GENE$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3935	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3936	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3937	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @CHEM-GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3938	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @CHEMICAL$, 139-148), and ""bottom area"" (@GENE$, 222-231)."
3939	CPRFalse	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @GENE$, 139-148), and ""bottom area"" (RTRGVGKVPR, 222-231)."
3940	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (@CHEMICAL$, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."
3941	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (@CHEMICAL$, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."
3942	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and @CHEMICAL$, 139-148), and ""bottom area"" (@GENE$, 222-231)."
3943	CPRFalse	"And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@CHEM-GENE$, 222-231)."
3944	CPRFalse	"And the most probable active sites of @CHEMICAL$ were predicted using the scoring matrix, which include three distant areas: ""head area"" (LGTGPLRTFV, 87-96), ""middle area"" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and ""bottom area"" (@GENE$, 222-231)."
3945	CPRFalse	Subsequently the structural model of @CHEMICAL$ was docked with @GENE$/ADP in comparison with P2Y1 (PDB code 1ddd).
3946	CPRFalse	Subsequently the structural model of P2Y12 was docked with @CHEMICAL$/ADP in comparison with @GENE$ (PDB code 1ddd).
3947	CPRFalse	Subsequently the structural model of P2Y12 was docked with @CHEMICAL$/ADP in comparison with P2Y1 (@GENE$).
3948	CPRFalse	Subsequently the structural model of @CHEMICAL$ was docked with ATP/@GENE$ in comparison with P2Y1 (PDB code 1ddd).
3949	CPRFalse	Subsequently the structural model of P2Y12 was docked with ATP/@CHEMICAL$ in comparison with @GENE$ (PDB code 1ddd).
3950	CPRFalse	Subsequently the structural model of P2Y12 was docked with ATP/@CHEMICAL$ in comparison with P2Y1 (@GENE$).
3951	CPR:4	Our results imply that @CHEMICAL$ has the potential to be inhibited by @GENE$/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.
3952	CPRFalse	Our results imply that P2Y12 has the potential to be inhibited by @CHEMICAL$/ATP analogs, and it suggests that @GENE$ acts as a target of new drugs that inhibit platelet aggregation.
3953	CPR:4	Our results imply that @CHEMICAL$ has the potential to be inhibited by ADP/@GENE$ analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.
3954	CPRFalse	Our results imply that P2Y12 has the potential to be inhibited by ADP/@CHEMICAL$ analogs, and it suggests that @GENE$ acts as a target of new drugs that inhibit platelet aggregation.
3955	CPRFalse	@CHEMICAL$ induces mitogenic signaling in breast cancer cell by an @GENE$-dependent mechanism.
3956	CPRFalse	@CHEMICAL$ (E2) stimulates BC cells proliferation by binding the @GENE$ (ER).
3957	CPRFalse	@CHEMICAL$ (E2) stimulates BC cells proliferation by binding the estrogen receptor (@GENE$).
3958	CPRFalse	Estradiol (@CHEMICAL$) stimulates BC cells proliferation by binding the @GENE$ (ER).
3959	CPRFalse	Estradiol (@CHEMICAL$) stimulates BC cells proliferation by binding the estrogen receptor (@GENE$).
3960	CPRFalse	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating @GENE$, Akt and PDGFRalpha kinases.
3961	CPRFalse	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating ERK1/2, @GENE$ and PDGFRalpha kinases.
3962	CPRFalse	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating ERK1/2, Akt and PDGFRalpha @GENE$.
3963	CPRFalse	Purpose of our study was to evaluate whether @CHEMICAL$ regulates MCF-7 cell proliferation by activating ERK1/2, Akt and @GENE$ kinases.
3964	CPRFalse	@CHEMICAL$ increased cell proliferation and the @GENE$-antagonist ICI 182,780 blunted it.
3965	CPR:4	@CHEMICAL$ decreased @GENE$ expression, but not ERbeta.
3966	CPRFalse	@CHEMICAL$ decreased ERalpha expression, but not @GENE$.
3967	CPRFalse	@CHEMICAL$ also increased @GENE$, Akt and PDGFRalpha phosphorylation while ICI blocked it.
3968	CPR:3	@CHEMICAL$ also increased ERK1/2, @GENE$ and PDGFRalpha phosphorylation while ICI blocked it.
3969	CPR:3	@CHEMICAL$ also increased ERK1/2, Akt and @GENE$ phosphorylation while ICI blocked it.
3970	CPR:3	@CHEMICAL$ rapidly increased @GENE$, c-fos and PDGFA expression.
3971	CPR:3	@CHEMICAL$ rapidly increased c-jun, @GENE$ and PDGFA expression.
3972	CPR:3	@CHEMICAL$ rapidly increased c-jun, c-fos and @GENE$ expression.
3973	CPRFalse	Cells were also co-incubated with the @CHEMICAL$ and specific @GENE$ inhibitors, which blocked the Cd-stimulated proliferation.
3974	CPRFalse	Cells were also co-incubated with the Cd and specific @CHEMICAL$ inhibitors, which blocked the @GENE$-stimulated proliferation.
3975	CPR:3	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating @GENE$, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.
3976	CPRFalse	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, @GENE$ and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.
3977	CPR:3	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha @GENE$ activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.
3978	CPR:3	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and @GENE$ kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.
3979	CPR:3	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating @GENE$, c-jun and PDGFA by an ERalpha-dependent mechanism.
3980	CPR:3	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, @GENE$ and PDGFA by an ERalpha-dependent mechanism.
3981	CPR:3	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and @GENE$ by an ERalpha-dependent mechanism.
3982	CPRFalse	In conclusion, our results indicate that @CHEMICAL$ increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an @GENE$-dependent mechanism.
3983	CPRFalse	@CHEM-GENE$ functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.
3984	CPRFalse	@CHEMICAL$ functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving @GENE$.
3985	CPR:6	@CHEMICAL$ functionally antagonizes testosterone activation of the @GENE$ in prostate cells through focal adhesion complexes involving Hic-5.
3986	CPRFalse	@CHEMICAL$ functionally antagonizes @GENE$ activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.
3987	CPRFalse	Gonadotropin-releasing hormone functionally antagonizes @CHEMICAL$ activation of the human androgen receptor in prostate cells through focal adhesion complexes involving @GENE$.
3988	CPR:3	Gonadotropin-releasing hormone functionally antagonizes @CHEMICAL$ activation of the @GENE$ in prostate cells through focal adhesion complexes involving Hic-5.
3989	CPRFalse	@CHEMICAL$ (@GENE$) analogs constitute the most widely employed medical treatment for prostatic cancer.
3990	CPRFalse	Gonadotropin-releasing hormone (@CHEM-GENE$) analogs constitute the most widely employed medical treatment for prostatic cancer.
3991	CPRFalse	@CHEM-GENE$ (GnRH) analogs constitute the most widely employed medical treatment for prostatic cancer.
3992	CPRFalse	@CHEMICAL$ (@GENE$) analogs constitute the most widely employed medical treatment for prostatic cancer.
3993	CPRFalse	However, @CHEM-GENE$ analogs have also been shown to directly inhibit prostate cancer cells both in vitro and in vivo through antiproliferative cell cycle arrest and stimulation of apoptosis.
3994	CPRFalse	Since the @CHEMICAL$ receptor has been shown to affect @GENE$ function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human androgen receptor.
3995	CPRFalse	Since the @CHEM-GENE$ has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the human androgen receptor.
3996	CPRFalse	Since the @CHEMICAL$ receptor has been shown to affect sex steroid hormone receptor function, we considered that part of @GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.
3997	CPRFalse	Since the @CHEMICAL$ receptor has been shown to affect sex steroid hormone receptor function, we considered that part of GnRH analog actions on prostate cells may be mediated through modulation of the @GENE$.
3998	CPRFalse	Since the GnRH receptor has been shown to affect @CHEMICAL$ function, we considered that part of @GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.
3999	CPRFalse	Since the @CHEMICAL$ has been shown to affect sex steroid hormone receptor function, we considered that part of @GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.
4000	CPRFalse	Since the GnRH receptor has been shown to affect sex steroid hormone receptor function, we considered that part of @CHEM-GENE$ analog actions on prostate cells may be mediated through modulation of the human androgen receptor.
4001	CPRFalse	Since the GnRH receptor has been shown to affect sex steroid hormone receptor function, we considered that part of @CHEMICAL$ analog actions on prostate cells may be mediated through modulation of the @GENE$.
4002	CPRFalse	Using a model HEK293 cell line expressing the @CHEM-GENE$, we demonstrated a novel signalling pathway of the GnRH receptor that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.
4003	CPRFalse	Using a model HEK293 cell line expressing the @CHEMICAL$ receptor, we demonstrated a novel signalling pathway of the @GENE$ that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.
4004	CPRFalse	Using a model HEK293 cell line expressing the @CHEMICAL$ receptor, we demonstrated a novel signalling pathway of the GnRH receptor that induces nuclear translocation of the @GENE$ that renders it transcriptionally inactive.
4005	CPRFalse	Using a model HEK293 cell line expressing the @CHEMICAL$, we demonstrated a novel signalling pathway of the @GENE$ receptor that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.
4006	CPRFalse	Using a model HEK293 cell line expressing the GnRH receptor, we demonstrated a novel signalling pathway of the @CHEM-GENE$ that induces nuclear translocation of the androgen receptor that renders it transcriptionally inactive.
4007	CPRFalse	Using a model HEK293 cell line expressing the GnRH receptor, we demonstrated a novel signalling pathway of the @CHEMICAL$ receptor that induces nuclear translocation of the @GENE$ that renders it transcriptionally inactive.
4008	CPRFalse	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/@GENE$, Hic-5.
4009	CPRFalse	This mechanism involves the @CHEMICAL$-dependent @GENE$ Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4010	CPRFalse	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the @GENE$ c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4011	CPRFalse	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the @GENE$/steroid receptor co-factor, Hic-5.
4012	CPRFalse	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, @GENE$.
4013	CPRFalse	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase @GENE$, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4014	CPRFalse	This mechanism involves the @CHEMICAL$-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase @GENE$ and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4015	CPRFalse	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/@GENE$, Hic-5.
4016	CPRFalse	This mechanism involves the calcium-dependent @CHEM-GENE$ Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4017	CPRFalse	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the @GENE$ c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4018	CPRFalse	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase c-Src and the @GENE$/steroid receptor co-factor, Hic-5.
4019	CPRFalse	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, @GENE$.
4020	CPRFalse	This mechanism involves the calcium-dependent @CHEMICAL$ kinase @GENE$, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4021	CPRFalse	This mechanism involves the calcium-dependent @CHEMICAL$ kinase Pyk2, the non-receptor tyrosine kinase @GENE$ and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4022	CPRFalse	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase c-Src and the focal adhesion protein/@GENE$, Hic-5.
4023	CPRFalse	This mechanism involves the calcium-dependent @CHEMICAL$ Pyk2, the non-receptor @GENE$ kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4024	CPRFalse	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the @CHEM-GENE$ c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4025	CPRFalse	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase c-Src and the @GENE$/steroid receptor co-factor, Hic-5.
4026	CPRFalse	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase c-Src and the focal adhesion protein/steroid receptor co-factor, @GENE$.
4027	CPRFalse	This mechanism involves the calcium-dependent tyrosine kinase @CHEMICAL$, the non-receptor @GENE$ kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4028	CPRFalse	This mechanism involves the calcium-dependent tyrosine kinase Pyk2, the non-receptor @CHEMICAL$ kinase @GENE$ and the focal adhesion protein/steroid receptor co-factor, Hic-5.
4029	CPRFalse	In this setting there is a @CHEM-GENE$-induced association and nuclear translocation of the androgen receptor with Hic-5.
4030	CPRFalse	In this setting there is a @CHEMICAL$-induced association and nuclear translocation of the @GENE$ with Hic-5.
4031	CPRFalse	In this setting there is a @CHEMICAL$-induced association and nuclear translocation of the androgen receptor with @GENE$.
4032	CPRFalse	@CHEM-GENE$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4033	CPR:3	@CHEMICAL$-induced @GENE$ activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4034	CPR:4	@CHEMICAL$-induced Pyk2 activation opposed the association of @GENE$ with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4035	CPR:4	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with @GENE$ as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4036	CPRFalse	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative @GENE$ enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4037	CPRFalse	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4038	CPRFalse	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged @GENE$.
4039	CPRFalse	@CHEMICAL$-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4040	CPRFalse	GnRH-induced @CHEMICAL$ activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4041	CPRFalse	GnRH-induced Pyk2 activation opposed the association of @CHEMICAL$ with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4042	CPRFalse	GnRH-induced Pyk2 activation opposed the association of Hic-5 with @CHEMICAL$ as overexpression of a dominant negative Pyk2 enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4043	CPRFalse	GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative @CHEMICAL$ enhanced the @GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4044	CPRFalse	GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @CHEM-GENE$-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.
4045	CPRFalse	GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the @CHEMICAL$-induced nuclear translocation of a green fluorescent protein-tagged @GENE$.
4046	CPRFalse	@CHEM-GENE$-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.
4047	CPR:3	@CHEMICAL$-induced @GENE$ activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.
4048	CPRFalse	@CHEMICAL$-induced c-Src activation resulted in the phosphorylation of expressed @GENE$ and promoted its association with the human androgen receptor.
4049	CPRFalse	@CHEMICAL$-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the @GENE$.
4050	CPRFalse	In contrast to @CHEMICAL$, @GENE$-induced nuclear translocation did not transcriptionally activate the androgen receptor.
4051	CPR:3	In contrast to @CHEMICAL$, GnRH-induced nuclear translocation did not transcriptionally activate the @GENE$.
4052	CPRFalse	In contrast to testosterone, @CHEM-GENE$-induced nuclear translocation did not transcriptionally activate the androgen receptor.
4053	CPRFalse	In contrast to testosterone, @CHEMICAL$-induced nuclear translocation did not transcriptionally activate the @GENE$.
4054	CPRFalse	We then demonstrated that @CHEM-GENE$ can also stimulate androgen receptor mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.
4055	CPRFalse	We then demonstrated that @CHEMICAL$ can also stimulate @GENE$ mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.
4056	CPRFalse	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of @GENE$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4057	CPRFalse	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEM-GENE$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4058	CPRFalse	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEMICAL$ on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4059	CPRFalse	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4060	CPRFalse	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEMICAL$ on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4061	CPRFalse	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @CHEM-GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4062	CPRFalse	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of @GENE$ on prostate cell proliferation and tissue growth.
4063	CPRFalse	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of @CHEMICAL$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of @GENE$ on prostate cell proliferation and tissue growth.
4064	CPRFalse	To determine if GnRH could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @CHEMICAL$ can functionally antagonize the actions of @GENE$ on prostate cell proliferation and tissue growth.
4065	CPRFalse	To determine if @CHEM-GENE$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4066	CPRFalse	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of @GENE$ on rat ventral prostate organ cultures and demonstrated that GnRH can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4067	CPRFalse	To determine if @CHEMICAL$ could antagonize androgen effects in normal tissue, we examined the effect of GnRH on rat ventral prostate organ cultures and demonstrated that @GENE$ can functionally antagonize the actions of testosterone on prostate cell proliferation and tissue growth.
4068	CPRFalse	This antagonism of @CHEMICAL$ action by @GENE$ may underlie in part the capacity of GnRH receptor activation to inhibit prostate tumor growth.
4069	CPRFalse	This antagonism of @CHEMICAL$ action by GnRH may underlie in part the capacity of @GENE$ activation to inhibit prostate tumor growth.
4070	CPRFalse	This antagonism of testosterone action by @CHEM-GENE$ may underlie in part the capacity of GnRH receptor activation to inhibit prostate tumor growth.
4071	CPRFalse	This antagonism of testosterone action by @CHEMICAL$ may underlie in part the capacity of @GENE$ activation to inhibit prostate tumor growth.
4072	CPRFalse	This antagonism of testosterone action by @CHEMICAL$ may underlie in part the capacity of @GENE$ receptor activation to inhibit prostate tumor growth.
4073	CPRFalse	This antagonism of testosterone action by GnRH may underlie in part the capacity of @CHEM-GENE$ activation to inhibit prostate tumor growth.
4074	CPRFalse	@CHEMICAL$ displays species-dependent stereoselectivity for isomers of methamphetamine, @GENE$, and para-hydroxyamphetamine.
4075	CPRFalse	@CHEMICAL$ displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and @GENE$.
4076	CPRFalse	@CHEM-GENE$ displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.
4077	CPRFalse	@CHEMICAL$ displays species-dependent stereoselectivity for isomers of @GENE$, amphetamine, and para-hydroxyamphetamine.
4078	CPRFalse	Recently, it was reported that @CHEMICAL$, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4079	CPRFalse	Recently, it was reported that @CHEMICAL$, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4080	CPRFalse	Recently, it was reported that METH, @CHEMICAL$, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4081	CPRFalse	Recently, it was reported that METH, @CHEMICAL$, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4082	CPRFalse	Recently, it was reported that METH, AMPH, @CHEMICAL$, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4083	CPRFalse	Recently, it was reported that METH, AMPH, @CHEMICAL$, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4084	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs @CHEMICAL$ (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4085	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs @CHEMICAL$ (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4086	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (@CHEMICAL$) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4087	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (@CHEMICAL$) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4088	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and @CHEMICAL$ (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4089	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and @CHEMICAL$ (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4090	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (@CHEMICAL$) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4091	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (@CHEMICAL$) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4092	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate @CHEMICAL$ production in human embryonic kidney (HEK)-293 cells expressing @GENE$ (rTAAR1).
4093	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate @CHEMICAL$ production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (@GENE$).
4094	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing @CHEM-GENE$ (rTAAR1).
4095	CPRFalse	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace @CHEMICAL$-associated receptor 1 (@GENE$).
4096	CPR:3	The discovery that @CHEMICAL$ and AMPH activate the @GENE$ motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).
4097	CPRFalse	The discovery that @CHEMICAL$ and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the @GENE$ (mTAAR1) and a human-rat chimera (hrChTAAR1).
4098	CPRFalse	The discovery that @CHEMICAL$ and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (@GENE$) and a human-rat chimera (hrChTAAR1).
4099	CPRFalse	The discovery that @CHEMICAL$ and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (@GENE$).
4100	CPR:3	The discovery that METH and @CHEMICAL$ activate the @GENE$ motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).
4101	CPRFalse	The discovery that METH and @CHEMICAL$ activate the rTAAR1 motivated us to study the effect of these drugs on the @GENE$ (mTAAR1) and a human-rat chimera (hrChTAAR1).
4102	CPRFalse	The discovery that METH and @CHEMICAL$ activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (@GENE$) and a human-rat chimera (hrChTAAR1).
4103	CPRFalse	The discovery that METH and @CHEMICAL$ activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (@GENE$).
4104	CPR:3	Furthermore, because S-(+)-isomers of @CHEMICAL$ and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of @GENE$.
4105	CPR:3	Furthermore, because S-(+)-isomers of METH and @CHEMICAL$ are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of @GENE$.
4106	CPRFalse	In response to @CHEMICAL$, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.
4107	CPRFalse	In response to METH, @CHEMICAL$, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.
4108	CPRFalse	In response to METH, AMPH, or @CHEMICAL$ exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.
4109	CPRFalse	In response to METH, AMPH, or POHA exposure, the accumulation of @CHEMICAL$ by HEK-293 cells stably expressing different species of @GENE$ was concentration- and isomer-dependent.
4110	CPR:3	EC50 values for @CHEMICAL$ were 0.89, 0.92, and 4.44 microM for @GENE$, mTAAR1, and h-rChTAAR1, respectively.
4111	CPR:3	EC50 values for @CHEMICAL$ were 0.89, 0.92, and 4.44 microM for rTAAR1, @GENE$, and h-rChTAAR1, respectively.
4112	CPR:3	EC50 values for @CHEMICAL$ were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and @GENE$, respectively.
4113	CPR:5	@CHEMICAL$ was a potent and full agonist at each species of @GENE$, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.
4114	CPRFalse	@CHEMICAL$ was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the @GENE$ but was a partial agonist at h-rChTAAR1.
4115	CPRFalse	@CHEMICAL$ was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at @GENE$.
4116	CPRFalse	PEA was a potent and full agonist at each species of @CHEMICAL$, whereas @GENE$ was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.
4117	CPR:5	PEA was a potent and full agonist at each species of TAAR1, whereas @CHEMICAL$ was a full agonist for the @GENE$ but was a partial agonist at h-rChTAAR1.
4118	CPR:5	PEA was a potent and full agonist at each species of TAAR1, whereas @CHEMICAL$ was a full agonist for the rodent TAAR1s but was a partial agonist at @GENE$.
4119	CPR:5	Interestingly, both isomers of @CHEMICAL$ were full agonists at @GENE$ and h-rChTAAR1, whereas both were partial agonists at rTAAR1.
4120	CPR:5	Interestingly, both isomers of @CHEMICAL$ were full agonists at mTAAR1 and @GENE$, whereas both were partial agonists at rTAAR1.
4121	CPR:5	Interestingly, both isomers of @CHEMICAL$ were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at @GENE$.
4122	CPRFalse	RESULTS: We first showed that expression of the genes encoding @CHEMICAL$ and heparan @GENE$ 2-sulfotransferase decreased between E13.5 and E17.5.
4123	CPRFalse	RESULTS: We first showed that expression of the genes encoding glypicans 1, 2, 3 and 5 and @CHEM-GENE$ decreased between E13.5 and E17.5.
4124	CPRFalse	@CHEMICAL$-positive cells that developed in the presence of @GENE$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4125	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: @GENE$ (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4126	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (@GENE$), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4127	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), @GENE$ (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4128	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (@GENE$; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4129	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as @GENE$), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4130	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), @GENE$ (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4131	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (@GENE$; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4132	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as @GENE$) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4133	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and @GENE$ (Slc2a1; previously known as glucose transporter 2).
4134	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (@GENE$; previously known as glucose transporter 2).
4135	CPRFalse	Insulin-positive cells that developed in the presence of @CHEMICAL$ exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$).
4136	CPRFalse	@CHEMICAL$-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4137	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: @CHEMICAL$ (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4138	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (@CHEMICAL$), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4139	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), @CHEMICAL$ (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4140	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (@CHEMICAL$; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4141	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as @CHEMICAL$), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4142	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), @CHEMICAL$ (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4143	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (@CHEMICAL$; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4144	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as @CHEMICAL$) and solute carrier family 2 (facilitated @GENE$ transporter), member 2 (Slc2a1; previously known as glucose transporter 2).
4145	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and @CHEM-GENE$ (Slc2a1; previously known as glucose transporter 2).
4146	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @CHEMICAL$ transporter), member 2 (@GENE$; previously known as glucose transporter 2).
4147	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated @CHEMICAL$ transporter), member 2 (Slc2a1; previously known as @GENE$).
4148	CPRFalse	@CHEMICAL$-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4149	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: @CHEMICAL$ (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4150	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (@CHEMICAL$), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4151	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), @CHEMICAL$ (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4152	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (@CHEMICAL$; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4153	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as @CHEMICAL$), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4154	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), @CHEMICAL$ (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4155	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (@CHEMICAL$; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4156	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as @CHEMICAL$) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @GENE$ transporter 2).
4157	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and @CHEMICAL$ (Slc2a1; previously known as @GENE$ transporter 2).
4158	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (@CHEMICAL$; previously known as @GENE$ transporter 2).
4159	CPRFalse	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as @CHEM-GENE$).
4160	CPR:3	Finally, we showed that @CHEMICAL$ activated endocrine cell development by inducing @GENE$ (Neurog3) expression in early endocrine progenitor cells.
4161	CPR:3	Finally, we showed that @CHEMICAL$ activated endocrine cell development by inducing neurogenin 3 (@GENE$) expression in early endocrine progenitor cells.
4162	CPRFalse	@CHEMICAL$ inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for @GENE$ and sulfamate inhibitors.
4163	CPR:4	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the @CHEMICAL$, a new target for @GENE$ and sulfamate inhibitors.
4164	CPRFalse	@CHEMICAL$ inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and @GENE$ inhibitors.
4165	CPR:4	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the @CHEMICAL$, a new target for sulfonamide and @GENE$ inhibitors.
4166	CPR:9	The kinetic parameters for the @CHEMICAL$ hydration reaction proved @GENE$ to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C).
4167	CPRFalse	Simple @CHEMICAL$ were rather ineffective @GENE$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, 4-aminomethyl-, or 4-hydroxymethyl moieties or among halogenated sulfanilamides (KI values of 608-955 nM).
4168	CPRFalse	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing @GENE$-, 4-aminomethyl-, or 4-hydroxymethyl moieties or among halogenated sulfanilamides (KI values of 608-955 nM).
4169	CPRFalse	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, @GENE$-, or 4-hydroxymethyl moieties or among halogenated sulfanilamides (KI values of 608-955 nM).
4170	CPRFalse	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, 4-aminomethyl-, or @GENE$ moieties or among halogenated sulfanilamides (KI values of 608-955 nM).
4171	CPRFalse	Simple benzenesulfonamides were rather ineffective @CHEMICAL$ inhibitors, with inhibition constants in the range of 1090-6680 nM. Better inhibitors were detected among such derivatives bearing 2- or 4-amino-, 4-aminomethyl-, or 4-hydroxymethyl moieties or among halogenated @GENE$ (KI values of 608-955 nM).
4172	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, @CHEMICAL$, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4173	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, @CHEMICAL$, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4174	CPR:4	Some clinically used compounds, such as @CHEMICAL$, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4175	CPRFalse	Some clinically used compounds, such as @CHEMICAL$, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4176	CPR:4	Some clinically used compounds, such as acetazolamide, @CHEMICAL$, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4177	CPRFalse	Some clinically used compounds, such as acetazolamide, @CHEMICAL$, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4178	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, @CHEMICAL$, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4179	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, @CHEMICAL$, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4180	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, @CHEMICAL$, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4181	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, @CHEMICAL$, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4182	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, @CHEMICAL$, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4183	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, @CHEMICAL$, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4184	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, @CHEMICAL$, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4185	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, @CHEMICAL$, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4186	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, @CHEMICAL$, and indisulam, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4187	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, @CHEMICAL$, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4188	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and @CHEMICAL$, or the orphan drug benzolamide, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4189	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and @CHEMICAL$, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4190	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug @CHEMICAL$, showed effective @GENE$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4191	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug @CHEMICAL$, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4192	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @CHEMICAL$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were @GENE$ and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4193	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were @CHEMICAL$ and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4194	CPRFalse	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective @CHEMICAL$ inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and @GENE$ (KI values of 0.8-0.9 nM), the latter compound being also a CA VI-selective inhibitor.
4195	CPR:4	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM. The best inhibitors were brinzolamide and @CHEMICAL$ (KI values of 0.8-0.9 nM), the latter compound being also a @GENE$-selective inhibitor.
4196	CPR:4	The metallic taste reported as a side effect after the treatment with systemic @CHEMICAL$ may be due to the inhibition of the @GENE$.
4197	CPR:9	Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant @CHEMICAL$ hydrase activity of enamel @GENE$, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.
4198	CPR:9	Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel @CHEMICAL$, which leads to the formation of protons and @GENE$ and may have a role in cariogenesis.
4199	CPRFalse	Role of the @CHEM-GENE$ in the development of the retinal projections.
4200	CPRFalse	Role of the @CHEMICAL$ in the development of the @GENE$ projections.
4201	CPR:9	Transmembrane isoforms of @CHEMICAL$ (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate @GENE$ production in response to calcium entry.
4202	CPR:9	Transmembrane isoforms of adenylate cyclases (@CHEMICAL$) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate @GENE$ production in response to calcium entry.
4203	CPRFalse	Transmembrane isoforms of @CHEMICAL$ (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to @GENE$ entry.
4204	CPRFalse	Transmembrane isoforms of adenylate cyclases (@CHEMICAL$) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to @GENE$ entry.
4205	CPRFalse	Transmembrane isoforms of @CHEM-GENE$ (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry.
4206	CPRFalse	Transmembrane isoforms of @CHEMICAL$ cyclases (@GENE$) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry.
4207	CPRFalse	Based on observations in the barrelless mouse strain, the @CHEMICAL$ gene (AC1) was involved in the segregation of binocular @GENE$ inputs.
4208	CPRFalse	Based on observations in the barrelless mouse strain, the Adcy1 gene (@CHEMICAL$) was involved in the segregation of binocular @GENE$ inputs.
4209	CPRFalse	Using a genetic approach we tested the role of the @CHEM-GENE$ AC1, AC5 and AC8 for the segregation retinal fibres.
4210	CPRFalse	Using a genetic approach we tested the role of the @CHEMICAL$ modulated cyclases @GENE$, AC5 and AC8 for the segregation retinal fibres.
4211	CPRFalse	Using a genetic approach we tested the role of the @CHEMICAL$ modulated cyclases AC1, @GENE$ and AC8 for the segregation retinal fibres.
4212	CPRFalse	Using a genetic approach we tested the role of the @CHEMICAL$ modulated cyclases AC1, AC5 and @GENE$ for the segregation retinal fibres.
4213	CPRFalse	Using a genetic approach we tested the role of the @CHEMICAL$ AC1, AC5 and AC8 for the segregation @GENE$ fibres.
4214	CPRFalse	Using a genetic approach we tested the role of the calcium modulated cyclases @CHEMICAL$, AC5 and AC8 for the segregation @GENE$ fibres.
4215	CPRFalse	Using a genetic approach we tested the role of the calcium modulated cyclases AC1, @CHEMICAL$ and AC8 for the segregation @GENE$ fibres.
4216	CPRFalse	Using a genetic approach we tested the role of the calcium modulated cyclases AC1, AC5 and @CHEMICAL$ for the segregation @GENE$ fibres.
4217	CPRFalse	Ipsilateral retinal axons remained exuberant in the @CHEMICAL$(-/-) mice, with overlapping @GENE$ projections from both eyes in the superior colliculus and the visual thalamus.
4218	CPRFalse	Ipsilateral @CHEMICAL$ axons remained exuberant in the @GENE$(-/-) mice, with overlapping retinal projections from both eyes in the superior colliculus and the visual thalamus.
4219	CPRFalse	Thus, only @CHEMICAL$ is required for the maturation of the @GENE$ axon terminals whereas AC5 and AC8 are not needed.
4220	CPRFalse	Thus, only AC1 is required for the maturation of the @CHEMICAL$ axon terminals whereas @GENE$ and AC8 are not needed.
4221	CPRFalse	Thus, only AC1 is required for the maturation of the @CHEMICAL$ axon terminals whereas AC5 and @GENE$ are not needed.
4222	CPR:4	@CHEMICAL$ inhibits @GENE$ expression in malignant glioma cells.
4223	CPR:4	Here, we report that the antifibrotic drug @CHEMICAL$ (pirfenidone, PFD) elicits growth-inhibitory effects and reduces @GENE$ protein levels in human glioma cell lines.
4224	CPR:4	Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (@CHEMICAL$, PFD) elicits growth-inhibitory effects and reduces @GENE$ protein levels in human glioma cell lines.
4225	CPR:4	Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, @CHEMICAL$) elicits growth-inhibitory effects and reduces @GENE$ protein levels in human glioma cell lines.
4226	CPR:4	This reduction in @CHEMICAL$ is biologically relevant since @GENE$ treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.
4227	CPR:4	This reduction in TGF-beta2 is biologically relevant since @CHEMICAL$ treatment reduces the growth inhibition of @GENE$-sensitive CCL-64 cells mediated by conditioned media of glioma cells.
4228	CPR:4	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta @GENE$ furin.
4229	CPR:4	@CHEMICAL$ leads to a reduction of @GENE$ mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.
4230	CPR:4	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature @GENE$ protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.
4231	CPR:4	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the @GENE$ pro-protein convertase furin.
4232	CPR:4	@CHEMICAL$ leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase @GENE$.
4233	CPR:4	In addition, @CHEMICAL$ reduces the protein levels of the @GENE$, a TGF-beta target gene and furin substrate involved in carcinogenesis.
4234	CPR:4	In addition, @CHEMICAL$ reduces the protein levels of the matrix metalloproteinase (MMP)-11, a @GENE$ target gene and furin substrate involved in carcinogenesis.
4235	CPRFalse	In addition, @CHEMICAL$ reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and @GENE$ substrate involved in carcinogenesis.
4236	CPRFalse	These data define @CHEMICAL$ or PFD-related agents as promising agents for human cancers associated with enhanced @GENE$ activity.
4237	CPRFalse	These data define PFD or @CHEMICAL$-related agents as promising agents for human cancers associated with enhanced @GENE$ activity.
4238	CPRFalse	Human and rat @CHEMICAL$ are liver-specific peroxisomal enzymes: implications for intracellular @GENE$ transport.
4239	CPRFalse	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.
4240	CPRFalse	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.
4241	CPRFalse	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.
4242	CPRFalse	Human and rat @CHEM-GENE$ are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport.
4243	CPRFalse	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4244	CPRFalse	UNLABELLED: @CHEMICAL$-coenzyme A:amino acid N-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4245	CPR:9	UNLABELLED: @CHEMICAL$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary @GENE$ to taurine and glycine.
4246	CPR:9	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is the sole enzyme responsible for conjugation of primary and secondary @GENE$ to taurine and glycine.
4247	CPR:9	UNLABELLED: @CHEMICAL$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to @GENE$ and glycine.
4248	CPR:9	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to @GENE$ and glycine.
4249	CPR:9	UNLABELLED: @CHEMICAL$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and @GENE$.
4250	CPR:9	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and @GENE$.
4251	CPRFalse	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4252	CPRFalse	UNLABELLED: Bile acid-@CHEMICAL$:amino acid N-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4253	CPRFalse	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4254	CPRFalse	UNLABELLED: Bile acid-coenzyme A:@CHEMICAL$ N-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4255	CPRFalse	UNLABELLED: @CHEM-GENE$ (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4256	CPRFalse	UNLABELLED: Bile acid-coenzyme A:amino acid @CHEMICAL$-acyltransferase (@GENE$) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.
4257	CPR:9	The absence or presence of a cytosolic pool of @CHEMICAL$ has important implications for the intracellular transport of unconjugated/deconjugated @GENE$.
4258	CPRFalse	We used immunofluorescence microscopy and @CHEMICAL$ permeabilization assays to determine the subcellular location of endogenous @GENE$ in primary human and rat hepatocytes.
4259	CPRFalse	[Construction of the flavinogenic yeast Candida famata strains with high @CHEM-GENE$ activity using gene engineering].
4260	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$ kinase, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated @GENE$ or constitutive TEF1 promoter) were isolated.
4261	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$ kinase, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive @GENE$) were isolated.
4262	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the @CHEMICAL$ gene (encoding the @GENE$ kinase, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.
4263	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEM-GENE$, enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.
4264	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts @CHEMICAL$ to flavinmononucleotide) driven by the strong promoters (the regulated @GENE$ or constitutive TEF1 promoter) were isolated.
4265	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts @CHEMICAL$ to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive @GENE$) were isolated.
4266	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the @CHEMICAL$ gene (encoding the riboflavin kinase, enzyme that converts @GENE$ to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.
4267	CPR:9	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$, enzyme that converts @GENE$ to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.
4268	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts riboflavin to @CHEMICAL$) driven by the strong promoters (the regulated @GENE$ or constitutive TEF1 promoter) were isolated.
4269	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts riboflavin to @CHEMICAL$) driven by the strong promoters (the regulated RIB1 or constitutive @GENE$) were isolated.
4270	CPRFalse	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the @CHEMICAL$ gene (encoding the riboflavin kinase, enzyme that converts riboflavin to @GENE$) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.
4271	CPR:9	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the @CHEMICAL$, enzyme that converts riboflavin to @GENE$) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.
4272	CPRFalse	@CHEM-GENE$ activity in the isolated transformants was tested.
4273	CPRFalse	The 6-8-fold increase of the @CHEM-GENE$ activity was shown in the recombinant strains containing the integrated Debaryomyces hansenii FMN1 gene under the strong constitutive TEF1 promoter.
4274	CPRFalse	The 6-8-fold increase of the @CHEMICAL$ kinase activity was shown in the recombinant strains containing the integrated @GENE$ gene under the strong constitutive TEF1 promoter.
4275	CPRFalse	The 6-8-fold increase of the @CHEMICAL$ kinase activity was shown in the recombinant strains containing the integrated Debaryomyces hansenii FMN1 gene under the strong constitutive @GENE$.
4276	CPRFalse	The increased @CHEM-GENE$ activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the glutathione reductase activity.
4277	CPRFalse	The increased @CHEMICAL$ peroxidase activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the @GENE$ activity.
4278	CPRFalse	The increased @CHEMICAL$ activity in rats suffering from hyperthyroidism was associated with a fall of the reduced @GENE$ in the homogenate and a marked increase in the glutathione reductase activity.
4279	CPRFalse	The increased glutathione peroxidase activity in rats suffering from hyperthyroidism was associated with a fall of the reduced @CHEMICAL$ in the homogenate and a marked increase in the @GENE$ activity.
4280	CPRFalse	The increased @CHEMICAL$ activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the @GENE$ reductase activity.
4281	CPRFalse	The increased glutathione peroxidase activity in rats suffering from hyperthyroidism was associated with a fall of the reduced glutathione in the homogenate and a marked increase in the @CHEM-GENE$ activity.
4282	CPRFalse	Mechanism of the irreversible inactivation of @CHEM-GENE$ by alpha-difluoromethylornithine.
4283	CPR:4	Mechanism of the irreversible inactivation of @CHEMICAL$ by @GENE$.
4284	CPR:4	@CHEMICAL$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, @GENE$ (DFMO).
4285	CPR:4	Mouse ornithine decarboxylase (@CHEMICAL$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, @GENE$ (DFMO).
4286	CPR:4	@CHEMICAL$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (@GENE$).
4287	CPR:4	Mouse ornithine decarboxylase (@CHEMICAL$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (@GENE$).
4288	CPRFalse	@CHEM-GENE$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).
4289	CPRFalse	Mouse @CHEMICAL$ decarboxylase (@GENE$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).
4290	CPRFalse	@CHEMICAL$ (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for @GENE$ and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).
4291	CPRFalse	Mouse ornithine decarboxylase (@CHEMICAL$) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for @GENE$ and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).
4292	CPRFalse	The @CHEMICAL$ binding lysine in @GENE$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4293	CPRFalse	The @CHEMICAL$ binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4294	CPRFalse	The pyridoxal 5'-phosphate binding @CHEMICAL$ in @GENE$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4295	CPRFalse	The pyridoxal 5'-phosphate binding @CHEMICAL$ in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4296	CPRFalse	The pyridoxal 5'-phosphate binding lysine in @CHEMICAL$ was identified as @GENE$ 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4297	CPRFalse	The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as @CHEMICAL$ 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4298	CPRFalse	The pyridoxal 5'-phosphate binding lysine in @CHEMICAL$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with @GENE$ followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4299	CPRFalse	The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with @CHEMICAL$ followed by digestion of the carboxymethylated protein with @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4300	CPRFalse	The pyridoxal 5'-phosphate binding lysine in @CHEMICAL$ was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase @GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4301	CPRFalse	The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with @CHEM-GENE$, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.
4302	CPRFalse	This @CHEMICAL$ is contained in the sequence @GENE$, which is found in all known ODCs from eukaryotes.
4303	CPRFalse	This @CHEMICAL$ is contained in the sequence PFYAVKC, which is found in all known @GENE$ from eukaryotes.
4304	CPRFalse	This lysine is contained in the sequence @CHEM-GENE$, which is found in all known ODCs from eukaryotes.
4305	CPRFalse	This lysine is contained in the sequence @CHEMICAL$, which is found in all known @GENE$ from eukaryotes.
4306	CPRFalse	The preceding @CHEMICAL$ do not conform to the consensus sequence of @GENE$, which contains the pyridoxal 5'-phosphate binding lysine in a number of other decarboxylases including ODCs from E. coli.
4307	CPRFalse	The preceding @CHEMICAL$ do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding lysine in a number of other @GENE$ including ODCs from E. coli.
4308	CPRFalse	The preceding @CHEMICAL$ do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding lysine in a number of other decarboxylases including @GENE$ from E. coli.
4309	CPRFalse	The preceding amino acids do not conform to the consensus sequence of @CHEMICAL$, which contains the @GENE$ binding lysine in a number of other decarboxylases including ODCs from E. coli.
4310	CPRFalse	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the @CHEMICAL$ binding lysine in a number of other @GENE$ including ODCs from E. coli.
4311	CPRFalse	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the @CHEMICAL$ binding lysine in a number of other decarboxylases including @GENE$ from E. coli.
4312	CPRFalse	The preceding amino acids do not conform to the consensus sequence of @CHEMICAL$, which contains the pyridoxal 5'-phosphate binding @GENE$ in a number of other decarboxylases including ODCs from E. coli.
4313	CPRFalse	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding @CHEMICAL$ in a number of other @GENE$ including ODCs from E. coli.
4314	CPRFalse	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding @CHEMICAL$ in a number of other decarboxylases including @GENE$ from E. coli.
4315	CPRFalse	Using a similar procedure to analyze @CHEMICAL$ labeled by reaction with @GENE$, it was found that lysine 69 and cysteine 360 formed covalent adducts with the inhibitor.
4316	CPRFalse	Using a similar procedure to analyze @CHEMICAL$ labeled by reaction with [5-14C]DFMO, it was found that @GENE$ 69 and cysteine 360 formed covalent adducts with the inhibitor.
4317	CPRFalse	Using a similar procedure to analyze @CHEMICAL$ labeled by reaction with [5-14C]DFMO, it was found that lysine 69 and @GENE$ 360 formed covalent adducts with the inhibitor.
4318	CPRFalse	@CHEMICAL$ 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -@GENE$-, which is present in all known eukaryote ODCs.
4319	CPRFalse	@CHEMICAL$ 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -WGPTCDGL(I)D-, which is present in all known @GENE$.
4320	CPRFalse	Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -@CHEM-GENE$-, which is present in all known eukaryote ODCs.
4321	CPRFalse	Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -@CHEMICAL$-, which is present in all known @GENE$.
4322	CPRFalse	Pre-steady-state currents in @CHEM-GENE$ induced by photolysis of a new caged alanine derivative.
4323	CPRFalse	Pre-steady-state currents in @CHEMICAL$ induced by photolysis of a new caged @GENE$ derivative.
4324	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine @GENE$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4325	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine @GENE$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4326	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine @GENE$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4327	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4328	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEM-GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4329	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4330	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4331	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4332	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4333	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4334	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine @CHEMICAL$ cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4335	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine serine @GENE$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4336	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine serine @GENE$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4337	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine serine @GENE$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4338	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4339	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEM-GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4340	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4341	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4342	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4343	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4344	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4345	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine @CHEMICAL$ transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4346	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4347	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4348	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4349	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @CHEMICAL$ families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4350	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ (ASCT1), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4351	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@CHEMICAL$), and ASCT2] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4352	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @CHEMICAL$] and SLC38 families [@GENE$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4353	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEM-GENE$ (SNAT1), SNAT2, and SNAT4].
4354	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEMICAL$-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4355	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEMICAL$-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4356	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEMICAL$-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4357	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].
4358	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].
4359	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].
4360	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @CHEMICAL$ families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].
4361	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].
4362	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@CHEMICAL$), and ASCT2] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].
4363	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @CHEMICAL$] and SLC38 families [sodium-coupled neutral @GENE$ transporter 1 (SNAT1), SNAT2, and SNAT4].
4364	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@CHEM-GENE$ (SNAT1), SNAT2, and SNAT4].
4365	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @CHEMICAL$ transporter 1 (@GENE$), SNAT2, and SNAT4].
4366	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @CHEMICAL$ transporter 1 (SNAT1), @GENE$, and SNAT4].
4367	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral @CHEMICAL$ transporter 1 (SNAT1), SNAT2, and @GENE$].
4368	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4369	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4370	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4371	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4372	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4373	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4374	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4375	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4376	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4377	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4378	CPR:9	Na+-Dependent transmembrane transport of small neutral @CHEMICAL$, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4379	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4380	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4381	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4382	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4383	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4384	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4385	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4386	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4387	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4388	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4389	CPRFalse	@CHEMICAL$-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4390	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4391	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4392	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4393	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4394	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4395	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4396	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4397	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4398	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4399	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4400	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as @CHEMICAL$ and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4401	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the @GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4402	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4403	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4404	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4405	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4406	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4407	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4408	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4409	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4410	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4411	CPR:9	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and @CHEMICAL$, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4412	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEM-GENE$ of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4413	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the @GENE$ [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4414	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [@GENE$, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4415	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4416	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, @GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4417	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4418	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4419	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4420	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4421	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4422	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral @CHEMICAL$ transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4423	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the @CHEMICAL$ of the solute carrier 1 [SLC1, @GENE$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4424	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the @CHEMICAL$ [SLC1, @GENE$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4425	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [@CHEMICAL$, @GENE$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4426	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and @GENE$ families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4427	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEM-GENE$ (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4428	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (@GENE$), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4429	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and @GENE$] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].
4430	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [@GENE$ (SNAT1), SNAT2, and SNAT4].
4431	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (@GENE$), SNAT2, and SNAT4].
4432	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), @GENE$, and SNAT4].
4433	CPRFalse	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, @CHEMICAL$ serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and @GENE$].
4434	CPR:9	Here, we describe a new photolabile @CHEMICAL$ derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.
4435	CPR:9	Here, we describe a new photolabile @CHEMICAL$ derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.
4436	CPR:9	Here, we describe a new photolabile @CHEMICAL$ derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.
4437	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of @CHEMICAL$ with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.
4438	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of @CHEMICAL$ with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.
4439	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of @CHEMICAL$ with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.
4440	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of alanine with the @CHEMICAL$ (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.
4441	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of alanine with the @CHEMICAL$ (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.
4442	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of alanine with the @CHEMICAL$ (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.
4443	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (@CHEMICAL$) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by @GENE$, SNAT1, and SNAT2.
4444	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (@CHEMICAL$) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, @GENE$, and SNAT2.
4445	CPR:9	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (@CHEMICAL$) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and @GENE$.
4446	CPRFalse	Photolytic release of free @CHEMICAL$ results in the generation of significant transient current components in HEK293 cells expressing the @GENE$, SNAT1, and SNAT2 proteins.
4447	CPRFalse	Photolytic release of free @CHEMICAL$ results in the generation of significant transient current components in HEK293 cells expressing the ASCT2, @GENE$, and SNAT2 proteins.
4448	CPRFalse	Photolytic release of free @CHEMICAL$ results in the generation of significant transient current components in HEK293 cells expressing the ASCT2, SNAT1, and @GENE$ proteins.
4449	CPRFalse	Histochemical staining and quantification of @CHEMICAL$ dehydrogenase @GENE$ activity using blue native PAGE.
4450	CPRFalse	Histochemical staining and quantification of @CHEM-GENE$ diaphorase activity using blue native PAGE.
4451	CPRFalse	Mammalian mitochondrial @CHEMICAL$ dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @GENE$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4452	CPRFalse	@CHEM-GENE$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4453	CPRFalse	Mammalian mitochondrial @CHEMICAL$ dehydrogenase (@GENE$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4454	CPRFalse	Mammalian mitochondrial @CHEMICAL$ dehydrogenase (DLDH, @GENE$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4455	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).
4456	CPRFalse	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).
4457	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).
4458	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and @GENE$ (NBT).
4459	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).
4460	CPRFalse	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).
4461	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).
4462	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (@GENE$).
4463	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes @CHEMICAL$-dependent oxidation of dihydrolipoamide in vivo and can also act as a @GENE$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4464	CPRFalse	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes @GENE$-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4465	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes @GENE$-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4466	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes @GENE$-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4467	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of @CHEMICAL$ in vivo and can also act as a @GENE$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4468	CPRFalse	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of @GENE$ in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4469	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of @GENE$ in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4470	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of @GENE$ in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4471	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4472	CPRFalse	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4473	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4474	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro @GENE$ (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4475	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a @CHEMICAL$ catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4476	CPRFalse	@CHEMICAL$ (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4477	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (@CHEMICAL$, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4478	CPRFalse	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, @CHEMICAL$) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (@GENE$)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).
4479	CPRFalse	Rat brain mitochondrial extracts, used as the source of DLDH, were resolved by nongradient BN-PAGE (9%), which was followed by @CHEMICAL$ activity staining using @GENE$ as the electron donor and NBT as the electron acceptor.
4480	CPRFalse	Rat brain mitochondrial extracts, used as the source of @CHEMICAL$, were resolved by nongradient BN-PAGE (9%), which was followed by diaphorase activity staining using @GENE$ as the electron donor and NBT as the electron acceptor.
4481	CPRFalse	Rat brain mitochondrial extracts, used as the source of DLDH, were resolved by nongradient BN-PAGE (9%), which was followed by @CHEMICAL$ activity staining using NADH as the electron donor and @GENE$ as the electron acceptor.
4482	CPRFalse	Rat brain mitochondrial extracts, used as the source of @CHEMICAL$, were resolved by nongradient BN-PAGE (9%), which was followed by diaphorase activity staining using NADH as the electron donor and @GENE$ as the electron acceptor.
4483	CPRFalse	Moreover, this in-gel activity-staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures DLDH @CHEMICAL$ activity using @GENE$ as the substrate.
4484	CPRFalse	Moreover, this in-gel activity-staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures @CHEMICAL$ dehydrogenase activity using @GENE$ as the substrate.
4485	CPRFalse	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4486	CPRFalse	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4487	CPRFalse	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.
4488	CPRFalse	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4489	CPRFalse	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4490	CPRFalse	Finally, the effects of @CHEMICAL$-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.
4491	CPRFalse	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4492	CPRFalse	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4493	CPRFalse	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.
4494	CPRFalse	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4495	CPRFalse	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4496	CPRFalse	Finally, the effects of thiol-reactive reagents such as @CHEMICAL$ (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.
4497	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4498	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4499	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.
4500	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4501	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4502	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (@CHEMICAL$) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.
4503	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH @GENE$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4504	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @GENE$ activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4505	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.
4506	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on @GENE$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4507	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @GENE$ diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4508	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and @CHEMICAL$ donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.
4509	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH @CHEMICAL$ activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4510	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH @CHEMICAL$ activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4511	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @CHEMICAL$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH @GENE$ activity.
4512	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on @CHEMICAL$ diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4513	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, @CHEMICAL$ diaphorase activity can be determined without having to remove these @GENE$-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.
4514	CPRFalse	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these @CHEMICAL$-reactive reagents that may otherwise interfere with spectrophotometric measurement of @GENE$ dehydrogenase activity.
4515	CPRFalse	Reticulated platelets and uninhibited @CHEMICAL$ and COX-2 decrease the antiplatelet effects of @GENE$.
4516	CPRFalse	Reticulated platelets and uninhibited COX-1 and @CHEMICAL$ decrease the antiplatelet effects of @GENE$.
4517	CPRFalse	Immature (reticulated) platelets may modulate the antiplatelet effects of @CHEMICAL$ through uninhibited @GENE$ (COX)-1 and COX-2.
4518	CPRFalse	Immature (reticulated) platelets may modulate the antiplatelet effects of @CHEMICAL$ through uninhibited cyclooxygenase @GENE$ and COX-2.
4519	CPRFalse	Immature (reticulated) platelets may modulate the antiplatelet effects of @CHEMICAL$ through uninhibited cyclooxygenase (COX)-1 and @GENE$.
4520	CPRFalse	Platelet studies included light transmission aggregometry; P-selectin and @CHEMICAL$ expression, and serum @GENE$ (TxB(2)) levels.
4521	CPRFalse	Platelet studies included light transmission aggregometry; @CHEMICAL$ and integrin alpha(IIb)beta(3) expression, and serum @GENE$ (TxB(2)) levels.
4522	CPRFalse	Platelet studies included light transmission aggregometry; P-selectin and @CHEMICAL$ expression, and serum thromboxane B(2) (@GENE$) levels.
4523	CPRFalse	Platelet studies included light transmission aggregometry; @CHEMICAL$ and integrin alpha(IIb)beta(3) expression, and serum thromboxane B(2) (@GENE$) levels.
4524	CPRFalse	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm @CHEMICAL$ and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and @GENE$ expression were also higher in the upper tertile both before and after aspirin.
4525	CPRFalse	Baseline platelet aggregation to 1 microg mL(-1) @CHEMICAL$, and postaspirin aggregations to 5 microm and 20 microm @GENE$ and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.
4526	CPRFalse	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm @CHEMICAL$ and @GENE$, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.
4527	CPRFalse	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm @CHEMICAL$ and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated @GENE$ and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.
4528	CPR:3	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm ADP and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and @CHEMICAL$ expression were also higher in the upper tertile both before and after @GENE$.
4529	CPRFalse	Baseline platelet aggregation to 1 microg mL(-1) @CHEMICAL$, and postaspirin aggregations to 5 microm and 20 microm ADP and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after @GENE$.
4530	CPRFalse	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm ADP and @CHEMICAL$, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after @GENE$.
4531	CPR:3	Baseline platelet aggregation to 1 microg mL(-1) collagen, and postaspirin aggregations to 5 microm and 20 microm ADP and collagen, were greater in the upper than in the lower tertile of reticulated platelets. Stimulated @CHEMICAL$ and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after @GENE$.
4532	CPRFalse	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of @CHEMICAL$ and increased aspirin resistance, possibly because of increased reactivity, and uninhibited @GENE$ and COX-2 activity.
4533	CPRFalse	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of @CHEMICAL$ and increased aspirin resistance, possibly because of increased reactivity, and uninhibited COX-1 and @GENE$ activity.
4534	CPRFalse	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of aspirin and increased @CHEMICAL$ resistance, possibly because of increased reactivity, and uninhibited @GENE$ and COX-2 activity.
4535	CPRFalse	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of aspirin and increased @CHEMICAL$ resistance, possibly because of increased reactivity, and uninhibited COX-1 and @GENE$ activity.
4536	CPRFalse	Neuroprotection by @CHEMICAL$ against MPP+-induced dopamine neuron death is mediated by @GENE$ in primary cultures of mouse mesencephalon.
4537	CPRFalse	Neuroprotection by estrogen against @CHEMICAL$-induced dopamine neuron death is mediated by @GENE$ in primary cultures of mouse mesencephalon.
4538	CPRFalse	Neuroprotection by estrogen against MPP+-induced @CHEMICAL$ neuron death is mediated by @GENE$ in primary cultures of mouse mesencephalon.
4539	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both @CHEM-GENE$ (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4540	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (@GENE$) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4541	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (ERalpha) and @GENE$ (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4542	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (ERalpha) and estrogen receptor beta (@GENE$) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4543	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of @GENE$ on both dopamine neurons and astrocytes.
4544	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ (ERalpha) and @GENE$ receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4545	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (@CHEMICAL$) and @GENE$ receptor beta (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4546	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEM-GENE$ (ERbeta) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4547	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEMICAL$ receptor beta (@GENE$) with a predominance of ERalpha on both dopamine neurons and astrocytes.
4548	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEMICAL$ receptor beta (ERbeta) with a predominance of @GENE$ on both dopamine neurons and astrocytes.
4549	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both @CHEMICAL$ (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.
4550	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (@CHEMICAL$) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.
4551	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and @CHEMICAL$ (ERbeta) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.
4552	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and estrogen receptor beta (@CHEMICAL$) with a predominance of ERalpha on both @GENE$ neurons and astrocytes.
4553	CPRFalse	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of @CHEMICAL$ on both @GENE$ neurons and astrocytes.
4554	CPRFalse	We also found that @CHEMICAL$ protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and @GENE$-dependent manner.
4555	CPRFalse	We also found that 17beta-estradiol protects @CHEMICAL$ neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and @GENE$-dependent manner.
4556	CPRFalse	We also found that 17beta-estradiol protects dopamine neurons from injury induced by the complex I inhibitor, @CHEMICAL$ (MPP(+)) in a time- and @GENE$-dependent manner.
4557	CPRFalse	We also found that 17beta-estradiol protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (@CHEMICAL$) in a time- and @GENE$-dependent manner.
4558	CPRFalse	At least 4 h of @CHEMICAL$ pre-treatment was required to elicit protection, an effect that was blocked by the @GENE$ antagonist, ICI 182,780.
4559	CPR:6	At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the @CHEMICAL$ antagonist, @GENE$.
4560	CPRFalse	Moreover, @CHEMICAL$ mediated the protection afforded by @GENE$ since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss.
4561	CPRFalse	Moreover, ERalpha mediated the protection afforded by @CHEMICAL$ since only the @GENE$ agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss.
4562	CPRFalse	Moreover, ERalpha mediated the protection afforded by @CHEMICAL$ since only the ERalpha agonist, HPTE, but not the @GENE$ agonist, DPN, protected against dopamine cell loss.
4563	CPRFalse	Moreover, @CHEMICAL$ mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, @GENE$, protected against dopamine cell loss.
4564	CPRFalse	Moreover, ERalpha mediated the protection afforded by estrogen since only the @CHEMICAL$ agonist, HPTE, but not the ERbeta agonist, @GENE$, protected against dopamine cell loss.
4565	CPR:5	Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the @CHEMICAL$ agonist, @GENE$, protected against dopamine cell loss.
4566	CPRFalse	Moreover, @CHEMICAL$ mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against @GENE$ cell loss.
4567	CPRFalse	Moreover, ERalpha mediated the protection afforded by estrogen since only the @CHEMICAL$ agonist, HPTE, but not the ERbeta agonist, DPN, protected against @GENE$ cell loss.
4568	CPRFalse	Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the @CHEMICAL$ agonist, DPN, protected against @GENE$ cell loss.
4569	CPRFalse	Since glial cells were shown to express significant levels of @CHEMICAL$, we investigated a possible indirect mechanism of @GENE$-mediated neuroprotection through glial cell interaction.
4570	CPRFalse	These data indicate that neuroprotection provided by @CHEMICAL$ against MPP(+) toxicity is mediated by @GENE$ and involves an interplay among at least two cell types.
4571	CPRFalse	These data indicate that neuroprotection provided by estrogen against @CHEMICAL$ toxicity is mediated by @GENE$ and involves an interplay among at least two cell types.
4572	CPR:3	Differential activation of @CHEMICAL$ in discrete nucleus accumbens subregions during early and late @GENE$ sensitization.
4573	CPRFalse	Differential activation of @CHEM-GENE$ in discrete nucleus accumbens subregions during early and late cocaine sensitization.
4574	CPRFalse	The present study examined the differential cocaine-induced activation of the cyclic adenosine monophosphate (@CHEMICAL$) response element binding protein (@GENE$) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.
4575	CPRFalse	The present study examined the differential cocaine-induced activation of the @CHEM-GENE$ (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.
4576	CPR:3	The present study examined the differential @CHEMICAL$-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (@GENE$) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.
4577	CPR:3	The present study examined the differential @CHEMICAL$-induced activation of the @GENE$ (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.
4578	CPRFalse	The present study examined the differential cocaine-induced activation of the @CHEMICAL$ (cAMP) response element binding protein (@GENE$) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.
4579	CPRFalse	The present study examined the differential cocaine-induced activation of the @CHEM-GENE$ (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.
4580	CPRFalse	@CHEMICAL$-dependent gene transcription, which may underlie long-lasting drug-induced changes in behavior and the subjective effects of @GENE$, varies depending on the stage of drug exposure or withdrawal and the cell population involved.
4581	CPR:3	Using immunohistochemistry, the authors analyzed changes in @CHEMICAL$ phosphorylation in the NAc after 5 days of @GENE$, a short or long drug-free period, and a subsequent challenge injection.
4582	CPRFalse	Repeated @CHEMICAL$ resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of @GENE$ in the 3 most dorsomedial zones of the shell.
4583	CPR:3	Repeated @CHEMICAL$ resulted in @GENE$ phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.
4584	CPR:3	Repeated cocaine resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated @CHEMICAL$, but rats challenged after 2 drug-free days yielded a more localized activation of @GENE$ in the 3 most dorsomedial zones of the shell.
4585	CPRFalse	Repeated cocaine resulted in @CHEMICAL$ phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated @GENE$, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.
4586	CPR:3	The temporal and anatomical determinants of @CHEMICAL$-induced @GENE$ activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.
4587	CPRFalse	The temporal and anatomical determinants of @CHEMICAL$-induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of @GENE$ in early and late cocaine effects.
4588	CPRFalse	The temporal and anatomical determinants of cocaine-induced @CHEMICAL$ activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late @GENE$ effects.
4589	CPRFalse	The temporal and anatomical determinants of cocaine-induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of @CHEMICAL$ in early and late @GENE$ effects.
4590	CPRFalse	Fatal hemorrhage in mice lacking @CHEM-GENE$.
4591	CPRFalse	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the @CHEM-GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4592	CPRFalse	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent @CHEMICAL$ carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4593	CPR:9	The carboxylation of @CHEMICAL$ residues to gamma-carboxyglutamic acid (Gla) by the @GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4594	CPR:9	The carboxylation of @CHEMICAL$ residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4595	CPR:9	The carboxylation of glutamic acid residues to @CHEMICAL$ (Gla) by the @GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4596	CPR:9	The carboxylation of glutamic acid residues to @CHEMICAL$ (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4597	CPR:9	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (@CHEMICAL$) by the @GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4598	CPR:9	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (@CHEMICAL$) by the vitamin K-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4599	CPRFalse	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the @CHEM-GENE$ (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4600	CPRFalse	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the @CHEMICAL$-dependent gamma-glutamyl carboxylase (@GENE$) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.
4601	CPRFalse	Heterozygous mice carrying a null mutation at the gamma-carboxylase (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @CHEM-GENE$, and prothrombin.
4602	CPRFalse	Heterozygous mice carrying a null mutation at the @CHEMICAL$ (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @GENE$-dependent clotting factors IX, X, and prothrombin.
4603	CPRFalse	Heterozygous mice carrying a null mutation at the gamma-carboxylase (@CHEMICAL$) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @GENE$-dependent clotting factors IX, X, and prothrombin.
4604	CPRFalse	Heterozygous mice carrying a null mutation at the gamma-carboxylase (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @CHEMICAL$-dependent clotting factors IX, X, and @GENE$.
4605	CPRFalse	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of @GENE$ and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.
4606	CPRFalse	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and @GENE$ were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.
4607	CPRFalse	Genotyping of the single @CHEMICAL$ polymorphisms @GENE$-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.
4608	CPRFalse	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, @GENE$-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.
4609	CPRFalse	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, @GENE$-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.
4610	CPRFalse	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, @GENE$-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.
4611	CPRFalse	Genotyping of the single @CHEMICAL$ polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and @GENE$-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.
4612	CPRFalse	Furthermore, with respect to @CHEMICAL$ and GSTT1 there were statistically significant differences in @GENE$-levels between genotypes among exposed workers but not among controls.
4613	CPRFalse	Furthermore, with respect to GSTM1 and @CHEMICAL$ there were statistically significant differences in @GENE$-levels between genotypes among exposed workers but not among controls.
4614	CPRFalse	H3 @CHEMICAL$ receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/@GENE$/ELK-1 pathway.
4615	CPRFalse	H3 @CHEMICAL$ receptor agonist inhibits biliary growth of BDL rats by downregulation of the @GENE$/ERK1/2/ELK-1 pathway.
4616	CPRFalse	@CHEM-GENE$ agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway.
4617	CPRFalse	H3 @CHEMICAL$ receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/@GENE$ pathway.
4618	CPRFalse	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the @CHEMICAL$-dependent PKA/@GENE$/ELK-1 pathway.
4619	CPRFalse	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the @CHEM-GENE$/ERK1/2/ELK-1 pathway.
4620	CPRFalse	@CHEMICAL$ agonist inhibits biliary growth of BDL rats by downregulation of the @GENE$-dependent PKA/ERK1/2/ELK-1 pathway.
4621	CPRFalse	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the @CHEMICAL$-dependent PKA/ERK1/2/@GENE$ pathway.
4622	CPRFalse	@CHEMICAL$ regulates many functions by binding to four @GENE$ (H1R, H2R, H3R and H4R).
4623	CPRFalse	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, @GENE$ and H4R).
4624	CPRFalse	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and @GENE$).
4625	CPRFalse	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (@GENE$, H2R, H3R and H4R).
4626	CPRFalse	@CHEMICAL$ regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, @GENE$, H3R and H4R).
4627	CPRFalse	Histamine regulates many functions by binding to four @CHEM-GENE$ (H1R, H2R, H3R and H4R).
4628	CPRFalse	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (H1R, H2R, @GENE$ and H4R).
4629	CPRFalse	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (H1R, H2R, H3R and @GENE$).
4630	CPRFalse	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (@GENE$, H2R, H3R and H4R).
4631	CPRFalse	Histamine regulates many functions by binding to four @CHEMICAL$ G-coupled receptor proteins (H1R, @GENE$, H3R and H4R).
4632	CPRFalse	As @CHEMICAL$ exerts their effects by coupling to Galpha(i/o) proteins reducing @GENE$ (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.
4633	CPRFalse	As H3R exerts their effects by coupling to @CHEMICAL$ proteins reducing @GENE$ (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.
4634	CPRFalse	As H3R exerts their effects by coupling to Galpha(i/o) proteins reducing @CHEMICAL$ (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of @GENE$ in the regulation of biliary growth.
4635	CPRFalse	As @CHEMICAL$ exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (@GENE$) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.
4636	CPRFalse	As H3R exerts their effects by coupling to @CHEMICAL$ proteins reducing adenosine 3', 5'-monophosphate (@GENE$) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.
4637	CPRFalse	As H3R exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (@CHEMICAL$) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of @GENE$ in the regulation of biliary growth.
4638	CPRFalse	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of @GENE$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4639	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4640	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4641	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?
4642	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?
4643	CPR:5	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (@GENE$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4644	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (@GENE$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4645	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?
4646	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of @CHEMICAL$ (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?
4647	CPRFalse	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@GENE$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4648	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4649	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4650	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?
4651	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?
4652	CPR:5	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (@GENE$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4653	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (@GENE$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4654	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?
4655	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (@CHEMICAL$) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?
4656	CPRFalse	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @GENE$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4657	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4658	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4659	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?
4660	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?
4661	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), @GENE$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4662	CPR:6	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (@GENE$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4663	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?
4664	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), @CHEMICAL$ (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?
4665	CPRFalse	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @GENE$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4666	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4667	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4668	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?
4669	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?
4670	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or @GENE$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4671	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or @GENE$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4672	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?
4673	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or @CHEMICAL$, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?
4674	CPRFalse	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @GENE$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4675	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4676	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4677	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?
4678	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?
4679	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @GENE$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4680	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or histamine, in the absence/presence of @GENE$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4681	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?
4682	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of @CHEMICAL$, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?
4683	CPRFalse	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @GENE$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4684	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4685	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4686	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?
4687	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?
4688	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @GENE$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4689	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @GENE$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4690	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?
4691	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does @CHEMICAL$ inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?
4692	CPRFalse	We posed the following questions: (1) Do cholangiocytes express @CHEMICAL$? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @GENE$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4693	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of @GENE$ (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4694	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (@GENE$)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4695	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/@GENE$ (ERK1/2)/ets-like gene-1 (Elk-1)?
4696	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (@GENE$)/ets-like gene-1 (Elk-1)?
4697	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (@CHEMICAL$ agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @GENE$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4698	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (@CHEMICAL$ antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @GENE$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?
4699	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/@GENE$ (Elk-1)?
4700	CPRFalse	We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of @CHEMICAL$-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (@GENE$)?
4701	CPRFalse	Following in vivo treatment of BDL rats with @CHEMICAL$ for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and @GENE$, ERK1/2 and Elk-1 phosphorylation.
4702	CPRFalse	Following in vivo treatment of BDL rats with @CHEMICAL$ for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and PKA, @GENE$ and Elk-1 phosphorylation.
4703	CPRFalse	Following in vivo treatment of BDL rats with @CHEMICAL$ for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and @GENE$ phosphorylation.
4704	CPRFalse	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with @CHEMICAL$, we evaluated cholangiocyte proliferation, cAMP levels and @GENE$, ERK1/2 and Elk-1 phosphorylation.
4705	CPRFalse	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with @CHEMICAL$, we evaluated cholangiocyte proliferation, cAMP levels and PKA, @GENE$ and Elk-1 phosphorylation.
4706	CPRFalse	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with @CHEMICAL$, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and @GENE$ phosphorylation.
4707	CPRFalse	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, @CHEMICAL$ levels and @GENE$, ERK1/2 and Elk-1 phosphorylation.
4708	CPRFalse	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, @CHEMICAL$ levels and PKA, @GENE$ and Elk-1 phosphorylation.
4709	CPRFalse	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, @CHEMICAL$ levels and PKA, ERK1/2 and @GENE$ phosphorylation.
4710	CPR:4	@CHEMICAL$ inhibition of cholangiocyte growth was associated with decreased cAMP levels and @GENE$/ERK1/2/Elk-1 phosphorylation.
4711	CPR:4	@CHEMICAL$ inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/@GENE$/Elk-1 phosphorylation.
4712	CPR:4	@CHEMICAL$ inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/@GENE$ phosphorylation.
4713	CPRFalse	RAMH inhibition of cholangiocyte growth was associated with decreased @CHEMICAL$ levels and @GENE$/ERK1/2/Elk-1 phosphorylation.
4714	CPRFalse	RAMH inhibition of cholangiocyte growth was associated with decreased @CHEMICAL$ levels and PKA/@GENE$/Elk-1 phosphorylation.
4715	CPRFalse	RAMH inhibition of cholangiocyte growth was associated with decreased @CHEMICAL$ levels and PKA/ERK1/2/@GENE$ phosphorylation.
4716	CPRFalse	Downregulation of @CHEMICAL$-dependent @GENE$/ERK1/2/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.
4717	CPRFalse	Downregulation of @CHEMICAL$-dependent PKA/@GENE$/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.
4718	CPRFalse	Downregulation of @CHEMICAL$-dependent PKA/ERK1/2/@GENE$ phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.
4719	CPRFalse	Downregulation of @CHEMICAL$-dependent PKA/ERK1/2/Elk-1 phosphorylation (by activation of @GENE$) is important in the inhibition of cholangiocyte growth in liver diseases.
4720	CPRFalse	Structure and kinetics of monofunctional @CHEM-GENE$ from Thermus thermophilus.
4721	CPRFalse	@CHEM-GENE$ (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.
4722	CPRFalse	@CHEMICAL$ dehydrogenase (@GENE$) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.
4723	CPRFalse	@CHEMICAL$ dehydrogenase (PRODH) and @GENE$ (P5CDH) catalyze the two-step oxidation of proline to glutamate.
4724	CPRFalse	@CHEMICAL$ dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (@GENE$) catalyze the two-step oxidation of proline to glutamate.
4725	CPR:9	@CHEMICAL$ (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of @GENE$ to glutamate.
4726	CPR:9	Proline dehydrogenase (@CHEMICAL$) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of @GENE$ to glutamate.
4727	CPR:9	Proline dehydrogenase (PRODH) and @CHEMICAL$ (P5CDH) catalyze the two-step oxidation of @GENE$ to glutamate.
4728	CPR:9	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (@CHEMICAL$) catalyze the two-step oxidation of @GENE$ to glutamate.
4729	CPR:9	@CHEMICAL$ (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to @GENE$.
4730	CPR:9	Proline dehydrogenase (@CHEMICAL$) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to @GENE$.
4731	CPR:9	Proline dehydrogenase (PRODH) and @CHEMICAL$ (P5CDH) catalyze the two-step oxidation of proline to @GENE$.
4732	CPR:9	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (@CHEMICAL$) catalyze the two-step oxidation of proline to @GENE$.
4733	CPRFalse	@CHEMICAL$ (PRODH) and @GENE$ dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.
4734	CPRFalse	Proline dehydrogenase (@CHEMICAL$) and @GENE$ dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.
4735	CPRFalse	Proline dehydrogenase (PRODH) and @CHEM-GENE$ (P5CDH) catalyze the two-step oxidation of proline to glutamate.
4736	CPRFalse	Proline dehydrogenase (PRODH) and @CHEMICAL$ dehydrogenase (@GENE$) catalyze the two-step oxidation of proline to glutamate.
4737	CPRFalse	The 2.0-A resolution structure of Thermus thermophilus PRODH reveals a distorted @CHEMICAL$ and a hydrophobic alpha-helical domain located above the @GENE$-terminal ends of the strands of the barrel.
4738	CPRFalse	The 2.0-A resolution structure of Thermus thermophilus PRODH reveals a distorted (betaalpha)(8) barrel catalytic core domain and a @CHEMICAL$ located above the @GENE$-terminal ends of the strands of the barrel.
4739	CPRFalse	The 2.0-A resolution structure of @CHEMICAL$ reveals a distorted (betaalpha)(8) barrel catalytic core domain and a hydrophobic alpha-helical domain located above the @GENE$-terminal ends of the strands of the barrel.
4740	CPR:9	Finally, we demonstrate that @CHEMICAL$ reacts with @GENE$ producing superoxide.
4741	CPR:9	Finally, we demonstrate that @CHEMICAL$ reacts with O(2) producing @GENE$.
4742	CPRFalse	This is significant because @CHEMICAL$ production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between @GENE$.
4743	CPR:9	This is significant because @CHEMICAL$ production underlies the role of @GENE$ in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.
4744	CPRFalse	This is significant because @CHEMICAL$ production underlies the role of human PRODH in @GENE$-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.
4745	CPRFalse	@CHEMICAL$ uptake in brain and skeletal muscle of mice lacking @GENE$ assessed by magnetic resonance spectroscopy.
4746	CPRFalse	Creatine uptake in brain and skeletal muscle of mice lacking @CHEM-GENE$ assessed by magnetic resonance spectroscopy.
4747	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after @GENE$ supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4748	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after @CHEMICAL$ supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.
4749	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after @GENE$ supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4750	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 @GENE$ for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4751	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 @CHEMICAL$ for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.
4752	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 @GENE$ for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4753	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized @GENE$ magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4754	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized @CHEMICAL$ magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.
4755	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized @GENE$ magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4756	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@CHEMICAL$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after @GENE$ supplementation and in control (Con) mice.
4757	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @CHEMICAL$-/- mice before and after @GENE$ supplementation and in control (Con) mice.
4758	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after @GENE$ supplementation and in control (Con) mice.
4759	CPRFalse	@CHEMICAL$ (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4760	CPRFalse	@CHEMICAL$ (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.
4761	CPRFalse	@CHEMICAL$ (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4762	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of @CHEMICAL$ deficiency caused by guanidinoacetate methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4763	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of @CHEMICAL$ deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.
4764	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of @CHEMICAL$ deficiency caused by @GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4765	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4766	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEMICAL$ methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.
4767	CPRFalse	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @CHEM-GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4768	CPRFalse	Creatine (@CHEMICAL$) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (@GENE$-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4769	CPRFalse	Creatine (@CHEMICAL$) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of @GENE$-/- mice before and after Cr supplementation and in control (Con) mice.
4770	CPRFalse	Creatine (@CHEMICAL$) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by @GENE$ absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days. Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of GAMT-/- mice before and after Cr supplementation and in control (Con) mice.
4771	CPRFalse	As expected, a signal for @CHEMICAL$ was hardly detectable in MR spectra of @GENE$-/- mice before Cr supplementation.
4772	CPRFalse	As expected, a signal for Cr was hardly detectable in MR spectra of @CHEMICAL$-/- mice before @GENE$ supplementation.
4773	CPRFalse	Only because of the repeated MRS measurements performed in this longitudinal @CHEMICAL$ supplementation study on @GENE$-/- mice were we able to discover the initial faster uptake of Cr in skeletal muscle compared with brain, which may represent muscular Cr uptake independent of Cr transporter expression.
4774	CPRFalse	Only because of the repeated MRS measurements performed in this longitudinal Cr supplementation study on @CHEMICAL$-/- mice were we able to discover the initial faster uptake of @GENE$ in skeletal muscle compared with brain, which may represent muscular Cr uptake independent of Cr transporter expression.
4775	CPRFalse	Only because of the repeated MRS measurements performed in this longitudinal Cr supplementation study on @CHEMICAL$-/- mice were we able to discover the initial faster uptake of Cr in skeletal muscle compared with brain, which may represent muscular @GENE$ uptake independent of Cr transporter expression.
4776	CPRFalse	Only because of the repeated MRS measurements performed in this longitudinal Cr supplementation study on @CHEMICAL$-/- mice were we able to discover the initial faster uptake of Cr in skeletal muscle compared with brain, which may represent muscular Cr uptake independent of @GENE$ transporter expression.
4777	CPRFalse	Our results can provide the basis for additional experiments to optimize Cr supplementation in @CHEMICAL$ deficiency, as increases in brain Cr are slow in patients after @GENE$ supplementation.
4778	CPRFalse	Our results can provide the basis for additional experiments to optimize @CHEMICAL$ supplementation in @GENE$ deficiency, as increases in brain Cr are slow in patients after Cr supplementation.
4779	CPRFalse	Our results can provide the basis for additional experiments to optimize Cr supplementation in @CHEMICAL$ deficiency, as increases in brain @GENE$ are slow in patients after Cr supplementation.
4780	CPR:9	The @CHEMICAL$ is the predominant @GENE$ degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.
4781	CPR:4	Consequently, @CHEMICAL$ inhibitors including @GENE$ and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.
4782	CPR:4	Consequently, @CHEMICAL$ inhibitors including cilomilast and @GENE$ have been tested in several models of allergic and irritant skin inflammation.
4783	CPRFalse	These @CHEMICAL$ inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the @GENE$ induced skin inflammation in mice and in ovalbumin sensitised guinea pigs.
4784	CPRFalse	These PDE4 inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the @CHEMICAL$ induced skin inflammation in mice and in @GENE$ sensitised guinea pigs.
4785	CPR:4	Results of early clinical trials with both topically (@CHEMICAL$, CP80,633) and systemically (CC-10004) active @GENE$ inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.
4786	CPR:4	Results of early clinical trials with both topically (cipamfylline, @CHEMICAL$) and systemically (CC-10004) active @GENE$ inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.
4787	CPRFalse	Aberrant regulation of @CHEM-GENE$ by TNF-alpha in human epithelial ovarian cancer.
4788	CPRFalse	Aberrant regulation of @CHEMICAL$ synthetase by @GENE$ in human epithelial ovarian cancer.
4789	CPRFalse	Here, we show that @CHEMICAL$ also induces expression of arate-limiting enzyme in @GENE$ synthesis, argininosuccinate synthetase (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4790	CPRFalse	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in @CHEMICAL$ synthesis, @GENE$ (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4791	CPRFalse	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in @CHEMICAL$ synthesis, argininosuccinate synthetase (@GENE$), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4792	CPRFalse	Here, we show that @CHEMICAL$ also induces expression of arate-limiting enzyme in arginine synthesis, @GENE$ synthetase (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4793	CPRFalse	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, @CHEM-GENE$ (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4794	CPRFalse	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, @CHEMICAL$ synthetase (@GENE$), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4795	CPRFalse	Here, we show that @CHEMICAL$ also induces expression of arate-limiting enzyme in arginine synthesis, argininosuccinate synthetase (AS), thereby linking inflammation with several @GENE$-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4796	CPRFalse	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, @CHEMICAL$ (AS), thereby linking inflammation with several @GENE$-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4797	CPRFalse	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, argininosuccinate synthetase (@CHEMICAL$), thereby linking inflammation with several @GENE$-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.
4798	CPRFalse	In summary, high levels of @CHEMICAL$ expression, which may be required for several @GENE$-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4799	CPRFalse	In summary, high levels of AS expression, which may be required for several @CHEMICAL$-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4800	CPRFalse	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of @GENE$, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4801	CPRFalse	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of @CHEMICAL$, proline, pyrimidines and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4802	CPRFalse	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, @GENE$, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4803	CPRFalse	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, @CHEMICAL$, pyrimidines and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4804	CPRFalse	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, @GENE$ and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4805	CPRFalse	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, @CHEMICAL$ and polyamines, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4806	CPRFalse	In summary, high levels of @CHEMICAL$ expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and @GENE$, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4807	CPRFalse	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and @CHEMICAL$, is regulated by @GENE$ and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.
4808	CPRFalse	Mechanism of specific membrane targeting by @CHEMICAL$: localized pools of target lipids enhance @GENE$ affinity.
4809	CPR:3	Although considerable functional diversity exists, most @CHEMICAL$ are activated by @GENE$ binding and then dock to a specific cellular membrane.
4810	CPRFalse	The @CHEMICAL$ of protein kinase Calpha (PKCalpha) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.
4811	CPRFalse	The C2 domains of @CHEMICAL$ (PKCalpha) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.
4812	CPRFalse	The C2 domains of protein kinase Calpha (@CHEMICAL$) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.
4813	CPRFalse	The C2 domains of protein kinase Calpha (PKCalpha) and @CHEMICAL$ (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.
4814	CPRFalse	The C2 domains of protein kinase Calpha (PKCalpha) and cytosolic phospholipase A2alpha (@CHEMICAL$), for example, are known to dock to different membrane surfaces during an intracellular @GENE$ signal.
4815	CPRFalse	@CHEMICAL$ activation targets the @GENE$ to the plasma membrane and the cPLA2alpha C2 domain to the internal membranes, with no detectable spatial overlap.
4816	CPRFalse	@CHEMICAL$ activation targets the PKCalpha C2 domain to the plasma membrane and the @GENE$ to the internal membranes, with no detectable spatial overlap.
4817	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk @CHEMICAL$ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.
4818	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk @CHEMICAL$ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @GENE$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.
4819	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological @CHEMICAL$ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.
4820	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological @GENE$ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.
4821	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids @CHEMICAL$ (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.
4822	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids @GENE$ (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.
4823	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (@CHEMICAL$) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.
4824	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (@GENE$) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.
4825	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and @CHEMICAL$ (PIP2) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.
4826	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and @GENE$ (PIP2) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.
4827	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated PKCalpha C2 domain in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (@CHEMICAL$) are together sufficient to recruit the @GENE$n to a lipid mixture mimicking the plasma membrane inner leaflet.
4828	CPRFalse	It is crucial to determine how such targeting specificity is achieved at physiological bulk Ca2+ concentrations that during a typical signaling event rarely exceed 1 muM. For the isolated @CHEMICAL$ in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (@GENE$) are together sufficient to recruit the PKCalpha C2 domain to a lipid mixture mimicking the plasma membrane inner leaflet.
4829	CPRFalse	For the @CHEMICAL$, the target lipid @GENE$ (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.
4830	CPRFalse	For the @CHEMICAL$, the target lipid phosphatidylcholine (@GENE$) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.
4831	CPRFalse	For the @CHEMICAL$, the target lipid phosphatidylcholine (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological @GENE$ levels, although the results do not rule out a second, unknown target molecule.
4832	CPRFalse	In principle, @CHEMICAL$-directed intracellular targeting, which requires coincidence detection of multiple signals (@GENE$ and one or more target lipids), can exhibit two different mechanisms: messenger-activated target affinity (MATA) and target-activated messenger affinity (TAMA).
4833	CPRFalse	The @CHEMICAL$ studied here both utilize the TAMA mechanism, in which the C2 domain @GENE$ affinity is too low to be activated by physiological Ca2+ signals in most regions of the cell.
4834	CPRFalse	The C2 domains studied here both utilize the TAMA mechanism, in which the @CHEMICAL$ @GENE$ affinity is too low to be activated by physiological Ca2+ signals in most regions of the cell.
4835	CPRFalse	The @CHEMICAL$ studied here both utilize the TAMA mechanism, in which the C2 domain Ca2+ affinity is too low to be activated by physiological @GENE$ signals in most regions of the cell.
4836	CPRFalse	The C2 domains studied here both utilize the TAMA mechanism, in which the @CHEMICAL$ Ca2+ affinity is too low to be activated by physiological @GENE$ signals in most regions of the cell.
4837	CPRFalse	Only when the @CHEMICAL$ nears its target membrane, which provides a high local concentration of target lipid, is the effective Ca2+ affinity increased by the coupled binding equilibrium to a level that enables substantial @GENE$ activation and target docking.
4838	CPRFalse	Only when the @CHEMICAL$ nears its target membrane, which provides a high local concentration of target lipid, is the effective @GENE$ affinity increased by the coupled binding equilibrium to a level that enables substantial Ca2+ activation and target docking.
4839	CPRFalse	Quantification and regulation of the subcellular distribution of @CHEM-GENE$ activity in rat liver.
4840	CPRFalse	Quantification and regulation of the subcellular distribution of @CHEM-GENE$ activity in rat liver.
4841	CPRFalse	Quantification and regulation of the subcellular distribution of @CHEM-GENE$ activity in rat liver.
4842	CPR:9	@CHEMICAL$ (BAT) is responsible for the amidation of @GENE$ with the amino acids glycine and taurine.
4843	CPR:9	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of @GENE$ with the amino acids glycine and taurine.
4844	CPRFalse	@CHEM-GENE$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine.
4845	CPRFalse	@CHEMICAL$ coenzyme A:amino acid N-acyltransferase (@GENE$) is responsible for the amidation of bile acids with the amino acids glycine and taurine.
4846	CPRFalse	@CHEM-GENE$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine.
4847	CPRFalse	Bile acid @CHEMICAL$:amino acid N-acyltransferase (@GENE$) is responsible for the amidation of bile acids with the amino acids glycine and taurine.
4848	CPRFalse	@CHEMICAL$ (BAT) is responsible for the amidation of bile acids with the @GENE$ glycine and taurine.
4849	CPRFalse	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of bile acids with the @GENE$ glycine and taurine.
4850	CPRFalse	@CHEMICAL$ (BAT) is responsible for the amidation of bile acids with the amino acids @GENE$ and taurine.
4851	CPRFalse	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of bile acids with the amino acids @GENE$ and taurine.
4852	CPRFalse	@CHEMICAL$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and @GENE$.
4853	CPRFalse	Bile acid coenzyme A:amino acid N-acyltransferase (@CHEMICAL$) is responsible for the amidation of bile acids with the amino acids glycine and @GENE$.
4854	CPRFalse	@CHEM-GENE$ (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine.
4855	CPRFalse	Bile acid coenzyme A:@CHEMICAL$ N-acyltransferase (@GENE$) is responsible for the amidation of bile acids with the amino acids glycine and taurine.
4856	CPRFalse	Treatment with @CHEMICAL$ or cholestyramine had no effect on @GENE$ activity in any subcellular compartment.
4857	CPRFalse	Treatment with rosiglitazone or @CHEMICAL$ had no effect on @GENE$ activity in any subcellular compartment.
4858	CPRFalse	These data support the novel finding that @CHEMICAL$ treatment does not directly regulate @GENE$ activity but does alter the subcellular localization of BAT.
4859	CPRFalse	These data support the novel finding that @CHEMICAL$ treatment does not directly regulate BAT activity but does alter the subcellular localization of @GENE$.
4860	CPRFalse	Because of their low asparagine synthetase (@CHEMICAL$) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to @GENE$ depletion.
4861	CPRFalse	Because of their low @CHEMICAL$ (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to @GENE$ depletion.
4862	CPRFalse	Because of their low @CHEMICAL$ synthetase (@GENE$) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.
4863	CPRFalse	Because of their low @CHEM-GENE$ (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.
4864	CPR:9	Because of their low asparagine synthetase (@CHEMICAL$) expression and @GENE$ biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.
4865	CPR:9	Because of their low @CHEMICAL$ (ASNS) expression and @GENE$ biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.
4866	CPR:9	@CHEMICAL$ secretion by MSCs was directly related to their @GENE$ expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.
4867	CPRFalse	Asparagine secretion by MSCs was directly related to their @CHEMICAL$ expression levels, suggesting a mechanism - increased concentrations of @GENE$ in the leukemic cell microenvironment - for the protective effects we observed.
4868	CPRFalse	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B @CHEM-GENE$ subunits.
4869	CPRFalse	Toxicity of @CHEMICAL$ in HEK293 cells expressing NR1/NR2A or NR1/NR2B @GENE$ receptor subunits.
4870	CPRFalse	Toxicity of beta-amyloid in HEK293 cells expressing @CHEMICAL$/NR2A or NR1/NR2B @GENE$ receptor subunits.
4871	CPRFalse	Toxicity of beta-amyloid in HEK293 cells expressing NR1/@CHEMICAL$ or NR1/NR2B @GENE$ receptor subunits.
4872	CPRFalse	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or @CHEMICAL$/NR2B @GENE$ receptor subunits.
4873	CPRFalse	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/@CHEMICAL$ @GENE$ receptor subunits.
4874	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves @CHEMICAL$ toxicity, resulting from overactivation of @GENE$ and elevation of intracellular calcium.
4875	CPRFalse	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves @GENE$ toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular calcium.
4876	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves @GENE$ toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular calcium.
4877	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves glutamate toxicity, resulting from overactivation of @CHEM-GENE$ and elevation of intracellular calcium.
4878	CPRFalse	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves glutamate toxicity, resulting from overactivation of @GENE$ (NMDA) receptors and elevation of intracellular calcium.
4879	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves glutamate toxicity, resulting from overactivation of @GENE$ (NMDA) receptors and elevation of intracellular calcium.
4880	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves glutamate toxicity, resulting from overactivation of @CHEM-GENE$ and elevation of intracellular calcium.
4881	CPRFalse	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (@GENE$) receptors and elevation of intracellular calcium.
4882	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (@GENE$) receptors and elevation of intracellular calcium.
4883	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves glutamate toxicity, resulting from overactivation of @CHEMICAL$ and elevation of intracellular @GENE$.
4884	CPRFalse	Neurotoxicity induced by @CHEMICAL$ (Abeta) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular @GENE$.
4885	CPRFalse	Neurotoxicity induced by beta-amyloid peptide (@CHEMICAL$) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular @GENE$.
4886	CPRFalse	However, the heterogeneity of the @CHEM-GENE$, frequently composed of NR1 and NR2A-D subunits, has been less studied.
4887	CPRFalse	However, the heterogeneity of the @CHEMICAL$ receptors, frequently composed of NR1 and @GENE$ subunits, has been less studied.
4888	CPRFalse	However, the heterogeneity of the @CHEMICAL$ receptors, frequently composed of @GENE$ and NR2A-D subunits, has been less studied.
4889	CPRFalse	Thus, we determined the contribution of @CHEM-GENE$ subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/NR2B subunits.
4890	CPRFalse	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on @GENE$ toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/NR2B subunits.
4891	CPRFalse	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing @GENE$/NR2A or NR1/NR2B subunits.
4892	CPRFalse	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/@GENE$ or NR1/NR2B subunits.
4893	CPRFalse	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/NR2A or @GENE$/NR2B subunits.
4894	CPRFalse	Thus, we determined the contribution of @CHEMICAL$ receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/@GENE$ subunits.
4895	CPRFalse	Analysis of @CHEM-GENE$ (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4896	CPRFalse	Analysis of @CHEMICAL$ dehydrogenase (@GENE$) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4897	CPRFalse	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in @GENE$ toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4898	CPRFalse	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon @GENE$/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4899	CPRFalse	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/@GENE$ expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4900	CPRFalse	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to @GENE$/NR2B, indicating loss of plasma membrane integrity.
4901	CPRFalse	Analysis of @CHEMICAL$ dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/@GENE$, indicating loss of plasma membrane integrity.
4902	CPRFalse	Analysis of @CHEMICAL$ (LDH) release and @GENE$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4903	CPRFalse	Analysis of lactate dehydrogenase (@CHEMICAL$) release and @GENE$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4904	CPRFalse	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in @GENE$ toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4905	CPRFalse	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon @GENE$/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4906	CPRFalse	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/@GENE$ expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.
4907	CPRFalse	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to @GENE$/NR2B, indicating loss of plasma membrane integrity.
4908	CPRFalse	Analysis of lactate dehydrogenase (LDH) release and @CHEMICAL$ exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/@GENE$, indicating loss of plasma membrane integrity.
4909	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular @CHEMICAL$ in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.
4910	CPRFalse	Furthermore, @CHEMICAL$ decreased intracellular @GENE$ in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4911	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular @CHEMICAL$ in cells expressing @GENE$/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4912	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular @CHEMICAL$ in cells expressing NR1/@GENE$. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4913	CPR:6	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/NR2A. @CHEMICAL$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.
4914	CPRFalse	Furthermore, @CHEMICAL$ decreased intracellular ATP in cells expressing NR1/NR2A. @GENE$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4915	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing @CHEMICAL$/NR2A. @GENE$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4916	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/@CHEMICAL$. @GENE$ ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4917	CPR:6	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 (@CHEMICAL$), a noncompetitive @GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.
4918	CPRFalse	Furthermore, @CHEMICAL$ decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 (@GENE$), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4919	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing @CHEMICAL$/NR2A. MK-801 (@GENE$), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4920	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/@CHEMICAL$. MK-801 (@GENE$), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4921	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @CHEM-GENE$ antagonist, partially prevented the decrease in cell viability and the energy impairment.
4922	CPRFalse	Furthermore, @CHEMICAL$ decreased intracellular ATP in cells expressing NR1/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4923	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing @CHEMICAL$/NR2A. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4924	CPRFalse	Furthermore, Abeta(1-40) decreased intracellular ATP in cells expressing NR1/@CHEMICAL$. MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive @GENE$ receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.
4925	CPRFalse	Functional @CHEMICAL$/NR2A and NR1/NR2B receptor subtypes were further evidenced by single-cell @GENE$ imaging.
4926	CPRFalse	Functional NR1/@CHEMICAL$ and NR1/NR2B receptor subtypes were further evidenced by single-cell @GENE$ imaging.
4927	CPRFalse	Functional NR1/NR2A and @CHEMICAL$/NR2B receptor subtypes were further evidenced by single-cell @GENE$ imaging.
4928	CPRFalse	Functional NR1/NR2A and NR1/@CHEMICAL$ receptor subtypes were further evidenced by single-cell @GENE$ imaging.
4929	CPRFalse	Stimulation of @CHEMICAL$/NR2A receptors with @GENE$/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).
4930	CPRFalse	Stimulation of NR1/@CHEMICAL$ receptors with @GENE$/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).
4931	CPRFalse	Stimulation of NR1/NR2A receptors with @CHEMICAL$/glycine revealed an increase in intracellular calcium in cells pre-exposed to @GENE$.
4932	CPRFalse	Stimulation of @CHEMICAL$/NR2A receptors with NMDA/@GENE$ revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).
4933	CPRFalse	Stimulation of NR1/@CHEMICAL$ receptors with NMDA/@GENE$ revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).
4934	CPRFalse	Stimulation of NR1/NR2A receptors with NMDA/@CHEMICAL$ revealed an increase in intracellular calcium in cells pre-exposed to @GENE$.
4935	CPRFalse	Stimulation of @CHEMICAL$/NR2A receptors with NMDA/glycine revealed an increase in intracellular @GENE$ in cells pre-exposed to Abeta(1-40).
4936	CPRFalse	Stimulation of NR1/@CHEMICAL$ receptors with NMDA/glycine revealed an increase in intracellular @GENE$ in cells pre-exposed to Abeta(1-40).
4937	CPRFalse	Stimulation of NR1/NR2A receptors with NMDA/glycine revealed an increase in intracellular @CHEMICAL$ in cells pre-exposed to @GENE$.
4938	CPRFalse	These results suggest that NR1/NR2A-composed @CHEM-GENE$ mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.
4939	CPRFalse	These results suggest that @CHEMICAL$/NR2A-composed @GENE$ receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.
4940	CPRFalse	These results suggest that NR1/@CHEMICAL$-composed @GENE$ receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.
4941	CPRFalse	These results suggest that NR1/NR2A-composed @CHEMICAL$ receptors mediate necrotic cell death in HEK293 cells exposed to @GENE$ through changes in calcium homeostasis.
4942	CPRFalse	These results suggest that NR1/NR2A-composed @CHEMICAL$ mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in @GENE$ homeostasis.
4943	CPRFalse	These results suggest that @CHEMICAL$/NR2A-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in @GENE$ homeostasis.
4944	CPRFalse	These results suggest that NR1/@CHEMICAL$-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in @GENE$ homeostasis.
4945	CPRFalse	These results suggest that NR1/NR2A-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to @CHEMICAL$ through changes in @GENE$ homeostasis.
4946	CPR:9	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of @GENE$ from ALA.
4947	CPR:9	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of @GENE$ from ALA.
4948	CPR:9	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from @GENE$.
4949	CPR:9	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from @GENE$.
4950	CPR:9	The use of @CHEMICAL$ (D6D) twice in the conversion of @GENE$ (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4951	CPR:9	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of @GENE$ (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4952	CPR:9	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (@GENE$; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4953	CPR:9	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (@GENE$; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4954	CPR:9	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to @GENE$ (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4955	CPR:9	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to @GENE$ (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4956	CPR:9	The use of @CHEMICAL$ (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (@GENE$; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4957	CPR:9	The use of Delta 6 desaturase (@CHEMICAL$) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (@GENE$; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.
4958	CPR:9	The accumulation of the post-@CHEMICAL$ products of 22:5n-3, 24:6n-3 and @GENE$, in cell phospholipids was saturated at concentrations of >18 microM ALA.
4959	CPRFalse	The accumulation of the post-@CHEMICAL$ products of 22:5n-3, 24:6n-3 and DHA, in cell phospholipids was saturated at concentrations of >18 microM @GENE$.
4960	CPR:9	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for @CHEMICAL$ may contribute to the limited accumulation of @GENE$ in cell membranes.
4961	CPRFalse	The parallel pattern of accumulation of 24:6n-3 and @CHEMICAL$ in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for @GENE$ may contribute to the limited accumulation of DHA in cell membranes.
4962	CPRFalse	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of @CHEMICAL$ suggests that the competition between 24:5n-3 and ALA for @GENE$ may contribute to the limited accumulation of DHA in cell membranes.
4963	CPR:9	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and @CHEMICAL$ for @GENE$ may contribute to the limited accumulation of DHA in cell membranes.
4964	CPRFalse	Plasma S/R ratio of @CHEMICAL$ co-varies with @GENE$ haplotype.
4965	CPRFalse	We recently reported that the low-dose VKORC1*2 haplotype is an important genetic determinant for @CHEMICAL$ dose requirement and is associated with difficulties to attain stable therapeutic @GENE$ time--International Normalized Ratio in patients undergoing anticoagulation therapy.
4966	CPRFalse	We recently reported that the low-dose @CHEMICAL$*2 haplotype is an important genetic determinant for @GENE$ dose requirement and is associated with difficulties to attain stable therapeutic prothrombin time--International Normalized Ratio in patients undergoing anticoagulation therapy.
4967	CPRFalse	The aim of this study was to investigate whether patients with @CHEMICAL$*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @GENE$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.
4968	CPRFalse	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes @CHEMICAL$*3 or VKORC1*4 had different @GENE$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.
4969	CPRFalse	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or @CHEMICAL$*4 had different @GENE$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.
4970	CPRFalse	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @CHEMICAL$ ratios in their plasma, and whether that was related to @GENE$ variants CYP2C9*2 and CYP2C9*3 or other factors.
4971	CPRFalse	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @CHEMICAL$ ratios in their plasma, and whether that was related to CYP2C9 variants @GENE$*2 and CYP2C9*3 or other factors.
4972	CPRFalse	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different @CHEMICAL$ ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and @GENE$*3 or other factors.
4973	CPRFalse	Samples from patients previously haplotyped for @CHEMICAL$ and measured for plasma @GENE$ concentration were genotyped for the CYP2C9 variants CYP2C9*2 and CYP2C9*3.
4974	CPRFalse	Samples from patients previously haplotyped for VKORC1 and measured for plasma @CHEMICAL$ concentration were genotyped for the @GENE$ variants CYP2C9*2 and CYP2C9*3.
4975	CPRFalse	Samples from patients previously haplotyped for VKORC1 and measured for plasma @CHEMICAL$ concentration were genotyped for the CYP2C9 variants @GENE$*2 and CYP2C9*3.
4976	CPRFalse	Samples from patients previously haplotyped for VKORC1 and measured for plasma @CHEMICAL$ concentration were genotyped for the CYP2C9 variants CYP2C9*2 and @GENE$*3.
4977	CPRFalse	Our result shows that there is a significant difference (P<0.01) in @CHEMICAL$ ratios between VKORC1*2 and @GENE$*3 or VKORC1*4 patients.
4978	CPRFalse	Our result shows that there is a significant difference (P<0.01) in @CHEMICAL$ ratios between VKORC1*2 and VKORC1*3 or @GENE$*4 patients.
4979	CPRFalse	Our result shows that there is a significant difference (P<0.01) in @CHEMICAL$ ratios between @GENE$*2 and VKORC1*3 or VKORC1*4 patients.
4980	CPRFalse	We speculate that @CHEMICAL$ haplotypes possibly are linked to some unidentified factors involved in the metabolic clearance of @GENE$ enantiomers.
4981	CPRFalse	@CHEM-GENE$ agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.
4982	CPRFalse	@CHEMICAL$ D1 receptor agonist and @GENE$ antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.
4983	CPR:5	@CHEMICAL$ agonist and D2 receptor antagonist effects of the natural product @GENE$: molecular modeling and dynamics simulations.
4984	CPR:6	Dopamine D1 receptor agonist and @CHEMICAL$ antagonist effects of the natural product @GENE$: molecular modeling and dynamics simulations.
4985	CPR:5	@CHEMICAL$ (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @GENE$ agonist and D2 antagonist.
4986	CPR:6	@CHEMICAL$ (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and @GENE$ antagonist.
4987	CPRFalse	(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @CHEM-GENE$ agonist and D2 antagonist.
4988	CPRFalse	(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @CHEMICAL$ receptor D1 agonist and @GENE$ antagonist.
4989	CPR:5	(-)-Stepholidine (@CHEMICAL$), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a @GENE$ agonist and D2 antagonist.
4990	CPR:6	(-)-Stepholidine (@CHEMICAL$), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and @GENE$ antagonist.
4991	CPRFalse	Insights into dynamical behaviors of @CHEMICAL$ and their interaction modes with SPD are crucial in understanding the structural and functional characteristics of @GENE$ receptors.
4992	CPRFalse	Insights into dynamical behaviors of D1 and D2 receptors and their interaction modes with SPD are crucial in understanding the structural and functional characteristics of @CHEM-GENE$.
4993	CPRFalse	Insights into dynamical behaviors of @CHEMICAL$ and their interaction modes with @GENE$ are crucial in understanding the structural and functional characteristics of dopamine receptors.
4994	CPRFalse	Insights into dynamical behaviors of D1 and D2 receptors and their interaction modes with @CHEMICAL$ are crucial in understanding the structural and functional characteristics of @GENE$.
4995	CPRFalse	In this study a computational approach, integrating protein structure prediction, automated molecular docking, and molecular dynamics simulations were employed to investigate the dual action mechanism of @CHEMICAL$ on the @GENE$, with the eventual aim to develop new drugs for treating diseases affecting the central nervous system such as schizophrenia.
4996	CPRFalse	"The dynamics simulations revealed the surface features of the electrostatic potentials and the conformational ""open-closed"" process of the binding entrances of two @CHEM-GENE$."
4997	CPRFalse	Potential binding conformations of @CHEMICAL$ were obtained, and the D1-@GENE$ and D2-SPD complexes were generated, which are in good agreement with most of experimental data.
4998	CPRFalse	Potential binding conformations of D1 and D2 receptors were obtained, and the D1-@CHEMICAL$ and @GENE$-SPD complexes were generated, which are in good agreement with most of experimental data.
4999	CPRFalse	Potential binding conformations of D1 and D2 receptors were obtained, and the @CHEMICAL$-@GENE$ and D2-SPD complexes were generated, which are in good agreement with most of experimental data.
5000	CPRFalse	Potential binding conformations of @CHEMICAL$ were obtained, and the D1-SPD and D2-@GENE$ complexes were generated, which are in good agreement with most of experimental data.
5001	CPRFalse	Potential binding conformations of D1 and D2 receptors were obtained, and the D1-SPD and @CHEMICAL$-@GENE$ complexes were generated, which are in good agreement with most of experimental data.
5002	CPRFalse	Potential binding conformations of D1 and D2 receptors were obtained, and the @CHEMICAL$-SPD and D2-@GENE$ complexes were generated, which are in good agreement with most of experimental data.
5003	CPRFalse	The @CHEMICAL$-@GENE$ structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of SPD.
5004	CPRFalse	The @CHEMICAL$-SPD structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of @GENE$.
5005	CPRFalse	UNLABELLED: Peptide hormone receptors overexpressed in human tumors, such as @CHEM-GENE$, can be used for in vivo targeting for diagnostic and therapeutic purposes.
5006	CPRFalse	UNLABELLED: @CHEMICAL$ overexpressed in human tumors, such as @GENE$ receptors, can be used for in vivo targeting for diagnostic and therapeutic purposes.
5007	CPRFalse	A novel variant @CHEMICAL$ in human @GENE$ dehydrogenase 2 is associated with diminished enzyme activity.
5008	CPRFalse	A novel variant L263F in @CHEM-GENE$ is associated with diminished enzyme activity.
5009	CPRFalse	BACKGROUND AND OBJECTIVE: @CHEM-GENE$ is required for purine synthesis in activated lymphocytes.
5010	CPRFalse	Variants in the @CHEMICAL$ gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving @GENE$.
5011	CPRFalse	Genetic variant was constructed by site-directed mutagenesis and transformed to an @CHEM-GENE$-deficient strain of Escherichia coli h712.
5012	CPRFalse	A novel nonsynonymous variant @CHEMICAL$ was identified, and the kinetic assay demonstrated that the @GENE$ dehydrogenase activity of L263F variant was decreased to 10% of the wild-type.
5013	CPRFalse	A novel nonsynonymous variant L263F was identified, and the kinetic assay demonstrated that the @CHEM-GENE$ activity of L263F variant was decreased to 10% of the wild-type.
5014	CPRFalse	A novel nonsynonymous variant L263F was identified, and the kinetic assay demonstrated that the @CHEMICAL$ dehydrogenase activity of @GENE$ variant was decreased to 10% of the wild-type.
5015	CPR:4	The Ki for @CHEMICAL$ inhibition of the @GENE$ variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.
5016	CPRFalse	The Ki for mycophenolic acid inhibition of the @CHEMICAL$ variant was comparable with the wild-type, and the variant Km for @GENE$ and nicotinamide adenine dinucleotide did not change significantly.
5017	CPRFalse	The Ki for mycophenolic acid inhibition of the @CHEMICAL$ variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and @GENE$ did not change significantly.
5018	CPRFalse	CONCLUSIONS: IMPDH2 has low genetic diversity, but the nonsynonymous variant @CHEMICAL$ has a significant impact on @GENE$ dehydrogenase activity.
5019	CPRFalse	CONCLUSIONS: IMPDH2 has low genetic diversity, but the nonsynonymous variant L263F has a significant impact on @CHEM-GENE$ activity.
5020	CPRFalse	CONCLUSIONS: @CHEMICAL$ has low genetic diversity, but the nonsynonymous variant L263F has a significant impact on @GENE$ dehydrogenase activity.
5021	CPRFalse	This novel functional variant may be one of the factors contributing to the inter-individual difference of baseline @CHEM-GENE$ activity as well as drug efficacy and adverse events in transplant patients.
5022	CPRFalse	[Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and @CHEM-GENE$ after cerebral ischemia-reperfusion in rats].
5023	CPRFalse	[Effects of Panax notoginseng saponins on mRNA expressions of @CHEMICAL$, its correlative factors and @GENE$ specific protease after cerebral ischemia-reperfusion in rats].
5024	CPRFalse	[Effects of Panax notoginseng @CHEMICAL$ on mRNA expressions of interleukin-1 beta, its correlative factors and @GENE$ after cerebral ischemia-reperfusion in rats].
5025	CPRFalse	[Effects of Panax notoginseng @CHEMICAL$ on mRNA expressions of @GENE$, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats].
5026	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (@CHEMICAL$), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5027	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), @CHEMICAL$ (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5028	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (@CHEMICAL$), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5029	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), @CHEMICAL$ (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5030	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (@CHEMICAL$), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5031	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), @CHEMICAL$ (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5032	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (@CHEMICAL$), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5033	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEM-GENE$ (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5034	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEMICAL$ specific protease-1 (@GENE$), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5035	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEMICAL$ specific protease-1 (caspase-1), @GENE$ and caspase-8 after cerebral ischemia-reperfusion in rats.
5036	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @CHEMICAL$ specific protease-1 (caspase-1), caspase-3 and @GENE$ after cerebral ischemia-reperfusion in rats.
5037	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of @CHEMICAL$ (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5038	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (@GENE$), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5039	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), @GENE$ (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5040	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (@GENE$), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5041	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), @GENE$ (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5042	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (@GENE$), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5043	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), @GENE$ (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5044	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (@GENE$), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5045	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), @GENE$ (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5046	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (@GENE$), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5047	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), @GENE$ and caspase-8 after cerebral ischemia-reperfusion in rats.
5048	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and @GENE$ after cerebral ischemia-reperfusion in rats.
5049	CPRFalse	OBJECTIVE: To investigate the effects of Panax notoginseng @CHEMICAL$ (PNS) on mRNA expressions of @GENE$ (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.
5050	CPRFalse	Downregulation of @CHEMICAL$ but not @GENE$ loss leads to mitochondrial dysfunction in female mice CNS: implications in excitotoxicity.
5051	CPRFalse	We examined the critical roles played by the antioxidant, non-protein @CHEMICAL$, glutathione and related enzyme, @GENE$ in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.
5052	CPRFalse	We examined the critical roles played by the antioxidant, non-protein thiol, @CHEMICAL$ and related enzyme, @GENE$ in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.
5053	CPRFalse	We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, @CHEMICAL$ in maintaining mitochondrial function during excitotoxicity caused by @GENE$ (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.
5054	CPRFalse	We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, @CHEMICAL$ in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (@GENE$), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.
5055	CPR:4	@CHEMICAL$ causes loss of GSH and inhibition of @GENE$ in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.
5056	CPRFalse	L-BOAA causes loss of @CHEMICAL$ and inhibition of @GENE$ in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.
5057	CPRFalse	L-BOAA causes loss of GSH and inhibition of @CHEMICAL$ in lumbosacral cord of male mice through oxidation of @GENE$ groups, while female mice are resistant.
5058	CPRFalse	Reducing @CHEMICAL$ levels in female mice CNS by pretreatment with diethyl maleate or L-propargyl glycine did not result in inhibition of @GENE$ activity, unlike male mice.
5059	CPRFalse	Reducing GSH levels in female mice CNS by pretreatment with @CHEMICAL$ or L-propargyl glycine did not result in inhibition of @GENE$ activity, unlike male mice.
5060	CPRFalse	Reducing GSH levels in female mice CNS by pretreatment with diethyl maleate or @CHEMICAL$ did not result in inhibition of @GENE$ activity, unlike male mice.
5061	CPRFalse	Further, treatment of female mice depleted of @CHEMICAL$ with L-BOAA did not induce inhibition of @GENE$ indicating that GSH levels were not critical for maintaining complex I activity in female mice unlike their male counterpart.
5062	CPRFalse	Further, treatment of female mice depleted of @CHEMICAL$ with L-BOAA did not induce inhibition of complex I indicating that GSH levels were not critical for maintaining @GENE$ activity in female mice unlike their male counterpart.
5063	CPRFalse	Further, treatment of female mice depleted of GSH with @CHEMICAL$ did not induce inhibition of @GENE$ indicating that GSH levels were not critical for maintaining complex I activity in female mice unlike their male counterpart.
5064	CPRFalse	Further, treatment of female mice depleted of GSH with @CHEMICAL$ did not induce inhibition of complex I indicating that GSH levels were not critical for maintaining @GENE$ activity in female mice unlike their male counterpart.
5065	CPRFalse	Further, treatment of female mice depleted of GSH with L-BOAA did not induce inhibition of @CHEMICAL$ indicating that @GENE$ levels were not critical for maintaining complex I activity in female mice unlike their male counterpart.
5066	CPRFalse	Further, treatment of female mice depleted of GSH with L-BOAA did not induce inhibition of complex I indicating that @CHEMICAL$ levels were not critical for maintaining @GENE$ activity in female mice unlike their male counterpart.
5067	CPRFalse	@CHEMICAL$, a thiol @GENE$ oxidoreductase helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of mitochondrial complex I activity.
5068	CPRFalse	Glutaredoxin, a @CHEM-GENE$ helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of mitochondrial complex I activity.
5069	CPRFalse	Glutaredoxin, a thiol @CHEMICAL$ oxidoreductase helps maintain redox status of proteins and downregulation of @GENE$ results in loss of mitochondrial complex I activity.
5070	CPRFalse	Glutaredoxin, a thiol @CHEMICAL$ oxidoreductase helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of @GENE$ activity.
5071	CPRFalse	Female mice express higher levels of @CHEMICAL$ in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to @GENE$ toxicity seen as mitochondrial complex I loss.
5072	CPRFalse	Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of @CHEMICAL$ using antisense oligonucleotides sensitizes them to @GENE$ toxicity seen as mitochondrial complex I loss.
5073	CPR:4	Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to @CHEMICAL$ toxicity seen as @GENE$ loss.
5074	CPRFalse	Ovariectomy downregulates @CHEMICAL$ and renders female mice vulnerable to @GENE$ toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.
5075	CPR:3	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to @CHEMICAL$ toxicity as evidenced by activation of AP1, loss of GSH and @GENE$ activity indicating the important role of glutaredoxin in neuroprotection.
5076	CPRFalse	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to @CHEMICAL$ toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of @GENE$ in neuroprotection.
5077	CPR:3	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to @CHEMICAL$ toxicity as evidenced by activation of @GENE$, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.
5078	CPRFalse	Ovariectomy downregulates @CHEMICAL$ and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of @GENE$ and complex I activity indicating the important role of glutaredoxin in neuroprotection.
5079	CPRFalse	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of @CHEMICAL$ and @GENE$ activity indicating the important role of glutaredoxin in neuroprotection.
5080	CPRFalse	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of @CHEMICAL$ and complex I activity indicating the important role of @GENE$ in neuroprotection.
5081	CPRFalse	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of @CHEMICAL$, loss of @GENE$ and complex I activity indicating the important role of glutaredoxin in neuroprotection.
5082	CPR:3	@CHEMICAL$ protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of @GENE$ in the CNS.
5083	CPRFalse	The @CHEMICAL$ of Vav1 associates with calmodulin and is prerequisite to T cell antigen receptor-induced @GENE$ release in Jurkat T lymphocytes.
5084	CPRFalse	The calponin homology domain of Vav1 associates with calmodulin and is prerequisite to @CHEMICAL$-induced @GENE$ release in Jurkat T lymphocytes.
5085	CPRFalse	The calponin homology domain of @CHEMICAL$ associates with calmodulin and is prerequisite to T cell antigen receptor-induced @GENE$ release in Jurkat T lymphocytes.
5086	CPRFalse	The calponin homology domain of Vav1 associates with @CHEMICAL$ and is prerequisite to T cell antigen receptor-induced @GENE$ release in Jurkat T lymphocytes.
5087	CPRFalse	Vav1 is a @CHEM-GENE$ that is expressed specifically in hematopoietic cells and plays important roles in T cell development and activation.
5088	CPRFalse	@CHEMICAL$ is a @GENE$ exchange factor that is expressed specifically in hematopoietic cells and plays important roles in T cell development and activation.
5089	CPRFalse	Vav1 consists of multiple structural domains so as to facilitate both its @CHEMICAL$ exchange activity and scaffold function following @GENE$ (TCR) engagement.
5090	CPRFalse	Vav1 consists of multiple structural domains so as to facilitate both its @CHEMICAL$ exchange activity and scaffold function following T cell antigen receptor (@GENE$) engagement.
5091	CPRFalse	@CHEMICAL$ consists of multiple structural domains so as to facilitate both its @GENE$ exchange activity and scaffold function following T cell antigen receptor (TCR) engagement.
5092	CPRFalse	Previous studies demonstrated that the @CHEMICAL$ of Vav1 is required for TCR-stimulated @GENE$ mobilization and thus downstream activation of nuclear factor of activated T cells.
5093	CPRFalse	Previous studies demonstrated that the calponin homology (CH) domain of Vav1 is required for TCR-stimulated @CHEMICAL$ mobilization and thus downstream activation of @GENE$.
5094	CPRFalse	Previous studies demonstrated that the calponin homology (CH) domain of @CHEMICAL$ is required for TCR-stimulated @GENE$ mobilization and thus downstream activation of nuclear factor of activated T cells.
5095	CPRFalse	Previous studies demonstrated that the calponin homology (CH) domain of Vav1 is required for @CHEMICAL$-stimulated @GENE$ mobilization and thus downstream activation of nuclear factor of activated T cells.
5096	CPRFalse	However, it remained obscure how @CHEMICAL$ functions in regulating @GENE$ flux.
5097	CPRFalse	In an effort to explore molecules interacting with Vav1, we found that calmodulin bound to Vav1 in a @CHEMICAL$-dependent and @GENE$ activation-independent manner.
5098	CPRFalse	In an effort to explore molecules interacting with @CHEMICAL$, we found that calmodulin bound to Vav1 in a @GENE$-dependent and TCR activation-independent manner.
5099	CPRFalse	In an effort to explore molecules interacting with Vav1, we found that @CHEMICAL$ bound to Vav1 in a @GENE$-dependent and TCR activation-independent manner.
5100	CPRFalse	In an effort to explore molecules interacting with Vav1, we found that calmodulin bound to @CHEMICAL$ in a @GENE$-dependent and TCR activation-independent manner.
5101	CPRFalse	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with @CHEMICAL$-deleted Vav1 exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.
5102	CPRFalse	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in @CHEMICAL$ release to the same extent as that of Jurkat cells treated with the @GENE$ inhibitor or J.Vav1 cells.
5103	CPRFalse	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in @CHEMICAL$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.@GENE$ cells.
5104	CPRFalse	Reconstitution of @CHEMICAL$-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.
5105	CPRFalse	Reconstitution of vav1-null Jurkat T cells (J.@CHEMICAL$) with CH-deleted Vav1 exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.
5106	CPRFalse	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted @CHEMICAL$ exhibited a severe deficiency in @GENE$ release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.
5107	CPRFalse	The defect persisted even when phospholipase-Cgamma1 was fully activated, indicating a prerequisite role of @CHEMICAL$ in @GENE$ signaling.
5108	CPRFalse	The defect persisted even when @CHEMICAL$ was fully activated, indicating a prerequisite role of Vav1 CH domain in @GENE$ signaling.
5109	CPRFalse	The results suggest that Vav1 and calmodulin function cooperatively to potentiate @CHEMICAL$-induced @GENE$ release.
5110	CPRFalse	The results suggest that @CHEMICAL$ and calmodulin function cooperatively to potentiate TCR-induced @GENE$ release.
5111	CPRFalse	The results suggest that Vav1 and @CHEMICAL$ function cooperatively to potentiate TCR-induced @GENE$ release.
5112	CPRFalse	This study unveiled a mechanism by which the @CHEMICAL$ is involved in @GENE$ signaling and provides insight into our understanding of the role of Vav1 in T cell activation.
5113	CPRFalse	This study unveiled a mechanism by which the Vav1 CH domain is involved in @CHEMICAL$ signaling and provides insight into our understanding of the role of @GENE$ in T cell activation.
5114	CPR:9	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, @CHEMICAL$ and GABA, share the same @GENE$ (VIAAT) and are both present in neurons during postnatal development.
5115	CPR:9	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, @CHEMICAL$ and GABA, share the same vesicular inhibitory amino acid transporter (@GENE$) and are both present in neurons during postnatal development.
5116	CPR:9	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and @CHEMICAL$, share the same @GENE$ (VIAAT) and are both present in neurons during postnatal development.
5117	CPR:9	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and @CHEMICAL$, share the same vesicular inhibitory amino acid transporter (@GENE$) and are both present in neurons during postnatal development.
5118	CPRFalse	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same @CHEM-GENE$ (VIAAT) and are both present in neurons during postnatal development.
5119	CPRFalse	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory @CHEMICAL$ transporter (@GENE$) and are both present in neurons during postnatal development.
5120	CPR:9	We have expressed VIAAT and the @CHEMICAL$ for glycine and @GENE$ in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.
5121	CPR:9	We have expressed @CHEMICAL$ and the plasmalemmal transporters for glycine and @GENE$ in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.
5122	CPRFalse	We have expressed VIAAT and the @CHEMICAL$ for glycine and GABA in a neuroendocrine cell line and measured the quantal release of @GENE$ and GABA using a novel double-sniffer patch-clamp technique.
5123	CPRFalse	We have expressed @CHEMICAL$ and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of @GENE$ and GABA using a novel double-sniffer patch-clamp technique.
5124	CPRFalse	We have expressed VIAAT and the @CHEMICAL$ for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and @GENE$ using a novel double-sniffer patch-clamp technique.
5125	CPRFalse	We have expressed @CHEMICAL$ and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and @GENE$ using a novel double-sniffer patch-clamp technique.
5126	CPR:9	We have expressed VIAAT and the @CHEMICAL$ for @GENE$ and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.
5127	CPR:9	We have expressed @CHEMICAL$ and the plasmalemmal transporters for @GENE$ and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.
5128	CPRFalse	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the @GENE$ GlyT2 or the glial transporter GlyT1.
5129	CPRFalse	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the @GENE$ GlyT1.
5130	CPR:9	We found that @CHEMICAL$ is released from vesicles when @GENE$ is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.
5131	CPRFalse	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the neuronal transporter @GENE$ or the glial transporter GlyT1.
5132	CPRFalse	We found that @CHEMICAL$ is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the glial transporter @GENE$.
5133	CPRFalse	However, @CHEMICAL$ was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @GENE$ concentration required for efficient vesicular loading by VIAAT.
5134	CPRFalse	However, GlyT2 was more effective than @CHEMICAL$, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @GENE$ concentration required for efficient vesicular loading by VIAAT.
5135	CPRFalse	However, GlyT2 was more effective than GlyT1, probably because @CHEMICAL$ is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @GENE$ concentration required for efficient vesicular loading by VIAAT.
5136	CPR:9	However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic @CHEMICAL$ concentration required for efficient vesicular loading by @GENE$.
5137	CPR:9	The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when @CHEMICAL$ is introduced into the secretory cell and competes for uptake by @GENE$.
5138	CPRFalse	Interestingly, the @CHEMICAL$ ortholog from Caenorhabditis elegans (UNC-47), a species lacking @GENE$ transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.
5139	CPRFalse	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking @CHEMICAL$ transmission, also supports glycine exocytosis in the presence of @GENE$, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.
5140	CPRFalse	Interestingly, the @CHEMICAL$ ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports @GENE$ exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.
5141	CPR:9	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports @CHEMICAL$ exocytosis in the presence of @GENE$, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.
5142	CPRFalse	Interestingly, the @CHEMICAL$ ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes @GENE$ transmission in the worm confers glycine specificity.
5143	CPRFalse	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of @CHEMICAL$, and a point mutation of UNC-47 that abolishes @GENE$ transmission in the worm confers glycine specificity.
5144	CPR:9	Together, these results suggest that an increased cytosolic availability of @CHEMICAL$ in @GENE$-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.
5145	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (@GENE$), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5146	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), @GENE$ (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5147	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (@GENE$), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5148	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5149	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).
5150	CPRFalse	The following AOD was examined: @CHEM-GENE$ (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5151	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (SOD), @GENE$ (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5152	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (@GENE$), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5153	CPRFalse	The following AOD was examined: @CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).
5154	CPRFalse	The following AOD was examined: superoxide dismutase (@CHEMICAL$), catalase (CAT), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5155	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEM-GENE$ (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5156	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (@GENE$), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5157	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5158	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).
5159	CPRFalse	The following AOD was examined: @CHEMICAL$ (SOD), catalase (CAT), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5160	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), @CHEMICAL$ (CAT), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5161	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (@CHEMICAL$), @GENE$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5162	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).
5163	CPRFalse	The following AOD was examined: superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5164	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5165	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5166	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), @CHEMICAL$, and vitamin A. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5167	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), @CHEMICAL$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).
5168	CPRFalse	The following AOD was examined: @CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5169	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5170	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GPX), @GENE$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5171	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), @CHEMICAL$, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).
5172	CPRFalse	The following AOD was examined: superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5173	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5174	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5175	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @CHEMICAL$. Inactive persons with ID had significantly lower @GENE$ (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5176	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @CHEMICAL$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and @GENE$ (p<0.05).
5177	CPRFalse	The following AOD was examined: @CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5178	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5179	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GPX), vitamin E, and @GENE$. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).
5180	CPRFalse	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and @CHEMICAL$. Inactive persons with ID had significantly lower SOD (p<0.05), @GENE$ (p<0.05), and GPX (p<0.05).
5181	CPR:3	@CHEMICAL$/Cl- dipole couples agonist binding to @GENE$ activation.
5182	CPRFalse	Na+/Cl- dipole couples agonist binding to @CHEM-GENE$ activation.
5183	CPR:3	Na+/@CHEMICAL$ dipole couples agonist binding to @GENE$ activation.
5184	CPRFalse	@CHEM-GENE$ (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.
5185	CPRFalse	@CHEMICAL$-selective ionotropic glutamate receptors (@GENE$) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.
5186	CPR:3	@CHEMICAL$ (GluRs) require external Na+ and Cl- as well as the neurotransmitter @GENE$ for activation.
5187	CPR:3	Kainate-selective ionotropic glutamate receptors (@CHEMICAL$) require external Na+ and Cl- as well as the neurotransmitter @GENE$ for activation.
5188	CPRFalse	@CHEM-GENE$ (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.
5189	CPRFalse	Kainate-selective ionotropic @CHEMICAL$ receptors (@GENE$) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.
5190	CPR:3	@CHEMICAL$ (GluRs) require external @GENE$ and Cl- as well as the neurotransmitter L-glutamate for activation.
5191	CPR:3	Kainate-selective ionotropic glutamate receptors (@CHEMICAL$) require external @GENE$ and Cl- as well as the neurotransmitter L-glutamate for activation.
5192	CPR:3	@CHEMICAL$ (GluRs) require external Na+ and @GENE$ as well as the neurotransmitter L-glutamate for activation.
5193	CPR:3	Kainate-selective ionotropic glutamate receptors (@CHEMICAL$) require external Na+ and @GENE$ as well as the neurotransmitter L-glutamate for activation.
5194	CPRFalse	Although, external anions and cations apparently coactivate @CHEM-GENE$ (KARs) in an identical manner, it has yet to be established how ions of opposite charge achieve this.
5195	CPRFalse	Although, external anions and cations apparently coactivate @CHEMICAL$ receptors (@GENE$) in an identical manner, it has yet to be established how ions of opposite charge achieve this.
5196	CPRFalse	Consequently, other cation species may compete with @CHEMICAL$ to regulate the time @GENE$ remain in the open state.
5197	CPRFalse	Additionally, @CHEMICAL$ and Cl- ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on @GENE$.
5198	CPR:3	Additionally, @CHEMICAL$ and Cl- ions coactivate @GENE$ receptors by establishing a dipole, accounting for their common effect on KARs.
5199	CPRFalse	Additionally, Na+ and @CHEMICAL$ ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on @GENE$.
5200	CPR:3	Additionally, Na+ and @CHEMICAL$ ions coactivate @GENE$ receptors by establishing a dipole, accounting for their common effect on KARs.
5201	CPRFalse	@CHEMICAL$ receptor gene @GENE$ modulates early event-related potentials in auditory and visual oddball target detection tasks.
5202	CPRFalse	The same sense @CHEMICAL$-to-cytosine polymorphism (c.@GENE$; Ser543Ser) was shown to preferentially modulate early components in both modalities.
5203	CPRFalse	The same sense @CHEMICAL$-to-cytosine polymorphism (c.1629T-C; @GENE$) was shown to preferentially modulate early components in both modalities.
5204	CPRFalse	The same sense thymine-to-@CHEMICAL$ polymorphism (c.@GENE$; Ser543Ser) was shown to preferentially modulate early components in both modalities.
5205	CPRFalse	The same sense thymine-to-@CHEMICAL$ polymorphism (c.1629T-C; @GENE$) was shown to preferentially modulate early components in both modalities.
5206	CPR:4	@CHEMICAL$, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (@GENE$) and was shown to improve cognition in various experimental paradigms in rodents and dogs.
5207	CPR:4	@CHEMICAL$, a derivative of physostigmine, was first described as an inhibitor of @GENE$ (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.
5208	CPR:4	Phenserine, a derivative of @CHEMICAL$, was first described as an inhibitor of acetylcholinesterase (@GENE$) and was shown to improve cognition in various experimental paradigms in rodents and dogs.
5209	CPR:4	Phenserine, a derivative of @CHEMICAL$, was first described as an inhibitor of @GENE$ (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.
5210	CPR:4	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting @GENE$, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation.
5211	CPRFalse	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of @GENE$ (APP) in neuronal cell culture by reducing APP translation.
5212	CPRFalse	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (@GENE$) in neuronal cell culture by reducing APP translation.
5213	CPR:4	@CHEMICAL$ deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing @GENE$ translation.
5214	CPRFalse	This effect probably involves interaction of @CHEMICAL$ with a regulatory element in the 5'-untranslated region of the @GENE$ gene that controls APP expression.
5215	CPRFalse	This effect probably involves interaction of @CHEMICAL$ with a regulatory element in the 5'-untranslated region of the APP gene that controls @GENE$ expression.
5216	CPR:4	@CHEMICAL$ apparently reduces translational efficiency of @GENE$ mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.
5217	CPRFalse	Phenserine apparently reduces translational efficiency of @CHEMICAL$ mRNA into protein, a process that may involve an interaction with @GENE$ and/or an iron-responsive element.
5218	CPRFalse	Phenserine apparently reduces translational efficiency of @CHEMICAL$ mRNA into protein, a process that may involve an interaction with iron and/or an @GENE$-responsive element.
5219	CPR:4	As a consequence, @CHEMICAL$ reduces @GENE$ peptide (Abeta) formation in vitro and in vivo.
5220	CPR:4	As a consequence, @CHEMICAL$ reduces beta-amyloid peptide (@GENE$) formation in vitro and in vivo.
5221	CPRFalse	@CHEMICAL$ is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of @GENE$, whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.
5222	CPRFalse	@CHEMICAL$ is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('posiphen') has weak activity as an @GENE$ inhibitor and can be dosed much higher.
5223	CPR:4	Phenserine is also unique because of differing actions of its enantiomers: @CHEMICAL$ is the active enantiomer for inhibition of @GENE$, whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.
5224	CPRFalse	Phenserine is also unique because of differing actions of its enantiomers: @CHEMICAL$ is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('posiphen') has weak activity as an @GENE$ inhibitor and can be dosed much higher.
5225	CPRFalse	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of @CHEMICAL$, whereas @GENE$ ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.
5226	CPR:4	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas @CHEMICAL$ ('posiphen') has weak activity as an @GENE$ inhibitor and can be dosed much higher.
5227	CPRFalse	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of @CHEMICAL$, whereas (+)-phenserine ('@GENE$') has weak activity as an AChE inhibitor and can be dosed much higher.
5228	CPR:4	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('@CHEMICAL$') has weak activity as an @GENE$ inhibitor and can be dosed much higher.
5229	CPRFalse	Both enantiomers are equipotent in downregulating @CHEMICAL$ expression. @GENE$ may be a promising drug, either alone or in combination with (-)-phenserine, to attenuate the progression of Alzheimer's disease.
5230	CPRFalse	Both enantiomers are equipotent in downregulating @CHEMICAL$ expression. (+)-Posiphen may be a promising drug, either alone or in combination with @GENE$, to attenuate the progression of Alzheimer's disease.
5231	CPRFalse	Contractile tension of the vas deferens in response to @CHEMICAL$ was markedly decreased in alpha(1A)-adrenoceptor KO mice, and this contraction was completely abolished in @GENE$ triple-KO mice.
5232	CPRFalse	Contractile tension of the vas deferens in response to @CHEMICAL$ was markedly decreased in @GENE$ KO mice, and this contraction was completely abolished in alpha(1)-adrenoceptor triple-KO mice.
5233	CPRFalse	Pharmacological activators of @CHEM-GENE$ have different effects on Na+ transport processes across human lung epithelial cells.
5234	CPRFalse	Pharmacological activators of @CHEMICAL$ have different effects on @GENE$ transport processes across human lung epithelial cells.
5235	CPR:3	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (@GENE$).
5236	CPR:3	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (@GENE$).
5237	CPRFalse	BACKGROUND AND PURPOSE: @CHEM-GENE$ (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5238	CPRFalse	BACKGROUND AND PURPOSE: @CHEMICAL$-activated protein kinase (@GENE$) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5239	CPRFalse	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, phenformin, and the @GENE$ mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5240	CPRFalse	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, phenformin, and the @GENE$ mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5241	CPR:3	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by @GENE$, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5242	CPR:3	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by @GENE$, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5243	CPR:3	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, @GENE$, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5244	CPR:3	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, @GENE$, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
5245	CPR:3	BACKGROUND AND PURPOSE: @CHEMICAL$ (AMPK) is activated by metformin, phenformin, and the AMP mimetic, @GENE$ (AICAR).
5246	CPR:3	BACKGROUND AND PURPOSE: AMP-activated protein kinase (@CHEMICAL$) is activated by metformin, phenformin, and the AMP mimetic, @GENE$ (AICAR).
5247	CPRFalse	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, @GENE$ concentration, transepithelial amiloride-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.
5248	CPRFalse	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial @GENE$-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.
5249	CPRFalse	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(@GENE$)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.
5250	CPRFalse	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and @GENE$-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.
5251	CPRFalse	We have completed an extensive study of the pharmacological effects of these drugs on @CHEMICAL$ activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(@GENE$)) short circuit current in H441 lung epithelial cells.
5252	CPRFalse	@CHEMICAL$ activity was measured as the amount of radiolabelled @GENE$ transferred to the SAMS peptide.
5253	CPR:3	KEY RESULTS: @CHEMICAL$, AICAR and metformin increased @GENE$ activity and decreased I(amiloride).
5254	CPR:3	KEY RESULTS: Phenformin, @CHEMICAL$ and metformin increased @GENE$ activity and decreased I(amiloride).
5255	CPR:3	KEY RESULTS: Phenformin, AICAR and @CHEMICAL$ increased @GENE$ activity and decreased I(amiloride).
5256	CPRFalse	KEY RESULTS: Phenformin, AICAR and metformin increased @CHEMICAL$ activity and decreased I(@GENE$).
5257	CPRFalse	The @CHEMICAL$ inhibitor Compound C prevented the action of @GENE$ and AICAR but not phenformin.
5258	CPRFalse	The @CHEMICAL$ inhibitor Compound C prevented the action of metformin and @GENE$ but not phenformin.
5259	CPR:3	The @CHEMICAL$ inhibitor Compound C prevented the action of metformin and AICAR but not @GENE$.
5260	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEM-GENE$ (ENaC), which has important implications for the clinical use of metformin.
5261	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEMICAL$-sensitive Na(+) channels (@GENE$), which has important implications for the clinical use of metformin.
5262	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of @CHEMICAL$ is associated with inhibition of apical @GENE$-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of metformin.
5263	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEM-GENE$ (ENaC), which has important implications for the clinical use of metformin.
5264	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive @CHEMICAL$ channels (@GENE$), which has important implications for the clinical use of metformin.
5265	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of @CHEMICAL$ is associated with inhibition of apical amiloride-sensitive @GENE$ channels (ENaC), which has important implications for the clinical use of metformin.
5266	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical @CHEMICAL$ (ENaC), which has important implications for the clinical use of @GENE$.
5267	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive Na(+) channels (@CHEMICAL$), which has important implications for the clinical use of @GENE$.
5268	CPRFalse	CONCLUSIONS AND IMPLICATIONS: Activation of @CHEMICAL$ is associated with inhibition of apical amiloride-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of @GENE$.
5269	CPRFalse	Additional pharmacological effects evoked by @CHEMICAL$ and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.
5270	CPRFalse	Additional pharmacological effects evoked by @CHEMICAL$ and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.
5271	CPR:3	Additional pharmacological effects evoked by @CHEMICAL$ and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.
5272	CPRFalse	Additional pharmacological effects evoked by AICAR and @CHEMICAL$ on I(ouabain), with potential secondary effects on apical Na+ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.
5273	CPRFalse	Additional pharmacological effects evoked by AICAR and @CHEMICAL$ on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.
5274	CPR:3	Additional pharmacological effects evoked by AICAR and @CHEMICAL$ on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.
5275	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(@CHEMICAL$), with potential secondary effects on apical Na+ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.
5276	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(@CHEMICAL$), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.
5277	CPR:3	Additional pharmacological effects evoked by AICAR and phenformin on I(@CHEMICAL$), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.
5278	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical @CHEMICAL$ conductance, @GENE$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.
5279	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical @CHEMICAL$ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$ is an important component.
5280	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical @CHEMICAL$ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @GENE$ in cell systems where Na+K+ATPase is an important component.
5281	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, @CHEMICAL$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @GENE$+K+ATPase is an important component.
5282	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @CHEM-GENE$ is an important component.
5283	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @CHEMICAL$ in cell systems where @GENE$+K+ATPase is an important component.
5284	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, @CHEMICAL$ activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+@GENE$+ATPase is an important component.
5285	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where @CHEM-GENE$ is an important component.
5286	CPRFalse	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of @CHEMICAL$ in cell systems where Na+@GENE$+ATPase is an important component.
5287	CPR:4	Neuroprotective effect of @CHEMICAL$, a preferential @GENE$ inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.
5288	CPRFalse	Neuroprotective effect of nimesulide, a preferential @CHEMICAL$ inhibitor, against @GENE$ (PTZ)-induced chemical kindling and associated biochemical parameters in mice.
5289	CPRFalse	Neuroprotective effect of nimesulide, a preferential @CHEMICAL$ inhibitor, against pentylenetetrazol (@GENE$)-induced chemical kindling and associated biochemical parameters in mice.
5290	CPR:9	Brain cyclooxygenases (@CHEMICAL$), the rate-limiting enzyme in @GENE$ synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.
5291	CPR:9	Brain @CHEMICAL$ (COX), the rate-limiting enzyme in @GENE$ synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.
5292	CPRFalse	Previous studies have explored the protective effect of naproxen (non-selective @CHEMICAL$-inhibitor) or @GENE$ (selective COX-2 inhibitor) against chemical kindling in mice.
5293	CPR:4	Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or @CHEMICAL$ (selective @GENE$ inhibitor) against chemical kindling in mice.
5294	CPR:4	Previous studies have explored the protective effect of @CHEMICAL$ (non-selective @GENE$-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice.
5295	CPRFalse	Previous studies have explored the protective effect of @CHEMICAL$ (non-selective COX-inhibitor) or rofecoxib (selective @GENE$ inhibitor) against chemical kindling in mice.
5296	CPR:4	With this background, the present study was designed to explore the possible effect of @CHEMICAL$ (a preferential @GENE$ inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.
5297	CPRFalse	With this background, the present study was designed to explore the possible effect of nimesulide (a preferential @CHEMICAL$ inhibitor) against @GENE$ (PTZ)-induced kindling epilepsy in mice.
5298	CPRFalse	With this background, the present study was designed to explore the possible effect of nimesulide (a preferential @CHEMICAL$ inhibitor) against pentylenetetrazol (@GENE$)-induced kindling epilepsy in mice.
5299	CPR:3	Compared with normal control group, @CHEMICAL$-kindled mice had significantly higher levels of malondialdehyde, nitrite, @GENE$ but had lower levels of reduced glutathione in the whole brain homogenate.
5300	CPRFalse	Compared with normal control group, PTZ-kindled mice had significantly higher levels of @CHEMICAL$, nitrite, @GENE$ but had lower levels of reduced glutathione in the whole brain homogenate.
5301	CPRFalse	Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, @CHEMICAL$, @GENE$ but had lower levels of reduced glutathione in the whole brain homogenate.
5302	CPRFalse	Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, nitrite, @CHEMICAL$ but had lower levels of reduced @GENE$ in the whole brain homogenate.
5303	CPR:4	These results suggested that @CHEMICAL$, a preferential @GENE$ inhibitor offered neuroprotection against PTZ-induced kindling in mice.
5304	CPRFalse	These results suggested that nimesulide, a preferential @CHEMICAL$ inhibitor offered neuroprotection against @GENE$-induced kindling in mice.
5305	CPRFalse	@CHEM-GENE$ polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study.
5306	CPRFalse	@CHEM-GENE$ polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study.
5307	CPRFalse	@CHEMICAL$, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @GENE$ (GSTs) before urinary excretion.
5308	CPRFalse	@CHEMICAL$, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione S-transferases (@GENE$) before urinary excretion.
5309	CPRFalse	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to @CHEMICAL$ by @GENE$ (GSTs) before urinary excretion.
5310	CPRFalse	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to @CHEMICAL$ by glutathione S-transferases (@GENE$) before urinary excretion.
5311	CPRFalse	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @CHEM-GENE$ (GSTs) before urinary excretion.
5312	CPRFalse	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @CHEMICAL$ S-transferases (@GENE$) before urinary excretion.
5313	CPRFalse	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by @CHEM-GENE$ (GSTs) before urinary excretion.
5314	CPRFalse	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione @CHEMICAL$-transferases (@GENE$) before urinary excretion.
5315	CPRFalse	Regulated function of the @CHEM-GENE$.
5316	CPRFalse	Regulated function of the @CHEM-GENE$.
5317	CPRFalse	Cellular oxygen is sensed by @CHEM-GENE$ that hydroxylate hypoxia-inducible factor (HIF) alpha subunits.
5318	CPRFalse	Cellular oxygen is sensed by @CHEMICAL$-4-hydroxylase domain (PHD) proteins that hydroxylate @GENE$ subunits.
5319	CPRFalse	Cellular oxygen is sensed by @CHEMICAL$ that @GENE$ hypoxia-inducible factor (HIF) alpha subunits.
5320	CPRFalse	Cellular oxygen is sensed by prolyl-4-hydroxylase domain (PHD) proteins that @CHEMICAL$ @GENE$ subunits.
5321	CPRFalse	Cellular @CHEMICAL$ is sensed by @GENE$ that hydroxylate hypoxia-inducible factor (HIF) alpha subunits.
5322	CPRFalse	Cellular @CHEMICAL$ is sensed by prolyl-4-hydroxylase domain (PHD) proteins that hydroxylate @GENE$ subunits.
5323	CPRFalse	Thus, the @CHEMICAL$ @GENE$ sensors themselves represent effectors of cellular signalling pathways as well as potential drug targets.
5324	CPRFalse	Here, a cell-free in vitro microtiter plate-based peptide hydroxylation assay was used to investigate the influence of @CHEMICAL$, Krebs cycle intermediates, transition metals, and vitamin C and other antioxidants on the activity of purified @GENE$.
5325	CPRFalse	Here, a cell-free in vitro microtiter plate-based peptide hydroxylation assay was used to investigate the influence of ferrous iron, Krebs cycle intermediates, transition metals, and @CHEMICAL$ and other antioxidants on the activity of purified @GENE$.
5326	CPRFalse	@CHEMICAL$ activity depends not only on @GENE$ availability but is also regulated by iron, vitamin C, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.
5327	CPRFalse	@CHEMICAL$ activity depends not only on oxygen availability but is also regulated by @GENE$, vitamin C, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.
5328	CPRFalse	@CHEMICAL$ activity depends not only on oxygen availability but is also regulated by iron, @GENE$, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.
5329	CPRFalse	While vitamin C is essential for @CHEMICAL$ activity in vitro, N-acetyl-L-cysteine had no effect, and @GENE$ or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.
5330	CPR:4	While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and @CHEMICAL$ or n-propyl gallate efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.
5331	CPRFalse	While vitamin C is essential for @CHEMICAL$ activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or @GENE$ efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.
5332	CPR:4	While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or @CHEMICAL$ efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.
5333	CPRFalse	While @CHEMICAL$ is essential for @GENE$ activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.
5334	CPRFalse	While @CHEMICAL$ is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.
5335	CPRFalse	While vitamin C is essential for @CHEMICAL$ activity in vitro, @GENE$ had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.
5336	CPRFalse	While vitamin C is essential for PHD activity in vitro, @CHEMICAL$ had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three @GENE$, demonstrating different functions of these antioxidants.
5337	CPRFalse	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @CHEM-GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5338	CPRFalse	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @CHEMICAL$ synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5339	CPR:9	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @CHEMICAL$ (LTC4S), the pivotal enzyme for the biosynthesis of @GENE$ (ref.
5340	CPR:9	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@CHEMICAL$), the pivotal enzyme for the biosynthesis of @GENE$ (ref.
5341	CPRFalse	The cysteinyl leukotrienes, namely @CHEMICAL$ and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5342	CPRFalse	The cysteinyl leukotrienes, namely @CHEMICAL$ and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5343	CPRFalse	The @CHEMICAL$, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5344	CPRFalse	The @CHEMICAL$, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5345	CPRFalse	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites @CHEMICAL$ and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5346	CPRFalse	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites @CHEMICAL$ and LTE4, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5347	CPRFalse	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and @CHEMICAL$, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. @GENE$ (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5348	CPRFalse	The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and @CHEMICAL$, the components of slow-reacting substance of anaphylaxis, are lipid mediators of smooth muscle constriction and inflammation, particularly implicated in bronchial asthma. LTC4 synthase (@GENE$), the pivotal enzyme for the biosynthesis of LTC4 (ref.
5349	CPR:9	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes 5-lipoxygenase-activating protein, @GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5350	CPR:9	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.
5351	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes @GENE$, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5352	CPR:9	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in @CHEMICAL$ and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and @GENE$ (ref.
5353	CPR:9	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes 5-lipoxygenase-activating protein, @GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5354	CPR:9	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.
5355	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes @GENE$, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5356	CPR:9	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and @CHEMICAL$ metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and @GENE$ (ref.
5357	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, @CHEM-GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5358	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal @CHEMICAL$ S-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.
5359	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes @CHEMICAL$, microsomal @GENE$ S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5360	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal @CHEMICAL$ S-transferases (MGSTs), and @GENE$ (ref.
5361	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, @CHEM-GENE$ (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5362	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione @CHEMICAL$-transferases (@GENE$), and microsomal prostaglandin E synthase 1 (ref.
5363	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes @CHEMICAL$, microsomal glutathione @GENE$-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.
5364	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione @CHEMICAL$-transferases (MGSTs), and @GENE$ (ref.
5365	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, @CHEMICAL$ (MGSTs), and microsomal @GENE$ synthase 1 (ref.
5366	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (@CHEMICAL$), and microsomal @GENE$ synthase 1 (ref.
5367	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes @CHEMICAL$, microsomal glutathione S-transferases (MGSTs), and microsomal @GENE$ synthase 1 (ref.
5368	CPRFalse	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and @CHEM-GENE$ (ref.
5369	CPRFalse	@CHEMICAL$ conjugates @GENE$ to LTA4, the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway.
5370	CPRFalse	LTC4S conjugates @CHEMICAL$ to LTA4, the endogenous substrate derived from arachidonic acid through the @GENE$ pathway.
5371	CPRFalse	@CHEMICAL$ conjugates glutathione to @GENE$, the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway.
5372	CPRFalse	LTC4S conjugates glutathione to @CHEMICAL$, the endogenous substrate derived from arachidonic acid through the @GENE$ pathway.
5373	CPRFalse	@CHEMICAL$ conjugates glutathione to LTA4, the endogenous substrate derived from @GENE$ through the 5-lipoxygenase pathway.
5374	CPRFalse	LTC4S conjugates glutathione to LTA4, the endogenous substrate derived from @CHEMICAL$ through the @GENE$ pathway.
5375	CPRFalse	In contrast with @CHEMICAL$ and MGST3 (refs 15, 16), LTC4S does not conjugate @GENE$ to xenobiotics.
5376	CPRFalse	In contrast with MGST2 and @CHEMICAL$ (refs 15, 16), LTC4S does not conjugate @GENE$ to xenobiotics.
5377	CPRFalse	In contrast with MGST2 and MGST3 (refs 15, 16), @CHEMICAL$ does not conjugate @GENE$ to xenobiotics.
5378	CPRFalse	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for @CHEMICAL$ and LTA4 that distinguishes LTC4S from other @GENE$.
5379	CPRFalse	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for @CHEMICAL$ and LTA4 that distinguishes @GENE$ from other MGSTs.
5380	CPRFalse	Here we show the atomic structure of @CHEMICAL$ in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for @GENE$ and LTA4 that distinguishes LTC4S from other MGSTs.
5381	CPRFalse	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and @CHEMICAL$ that distinguishes LTC4S from other @GENE$.
5382	CPRFalse	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and @CHEMICAL$ that distinguishes @GENE$ from other MGSTs.
5383	CPRFalse	Here we show the atomic structure of @CHEMICAL$ in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and @GENE$ that distinguishes LTC4S from other MGSTs.
5384	CPRFalse	Here we show the atomic structure of human LTC4S in a complex with @CHEMICAL$ at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA4 that distinguishes LTC4S from other @GENE$.
5385	CPRFalse	Here we show the atomic structure of human LTC4S in a complex with @CHEMICAL$ at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA4 that distinguishes @GENE$ from other MGSTs.
5386	CPRFalse	Here we show the atomic structure of @CHEMICAL$ in a complex with @GENE$ at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA4 that distinguishes LTC4S from other MGSTs.
5387	CPRFalse	These findings provide a structural basis for the development of LTC4S inhibitors for a proinflammatory pathway mediated by three @CHEMICAL$ ligands whose stability and potency are different and by multiple @GENE$ whose functions may be non-redundant.
5388	CPRFalse	These findings provide a structural basis for the development of @CHEMICAL$ inhibitors for a proinflammatory pathway mediated by three @GENE$ ligands whose stability and potency are different and by multiple cysteinyl leukotriene receptors whose functions may be non-redundant.
5389	CPRFalse	These findings provide a structural basis for the development of LTC4S inhibitors for a proinflammatory pathway mediated by three cysteinyl leukotriene ligands whose stability and potency are different and by multiple @CHEM-GENE$ whose functions may be non-redundant.
5390	CPRFalse	These findings provide a structural basis for the development of @CHEMICAL$ inhibitors for a proinflammatory pathway mediated by three cysteinyl leukotriene ligands whose stability and potency are different and by multiple @GENE$ receptors whose functions may be non-redundant.
5391	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any @GENE$ allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5392	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any @CHEMICAL$ allele, and @GENE$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5393	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any @CHEMICAL$ allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@GENE$ arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5394	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any @GENE$ allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5395	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any @GENE$ allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5396	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any @CHEMICAL$ allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@GENE$ arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5397	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A @GENE$/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5398	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A @GENE$/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5399	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ @GENE$/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5400	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/@GENE$ or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5401	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/@GENE$ or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5402	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ arginine/@GENE$ or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5403	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or @GENE$/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5404	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or @GENE$/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5405	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ arginine/arginine or @GENE$/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5406	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (@CHEMICAL$, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/@GENE$) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5407	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and @CHEMICAL$, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/@GENE$) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5408	CPRFalse	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (@CHEMICAL$ arginine/arginine or valine/@GENE$) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).
5409	CPR:4	@CHEMICAL$ causes an increase in brain ornithine that is prevented by prior @GENE$ inhibition.
5410	CPRFalse	Phenelzine causes an increase in brain ornithine that is prevented by prior @CHEM-GENE$ inhibition.
5411	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain @GENE$ levels.
5412	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@CHEMICAL$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain @GENE$ levels.
5413	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@CHEMICAL$), markedly increasing brain @GENE$ levels.
5414	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEMICAL$ (GABA-T), markedly increasing brain @GENE$ levels.
5415	CPR:4	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of @GENE$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.
5416	CPR:4	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@GENE$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.
5417	CPR:4	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@GENE$), markedly increasing brain GABA levels.
5418	CPR:4	@CHEMICAL$ (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @GENE$ (GABA-T), markedly increasing brain GABA levels.
5419	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEM-GENE$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.
5420	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (@GENE$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.
5421	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), also inhibits GABA-transaminase (@GENE$), markedly increasing brain GABA levels.
5422	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ oxidase (MAO), also inhibits @GENE$ (GABA-T), markedly increasing brain GABA levels.
5423	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ (MAO), also inhibits @GENE$-transaminase (GABA-T), markedly increasing brain GABA levels.
5424	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@CHEMICAL$), also inhibits @GENE$-transaminase (GABA-T), markedly increasing brain GABA levels.
5425	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEMICAL$-transaminase (@GENE$), markedly increasing brain GABA levels.
5426	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEM-GENE$ (GABA-T), markedly increasing brain GABA levels.
5427	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of @CHEMICAL$ (MAO), also inhibits GABA-transaminase (@GENE$-T), markedly increasing brain GABA levels.
5428	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (@CHEMICAL$), also inhibits GABA-transaminase (@GENE$-T), markedly increasing brain GABA levels.
5429	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@CHEM-GENE$), markedly increasing brain GABA levels.
5430	CPRFalse	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @CHEMICAL$ (@GENE$-T), markedly increasing brain GABA levels.
5431	CPR:4	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of @GENE$ (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.
5432	CPR:4	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of monoamine oxidase (@GENE$), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.
5433	CPR:4	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (@GENE$), markedly increasing brain GABA levels.
5434	CPR:4	Phenelzine (@CHEMICAL$), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits @GENE$ (GABA-T), markedly increasing brain GABA levels.
5435	CPR:9	@CHEMICAL$ is also a substrate for @GENE$, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.
5436	CPRFalse	PLZ is also a substrate for @CHEMICAL$, and studies suggest that a metabolite formed by the action of this enzyme on @GENE$ may be responsible for the increase in GABA observed.
5437	CPRFalse	PLZ is also a substrate for @CHEMICAL$, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in @GENE$ observed.
5438	CPRFalse	To determine whether a metabolite formed by the action of @CHEMICAL$ on @GENE$ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5439	CPRFalse	To determine whether a metabolite formed by the action of MAO on @CHEMICAL$ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @GENE$ inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5440	CPRFalse	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or @GENE$ (15 mg/kg), and brains collected 3 h later.
5441	CPRFalse	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @CHEMICAL$ inhibitor tranylcypromine (TCP) before vehicle or @GENE$ (15 mg/kg), and brains collected 3 h later.
5442	CPRFalse	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain @GENE$ observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5443	CPRFalse	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain @CHEMICAL$ observed, animals were pretreated with vehicle or the @GENE$ inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5444	CPRFalse	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor @GENE$ (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5445	CPR:4	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @CHEMICAL$ inhibitor @GENE$ (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5446	CPRFalse	To determine whether a metabolite formed by the action of @CHEMICAL$ on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (@GENE$) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5447	CPR:4	To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the @CHEMICAL$ inhibitor tranylcypromine (@GENE$) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.
5448	CPRFalse	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with @CHEMICAL$, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.
5449	CPR:9	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of @CHEMICAL$ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.
5450	CPRFalse	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @CHEMICAL$ is responsible for the elevation of brain @GENE$ observed.
5451	CPRFalse	@CHEMICAL$ levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.
5452	CPRFalse	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in @CHEMICAL$-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.
5453	CPRFalse	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with @CHEMICAL$ completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.
5454	CPRFalse	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the @CHEMICAL$-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.
5455	CPRFalse	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain @CHEMICAL$, suggesting, as with GABA, that a metabolite of PLZ formed by the action of @GENE$ is responsible for the elevation of brain ORN observed.
5456	CPRFalse	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @CHEM-GENE$ (eNOS).
5457	CPRFalse	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial @CHEMICAL$ synthase (@GENE$).
5458	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (@CHEMICAL$) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).
5459	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (@CHEMICAL$) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).
5460	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. @CHEMICAL$ (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).
5461	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. @CHEMICAL$ (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).
5462	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with @CHEMICAL$ from L-arginine in a reaction catalyzed by @GENE$ (eNOS).
5463	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with @CHEMICAL$ from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).
5464	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from @CHEMICAL$ in a reaction catalyzed by @GENE$ (eNOS).
5465	CPR:9	Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from @CHEMICAL$ in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).
5466	CPRFalse	Endothelial @CHEMICAL$ production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).
5467	CPRFalse	Endothelial @CHEMICAL$ production is tightly coupled to the citrulline-NO cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).
5468	CPRFalse	Endothelial nitric oxide production is tightly coupled to the @CHEMICAL$ cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by @GENE$ (eNOS).
5469	CPRFalse	Endothelial nitric oxide production is tightly coupled to the @CHEMICAL$ cycle. Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (@GENE$).
5470	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEM-GENE$ (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.
5471	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ synthase (@GENE$), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.
5472	CPR:4	As further support, @CHEMICAL$, an inhibitor of @GENE$ (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.
5473	CPR:4	As further support, @CHEMICAL$, an inhibitor of argininosuccinate synthase (@GENE$), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.
5474	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ (AS), a component of the @GENE$-NO cycle, inhibited NO production in a dose-dependent manner.
5475	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (@CHEMICAL$), a component of the @GENE$-NO cycle, inhibited NO production in a dose-dependent manner.
5476	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ (AS), a component of the citrulline-@GENE$ cycle, inhibited NO production in a dose-dependent manner.
5477	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (@CHEMICAL$), a component of the citrulline-@GENE$ cycle, inhibited NO production in a dose-dependent manner.
5478	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of @CHEMICAL$ (AS), a component of the citrulline-NO cycle, inhibited @GENE$ production in a dose-dependent manner.
5479	CPRFalse	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (@CHEMICAL$), a component of the citrulline-NO cycle, inhibited @GENE$ production in a dose-dependent manner.
5480	CPRFalse	It is more potent and selective than @CHEMICAL$ in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and @GENE$.
5481	CPRFalse	It is more potent and selective than @CHEMICAL$ in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @GENE$ and muscarinic receptors.
5482	CPRFalse	It is more potent and selective than citalopram in inhibiting @CHEMICAL$ re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and @GENE$.
5483	CPRFalse	It is more potent and selective than citalopram in inhibiting @CHEMICAL$ re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @GENE$ and muscarinic receptors.
5484	CPRFalse	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective @CHEMICAL$ re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and @GENE$.
5485	CPRFalse	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective @CHEMICAL$ re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @GENE$ and muscarinic receptors.
5486	CPRFalse	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than @CHEMICAL$ in binding to the histamine H1 and @GENE$.
5487	CPRFalse	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than @CHEMICAL$ in binding to the @GENE$ and muscarinic receptors.
5488	CPRFalse	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @CHEMICAL$ H1 and @GENE$.
5489	CPRFalse	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the @CHEM-GENE$ and muscarinic receptors.
5490	CPR:9	Caution is necessary only when it is coadministered with drugs metabolised by @CHEMICAL$, such as @GENE$, or administered to the elderly or patients with severe hepatic or renal impairment.
5491	CPR:6	Inhibition of platelet aggregation by AZD6140, a reversible oral @CHEMICAL$ receptor antagonist, compared with @GENE$ in patients with acute coronary syndromes.
5492	CPR:6	Inhibition of platelet aggregation by @CHEMICAL$, a reversible oral @GENE$ receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
5493	CPR:6	@CHEMICAL$ is a reversible oral @GENE$ receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).
5494	CPR:6	AZD6140 is a reversible oral @CHEMICAL$ receptor antagonist that has been studied in ACS patients in comparison with @GENE$ (DISPERSE-2 study).
5495	CPR:6	The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. @CHEMICAL$ (1) is a non-selective @GENE$ antagonist that is used clinically for the treatment of urinary incontinence.
5496	CPRFalse	The preparation and @CHEMICAL$ profiling of oxybutynin and N-desethyloxybutynin enantiomers. @GENE$ (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.
5497	CPRFalse	The preparation and human muscarinic receptor profiling of @CHEMICAL$ and N-desethyloxybutynin enantiomers. Oxybutynin (1) is a non-selective @GENE$ antagonist that is used clinically for the treatment of urinary incontinence.
5498	CPRFalse	The preparation and @CHEMICAL$ profiling of @GENE$ and N-desethyloxybutynin enantiomers. Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.
5499	CPRFalse	The preparation and human muscarinic receptor profiling of oxybutynin and @CHEMICAL$ enantiomers. Oxybutynin (1) is a non-selective @GENE$ antagonist that is used clinically for the treatment of urinary incontinence.
5500	CPRFalse	The preparation and @CHEMICAL$ profiling of oxybutynin and @GENE$ enantiomers. Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.
5501	CPRFalse	We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace @CHEMICAL$ ((3)H-NMS) binding on @GENE$.
5502	CPRFalse	We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT(3)-scopolamine chloride (@CHEMICAL$) binding on @GENE$.
5503	CPRFalse	Compounds 1 and 2 potently displaced @CHEMICAL$ binding at @GENE$, but were less potent at the m2 and m5 subtypes.
5504	CPRFalse	Compounds 1 and 2 potently displaced @CHEMICAL$ binding at m1, m3 and m4 receptors, but were less potent at the @GENE$ and m5 subtypes.
5505	CPRFalse	Compounds 1 and 2 potently displaced @CHEMICAL$ binding at m1, m3 and m4 receptors, but were less potent at the m2 and @GENE$ subtypes.
5506	CPR:5	Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by @CHEMICAL$, an @GENE$ agonist.
5507	CPR:3	Degradation of submandibular gland @CHEMICAL$ by parasympathetic denervation of chorda tympani and its recovery by @GENE$, an M3 muscarinic receptor agonist.
5508	CPR:5	Administration of @CHEMICAL$, an @GENE$ agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.
5509	CPR:3	Administration of @CHEMICAL$, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the @GENE$ protein level reduced by CTD and increased the AQP1 protein level above the control one.
5510	CPR:3	Administration of @CHEMICAL$, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the @GENE$ protein level above the control one.
5511	CPRFalse	Administration of cevimeline hydrochloride, an @CHEMICAL$ agonist (10 mg/kg for 7 days po), but not @GENE$ (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.
5512	CPRFalse	Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not @CHEMICAL$ (0.3 mg/kg for 7 days po), recovered the @GENE$ protein level reduced by CTD and increased the AQP1 protein level above the control one.
5513	CPRFalse	Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not @CHEMICAL$ (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the @GENE$ protein level above the control one.
5514	CPRFalse	The mRNA level of @CHEMICAL$ was scarcely affected by CTD and @GENE$ administration.
5515	CPR:3	Administration of @CHEMICAL$ (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the @GENE$ protein level reduced by CTD.
5516	CPRFalse	There are few prospective clinical trials of @CHEM-GENE$ inhibitors (or proliferation signal inhibitors) combined with CNI inhibitors in de novo pediatric renal transplantation.
5517	CPRFalse	threo-methylphenidate inhibits the @CHEM-GENE$ and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.
5518	CPRFalse	threo-methylphenidate inhibits the @CHEMICAL$ transporter and the @GENE$, resulting in elevations of these monoamines after impulse release.
5519	CPRFalse	threo-methylphenidate inhibits the @CHEMICAL$ and the @GENE$ transporter, resulting in elevations of these monoamines after impulse release.
5520	CPRFalse	threo-methylphenidate inhibits the dopamine transporter and the @CHEM-GENE$, resulting in elevations of these monoamines after impulse release.
5521	CPR:9	threo-methylphenidate inhibits the @CHEMICAL$ and the norepinephrine transporter, resulting in elevations of these @GENE$ after impulse release.
5522	CPR:9	threo-methylphenidate inhibits the dopamine transporter and the @CHEMICAL$, resulting in elevations of these @GENE$ after impulse release.
5523	CPR:4	@CHEMICAL$ inhibits the @GENE$ and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.
5524	CPR:4	@CHEMICAL$ inhibits the dopamine transporter and the @GENE$, resulting in elevations of these monoamines after impulse release.
5525	CPRFalse	In both rodent and primate animal models, the binding of radiolabeled @CHEMICAL$ to @GENE$ was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.
5526	CPRFalse	In both rodent and primate animal models, the binding of radiolabeled d-MPH to @CHEM-GENE$ was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.
5527	CPRFalse	In both rodent and primate animal models, the binding of radiolabeled d-MPH to @CHEMICAL$ was found to be selective, saturable, and reversible, whereas binding of @GENE$ was diffuse and nonspecific.
5528	CPRFalse	The importance of MPH chirality to central nervous system @CHEM-GENE$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas l-MPH binding is nonspecific.
5529	CPRFalse	The importance of MPH chirality to central nervous system @CHEMICAL$ targeting has culminated in human imaging studies revealing that @GENE$ binds specifically to striatal structures, whereas l-MPH binding is nonspecific.
5530	CPRFalse	The importance of MPH chirality to central nervous system @CHEMICAL$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas @GENE$ binding is nonspecific.
5531	CPRFalse	The importance of @CHEMICAL$ chirality to central nervous system @GENE$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas l-MPH binding is nonspecific.
5532	CPRFalse	Identification of @CHEMICAL$-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and @GENE$ function.
5533	CPRFalse	Identification of @CHEMICAL$-terminal receptor activity-modifying protein residues important for @GENE$, adrenomedullin, and amylin receptor function.
5534	CPRFalse	Identification of @CHEMICAL$-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, @GENE$, and amylin receptor function.
5535	CPRFalse	We therefore sought to establish a role for @CHEMICAL$ in malignant glioma cell motility, migration, and invasion and determine the effects of @GENE$ on these cell movement-related processes.
5536	CPRFalse	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular @CHEMICAL$ levels and in the absence and presence of sublethal nitrosourea ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]; @GENE$) concentrations.
5537	CPRFalse	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular @CHEMICAL$ levels and in the absence and presence of sublethal @GENE$ ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]; CCNU) concentrations.
5538	CPRFalse	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular @CHEMICAL$ levels and in the absence and presence of sublethal nitrosourea (@GENE$; CCNU) concentrations.
5539	CPR:4	The direct inhibition of @CHEMICAL$ by @GENE$ is likely a contributing factor.
5540	CPRFalse	Interaction with the @CHEMICAL$ channel and cytotoxicity of @GENE$ and amiodarone analogues.
5541	CPRFalse	Interaction with the @CHEMICAL$ channel and cytotoxicity of amiodarone and @GENE$ analogues.
5542	CPR:4	The principal aim of the study was to find @CHEMICAL$ analogues that retained @GENE$ inhibition but with reduced cytotoxicity.
5543	CPRFalse	Pharmacological and in silico investigations concerning the interactions of these compounds with the @CHEMICAL$ channel revealed that compounds carrying a basic @GENE$ in the side chain display a much higher affinity than those lacking such a group.
5544	CPRFalse	Specifically, @CHEMICAL$ and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards @GENE$ channels than amiodarone.
5545	CPRFalse	Specifically, B2-O-CH(2)-CH(2)-N-piperidine and @CHEMICAL$ revealed a higher affinity towards @GENE$ channels than amiodarone.
5546	CPRFalse	Specifically, B2-O-CH(2)-CH(2)-N-piperidine and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards @CHEMICAL$ channels than @GENE$.
5547	CPR:4	CONCLUSIONS AND IMPLICATIONS: @CHEMICAL$ analogues with better @GENE$ channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.
5548	CPRFalse	CONCLUSIONS AND IMPLICATIONS: @CHEMICAL$ analogues with better hERG channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and @GENE$ channel interaction are mechanistically distinct and separable properties of the compounds.
5549	CPRFalse	Interaction of @CHEMICAL$ with @GENE$: determination of binding parameters.
5550	CPRFalse	The interaction of holo- and apo-forms of @CHEMICAL$ with @GENE$ was studied by a partition equilibrium method.
5551	CPRFalse	@CHEMICAL$, obtained by treatment with @GENE$, displays one binding site for fatty acids, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.
5552	CPRFalse	@CHEMICAL$, obtained by treatment with EDTA, displays one binding site for @GENE$, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.
5553	CPRFalse	@CHEMICAL$, obtained by treatment with EDTA, displays one binding site for fatty acids, the association constants for @GENE$ being 1.9.10(6) and 4.2.10(5) M(-1), respectively.
5554	CPRFalse	However, @CHEMICAL$ was unable to bind @GENE$ as measured by this technique.
5555	CPRFalse	Likewise, no @CHEMICAL$ bound to @GENE$, isolated using nondenaturing conditions, were detected by gas chromatography.
5556	CPRFalse	These results demonstrate that the conformational change induced in @CHEMICAL$ by the removal of @GENE$ enables the protein to interact with fatty acids.
5557	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEM-GENE$ and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
5558	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and @GENE$ V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
5559	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin @GENE$, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
5560	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, @GENE$, V2 and OT receptors: research tools and potential therapeutic agents.
5561	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, V1b, @GENE$ and OT receptors: research tools and potential therapeutic agents.
5562	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, V1b, V2 and @GENE$: research tools and potential therapeutic agents.
5563	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and @GENE$ V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
5564	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEM-GENE$ V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
5565	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ @GENE$, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
5566	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, @GENE$, V2 and OT receptors: research tools and potential therapeutic agents.
5567	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, V1b, @GENE$ and OT receptors: research tools and potential therapeutic agents.
5568	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, V1b, V2 and @GENE$: research tools and potential therapeutic agents.
5569	CPRFalse	Peptide and non-peptide agonists and antagonists for the @CHEMICAL$ and oxytocin V1a, V1b, V2 and @GENE$ receptors: research tools and potential therapeutic agents.
5570	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and @CHEMICAL$ V1a, V1b, V2 and @GENE$ receptors: research tools and potential therapeutic agents.
5571	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin @CHEMICAL$, V1b, V2 and @GENE$ receptors: research tools and potential therapeutic agents.
5572	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, @CHEMICAL$, V2 and @GENE$ receptors: research tools and potential therapeutic agents.
5573	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, @CHEMICAL$ and @GENE$ receptors: research tools and potential therapeutic agents.
5574	CPRFalse	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and @CHEM-GENE$: research tools and potential therapeutic agents.
5575	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.
5576	CPRFalse	@CHEM-GENE$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5577	CPRFalse	@CHEMICAL$ (@GENE$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5578	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5579	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5580	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5581	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5582	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5583	CPRFalse	@CHEMICAL$ (OT) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5584	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5585	CPRFalse	@CHEMICAL$ (OT) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5586	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.
5587	CPRFalse	@CHEMICAL$ (OT) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5588	CPRFalse	Oxytocin (@CHEMICAL$) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5589	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5590	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5591	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5592	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5593	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5594	CPRFalse	Oxytocin (OT) and @CHEM-GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5595	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5596	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5597	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @CHEMICAL$ @GENE$? (vasodilating) receptor.
5598	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5599	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5600	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5601	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5602	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @CHEMICAL$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5603	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @CHEMICAL$ (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5604	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @CHEMICAL$ (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5605	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5606	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @CHEM-GENE$ V(1c)? (vasodilating) receptor.
5607	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5608	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.
5609	CPRFalse	@CHEMICAL$ (OT) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5610	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5611	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5612	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5613	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5614	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5615	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5616	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5617	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5618	CPRFalse	Oxytocin (OT) and vasopressin (@CHEM-GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5619	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.
5620	CPRFalse	@CHEMICAL$ (@GENE$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5621	CPRFalse	Oxytocin (@CHEM-GENE$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5622	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5623	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5624	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5625	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5626	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5627	CPRFalse	Oxytocin (@CHEMICAL$) and @GENE$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5628	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5629	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (@GENE$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5630	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.
5631	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5632	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5633	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEM-GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5634	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5635	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5636	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5637	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5638	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5639	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5640	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The @GENE$ (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5641	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP @GENE$? (vasodilating) receptor.
5642	CPRFalse	@CHEMICAL$ (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5643	CPRFalse	Oxytocin (@CHEMICAL$) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5644	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The @CHEMICAL$ (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5645	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEM-GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5646	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ @GENE$ (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5647	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), @GENE$ (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5648	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), @GENE$ (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5649	CPRFalse	Oxytocin (OT) and @CHEMICAL$ (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5650	CPRFalse	Oxytocin (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @CHEMICAL$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative @GENE$ V(1c)? (vasodilating) receptor.
5651	CPRFalse	Oxytocin (OT) and vasopressin (@CHEMICAL$) mediate their biological actions by acting on four known receptors: The OT (uterine) and the @GENE$ V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)? (vasodilating) receptor.
5652	CPRFalse	The pharmacological properties of promising new selective @CHEM-GENE$ antagonists and V(1b) agonists are also presented.
5653	CPRFalse	The pharmacological properties of promising new selective @CHEMICAL$ antagonists and @GENE$ agonists are also presented.
5654	CPRFalse	The current status of non-peptide @CHEM-GENE$ and AVP antagonists and agonists is also summarized.
5655	CPRFalse	The current status of non-peptide @CHEMICAL$ and @GENE$ antagonists and agonists is also summarized.
5656	CPRFalse	The current status of non-peptide @CHEMICAL$ and @GENE$ antagonists and agonists is also summarized.
5657	CPRFalse	The current status of non-peptide OT and @CHEM-GENE$ antagonists and agonists is also summarized.
5658	CPRFalse	The relative merits of peptide and non-peptide @CHEM-GENE$ and OT agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.
5659	CPRFalse	The relative merits of peptide and non-peptide @CHEMICAL$ and @GENE$ agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.
5660	CPRFalse	The relative merits of peptide and non-peptide @CHEMICAL$ and @GENE$ agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.
5661	CPRFalse	The relative merits of peptide and non-peptide AVP and @CHEM-GENE$ agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.
5662	CPRFalse	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of @CHEM-GENE$ and AVP than their non-peptide counterparts.
5663	CPRFalse	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of @CHEMICAL$ and @GENE$ than their non-peptide counterparts.
5664	CPRFalse	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of @CHEMICAL$ and @GENE$ than their non-peptide counterparts.
5665	CPRFalse	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of OT and @CHEM-GENE$ than their non-peptide counterparts.
5666	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5667	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5668	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5669	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEM-GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5670	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5671	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5672	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5673	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5674	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5675	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5676	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5677	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5678	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5679	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as @GENE$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5680	CPR:5	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5681	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5682	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5683	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5684	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5685	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as @CHEMICAL$ (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5686	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5687	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5688	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5689	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5690	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEM-GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5691	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5692	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5693	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5694	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5695	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5696	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5697	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5698	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5699	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5700	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5701	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (@GENE$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5702	CPR:5	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5703	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5704	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5705	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (@CHEMICAL$, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5706	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5707	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5708	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5709	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5710	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5711	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5712	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), @GENE$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5713	CPR:5	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @CHEMICAL$ (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5714	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @CHEMICAL$ (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5715	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), @CHEMICAL$ (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5716	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5717	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5718	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5719	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5720	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5721	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5722	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5723	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), @GENE$ (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5724	CPR:5	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @CHEMICAL$ (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5725	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), @CHEMICAL$ (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5726	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5727	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5728	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5729	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5730	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5731	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5732	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5733	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), felypressin (V(1a) agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5734	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@CHEMICAL$ agonist) and @GENE$ (Tractocile OT antagonist) are also in clinical use.
5735	CPR:6	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and @CHEMICAL$ (Tractocile @GENE$ antagonist) are also in clinical use.
5736	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5737	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5738	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5739	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5740	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5741	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5742	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5743	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), felypressin (V(1a) agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5744	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@CHEMICAL$ agonist) and atosiban (@GENE$ OT antagonist) are also in clinical use.
5745	CPR:6	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (@CHEMICAL$ @GENE$ antagonist) are also in clinical use.
5746	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5747	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5748	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5749	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and @CHEMICAL$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5750	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@CHEMICAL$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5751	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@CHEMICAL$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5752	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @CHEMICAL$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5753	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@CHEMICAL$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5754	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@CHEMICAL$ agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5755	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @CHEM-GENE$ antagonist) are also in clinical use.
5756	CPRFalse	In addition to @CHEM-GENE$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5757	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent @GENE$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5758	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5759	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5760	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5761	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5762	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5763	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5764	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5765	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5766	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent @GENE$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5767	CPRFalse	In addition to OT and to a lesser extent @CHEM-GENE$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5768	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5769	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5770	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5771	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5772	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5773	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5774	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5775	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5776	CPRFalse	In addition to @CHEMICAL$ and to a lesser extent AVP (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5777	CPRFalse	In addition to OT and to a lesser extent @CHEMICAL$ (pitressin), a number of @GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5778	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEM-GENE$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5779	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and @GENE$ analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5780	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (@GENE$ agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5781	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dD@GENE$ (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5782	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, @GENE$ agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5783	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (@GENE$ agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5784	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (@GENE$ agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.
5785	CPRFalse	In addition to OT and to a lesser extent AVP (pitressin), a number of @CHEMICAL$ and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile @GENE$ antagonist) are also in clinical use.
5786	CPR:6	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, @GENE$, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5787	CPRFalse	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, @CHEMICAL$, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @GENE$/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5788	CPRFalse	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, @CHEMICAL$, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@GENE$, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5789	CPR:6	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, @GENE$ and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5790	CPRFalse	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, @CHEMICAL$ and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @GENE$/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5791	CPRFalse	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, @CHEMICAL$ and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@GENE$, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5792	CPR:6	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and @GENE$, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5793	CPRFalse	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and @CHEMICAL$, are currently in Phase III clinical trials; to date, only the mixed @GENE$/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5794	CPRFalse	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and @CHEMICAL$, are currently in Phase III clinical trials; to date, only the mixed V(2)/@GENE$, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5795	CPRFalse	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist @GENE$ (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5796	CPR:6	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @CHEMICAL$/V(1a), antagonist @GENE$ (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5797	CPR:6	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@CHEMICAL$, antagonist @GENE$ (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5798	CPRFalse	While a number of orally active non-peptide @CHEMICAL$ antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (@GENE$), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5799	CPR:6	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed @CHEMICAL$/V(1a), antagonist Conivaptan (@GENE$), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5800	CPR:6	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/@CHEMICAL$, antagonist Conivaptan (@GENE$), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.
5801	CPRFalse	Promising new non-peptide @CHEMICAL$ and @GENE$ antagonists, as well as non-peptide V(2) and OT agonists are now in pre-clinical development.
5802	CPRFalse	Promising new non-peptide V(1b) and @CHEM-GENE$ antagonists, as well as non-peptide V(2) and OT agonists are now in pre-clinical development.
5803	CPRFalse	Promising new non-peptide V(1b) and @CHEMICAL$ antagonists, as well as non-peptide @GENE$ and OT agonists are now in pre-clinical development.
5804	CPRFalse	Promising new non-peptide V(1b) and @CHEMICAL$ antagonists, as well as non-peptide V(2) and @GENE$ agonists are now in pre-clinical development.
5805	CPRFalse	Promising new non-peptide @CHEMICAL$ and OT antagonists, as well as non-peptide V(2) and @GENE$ agonists are now in pre-clinical development.
5806	CPRFalse	Promising new non-peptide V(1b) and @CHEMICAL$ antagonists, as well as non-peptide V(2) and @GENE$ agonists are now in pre-clinical development.
5807	CPRFalse	Promising new non-peptide V(1b) and OT antagonists, as well as non-peptide @CHEMICAL$ and @GENE$ agonists are now in pre-clinical development.
5808	CPRFalse	Promising new non-peptide V(1b) and OT antagonists, as well as non-peptide V(2) and @CHEM-GENE$ agonists are now in pre-clinical development.
5809	CPR:4	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5810	CPR:4	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5811	CPR:4	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.
5812	CPR:4	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.
5813	CPRFalse	Absorbable drugs (@CHEMICAL$, nicotinic acid, probucol, @GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5814	CPR:4	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5815	CPR:4	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5816	CPR:4	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.
5817	CPR:4	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.
5818	CPRFalse	Absorbable drugs (fibric acids, @CHEMICAL$, probucol, @GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5819	CPR:4	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5820	CPR:4	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5821	CPR:4	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.
5822	CPR:4	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.
5823	CPRFalse	Absorbable drugs (fibric acids, nicotinic acid, @CHEMICAL$, @GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5824	CPRFalse	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce @GENE$ (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5825	CPRFalse	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce plasma very-low-density lipoproteins (@GENE$) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5826	CPRFalse	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or @GENE$ (LDL) by a variety of mechanisms.
5827	CPRFalse	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEMICAL$ reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (@GENE$) by a variety of mechanisms.
5828	CPRFalse	Absorbable drugs (fibric acids, nicotinic acid, probucol, @CHEM-GENE$ inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.
5829	CPR:4	@CHEMICAL$, in particular, act by stimulating the catabolism of @GENE$ and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.
5830	CPRFalse	@CHEMICAL$, in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving @GENE$ delipidation, thus favoring receptor uptake.
5831	CPRFalse	@CHEMICAL$ and acipimox interfere with the biosynthesis of @GENE$ and can also improve the clearance of VLDL/LDL.
5832	CPRFalse	@CHEMICAL$ and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of @GENE$/LDL.
5833	CPRFalse	@CHEMICAL$ and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of VLDL/@GENE$.
5834	CPRFalse	@CHEMICAL$ acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from @GENE$ to lower-density lipoproteins.
5835	CPRFalse	@CHEMICAL$ acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from high-density lipoproteins to @GENE$.
5836	CPR:9	Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of @CHEMICAL$ from @GENE$ to lower-density lipoproteins.
5837	CPR:9	Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of @CHEMICAL$ from high-density lipoproteins to @GENE$.
5838	CPRFalse	Finally, @CHEMICAL$ reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity @GENE$.
5839	CPRFalse	Finally, @CHEM-GENE$ inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors.
5840	CPRFalse	Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of @CHEMICAL$, can induce an increased expression of liver high-affinity @GENE$.
5841	CPRFalse	Finally, @CHEMICAL$ inhibitors, interfering with the biosynthesis of @GENE$, can induce an increased expression of liver high-affinity lipoprotein receptors.
5842	CPR:4	@CHEMICAL$: a dual inhibitor of human epidermal growth factor receptor @GENE$.
5843	CPR:4	@CHEMICAL$: a dual inhibitor of @GENE$ tyrosine kinases.
5844	CPRFalse	Lapatinib: a dual inhibitor of human epidermal growth factor receptor @CHEM-GENE$.
5845	CPRFalse	Lapatinib: a dual inhibitor of @CHEMICAL$ @GENE$ kinases.
5846	CPR:4	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) @GENE$, was approved by the US Food and Drug Administration (FDA) in 2007.
5847	CPR:4	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (@GENE$) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5848	CPR:4	BACKGROUND: @CHEMICAL$, the first dual inhibitor of @GENE$ (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5849	CPR:4	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (@GENE$) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5850	CPR:4	BACKGROUND: @CHEMICAL$, the first dual inhibitor of epidermal growth factor receptor (EGFR) and @GENE$ (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5851	CPRFalse	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) @CHEM-GENE$, was approved by the US Food and Drug Administration (FDA) in 2007.
5852	CPRFalse	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (@CHEMICAL$) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5853	CPRFalse	BACKGROUND: Lapatinib, the first dual inhibitor of @CHEMICAL$ (EGFR) and human epidermal growth factor receptor 2 (HER2) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5854	CPRFalse	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (@CHEMICAL$) and human epidermal growth factor receptor 2 (HER2) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5855	CPRFalse	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and @CHEMICAL$ (HER2) @GENE$ kinases, was approved by the US Food and Drug Administration (FDA) in 2007.
5856	CPRFalse	It is indicated for use in combination with @CHEMICAL$ for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress @GENE$ (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.
5857	CPRFalse	It is indicated for use in combination with @CHEMICAL$ for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (@GENE$) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.
5858	CPRFalse	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress @CHEMICAL$ (ErbB2) and who have received previous treatment that included an @GENE$, a taxane, and trastuzumab.
5859	CPRFalse	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (@CHEMICAL$) and who have received previous treatment that included an @GENE$, a taxane, and trastuzumab.
5860	CPRFalse	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress @CHEMICAL$ (ErbB2) and who have received previous treatment that included an anthracycline, a @GENE$, and trastuzumab.
5861	CPRFalse	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (@CHEMICAL$) and who have received previous treatment that included an anthracycline, a @GENE$, and trastuzumab.
5862	CPRFalse	Search terms included @CHEMICAL$, GW572016, HER2, EGFR, @GENE$, dual-receptor blockade, adverse events, and clinical trials.
5863	CPRFalse	Search terms included @CHEMICAL$, GW572016, @GENE$, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.
5864	CPRFalse	Search terms included @CHEMICAL$, GW572016, HER2, @GENE$, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.
5865	CPRFalse	Search terms included lapatinib, @CHEMICAL$, HER2, EGFR, @GENE$, dual-receptor blockade, adverse events, and clinical trials.
5866	CPRFalse	Search terms included lapatinib, @CHEMICAL$, @GENE$, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.
5867	CPRFalse	Search terms included lapatinib, @CHEMICAL$, HER2, @GENE$, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.
5868	CPRFalse	Search terms included lapatinib, GW572016, HER2, EGFR, @CHEM-GENE$, dual-receptor blockade, adverse events, and clinical trials.
5869	CPRFalse	Search terms included lapatinib, GW572016, @CHEMICAL$, EGFR, receptor @GENE$ kinase, dual-receptor blockade, adverse events, and clinical trials.
5870	CPRFalse	Search terms included lapatinib, GW572016, HER2, @CHEMICAL$, receptor @GENE$ kinase, dual-receptor blockade, adverse events, and clinical trials.
5871	CPR:9	@CHEMICAL$ is metabolized primarily by the @GENE$ isozyme, with 1 metabolite remaining active against EGFR but not HER2.
5872	CPRFalse	@CHEMICAL$ is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against @GENE$ but not HER2.
5873	CPRFalse	@CHEMICAL$ is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not @GENE$.
5874	CPRFalse	In a Phase III trial comparing lapatinib and @CHEMICAL$ with capecitabine alone in women with @GENE$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5875	CPRFalse	In a Phase III trial comparing lapatinib and capecitabine with @CHEMICAL$ alone in women with @GENE$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5876	CPRFalse	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an @GENE$, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5877	CPRFalse	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a @GENE$, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5878	CPRFalse	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of @GENE$ and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5879	CPRFalse	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and @GENE$ was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5880	CPRFalse	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with @CHEMICAL$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with @GENE$ alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5881	CPRFalse	In a Phase III trial comparing @CHEMICAL$ and capecitabine with capecitabine alone in women with @GENE$-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).
5882	CPR:4	CONCLUSIONS: @CHEMICAL$ is a dual inhibitor of the EGFR and HER2 @GENE$.
5883	CPR:4	CONCLUSIONS: @CHEMICAL$ is a dual inhibitor of the @GENE$ and HER2 tyrosine kinases.
5884	CPR:4	CONCLUSIONS: @CHEMICAL$ is a dual inhibitor of the EGFR and @GENE$ tyrosine kinases.
5885	CPRFalse	CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 @CHEM-GENE$.
5886	CPRFalse	CONCLUSIONS: Lapatinib is a dual inhibitor of the @CHEMICAL$ and HER2 @GENE$ kinases.
5887	CPRFalse	CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and @CHEMICAL$ @GENE$ kinases.
5888	CPRFalse	It is approved by the FDA for use in combination with @CHEMICAL$ for the treatment of @GENE$-positive MBC that has progressed with standard treatment.
5889	CPRFalse	@CHEMICAL$ is a relatively potent inhibitor of @GENE$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.
5890	CPRFalse	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEM-GENE$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.
5891	CPRFalse	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of @GENE$ and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.
5892	CPRFalse	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and @GENE$, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.
5893	CPRFalse	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in @GENE$, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.
5894	CPRFalse	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, @GENE$, and 3,4-dihydroxyphenylacetic acetic after acute i.p.
5895	CPRFalse	N2-Acetylphenelzine is a relatively potent inhibitor of @CHEMICAL$ and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and @GENE$ after acute i.p.
5896	CPRFalse	Phenelzine is a more potent @CHEM-GENE$ inhibitor than is N2-acetylphenelzine.
5897	CPR:4	Phenelzine is a more potent @CHEMICAL$ inhibitor than is @GENE$.
5898	CPR:4	@CHEMICAL$ is a more potent @GENE$ inhibitor than is N2-acetylphenelzine.
5899	CPR:4	Acetylation of @CHEMICAL$ at the N2 position presumably interferes with the inhibition of the @GENE$ enzymes for gamma-aminobutyric acid and alanine.
5900	CPR:4	Acetylation of phenelzine at the @CHEMICAL$ position presumably interferes with the inhibition of the @GENE$ enzymes for gamma-aminobutyric acid and alanine.
5901	CPR:4	Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the @CHEMICAL$ enzymes for @GENE$ and alanine.
5902	CPR:4	Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the @CHEMICAL$ enzymes for gamma-aminobutyric acid and @GENE$.
5903	CPRFalse	@CHEMICAL$ D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via @GENE$ phosphorylation.
5904	CPRFalse	@CHEM-GENE$-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
5905	CPRFalse	Clinical improvements in Parkinson's disease produced by @CHEM-GENE$-preferring agonists have been related to their neuroprotective actions and, more recently, to their neuroregenerative properties.
5906	CPRFalse	However, it is unclear whether @CHEMICAL$ agonists produce their neurotrophic effects by acting directly on receptors expressed by the mesencephalic dopaminergic neurons or indirectly on receptors expressed by astrocytes, via release of @GENE$.
5907	CPRFalse	In this study, we investigated the effects of the @CHEM-GENE$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).
5908	CPRFalse	In this study, we investigated the effects of the @CHEMICAL$ D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).
5909	CPRFalse	In this study, we investigated the effects of the @CHEMICAL$ D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).
5910	CPRFalse	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists @GENE$ and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).
5911	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists @CHEMICAL$ and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).
5912	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists @CHEMICAL$ and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).
5913	CPRFalse	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and @GENE$ (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).
5914	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and @CHEMICAL$ (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).
5915	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and @CHEMICAL$ (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).
5916	CPRFalse	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (@GENE$), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).
5917	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (@CHEMICAL$), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).
5918	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (@CHEMICAL$), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).
5919	CPRFalse	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist @GENE$, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).
5920	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist @CHEMICAL$, on dopaminergic neurons identified by @GENE$ immunoreactivity (TH-IR).
5921	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist @CHEMICAL$, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (@GENE$-IR).
5922	CPRFalse	In this study, we investigated the effects of the @CHEMICAL$-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @GENE$ hydroxylase immunoreactivity (TH-IR).
5923	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @CHEM-GENE$ immunoreactivity (TH-IR).
5924	CPRFalse	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by @CHEMICAL$ hydroxylase immunoreactivity (@GENE$-IR).
5925	CPRFalse	After 3 days of incubation, both quinpirole (1-10 microm) and 7-OH-DPAT (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and @CHEMICAL$ uptake (P < 0.01) of @GENE$-IR-positive mesencephalic neurons.
5926	CPRFalse	After 3 days of incubation, both @CHEMICAL$ (1-10 microm) and 7-OH-DPAT (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and [3H]dopamine uptake (P < 0.01) of @GENE$-IR-positive mesencephalic neurons.
5927	CPRFalse	After 3 days of incubation, both quinpirole (1-10 microm) and @CHEMICAL$ (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and [3H]dopamine uptake (P < 0.01) of @GENE$-IR-positive mesencephalic neurons.
5928	CPRFalse	All neurotrophic effects were blocked by the unselective @CHEMICAL$ antagonist @GENE$ (5 microm) and by the selective D3 receptor antagonist SB-277011-A at a low dose (50 nm).
5929	CPRFalse	All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist @CHEMICAL$ (5 microm) and by the selective @GENE$ antagonist SB-277011-A at a low dose (50 nm).
5930	CPRFalse	All neurotrophic effects were blocked by the unselective @CHEMICAL$ antagonist sulpiride (5 microm) and by the selective D3 receptor antagonist @GENE$ at a low dose (50 nm).
5931	CPR:6	All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective @CHEMICAL$ antagonist @GENE$ at a low dose (50 nm).
5932	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.
5933	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.
5934	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @CHEMICAL$ signalling pathway to ERK was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.
5935	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @CHEMICAL$ was obtained with PD98059, GF109203 or @GENE$, resulting in blockade of neurotrophic effects.
5936	CPR:3	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of @GENE$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5937	CPR:3	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@GENE$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5938	CPRFalse	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @GENE$ signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5939	CPRFalse	@CHEMICAL$ and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @GENE$ was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5940	CPR:3	Quinpirole and @CHEMICAL$ also increased the phosphorylation of @GENE$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5941	CPR:3	Quinpirole and @CHEMICAL$ also increased the phosphorylation of extracellular signal-regulated kinase (@GENE$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5942	CPRFalse	Quinpirole and @CHEMICAL$ also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @GENE$ signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5943	CPRFalse	Quinpirole and @CHEMICAL$ also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @GENE$ was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5944	CPR:4	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with @GENE$. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5945	CPR:4	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with @GENE$. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5946	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with @CHEMICAL$. Inhibition of the @GENE$ signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5947	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with @CHEMICAL$. Inhibition of the D2/D3 receptor signalling pathway to @GENE$ was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5948	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5949	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5950	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @CHEMICAL$ signalling pathway to ERK was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5951	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @CHEMICAL$ was obtained with @GENE$, GF109203 or LY294002, resulting in blockade of neurotrophic effects.
5952	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of @CHEMICAL$ (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.
5953	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (@CHEMICAL$) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.
5954	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the @CHEMICAL$ signalling pathway to ERK was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.
5955	CPRFalse	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A. Inhibition of the D2/D3 receptor signalling pathway to @CHEMICAL$ was obtained with PD98059, @GENE$ or LY294002, resulting in blockade of neurotrophic effects.
5956	CPRFalse	These data suggest that @CHEMICAL$ agonists increase dendritic arborizations of mesencephalic dopaminergic neurons via a direct effect on @GENE$, preferentially involving D3 receptor-dependent neurotransmission.
5957	CPRFalse	These data suggest that @CHEMICAL$ agonists increase dendritic arborizations of mesencephalic dopaminergic neurons via a direct effect on D2/D3 receptors, preferentially involving @GENE$-dependent neurotransmission.
5958	CPRFalse	Molecular pharmacology of human Cav3.2 @CHEM-GENE$: block by antihypertensives, antiarrhythmics, and their analogs.
5959	CPRFalse	Molecular pharmacology of @CHEMICAL$ T-type @GENE$ channels: block by antihypertensives, antiarrhythmics, and their analogs.
5960	CPRFalse	"Antihypertensive drugs of the ""calcium channel blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of @CHEM-GENE$ in vascular smooth muscle."
5961	CPRFalse	"Antihypertensive drugs of the ""@CHEMICAL$ blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of L-type @GENE$ channels in vascular smooth muscle."
5962	CPRFalse	"Antihypertensive drugs of the ""@CHEMICAL$ channel blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of @GENE$ in vascular smooth muscle."
5963	CPRFalse	"Antihypertensive drugs of the ""@CHEM-GENE$ blocker"" or ""calcium antagonist"" class have been used to establish the physiological role of L-type Ca(2+) channels in vascular smooth muscle."
5964	CPRFalse	"Antihypertensive drugs of the ""calcium channel blocker"" or ""@CHEMICAL$ antagonist"" class have been used to establish the physiological role of @GENE$ in vascular smooth muscle."
5965	CPRFalse	"Antihypertensive drugs of the ""@CHEMICAL$ blocker"" or ""@GENE$ antagonist"" class have been used to establish the physiological role of L-type Ca(2+) channels in vascular smooth muscle."
5966	CPRFalse	In contrast, there has been limited progress on the pharmacology @CHEM-GENE$.
5967	CPRFalse	@CHEMICAL$ play a role in cardiac pacemaking, @GENE$ secretion, and renal hemodynamics, leading to the hypothesis that mixed T- and L-type blockers may have therapeutic advantages over selective L-type blockers.
5968	CPRFalse	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., @GENE$) and dihydropyridines (e.g., efonidipine).
5969	CPRFalse	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., @GENE$) and dihydropyridines (e.g., efonidipine).
5970	CPRFalse	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and @GENE$ (e.g., efonidipine).
5971	CPRFalse	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and @GENE$ (e.g., efonidipine).
5972	CPRFalse	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and dihydropyridines (e.g., @GENE$).
5973	CPRFalse	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and dihydropyridines (e.g., @GENE$).
5974	CPRFalse	The goal of this study was to identify compounds that block the Ca(v)3.2 @CHEMICAL$ with high affinity, focusing on two classes of compounds: @GENE$ (e.g., mibefradil) and dihydropyridines (e.g., efonidipine).
5975	CPRFalse	The goal of this study was to identify compounds that block the @CHEMICAL$ T-type channel with high affinity, focusing on two classes of compounds: @GENE$ (e.g., mibefradil) and dihydropyridines (e.g., efonidipine).
5976	CPRFalse	Compounds were tested using a validated @CHEMICAL$ influx assay into a cell line expressing recombinant @GENE$ channels.
5977	CPR:4	This study identified four clinically approved antihypertensive drugs (@CHEMICAL$, felodipine, isradipine, and nitrendipine) as potent @GENE$ blockers (IC(50) < 3 microM).
5978	CPR:4	This study identified four clinically approved antihypertensive drugs (efonidipine, @CHEMICAL$, isradipine, and nitrendipine) as potent @GENE$ blockers (IC(50) < 3 microM).
5979	CPR:4	This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, @CHEMICAL$, and nitrendipine) as potent @GENE$ blockers (IC(50) < 3 microM).
5980	CPR:4	This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and @CHEMICAL$) as potent @GENE$ blockers (IC(50) < 3 microM).
5981	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, @GENE$, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5982	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, @GENE$, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5983	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, @GENE$, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5984	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, @GENE$, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5985	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, @GENE$, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5986	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, @GENE$, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5987	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, @GENE$, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5988	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, @GENE$, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5989	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, @GENE$, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5990	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, @GENE$, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5991	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, @GENE$, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5992	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, @GENE$, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5993	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, @GENE$, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5994	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, @GENE$, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5995	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, @GENE$, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5996	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, @GENE$, erectile dysfunction, sildenafil, vardenafil and tadalafil.
5997	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, @GENE$, vardenafil and tadalafil.
5998	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, @GENE$, vardenafil and tadalafil.
5999	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, @GENE$ and tadalafil.
6000	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, @GENE$ and tadalafil.
6001	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and @GENE$.
6002	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and @GENE$.
6003	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, @GENE$, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
6004	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, @GENE$, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
6005	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, @CHEMICAL$ antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, @GENE$, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
6006	CPRFalse	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, @CHEMICAL$ inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, @GENE$, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.
6007	CPRFalse	Pannexin (Panx) 1 is a widely expressed protein that shares structural, but not @CHEMICAL$, homology with gap junction proteins, the @GENE$.
6008	CPRFalse	@CHEMICAL$ is a widely expressed protein that shares structural, but not @GENE$, homology with gap junction proteins, the connexins.
6009	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: @GENE$ > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.
6010	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > @GENE$ (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.
6011	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (@GENE$) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.
6012	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately @GENE$ approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.
6013	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately @GENE$ > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.
6014	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > @GENE$ >> probenecid >> flufenamic acid = niflumic acid.
6015	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> @GENE$ >> flufenamic acid = niflumic acid.
6016	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> @GENE$ = niflumic acid.
6017	CPR:4	We found compounds that inhibited @CHEMICAL$ currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = @GENE$.
6018	CPRFalse	Triphosphate nucleotides (ATP, GTP, and @CHEMICAL$) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.
6019	CPR:4	Triphosphate nucleotides (ATP, GTP, and @CHEMICAL$) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.
6020	CPRFalse	@CHEMICAL$ (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.
6021	CPR:4	@CHEMICAL$ (ATP, GTP, and UTP) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.
6022	CPRFalse	Triphosphate nucleotides (@CHEMICAL$, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.
6023	CPR:4	Triphosphate nucleotides (@CHEMICAL$, GTP, and UTP) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.
6024	CPRFalse	Triphosphate nucleotides (ATP, @CHEMICAL$, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of @GENE$.
6025	CPR:4	Triphosphate nucleotides (ATP, @CHEMICAL$, and UTP) rapidly and reversibly inhibited @GENE$ currents via mechanism(s) independent of purine receptors.
6026	CPRFalse	When @CHEMICAL$ was coexpressed with purinergic P2X(7) receptor (P2X(7)R), @GENE$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6027	CPRFalse	When Panx1 was coexpressed with @CHEMICAL$ (P2X(7)R), @GENE$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6028	CPRFalse	When Panx1 was coexpressed with purinergic P2X(7) receptor (@CHEMICAL$), @GENE$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6029	CPR:6	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), @CHEMICAL$ was found to act as a @GENE$ antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6030	CPRFalse	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), @CHEMICAL$ was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited @GENE$ currents.
6031	CPRFalse	When @CHEMICAL$ was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6032	CPRFalse	When Panx1 was coexpressed with @CHEMICAL$ (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6033	CPRFalse	When Panx1 was coexpressed with purinergic P2X(7) receptor (@CHEMICAL$), DIDS was found to act as a P2X(7)R antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6034	CPRFalse	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a @CHEMICAL$ antagonist to inhibit @GENE$-evoked currents, but none of the other compounds inhibited P2X(7)R currents.
6035	CPRFalse	When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit @CHEMICAL$-evoked currents, but none of the other compounds inhibited @GENE$ currents.
6036	CPRFalse	@CHEMICAL$ attenuates @GENE$ in monocrotaline-induced right ventricular hypertrophy in rats.
6037	CPRFalse	Captopril attenuates @CHEMICAL$ in @GENE$-induced right ventricular hypertrophy in rats.
6038	CPRFalse	Little is known about the influence of @CHEMICAL$ converting enzyme (ACE) inhibitors on matrix metalloproteinase (@GENE$) in right ventricular remodeling.
6039	CPRFalse	Little is known about the influence of @CHEMICAL$ converting enzyme (ACE) inhibitors on @GENE$ (MMP) in right ventricular remodeling.
6040	CPRFalse	Little is known about the influence of @CHEM-GENE$ (ACE) inhibitors on matrix metalloproteinase (MMP) in right ventricular remodeling.
6041	CPRFalse	Little is known about the influence of @CHEMICAL$ converting enzyme (@GENE$) inhibitors on matrix metalloproteinase (MMP) in right ventricular remodeling.
6042	CPR:4	We investigated the effect of @CHEMICAL$, an @GENE$ inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.
6043	CPRFalse	We investigated the effect of @CHEMICAL$, an ACE inhibitor, on @GENE$ and MMP-9 in monocrotaline-induced right ventricular hypertrophy.
6044	CPRFalse	We investigated the effect of @CHEMICAL$, an ACE inhibitor, on MMP-2 and @GENE$ in monocrotaline-induced right ventricular hypertrophy.
6045	CPRFalse	We investigated the effect of captopril, an @CHEMICAL$ inhibitor, on MMP-2 and MMP-9 in @GENE$-induced right ventricular hypertrophy.
6046	CPRFalse	We investigated the effect of captopril, an ACE inhibitor, on @CHEMICAL$ and MMP-9 in @GENE$-induced right ventricular hypertrophy.
6047	CPRFalse	We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and @CHEMICAL$ in @GENE$-induced right ventricular hypertrophy.
6048	CPRFalse	However, @CHEMICAL$ did not attenuate an increase in pulmonary artery pressure. @GENE$ and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.
6049	CPRFalse	However, @CHEMICAL$ did not attenuate an increase in pulmonary artery pressure. MMP-2 and @GENE$ expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.
6050	CPR:3	However, captopril did not attenuate an increase in pulmonary artery pressure. @CHEMICAL$ and MMP-9 expressions and activities in right ventricles increased significantly in @GENE$-injected rats and captopril inhibited them.
6051	CPR:3	However, captopril did not attenuate an increase in pulmonary artery pressure. MMP-2 and @CHEMICAL$ expressions and activities in right ventricles increased significantly in @GENE$-injected rats and captopril inhibited them.
6052	CPR:4	However, captopril did not attenuate an increase in pulmonary artery pressure. @CHEMICAL$ and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and @GENE$ inhibited them.
6053	CPR:4	However, captopril did not attenuate an increase in pulmonary artery pressure. MMP-2 and @CHEMICAL$ expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and @GENE$ inhibited them.
6054	CPR:4	These findings indicate that @CHEMICAL$ attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of @GENE$ and MMP-9 in rats.
6055	CPR:4	These findings indicate that @CHEMICAL$ attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and @GENE$ in rats.
6056	CPR:3	These findings indicate that captopril attenuates the development of @CHEMICAL$-induced right ventricular hypertrophy in association with inhibition of @GENE$ and MMP-9 in rats.
6057	CPR:3	These findings indicate that captopril attenuates the development of @CHEMICAL$-induced right ventricular hypertrophy in association with inhibition of MMP-2 and @GENE$ in rats.
6058	CPR:4	@CHEMICAL$ and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@GENE$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.
6059	CPR:4	@CHEMICAL$ and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @GENE$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.
6060	CPR:4	@CHEMICAL$ and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @GENE$) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.
6061	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@CHEMICAL$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as @GENE$, methazolamide, and ethoxzolamide.
6062	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @CHEMICAL$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as @GENE$, methazolamide, and ethoxzolamide.
6063	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @CHEMICAL$) with a very different profile as compared to classical inhibitors, such as @GENE$, methazolamide, and ethoxzolamide.
6064	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@CHEMICAL$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, @GENE$, and ethoxzolamide.
6065	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @CHEMICAL$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, @GENE$, and ethoxzolamide.
6066	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @CHEMICAL$) with a very different profile as compared to classical inhibitors, such as acetazolamide, @GENE$, and ethoxzolamide.
6067	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (@CHEMICAL$, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and @GENE$.
6068	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of @CHEMICAL$ (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and @GENE$.
6069	CPR:4	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, @CHEMICAL$) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and @GENE$.
6070	CPRFalse	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with @GENE$, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).
6071	CPR:4	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with @CHEMICAL$, trichloromethiazide, and furosemide being efficient inhibitors against @GENE$ (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).
6072	CPRFalse	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with chlorthalidone, @GENE$, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).
6073	CPR:4	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, @CHEMICAL$, and furosemide being efficient inhibitors against @GENE$ (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).
6074	CPRFalse	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with chlorthalidone, trichloromethiazide, and @GENE$ being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).
6075	CPR:4	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and @CHEMICAL$ being efficient inhibitors against @GENE$ (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).
6076	CPRFalse	Some of these structurally related compounds have a very different behavior against the widespread isozyme @CHEMICAL$, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas @GENE$ is a much weaker one (K(I) of 2520 nM).
6077	CPR:4	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against @CHEMICAL$ (K(I)s of 65-138 nM), whereas @GENE$ is a much weaker one (K(I) of 2520 nM).
6078	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against @GENE$; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.
6079	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against hCA VB, VII, IX, and XIII; indapamide against @GENE$, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.
6080	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against @GENE$, and furosemide against CA I and XIV.
6081	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, @CHEMICAL$ against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against @GENE$.
6082	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against @CHEMICAL$; @GENE$ against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.
6083	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; @CHEMICAL$ against @GENE$, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.
6084	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; @CHEMICAL$ against CA VII, IX, XII, and XIII, trichloromethiazide against @GENE$, and furosemide against CA I and XIV.
6085	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; @CHEMICAL$ against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against @GENE$.
6086	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against @CHEMICAL$; indapamide against CA VII, IX, XII, and XIII, @GENE$ against CA VII and IX, and furosemide against CA I and XIV.
6087	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against @CHEMICAL$, @GENE$ against CA VII and IX, and furosemide against CA I and XIV.
6088	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, @CHEMICAL$ against @GENE$, and furosemide against CA I and XIV.
6089	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, @CHEMICAL$ against CA VII and IX, and furosemide against @GENE$.
6090	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against @CHEMICAL$; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and @GENE$ against CA I and XIV.
6091	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against @CHEMICAL$, trichloromethiazide against CA VII and IX, and @GENE$ against CA I and XIV.
6092	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against @CHEMICAL$, and @GENE$ against CA I and XIV.
6093	CPRFalse	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and @CHEMICAL$ against @GENE$.
6094	CPRFalse	Examining the four X-ray crystal structures of their @CHEMICAL$ adducts, we observed several (2-3) active site water molecules interacting with the @GENE$, trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity.
6095	CPRFalse	Examining the four X-ray crystal structures of their @CHEMICAL$ adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, @GENE$, and furosemide scaffolds which may be responsible for this important difference of activity.
6096	CPRFalse	Examining the four X-ray crystal structures of their @CHEMICAL$ adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and @GENE$ scaffolds which may be responsible for this important difference of activity.
6097	CPRFalse	Indeed, @CHEMICAL$ bound to @GENE$ has no interactions with active site water molecules.
6098	CPRFalse	@CHEMICAL$ bound within the @GENE$ active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong hydrogen bonds with Asn67 and a water molecule.
6099	CPRFalse	Chlorthalidone bound within the @CHEMICAL$ active site is in an enolic (lactimic) tautomeric form, with the enolic @GENE$ also participating in two strong hydrogen bonds with Asn67 and a water molecule.
6100	CPRFalse	Chlorthalidone bound within the @CHEMICAL$ active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong @GENE$ bonds with Asn67 and a water molecule.
6101	CPR:4	@CHEMICAL$, a selective @GENE$ inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
6102	CPRFalse	Sergliflozin etabonate, a selective @CHEMICAL$ inhibitor, improves glycemic control in @GENE$-induced diabetic rats and Zucker fatty rats.
6103	CPRFalse	The low-affinity @CHEM-GENE$ (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.
6104	CPRFalse	The low-affinity @CHEMICAL$ glucose cotransporter (@GENE$) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.
6105	CPRFalse	The low-affinity @CHEM-GENE$ (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.
6106	CPRFalse	The low-affinity sodium @CHEMICAL$ cotransporter (@GENE$) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.
6107	CPR:9	The low-affinity @CHEMICAL$ (SGLT2) is responsible for most of the @GENE$ reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.
6108	CPR:9	The low-affinity sodium glucose cotransporter (@CHEMICAL$) is responsible for most of the @GENE$ reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.
6109	CPR:4	We discovered @CHEMICAL$, a novel selective @GENE$ inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.
6110	CPR:4	We discovered @CHEMICAL$, a novel selective SGLT2 inhibitor, and found that selective inhibition of @GENE$ increased urinary glucose excretion and consequently decreased plasma glucose levels.
6111	CPRFalse	We discovered sergliflozin etabonate, a novel selective @CHEMICAL$ inhibitor, and found that selective inhibition of SGLT2 increased urinary @GENE$ excretion and consequently decreased plasma glucose levels.
6112	CPRFalse	We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of @CHEMICAL$ increased urinary @GENE$ excretion and consequently decreased plasma glucose levels.
6113	CPRFalse	We discovered sergliflozin etabonate, a novel selective @CHEMICAL$ inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma @GENE$ levels.
6114	CPRFalse	We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of @CHEMICAL$ increased urinary glucose excretion and consequently decreased plasma @GENE$ levels.
6115	CPRFalse	In this report, we examined the antihyperglycemic effects of @CHEMICAL$ in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an @GENE$ inhibitor (voglibose).
6116	CPRFalse	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a @CHEMICAL$ (gliclazide) and an @GENE$ inhibitor (voglibose).
6117	CPRFalse	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (@CHEMICAL$) and an @GENE$ inhibitor (voglibose).
6118	CPR:4	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an @CHEMICAL$ inhibitor (@GENE$).
6119	CPRFalse	@CHEMICAL$ increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of @GENE$ secretion in normal rats.
6120	CPRFalse	Sergliflozin etabonate increased urinary @CHEMICAL$ excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of @GENE$ secretion in normal rats.
6121	CPRFalse	Sergliflozin etabonate increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma @CHEMICAL$ after sucrose loading independently of @GENE$ secretion in normal rats.
6122	CPRFalse	Sergliflozin etabonate increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after @CHEMICAL$ loading independently of @GENE$ secretion in normal rats.
6123	CPR:4	Chronic treatment with @CHEMICAL$ reduced the levels of @GENE$ and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.
6124	CPRFalse	Chronic treatment with sergliflozin etabonate reduced the levels of @CHEMICAL$ and fasting plasma @GENE$, and improved the glycemic response after glucose loading in Zucker fatty rats.
6125	CPRFalse	Chronic treatment with sergliflozin etabonate reduced the levels of @CHEMICAL$ and fasting plasma glucose, and improved the glycemic response after @GENE$ loading in Zucker fatty rats.
6126	CPRFalse	These data indicate that @CHEMICAL$ could improve glycemic control without its use resulting in @GENE$ secretion, hypoglycemia, and body weight gain, and may provide a unique approach to the treatment of diabetes.
6127	CPRFalse	Our previous study showed that the stimulatory effect of @CHEMICAL$ on VSMC proliferation is inhibited by @GENE$ and the D3 dopamine receptor, a member of the D2-like receptor family.
6128	CPRFalse	Our previous study showed that the stimulatory effect of @CHEMICAL$ on VSMC proliferation is inhibited by D1-like receptors and the D3 dopamine receptor, a member of the @GENE$ family.
6129	CPRFalse	Our previous study showed that the stimulatory effect of @CHEMICAL$ on VSMC proliferation is inhibited by D1-like receptors and the @GENE$, a member of the D2-like receptor family.
6130	CPRFalse	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by @CHEMICAL$ and the D3 @GENE$ receptor, a member of the D2-like receptor family.
6131	CPRFalse	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by D1-like receptors and the D3 @CHEMICAL$ receptor, a member of the @GENE$ family.
6132	CPRFalse	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by D1-like receptors and the @CHEM-GENE$, a member of the D2-like receptor family.
6133	CPRFalse	METHODS: VSMC proliferation was determined by @CHEMICAL$ incorporation; @GENE$ mRNA and protein expressions were determined by RT-PCR, immunoblotting, and immunohistochemistry.
6134	CPRFalse	RESULTS: @CHEMICAL$ increased VSMC proliferation in immortalized aortic A10 cells, determined by @GENE$ incorporation.
6135	CPRFalse	Although the @CHEMICAL$, by itself, had no effect on VSMC proliferation, stimulation with @GENE$, a D1-like receptor agonist, inhibited the stimulatory effect of insulin.
6136	CPR:5	Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with @CHEMICAL$, a @GENE$ agonist, inhibited the stimulatory effect of insulin.
6137	CPR:4	Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with @CHEMICAL$, a D1-like receptor agonist, inhibited the stimulatory effect of @GENE$.
6138	CPRFalse	The inhibitory effect of @CHEMICAL$ on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a @GENE$ antagonist.
6139	CPR:4	The inhibitory effect of @CHEMICAL$ on @GENE$-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.
6140	CPR:6	The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by @CHEMICAL$, a @GENE$ antagonist.
6141	CPRFalse	The inhibitory effect of fenoldopam on @CHEMICAL$-mediated VSMC proliferation was receptor specific, because its effect could be blocked by @GENE$, a D1-like receptor antagonist.
6142	CPR:4	@CHEMICAL$ also inhibited @GENE$ mRNA and protein expression, which was time dependent and concentration dependent.
6143	CPRFalse	A @CHEMICAL$ or MAP kinase inhibitor blocked the inhibitory effect of @GENE$ on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway.
6144	CPRFalse	A PKC or @CHEMICAL$ inhibitor blocked the inhibitory effect of @GENE$ on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway.
6145	CPRFalse	A PKC or MAP kinase inhibitor blocked the inhibitory effect of @CHEMICAL$ on insulin receptor expression, indicating that @GENE$ and MAP kinase were involved in the signaling pathway.
6146	CPRFalse	A PKC or MAP kinase inhibitor blocked the inhibitory effect of @CHEMICAL$ on insulin receptor expression, indicating that PKC and @GENE$ were involved in the signaling pathway.
6147	CPR:4	A PKC or MAP kinase inhibitor blocked the inhibitory effect of @CHEMICAL$ on @GENE$ expression, indicating that PKC and MAP kinase were involved in the signaling pathway.
6148	CPRFalse	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hemolytic anemia caused by somatic mutations in the @CHEM-GENE$ gene and the resulting absence of a key complement regulatory protein, CD59.
6149	CPRFalse	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hemolytic anemia caused by somatic mutations in the @CHEMICAL$ glycan-complementation class A gene and the resulting absence of a key complement regulatory protein, @GENE$.
6150	CPR:9	The progress of the enzymatic reaction of the hydrolysis of @CHEMICAL$ at pH 8 in the presence of @GENE$ and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).
6151	CPRFalse	The progress of the enzymatic reaction of the hydrolysis of acetylthiocholine at pH 8 in the presence of @CHEMICAL$ and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product @GENE$ (TCh).
6152	CPRFalse	In the method employed the capillary was first filled with 30 mM @CHEMICAL$-phosphate buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) @GENE$ solution, (iii) substrate solution with or without inhibitor, (iv) AChE solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.
6153	CPRFalse	In the method employed the capillary was first filled with 30 mM @CHEMICAL$-phosphate buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) AChE solution, (iii) substrate solution with or without inhibitor, (iv) @GENE$ solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.
6154	CPRFalse	In the method employed the capillary was first filled with 30 mM borate-@CHEMICAL$ buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) @GENE$ solution, (iii) substrate solution with or without inhibitor, (iv) AChE solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.
6155	CPRFalse	In the method employed the capillary was first filled with 30 mM borate-@CHEMICAL$ buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) AChE solution, (iii) substrate solution with or without inhibitor, (iv) @GENE$ solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.
6156	CPRFalse	@CHEM-GENE$ binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
6157	CPRFalse	@CHEMICAL$ binding potential and occupancy in midbrain and temporal cortex by haloperidol, @GENE$ and clozapine.
6158	CPRFalse	@CHEMICAL$ binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and @GENE$.
6159	CPRFalse	@CHEMICAL$ binding potential and occupancy in midbrain and temporal cortex by @GENE$, olanzapine and clozapine.
6160	CPRFalse	Differences between typical and second-generation antipsychotics in @CHEM-GENE$ modulation within various brain areas remain a topic for debate.
6161	CPRFalse	The aim of the present study was therefore to investigate @CHEM-GENE$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, olanzapine- and haloperidol-treated schizophrenia patients.
6162	CPRFalse	The aim of the present study was therefore to investigate @CHEMICAL$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among @GENE$-, olanzapine- and haloperidol-treated schizophrenia patients.
6163	CPRFalse	The aim of the present study was therefore to investigate @CHEMICAL$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, @GENE$- and haloperidol-treated schizophrenia patients.
6164	CPRFalse	The aim of the present study was therefore to investigate @CHEMICAL$ apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, olanzapine- and @GENE$-treated schizophrenia patients.
6165	CPRFalse	METHODS: @CHEM-GENE$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.
6166	CPRFalse	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand @GENE$ in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.
6167	CPRFalse	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with @GENE$, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.
6168	CPRFalse	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with @GENE$ and seven with clozapine), six drug-naive patients and seven healthy controls.
6169	CPRFalse	METHODS: @CHEMICAL$ binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with @GENE$), six drug-naive patients and seven healthy controls.
6170	CPRFalse	RESULTS: Statistically significant differences in midbrain @CHEM-GENE$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, olanzapine and haloperidol groups.
6171	CPRFalse	RESULTS: Statistically significant differences in midbrain @CHEMICAL$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, olanzapine and @GENE$ groups.
6172	CPRFalse	RESULTS: Statistically significant differences in midbrain @CHEMICAL$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the @GENE$, olanzapine and haloperidol groups.
6173	CPRFalse	RESULTS: Statistically significant differences in midbrain @CHEMICAL$ BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, @GENE$ and haloperidol groups.
6174	CPRFalse	CONCLUSION: Both typical and second-generation antipsychotics occupy cortical @CHEM-GENE$, thus mediating therapeutic efficacy.
6175	CPRFalse	Observed differences in midbrain @CHEM-GENE$ occupancy between classical antipsychotics and second-generation antipsychotics may have clinical relevance by modulating altered nigrostriatal dopamine neurotransmission during the acute phase of schizophrenia.
6176	CPRFalse	Observed differences in midbrain @CHEMICAL$ occupancy between classical antipsychotics and second-generation antipsychotics may have clinical relevance by modulating altered nigrostriatal @GENE$ neurotransmission during the acute phase of schizophrenia.
6177	CPR:4	The mechanism of @CHEMICAL$ poisoning involves inhibition of @GENE$ (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.
6178	CPR:4	The mechanism of @CHEMICAL$ poisoning involves inhibition of acetylcholinesterase (@GENE$) leading to inactivation of the enzyme which has an important role in neurotransmission.
6179	CPRFalse	@CHEMICAL$ inhibition results in the accumulation of @GENE$ at cholinergic receptor sites, producing continuous stimulation of cholinergic fibers throughout the nervous systems.
6180	CPR:4	They act by reactivation of @CHEMICAL$ inhibited by @GENE$.
6181	CPR:3	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, @GENE$, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.
6182	CPR:3	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, @GENE$ and HI-6) and diazepam are used for the treatment of OP poisoning in humans.
6183	CPR:3	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and @GENE$) and diazepam are used for the treatment of OP poisoning in humans.
6184	CPR:3	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and @GENE$ are used for the treatment of OP poisoning in humans.
6185	CPR:4	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of @GENE$ poisoning in humans.
6186	CPR:3	Presently, a combination of an antimuscarinic agent, e.g. @CHEMICAL$, @GENE$ reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.
6187	CPR:3	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended @GENE$ (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.
6188	CPR:3	Presently, a combination of an antimuscarinic agent, e.g. atropine, @CHEMICAL$ reactivator such as one of the recommended pyridinium oximes (@GENE$, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.
6189	CPRFalse	Preclinical properties of @CHEMICAL$: a PET agent for @GENE$ plaques in the brain.
6190	CPRFalse	@CHEMICAL$ ((18)F-AV-45) is such as an agent currently in phase III clinical studies for PET of @GENE$ plaques in the brain.
6191	CPRFalse	(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine (@CHEMICAL$) is such as an agent currently in phase III clinical studies for PET of @GENE$ plaques in the brain.
6192	CPRFalse	METHODS: In vitro binding of @CHEMICAL$ to @GENE$ plaques in the postmortem AD brain tissue was evaluated by in vitro binding assay and autoradiography.
6193	CPRFalse	In vivo biodistribution of @CHEMICAL$ in mice and ex vivo autoradiography of AD transgenic mice (@GENE$/PSEN1) with Abeta aggregates in the brain were performed.
6194	CPRFalse	In vivo biodistribution of @CHEMICAL$ in mice and ex vivo autoradiography of AD transgenic mice (APPswe/@GENE$) with Abeta aggregates in the brain were performed.
6195	CPRFalse	In vivo biodistribution of @CHEMICAL$ in mice and ex vivo autoradiography of AD transgenic mice (APPswe/PSEN1) with @GENE$ aggregates in the brain were performed.
6196	CPRFalse	RESULTS: @CHEMICAL$ displayed a high binding affinity and specificity to @GENE$ plaques (K(d), 3.72 +/- 0.30 nM).
6197	CPRFalse	@CHEMICAL$ displayed excellent binding affinity to @GENE$ plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice.
6198	CPRFalse	The results lend support that @CHEMICAL$ may be a useful PET agent for detecting @GENE$ plaques in the living human brain.
6199	CPRFalse	Palonosetron is a second-generation @CHEMICAL$ 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation @GENE$ antagonists.
6200	CPRFalse	Palonosetron is a second-generation @CHEM-GENE$ antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.
6201	CPR:6	@CHEMICAL$ is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation @GENE$ antagonists.
6202	CPR:6	@CHEMICAL$ is a second-generation @GENE$ antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.
6203	CPR:6	Oral @CHEMICAL$ is likely to be a useful addition to oral formulations of other @GENE$r antagonists in preventing CINV in patients receiving MEC.
6204	CPRFalse	Besides providing the content of terminal groups and individual @CHEMICAL$ and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.
6205	CPRFalse	Besides providing the content of terminal groups and individual glucosamine and @CHEMICAL$ residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.
6206	CPRFalse	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different @CHEMICAL$ substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.
6207	CPRFalse	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the @CHEMICAL$, AT-binding sequence @GENE$ (AT-bs) through quantification of signals of the disaccharide sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.
6208	CPRFalse	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence @CHEMICAL$ (AT-bs) through quantification of signals of the @GENE$ sequence G-A*. Whereas the percent content of HA species is approximately the same for the three LMWHs, substantial differences were observed for the chain distribution of AT-bs as a function of length, with the AT-bs being preferentially contained in the longest chains of each LMWH.
6209	CPRFalse	@CHEMICAL$ and other @GENE$ antagonists in prostate cancer.
6210	CPRFalse	Abarelix and other @CHEM-GENE$ antagonists in prostate cancer.
6211	CPRFalse	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (@CHEMICAL$) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.
6212	CPRFalse	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (@GENE$) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6213	CPRFalse	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (@GENE$) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6214	CPRFalse	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEM-GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6215	CPRFalse	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @CHEMICAL$ and @GENE$ levels.
6216	CPRFalse	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and @GENE$ levels.
6217	CPRFalse	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and @GENE$ levels.
6218	CPRFalse	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEMICAL$, ultimately leading to its de-sensitization and subsequent reduction of LH and @GENE$ levels.
6219	CPR:4	Luteinizing hormone-releasing hormone (LHRH) agonists, such as @CHEMICAL$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.
6220	CPR:5	@CHEMICAL$ (LHRH) agonists, such as @GENE$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6221	CPR:5	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as @GENE$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6222	CPR:3	Luteinizing hormone-releasing hormone (LHRH) agonists, such as @CHEMICAL$, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6223	CPR:4	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, @CHEMICAL$, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.
6224	CPR:5	@CHEMICAL$ (LHRH) agonists, such as buserelin, @GENE$, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6225	CPR:5	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, @GENE$, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6226	CPR:3	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, @CHEMICAL$, leuprorelin and triptorelin, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6227	CPR:4	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, @CHEMICAL$ and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.
6228	CPR:5	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, @GENE$ and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6229	CPR:5	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, @GENE$ and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6230	CPR:3	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, @CHEMICAL$ and triptorelin, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6231	CPR:4	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and @CHEMICAL$, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.
6232	CPR:5	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and @GENE$, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6233	CPR:5	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and @GENE$, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6234	CPR:3	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and @CHEMICAL$, stimulate the pituitary's @GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6235	CPRFalse	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEMICAL$ (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of @GENE$ and testosterone levels.
6236	CPRFalse	@CHEMICAL$ (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @GENE$ (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6237	CPRFalse	Luteinizing hormone-releasing hormone (@CHEMICAL$) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @GENE$ (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6238	CPRFalse	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's @CHEM-GENE$, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.
6239	CPRFalse	However, this reduction is accompanied by a well described increase or 'surge' in @CHEMICAL$ and @GENE$ levels, necessitating the concomitant administration of an antiandrogen to combat the potential effects of transient acceleration in cancer activity.
6240	CPRFalse	Two pure @CHEM-GENE$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.
6241	CPRFalse	Two pure @CHEMICAL$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @GENE$ and consequently do not result in testosterone flare.
6242	CPR:6	Two pure @CHEMICAL$ antagonists have been developed, @GENE$ and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.
6243	CPRFalse	Two pure GnRH antagonists have been developed, @CHEMICAL$ and degarelix, that are devoid of any agonist effect on the @GENE$ and consequently do not result in testosterone flare.
6244	CPR:6	Two pure @CHEMICAL$ antagonists have been developed, abarelix and @GENE$, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.
6245	CPRFalse	Two pure GnRH antagonists have been developed, abarelix and @CHEMICAL$, that are devoid of any agonist effect on the @GENE$ and consequently do not result in testosterone flare.
6246	CPRFalse	Two pure @CHEMICAL$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @GENE$ receptor and consequently do not result in testosterone flare.
6247	CPRFalse	Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @CHEM-GENE$ and consequently do not result in testosterone flare.
6248	CPRFalse	Two pure @CHEMICAL$ antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in @GENE$ flare.
6249	CPRFalse	Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the @CHEMICAL$ and consequently do not result in @GENE$ flare.
6250	CPR:6	@CHEMICAL$ was the first @GENE$ antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.
6251	CPRFalse	Abarelix was the first @CHEM-GENE$ antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.
6252	CPRFalse	Abarelix was the first @CHEMICAL$ antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid @GENE$ suppression is necessary.
6253	CPRFalse	Pharmacologic advances in the field in the past decades, including @CHEMICAL$ and the @GENE$ inhibitors, have contributed significantly to the reduced mortality of estrogen-sensitive breast cancer.
6254	CPRFalse	Pharmacologic advances in the field in the past decades, including tamoxifen and the @CHEMICAL$ inhibitors, have contributed significantly to the reduced mortality of @GENE$-sensitive breast cancer.
6255	CPR:4	@CHEMICAL$, a pure @GENE$ downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.
6256	CPRFalse	Fulvestrant, a pure @CHEM-GENE$ downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.
6257	CPRFalse	@CHEMICAL$ mediated hemodynamic profile of @GENE$.
6258	CPRFalse	Its pathophysiological process is mainly via the competitive inhibition of @CHEM-GENE$.
6259	CPRFalse	Isovaleric acidemia is an autosomal recessive disease of @CHEMICAL$ metabolism due to deficiency of @GENE$.
6260	CPRFalse	Isovaleric acidemia is an autosomal recessive disease of leucine metabolism due to deficiency of @CHEM-GENE$.
6261	CPRFalse	Stoichiometry of @CHEMICAL$ binding to MAP2 measured by the disassembly of chick brain MAP2:@GENE$ microtubules.
6262	CPRFalse	Stoichiometry of @CHEMICAL$ binding to @GENE$ measured by the disassembly of chick brain MAP2:tubulin microtubules.
6263	CPRFalse	Stoichiometry of @CHEMICAL$ binding to MAP2 measured by the disassembly of @GENE$:tubulin microtubules.
6264	CPR:4	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of chick brain MAP2:@GENE$ microtubules is markedly dependent upon the microtubule protein concentration.
6265	CPR:3	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of chick brain MAP2:@GENE$ microtubules is markedly dependent upon the microtubule protein concentration.
6266	CPR:4	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of @GENE$:tubulin microtubules is markedly dependent upon the microtubule protein concentration.
6267	CPR:3	The concentration of @CHEMICAL$ required to inhibit the assembly or to induce the disassembly of @GENE$:tubulin microtubules is markedly dependent upon the microtubule protein concentration.
6268	CPRFalse	Analysis of this relationship shows that @CHEMICAL$ and @GENE$ compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.
6269	CPRFalse	Analysis of this relationship shows that @CHEMICAL$ and tubulin compete for common @GENE$ sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.
6270	CPRFalse	Analysis of this relationship shows that @CHEMICAL$ and tubulin compete for common MAP2 sites, that @GENE$ can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.
6271	CPRFalse	Analysis of this relationship shows that estramustine phosphate and @CHEMICAL$ compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 @GENE$, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.
6272	CPRFalse	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common @CHEMICAL$ sites, that MAP2 can bind 5-6 moles.mole-1 @GENE$, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.
6273	CPRFalse	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common MAP2 sites, that @CHEMICAL$ can bind 5-6 moles.mole-1 @GENE$, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.
6274	CPRFalse	Analysis of this relationship shows that estramustine phosphate and @CHEMICAL$ compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM @GENE$.
6275	CPRFalse	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common @CHEMICAL$ sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM @GENE$.
6276	CPRFalse	Analysis of this relationship shows that estramustine phosphate and tubulin compete for common MAP2 sites, that @CHEMICAL$ can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM @GENE$.
6277	CPR:4	It is proposed that two molecules of @CHEMICAL$ interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:@GENE$ interaction by neutralising two highly conserved basic residues.
6278	CPRFalse	It is proposed that two molecules of @CHEMICAL$ interact with each of the three tubulin-binding sites of @GENE$ and inhibit the MAP2:tubulin interaction by neutralising two highly conserved basic residues.
6279	CPR:4	It is proposed that two molecules of @CHEMICAL$ interact with each of the three tubulin-binding sites of MAP2 and inhibit the @GENE$:tubulin interaction by neutralising two highly conserved basic residues.
6280	CPR:4	Activity of @CHEMICAL$ (Cabozantinib), an oral @GENE$ inhibitor, in patients with medullary thyroid cancer.
6281	CPR:4	Activity of XL184 (@CHEMICAL$), an oral @GENE$ inhibitor, in patients with medullary thyroid cancer.
6282	CPRFalse	Activity of XL184 (Cabozantinib), an oral @CHEM-GENE$ inhibitor, in patients with medullary thyroid cancer.
6283	CPR:4	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (@GENE$), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6284	CPR:4	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and @GENE$, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6285	CPR:4	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of @GENE$, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6286	CPR:4	PURPOSE: XL184 (@CHEMICAL$) is a potent inhibitor of MET, @GENE$ (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6287	CPR:4	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (@GENE$), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6288	CPR:4	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and @GENE$, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6289	CPR:4	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of @GENE$, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6290	CPR:4	PURPOSE: @CHEMICAL$ (cabozantinib) is a potent inhibitor of MET, @GENE$ (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.
6291	CPRFalse	@CHEMICAL$ may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including @GENE$, VEGFR2, and RET.
6292	CPRFalse	@CHEMICAL$ may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, @GENE$, and RET.
6293	CPRFalse	@CHEMICAL$ may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and @GENE$.
6294	CPRFalse	Blood complete counts, high-sensitive @CHEMICAL$, @GENE$ and routine biochemical tests were carried out by routine procedures.
6295	CPRFalse	The activities of @CHEM-GENE$, catalase and glutathione peroxidase were found significantly higher in combined treated than untreated rats.
6296	CPRFalse	The activities of @CHEMICAL$ dismutase, catalase and @GENE$ were found significantly higher in combined treated than untreated rats.
6297	CPRFalse	The activities of @CHEMICAL$ dismutase, @GENE$ and glutathione peroxidase were found significantly higher in combined treated than untreated rats.
6298	CPRFalse	The activities of @CHEMICAL$, catalase and @GENE$ peroxidase were found significantly higher in combined treated than untreated rats.
6299	CPRFalse	The activities of superoxide dismutase, catalase and @CHEM-GENE$ were found significantly higher in combined treated than untreated rats.
6300	CPRFalse	The activities of superoxide dismutase, @CHEMICAL$ and @GENE$ peroxidase were found significantly higher in combined treated than untreated rats.
6301	CPRFalse	Oncogenic mutations in PIK3CA, which encodes the @CHEM-GENE$, occur in ~25% of human breast cancers.
6302	CPRFalse	Oncogenic mutations in @CHEMICAL$, which encodes the @GENE$-3-kinase (PI3K) catalytic subunit p110a, occur in ~25% of human breast cancers.
6303	CPRFalse	Whole-exome analysis of the Pik3ca(@CHEMICAL$)-driven mammary tumors identified multiple mutations, including @GENE$53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.
6304	CPRFalse	Whole-exome analysis of the @CHEMICAL$(H1047R)-driven mammary tumors identified multiple mutations, including @GENE$53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.
6305	CPRFalse	Whole-exome analysis of the Pik3ca(H1047R)-driven mammary tumors identified multiple mutations, including @CHEM-GENE$ mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.
6306	CPR:4	Further, we used this model to test the efficacy of @CHEMICAL$, a @GENE$ inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.
6307	CPR:4	Further, we used this model to test the efficacy of @CHEMICAL$, a PI3K inhibitor, in clinical development, and showed that the tumors respond to @GENE$ inhibition.
6308	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including @GENE$, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6309	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, @GENE$, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6310	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, @GENE$, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6311	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, @GENE$, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6312	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, @GENE$, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6313	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, @GENE$, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6314	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, @GENE$, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6315	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, @GENE$, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.
6316	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, @GENE$, Fdft1, and Fasn, relative to those in HFD control mice.
6317	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, @GENE$, and Fasn, relative to those in HFD control mice.
6318	CPRFalse	@CHEMICAL$ supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and @GENE$, relative to those in HFD control mice.
6319	CPRFalse	A @CHEMICAL$-inducible transgenic mouse model expressing truncated @GENE$ (DN89b-catenin) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic b-catenin expression both in 3D 'crypt culture' and in vivo.
6320	CPRFalse	A @CHEMICAL$-inducible transgenic mouse model expressing truncated b-catenin (DN89@GENE$) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic b-catenin expression both in 3D 'crypt culture' and in vivo.
6321	CPRFalse	A @CHEMICAL$-inducible transgenic mouse model expressing truncated b-catenin (DN89b-catenin) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic @GENE$ expression both in 3D 'crypt culture' and in vivo.
6322	CPRFalse	The interplay between cardiac sarcoplasmic @CHEM-GENE$ and phospholamban is a key regulating factor of contraction and relaxation in the cardiac muscle.
6323	CPRFalse	The interplay between cardiac sarcoplasmic @CHEMICAL$ATPase and @GENE$ is a key regulating factor of contraction and relaxation in the cardiac muscle.
6324	CPRFalse	In heart failure, aberrations in the inhibition of sarcoplasmic @CHEM-GENE$ by phospholamban are associated with anomalies in cardiac functions.
6325	CPRFalse	In heart failure, aberrations in the inhibition of sarcoplasmic @CHEMICAL$ATPase by @GENE$ are associated with anomalies in cardiac functions.
6326	CPRFalse	The aim of our research was to find molecules able to interfere with the inhibitory activity of phospholamban on sarcoplasmic @CHEM-GENE$.
6327	CPRFalse	The aim of our research was to find molecules able to interfere with the inhibitory activity of @CHEMICAL$ on sarcoplasmic @GENE$ATPase.
6328	CPRFalse	By synthesizing and testing a series of alanine point-mutated @CHEMICAL$, we identified which @GENE$ was important for the inhibition of the phospholamban function.
6329	CPRFalse	By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which @CHEMICAL$ was important for the inhibition of the @GENE$ function.
6330	CPRFalse	By synthesizing and testing a series of @CHEMICAL$ point-mutated @GENE$, we identified which amino acid was important for the inhibition of the phospholamban function.
6331	CPRFalse	By synthesizing and testing a series of @CHEMICAL$ point-mutated cyclic peptides, we identified which amino acid was important for the inhibition of the @GENE$ function.
6332	CPRFalse	The structures of active and inactive @CHEMICAL$-mutated @GENE$, and of phospholamban (1-36), were determined by NMR.
6333	CPRFalse	The structures of active and inactive @CHEMICAL$-mutated cyclic peptides, and of @GENE$, were determined by NMR.
6334	CPRFalse	BMMs are the major source of inflammatory factors and @CHEMICAL$, including @GENE$ protease cathepsin K (CTSK).
6335	CPRFalse	BMMs are the major source of inflammatory factors and proteases, including @CHEM-GENE$ cathepsin K (CTSK).
6336	CPRFalse	BMMs are the major source of inflammatory factors and proteases, including @CHEMICAL$ protease @GENE$ (CTSK).
6337	CPRFalse	BMMs are the major source of inflammatory factors and proteases, including @CHEMICAL$ protease cathepsin K (@GENE$).
6338	CPR:4	Inhibitory effect of synthetic @CHEMICAL$, 4-MA and cyanoketone on @GENE$ activity.
6339	CPR:4	Inhibitory effect of synthetic progestins, @CHEMICAL$ and cyanoketone on @GENE$ activity.
6340	CPR:4	Inhibitory effect of synthetic progestins, 4-MA and @CHEMICAL$ on @GENE$ activity.
6341	CPRFalse	Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on @CHEM-GENE$ activity.
6342	CPR:9	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (@GENE$ and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6343	CPR:9	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (@GENE$ and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6344	CPR:9	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and @GENE$) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6345	CPR:9	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and @GENE$) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6346	CPRFalse	@CHEM-GENE$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6347	CPRFalse	Human placental @CHEMICAL$ dehydrogenase/5----4-ene isomerase (@GENE$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6348	CPR:9	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (@GENE$ and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6349	CPR:9	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (@GENE$ and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6350	CPR:9	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and @GENE$) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6351	CPR:9	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and @GENE$) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.
6352	CPR:9	@CHEMICAL$ (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding @GENE$ and is thus involved in the biosynthesis of all classes of hormonal steroids.
6353	CPR:9	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (@CHEMICAL$) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding @GENE$ and is thus involved in the biosynthesis of all classes of hormonal steroids.
6354	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. @GENE$, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6355	CPR:4	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. @CHEMICAL$, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6356	CPR:4	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. @CHEMICAL$, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6357	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic @GENE$ compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6358	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @CHEMICAL$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic @GENE$ compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6359	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @CHEMICAL$ with a Ki value of 56 nM. Synthetic @GENE$ compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6360	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as @GENE$ and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6361	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @CHEMICAL$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as @GENE$ and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6362	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @CHEMICAL$ with a Ki value of 56 nM. Synthetic progestin compounds such as @GENE$ and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6363	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of @CHEMICAL$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and @GENE$ show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6364	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @CHEMICAL$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and @GENE$ show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6365	CPRFalse	Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @CHEMICAL$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and @GENE$ show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6366	CPR:4	@CHEMICAL$, epostane and cyanoketone are potent inhibitors of @GENE$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6367	CPRFalse	@CHEMICAL$, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6368	CPRFalse	@CHEMICAL$, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6369	CPR:4	Trilostane, @CHEMICAL$ and cyanoketone are potent inhibitors of @GENE$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6370	CPRFalse	Trilostane, @CHEMICAL$ and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6371	CPRFalse	Trilostane, @CHEMICAL$ and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6372	CPR:4	Trilostane, epostane and @CHEMICAL$ are potent inhibitors of @GENE$ with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6373	CPRFalse	Trilostane, epostane and @CHEMICAL$ are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known @GENE$ inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6374	CPRFalse	Trilostane, epostane and @CHEMICAL$ are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM. 4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of @GENE$ with a Ki value of 56 nM. Synthetic progestin compounds such as promegestone and RU2323 show relatively strong inhibitory effects with Ki values of 110 and 190 nM, respectively.
6375	CPR:4	@CHEMICAL$, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.
6376	CPR:4	Cyproterone acetate, a @CHEMICAL$ used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.
6377	CPR:4	Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as @CHEMICAL$ and norethindrone that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.
6378	CPR:4	Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and @CHEMICAL$ that are widely used as oral contraceptives also inhibit @GENE$ activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.
6379	CPRFalse	We also examined @CHEMICAL$ receptor signaling by in vivo measurement of @GENE$-stimulated polyphosphoinositides hydrolysis.
6380	CPRFalse	We also examined @CHEMICAL$ receptor signaling by in vivo measurement of DHPG-stimulated @GENE$ hydrolysis.
6381	CPR:3	However, chronic treatment of cLH rats with @CHEMICAL$ did not reverse learned helplessness, indicating that the enhanced @GENE$ function is not the only player in the behavioral phenotype of this genetic model of depression.
6382	CPRFalse	This article is part of a Special Issue entitled '@CHEM-GENE$'.
6383	CPRFalse	Rescue of this impaired extinction consolidation/retrieval was achieved with @CHEMICAL$ (N-methly-d-aspartate partial agonist) or MS-275 (@GENE$ (HDAC) inhibitor), applied after extinction training.
6384	CPRFalse	Rescue of this impaired extinction consolidation/retrieval was achieved with @CHEMICAL$ (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (@GENE$) inhibitor), applied after extinction training.
6385	CPRFalse	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (@CHEMICAL$ partial agonist) or MS-275 (@GENE$ (HDAC) inhibitor), applied after extinction training.
6386	CPRFalse	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (@CHEMICAL$ partial agonist) or MS-275 (histone deacetylase (@GENE$) inhibitor), applied after extinction training.
6387	CPR:4	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or @CHEMICAL$ (@GENE$ (HDAC) inhibitor), applied after extinction training.
6388	CPR:4	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or @CHEMICAL$ (histone deacetylase (@GENE$) inhibitor), applied after extinction training.
6389	CPR:4	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and @GENE$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6390	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.
6391	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@GENE$ (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6392	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of @CHEMICAL$ (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@GENE$) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6393	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or @GENE$ [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6394	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or @CHEMICAL$ [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.
6395	CPR:5	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or @CHEMICAL$ [@GENE$ (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6396	CPR:5	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or @CHEMICAL$ [metabotropic glutamate receptor 7 (@GENE$) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6397	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic @GENE$ receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6398	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic @CHEMICAL$ receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.
6399	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEM-GENE$ (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6400	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic @CHEMICAL$ receptor 7 (@GENE$) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6401	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while @GENE$ or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6402	CPR:3	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while @CHEMICAL$ or PEPA (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.
6403	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEMICAL$ (mGlu7) agonist], while @GENE$ or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6404	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@CHEMICAL$) agonist], while @GENE$ or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6405	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or @GENE$ (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6406	CPR:3	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or @CHEMICAL$ (@GENE$ potentiator) failed to affect extinction acquisition in S1 mice.
6407	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEMICAL$ (mGlu7) agonist], while MS-275 or @GENE$ (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6408	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@CHEMICAL$) agonist], while MS-275 or @GENE$ (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.
6409	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and @CHEMICAL$ inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@GENE$ receptor potentiator) failed to affect extinction acquisition in S1 mice.
6410	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (@CHEM-GENE$ potentiator) failed to affect extinction acquisition in S1 mice.
6411	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [@CHEMICAL$ (mGlu7) agonist], while MS-275 or PEPA (@GENE$ receptor potentiator) failed to affect extinction acquisition in S1 mice.
6412	CPRFalse	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (@CHEMICAL$) agonist], while MS-275 or PEPA (@GENE$ receptor potentiator) failed to affect extinction acquisition in S1 mice.
6413	CPR:4	Electroencephalographic recordings during substance consumption showed reduced alpha activity and @CHEMICAL$ latencies in the @GENE$ group compared to the control group.
6414	CPR:3	These findings suggest that oral consumption of @CHEMICAL$ enhances the efficacy of @GENE$.
6415	CPRFalse	These findings suggest that oral consumption of nicotine enhances the efficacy of @CHEM-GENE$.
6416	CPRFalse	Rats treated with @CHEMICAL$ plus hCG displayed abnormal estrous cycles with increasing @GENE$ biosynthesis.
6417	CPRFalse	Rats treated with insulin plus @CHEMICAL$ displayed abnormal estrous cycles with increasing @GENE$ biosynthesis.
6418	CPRFalse	It was hypothesized that because @CHEMICAL$ accumulates in the proximal tubules (PTs), @GENE$ (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).
6419	CPRFalse	It was hypothesized that because @CHEMICAL$ accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).
6420	CPRFalse	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEM-GENE$ (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).
6421	CPRFalse	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEMICAL$-S-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).
6422	CPRFalse	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEM-GENE$ (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).
6423	CPRFalse	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), glutathione-@CHEMICAL$-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).
6424	CPRFalse	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), @CHEMICAL$ (suggestive of kidney damage at the level of PT) would be expected to be more related to @GENE$ exposure than GST-p (suggestive of kidney damage at the level of the distal tubules).
6425	CPRFalse	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)-a (suggestive of kidney damage at the level of PT) would be expected to be more related to @CHEMICAL$ exposure than @GENE$ (suggestive of kidney damage at the level of the distal tubules).
6426	CPRFalse	Our study determined whether there was a significant dose-dependent correlation between increasing @CHEMICAL$ exposure from dental amalgams and @GENE$ and GST-p as biomarkers of kidney integrity.
6427	CPRFalse	Our study determined whether there was a significant dose-dependent correlation between increasing @CHEMICAL$ exposure from dental amalgams and GST-a and @GENE$ as biomarkers of kidney integrity.
6428	CPRFalse	Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose-dependent correlation between cumulative exposure to @CHEMICAL$ from dental amalgams and urinary levels of @GENE$, after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of GST-p.
6429	CPRFalse	Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose-dependent correlation between cumulative exposure to @CHEMICAL$ from dental amalgams and urinary levels of GST-a, after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of @GENE$.
6430	CPRFalse	Following a 2-h control period during which @CHEMICAL$ infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal @GENE$ (INS) or portal vein glucose infusion (PoG) was measured.
6431	CPRFalse	Following a 2-h control period during which @CHEMICAL$ infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal insulin (@GENE$) or portal vein glucose infusion (PoG) was measured.
6432	CPRFalse	Following a 2-h control period during which fructose infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal @CHEMICAL$ (INS) or portal vein @GENE$ infusion (PoG) was measured.
6433	CPRFalse	Following a 2-h control period during which fructose infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4* basal insulin (@CHEMICAL$) or portal vein @GENE$ infusion (PoG) was measured.
6434	CPRFalse	Increased hepatic glycogen reduced the percent of @CHEMICAL$ taken up by the liver that was deposited in glycogen (74 + 3 vs. 53 + 5% in Gly+INS and SCGly+@GENE$, respectively, and 72 + 3 vs. 50 + 6% in Gly+PoG and SCGly+PoG, respectively).
6435	CPRFalse	Increased hepatic glycogen reduced the percent of @CHEMICAL$ taken up by the liver that was deposited in glycogen (74 + 3 vs. 53 + 5% in Gly+@GENE$ and SCGly+INS, respectively, and 72 + 3 vs. 50 + 6% in Gly+PoG and SCGly+PoG, respectively).
6436	CPRFalse	1. @CHEM-GENE$ (UGTs) are a group of drug-metabolizing enzymes that catalyse the conjugation of endogeonous compounds and xenobiotics to yield hydrophilic glucuronides which subsequently undergo excretion.
6437	CPRFalse	1. @CHEMICAL$-glucuronosyltransferases (@GENE$) are a group of drug-metabolizing enzymes that catalyse the conjugation of endogeonous compounds and xenobiotics to yield hydrophilic glucuronides which subsequently undergo excretion.
6438	CPR:6	Toxicity profile of small-molecule @CHEMICAL$ antagonist @GENE$ is linked to TNF-a pharmacology.
6439	CPRFalse	Toxicity profile of small-molecule IAP antagonist @CHEMICAL$ is linked to @GENE$ pharmacology.
6440	CPR:6	@CHEMICAL$ is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing @GENE$.
6441	CPR:3	@CHEMICAL$ induces @GENE$ transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-a) is the most important for single-agent tumor activity.
6442	CPRFalse	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several @GENE$ and cytokines, of which tumor necrosis factor alpha (TNF-a) is the most important for single-agent tumor activity.
6443	CPRFalse	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several chemokines and @GENE$, of which tumor necrosis factor alpha (TNF-a) is the most important for single-agent tumor activity.
6444	CPRFalse	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several chemokines and cytokines, of which @GENE$ (TNF-a) is the most important for single-agent tumor activity.
6445	CPRFalse	@CHEMICAL$ induces NF-kB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (@GENE$) is the most important for single-agent tumor activity.
6446	CPRFalse	Furthermore, elevations in blood neutrophil count, serum @CHEMICAL$, and other markers of inflammation corresponded to @GENE$ exposure and toxicity and thus may have utility as safety biomarkers.
6447	CPRFalse	In the current study, we investigated whether @CHEMICAL$, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @GENE$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and Tub antisense oligonucleotide (ASO).
6448	CPRFalse	In the current study, we investigated whether insulin, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @CHEMICAL$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular @GENE$ and leptin, and Tub antisense oligonucleotide (ASO).
6449	CPRFalse	In the current study, we investigated whether insulin, @CHEMICAL$, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @GENE$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and Tub antisense oligonucleotide (ASO).
6450	CPRFalse	In the current study, we investigated whether insulin, leptin, and obesity can modulate @CHEMICAL$ in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @GENE$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and Tub antisense oligonucleotide (ASO).
6451	CPRFalse	In the current study, we investigated whether insulin, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @CHEMICAL$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and @GENE$, and Tub antisense oligonucleotide (ASO).
6452	CPRFalse	In the current study, we investigated whether insulin, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic @CHEMICAL$ metabolism. Food intake, metabolic characteristics, signaling proteins, and neuropeptide expression were measured in response to fasting and refeeding, intracerebroventricular insulin and leptin, and @GENE$ antisense oligonucleotide (ASO).
6453	CPRFalse	@CHEMICAL$ @GENE$ phosphorylation (Tub-p-tyr) is modulated by nutritional status.
6454	CPRFalse	@CHEMICAL$ tyrosine phosphorylation (Tub-p-@GENE$) is modulated by nutritional status.
6455	CPRFalse	@CHEMICAL$ is a substrate of insulin receptor @GENE$ kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.
6456	CPRFalse	Tub is a substrate of @CHEM-GENE$ (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.
6457	CPRFalse	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (@GENE$) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.
6458	CPRFalse	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and @GENE$ (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.
6459	CPRFalse	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and leptin receptor (@GENE$)-Janus kinase 2 (JAK2) in hypothalamic nuclei.
6460	CPRFalse	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and leptin receptor (LEPR)-@GENE$ (JAK2) in hypothalamic nuclei.
6461	CPRFalse	Tub is a substrate of insulin receptor @CHEMICAL$ kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (@GENE$) in hypothalamic nuclei.
6462	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of @GENE$ or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6463	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or @GENE$ on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6464	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on @GENE$, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6465	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, @GENE$, melanin-concentrating hormone, and orexin expression.
6466	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, @GENE$, and orexin expression.
6467	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @CHEMICAL$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and @GENE$ expression.
6468	CPRFalse	Inhibition of @CHEMICAL$ expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased @GENE$ consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6469	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of @GENE$ or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6470	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or @GENE$ on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6471	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on @GENE$, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6472	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, @GENE$, melanin-concentrating hormone, and orexin expression.
6473	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, @GENE$, and orexin expression.
6474	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood @CHEMICAL$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and @GENE$ expression.
6475	CPRFalse	Inhibition of @CHEMICAL$ expression in hypothalamus by ASO increased food intake, fasting blood @GENE$, and hepatic glucose output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6476	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of @GENE$ or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6477	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or @GENE$ on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6478	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on @GENE$, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6479	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, @GENE$, melanin-concentrating hormone, and orexin expression.
6480	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, @GENE$, and orexin expression.
6481	CPRFalse	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @CHEMICAL$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and @GENE$ expression.
6482	CPRFalse	Inhibition of @CHEMICAL$ expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic @GENE$ output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.
6483	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and @CHEMICAL$-induced Tub-p-@GENE$ and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.
6484	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in @CHEMICAL$ and insulin-induced Tub-p-@GENE$ and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.
6485	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced @CHEMICAL$-p-@GENE$ and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.
6486	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced Tub-p-@CHEMICAL$ and nuclear translocation, which is reversed by reducing @GENE$ expression.
6487	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and @CHEMICAL$-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing protein @GENE$ phosphatase 1B expression.
6488	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in @CHEMICAL$ and insulin-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing protein @GENE$ phosphatase 1B expression.
6489	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced @CHEMICAL$-p-tyr and nuclear translocation, which is reversed by reducing protein @GENE$ phosphatase 1B expression.
6490	CPRFalse	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing @CHEM-GENE$ expression.
6491	CPR:4	The @CHEMICAL$ inhibitor @GENE$ modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.
6492	CPRFalse	The PARP inhibitor @CHEMICAL$ modifies proliferation, @GENE$ expression and epigenetic marks in thyroid cancer cell lines.
6493	CPR:4	Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the @CHEMICAL$ inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.
6494	CPRFalse	Since @CHEMICAL$ is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the PARP inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.
6495	CPRFalse	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEMICAL$ (NIS) expression, in this study the effect of the PARP inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.
6496	CPRFalse	Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (@CHEMICAL$) expression, in this study the effect of the PARP inhibitor @GENE$ on several properties of thyroid cancer cell lines was investigated.
6497	CPRFalse	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEMICAL$ symporter (NIS) expression, in this study the effect of the @GENE$ inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.
6498	CPRFalse	Since @CHEMICAL$ is supposed to be part of a multimeric repressor of @GENE$ symporter (NIS) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.
6499	CPRFalse	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEM-GENE$ (NIS) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.
6500	CPRFalse	Since PARP-1 is supposed to be part of a multimeric repressor of @CHEMICAL$ symporter (@GENE$) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.
6501	CPR:3	In TPC1, BCPAP, FRO, WRO cell lines @CHEMICAL$ induced a strong increase in @GENE$ mRNA levels.
6502	CPR:3	Accordingly, in transfection experiments performed in TPC1 cells, treatment with @CHEMICAL$ increased @GENE$ activity without affecting PARP-1 binding to the promoter sequence.
6503	CPRFalse	Accordingly, in transfection experiments performed in TPC1 cells, treatment with @CHEMICAL$ increased NIS promoter activity without affecting @GENE$ binding to the promoter sequence.
6504	CPRFalse	We also investigated the epigenetic status of @CHEMICAL$ after @GENE$ treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.
6505	CPR:3	We also investigated the epigenetic status of NIS promoter after @CHEMICAL$ treatment in TPC1 cell line: in addition to an increase of @GENE$ (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.
6506	CPR:3	We also investigated the epigenetic status of NIS promoter after @CHEMICAL$ treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (@GENE$, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.
6507	CPR:3	We also investigated the epigenetic status of NIS promoter after @CHEMICAL$ treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, @GENE$), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.
6508	CPR:4	Both @CHEMICAL$ also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in @GENE$ and COX-2 expressions caused by CSE.
6509	CPR:4	Both @CHEMICAL$ also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and @GENE$ expressions caused by CSE.
6510	CPRFalse	Both apo-lycopenoic acids also decreased CSE-induced ROS production, @CHEMICAL$ formation and reduced the increase in @GENE$ and COX-2 expressions caused by CSE.
6511	CPRFalse	Both apo-lycopenoic acids also decreased CSE-induced ROS production, @CHEMICAL$ formation and reduced the increase in NOX-4 and @GENE$ expressions caused by CSE.
6512	CPRFalse	Plants as a source of butyrylcholinesterase variants designed for enhanced @CHEM-GENE$ activity.
6513	CPRFalse	Plants as a source of @CHEMICAL$ variants designed for enhanced @GENE$ hydrolase activity.
6514	CPR:9	Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme @CHEMICAL$ (BChE), which is capable of breaking down naturally occurring @GENE$ before the drug can influence the reward centers of the brain or affect other areas of the body.
6515	CPR:9	Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (@CHEMICAL$), which is capable of breaking down naturally occurring @GENE$ before the drug can influence the reward centers of the brain or affect other areas of the body.
6516	CPR:9	This prompted the design of variants of @CHEMICAL$ which exhibit significantly improved catalytic activity against @GENE$.
6517	CPRFalse	Plants are a promising means to produce large amounts of these @CHEM-GENE$ variants of BChE, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources.
6518	CPRFalse	Plants are a promising means to produce large amounts of these @CHEMICAL$ hydrolase variants of @GENE$, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources.
6519	CPR:9	Here, in expressing @CHEMICAL$-hydrolyzing mutants of @GENE$ in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.
6520	CPRFalse	Here, in expressing @CHEMICAL$-hydrolyzing mutants of BChE in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered @GENE$ proteins with desired properties.
6521	CPRFalse	Nerve fibers immunoreactive for not only sensory neuromarkers, such as @CHEMICAL$ (CGRP), but also sympathetic neuromarkers, such as @GENE$ hydroxylase (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.
6522	CPRFalse	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (@CHEMICAL$), but also sympathetic neuromarkers, such as @GENE$ hydroxylase (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.
6523	CPRFalse	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEM-GENE$ (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.
6524	CPRFalse	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEMICAL$ hydroxylase (@GENE$) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.
6525	CPRFalse	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEMICAL$ hydroxylase (TH) and @GENE$ (NPY) were increased in the periodontal ligament during ETM.
6526	CPRFalse	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as @CHEMICAL$ hydroxylase (TH) and neuropeptide Y (@GENE$) were increased in the periodontal ligament during ETM.
6527	CPRFalse	@CHEMICAL$ knockout mice exhibit impaired adipocyte @GENE$-dependent insulinotropic polypeptide receptor (GIPR) expression.
6528	CPRFalse	Resistin knockout mice exhibit impaired adipocyte @CHEMICAL$-dependent insulinotropic polypeptide receptor (@GENE$) expression.
6529	CPRFalse	Resistin knockout mice exhibit impaired adipocyte @CHEM-GENE$ (GIPR) expression.
6530	CPRFalse	@CHEMICAL$-dependent insulinotropic polypeptide (GIP) is an @GENE$ that also plays a regulatory role in fat metabolism.
6531	CPRFalse	@CHEMICAL$-dependent insulinotropic polypeptide (@GENE$) is an incretin hormone that also plays a regulatory role in fat metabolism.
6532	CPRFalse	@CHEM-GENE$ (GIP) is an incretin hormone that also plays a regulatory role in fat metabolism.
6533	CPRFalse	In 3T3-L1 cells, @CHEMICAL$ was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).
6534	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of @CHEMICAL$ stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).
6535	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of @CHEMICAL$ (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).
6536	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (@CHEMICAL$) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).
6537	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of @CHEMICAL$ (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).
6538	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (@CHEMICAL$) and reduced phosphorylation of liver kinase B1 (LKB1) and @GENE$-activated protein kinase (AMPK).
6539	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of @CHEMICAL$ (LKB1) and @GENE$-activated protein kinase (AMPK).
6540	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (@CHEMICAL$) and @GENE$-activated protein kinase (AMPK).
6541	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @CHEM-GENE$ (AMPK).
6542	CPRFalse	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and @CHEMICAL$-activated protein kinase (@GENE$).
6543	CPRFalse	Analysis of primary adipocytes isolated from @CHEMICAL$(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6544	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), @CHEMICAL$(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6545	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and @CHEMICAL$(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6546	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that @CHEMICAL$ stimulated the PKB/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6547	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the @CHEMICAL$/LKB1/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6548	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/@CHEMICAL$/AMPK/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6549	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/@CHEMICAL$/LPL pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6550	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/@CHEMICAL$ pathway and @GENE$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6551	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in @GENE$(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6552	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that @GENE$ signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6553	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or @GENE$ responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.
6554	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in @GENE$(+/-) and Retn(-/-) adipocytes.
6555	CPRFalse	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and @CHEMICAL$ uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and @GENE$(-/-) adipocytes.
6556	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins @CHEMICAL$ (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6557	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (@CHEMICAL$)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6558	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/@CHEM-GENE$ (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6559	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (@GENE$), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6560	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of @GENE$/JNK/c-Jun were decreased in Retn(-/-) mice.
6561	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/@GENE$/c-Jun were decreased in Retn(-/-) mice.
6562	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), @CHEMICAL$ (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6563	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (@CHEMICAL$), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6564	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/@GENE$ were decreased in Retn(-/-) mice.
6565	CPRFalse	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @CHEMICAL$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in @GENE$(-/-) mice.
6566	CPRFalse	In addition, genes encoding @CHEMICAL$ (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6567	CPRFalse	In addition, genes encoding tumor necrosis factor (@CHEMICAL$), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun @GENE$-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.
6568	CPRFalse	Chromatin immunoprecipitation assays were used to identify a @CHEM-GENE$ (TRE-III) responsible for c-Jun-mediated transcriptional activation of Gipr.
6569	CPRFalse	Chromatin immunoprecipitation assays were used to identify a @CHEMICAL$ (TPA)-response element (@GENE$) responsible for c-Jun-mediated transcriptional activation of Gipr.
6570	CPRFalse	Chromatin immunoprecipitation assays were used to identify a @CHEMICAL$ (TPA)-response element (TRE-III) responsible for @GENE$-mediated transcriptional activation of Gipr.
6571	CPRFalse	Chromatin immunoprecipitation assays were used to identify a @CHEMICAL$ (TPA)-response element (TRE-III) responsible for c-Jun-mediated transcriptional activation of @GENE$.
6572	CPRFalse	Chromatin immunoprecipitation assays were used to identify a @CHEM-GENE$ (TRE-III) responsible for c-Jun-mediated transcriptional activation of Gipr.
6573	CPRFalse	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (@CHEMICAL$)-response element (@GENE$) responsible for c-Jun-mediated transcriptional activation of Gipr.
6574	CPRFalse	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (@CHEMICAL$)-response element (TRE-III) responsible for @GENE$-mediated transcriptional activation of Gipr.
6575	CPRFalse	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (@CHEMICAL$)-response element (TRE-III) responsible for c-Jun-mediated transcriptional activation of @GENE$.
6576	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @CHEMICAL$ isoforms and @GENE$ (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6577	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and @CHEMICAL$ (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.
6578	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and @GENE$ (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6579	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and @GENE$ (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6580	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @CHEMICAL$ isoforms and prostaglandin E(2) (@GENE$) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6581	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (@CHEMICAL$) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.
6582	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (@GENE$) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6583	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (@GENE$) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6584	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (@CHEMICAL$, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6585	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (@CHEMICAL$, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.
6586	CPR:4	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (@GENE$, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6587	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (@CHEMICAL$, ketorolac) and @GENE$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6588	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, @CHEMICAL$) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6589	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, @CHEMICAL$) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.
6590	CPR:4	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, @GENE$) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6591	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, @CHEMICAL$) and @GENE$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6592	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (@CHEMICAL$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6593	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (@CHEMICAL$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.
6594	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (@GENE$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6595	CPR:4	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (@GENE$, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6596	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, @CHEMICAL$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6597	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, @CHEMICAL$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.
6598	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, @GENE$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6599	CPR:4	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, @GENE$) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6600	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @CHEMICAL$ on the expression of @GENE$ isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6601	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @CHEMICAL$ on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of @GENE$ isoforms in the duodenum.
6602	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective @CHEMICAL$ (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @GENE$ on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6603	CPRFalse	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and @CHEMICAL$ (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and @GENE$ on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.
6604	CPRFalse	Localization and expression of @CHEMICAL$ isoforms (by immunohistochemistry, Western blot) and @GENE$ level (by enzyme immunoassay) were examined.
6605	CPRFalse	Second, feeding increased both the expression of @CHEMICAL$ isoforms and @GENE$ level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine.
6606	CPR:4	Second, feeding increased both the expression of @CHEMICAL$ isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with @GENE$.
6607	CPRFalse	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on @GENE$, G protein-coupled receptor kinase, and dynamin.
6608	CPRFalse	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, @GENE$, and dynamin.
6609	CPRFalse	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and @GENE$.
6610	CPRFalse	Reversal of @CHEMICAL$ D2 agonist-induced inhibition of ventral tegmental area neurons by @GENE$-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and dynamin.
6611	CPRFalse	Reversal of @CHEM-GENE$ agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and dynamin.
6612	CPRFalse	DIR is mediated by @CHEMICAL$ and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.
6613	CPRFalse	DIR is mediated by phospholipase C and @CHEMICAL$ (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.
6614	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (@CHEMICAL$) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.
6615	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and @CHEMICAL$, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.
6616	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @CHEM-GENE$ or neurotensin receptors.
6617	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @CHEMICAL$(2) or @GENE$.
6618	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of @CHEMICAL$ and D1-like DA receptors, or by D2 stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.
6619	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by @CHEMICAL$ stimulation concurrent with activation of @GENE$(2) or neurotensin receptors.
6620	CPRFalse	DIR is mediated by @CHEMICAL$ and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.
6621	CPRFalse	DIR is mediated by phospholipase C and @CHEMICAL$ (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.
6622	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (@CHEMICAL$) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.
6623	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and @CHEMICAL$, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.
6624	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of @CHEMICAL$ or @GENE$ receptors.
6625	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @CHEM-GENE$.
6626	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of @CHEMICAL$ and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.
6627	CPRFalse	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by @CHEMICAL$ stimulation concurrent with activation of 5-HT(2) or @GENE$ receptors.
6628	CPR:3	Reversal of inhibition by @CHEMICAL$ agonist quinpirole was produced by serotonin (50 mM) and by @GENE$ (5-10 nM).
6629	CPRFalse	Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 mM) and by @CHEM-GENE$ (5-10 nM).
6630	CPR:5	Reversal of inhibition by @CHEMICAL$ agonist @GENE$ was produced by serotonin (50 mM) and by neurotensin (5-10 nM).
6631	CPRFalse	Reversal of inhibition by D2 agonist @CHEMICAL$ was produced by serotonin (50 mM) and by @GENE$ (5-10 nM).
6632	CPR:3	Reversal of inhibition by @CHEMICAL$ agonist quinpirole was produced by @GENE$ (50 mM) and by neurotensin (5-10 nM).
6633	CPRFalse	Reversal of inhibition by D2 agonist quinpirole was produced by @CHEMICAL$ (50 mM) and by @GENE$ (5-10 nM).
6634	CPRFalse	@CHEMICAL$-induced or neurotensin-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @GENE$ antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).
6635	CPRFalse	@CHEMICAL$-induced or @GENE$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).
6636	CPRFalse	Serotonin-induced or @CHEMICAL$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @GENE$ antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).
6637	CPRFalse	Serotonin-induced or @CHEM-GENE$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (Go6976).
6638	CPR:6	Serotonin-induced or neurotensin-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @CHEMICAL$ antagonist @GENE$ (Go6976).
6639	CPRFalse	Serotonin-induced or @CHEMICAL$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist @GENE$ (Go6976).
6640	CPR:6	Serotonin-induced or neurotensin-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or @CHEMICAL$ antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (@GENE$).
6641	CPRFalse	Serotonin-induced or @CHEMICAL$-induced reversal was blocked by b-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (@GENE$).
6642	CPRFalse	RSV targets and activates the @CHEM-GENE$; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).
6643	CPRFalse	RSV targets and activates the @CHEMICAL$-dependent protein deacetylase SIRT1; in turn, @GENE$ induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).
6644	CPRFalse	RSV targets and activates the @CHEMICAL$-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing @GENE$ (SOD2).
6645	CPRFalse	RSV targets and activates the @CHEMICAL$-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (@GENE$).
6646	CPRFalse	RSV targets and activates the @CHEMICAL$; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial @GENE$ dismutase (SOD2).
6647	CPRFalse	RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, @CHEMICAL$ induces an intracellular antioxidative mechanism by inducing mitochondrial @GENE$ dismutase (SOD2).
6648	CPRFalse	RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing @CHEM-GENE$ (SOD2).
6649	CPRFalse	RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial @CHEMICAL$ dismutase (@GENE$).
6650	CPR:3	@CHEMICAL$ targets and activates the @GENE$; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).
6651	CPR:3	@CHEMICAL$ targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, @GENE$ induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).
6652	CPR:3	@CHEMICAL$ targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing @GENE$ (SOD2).
6653	CPR:3	@CHEMICAL$ targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (@GENE$).
6654	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with @GENE$, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6655	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with @CHEMICAL$, @GENE$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6656	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with @GENE$, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6657	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with @GENE$, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6658	CPRFalse	However, @CHEMICAL$, but not 3G-RSV, induced SIRT1-dependent @GENE$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6659	CPRFalse	However, @CHEMICAL$, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @GENE$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6660	CPR:3	However, @CHEMICAL$, but not 3G-RSV, induced @GENE$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6661	CPR:3	However, @CHEMICAL$, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @GENE$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6662	CPRFalse	However, 4'G-RSV, but not @CHEMICAL$, induced SIRT1-dependent @GENE$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6663	CPRFalse	However, 4'G-RSV, but not @CHEMICAL$, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @GENE$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6664	CPRFalse	However, 4'G-RSV, but not @CHEMICAL$, induced @GENE$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6665	CPRFalse	However, 4'G-RSV, but not @CHEMICAL$, induced SIRT1-dependent histone H3 deacetylation and @GENE$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6666	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6667	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6668	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6669	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. @GENE$ and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6670	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6671	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6672	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6673	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and @GENE$, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6674	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6675	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6676	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6677	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not @GENE$, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6678	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6679	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6680	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6681	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. @GENE$ and 4'G-RSV inhibited C2C12 cell proliferation, but 3G-RSV did not.
6682	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.
6683	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.
6684	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.
6685	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and @GENE$ inhibited C2C12 cell proliferation, but 3G-RSV did not.
6686	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent @CHEMICAL$ deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.
6687	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, @CHEMICAL$ knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.
6688	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced @CHEMICAL$-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.
6689	CPRFalse	However, 4'G-RSV, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and @CHEMICAL$ expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects. RSV and 4'G-RSV, but not 3G-RSV, mitigated oxidative stress-induced cell death in C2C12 cells and primary neonatal rat cardiomyocytes. RSV and 4'G-RSV inhibited C2C12 cell proliferation, but @GENE$ did not.
6690	CPRFalse	Hydrophobic @CHEMICAL$ in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the @GENE$ transporter.
6691	CPRFalse	Hydrophobic @CHEMICAL$ in the hinge region of the @GENE$ mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.
6692	CPR:9	Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting @CHEMICAL$ efflux by the @GENE$ transporter.
6693	CPRFalse	Hydrophobic amino acids in the hinge region of the @CHEMICAL$ mimetic peptide are essential for promoting @GENE$ efflux by the ABCA1 transporter.
6694	CPR:9	The bihelical @CHEMICAL$ effluxes @GENE$ from cells and reduces inflammation and atherosclerosis in animal models.
6695	CPR:9	Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing @CHEMICAL$ by the @GENE$ transporter.
6696	CPRFalse	These results provide a rationale for future design of therapeutic @CHEMICAL$ mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the ABCA1 transporter during the @GENE$ efflux process.
6697	CPR:9	These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the @CHEMICAL$ transporter during the @GENE$ efflux process.
6698	CPRFalse	Efficacy of the GluK1/@CHEM-GENE$ antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
6699	CPRFalse	Efficacy of the @CHEMICAL$/@GENE$ receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
6700	CPR:6	Efficacy of the GluK1/@CHEMICAL$ antagonist @GENE$ against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
6701	CPR:6	Efficacy of the @CHEMICAL$/AMPA receptor antagonist @GENE$ against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
6702	CPR:6	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEMICAL$ antagonist @GENE$ (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6703	CPR:6	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist @GENE$ (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6704	CPR:6	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist @GENE$ (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6705	CPR:6	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEMICAL$ antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (@GENE$) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6706	CPR:6	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (@GENE$) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6707	CPR:6	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (@GENE$) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6708	CPRFalse	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEM-GENE$ antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6709	CPRFalse	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/@GENE$ (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6710	CPRFalse	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/@GENE$ (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6711	CPRFalse	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/@CHEM-GENE$ antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6712	CPRFalse	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the @CHEMICAL$ (GluR5)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (@GENE$) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6713	CPRFalse	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (@CHEMICAL$)/a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (@GENE$) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.
6714	CPRFalse	@CHEM-GENE$ (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.
6715	CPRFalse	@CHEMICAL$-resistant acid phosphatase (@GENE$) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.
6716	CPRFalse	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old @GENE$-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.
6717	CPRFalse	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-@GENE$ mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.
6718	CPRFalse	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with @GENE$-Cnn1 osteoblasts.
6719	CPRFalse	@CHEMICAL$-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-@GENE$ osteoblasts.
6720	CPR:9	Although acetylcholinesterase (@CHEMICAL$) is primarily a hydrolytic enzyme, metabolising the neurotransmitter @GENE$ in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.
6721	CPR:9	Although @CHEMICAL$ (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter @GENE$ in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.
6722	CPRFalse	Since AChE does not possess a @CHEMICAL$, its anchorage in the membrane is established via the @GENE$ Rich Membrane Anchor (PRiMA), a transmembrane protein.
6723	CPRFalse	Since @CHEMICAL$ does not possess a transmembrane domain, its anchorage in the membrane is established via the @GENE$ Rich Membrane Anchor (PRiMA), a transmembrane protein.
6724	CPRFalse	Since AChE does not possess a transmembrane domain, its anchorage in the membrane is established via the @CHEM-GENE$ (PRiMA), a transmembrane protein.
6725	CPRFalse	Since AChE does not possess a transmembrane domain, its anchorage in the membrane is established via the @CHEMICAL$ Rich Membrane Anchor (@GENE$), a transmembrane protein.
6726	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an @CHEMICAL$- and batimastat-sensitive, but GM6001-insensitive @GENE$, with the possible additional involvement of a thiol isomerase.
6727	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an @CHEMICAL$- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @GENE$.
6728	CPRFalse	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an @GENE$- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.
6729	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and @CHEMICAL$-sensitive, but GM6001-insensitive @GENE$, with the possible additional involvement of a thiol isomerase.
6730	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and @CHEMICAL$-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @GENE$.
6731	CPRFalse	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and @GENE$-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.
6732	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but @CHEMICAL$-insensitive @GENE$, with the possible additional involvement of a thiol isomerase.
6733	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but @CHEMICAL$-insensitive metalloprotease, with the possible additional involvement of a @GENE$.
6734	CPRFalse	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but @GENE$-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.
6735	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive @CHEMICAL$, with the possible additional involvement of a @GENE$ isomerase.
6736	CPRFalse	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @CHEM-GENE$.
6737	CPRFalse	In an effort to understand the shedding process of @CHEMICAL$, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a @GENE$ isomerase.
6738	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist @GENE$.
6739	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist @GENE$.
6740	CPR:6	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the @CHEMICAL$ antagonist @GENE$.
6741	CPR:4	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist @GENE$.
6742	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEM-GENE$ (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.
6743	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic @CHEMICAL$ receptor (@GENE$) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.
6744	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic @CHEMICAL$ receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the @GENE$ antagonist atropine.
6745	CPRFalse	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic @GENE$ receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.
6746	CPR:5	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists @GENE$ or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.
6747	CPR:5	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists @GENE$ or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.
6748	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists @CHEMICAL$ or muscarine, with the effect of carbachol blocked by the @GENE$ antagonist atropine.
6749	CPR:3	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists @GENE$ or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.
6750	CPR:5	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists carbachol or @GENE$, with the effect of carbachol blocked by the mAChR antagonist atropine.
6751	CPR:5	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists carbachol or @GENE$, with the effect of carbachol blocked by the mAChR antagonist atropine.
6752	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or @CHEMICAL$, with the effect of carbachol blocked by the @GENE$ antagonist atropine.
6753	CPR:3	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or @GENE$, with the effect of carbachol blocked by the mAChR antagonist atropine.
6754	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the @CHEMICAL$ (mAChR) agonists carbachol or muscarine, with the effect of @GENE$ blocked by the mAChR antagonist atropine.
6755	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (@CHEMICAL$) agonists carbachol or muscarine, with the effect of @GENE$ blocked by the mAChR antagonist atropine.
6756	CPRFalse	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of @CHEMICAL$ blocked by the @GENE$ antagonist atropine.
6757	CPR:3	Cellular release of @CHEMICAL$ by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of @GENE$ blocked by the mAChR antagonist atropine.
6758	CPRFalse	Circulating very-@CHEMICAL$ from subjects with impaired glucose tolerance accelerates adrenocortical @GENE$ and aldosterone synthesis.
6759	CPRFalse	Circulating very-@CHEMICAL$ from subjects with impaired glucose tolerance accelerates adrenocortical cortisol and @GENE$ synthesis.
6760	CPRFalse	Circulating very-@CHEMICAL$ from subjects with impaired @GENE$ tolerance accelerates adrenocortical cortisol and aldosterone synthesis.
6761	CPRFalse	Apart from their role in cardiovascular homeostasis and immunomodulation, aldosterone and @CHEMICAL$ are also implicated in the pathogenesis of @GENE$ resistance and type 2 diabetes mellitus (T2DM).
6762	CPRFalse	Apart from their role in cardiovascular homeostasis and immunomodulation, @CHEMICAL$ and cortisol are also implicated in the pathogenesis of @GENE$ resistance and type 2 diabetes mellitus (T2DM).
6763	CPRFalse	@CHEMICAL$ induced a greater stimulating effect on adrenocortical @GENE$ and cortisol release compared to HDL and LDL.
6764	CPRFalse	VLDL induced a greater stimulating effect on adrenocortical @CHEMICAL$ and cortisol release compared to @GENE$ and LDL.
6765	CPRFalse	VLDL induced a greater stimulating effect on adrenocortical @CHEMICAL$ and cortisol release compared to HDL and @GENE$.
6766	CPRFalse	@CHEMICAL$ induced a greater stimulating effect on adrenocortical aldosterone and @GENE$ release compared to HDL and LDL.
6767	CPRFalse	VLDL induced a greater stimulating effect on adrenocortical aldosterone and @CHEMICAL$ release compared to @GENE$ and LDL.
6768	CPRFalse	VLDL induced a greater stimulating effect on adrenocortical aldosterone and @CHEMICAL$ release compared to HDL and @GENE$.
6769	CPR:3	@CHEMICAL$ induced ER stress and enhanced @GENE$ cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.
6770	CPR:3	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, @GENE$ and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2a in SH-SY5Y cells.
6771	CPR:3	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and @GENE$ activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2a in SH-SY5Y cells.
6772	CPR:3	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker @GENE$, and enhanced phosphorylation of elf2a in SH-SY5Y cells.
6773	CPR:3	Nevertheless, low @CHEMICAL$ concentrations (> 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of @GENE$ in SH-SY5Y cells.
6774	CPR:3	@CHEMICAL$-induced intracellular GTP depletion activates transcription elongation in @GENE$ gene expression.
6775	CPRFalse	Ribavirin-induced intracellular @CHEMICAL$ depletion activates transcription elongation in @GENE$ gene expression.
6776	CPRFalse	@CHEMICAL$ (Factor VII) is a @GENE$-dependent glycoprotein synthesized in hepatocytes.
6777	CPRFalse	Coagulation FVII (@CHEMICAL$) is a @GENE$-dependent glycoprotein synthesized in hepatocytes.
6778	CPR:3	It was reported previously that @CHEMICAL$ gene (F7) expression was up-regulated by @GENE$ treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.
6779	CPR:3	It was reported previously that FVII gene (@CHEMICAL$) expression was up-regulated by @GENE$ treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.
6780	CPR:3	In the present study, we investigated the molecular mechanism of @CHEMICAL$-induced up-regulation of @GENE$ expression in HepG2 (human hepatoma cell line).
6781	CPRFalse	We found that intracellular GTP depletion by @CHEMICAL$ as well as other @GENE$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.
6782	CPRFalse	We found that intracellular GTP depletion by @CHEMICAL$ as well as other IMPDH (@GENE$) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.
6783	CPRFalse	We found that intracellular GTP depletion by @CHEMICAL$ as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated @GENE$ expression.
6784	CPRFalse	We found that intracellular GTP depletion by ribavirin as well as other @CHEMICAL$ (@GENE$ dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.
6785	CPRFalse	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEM-GENE$) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.
6786	CPRFalse	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEMICAL$ dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated @GENE$ expression.
6787	CPRFalse	We found that intracellular GTP depletion by ribavirin as well as other @CHEMICAL$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as @GENE$ and 6-mercaptopurine, up-regulated F7 expression.
6788	CPRFalse	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEMICAL$) inhibitors, such as @GENE$ and 6-mercaptopurine, up-regulated F7 expression.
6789	CPR:3	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as @CHEMICAL$ and 6-mercaptopurine, up-regulated @GENE$ expression.
6790	CPRFalse	We found that intracellular GTP depletion by ribavirin as well as other @CHEMICAL$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and @GENE$, up-regulated F7 expression.
6791	CPRFalse	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (@CHEMICAL$) inhibitors, such as mycophenolic acid and @GENE$, up-regulated F7 expression.
6792	CPR:3	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and @CHEMICAL$, up-regulated @GENE$ expression.
6793	CPRFalse	We found that intracellular @CHEMICAL$ depletion by ribavirin as well as other @GENE$ (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.
6794	CPRFalse	We found that intracellular @CHEMICAL$ depletion by ribavirin as well as other IMPDH (@GENE$) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.
6795	CPRFalse	We found that intracellular @CHEMICAL$ depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated @GENE$ expression.
6796	CPR:3	@CHEMICAL$ unregulated @GENE$ (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.
6797	CPR:3	@CHEMICAL$ unregulated ELL (@GENE$ mRNA expression before F7 up-regulation.
6798	CPR:3	@CHEMICAL$ unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before @GENE$ up-regulation.
6799	CPRFalse	Ribavirin unregulated @CHEMICAL$ (eleven-nineteen @GENE$-rich leukaemia) 3 mRNA expression before F7 up-regulation.
6800	CPRFalse	Ribavirin unregulated ELL (@CHEM-GENE$ mRNA expression before F7 up-regulation.
6801	CPRFalse	Ribavirin unregulated ELL (eleven-nineteen @CHEMICAL$-rich leukaemia) 3 mRNA expression before @GENE$ up-regulation.
6802	CPR:3	We observed that @CHEMICAL$ enhanced @GENE$ recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.
6803	CPR:3	We observed that @CHEMICAL$ enhanced ELL3 recruitment to @GENE$, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.
6804	CPRFalse	We observed that @CHEMICAL$ enhanced ELL3 recruitment to F7, whereas knockdown of @GENE$ diminished ribavirin-induced FVII mRNA up-regulation.
6805	CPRFalse	We observed that @CHEMICAL$ enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced @GENE$ mRNA up-regulation.
6806	CPRFalse	We observed that ribavirin enhanced @CHEMICAL$ recruitment to F7, whereas knockdown of ELL3 diminished @GENE$-induced FVII mRNA up-regulation.
6807	CPRFalse	We observed that ribavirin enhanced ELL3 recruitment to @CHEMICAL$, whereas knockdown of ELL3 diminished @GENE$-induced FVII mRNA up-regulation.
6808	CPRFalse	We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of @CHEMICAL$ diminished @GENE$-induced FVII mRNA up-regulation.
6809	CPR:3	We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished @CHEMICAL$-induced @GENE$ mRNA up-regulation.
6810	CPR:3	@CHEMICAL$ also enhanced recruitment of @GENE$ (cyclin-dependent kinase 9) and AFF4 to F7.
6811	CPR:3	@CHEMICAL$ also enhanced recruitment of CDK9 (@GENE$) and AFF4 to F7.
6812	CPR:3	@CHEMICAL$ also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and @GENE$ to F7.
6813	CPR:3	@CHEMICAL$ also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to @GENE$.
6814	CPR:3	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing @GENE$, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.
6815	CPR:3	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, @GENE$ and ELL3, to F7, and modulates FVII mRNA transcription elongation.
6816	CPR:3	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and @GENE$, to F7, and modulates FVII mRNA transcription elongation.
6817	CPR:3	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to @GENE$, and modulates FVII mRNA transcription elongation.
6818	CPRFalse	These data suggest that @CHEMICAL$-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates @GENE$ mRNA transcription elongation.
6819	CPRFalse	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing @GENE$, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.
6820	CPRFalse	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, @GENE$ and ELL3, to F7, and modulates FVII mRNA transcription elongation.
6821	CPRFalse	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, AFF4 and @GENE$, to F7, and modulates FVII mRNA transcription elongation.
6822	CPRFalse	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to @GENE$, and modulates FVII mRNA transcription elongation.
6823	CPRFalse	These data suggest that ribavirin-induced intracellular @CHEMICAL$ depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates @GENE$ mRNA transcription elongation.
6824	CPR:3	Collectively, we have elucidated a basal mechanism for @CHEMICAL$-induced @GENE$ mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.
6825	CPRFalse	Neuropeptide Y Y1 receptor knockdown can modify @CHEMICAL$ and c-AMP response element-binding protein in @GENE$-treated rats.
6826	CPRFalse	Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and @CHEMICAL$ in @GENE$-treated rats.
6827	CPRFalse	@CHEMICAL$ knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in @GENE$-treated rats.
6828	CPRFalse	Neuropeptide Y Y1 receptor knockdown can modify @CHEM-GENE$ and c-AMP response element-binding protein in phenylpropanolamine-treated rats.
6829	CPRFalse	Neuropeptide Y Y1 receptor knockdown can modify @CHEMICAL$ peroxidase and @GENE$ in phenylpropanolamine-treated rats.
6830	CPRFalse	@CHEMICAL$ knockdown can modify @GENE$ peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.
6831	CPRFalse	Neuropeptide Y Y1 receptor knockdown can modify @CHEMICAL$ and @GENE$ response element-binding protein in phenylpropanolamine-treated rats.
6832	CPRFalse	Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and @CHEM-GENE$ in phenylpropanolamine-treated rats.
6833	CPRFalse	@CHEMICAL$ knockdown can modify glutathione peroxidase and @GENE$ response element-binding protein in phenylpropanolamine-treated rats.
6834	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (@CHEMICAL$) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.
6835	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEMICAL$ (CREB) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.
6836	CPRFalse	It has been reported that antioxidative enzymes, @CHEMICAL$ (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.
6837	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (@CHEMICAL$), and c-AMP response element-binding protein (CREB) are involved in regulating @GENE$ (PPA)-mediated appetite suppression.
6838	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (@CHEMICAL$) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.
6839	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEMICAL$ (CREB) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.
6840	CPRFalse	It has been reported that antioxidative enzymes, @CHEMICAL$ (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.
6841	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (@CHEMICAL$), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (@GENE$)-mediated appetite suppression.
6842	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEMICAL$ response element-binding protein (@GENE$) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.
6843	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and @CHEM-GENE$ (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.
6844	CPRFalse	It has been reported that antioxidative enzymes, @CHEMICAL$ (NPY), and @GENE$ response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.
6845	CPRFalse	It has been reported that antioxidative enzymes, neuropeptide Y (@CHEMICAL$), and @GENE$ response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.
6846	CPRFalse	Changes in the contents of NPY, Y1R, @CHEM-GENE$ (GP), and CREB were assessed and compared.
6847	CPRFalse	Changes in the contents of NPY, Y1R, @CHEMICAL$ peroxidase (@GENE$), and CREB were assessed and compared.
6848	CPRFalse	Changes in the contents of NPY, Y1R, @CHEMICAL$ peroxidase (GP), and @GENE$ were assessed and compared.
6849	CPRFalse	Changes in the contents of @CHEMICAL$, Y1R, @GENE$ peroxidase (GP), and CREB were assessed and compared.
6850	CPRFalse	Changes in the contents of NPY, @CHEMICAL$, @GENE$ peroxidase (GP), and CREB were assessed and compared.
6851	CPRFalse	By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @CHEMICAL$ treatment was opposite to those of Y1R, @GENE$, and CREB.
6852	CPRFalse	By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @CHEMICAL$ treatment was opposite to those of Y1R, GP, and @GENE$.
6853	CPRFalse	By contrast, @CHEMICAL$ decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @GENE$ treatment was opposite to those of Y1R, GP, and CREB.
6854	CPRFalse	By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during @CHEMICAL$ treatment was opposite to those of @GENE$, GP, and CREB.
6855	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and @GENE$ (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB.
6856	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or @GENE$), revealing an essential role of Y1R in regulating NPY, GP, and CREB.
6857	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, @GENE$, and CREB.
6858	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and @GENE$.
6859	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of @CHEMICAL$ expression modulated the anorectic response of @GENE$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB.
6860	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between @GENE$ and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB.
6861	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of @GENE$ in regulating NPY, GP, and CREB.
6862	CPRFalse	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of @CHEMICAL$ and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating @GENE$, GP, and CREB.
6863	CPRFalse	These results suggest that Y1R participates in the reciprocal regulation of NPY, @CHEMICAL$, and CREB in the hypothalamus during @GENE$ treatment in conscious rats.
6864	CPRFalse	These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and @CHEMICAL$ in the hypothalamus during @GENE$ treatment in conscious rats.
6865	CPRFalse	These results suggest that @CHEMICAL$ participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during @GENE$ treatment in conscious rats.
6866	CPRFalse	These results suggest that Y1R participates in the reciprocal regulation of @CHEMICAL$, GP, and CREB in the hypothalamus during @GENE$ treatment in conscious rats.
6867	CPRFalse	Activation of @CHEM-GENE$ potentiates heteromeric kainate receptors.
6868	CPRFalse	Activation of group I metabotropic @CHEMICAL$ receptors potentiates heteromeric @GENE$.
6869	CPRFalse	Activation of @CHEMICAL$ potentiates heteromeric @GENE$ receptors.
6870	CPRFalse	Activation of group I metabotropic glutamate receptors potentiates heteromeric @CHEM-GENE$.
6871	CPRFalse	@CHEMICAL$ (KARs), a family of ionotropic @GENE$ receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.
6872	CPRFalse	Kainate receptors (@CHEMICAL$), a family of ionotropic @GENE$ receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.
6873	CPRFalse	Kainate receptors (KARs), a family of @CHEM-GENE$, are widely expressed in the central nervous system and are critically involved in synaptic transmission.
6874	CPRFalse	@CHEM-GENE$ (KARs), a family of ionotropic glutamate receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.
6875	CPRFalse	@CHEMICAL$ receptors (@GENE$), a family of ionotropic glutamate receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.
6876	CPRFalse	@CHEMICAL$ receptors (KARs), a family of @GENE$, are widely expressed in the central nervous system and are critically involved in synaptic transmission.
6877	CPRFalse	@CHEMICAL$ activation is influenced by metabotropic @GENE$ receptor (mGlu) signaling, but the underlying mechanisms are not understood.
6878	CPRFalse	KAR activation is influenced by @CHEM-GENE$ (mGlu) signaling, but the underlying mechanisms are not understood.
6879	CPRFalse	KAR activation is influenced by metabotropic @CHEMICAL$ receptor (@GENE$) signaling, but the underlying mechanisms are not understood.
6880	CPRFalse	In hippocampal and cortical cultures, the @CHEMICAL$ signal caused by activation of native @GENE$ was potentiated by activation of group I mGlu receptors.
6881	CPRFalse	In hippocampal and cortical cultures, the @CHEMICAL$ signal caused by activation of native KARs was potentiated by activation of @GENE$.
6882	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @GENE$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6883	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6884	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6885	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6886	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6887	CPRFalse	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @GENE$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6888	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the @GENE$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6889	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6890	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6891	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6892	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.
6893	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @CHEMICAL$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.
6894	CPRFalse	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the @GENE$ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6895	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the @GENE$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6896	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6897	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6898	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6899	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6900	CPR:4	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @GENE$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6901	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator @GENE$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6902	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6903	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6904	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6905	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.
6906	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @CHEMICAL$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.
6907	CPR:4	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator @GENE$ (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6908	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the @GENE$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6909	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6910	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6911	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6912	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6913	CPR:4	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@GENE$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6914	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@GENE$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6915	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6916	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6917	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6918	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.
6919	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@CHEMICAL$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.
6920	CPR:4	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (@GENE$), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6921	CPR:4	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6922	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the @GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6923	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6924	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6925	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6926	CPR:4	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6927	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6928	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6929	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6930	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6931	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.
6932	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @CHEMICAL$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.
6933	CPR:4	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor @GENE$, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6934	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6935	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEM-GENE$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6936	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6937	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6938	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6939	CPRFalse	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6940	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6941	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6942	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6943	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6944	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.
6945	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.
6946	CPRFalse	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @GENE$ kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6947	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6948	CPR:4	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6949	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. @GENE$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6950	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (@GENE$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6951	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @GENE$ by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6952	CPR:4	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6953	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6954	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by @GENE$ of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6955	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @GENE$/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6956	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@GENE$, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6957	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated @GENE$/GluK5.
6958	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @CHEMICAL$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/@GENE$.
6959	CPR:4	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor @GENE$. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.
6960	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the @CHEMICAL$ inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6961	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the @CHEMICAL$ inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6962	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. @CHEMICAL$ (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6963	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (@CHEMICAL$) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6964	CPR:3	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of @CHEMICAL$ by @GENE$ potentiated GluK2/GluK5.
6965	CPRFalse	The potentiation of heteromeric @CHEMICAL$ by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6966	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of @CHEMICAL$ or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6967	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by @CHEMICAL$ of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6968	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of @CHEMICAL$/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6969	CPRFalse	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/@CHEMICAL$, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6970	CPR:3	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @CHEMICAL$ potentiated @GENE$/GluK5.
6971	CPR:3	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @CHEMICAL$ potentiated GluK2/@GENE$.
6972	CPRFalse	The potentiation of heteromeric KARs by @CHEMICAL$ activation was attenuated by GDPbS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by @GENE$ potentiated GluK2/GluK5.
6973	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, @CHEMICAL$836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.
6974	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, @CHEMICAL$836, and Ser840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.
6975	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, @CHEMICAL$836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.
6976	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and @CHEMICAL$840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.
6977	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and @CHEMICAL$840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.
6978	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and @CHEMICAL$840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.
6979	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 @CHEMICAL$-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.
6980	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the @CHEMICAL$ @GENE$-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.
6981	CPRFalse	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 @CHEMICAL$-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.
6982	CPRFalse	Using site-directed mutagenesis, we identified three @CHEMICAL$ (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.
6983	CPRFalse	Using site-directed mutagenesis, we identified three @CHEMICAL$ (Ser833, Ser836, and Ser840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.
6984	CPRFalse	Using site-directed mutagenesis, we identified three @CHEMICAL$ (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.
6985	CPRFalse	Using site-directed mutagenesis, we identified three serines (@CHEMICAL$833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of @GENE$.
6986	CPRFalse	Using site-directed mutagenesis, we identified three serines (@CHEMICAL$833, Ser836, and Ser840) within the membrane proximal region of the @GENE$ C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.
6987	CPRFalse	Using site-directed mutagenesis, we identified three serines (@CHEMICAL$833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for @GENE$-mediated potentiation of KARs.
6988	CPR:3	@CHEMICAL$ (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @GENE$ (S1PR) subtypes.
6989	CPR:3	@CHEMICAL$ (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (@GENE$) subtypes.
6990	CPR:3	Fingolimod (@CHEMICAL$), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @GENE$ (S1PR) subtypes.
6991	CPR:3	Fingolimod (@CHEMICAL$), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (@GENE$) subtypes.
6992	CPRFalse	Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @CHEM-GENE$ (S1PR) subtypes.
6993	CPRFalse	Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different @CHEMICAL$ receptor (@GENE$) subtypes.
6994	CPRFalse	However, recent evidence suggests that the action of @CHEMICAL$ involves @GENE$ expressed by cells resident in the CNS, including neurons.
6995	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the @GENE$ (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.
6996	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the mitogen associated protein kinase (@GENE$) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.
6997	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$ (PtdIns-3-K) pathways.
6998	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @CHEMICAL$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (@GENE$) pathways.
6999	CPRFalse	Neuroprotection was attenuated by @CHEMICAL$, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, @GENE$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.
7000	CPR:6	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective @CHEMICAL$ (S1P1R) antagonist, @GENE$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.
7001	CPR:6	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (@CHEMICAL$) antagonist, @GENE$, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.
7002	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the @CHEMICAL$ (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.
7003	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (@CHEMICAL$) and the @GENE$-3-kinase (PtdIns-3-K) pathways.
7004	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @CHEM-GENE$ (PtdIns-3-K) pathways.
7005	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @CHEMICAL$-3-kinase (@GENE$) pathways.
7006	CPRFalse	Neuroprotection was attenuated by @CHEMICAL$, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.
7007	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective @CHEMICAL$ (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.
7008	CPRFalse	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (@CHEMICAL$) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the @GENE$-3-kinase (PtdIns-3-K) pathways.
7009	CPR:4	Pharmacokinetics and metabolism of @CHEMICAL$, a novel @GENE$ inhibitor, in humans.
7010	CPRFalse	The disposition of anagliptin, an orally active, highly selective @CHEMICAL$ inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq @GENE$ to six healthy men.
7011	CPR:4	The disposition of @CHEMICAL$, an orally active, highly selective @GENE$ inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.
7012	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of @GENE$, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7013	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, @GENE$, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7014	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, @GENE$ and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7015	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and @GENE$, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7016	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of @GENE$, BCRP, MRP2 and MRP4.
7017	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, @GENE$, MRP2 and MRP4.
7018	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, @GENE$ and MRP4.
7019	CPRFalse	Renal clearance of unbound @CHEMICAL$ and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and @GENE$.
7020	CPR:9	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of @GENE$, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7021	CPR:9	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, @GENE$, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7022	CPR:9	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, @GENE$ and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7023	CPR:9	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and @GENE$, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
7024	CPRFalse	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of @GENE$, BCRP, MRP2 and MRP4.
7025	CPRFalse	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, @GENE$, MRP2 and MRP4.
7026	CPRFalse	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, @GENE$ and MRP4.
7027	CPRFalse	Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that @CHEMICAL$ may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and @GENE$.
7028	CPRFalse	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating @CHEMICAL$ and LDL-@GENE$ (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.
7029	CPRFalse	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and @CHEMICAL$-@GENE$ (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.
7030	CPRFalse	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-@CHEMICAL$ (p < 0.001) and improved @GENE$ sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.
7031	CPRFalse	Twice daily injection of @CHEMICAL$ in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-@GENE$ (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.
7032	CPRFalse	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating @CHEMICAL$ and LDL-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.
7033	CPRFalse	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and @CHEMICAL$-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.
7034	CPRFalse	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-cholesterol (p < 0.001) and improved @CHEMICAL$ sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.
7035	CPRFalse	Twice daily injection of @CHEMICAL$ in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) @GENE$ tolerance.
7036	CPRFalse	Energy intake, body weight, circulating @CHEMICAL$ and @GENE$ tolerance of (pGlu-Gln)-CCK-8 mice were similar to lean controls.
7037	CPRFalse	Energy intake, body weight, circulating insulin and @CHEMICAL$ tolerance of @GENE$ mice were similar to lean controls.
7038	CPRFalse	In addition, @CHEMICAL$ prevented the effect of high fat feeding on @GENE$ accumulation in liver and muscle.
7039	CPRFalse	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating @CHEMICAL$ (p < 0.05 to p < 0.01) and @GENE$ (p < 0.05 to p < 0.001) and improved glucose tolerance (p < 0.05) and insulin sensitivity (p < 0.001).
7040	CPRFalse	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating @CHEMICAL$ (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved glucose tolerance (p < 0.05) and @GENE$ sensitivity (p < 0.001).
7041	CPRFalse	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with @CHEMICAL$ for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating @GENE$ (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved glucose tolerance (p < 0.05) and insulin sensitivity (p < 0.001).
7042	CPRFalse	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating glucose (p < 0.05 to p < 0.01) and @CHEMICAL$ (p < 0.05 to p < 0.001) and improved @GENE$ tolerance (p < 0.05) and insulin sensitivity (p < 0.001).
7043	CPRFalse	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating glucose (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved @CHEMICAL$ tolerance (p < 0.05) and @GENE$ sensitivity (p < 0.001).
7044	CPRFalse	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with @CHEMICAL$ for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating glucose (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved @GENE$ tolerance (p < 0.05) and insulin sensitivity (p < 0.001).
7045	CPRFalse	Inhibition of the @CHEM-GENE$ (BSEP) can cause intracellular accumulation of bile acids and is a risk factor for drug-induced liver injury in humans.
7046	CPRFalse	Inhibition of the @CHEMICAL$ export pump (@GENE$) can cause intracellular accumulation of bile acids and is a risk factor for drug-induced liver injury in humans.
7047	CPRFalse	Inhibition of the @CHEMICAL$ (BSEP) can cause intracellular accumulation of @GENE$ and is a risk factor for drug-induced liver injury in humans.
7048	CPRFalse	Inhibition of the bile salt export pump (@CHEMICAL$) can cause intracellular accumulation of @GENE$ and is a risk factor for drug-induced liver injury in humans.
7049	CPR:4	Antiretroviral @CHEMICAL$ inhibitors @GENE$ (LPV) and ritonavir (RTV) are reported BSEP inhibitors.
7050	CPR:4	Antiretroviral protease inhibitors @CHEMICAL$ (LPV) and ritonavir (RTV) are reported @GENE$ inhibitors.
7051	CPR:4	Antiretroviral @CHEMICAL$ inhibitors lopinavir (@GENE$) and ritonavir (RTV) are reported BSEP inhibitors.
7052	CPR:4	Antiretroviral protease inhibitors lopinavir (@CHEMICAL$) and ritonavir (RTV) are reported @GENE$ inhibitors.
7053	CPR:4	Antiretroviral @CHEMICAL$ inhibitors lopinavir (LPV) and @GENE$ (RTV) are reported BSEP inhibitors.
7054	CPR:4	Antiretroviral protease inhibitors lopinavir (LPV) and @CHEMICAL$ (RTV) are reported @GENE$ inhibitors.
7055	CPR:4	Antiretroviral @CHEMICAL$ inhibitors lopinavir (LPV) and ritonavir (@GENE$) are reported BSEP inhibitors.
7056	CPR:4	Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (@CHEMICAL$) are reported @GENE$ inhibitors.
7057	CPRFalse	Quantification of endogenous @CHEMICAL$ in SCRH may reveal important adaptive responses associated with exposure to known @GENE$ inhibitors.
7058	CPRFalse	Pharmacokinetic study of @CHEM-GENE$ (GHRP-6) in nine male healthy volunteers.
7059	CPRFalse	Pharmacokinetic study of @CHEMICAL$-Releasing Peptide 6 (@GENE$) in nine male healthy volunteers.
7060	CPR:3	@CHEMICAL$ is a @GENE$ secretagogue that also enhances tissue viability in different organs.
7061	CPRFalse	Diabetic rats showed significant (p<0.05) increased in plasma @CHEMICAL$, @GENE$ and significant (p<0.05) decreased in circulating insulin and hemoglobin.
7062	CPRFalse	Diabetic rats showed significant (p<0.05) increased in plasma @CHEMICAL$, glycosylated hemoglobin and significant (p<0.05) decreased in circulating @GENE$ and hemoglobin.
7063	CPRFalse	Diabetic rats showed significant (p<0.05) increased in plasma @CHEMICAL$, glycosylated hemoglobin and significant (p<0.05) decreased in circulating insulin and @GENE$.
7064	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7065	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).
7066	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).
7067	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).
7068	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).
7069	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @GENE$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7070	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7071	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7072	CPRFalse	The altered activities of key enzymes such as @CHEM-GENE$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7073	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and @GENE$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7074	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7075	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7076	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).
7077	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).
7078	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).
7079	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).
7080	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @GENE$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7081	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7082	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7083	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$ and @GENE$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7084	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEM-GENE$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7085	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7086	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7087	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).
7088	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).
7089	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).
7090	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).
7091	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas @GENE$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7092	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7093	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7094	CPR:9	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of @GENE$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7095	CPR:9	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of @GENE$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7096	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of @CHEMICAL$ metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7097	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7098	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).
7099	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).
7100	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).
7101	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).
7102	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, @GENE$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7103	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEM-GENE$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7104	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7105	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7106	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @GENE$ kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7107	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$ kinase, @GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7108	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7109	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).
7110	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).
7111	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).
7112	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).
7113	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, pyruvate kinase, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7114	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7115	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7116	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7117	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @GENE$ dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7118	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEM-GENE$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7119	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (@GENE$), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7120	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), @GENE$ (ALT) and alkaline phosphatase (ALP).
7121	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), alanine transaminase (@GENE$) and alkaline phosphatase (ALP).
7122	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), alanine transaminase (ALT) and @GENE$ (ALP).
7123	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (@GENE$).
7124	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7125	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7126	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEM-GENE$ (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7127	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7128	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7129	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @GENE$ transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).
7130	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (@CHEMICAL$), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).
7131	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEM-GENE$ (ALT) and alkaline phosphatase (ALP).
7132	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEMICAL$ transaminase (@GENE$) and alkaline phosphatase (ALP).
7133	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEMICAL$ transaminase (ALT) and @GENE$ (ALP).
7134	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @CHEMICAL$ transaminase (ALT) and alkaline phosphatase (@GENE$).
7135	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas @CHEMICAL$, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).
7136	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, @CHEMICAL$, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).
7137	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of @CHEMICAL$ (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).
7138	CPRFalse	The altered activities of key enzymes such as @CHEMICAL$ and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).
7139	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and @CHEMICAL$ of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).
7140	CPRFalse	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, @CHEMICAL$ and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), @GENE$ transaminase (ALT) and alkaline phosphatase (ALP).
7141	CPR:3	@CHEMICAL$ increases the expression of the pro-apoptotic gene @GENE$ by epigenetic mechanisms in tumor cells.
7142	CPRFalse	Further we found stimulation of @CHEMICAL$-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both @GENE$ and farnesylpyrophosphate.
7143	CPR:3	Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of @CHEMICAL$, which was rescued by re-isoprenylation by both @GENE$ and farnesylpyrophosphate.
7144	CPRFalse	Further we found stimulation of @CHEMICAL$-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and @GENE$.
7145	CPR:3	Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of @CHEMICAL$, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and @GENE$.
7146	CPRFalse	In contrast, @CHEMICAL$ did not affect @GENE$ and DNMT1 expression in MC3T3-E1 non-neoplastic cells.
7147	CPRFalse	In contrast, @CHEMICAL$ did not affect FAS and @GENE$ expression in MC3T3-E1 non-neoplastic cells.
7148	CPRFalse	Data suggest that @CHEMICAL$ via modulation of the activity of small-@GENE$ induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.
7149	CPRFalse	Data suggest that @CHEMICAL$ via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-@GENE$-demethylation and stimulation of FAS-expression.
7150	CPR:3	Data suggest that @CHEMICAL$ via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of @GENE$-expression.
7151	CPRFalse	Data suggest that bisphosphonates via modulation of the activity of small-@CHEMICAL$ induce apoptosis in neoplastic cells by DNA-@GENE$-demethylation and stimulation of FAS-expression.
7152	CPRFalse	Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-@CHEM-GENE$-demethylation and stimulation of FAS-expression.
7153	CPRFalse	Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-@CHEMICAL$-demethylation and stimulation of @GENE$-expression.
7154	CPRFalse	In conclusion the shown epigenetic mechanism underlying the anti-neoplastic activity of @CHEM-GENE$-inhibition, also explains the clinical success of other drugs, which target this pathway.
7155	CPRFalse	@CHEMICAL$ receptor @GENE$ length modifies the effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor activity in human prostate cells.
7156	CPRFalse	@CHEM-GENE$ CAG repeat length modifies the effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on receptor activity in human prostate cells.
7157	CPRFalse	Androgen receptor @CHEMICAL$ length modifies the effect of @GENE$ on receptor activity in human prostate cells.
7158	CPRFalse	@CHEMICAL$ CAG repeat length modifies the effect of @GENE$ on receptor activity in human prostate cells.
7159	CPRFalse	@CHEMICAL$ acts through the @GENE$ (AhR), which interacts with the androgen receptor (AR).
7160	CPRFalse	@CHEMICAL$ acts through the aryl hydrocarbon receptor (@GENE$), which interacts with the androgen receptor (AR).
7161	CPRFalse	@CHEMICAL$ acts through the aryl hydrocarbon receptor (AhR), which interacts with the @GENE$ (AR).
7162	CPRFalse	@CHEMICAL$ acts through the aryl hydrocarbon receptor (AhR), which interacts with the androgen receptor (@GENE$).
7163	CPRFalse	TCDD acts through the @CHEM-GENE$ (AhR), which interacts with the androgen receptor (AR).
7164	CPRFalse	TCDD acts through the @CHEMICAL$ receptor (@GENE$), which interacts with the androgen receptor (AR).
7165	CPRFalse	TCDD acts through the @CHEMICAL$ receptor (AhR), which interacts with the @GENE$ (AR).
7166	CPRFalse	TCDD acts through the @CHEMICAL$ receptor (AhR), which interacts with the androgen receptor (@GENE$).
7167	CPRFalse	TCDD acts through the @CHEMICAL$ (AhR), which interacts with the @GENE$ receptor (AR).
7168	CPRFalse	TCDD acts through the aryl hydrocarbon receptor (@CHEMICAL$), which interacts with the @GENE$ receptor (AR).
7169	CPRFalse	TCDD acts through the aryl hydrocarbon receptor (AhR), which interacts with the @CHEM-GENE$ (AR).
7170	CPRFalse	TCDD acts through the aryl hydrocarbon receptor (AhR), which interacts with the @CHEMICAL$ receptor (@GENE$).
7171	CPRFalse	We investigated the influence of @CHEMICAL$ on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on 5a-dihydrotestosterone-activated ARs containing @GENE$ within normal length range (16, 22, and 28).
7172	CPRFalse	We investigated the influence of @CHEMICAL$ on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on 5a-dihydrotestosterone-activated @GENE$ containing CAG repeats within normal length range (16, 22, and 28).
7173	CPRFalse	We investigated the influence of TCDD on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on @CHEMICAL$-activated ARs containing @GENE$ within normal length range (16, 22, and 28).
7174	CPRFalse	We investigated the influence of TCDD on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on @CHEMICAL$-activated @GENE$ containing CAG repeats within normal length range (16, 22, and 28).
7175	CPRFalse	The AhR target gene CYP1A1 mRNA expression was induced by @CHEMICAL$, but was not affected by the AR @GENE$ length.
7176	CPRFalse	The @CHEMICAL$ target gene CYP1A1 mRNA expression was induced by @GENE$, but was not affected by the AR CAG length.
7177	CPR:3	The AhR target gene @CHEMICAL$ mRNA expression was induced by @GENE$, but was not affected by the AR CAG length.
7178	CPRFalse	The AhR target gene CYP1A1 mRNA expression was induced by @CHEMICAL$, but was not affected by the @GENE$ CAG length.
7179	CPRFalse	@CHEMICAL$ had no effect on @GENE$ activity in PC-3 cells, whereas the shortest AR variant was induced by TCDD in PNT1A cells.
7180	CPRFalse	@CHEMICAL$ had no effect on AR activity in PC-3 cells, whereas the shortest @GENE$ variant was induced by TCDD in PNT1A cells.
7181	CPRFalse	TCDD had no effect on @CHEMICAL$ activity in PC-3 cells, whereas the shortest AR variant was induced by @GENE$ in PNT1A cells.
7182	CPR:3	TCDD had no effect on AR activity in PC-3 cells, whereas the shortest @CHEMICAL$ variant was induced by @GENE$ in PNT1A cells.
7183	CPRFalse	In conclusion, the @CHEMICAL$ length dependent effect of @GENE$ on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of TCDD on AR activity.
7184	CPRFalse	In conclusion, the CAG length dependent effect of @CHEMICAL$ on @GENE$ activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of TCDD on AR activity.
7185	CPRFalse	In conclusion, the CAG length dependent effect of @CHEMICAL$ on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of TCDD on @GENE$ activity.
7186	CPRFalse	In conclusion, the @CHEMICAL$ length dependent effect of TCDD on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of @GENE$ on AR activity.
7187	CPRFalse	In conclusion, the CAG length dependent effect of TCDD on @CHEMICAL$ activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of @GENE$ on AR activity.
7188	CPRFalse	In conclusion, the CAG length dependent effect of TCDD on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of @CHEMICAL$ on @GENE$ activity.
7189	CPRFalse	Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several @CHEMICAL$ in mice and replacement of plasmid by @GENE$ reduced the elevation of all assayed cytokines.
7190	CPR:4	Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by @CHEMICAL$ reduced the elevation of all assayed @GENE$.
7191	CPR:3	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as @GENE$, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).
7192	CPR:3	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, @GENE$ (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).
7193	CPR:3	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (@GENE$) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).
7194	CPR:3	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the @GENE$ (CHOP).
7195	CPR:3	We found that @CHEMICAL$ markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (@GENE$).
7196	CPRFalse	However, down-regulation of @CHEMICAL$ and/or CHOP expression by siRNA had no effect on @GENE$-induced apoptosis in Caki and HCT116 cells.
7197	CPRFalse	However, down-regulation of ATF4 and/or @CHEMICAL$ expression by siRNA had no effect on @GENE$-induced apoptosis in Caki and HCT116 cells.
7198	CPR:9	Contributions of @CHEMICAL$ to the uptake and toxicity of @GENE$ and platinum anticancer drugs in dorsal root ganglion neurons.
7199	CPR:9	Contributions of @CHEMICAL$ to the uptake and toxicity of copper and @GENE$ anticancer drugs in dorsal root ganglion neurons.
7200	CPRFalse	This study aimed to understand the role of @CHEM-GENE$ (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.
7201	CPRFalse	This study aimed to understand the role of @CHEMICAL$ transporter 1 (@GENE$) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.
7202	CPRFalse	This study aimed to understand the role of @CHEMICAL$ transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of @GENE$ (rCtr1) as a membrane transporter of copper and platinum drugs.
7203	CPRFalse	This study aimed to understand the role of @CHEMICAL$ transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@GENE$) as a membrane transporter of copper and platinum drugs.
7204	CPRFalse	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of @GENE$ and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.
7205	CPRFalse	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of @GENE$ and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.
7206	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of @CHEMICAL$ and platinum drugs in cultured rat DRG neurons, and the functional activities of @GENE$ (rCtr1) as a membrane transporter of copper and platinum drugs.
7207	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of @CHEMICAL$ and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@GENE$) as a membrane transporter of copper and platinum drugs.
7208	CPRFalse	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of copper and @GENE$ drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.
7209	CPRFalse	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of copper and @GENE$ drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and platinum drugs.
7210	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and @CHEMICAL$ drugs in cultured rat DRG neurons, and the functional activities of @GENE$ (rCtr1) as a membrane transporter of copper and platinum drugs.
7211	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and @CHEMICAL$ drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@GENE$) as a membrane transporter of copper and platinum drugs.
7212	CPRFalse	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of @GENE$ and platinum drugs.
7213	CPRFalse	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of @GENE$ and platinum drugs.
7214	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of @CHEMICAL$ (rCtr1) as a membrane transporter of @GENE$ and platinum drugs.
7215	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@CHEMICAL$) as a membrane transporter of @GENE$ and platinum drugs.
7216	CPRFalse	This study aimed to understand the role of @CHEMICAL$ (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and @GENE$ drugs.
7217	CPRFalse	This study aimed to understand the role of copper transporter 1 (@CHEMICAL$) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and @GENE$ drugs.
7218	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of @CHEMICAL$ (rCtr1) as a membrane transporter of copper and @GENE$ drugs.
7219	CPRFalse	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (@CHEMICAL$) as a membrane transporter of copper and @GENE$ drugs.
7220	CPR:9	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of @GENE$, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.
7221	CPR:9	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of @GENE$, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.
7222	CPR:9	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, @GENE$, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.
7223	CPR:9	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of copper, @GENE$, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.
7224	CPR:9	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, @GENE$ and carboplatin, in comparison to isogenic vector-transfected control cells.
7225	CPR:9	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of copper, oxaliplatin, @GENE$ and carboplatin, in comparison to isogenic vector-transfected control cells.
7226	CPR:9	Heterologous expression of @CHEMICAL$ in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and @GENE$, in comparison to isogenic vector-transfected control cells.
7227	CPR:9	Heterologous expression of rCtr1 in HEK293 cells (HEK/@CHEMICAL$ cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and @GENE$, in comparison to isogenic vector-transfected control cells.
7228	CPR:9	Cultured rat DRG neurons endogenously expressed @CHEMICAL$ protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up @GENE$, but were resistant to copper toxicity.
7229	CPRFalse	Cultured rat DRG neurons endogenously expressed @CHEMICAL$ protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up copper, but were resistant to @GENE$ toxicity.
7230	CPRFalse	The uptake of copper by both cultured rat DRG neurons and HEK/rCtr1 cells was saturable and inhibited by cold temperature, silver and @CHEMICAL$, consistent with it being mediated by @GENE$.
7231	CPRFalse	The uptake of copper by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells was saturable and inhibited by cold temperature, silver and @GENE$, consistent with it being mediated by rCtr1.
7232	CPRFalse	The uptake of @CHEMICAL$ by both cultured rat DRG neurons and HEK/rCtr1 cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by @GENE$.
7233	CPR:9	The uptake of @CHEMICAL$ by both cultured rat DRG neurons and HEK/@GENE$ cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1.
7234	CPRFalse	The uptake of copper by both cultured rat DRG neurons and HEK/rCtr1 cells was saturable and inhibited by cold temperature, @CHEMICAL$ and zinc, consistent with it being mediated by @GENE$.
7235	CPRFalse	The uptake of copper by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells was saturable and inhibited by cold temperature, @GENE$ and zinc, consistent with it being mediated by rCtr1.
7236	CPRFalse	The accumulation of @CHEMICAL$ by both cultured rat DRG neurons and HEK/@GENE$ cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/rCtr1 cells.
7237	CPRFalse	The accumulation of @CHEMICAL$ by both cultured rat DRG neurons and HEK/rCtr1 cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/@GENE$ cells.
7238	CPRFalse	The accumulation of platinum by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells, during @GENE$ exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/rCtr1 cells.
7239	CPRFalse	The accumulation of platinum by both cultured rat DRG neurons and HEK/rCtr1 cells, during @CHEMICAL$ exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/@GENE$ cells.
7240	CPRFalse	The accumulation of platinum by both cultured rat DRG neurons and HEK/@CHEMICAL$ cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by @GENE$ only in HEK/rCtr1 cells.
7241	CPRFalse	The accumulation of platinum by both cultured rat DRG neurons and HEK/rCtr1 cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by @CHEMICAL$ only in HEK/@GENE$ cells.
7242	CPR:9	In conclusion, @CHEMICAL$ can transport copper and @GENE$ drugs, and sensitizes cells to their cytotoxicities.
7243	CPR:9	In conclusion, @CHEMICAL$ can transport @GENE$ and platinum drugs, and sensitizes cells to their cytotoxicities.
7244	CPR:9	DRG neurons display substantial capacity for accumulating @CHEMICAL$ via a transport process mediated by @GENE$, but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.
7245	CPRFalse	DRG neurons display substantial capacity for accumulating copper via a transport process mediated by @CHEMICAL$, but appear able to resist @GENE$ toxicity and use alternative mechanisms to take up oxaliplatin.
7246	CPR:9	DRG neurons display substantial capacity for accumulating copper via a transport process mediated by @CHEMICAL$, but appear able to resist copper toxicity and use alternative mechanisms to take up @GENE$.
7247	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of @CHEMICAL$ and @GENE$ oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.
7248	CPRFalse	Examination of phosphorylation in @CHEMICAL$, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @GENE$ oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.
7249	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @CHEM-GENE$ (HO-1), but also caused a reduction in p21 protein expression.
7250	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @CHEMICAL$ oxygenase-1 (@GENE$), but also caused a reduction in p21 protein expression.
7251	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @CHEMICAL$ oxygenase-1 (HO-1), but also caused a reduction in @GENE$ protein expression.
7252	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of @GENE$ and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.
7253	CPR:4	Examination of phosphorylation in @CHEMICAL$, we found an inhibitory effect by @GENE$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.
7254	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @GENE$ (HO-1), but also caused a reduction in p21 protein expression.
7255	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (@GENE$), but also caused a reduction in p21 protein expression.
7256	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by @CHEMICAL$ at 20 and 50 mM. Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in @GENE$ protein expression.
7257	CPR:3	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of @GENE$ and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.
7258	CPRFalse	Examination of phosphorylation in @CHEMICAL$, we found an inhibitory effect by glucosamine at 20 and 50 mM. @GENE$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.
7259	CPR:3	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and @GENE$ (HO-1), but also caused a reduction in p21 protein expression.
7260	CPRFalse	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (@GENE$), but also caused a reduction in p21 protein expression.
7261	CPR:4	Examination of phosphorylation in retinoblastoma (Rb) protein, we found an inhibitory effect by glucosamine at 20 and 50 mM. @CHEMICAL$ at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in @GENE$ protein expression.
7262	CPR:4	In addition, @CHEMICAL$ attenuated @GENE$ protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.
7263	CPR:3	In addition, @CHEMICAL$ attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing @GENE$ nuclear accumulation.
7264	CPRFalse	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, @GENE$ and HO-1 expression, and nuclear p21 accumulation.
7265	CPR:4	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in @GENE$ phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.
7266	CPRFalse	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of @GENE$, p53 and HO-1 expression, and nuclear p21 accumulation.
7267	CPRFalse	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and @GENE$ expression, and nuclear p21 accumulation.
7268	CPR:3	Altogether, our results suggest that a high dose of @CHEMICAL$ may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear @GENE$ accumulation.
7269	CPR:5	Characterization of substituted @CHEMICAL$ as highly selective agonists at the @GENE$.
7270	CPRFalse	Characterization of substituted phenylpropylamides as highly selective agonists at the @CHEM-GENE$.
7271	CPRFalse	The two subtypes of @CHEMICAL$ are primarily responsible for mediating the actions of @GENE$.
7272	CPRFalse	Because synthetic @CHEM-GENE$ agonists have considerable therapeutic potentials in modulating insomnia and circadian- related sleep disorders, it is highly desirable to develop subtype-selective melatoninergic compounds.
7273	CPRFalse	The pharmacological potencies of a series of substituted @CHEMICAL$ towards human melatonin MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with @GENE$ phosphorylation and cAMP assays.
7274	CPRFalse	The pharmacological potencies of a series of substituted @CHEMICAL$ towards @GENE$ and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.
7275	CPRFalse	The pharmacological potencies of a series of substituted @CHEMICAL$ towards human melatonin MT(1) and @GENE$ were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.
7276	CPRFalse	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human @CHEMICAL$ MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with @GENE$ phosphorylation and cAMP assays.
7277	CPRFalse	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards @CHEM-GENE$ and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.
7278	CPRFalse	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human @CHEMICAL$ MT(1) and @GENE$ were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.
7279	CPRFalse	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human melatonin MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with @CHEMICAL$ phosphorylation and @GENE$ assays.
7280	CPRFalse	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards @CHEMICAL$ and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and @GENE$ assays.
7281	CPRFalse	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human melatonin MT(1) and @CHEMICAL$ were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and @GENE$ assays.
7282	CPRFalse	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a @CHEMICAL$ substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the @GENE$ potency and at the same time decreased MT(1) potency.
7283	CPRFalse	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a @CHEMICAL$ substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased @GENE$ potency.
7284	CPRFalse	Structure-activity relationship analysis of highly potent subtype-selective ligands (@CHEMICAL$ EC(50) 10-90 pM) revealed that a @GENE$ substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased MT(1) potency.
7285	CPRFalse	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the @CHEMICAL$ ring dramatically enhanced the @GENE$ potency and at the same time decreased MT(1) potency.
7286	CPRFalse	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the @CHEMICAL$ ring dramatically enhanced the MT(2) potency and at the same time decreased @GENE$ potency.
7287	CPRFalse	Structure-activity relationship analysis of highly potent subtype-selective ligands (@CHEMICAL$ EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the @GENE$ ring dramatically enhanced the MT(2) potency and at the same time decreased MT(1) potency.
7288	CPRFalse	The most potent subtype-selective ligand, 2q had a substantially higher potency for @CHEMICAL$ than @GENE$ for elevation of [Ca(2+)]i and inhibition of forskolin-elevated cAMP.
7289	CPRFalse	The most potent subtype-selective ligand, 2q had a substantially higher potency for @CHEMICAL$ than melatonin for elevation of [@GENE$]i and inhibition of forskolin-elevated cAMP.
7290	CPRFalse	These ligands represent invaluable tools for delineating the functional roles of distinct @CHEM-GENE$ subtypes and are viable candidates for drug development.
7291	CPRFalse	@CHEMICAL$ PIM-1 is a novel @GENE$ receptor target associating with high grade breast tumors.
7292	CPRFalse	Proto-oncogene @CHEMICAL$ is a novel @GENE$ receptor target associating with high grade breast tumors.
7293	CPRFalse	Proto-oncogene PIM-1 is a novel @CHEM-GENE$ target associating with high grade breast tumors.
7294	CPR:3	We show that the expression of @CHEMICAL$ is induced in response to @GENE$ in MCF-7 cells and that the induction is mediated by ERa-regulated enhancers located distally upstream from the gene.
7295	CPR:3	We show that the expression of PIM-1 is induced in response to @CHEMICAL$ in MCF-7 cells and that the induction is mediated by @GENE$-regulated enhancers located distally upstream from the gene.
7296	CPRFalse	In sum, identification of @CHEMICAL$ as an ERa target gene adds a novel potential mechanism by which @GENE$ can contribute to breast cancer cell proliferation and carcinogenesis.
7297	CPRFalse	In sum, identification of PIM-1 as an @CHEMICAL$ target gene adds a novel potential mechanism by which @GENE$ can contribute to breast cancer cell proliferation and carcinogenesis.
7298	CPR:9	In this work, the metabolism of four frequently prescribed inhaled GCs, @CHEMICAL$, flunisolide, budesonide, and fluticasone propionate, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.
7299	CPR:9	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, @CHEMICAL$, budesonide, and fluticasone propionate, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.
7300	CPR:9	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, @CHEMICAL$, and fluticasone propionate, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.
7301	CPR:9	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and @CHEMICAL$, by the @GENE$ family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.
7302	CPR:9	@CHEMICAL$, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize @GENE$, budesonide, and fluticasone propionate.
7303	CPR:9	@CHEMICAL$, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, @GENE$, and fluticasone propionate.
7304	CPR:9	@CHEMICAL$, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and @GENE$.
7305	CPR:9	In contrast, @CHEMICAL$ was only metabolized via @GENE$, with no significant turnover by CYP3A5 or CYP3A7.
7306	CPRFalse	In contrast, @CHEMICAL$ was only metabolized via CYP3A4, with no significant turnover by @GENE$ or CYP3A7.
7307	CPRFalse	In contrast, @CHEMICAL$ was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or @GENE$.
7308	CPR:3	Distinct roles of @CHEMICAL$ in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of @GENE$ and CREB activation in hippocampus and prefrontal cortex.
7309	CPR:3	Distinct roles of @CHEMICAL$ in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and @GENE$ activation in hippocampus and prefrontal cortex.
7310	CPRFalse	The @CHEMICAL$ (ERK) and the transcription factor @GENE$ response element-binding protein (CREB) were involved in neuroplastic changes associated with learning and memory.
7311	CPRFalse	The extracellular signal-regulated kinase (@CHEMICAL$) and the transcription factor @GENE$ response element-binding protein (CREB) were involved in neuroplastic changes associated with learning and memory.
7312	CPRFalse	The extracellular signal-regulated kinase (ERK) and the transcription factor @CHEM-GENE$ (CREB) were involved in neuroplastic changes associated with learning and memory.
7313	CPRFalse	The extracellular signal-regulated kinase (ERK) and the transcription factor @CHEMICAL$ response element-binding protein (@GENE$) were involved in neuroplastic changes associated with learning and memory.
7314	CPRFalse	Furthermore, 1.0 mg/kg dose of @CHEMICAL$ injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both @GENE$ and CREB in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in METH-treated mouse groups.
7315	CPRFalse	Furthermore, 1.0 mg/kg dose of @CHEMICAL$ injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both ERK and @GENE$ in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in METH-treated mouse groups.
7316	CPRFalse	Furthermore, 1.0 mg/kg dose of METH injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both @CHEMICAL$ and CREB in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in @GENE$-treated mouse groups.
7317	CPRFalse	Furthermore, 1.0 mg/kg dose of METH injected immediately after retrieval had no effect on spatial memory reconsolidation. Activation of both ERK and @CHEMICAL$ in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in @GENE$-treated mouse groups.
7318	CPR:3	In contrast, activation of both @CHEMICAL$ and CREB in the PFC was found following memory retrieval but not other processes in @GENE$-treated mouse groups.
7319	CPR:3	In contrast, activation of both ERK and @CHEMICAL$ in the PFC was found following memory retrieval but not other processes in @GENE$-treated mouse groups.
7320	CPR:3	Moreover, activation of the @CHEMICAL$ and CREB signaling pathway in the hippocampus might be involved in @GENE$-induced spatial memory changes.
7321	CPR:3	Moreover, activation of the ERK and @CHEMICAL$ signaling pathway in the hippocampus might be involved in @GENE$-induced spatial memory changes.
7322	CPRFalse	The impact of @CHEM-GENE$ administration and maternal love withdrawal on event-related potential (ERP) responses to emotional faces with performance feedback.
7323	CPRFalse	This is the first experimental study on the effect of @CHEM-GENE$ administration on the neural processing of facial stimuli conducted with female participants that uses event-related potentials (ERPs).
7324	CPRFalse	Using a double-blind, placebo-controlled within-subjects design, we studied the effects of 16 IU of intranasal @CHEM-GENE$ on ERPs to pictures combining performance feedback with emotional facial expressions in 48 female undergraduate students.
7325	CPRFalse	Vertex positive potential (VPP) and late positive potential (LPP) amplitudes were more positive after @CHEM-GENE$ compared to placebo administration.
7326	CPRFalse	This suggests that @CHEM-GENE$ increased attention to the feedback stimuli (LPP) and enhanced the processing of emotional faces (VPP).
7327	CPRFalse	@CHEM-GENE$ heightened processing of the happy and disgusted faces primarily for those reporting less love withdrawal.
7328	CPR:3	A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative @CHEMICAL$ and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by @GENE$.
7329	CPR:3	A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential @CHEMICAL$, was highly activated in embryonic pituitary cells and up-regulated by @GENE$.
7330	CPR:3	A reporter construct driven by 4 kb of the @CHEMICAL$ 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by @GENE$.
7331	CPR:3	However, mutating putative @CHEMICAL$ did not substantially reduce induction of ras-dva promoter activity by @GENE$, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.
7332	CPR:3	However, mutating putative GR binding sites did not substantially reduce induction of @CHEMICAL$ activity by @GENE$, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.
7333	CPRFalse	However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by @CHEMICAL$, suggesting additional @GENE$ within the 5'-flanking region are responsible for glucocorticoid regulation.
7334	CPRFalse	Differential modulation of retinal ganglion cell light responses by orthosteric and allosteric @CHEM-GENE$ compounds.
7335	CPRFalse	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of @CHEMICAL$, @GENE$ (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).
7336	CPRFalse	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, @CHEMICAL$ (AZ) and the @GENE$-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).
7337	CPRFalse	To investigate the role of @CHEMICAL$ in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, @GENE$ (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).
7338	CPRFalse	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of @CHEMICAL$, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist @GENE$ (DCPG).
7339	CPR:5	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the @CHEMICAL$-specific orthosteric agonist @GENE$ (DCPG).
7340	CPRFalse	To investigate the role of @CHEMICAL$ in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist @GENE$ (DCPG).
7341	CPRFalse	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of @CHEMICAL$, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (@GENE$).
7342	CPR:5	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the @CHEMICAL$-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (@GENE$).
7343	CPRFalse	To investigate the role of @CHEMICAL$ in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (@GENE$).
7344	CPRFalse	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous @CHEMICAL$ being stronger during bright light stimulation and with @GENE$ receptors mainly being localized away from glutamate release sites, immuno-labeled with VGLUT1.
7345	CPRFalse	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous @CHEMICAL$ being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from glutamate release sites, immuno-labeled with @GENE$.
7346	CPRFalse	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous glutamate being stronger during bright light stimulation and with @CHEMICAL$ receptors mainly being localized away from @GENE$ release sites, immuno-labeled with VGLUT1.
7347	CPRFalse	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous glutamate being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from @CHEMICAL$ release sites, immuno-labeled with @GENE$.
7348	CPRFalse	The differential sensitivity of ganglion cell light responses to @CHEMICAL$ and AZ supports multiple sites where @GENE$ modulates the light responses of ganglion cells.
7349	CPRFalse	@CHEMICAL$, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the @GENE$ antagonist MK-801.
7350	CPRFalse	UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the @CHEM-GENE$ antagonist MK-801.
7351	CPR:6	UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the @CHEMICAL$ antagonist @GENE$.
7352	CPRFalse	Excessive @CHEMICAL$ (NMDAR)-dependent production of @GENE$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).
7353	CPRFalse	Excessive N-Methyl-d-aspartate receptor (@CHEMICAL$)-dependent production of @GENE$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).
7354	CPRFalse	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of @CHEMICAL$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by @GENE$ (PSD-95).
7355	CPRFalse	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of @CHEMICAL$ (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (@GENE$).
7356	CPRFalse	Excessive @CHEMICAL$ (NMDAR)-dependent production of nitric oxide (@GENE$) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).
7357	CPRFalse	Excessive N-Methyl-d-aspartate receptor (@CHEMICAL$)-dependent production of nitric oxide (@GENE$) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).
7358	CPRFalse	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (@CHEMICAL$) is involved in the development and maintenance of chronic pain states, and is mediated by @GENE$ (PSD-95).
7359	CPRFalse	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (@CHEMICAL$) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (@GENE$).
7360	CPRFalse	Excessive @CHEM-GENE$ (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).
7361	CPRFalse	Excessive @CHEMICAL$ receptor (@GENE$)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).
7362	CPRFalse	Excessive @CHEMICAL$ receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by @GENE$ (PSD-95).
7363	CPRFalse	Excessive @CHEMICAL$ receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (@GENE$).
7364	CPRFalse	By binding to both the @CHEMICAL$ and neuronal NO synthase (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and @GENE$ production.
7365	CPRFalse	By binding to both the NMDAR and neuronal NO synthase (nNOS), PSD-95 mediates a specific coupling between @CHEMICAL$ activation and @GENE$ production.
7366	CPRFalse	By binding to both the NMDAR and @CHEMICAL$ (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and @GENE$ production.
7367	CPRFalse	By binding to both the NMDAR and neuronal NO synthase (@CHEMICAL$), PSD-95 mediates a specific coupling between NMDAR activation and @GENE$ production.
7368	CPRFalse	By binding to both the NMDAR and neuronal NO synthase (nNOS), @CHEMICAL$ mediates a specific coupling between NMDAR activation and @GENE$ production.
7369	CPRFalse	By binding to both the @CHEMICAL$ and neuronal @GENE$ synthase (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and NO production.
7370	CPRFalse	By binding to both the NMDAR and neuronal @CHEMICAL$ synthase (nNOS), PSD-95 mediates a specific coupling between @GENE$ activation and NO production.
7371	CPRFalse	By binding to both the NMDAR and @CHEM-GENE$ (nNOS), PSD-95 mediates a specific coupling between NMDAR activation and NO production.
7372	CPRFalse	By binding to both the NMDAR and neuronal @CHEMICAL$ synthase (@GENE$), PSD-95 mediates a specific coupling between NMDAR activation and NO production.
7373	CPRFalse	By binding to both the NMDAR and neuronal @CHEMICAL$ synthase (nNOS), @GENE$ mediates a specific coupling between NMDAR activation and NO production.
7374	CPRFalse	An alternative approach to modulate the @CHEMICAL$-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.
7375	CPRFalse	An alternative approach to modulate the NMDAR-related activity is to perturb the @CHEMICAL$/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.
7376	CPRFalse	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting @CHEMICAL$, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.
7377	CPRFalse	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @CHEMICAL$ production without interfering with the @GENE$ ion channel function.
7378	CPRFalse	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/nNOS complex by targeting PSD-95, thereby decreasing @CHEMICAL$ production without interfering with the NMDAR @GENE$ function.
7379	CPRFalse	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/@CHEMICAL$/nNOS complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.
7380	CPRFalse	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/@CHEMICAL$ complex by targeting PSD-95, thereby decreasing @GENE$ production without interfering with the NMDAR ion channel function.
7381	CPRFalse	Here, we compared the effects of a dimeric PSD-95 inhibitor, @CHEMICAL$, and the @GENE$ antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.
7382	CPR:4	Here, we compared the effects of a dimeric @CHEMICAL$ inhibitor, @GENE$, and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.
7383	CPR:6	Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the @CHEMICAL$ antagonist, @GENE$, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.
7384	CPRFalse	Here, we compared the effects of a dimeric @CHEMICAL$ inhibitor, UCCB01-125, and the NMDAR antagonist, @GENE$, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.
7385	CPRFalse	Control of hypercholesterolemia and atherosclerosis using the @CHEMICAL$ recognition/interaction amino acid sequence of the @GENE$.
7386	CPRFalse	Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction @CHEMICAL$ sequence of the @GENE$.
7387	CPRFalse	The @CHEMICAL$ is an ubiquitous high affinity @GENE$-binding protein reported to be present in the endothelial and smooth muscle cells of the blood vessels; its expression dramatically increased in macrophages found in atherosclerotic plaques.
7388	CPRFalse	A domain in the @CHEMICAL$-terminus of @GENE$ was identified and characterized as the cholesterol recognition/interaction amino acid consensus (CRAC).
7389	CPRFalse	A domain in the carboxy-terminus of @CHEMICAL$ was identified and characterized as the @GENE$ recognition/interaction amino acid consensus (CRAC).
7390	CPRFalse	A domain in the carboxy-terminus of @CHEMICAL$ was identified and characterized as the cholesterol recognition/interaction @GENE$ consensus (CRAC).
7391	CPRFalse	We report herein the therapeutic benefit that resulted for the administration of the VLNYYVWR human CRAC sequence to guinea pigs fed with a high @CHEMICAL$ diet and @GENE$ knock-out B6.129P2-Apoetm1Unc/J mice.
7392	CPRFalse	CRAC treatment (3 and 30mg/kg once daily for 6 weeks) resulted in reduced circulating @CHEMICAL$ levels in guinea pigs fed with 2% high cholesterol diet and @GENE$ knock-out B6.129P2-Apoetm1Unc/J mice.
7393	CPRFalse	CRAC treatment (3 and 30mg/kg once daily for 6 weeks) resulted in reduced circulating cholesterol levels in guinea pigs fed with 2% high @CHEMICAL$ diet and @GENE$ knock-out B6.129P2-Apoetm1Unc/J mice.
7394	CPR:3	The treatment also prevented the high @CHEMICAL$ diet-induced increase in serum @GENE$, total and isoforms, markers of neurological, cardiac and muscular damage.
7395	CPRFalse	The treatment also prevented the high cholesterol diet-induced increase in serum @CHEM-GENE$, total and isoforms, markers of neurological, cardiac and muscular damage.
7396	CPR:3	GIP potentiates @CHEMICAL$-stimulated @GENE$ secretion and induces energy accumulation into adipose tissue, resulting in obesity.
7397	CPRFalse	@CHEMICAL$ potentiates @GENE$-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity.
7398	CPR:3	Diet, physical exercise and @CHEMICAL$ administration increase serum @GENE$ (AMH) levels in women with polycystic ovary syndrome (PCOS).
7399	CPR:3	Diet, physical exercise and @CHEMICAL$ administration increase serum Anti-Mullerian Hormone (@GENE$) levels in women with polycystic ovary syndrome (PCOS).
7400	CPRFalse	The present study investigates the combined effect of diet, physical exercise and @CHEMICAL$ for 24 weeks, on serum Anti-Mullerian Hormone (@GENE$) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.
7401	CPRFalse	The present study investigates the combined effect of diet, physical exercise and @CHEMICAL$ for 24 weeks, on serum @GENE$e (AMH) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.
7402	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, @CHEMICAL$, LH, PRL, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7403	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, @CHEMICAL$, PRL, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7404	CPRFalse	At baseline, week 12 and week 24, serum levels of @CHEMICAL$, FSH, LH, PRL, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7405	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, @CHEMICAL$, @GENE$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7406	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, @GENE$ (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7407	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, sex hormone-binding globulin (@GENE$), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7408	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, sex hormone-binding globulin (SHBG), glucose, and @GENE$ were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7409	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, @CHEMICAL$, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and @GENE$ Resistance (IR) indices were calculated.
7410	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, @CHEMICAL$, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7411	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, @CHEMICAL$, PRL, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7412	CPRFalse	At baseline, week 12 and week 24, serum levels of @CHEMICAL$, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7413	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, @CHEMICAL$, androgens, sex hormone-binding globulin (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7414	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, @CHEMICAL$ (SHBG), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7415	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (@CHEMICAL$), @GENE$, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7416	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @CHEMICAL$, and @GENE$ were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.
7417	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), @CHEMICAL$, and insulin were measured and Free Androgen Index (FAI) and @GENE$ Resistance (IR) indices were calculated.
7418	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, @CHEMICAL$, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.
7419	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, @CHEMICAL$, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.
7420	CPRFalse	At baseline, week 12 and week 24, serum levels of @CHEMICAL$, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.
7421	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, @CHEMICAL$, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.
7422	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, @CHEMICAL$ (SHBG), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.
7423	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (@CHEMICAL$), glucose, and insulin were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.
7424	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and @CHEMICAL$ were measured and Free @GENE$ Index (FAI) and Insulin Resistance (IR) indices were calculated.
7425	CPRFalse	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free @CHEMICAL$ Index (FAI) and @GENE$ Resistance (IR) indices were calculated.
7426	CPRFalse	After 12 weeks @CHEMICAL$ and SHBG were increased, while @GENE$ decreased.
7427	CPRFalse	After 12 weeks LH and @CHEMICAL$ were increased, while @GENE$ decreased.
7428	CPRFalse	We concluded that in overweight and obese women with PCOS @CHEMICAL$ administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and @GENE$ sensitivity, and increased serum AMH levels.
7429	CPR:3	We concluded that in overweight and obese women with PCOS @CHEMICAL$ administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum @GENE$ levels.
7430	CPRFalse	Lessons from the dissection of the @CHEMICAL$ (AF-1 and AF-2) of the @GENE$ receptor alpha in vivo.
7431	CPRFalse	Lessons from the dissection of the activation functions (@CHEMICAL$ and AF-2) of the @GENE$ receptor alpha in vivo.
7432	CPRFalse	Lessons from the dissection of the activation functions (AF-1 and @CHEMICAL$) of the @GENE$ receptor alpha in vivo.
7433	CPRFalse	Lessons from the dissection of the activation functions (AF-1 and AF-2) of the @CHEM-GENE$ in vivo.
7434	CPRFalse	These actions are mediated by the activation of @CHEM-GENE$ (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).
7435	CPRFalse	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent @GENE$ (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).
7436	CPRFalse	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions @GENE$ and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).
7437	CPRFalse	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and @GENE$, but can also elicit rapid membrane initiated steroid signals (MISS).
7438	CPRFalse	These actions are mediated by the activation of @CHEMICAL$ receptors (ER) alpha (ERa) and beta (@GENE$), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).
7439	CPRFalse	These actions are mediated by the activation of @CHEMICAL$ (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).
7440	CPRFalse	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent @CHEMICAL$ (AF)-1 and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).
7441	CPRFalse	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions @CHEMICAL$ and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).
7442	CPRFalse	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (ERb), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and @CHEMICAL$, but can also elicit rapid membrane initiated @GENE$ signals (MISS).
7443	CPRFalse	These actions are mediated by the activation of estrogen receptors (ER) alpha (ERa) and beta (@CHEMICAL$), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated @GENE$ signals (MISS).
7444	CPRFalse	However, the use of these @CHEMICAL$ or selective @GENE$ modulators (SERMs) have also induced undesired effects.
7445	CPRFalse	However, the use of these estrogens or selective @CHEM-GENE$ modulators (SERMs) have also induced undesired effects.
7446	CPRFalse	Inhibitory effect of @CHEMICAL$ on excretion of JBP485 via @GENE$ in rats.
7447	CPRFalse	Inhibitory effect of 1a,25-dihydroxyvitamin D3 on excretion of @CHEMICAL$ via @GENE$ in rats.
7448	CPRFalse	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of @CHEMICAL$ (Oat)1 and Oat3 in rat kidney in response to @GENE$ treatment.
7449	CPRFalse	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter @CHEMICAL$ and Oat3 in rat kidney in response to @GENE$ treatment.
7450	CPRFalse	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter (Oat)1 and @CHEMICAL$ in rat kidney in response to @GENE$ treatment.
7451	CPR:4	Moreover, @CHEMICAL$ decreased expression of @GENE$ and Oat3 in rat kidney.
7452	CPR:4	Moreover, @CHEMICAL$ decreased expression of Oat1 and @GENE$ in rat kidney.
7453	CPRFalse	The mechanism of interaction between @CHEMICAL$ and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of @GENE$ in rat kidney.
7454	CPRFalse	The mechanism of interaction between JBP485 and @CHEMICAL$ could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of @GENE$ in rat kidney.
7455	CPR:4	The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of @CHEMICAL$ on expression of @GENE$ in rat kidney.
7456	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of @GENE$-G2.0-PAMAM or ethynyl-G3.0-PAMAM dendrons.
7457	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of @GENE$-G2.0-PAMAM or ethynyl-G3.0-PAMAM dendrons.
7458	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-@GENE$ or ethynyl-G3.0-PAMAM dendrons.
7459	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-@GENE$ or ethynyl-G3.0-PAMAM dendrons.
7460	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or @GENE$-G3.0-PAMAM dendrons.
7461	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or @GENE$-G3.0-PAMAM dendrons.
7462	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a @CHEMICAL$ (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or ethynyl-G3.0-@GENE$ dendrons.
7463	CPRFalse	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (@CHEMICAL$) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-PAMAM or ethynyl-G3.0-@GENE$ dendrons.
7464	CPRFalse	The attachment of @CHEMICAL$-G2.0-PAMAM dendrons to @GENE$ yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic PAMAM shell.
7465	CPRFalse	The attachment of ethynyl-G2.0-@CHEMICAL$ dendrons to @GENE$ yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic PAMAM shell.
7466	CPRFalse	The attachment of ethynyl-G2.0-PAMAM dendrons to @CHEMICAL$ yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic @GENE$ shell.
7467	CPRFalse	Significantly higher loading of @CHEMICAL$ was observed for dendronized G2-DHSA compared with the native protein due to the availability of binding pockets of the @GENE$ core, and interaction with the dendritic shell.
7468	CPRFalse	The present study investigated the effect of neonatal exposure to diazinon on hippocampus-dependent novel object recognition test performance and the expression of the @CHEM-GENE$ and its signal transduction pathway-related genes in the hippocampi of young adult and adult mice.
7469	CPRFalse	The present study investigated the effect of neonatal exposure to diazinon on hippocampus-dependent novel object recognition test performance and the expression of the @CHEM-GENE$ and its signal transduction pathway-related genes in the hippocampi of young adult and adult mice.
7470	CPRFalse	The present study investigated the effect of neonatal exposure to @CHEMICAL$ on hippocampus-dependent novel object recognition test performance and the expression of the @GENE$ and its signal transduction pathway-related genes in the hippocampi of young adult and adult mice.
7471	CPRFalse	The hippocampi were collected on PND 50 or PND 85 after the completion of the novel object recognition test, and the expression levels of @CHEMICAL$ and the @GENE$ receptor and its signal transduction pathway-related genes were examined using real-time RT-PCR.
7472	CPRFalse	The hippocampi were collected on PND 50 or PND 85 after the completion of the novel object recognition test, and the expression levels of neurotrophins and the @CHEM-GENE$ and its signal transduction pathway-related genes were examined using real-time RT-PCR.
7473	CPRFalse	The @CHEM-GENE$ and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7474	CPRFalse	The @CHEMICAL$ receptor subunits NR1 and NR2B and the related protein @GENE$ calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7475	CPRFalse	The @CHEMICAL$ receptor subunits NR1 and NR2B and the related protein kinase @GENE$ and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7476	CPRFalse	The @CHEMICAL$ receptor subunits NR1 and NR2B and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ mRNA levels were reduced in the PND 50 mice.
7477	CPRFalse	The @CHEMICAL$ and the related protein kinase @GENE$/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7478	CPRFalse	The NMDA receptor subunits NR1 and NR2B and the related protein @CHEMICAL$ @GENE$/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7479	CPRFalse	The NMDA receptor subunits NR1 and NR2B and the related protein kinase @CHEM-GENE$ and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7480	CPRFalse	The NMDA receptor subunits NR1 and NR2B and the related protein kinase @CHEMICAL$/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ mRNA levels were reduced in the PND 50 mice.
7481	CPRFalse	The @CHEMICAL$ and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7482	CPRFalse	The NMDA receptor subunits NR1 and NR2B and the related protein @CHEMICAL$ calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @GENE$ responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7483	CPRFalse	The NMDA receptor subunits NR1 and NR2B and the related protein kinase @CHEMICAL$ and the transcription factor @GENE$ responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.
7484	CPRFalse	The NMDA receptor subunits NR1 and NR2B and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor @CHEM-GENE$ mRNA levels were reduced in the PND 50 mice.
7485	CPRFalse	These results indicate that neonatal @CHEMICAL$ exposure impaired the hippocampus-dependent novel object recognition ability, accompanied by a modulation in the expressions of the @GENE$ and neurotrophin in young adult and adult mice.
7486	CPRFalse	These results indicate that neonatal diazinon exposure impaired the hippocampus-dependent novel object recognition ability, accompanied by a modulation in the expressions of the @CHEM-GENE$ and neurotrophin in young adult and adult mice.
7487	CPRFalse	Legumain is a lysosomal @CHEM-GENE$ whose biological function remains poorly defined.
7488	CPRFalse	@CHEMICAL$ is a lysosomal @GENE$ protease whose biological function remains poorly defined.
7489	CPRFalse	The accuracy of DNA synthesis depends on the accuracy of the @CHEMICAL$ as well as the quality and concentration(s) of the available @GENE$ DNA precursors (dNTPs).
7490	CPRFalse	The accuracy of DNA synthesis depends on the accuracy of the @CHEMICAL$ as well as the quality and concentration(s) of the available 5'-deoxynucleoside-triphosphate DNA precursors (@GENE$).
7491	CPRFalse	These strains, defective in @CHEMICAL$ and @GENE$ kinase, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.
7492	CPRFalse	These strains, defective in dCTP deaminase and @CHEM-GENE$, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.
7493	CPRFalse	These strains, defective in @CHEMICAL$ and nucleoside diphosphate kinase, respectively, are characterized by both disturbances of @GENE$ pools and a mutator phenotype.
7494	CPRFalse	These strains, defective in dCTP deaminase and @CHEMICAL$, respectively, are characterized by both disturbances of @GENE$ pools and a mutator phenotype.
7495	CPRFalse	These strains, defective in @CHEM-GENE$ and nucleoside diphosphate kinase, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.
7496	CPRFalse	These strains, defective in @CHEMICAL$ deaminase and @GENE$, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.
7497	CPRFalse	We show that dcd strains suffer from increased intracellular levels of @CHEMICAL$ (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for @GENE$ and A*T>T*A transversions (27- and 42-fold enhancement, respectively).
7498	CPRFalse	We show that dcd strains suffer from increased intracellular levels of @CHEMICAL$ (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and @GENE$ transversions (27- and 42-fold enhancement, respectively).
7499	CPRFalse	We show that @CHEMICAL$ strains suffer from increased intracellular levels of @GENE$ (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and A*T>T*A transversions (27- and 42-fold enhancement, respectively).
7500	CPRFalse	We show that dcd strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of @CHEMICAL$ (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for @GENE$ and A*T>T*A transversions (27- and 42-fold enhancement, respectively).
7501	CPRFalse	We show that dcd strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of @CHEMICAL$ (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and @GENE$ transversions (27- and 42-fold enhancement, respectively).
7502	CPRFalse	We show that @CHEMICAL$ strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of @GENE$ (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for G*C>T*A and A*T>T*A transversions (27- and 42-fold enhancement, respectively).
7503	CPRFalse	In contrast, ndk strains possess a lowered @CHEMICAL$ level (4-fold) and modestly enhanced dCTP level (2-fold), while its mutator effect is specific for just the @GENE$ transversions.
7504	CPRFalse	In contrast, @CHEMICAL$ strains possess a lowered @GENE$ level (4-fold) and modestly enhanced dCTP level (2-fold), while its mutator effect is specific for just the A*T>T*A transversions.
7505	CPRFalse	In contrast, ndk strains possess a lowered dATP level (4-fold) and modestly enhanced @CHEMICAL$ level (2-fold), while its mutator effect is specific for just the @GENE$ transversions.
7506	CPRFalse	In contrast, @CHEMICAL$ strains possess a lowered dATP level (4-fold) and modestly enhanced @GENE$ level (2-fold), while its mutator effect is specific for just the A*T>T*A transversions.
7507	CPRFalse	Overall, our analysis reveals for both strains a satisfactory correlation between @CHEMICAL$ pool alterations and the replication error rates, and also suggests that a minimal explanation for the @GENE$ mutator does not require assumptions beyond the predicted effect of the dNTP pools.
7508	CPRFalse	Overall, our analysis reveals for both strains a satisfactory correlation between dNTP pool alterations and the replication error rates, and also suggests that a minimal explanation for the @CHEMICAL$ mutator does not require assumptions beyond the predicted effect of the @GENE$ pools.
7509	CPRFalse	@CHEMICAL$ signaling pathways regulate mitochondrial-mediated apoptosis induced by @GENE$ in human hepatoblastoma cancer cells.
7510	CPR:4	@CHEMICAL$ is able to induce apoptosis through mitochondrial dysfunction and inhibition of @GENE$/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.
7511	CPR:4	@CHEMICAL$ is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/@GENE$ signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.
7512	CPRFalse	@CHEMICAL$ is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of ISO on @GENE$ signaling pathways remain unknown.
7513	CPRFalse	ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of @CHEMICAL$/Akt signaling pathway in HepG2 cells, however, the effects of @GENE$ on MAPK signaling pathways remain unknown.
7514	CPRFalse	ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/@CHEMICAL$ signaling pathway in HepG2 cells, however, the effects of @GENE$ on MAPK signaling pathways remain unknown.
7515	CPRFalse	ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of @CHEMICAL$ on @GENE$ signaling pathways remain unknown.
7516	CPRFalse	The present study investigated the effects of @CHEMICAL$ on this pathway, and the roles of @GENE$ kinases on mitochondrial-mediated apoptosis in HepG2 cells.
7517	CPRFalse	The present study investigated the effects of @CHEMICAL$ on this pathway, and the roles of MAPK @GENE$ on mitochondrial-mediated apoptosis in HepG2 cells.
7518	CPRFalse	@CHEMICAL$ significantly inhibited the levels of @GENE$ kinase and increased the expression of JNK and p38 kinases.
7519	CPR:3	@CHEMICAL$ significantly inhibited the levels of ERK1/2 kinase and increased the expression of @GENE$ and p38 kinases.
7520	CPR:3	@CHEMICAL$ significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and @GENE$ kinases.
7521	CPR:3	@CHEMICAL$ significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and p38 @GENE$.
7522	CPRFalse	Furthermore, @CHEMICAL$ (an @GENE$ inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.
7523	CPR:3	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the @GENE$/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.
7524	CPR:3	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/@GENE$ ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.
7525	CPRFalse	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of @GENE$ to the cytosol fraction, and the levels of cleaved caspase-3.
7526	CPRFalse	Furthermore, @CHEMICAL$ (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved @GENE$.
7527	CPRFalse	Furthermore, U0126 (an @CHEMICAL$ inhibitor) significantly enhanced the @GENE$-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.
7528	CPR:3	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the @GENE$/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.
7529	CPR:3	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the Bax/@GENE$ ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.
7530	CPRFalse	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the Bax/Bcl-2 ratio, the release of @GENE$ to the cytosol fraction, and the levels of cleaved caspase-3.
7531	CPRFalse	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the @CHEMICAL$-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved @GENE$.
7532	CPR:4	While @CHEMICAL$ (a @GENE$ inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.
7533	CPRFalse	While @CHEMICAL$ (a JNK inhibitor) and SB203580 (a @GENE$ inhibitor) markedly prevented the expression of these proteins induced by ISO.
7534	CPRFalse	While SP600125 (a @CHEMICAL$ inhibitor) and @GENE$ (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.
7535	CPR:4	While SP600125 (a JNK inhibitor) and @CHEMICAL$ (a @GENE$ inhibitor) markedly prevented the expression of these proteins induced by ISO.
7536	CPR:3	While SP600125 (a @CHEMICAL$ inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by @GENE$.
7537	CPR:3	While SP600125 (a JNK inhibitor) and SB203580 (a @CHEMICAL$ inhibitor) markedly prevented the expression of these proteins induced by @GENE$.
7538	CPRFalse	Furthermore, the ROS inhibitor (@CHEMICAL$) notably promoted the inhibited effect of ISO on the @GENE$ kinase.
7539	CPRFalse	Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of @CHEMICAL$ on the @GENE$ kinase.
7540	CPR:4	@CHEMICAL$ also suppressed the p-@GENE$ and p-p38, but failed to reverse the effects of ISO.
7541	CPR:4	@CHEMICAL$ also suppressed the p-JNK and @GENE$, but failed to reverse the effects of ISO.
7542	CPRFalse	NAC also suppressed the p-@CHEMICAL$ and p-p38, but failed to reverse the effects of @GENE$.
7543	CPRFalse	NAC also suppressed the p-JNK and @CHEMICAL$, but failed to reverse the effects of @GENE$.
7544	CPRFalse	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating @GENE$ kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7545	CPR:3	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating @GENE$ and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7546	CPR:3	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and @GENE$ kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7547	CPR:3	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 @GENE$, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7548	CPRFalse	These results demonstrated for the first time that @CHEMICAL$ induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the @GENE$ singaling pathway as the upstream signaling molecules.
7549	CPRFalse	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating @CHEMICAL$ kinase and activating JNK and p38 kinases, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7550	CPRFalse	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating @CHEMICAL$ and p38 kinases, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7551	CPRFalse	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and @CHEMICAL$ kinases, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7552	CPRFalse	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 @CHEMICAL$, and ROS stimulated by @GENE$ is able to activate the MAPK singaling pathway as the upstream signaling molecules.
7553	CPR:3	These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by @CHEMICAL$ is able to activate the @GENE$ singaling pathway as the upstream signaling molecules.
7554	CPRFalse	Initiating event of the mitochondrial-mediated apoptosis induced by @CHEMICAL$ is @GENE$ signals.
7555	CPR:4	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of @GENE$ and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.
7556	CPR:4	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @GENE$, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.
7557	CPRFalse	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of @GENE$ and FXa in HUVECs.
7558	CPRFalse	Treatment with @CHEMICAL$ and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and @GENE$ in HUVECs.
7559	CPR:4	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of @GENE$ and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.
7560	CPR:4	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @GENE$, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.
7561	CPRFalse	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of @GENE$ and FXa in HUVECs.
7562	CPRFalse	Treatment with IMG and @CHEMICAL$ resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and @GENE$ in HUVECs.
7563	CPRFalse	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of @CHEMICAL$ and FXa, and @GENE$ or hyperoside inhibited production of thrombin and FXa in HUVECs.
7564	CPRFalse	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @CHEMICAL$, and @GENE$ or hyperoside inhibited production of thrombin and FXa in HUVECs.
7565	CPR:3	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and @CHEMICAL$ or hyperoside inhibited production of @GENE$ and FXa in HUVECs.
7566	CPR:4	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and @CHEMICAL$ or hyperoside inhibited production of thrombin and @GENE$ in HUVECs.
7567	CPRFalse	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of @CHEMICAL$ and FXa, and IMG or @GENE$ inhibited production of thrombin and FXa in HUVECs.
7568	CPRFalse	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and @CHEMICAL$, and IMG or @GENE$ inhibited production of thrombin and FXa in HUVECs.
7569	CPR:4	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or @CHEMICAL$ inhibited production of @GENE$ and FXa in HUVECs.
7570	CPR:4	Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or @CHEMICAL$ inhibited production of thrombin and @GENE$ in HUVECs.
7571	CPR:4	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of @GENE$-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.
7572	CPR:4	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of TNF-a-induced production of @GENE$, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.
7573	CPRFalse	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the @GENE$ to t-PA ratio.
7574	CPRFalse	In addition, treatment with @CHEMICAL$ and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to @GENE$ ratio.
7575	CPR:4	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of @GENE$-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.
7576	CPR:4	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of TNF-a-induced production of @GENE$, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.
7577	CPRFalse	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the @GENE$ to t-PA ratio.
7578	CPRFalse	In addition, treatment with IMG and @CHEMICAL$ resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to @GENE$ ratio.
7579	CPRFalse	In addition, treatment with IMG and hyperoside resulted in inhibition of @CHEMICAL$-induced production of PAI-1, and treatment with @GENE$ resulted in significant reduction of the PAI-1 to t-PA ratio.
7580	CPRFalse	In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-a-induced production of @CHEMICAL$, and treatment with @GENE$ resulted in significant reduction of the PAI-1 to t-PA ratio.
7581	CPR:4	In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with @CHEMICAL$ resulted in significant reduction of the @GENE$ to t-PA ratio.
7582	CPR:4	In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-a-induced production of PAI-1, and treatment with @CHEMICAL$ resulted in significant reduction of the PAI-1 to @GENE$ ratio.
7583	CPR:4	Optimization of @CHEMICAL$ as dual function inhibitors targeting @GENE$ and leukotriene A4 hydrolase.
7584	CPR:4	Optimization of @CHEMICAL$ as dual function inhibitors targeting phospholipase A2 and @GENE$.
7585	CPR:9	Dual function inhibitors targeting phospholipase A(2) (@CHEMICAL$) and leukotriene A(4) hydrolase (LTA(4)H) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.
7586	CPR:9	Dual function inhibitors targeting @CHEMICAL$ (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.
7587	CPR:9	Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and @CHEMICAL$ (LTA(4)H) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.
7588	CPR:9	Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (@CHEMICAL$) may balance the @GENE$ (AA) metabolic network and be used as new anti-inflammatory drugs.
7589	CPR:4	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and @GENE$ (LTA(4)H-h) was found.
7590	CPR:4	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (@GENE$) was found.
7591	CPR:4	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for @GENE$ (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.
7592	CPR:4	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (@CHEMICAL$) for human nonpancreatic secretory phospholipase A(2) (@GENE$) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.
7593	CPRFalse	@CHEMICAL$ is a bimodal modulator of @GENE$ channels.
7594	CPRFalse	We wanted to test whether sensory @CHEMICAL$ are a molecular target for @GENE$.
7595	CPRFalse	Here, we show that @CHEMICAL$, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.
7596	CPRFalse	Here, we show that rTRPV1, @CHEMICAL$, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.
7597	CPRFalse	Here, we show that rTRPV1, rTRPV2, @CHEMICAL$, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.
7598	CPRFalse	Here, we show that rTRPV1, rTRPV2, rTRPV3, and @CHEMICAL$, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.
7599	CPRFalse	Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as @CHEMICAL$, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.
7600	CPRFalse	Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and @CHEMICAL$, which are expressed in dorsal root ganglion neurons, are insensitive toward @GENE$ treatment.
7601	CPRFalse	On the contrary, @CHEMICAL$ could be concentration-dependently modulated by @GENE$.
7602	CPR:4	Whereas the addition of @CHEMICAL$ in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed @GENE$ channels, resulting from a reduction of single-channel open times.
7603	CPRFalse	In addition, we provide evidence that @CHEMICAL$ also acts on endogenous @GENE$ in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of TRPA1.
7604	CPR:3	In addition, we provide evidence that @CHEMICAL$ also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of @GENE$.
7605	CPRFalse	In addition, we provide evidence that apomorphine also acts on endogenous @CHEMICAL$ in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which @GENE$ is released upon activation of TRPA1.
7606	CPRFalse	In addition, we provide evidence that apomorphine also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which @CHEMICAL$ is released upon activation of @GENE$.
7607	CPRFalse	Our study shows that @CHEMICAL$ is a target for @GENE$, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.
7608	CPR:3	Our study shows that human TRPA1 is a target for @CHEMICAL$, suggesting that an activation of @GENE$ might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.
7609	CPRFalse	Our study shows that @CHEMICAL$ is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with @GENE$.
7610	CPR:3	Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of @CHEMICAL$ might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with @GENE$.
7611	CPRFalse	Human stearoyl-CoA desaturase 1 (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of @CHEM-GENE$ to the gene promoter.
7612	CPRFalse	@CHEMICAL$ (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of @GENE$ receptor to the gene promoter.
7613	CPRFalse	Human stearoyl-CoA desaturase 1 (@CHEMICAL$) gene expression is negatively regulated by thyroid hormone without direct binding of @GENE$ receptor to the gene promoter.
7614	CPRFalse	Human @CHEMICAL$ desaturase 1 (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of @GENE$ to the gene promoter.
7615	CPRFalse	@CHEM-GENE$ (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter.
7616	CPRFalse	Human @CHEMICAL$ desaturase 1 (@GENE$) gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter.
7617	CPRFalse	Human stearoyl-CoA desaturase 1 (SCD-1) gene expression is negatively regulated by @CHEMICAL$ without direct binding of @GENE$ to the gene promoter.
7618	CPR:4	@CHEMICAL$ (SCD-1) gene expression is negatively regulated by @GENE$ without direct binding of thyroid hormone receptor to the gene promoter.
7619	CPR:4	Human stearoyl-CoA desaturase 1 (@CHEMICAL$) gene expression is negatively regulated by @GENE$ without direct binding of thyroid hormone receptor to the gene promoter.
7620	CPRFalse	@CHEM-GENE$ (SCD-1) plays a pivotal role in an increase of triglyceride by an excess of dietary carbohydrate intake.
7621	CPRFalse	@CHEMICAL$ desaturase-1 (@GENE$) plays a pivotal role in an increase of triglyceride by an excess of dietary carbohydrate intake.
7622	CPRFalse	@CHEMICAL$ (SCD-1) plays a pivotal role in an increase of triglyceride by an excess of dietary @GENE$ intake.
7623	CPRFalse	Stearoyl-CoA desaturase-1 (@CHEMICAL$) plays a pivotal role in an increase of triglyceride by an excess of dietary @GENE$ intake.
7624	CPRFalse	@CHEMICAL$ (SCD-1) plays a pivotal role in an increase of @GENE$ by an excess of dietary carbohydrate intake.
7625	CPRFalse	Stearoyl-CoA desaturase-1 (@CHEMICAL$) plays a pivotal role in an increase of @GENE$ by an excess of dietary carbohydrate intake.
7626	CPR:3	Dietary @CHEMICAL$ increase @GENE$ gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.
7627	CPRFalse	Dietary @CHEMICAL$ increase SCD-1 gene expression in liver by @GENE$-dependent and SREBP-1c -independent pathways.
7628	CPRFalse	Dietary @CHEMICAL$ increase SCD-1 gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and @GENE$ -independent pathways.
7629	CPRFalse	Dietary carbohydrates increase @CHEMICAL$ gene expression in liver by @GENE$ response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.
7630	CPRFalse	Dietary carbohydrates increase SCD-1 gene expression in liver by @CHEM-GENE$-dependent and SREBP-1c -independent pathways.
7631	CPRFalse	Dietary carbohydrates increase SCD-1 gene expression in liver by @CHEMICAL$ response element binding protein (SREBP)-1c-dependent and @GENE$ -independent pathways.
7632	CPR:4	Previous report demonstrated that @CHEMICAL$ (TH) negatively regulates @GENE$ before SREBP-1c was revealed.
7633	CPRFalse	Previous report demonstrated that @CHEMICAL$ (TH) negatively regulates mouse SCD-1 gene promoter before @GENE$ was revealed.
7634	CPRFalse	Diabetic cardiomyopathy is associated with suppression of cardiac autophagy, and activation of @CHEMICAL$-activated protein kinase (@GENE$) restores cardiac autophagy and prevents cardiomyopathy in diabetic mice, albeit by an unknown mechanism.
7635	CPRFalse	Diabetic cardiomyopathy is associated with suppression of cardiac autophagy, and activation of @CHEM-GENE$ (AMPK) restores cardiac autophagy and prevents cardiomyopathy in diabetic mice, albeit by an unknown mechanism.
7636	CPRFalse	We hypothesized that @CHEMICAL$-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.
7637	CPRFalse	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of @CHEMICAL$ on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.
7638	CPRFalse	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between @CHEMICAL$ and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.
7639	CPRFalse	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and @CHEMICAL$, a switch between autophagy and apoptosis, in diabetic mice and high @GENE$-treated H9c2 cardiac myoblast cells.
7640	CPR:4	Exposure of H9c2 cells to high @CHEMICAL$ reduced @GENE$ activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7641	CPR:4	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited @GENE$ (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7642	CPR:4	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (@GENE$)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7643	CPR:4	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-@GENE$ (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7644	CPR:4	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (@GENE$) signaling, and promoted Beclin1 binding to Bcl-2.
7645	CPRFalse	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted @GENE$ binding to Bcl-2.
7646	CPRFalse	Exposure of H9c2 cells to high @CHEMICAL$ reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to @GENE$.
7647	CPRFalse	Exposure of H9c2 cells to high glucose reduced @CHEMICAL$ activity, inhibited Jun @GENE$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7648	CPRFalse	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited @CHEM-GENE$ (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7649	CPRFalse	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (@GENE$)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7650	CPRFalse	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-@GENE$ (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.
7651	CPRFalse	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (@GENE$) signaling, and promoted Beclin1 binding to Bcl-2.
7652	CPRFalse	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted @GENE$ binding to Bcl-2.
7653	CPRFalse	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun @CHEMICAL$-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to @GENE$.
7654	CPRFalse	Activation of @CHEMICAL$, which normalized cardiac autophagy, attenuated high @GENE$-induced apoptosis in cultured H9c2 cells.
7655	CPRFalse	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and @GENE$.
7656	CPR:3	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating @GENE$-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.
7657	CPR:3	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating JNK1-@GENE$ pathways and dissociating Beclin1 and Bcl-2.
7658	CPRFalse	Finally, chronic administration of @CHEMICAL$ in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating @GENE$ and Bcl-2.
7659	CPR:4	@CHEMICAL$-mediated downregulation of @GENE$ mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
7660	CPR:4	@CHEMICAL$-mediated downregulation of p38 @GENE$-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
7661	CPRFalse	Metformin-mediated downregulation of @CHEMICAL$ mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to @GENE$.
7662	CPRFalse	Metformin-mediated downregulation of p38 @CHEMICAL$-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to @GENE$.
7663	CPRFalse	High expression levels of @CHEMICAL$ (ERCC1) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with @GENE$-containing chemotherapy.
7664	CPRFalse	High expression levels of excision repair cross-complementary 1 (@CHEMICAL$) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with @GENE$-containing chemotherapy.
7665	CPR:3	In this current study, @CHEMICAL$ was found to increase phosphorylation of @GENE$ (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.
7666	CPRFalse	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (@GENE$)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.
7667	CPR:3	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-@GENE$ MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.
7668	CPR:3	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 @GENE$ as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.
7669	CPR:3	In this current study, @CHEMICAL$ was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of @GENE$ in H1650 and H1703 cells.
7670	CPRFalse	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of @GENE$ activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).
7671	CPRFalse	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a @GENE$ MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).
7672	CPRFalse	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 @GENE$ inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).
7673	CPRFalse	Moreover, @CHEMICAL$-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or @GENE$ knockdown with specific small interfering RNA (siRNA).
7674	CPR:3	Moreover, @CHEMICAL$-induced @GENE$ protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).
7675	CPR:4	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of @CHEMICAL$ activity by either a p38 MAPK inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).
7676	CPR:4	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a @CHEMICAL$ MAPK inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).
7677	CPR:4	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 @CHEMICAL$ inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).
7678	CPRFalse	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor @CHEMICAL$ or @GENE$ knockdown with specific small interfering RNA (siRNA).
7679	CPRFalse	Moreover, paclitaxel-induced @CHEMICAL$ protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor @GENE$ or p38 knockdown with specific small interfering RNA (siRNA).
7680	CPRFalse	Specific inhibition of @CHEMICAL$ with siRNA was found to enhance the @GENE$-induced cytotoxic effect and growth inhibition.
7681	CPR:4	Furthermore, @CHEMICAL$ was able to not only decrease the paclitaxel-induced @GENE$ MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.
7682	CPR:4	Furthermore, @CHEMICAL$ was able to not only decrease the paclitaxel-induced p38 @GENE$-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.
7683	CPR:4	Furthermore, @CHEMICAL$ was able to not only decrease the paclitaxel-induced p38 MAPK-mediated @GENE$ expression, but also augment the cytotoxic effect induced by paclitaxel.
7684	CPR:3	Furthermore, metformin was able to not only decrease the @CHEMICAL$-induced @GENE$ MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.
7685	CPR:3	Furthermore, metformin was able to not only decrease the @CHEMICAL$-induced p38 @GENE$-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.
7686	CPR:3	Furthermore, metformin was able to not only decrease the @CHEMICAL$-induced p38 MAPK-mediated @GENE$ expression, but also augment the cytotoxic effect induced by paclitaxel.
7687	CPRFalse	Furthermore, metformin was able to not only decrease the paclitaxel-induced @CHEMICAL$ MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by @GENE$.
7688	CPRFalse	Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 @CHEMICAL$-mediated ERCC1 expression, but also augment the cytotoxic effect induced by @GENE$.
7689	CPRFalse	Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated @CHEMICAL$ expression, but also augment the cytotoxic effect induced by @GENE$.
7690	CPRFalse	Finally, expression of constitutive activate MKK6 or HA-@CHEMICAL$ MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.
7691	CPRFalse	Finally, expression of constitutive activate MKK6 or HA-p38 @CHEMICAL$ vectors in lung cancer cells was able to abrogate ERCC1 downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.
7692	CPRFalse	Finally, expression of constitutive activate @CHEMICAL$ or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.
7693	CPR:4	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate @CHEMICAL$ downregulation by @GENE$ and paclitaxel as well as cell viability and DNA repair capacity.
7694	CPRFalse	Finally, expression of constitutive activate MKK6 or HA-@CHEMICAL$ MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.
7695	CPRFalse	Finally, expression of constitutive activate MKK6 or HA-p38 @CHEMICAL$ vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.
7696	CPRFalse	Finally, expression of constitutive activate @CHEMICAL$ or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.
7697	CPR:4	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate @CHEMICAL$ downregulation by metformin and @GENE$ as well as cell viability and DNA repair capacity.
7698	CPR:4	Overall, our results suggest that inhibition of the @CHEMICAL$ MAPK signaling by @GENE$ coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.
7699	CPR:4	Overall, our results suggest that inhibition of the p38 @CHEMICAL$ signaling by @GENE$ coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.
7700	CPRFalse	Overall, our results suggest that inhibition of the @CHEMICAL$ MAPK signaling by metformin coupled with @GENE$ therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.
7701	CPRFalse	Overall, our results suggest that inhibition of the p38 @CHEMICAL$ signaling by metformin coupled with @GENE$ therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.
7702	CPRFalse	@CHEMICAL$ is a highly sensitive target of the antiobesity agent @GENE$ with profound implications in the activation of anticancer prodrugs.
7703	CPR:4	@CHEMICAL$ has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal @GENE$.
7704	CPR:4	This study was designed to test the hypothesis that @CHEMICAL$ inhibits @GENE$ with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.
7705	CPR:4	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward CES1 than CES2, a @GENE$ with little lipase activity.
7706	CPR:4	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little @GENE$ activity.
7707	CPR:4	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward @GENE$ than CES2, a carboxylesterase with little lipase activity.
7708	CPR:4	This study was designed to test the hypothesis that @CHEMICAL$ inhibits CESs with higher potency toward CES1 than @GENE$, a carboxylesterase with little lipase activity.
7709	CPRFalse	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of doxazolidine (@GENE$) and irinotecan.
7710	CPRFalse	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of doxazolidine (PPD) and @GENE$.
7711	CPRFalse	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs @GENE$ of p-aminobenzyl carbamate of doxazolidine (PPD) and irinotecan.
7712	CPRFalse	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of @GENE$ of doxazolidine (PPD) and irinotecan.
7713	CPRFalse	Liver microsomes and recombinant @CHEMICAL$ were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of @GENE$ (PPD) and irinotecan.
7714	CPR:4	Contrary to the hypothesis, orlistat at 1 nM inhibited @CHEMICAL$ activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of @GENE$.
7715	CPRFalse	Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on @CHEMICAL$, placing CES2 one of the most sensitive targets of @GENE$.
7716	CPR:4	Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing @CHEMICAL$ one of the most sensitive targets of @GENE$.
7717	CPR:4	Inhibition of this @CHEMICAL$ probably presents a major source for altered therapeutic activity of these medicines if co-administered with @GENE$.
7718	CPRFalse	Regions on @CHEM-GENE$ required for selective regulation by the G13 pathway.
7719	CPRFalse	Regions on @CHEMICAL$ cyclase VII required for selective regulation by the @GENE$ pathway.
7720	CPRFalse	Regulation of multiple @CHEM-GENE$ (AC) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function.
7721	CPRFalse	Regulation of multiple @CHEMICAL$ cyclases (@GENE$) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function.
7722	CPR:9	Regulation of multiple @CHEMICAL$ (AC) provides unique inputs to mediate the synthesis of @GENE$, a ubiquitous second messenger that controls many aspects of cellular function.
7723	CPR:9	Regulation of multiple adenylyl cyclases (@CHEMICAL$) provides unique inputs to mediate the synthesis of @GENE$, a ubiquitous second messenger that controls many aspects of cellular function.
7724	CPRFalse	On stimulation by @CHEMICAL$, the activities of ACs can be further selectively modulated by other pathways to ensure precise control of intracellular @GENE$ responses to specific stimuli.
7725	CPR:9	On stimulation by G(s), the activities of @CHEMICAL$ can be further selectively modulated by other pathways to ensure precise control of intracellular @GENE$ responses to specific stimuli.
7726	CPRFalse	Although both enzymes could fully restore regulation of @CHEMICAL$ by @GENE$, activation of the G(13) pathway preferentially synergized with AC7.
7727	CPRFalse	Although both enzymes could fully restore regulation of @CHEMICAL$ by Gbg, activation of the @GENE$ pathway preferentially synergized with AC7.
7728	CPRFalse	Although both enzymes could fully restore regulation of @CHEMICAL$ by Gbg, activation of the G(13) pathway preferentially synergized with @GENE$.
7729	CPRFalse	Exchange of domains between the two isoforms indicates that the @CHEMICAL$ and the @GENE$-terminus of the C1a domain are important for directing selective regulation of AC7 by the G(13) pathway.
7730	CPRFalse	Exchange of domains between the two isoforms indicates that the C1b domain and the @CHEMICAL$-terminus of the @GENE$ are important for directing selective regulation of AC7 by the G(13) pathway.
7731	CPRFalse	Exchange of domains between the two isoforms indicates that the C1b domain and the @CHEMICAL$-terminus of the C1a domain are important for directing selective regulation of @GENE$ by the G(13) pathway.
7732	CPRFalse	Exchange of domains between the two isoforms indicates that the C1b domain and the @CHEMICAL$-terminus of the C1a domain are important for directing selective regulation of AC7 by the @GENE$ pathway.
7733	CPRFalse	An important effector of the ISR is @CHEMICAL$ (ATF4), a transcription factor that regulates genes involved in redox homeostasis and @GENE$ metabolism and transport.
7734	CPRFalse	An important effector of the ISR is activating transcription factor 4 (@CHEMICAL$), a transcription factor that regulates genes involved in redox homeostasis and @GENE$ metabolism and transport.
7735	CPR:3	We identified one compound, @CHEMICAL$ (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of @GENE$ in transformed cells.
7736	CPR:3	We identified one compound, E235 @CHEMICAL$, that activated the ISR and dose-dependently increased levels of @GENE$ in transformed cells.
7737	CPRFalse	A dose-dependent decrease in viability was observed in several mouse and human tumor cell lines, and knockdown of @CHEMICAL$ significantly increased the antiproliferative effects of @GENE$.
7738	CPRFalse	@CHEMICAL$-mediated induction of senescence was not dependent on @GENE$ or p53; however, p21 conferred protection against the growth inhibitory effects of E235.
7739	CPRFalse	@CHEMICAL$-mediated induction of senescence was not dependent on p21 or @GENE$; however, p21 conferred protection against the growth inhibitory effects of E235.
7740	CPRFalse	@CHEMICAL$-mediated induction of senescence was not dependent on p21 or p53; however, @GENE$ conferred protection against the growth inhibitory effects of E235.
7741	CPRFalse	E235-mediated induction of senescence was not dependent on @CHEMICAL$ or p53; however, p21 conferred protection against the growth inhibitory effects of @GENE$.
7742	CPRFalse	E235-mediated induction of senescence was not dependent on p21 or @CHEMICAL$; however, p21 conferred protection against the growth inhibitory effects of @GENE$.
7743	CPRFalse	E235-mediated induction of senescence was not dependent on p21 or p53; however, @CHEMICAL$ conferred protection against the growth inhibitory effects of @GENE$.
7744	CPR:3	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-@GENE$, g-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.
7745	CPR:3	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, @GENE$, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.
7746	CPR:3	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and @GENE$ (Chk2), although E235 does not appear to cause physical DNA damage.
7747	CPR:3	@CHEMICAL$ also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and phosphorylated checkpoint kinase 2 (@GENE$), although E235 does not appear to cause physical DNA damage.
7748	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-@GENE$, g-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.
7749	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-phosphorylated p53, @GENE$, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.
7750	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-phosphorylated p53, g-H2AX, and @GENE$ (Chk2), although E235 does not appear to cause physical DNA damage.
7751	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of @CHEMICAL$15-phosphorylated p53, g-H2AX, and phosphorylated checkpoint kinase 2 (@GENE$), although E235 does not appear to cause physical DNA damage.
7752	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-@CHEMICAL$, g-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although @GENE$ does not appear to cause physical DNA damage.
7753	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, @CHEMICAL$, and phosphorylated checkpoint kinase 2 (Chk2), although @GENE$ does not appear to cause physical DNA damage.
7754	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and @CHEMICAL$ (Chk2), although @GENE$ does not appear to cause physical DNA damage.
7755	CPRFalse	E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, g-H2AX, and phosphorylated checkpoint kinase 2 (@CHEMICAL$), although @GENE$ does not appear to cause physical DNA damage.
7756	CPRFalse	"We aim to ""tilt"" the stability of the @CHEMICAL$ structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the @GENE$ sequence of the H1, H2, and proximal residues."
7757	CPRFalse	"We aim to ""tilt"" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the @CHEMICAL$ sequence of the @GENE$, H2, and proximal residues."
7758	CPRFalse	"We aim to ""tilt"" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the @CHEMICAL$ sequence of the H1, @GENE$, and proximal residues."
7759	CPR:4	Cell culture studies demonstrated that @CHEMICAL$ is capable of delivering anti-TNF (tumor necrosis factor)-a siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of @GENE$.
7760	CPRFalse	Cell culture studies demonstrated that @CHEMICAL$ is capable of delivering anti-@GENE$ (tumor necrosis factor)-a siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of TNF-a.
7761	CPRFalse	Cell culture studies demonstrated that @CHEMICAL$ is capable of delivering anti-TNF @GENE$ siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of TNF-a.
7762	CPR:4	@CHEMICAL$/anti-TNF-a siRNA nanocomplexes significantly reduced the @GENE$ (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.
7763	CPR:4	@CHEMICAL$/anti-TNF-a siRNA nanocomplexes significantly reduced the ALT (@GENE$) and the hepatic cellular damages in APAP-intoxicated mice.
7764	CPRFalse	@CHEMICAL$/anti-@GENE$ siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.
7765	CPRFalse	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the @CHEMICAL$ (@GENE$ transaminase) and the hepatic cellular damages in APAP-intoxicated mice.
7766	CPRFalse	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the ALT (@CHEM-GENE$) and the hepatic cellular damages in APAP-intoxicated mice.
7767	CPRFalse	PKAA/anti-@CHEMICAL$ siRNA nanocomplexes significantly reduced the ALT (@GENE$ transaminase) and the hepatic cellular damages in APAP-intoxicated mice.
7768	CPRFalse	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the @CHEMICAL$ (alanine transaminase) and the hepatic cellular damages in @GENE$-intoxicated mice.
7769	CPRFalse	PKAA/anti-TNF-a siRNA nanocomplexes significantly reduced the ALT (@CHEMICAL$) and the hepatic cellular damages in @GENE$-intoxicated mice.
7770	CPRFalse	PKAA/anti-@CHEMICAL$ siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in @GENE$-intoxicated mice.
7771	CPR:4	@CHEMICAL$ inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of @GENE$.
7772	CPR:3	Wogonin inhibits @CHEMICAL$-induced vascular permeability through suppressing the phosphorylation of @GENE$.
7773	CPR:4	We found that @CHEMICAL$ can suppress the H2O2-stimulated @GENE$ remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.
7774	CPR:4	We found that @CHEMICAL$ can suppress the H2O2-stimulated actin remodeling and @GENE$ uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.
7775	CPR:3	We found that wogonin can suppress the @CHEMICAL$-stimulated @GENE$ remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.
7776	CPR:3	We found that wogonin can suppress the @CHEMICAL$-stimulated actin remodeling and @GENE$ uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.
7777	CPR:4	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of @GENE$ (cav-1) associating with the suppression of stabilization of VE-cadherin and b-catenin.
7778	CPR:4	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of caveolin-1 (@GENE$) associating with the suppression of stabilization of VE-cadherin and b-catenin.
7779	CPR:4	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of @GENE$ and b-catenin.
7780	CPR:4	The mechanism revealed that @CHEMICAL$ inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and @GENE$.
7781	CPR:3	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of @GENE$ (cav-1) associating with the suppression of stabilization of VE-cadherin and b-catenin.
7782	CPR:3	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of caveolin-1 (@GENE$) associating with the suppression of stabilization of VE-cadherin and b-catenin.
7783	CPRFalse	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of @GENE$ and b-catenin.
7784	CPRFalse	The mechanism revealed that wogonin inhibited @CHEMICAL$-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and @GENE$.
7785	CPR:4	Moreover, @CHEMICAL$ repressed anisomycin-induced phosphorylation of @GENE$, cav-1 and vascular permeability.
7786	CPR:4	Moreover, @CHEMICAL$ repressed anisomycin-induced phosphorylation of p38, @GENE$ and vascular permeability.
7787	CPR:3	Moreover, wogonin repressed @CHEMICAL$-induced phosphorylation of @GENE$, cav-1 and vascular permeability.
7788	CPR:3	Moreover, wogonin repressed @CHEMICAL$-induced phosphorylation of p38, @GENE$ and vascular permeability.
7789	CPR:4	These results suggested that @CHEMICAL$ could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of @GENE$, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.
7790	CPR:3	These results suggested that wogonin could inhibit @CHEMICAL$-induced vascular permeability by downregulating the phosphorylation of @GENE$, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.
7791	CPRFalse	The discovery of fused @CHEMICAL$ as @GENE$ modulators for treatment of Alzheimer's disease.
7792	CPRFalse	In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the @CHEMICAL$ activity, conformational modifications of the core structure resulted in the identification of fused @GENE$ such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.
7793	CPR:4	In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused @CHEMICAL$ such as 7i which had an improved @GENE$ inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.
7794	CPRFalse	In an attempt to further improve overall profiles of the @CHEMICAL$ series of GSMs, in particular the @GENE$ activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.
7795	CPRFalse	In an attempt to further improve overall profiles of the @CHEMICAL$ series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved @GENE$ inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.
7796	CPR:4	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of @CHEMICAL$, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.
7797	CPR:4	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, @CHEMICAL$, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.
7798	CPR:4	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and @CHEMICAL$ and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.
7799	CPR:4	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors @CHEMICAL$, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.
7800	CPR:4	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, @CHEMICAL$, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by @GENE$.
7801	CPR:4	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and @CHEMICAL$, These effects could be completely blocked by @GENE$.
7802	CPRFalse	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of @CHEMICAL$, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @GENE$ receptor and amphiregulin expression were weaker than E(2).
7803	CPRFalse	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, @CHEMICAL$, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @GENE$ receptor and amphiregulin expression were weaker than E(2).
7804	CPRFalse	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and @CHEMICAL$, whereas the stimulatory effects of CE on @GENE$ receptor and amphiregulin expression were weaker than E(2).
7805	CPRFalse	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @CHEM-GENE$ and amphiregulin expression were weaker than E(2).
7806	CPRFalse	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on @CHEMICAL$ receptor and @GENE$ expression were weaker than E(2).
7807	CPR:4	We used @CHEMICAL$, a well-known disruptor of @GENE$-Mdm2 interaction, to validate the specificity of the assay.
7808	CPR:4	We used @CHEMICAL$, a well-known disruptor of p53-@GENE$ interaction, to validate the specificity of the assay.
7809	CPR:3	The reduction of BiFC signal mediated by @CHEMICAL$ was correlated with an increase in Puma transactivation, @GENE$ cleavage, and cell death.
7810	CPR:3	The reduction of BiFC signal mediated by @CHEMICAL$ was correlated with an increase in @GENE$ transactivation, PARP cleavage, and cell death.
7811	CPRFalse	@CHEMICAL$ induced apoptotic changes in neural stem cells: amelioration by @GENE$ support.
7812	CPRFalse	In this study we explored the toxicity of @CHEMICAL$ toward NSCs focusing on apoptosis and status of @GENE$ survival signaling.
7813	CPR:4	@CHEMICAL$ toxicity coincided with reduced @GENE$ level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.
7814	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: @GENE$, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.
7815	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and @GENE$ GDNF, BDNF suggesting repressed PI3K/Akt signaling.
7816	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed @GENE$/Akt signaling.
7817	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/@GENE$ signaling.
7818	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, @GENE$, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.
7819	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, @GENE$ and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.
7820	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins @GENE$, BDNF suggesting repressed PI3K/Akt signaling.
7821	CPR:4	@CHEMICAL$ toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3b, Bcl-2 and neurotrophins GDNF, @GENE$ suggesting repressed PI3K/Akt signaling.
7822	CPRFalse	Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against @CHEMICAL$ through activating @GENE$/Akt pathway.
7823	CPRFalse	Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against @CHEMICAL$ through activating PI3K/@GENE$ pathway.
7824	CPR:4	This was confirmed on adding @CHEMICAL$ the @GENE$ inhibitor which abolished the protection.
7825	CPR:4	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @GENE$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7826	CPR:4	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7827	CPR:4	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7828	CPR:4	@CHEMICAL$ induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7829	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial @GENE$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7830	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7831	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7832	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, @CHEMICAL$, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7833	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEM-GENE$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7834	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$ peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7835	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$ peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7836	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$ peroxidase, @GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7837	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, @GENE$ reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7838	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$ reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7839	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$ reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7840	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEM-GENE$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7841	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, @GENE$, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7842	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, @CHEMICAL$, isocitrate, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7843	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, @CHEMICAL$, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7844	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, @GENE$, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7845	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, @GENE$, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7846	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, @CHEMICAL$, succinate, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7847	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, @CHEMICAL$, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7848	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, @GENE$, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7849	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, @GENE$, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7850	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, @CHEMICAL$, malate, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7851	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, @CHEMICAL$, malate, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7852	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, @GENE$, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7853	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, @GENE$, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7854	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, @CHEMICAL$, a-ketoglutarate and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7855	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, @CHEMICAL$, a-ketoglutarate and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7856	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, @GENE$, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7857	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, @GENE$ and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7858	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, @CHEMICAL$ and @GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7859	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, @CHEMICAL$ and NADH-dehydrogenases, @GENE$ and adenosine triphosphate.
7860	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, malate, @GENE$ and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7861	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7862	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @CHEM-GENE$, cytochrome-C-oxidase and adenosine triphosphate.
7863	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @CHEMICAL$-dehydrogenases, @GENE$ and adenosine triphosphate.
7864	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @GENE$-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.
7865	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial @CHEMICAL$, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and @GENE$.
7866	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and @CHEMICAL$, cytochrome-C-oxidase and @GENE$.
7867	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, @CHEMICAL$ and @GENE$.
7868	CPRFalse	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, @CHEMICAL$, reduced glutathione, isocitrate, succinate, malate, a-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and @GENE$.
7869	CPR:3	Increased urinary excretion of @CHEMICAL$, hemopexin, transferrin and VDBP correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.
7870	CPR:3	Increased urinary excretion of albumin, @CHEMICAL$, transferrin and VDBP correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.
7871	CPR:3	Increased urinary excretion of albumin, hemopexin, @CHEMICAL$ and VDBP correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.
7872	CPR:3	Increased urinary excretion of albumin, hemopexin, transferrin and @CHEMICAL$ correlates with chronic sensitization to @GENE$ nephrotoxicity in rats.
7873	CPRFalse	Four proteins, namely @CHEMICAL$, hemopexin, transferrin and @GENE$ binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.
7874	CPRFalse	Four proteins, namely albumin, hemopexin, transferrin and @CHEM-GENE$ were increased in the urine in temporal association with the appearance of chronic predisposition.
7875	CPRFalse	Four proteins, namely albumin, @CHEMICAL$, transferrin and @GENE$ binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.
7876	CPRFalse	Four proteins, namely albumin, hemopexin, @CHEMICAL$ and @GENE$ binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.
7877	CPRFalse	They also increased catalase (CAT), @CHEMICAL$ (SOD) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7878	CPRFalse	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7879	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEM-GENE$ (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7880	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ peroxidase (@GENE$) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7881	CPRFalse	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7882	CPRFalse	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and @GENE$ peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7883	CPRFalse	They also increased catalase (CAT), @CHEMICAL$ (SOD) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7884	CPRFalse	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7885	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7886	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@CHEM-GENE$) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7887	CPRFalse	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7888	CPRFalse	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and glutathione peroxidase (@GENE$-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7889	CPRFalse	They also increased catalase (CAT), @CHEMICAL$ (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.
7890	CPRFalse	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.
7891	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.
7892	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@CHEMICAL$) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.
7893	CPRFalse	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.
7894	CPRFalse	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing @GENE$ (MDA) levels in serum and in the livers of mice.
7895	CPRFalse	They also increased catalase (CAT), @CHEMICAL$ (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.
7896	CPRFalse	They also increased catalase (CAT), superoxide dismutase (@CHEMICAL$) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.
7897	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and @CHEMICAL$ (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.
7898	CPRFalse	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (@CHEMICAL$) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.
7899	CPRFalse	They also increased @CHEMICAL$ (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.
7900	CPRFalse	They also increased catalase (@CHEMICAL$), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (@GENE$) levels in serum and in the livers of mice.
7901	CPRFalse	They also increased catalase (CAT), @CHEM-GENE$ (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7902	CPRFalse	They also increased catalase (CAT), @CHEMICAL$ dismutase (@GENE$) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7903	CPRFalse	They also increased catalase (CAT), @CHEMICAL$ dismutase (SOD) and @GENE$ (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7904	CPRFalse	They also increased catalase (CAT), @CHEMICAL$ dismutase (SOD) and glutathione peroxidase (@GENE$) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7905	CPRFalse	They also increased @CHEMICAL$ (CAT), @GENE$ dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7906	CPRFalse	They also increased catalase (@CHEMICAL$), @GENE$ dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.
7907	CPR:4	Design and synthesis of novel @CHEMICAL$ derivatives as @GENE$ inhibitors.
7908	CPR:4	@CHEMICAL$ induced dose-dependent reduction of the protein levels of @GENE$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7909	CPR:4	@CHEMICAL$ induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@GENE$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7910	CPR:4	@CHEMICAL$ induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @GENE$ (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7911	CPR:4	@CHEMICAL$ induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@GENE$) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7912	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of @CHEM-GENE$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7913	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible @CHEMICAL$ synthase (@GENE$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7914	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible @CHEMICAL$ synthase (iNOS) and @GENE$ (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7915	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible @CHEMICAL$ synthase (iNOS) and cyclooxygenase-2 (@GENE$) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).
7916	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of @CHEMICAL$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).
7917	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@CHEMICAL$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).
7918	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @CHEMICAL$ (COX-2) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).
7919	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@CHEMICAL$) and concomitant reduction in the production of @GENE$ and prostaglandin E(2) (PGE(2)).
7920	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of @CHEMICAL$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).
7921	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@CHEMICAL$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).
7922	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @CHEMICAL$ (COX-2) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).
7923	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@CHEMICAL$) and concomitant reduction in the production of NO and @GENE$ (PGE(2)).
7924	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of @CHEMICAL$ (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).
7925	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (@CHEMICAL$) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).
7926	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and @CHEMICAL$ (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).
7927	CPRFalse	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (@CHEMICAL$) and concomitant reduction in the production of NO and prostaglandin E(2) (@GENE$).
7928	CPR:4	Additionally, @CHEMICAL$ suppressed the production of inflammatory @GENE$, including tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, and IL-6.
7929	CPR:4	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including @GENE$ (TNF-a), interleukin (IL)-1b, and IL-6.
7930	CPR:4	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including tumor necrosis factor-a (@GENE$), interleukin (IL)-1b, and IL-6.
7931	CPR:4	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including tumor necrosis factor-a (TNF-a), @GENE$, and IL-6.
7932	CPR:4	Additionally, @CHEMICAL$ suppressed the production of inflammatory cytokines, including tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, and @GENE$.
7933	CPRFalse	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of @GENE$ (NF-kB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7934	CPRFalse	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of nuclear factor-kB (@GENE$) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7935	CPRFalse	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the @GENE$ (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7936	CPRFalse	We investigated the mechanism by which DPEP inhibits @CHEMICAL$ and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the mitogen-activated protein kinase (@GENE$) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7937	CPRFalse	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of @GENE$ (NF-kB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7938	CPRFalse	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of nuclear factor-kB (@GENE$) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7939	CPRFalse	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of nuclear factor-kB (NF-kB) activation within the @GENE$ (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7940	CPRFalse	We investigated the mechanism by which DPEP inhibits NO and @CHEMICAL$ by examining the level of nuclear factor-kB (NF-kB) activation within the mitogen-activated protein kinase (@GENE$) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7941	CPRFalse	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of @GENE$ (NF-kB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7942	CPRFalse	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of nuclear factor-kB (@GENE$) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7943	CPRFalse	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the @GENE$ (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7944	CPRFalse	We investigated the mechanism by which @CHEMICAL$ inhibits NO and PGE(2) by examining the level of nuclear factor-kB (NF-kB) activation within the mitogen-activated protein kinase (@GENE$) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.
7945	CPR:4	@CHEMICAL$ inhibited LPS-induced phosphorylation of @GENE$, JNK, and p38.
7946	CPR:4	@CHEMICAL$ inhibited LPS-induced phosphorylation of ERK, @GENE$, and p38.
7947	CPR:4	@CHEMICAL$ inhibited LPS-induced phosphorylation of ERK, JNK, and @GENE$.
7948	CPR:4	Furthermore, @CHEMICAL$ inhibited the LPS-induced phosphorylation of inhibitor kB (IkB)-a and @GENE$ p50.
7949	CPR:4	Furthermore, @CHEMICAL$ inhibited the LPS-induced phosphorylation of inhibitor kB (IkB)-a and NF-kB @GENE$.
7950	CPR:4	Furthermore, @CHEMICAL$ inhibited the LPS-induced phosphorylation of @GENE$ and NF-kB p50.
7951	CPR:4	Taken together, the results of this study demonstrate that @CHEMICAL$ inhibits LPS-stimulated inflammation by blocking the @GENE$ and MAPK pathways in macrophages.
7952	CPR:4	Taken together, the results of this study demonstrate that @CHEMICAL$ inhibits LPS-stimulated inflammation by blocking the NF-kB and @GENE$ pathways in macrophages.
7953	CPRFalse	@CHEMICAL$ interactions modulate mutagenic bypass of a templating @GENE$ lesion.
7954	CPRFalse	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite @CHEMICAL$. To determine how pol b discriminates between anti- and syn-8-oxoG, we introduced a point mutation (@GENE$) to alter insertion specificity.
7955	CPRFalse	During base excision repair of this mispair, @CHEMICAL$ is confronted with gap filling opposite @GENE$. To determine how pol b discriminates between anti- and syn-8-oxoG, we introduced a point mutation (R283K) to alter insertion specificity.
7956	CPRFalse	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite @CHEMICAL$. To determine how @GENE$ discriminates between anti- and syn-8-oxoG, we introduced a point mutation (R283K) to alter insertion specificity.
7957	CPRFalse	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite 8-oxoG. To determine how pol b discriminates between @CHEMICAL$, we introduced a point mutation (@GENE$) to alter insertion specificity.
7958	CPRFalse	During base excision repair of this mispair, @CHEMICAL$ is confronted with gap filling opposite 8-oxoG. To determine how pol b discriminates between @GENE$, we introduced a point mutation (R283K) to alter insertion specificity.
7959	CPRFalse	During base excision repair of this mispair, DNA polymerase (pol) b is confronted with gap filling opposite 8-oxoG. To determine how @CHEMICAL$ discriminates between @GENE$, we introduced a point mutation (R283K) to alter insertion specificity.
7960	CPRFalse	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite @CHEMICAL$. Structural studies with @GENE$ pol b show that the binary DNA complex has 8-oxoG in equilibrium between anti- and syn-forms.
7961	CPRFalse	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite @CHEMICAL$. Structural studies with R283K @GENE$ show that the binary DNA complex has 8-oxoG in equilibrium between anti- and syn-forms.
7962	CPRFalse	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite 8-oxoG. Structural studies with @CHEMICAL$ pol b show that the binary DNA complex has @GENE$ in equilibrium between anti- and syn-forms.
7963	CPRFalse	Kinetic studies demonstrate that this substitution results in an increased fidelity opposite 8-oxoG. Structural studies with R283K @CHEMICAL$ show that the binary DNA complex has @GENE$ in equilibrium between anti- and syn-forms.
7964	CPRFalse	In contrast to wild-type pol b, the ternary complex of the @CHEMICAL$ mutant with an incoming @GENE$-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.
7965	CPRFalse	In contrast to wild-type @CHEMICAL$, the ternary complex of the R283K mutant with an incoming @GENE$-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.
7966	CPRFalse	In contrast to wild-type pol b, the ternary complex of the @CHEMICAL$ mutant with an incoming dATP-analogue and templating @GENE$ resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.
7967	CPRFalse	In contrast to wild-type @CHEMICAL$, the ternary complex of the R283K mutant with an incoming dATP-analogue and templating @GENE$ resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.
7968	CPRFalse	In contrast to wild-type pol b, the ternary complex of the @CHEMICAL$ mutant with an incoming dATP-analogue and templating 8-oxoG resembles a G-A mismatched structure with @GENE$ adopting an anti-conformation.
7969	CPRFalse	In contrast to wild-type @CHEMICAL$, the ternary complex of the R283K mutant with an incoming dATP-analogue and templating 8-oxoG resembles a G-A mismatched structure with @GENE$ adopting an anti-conformation.
7970	CPRFalse	These results demonstrate that the incoming @CHEMICAL$ is unable to induce a syn-8-oxoG conformation without @GENE$ DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.
7971	CPRFalse	These results demonstrate that the incoming @CHEMICAL$ is unable to induce a syn-8-oxoG conformation without minor groove @GENE$ interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.
7972	CPRFalse	These results demonstrate that the incoming nucleotide is unable to induce a @CHEMICAL$ conformation without @GENE$ DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.
7973	CPRFalse	These results demonstrate that the incoming nucleotide is unable to induce a @CHEMICAL$ conformation without minor groove @GENE$ interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.
7974	CPRFalse	These results demonstrate that the incoming nucleotide is unable to induce a syn-8-oxoG conformation without @CHEMICAL$ DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of @GENE$ while modulating fidelity.
7975	CPRFalse	These results demonstrate that the incoming nucleotide is unable to induce a syn-8-oxoG conformation without minor groove @CHEMICAL$ interactions that influence templating (anti-/syn-equilibrium) of @GENE$ while modulating fidelity.
7976	CPRFalse	@CHEM-GENE$ mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of curcumin.
7977	CPRFalse	@CHEMICAL$ mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of @GENE$.
7978	CPRFalse	@CHEMICAL$ mediated excitotoxicity in cerebral cortex of @GENE$ induced diabetic rat: ameliorating effects of curcumin.
7979	CPRFalse	@CHEM-GENE$ mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of curcumin.
7980	CPRFalse	Gene expression studies in diabetic rats showed a down regulation of @CHEM-GENE$ mRNA leading to accumulation of glutamate.
7981	CPRFalse	Gene expression studies in diabetic rats showed a down regulation of @CHEMICAL$ mRNA leading to accumulation of @GENE$.
7982	CPRFalse	Radioreceptor binding assays showed a significant increase in @CHEM-GENE$ density which was confirmed by immunohistochemical studies.
7983	CPRFalse	Radioreceptor binding assays showed a significant increase in @CHEM-GENE$ density which was confirmed by immunohistochemical studies.
7984	CPRFalse	Decreased @CHEM-GENE$ gene expression indicates enhanced oxidative stress in diabetic rats.
7985	CPRFalse	This leads to decreased expression of @CHEM-GENE$, which in turn reduces glutamate transport.
7986	CPRFalse	This leads to decreased expression of @CHEM-GENE$, which in turn reduces glutamate transport.
7987	CPR:9	This leads to decreased expression of @CHEMICAL$, which in turn reduces @GENE$ transport.
7988	CPRFalse	@CHEMICAL$ and @GENE$ treatment reversed these altered parameters to near control.
7989	CPRFalse	Inactivation of @CHEMICAL$ in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of @GENE$ carbon into lipids, and biomass accumulation.
7990	CPRFalse	Inactivation of @CHEMICAL$ in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of glucose @GENE$ into lipids, and biomass accumulation.
7991	CPR:4	@CHEMICAL$ type dual inhibitors of @GENE$/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
7992	CPR:4	@CHEMICAL$ type dual inhibitors of aromatase/@GENE$ as a novel strategy for breast cancer patients with elevated cardiovascular risks.
7993	CPRFalse	Tetrahydropyrroloquinolinone type dual inhibitors of @CHEMICAL$/@GENE$ synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
7994	CPRFalse	Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/@CHEM-GENE$ as a novel strategy for breast cancer patients with elevated cardiovascular risks.
7995	CPRFalse	Dual inhibitors of @CHEMICAL$ (CYP19) and @GENE$ synthase (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.
7996	CPRFalse	Dual inhibitors of aromatase (@CHEMICAL$) and @GENE$ synthase (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.
7997	CPRFalse	Dual inhibitors of aromatase (CYP19) and @CHEM-GENE$ (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.
7998	CPRFalse	Dual inhibitors of aromatase (CYP19) and @CHEMICAL$ synthase (@GENE$) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.
7999	CPRFalse	By combining decisive structural features of @CHEMICAL$ and CYP19 inhibitors into a common template, a series of @GENE$ were designed and synthesized.
8000	CPRFalse	By combining decisive structural features of CYP11B2 and @CHEMICAL$ inhibitors into a common template, a series of @GENE$ were designed and synthesized.
8001	CPRFalse	Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by @CHEMICAL$ enzymes via in vivo and in vitro oxidation of @GENE$ and triazolam.
8002	CPRFalse	Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by @CHEMICAL$ enzymes via in vivo and in vitro oxidation of midazolam and @GENE$.
8003	CPR:4	Furthermore, @CHEMICAL$ caused mechanism-based inactivation of @GENE$-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.
8004	CPR:9	Furthermore, MDZ caused mechanism-based inactivation of @CHEMICAL$-dependent @GENE$ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.
8005	CPRFalse	We previously found that the @CHEMICAL$-enriched microdomains (ganglioside clusters) in presynaptic neuronal membranes play a key role in the initiation of the @GENE$ assembly process.
8006	CPRFalse	We previously found that the ganglioside-enriched microdomains (@CHEMICAL$ clusters) in presynaptic neuronal membranes play a key role in the initiation of the @GENE$ assembly process.
8007	CPRFalse	However, not all @CHEMICAL$ clusters accelerate @GENE$ assembly.
8008	CPRFalse	The Ab assembly was generated on a distinctive @CHEMICAL$, which was characterized as the Ab-sensitive @GENE$ nanocluster (ASIGN).
8009	CPRFalse	The @CHEMICAL$ assembly was generated on a distinctive GM1 domain, which was characterized as the Ab-sensitive @GENE$ nanocluster (ASIGN).
8010	CPRFalse	The Ab assembly was generated on a distinctive GM1 domain, which was characterized as the @CHEMICAL$-sensitive @GENE$ nanocluster (ASIGN).
8011	CPRFalse	These results suggest that @CHEMICAL$-bound @GENE$ (GAb), which acts as an endogenous seed for Ab fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.
8012	CPRFalse	These results suggest that @CHEMICAL$-bound Ab (G@GENE$), which acts as an endogenous seed for Ab fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.
8013	CPRFalse	These results suggest that @CHEMICAL$-bound Ab (GAb), which acts as an endogenous seed for @GENE$ fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.
8014	CPR:4	@CHEMICAL$ represses @GENE$ microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.
8015	CPR:3	@CHEMICAL$ represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating @GENE$ in endometrial carcinoma cell lines.
8016	CPRFalse	Although tamoxifen (TAM), a selective @CHEM-GENE$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.
8017	CPRFalse	Although @CHEMICAL$ (TAM), a selective @GENE$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.
8018	CPRFalse	Although tamoxifen (TAM), a selective @CHEMICAL$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its @GENE$-like effect increases the risk of endometrial cancer.
8019	CPRFalse	Although tamoxifen (@CHEMICAL$), a selective @GENE$ modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.
8020	CPRFalse	In this report, we explored the role of microRNAs (miRNAs) in @CHEMICAL$-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found @GENE$ is involved in this process via the regulation of c-Myc.
8021	CPRFalse	In this report, we explored the role of microRNAs (miRNAs) in @CHEMICAL$-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found miR-200 is involved in this process via the regulation of @GENE$.
8022	CPR:4	@CHEMICAL$, a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to @GENE$ treatment.
8023	CPRFalse	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas @GENE$ decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8024	CPRFalse	Consistent with @CHEM-GENE$, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8025	CPRFalse	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of @GENE$ in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8026	CPRFalse	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as @GENE$ and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8027	CPRFalse	Consistent with @CHEMICAL$ finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and @GENE$ increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8028	CPR:4	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas @CHEMICAL$ decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8029	CPRFalse	Consistent with @CHEMICAL$, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8030	CPRFalse	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of @CHEMICAL$ in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8031	CPR:3	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as @CHEMICAL$ and N-cadherin increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8032	CPR:3	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and @CHEMICAL$ increased, whereas E-cadherin decreased in the @GENE$-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.
8033	CPRFalse	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas @CHEMICAL$ decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.
8034	CPRFalse	Consistent with @CHEMICAL$, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.
8035	CPRFalse	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of @CHEMICAL$ in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.
8036	CPRFalse	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as @CHEMICAL$ and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.
8037	CPRFalse	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and @CHEMICAL$ increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to @GENE$-induced EMT in these endometrial cancer cells.
8038	CPRFalse	In addition, we showed that c-Myc directly binds to and represses the promoter of @CHEMICAL$ miRNAs, and its up-regulation in @GENE$-treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT.
8039	CPR:4	In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in @CHEMICAL$-treated endometrial cancer cells leads to the down-regulation of @GENE$ and eventually to EMT.
8040	CPRFalse	In addition, we showed that @CHEMICAL$ directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in @GENE$-treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT.
8041	CPR:4	Collectively, our data suggest that @CHEMICAL$ can repress the @GENE$ family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.
8042	CPR:3	Collectively, our data suggest that @CHEMICAL$ can repress the miR-200 family and induce EMT via the up-regulation of @GENE$ in endometrial cancer cells.
8043	CPRFalse	@CHEMICAL$ improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of @GENE$ protein.
8044	CPRFalse	@CHEMICAL$ improves cardiomyopathy in @GENE$-deficient mice through SIRT1 protein-mediated modulation of p300 protein.
8045	CPRFalse	@CHEMICAL$ improves cardiomyopathy in dystrophin-deficient mice through @GENE$ protein-mediated modulation of p300 protein.
8046	CPR:3	Here, we show that oral administration of @CHEMICAL$, which leads to activation of an @GENE$, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.
8047	CPRFalse	Here, we show that oral administration of @CHEMICAL$, which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in @GENE$-deficient mdx mice.
8048	CPRFalse	Here, we show that oral administration of resveratrol, which leads to activation of an @CHEM-GENE$, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.
8049	CPRFalse	Here, we show that oral administration of resveratrol, which leads to activation of an @CHEMICAL$-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in @GENE$-deficient mdx mice.
8050	CPRFalse	The pro-hypertrophic co-activator @CHEMICAL$ protein but not p300 mRNA was up-regulated in the mdx heart, and @GENE$ administration down-regulated the p300 protein level.
8051	CPRFalse	The pro-hypertrophic co-activator p300 protein but not @CHEMICAL$ mRNA was up-regulated in the mdx heart, and @GENE$ administration down-regulated the p300 protein level.
8052	CPR:4	The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and @CHEMICAL$ administration down-regulated the @GENE$ protein level.
8053	CPRFalse	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist @CHEMICAL$ was inhibited by the overexpression of @GENE$ as well as resveratrol, both of which down-regulated p300 protein levels but not p300 mRNA levels.
8054	CPRFalse	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist @CHEMICAL$ was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated @GENE$ protein levels but not p300 mRNA levels.
8055	CPRFalse	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist @CHEMICAL$ was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated p300 protein levels but not @GENE$ mRNA levels.
8056	CPRFalse	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist phenylephrine was inhibited by the overexpression of @CHEMICAL$ as well as @GENE$, both of which down-regulated p300 protein levels but not p300 mRNA levels.
8057	CPR:4	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as @CHEMICAL$, both of which down-regulated @GENE$ protein levels but not p300 mRNA levels.
8058	CPRFalse	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the a(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as @CHEMICAL$, both of which down-regulated p300 protein levels but not @GENE$ mRNA levels.
8059	CPRFalse	We found that SIRT1 induced p300 down-regulation via the @CHEMICAL$-proteasome pathway by deacetylation of @GENE$ residues for ubiquitination.
8060	CPRFalse	We found that SIRT1 induced p300 down-regulation via the ubiquitin-@CHEMICAL$ pathway by deacetylation of @GENE$ residues for ubiquitination.
8061	CPRFalse	We found that @CHEMICAL$ induced p300 down-regulation via the ubiquitin-proteasome pathway by deacetylation of @GENE$ residues for ubiquitination.
8062	CPRFalse	We found that SIRT1 induced @CHEMICAL$ down-regulation via the ubiquitin-proteasome pathway by deacetylation of @GENE$ residues for ubiquitination.
8063	CPRFalse	The in vivo blood level and tissue distribution studies in albino rats also demonstrated potential of dual targeted system towards sialoadhesin and @CHEM-GENE$.
8064	CPRFalse	The in vivo blood level and tissue distribution studies in albino rats also demonstrated potential of dual targeted system towards @CHEMICAL$ and @GENE$ receptors.
8065	CPRFalse	The @CHEMICAL$ constitutive @GENE$ receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8066	CPRFalse	The nuclear receptors constitutive @CHEMICAL$ receptor (@GENE$), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8067	CPRFalse	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), @GENE$ (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8068	CPRFalse	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), pregnane X receptor (@GENE$) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8069	CPRFalse	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), pregnane X receptor (PXR) and @GENE$ (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8070	CPRFalse	The nuclear receptors constitutive @CHEMICAL$ receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (@GENE$) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8071	CPRFalse	The nuclear receptors @CHEM-GENE$ (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8072	CPRFalse	The @CHEMICAL$ constitutive androstane receptor (CAR), @GENE$ X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8073	CPRFalse	The nuclear receptors constitutive androstane receptor (@CHEMICAL$), @GENE$ X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8074	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), @CHEM-GENE$ (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8075	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ X receptor (@GENE$) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8076	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ X receptor (PXR) and @GENE$ (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8077	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ X receptor (PXR) and vitamin D receptor (@GENE$) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8078	CPRFalse	The nuclear receptors @CHEMICAL$ (CAR), @GENE$ X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8079	CPRFalse	The @CHEMICAL$ constitutive androstane receptor (CAR), pregnane X receptor (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8080	CPRFalse	The nuclear receptors constitutive androstane receptor (@CHEMICAL$), pregnane X receptor (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8081	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), @CHEMICAL$ (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8082	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (@CHEMICAL$) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8083	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and @CHEM-GENE$ (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8084	CPRFalse	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and @CHEMICAL$ receptor (@GENE$) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8085	CPRFalse	The nuclear receptors @CHEMICAL$ (CAR), pregnane X receptor (PXR) and @GENE$ receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.
8086	CPR:4	Synthesis and dual biological effects of @CHEMICAL$/prolyl hydroxamic acid derivatives as @GENE$ inhibitor and antioxidant.
8087	CPR:4	Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl/@CHEMICAL$ derivatives as @GENE$ inhibitor and antioxidant.
8088	CPR:4	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (@CHEMICAL$) acted as both a good antioxidant and @GENE$ inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.
8089	CPRFalse	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when @GENE$ was conjugated with proline or amino acids having aromatic ring like phenylalanine.
8090	CPRFalse	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when caffeic acid was conjugated with @GENE$ or amino acids having aromatic ring like phenylalanine.
8091	CPRFalse	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when caffeic acid was conjugated with proline or @GENE$ having aromatic ring like phenylalanine.
8092	CPRFalse	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and @CHEMICAL$ inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like @GENE$.
8093	CPR:4	We previously reported that @CHEMICAL$ (CA-Xaa-NHOH) acted as both a good antioxidant and @GENE$ inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.
8094	CPRFalse	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (@CHEMICAL$ and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.
8095	CPRFalse	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and @CHEMICAL$) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.
8096	CPRFalse	Here, various @CHEMICAL$ (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.
8097	CPRFalse	Here, various hydroxycinnamic acid (@CHEMICAL$) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.
8098	CPRFalse	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with @CHEMICAL$ and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.
8099	CPRFalse	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and @CHEMICAL$ (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and @GENE$ inhibitors.
8100	CPR:4	In addition, derivatives of @CHEMICAL$ and sinapic acid efficiently inhibited @GENE$ activity and reduced melanin content in melanocytes Mel-Ab cell.
8101	CPR:4	In addition, derivatives of caffeic acid and @CHEMICAL$ efficiently inhibited @GENE$ activity and reduced melanin content in melanocytes Mel-Ab cell.
8102	CPR:4	@CHEMICAL$ is a small-molecule inhibitor of @GENE$ and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.
8103	CPR:4	@CHEMICAL$ is a small-molecule inhibitor of JAK1 and @GENE$ and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.
8104	CPRFalse	Stenesen and colleagues (2012) activate @CHEMICAL$ both directly and indirectly by altering @GENE$ biosynthesis to slow aging in Drosophila, highlighting AMPK as a conserved life span modulator that links energy sensing to longevity.
8105	CPRFalse	Stenesen and colleagues (2012) activate AMPK both directly and indirectly by altering @CHEMICAL$ biosynthesis to slow aging in Drosophila, highlighting @GENE$ as a conserved life span modulator that links energy sensing to longevity.
8106	CPRFalse	Ex vivo samples of human oral mucosa were exposed to @CHEMICAL$ or BaP, and immunohistochemical staining was performed to evaluate active @GENE$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).
8107	CPRFalse	Ex vivo samples of human oral mucosa were exposed to Pb or @CHEMICAL$, and immunohistochemical staining was performed to evaluate active @GENE$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).
8108	CPRFalse	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, @GENE$ (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).
8109	CPRFalse	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, 8-epi-prostaglandin F2 alpha (@GENE$), and 3-nitrotyrosine (3-NT).
8110	CPRFalse	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and @GENE$ (3-NT).
8111	CPRFalse	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active @CHEMICAL$, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (@GENE$).
8112	CPR:3	@CHEMICAL$ and BaP treatments significantly increased active @GENE$ levels in a time-dependent manner.
8113	CPR:3	Pb and @CHEMICAL$ treatments significantly increased active @GENE$ levels in a time-dependent manner.
8114	CPRFalse	TAA increased the number and area of @CHEM-GENE$ (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.
8115	CPRFalse	TAA increased the number and area of glutathione @CHEMICAL$-transferase placental form (@GENE$)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.
8116	CPR:3	@CHEMICAL$ increased the number and area of @GENE$ (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.
8117	CPR:3	@CHEMICAL$ increased the number and area of glutathione S-transferase placental form (@GENE$)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.
8118	CPRFalse	TAA increased the number and area of @CHEM-GENE$ (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.
8119	CPRFalse	TAA increased the number and area of @CHEMICAL$ S-transferase placental form (@GENE$)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.
8120	CPR:4	@CHEMICAL$ also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of @GENE$(+) lymphocytes.
8121	CPR:4	@CHEMICAL$ also increased the numbers of ED2(+), @GENE$(+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.
8122	CPR:4	@CHEMICAL$ also increased the numbers of ED2(+), cyclooxygenase-2(+), and @GENE$(+) liver cells, as well as the number of CD3(+) lymphocytes.
8123	CPRFalse	TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and @CHEMICAL$ oxygenase-1(+) liver cells, as well as the number of @GENE$(+) lymphocytes.
8124	CPRFalse	TAA also increased the numbers of ED2(+), @CHEMICAL$(+), and @GENE$ oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.
8125	CPRFalse	TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and @CHEM-GENE$(+) liver cells, as well as the number of CD3(+) lymphocytes.
8126	CPRFalse	EMIQ increased liver levels of @CHEMICAL$-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within @GENE$(+) foci.
8127	CPRFalse	EMIQ increased liver levels of @CHEMICAL$-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, @GENE$ (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.
8128	CPRFalse	EMIQ increased liver levels of @CHEMICAL$-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (@GENE$)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.
8129	CPRFalse	EMIQ increased liver levels of thiobarbituric acid-reactive substance and @CHEMICAL$, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within @GENE$(+) foci.
8130	CPRFalse	EMIQ increased liver levels of thiobarbituric acid-reactive substance and @CHEMICAL$, and TUNEL(+) apoptotic cells, @GENE$ (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.
8131	CPRFalse	EMIQ increased liver levels of thiobarbituric acid-reactive substance and @CHEMICAL$, and TUNEL(+) apoptotic cells, death receptor 5 (@GENE$)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.
8132	CPRFalse	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and @CHEMICAL$(+) cells within @GENE$(+) foci.
8133	CPRFalse	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, @CHEMICAL$ (DR5)(+) cells and @GENE$(+) cells within GST-P(+) foci.
8134	CPRFalse	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (@CHEMICAL$)(+) cells and @GENE$(+) cells within GST-P(+) foci.
8135	CPR:3	@CHEMICAL$ interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG @GENE$.
8136	CPR:3	@CHEMICAL$ interacts with a common binding site to elicit opposite effects on inactivation gating of @GENE$ and ERG potassium channels.
8137	CPR:3	@CHEMICAL$ interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and @GENE$ potassium channels.
8138	CPRFalse	ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG @CHEM-GENE$.
8139	CPRFalse	ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of @CHEMICAL$ and ERG @GENE$ channels.
8140	CPRFalse	ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and @CHEMICAL$ @GENE$ channels.
8141	CPRFalse	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEMICAL$-a-go-go-related gene (ERG) @GENE$.
8142	CPRFalse	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEMICAL$-a-go-go-related gene (@GENE$) K(+) channels.
8143	CPRFalse	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEM-GENE$ (ERG) K(+) channels.
8144	CPRFalse	Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (ERG) @CHEM-GENE$.
8145	CPRFalse	Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (@CHEMICAL$) @GENE$ channels.
8146	CPRFalse	Rapid and voltage-dependent inactivation greatly attenuates outward currents in @CHEMICAL$ (ERG) @GENE$ channels.
8147	CPRFalse	In contrast, inactivation of related @CHEMICAL$-a-go-go (EAG) @GENE$ is very slow and minimally reduces outward currents.
8148	CPRFalse	In contrast, inactivation of related @CHEM-GENE$ (EAG) K(+) channels is very slow and minimally reduces outward currents.
8149	CPRFalse	In contrast, inactivation of related @CHEMICAL$-a-go-go (@GENE$) K(+) channels is very slow and minimally reduces outward currents.
8150	CPRFalse	In contrast, inactivation of related ether-a-go-go (EAG) @CHEM-GENE$ is very slow and minimally reduces outward currents.
8151	CPRFalse	In contrast, inactivation of related @CHEMICAL$ (EAG) @GENE$ channels is very slow and minimally reduces outward currents.
8152	CPRFalse	In contrast, inactivation of related ether-a-go-go (@CHEMICAL$) @GENE$ channels is very slow and minimally reduces outward currents.
8153	CPR:3	Although @CHEMICAL$ greatly attenuates @GENE$ inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.
8154	CPR:4	Although @CHEMICAL$ greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of @GENE$ inactivation without altering its voltage dependence.
8155	CPRFalse	Here, we investigate whether the inverse functional response to @CHEMICAL$ in @GENE$ and ERG channels is related to differences in ICA binding site or to intrinsic mechanisms of inactivation.
8156	CPRFalse	Here, we investigate whether the inverse functional response to @CHEMICAL$ in EAG and @GENE$ channels is related to differences in ICA binding site or to intrinsic mechanisms of inactivation.
8157	CPRFalse	Here, we investigate whether the inverse functional response to ICA in @CHEMICAL$ and ERG channels is related to differences in @GENE$ binding site or to intrinsic mechanisms of inactivation.
8158	CPRFalse	Here, we investigate whether the inverse functional response to ICA in EAG and @CHEMICAL$ channels is related to differences in @GENE$ binding site or to intrinsic mechanisms of inactivation.
8159	CPR:5	@CHEMICAL$ is a mixed agonist of mutant @GENE$ and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.
8160	CPR:5	@CHEMICAL$ is a mixed agonist of mutant EAG and @GENE$/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.
8161	CPR:5	@CHEMICAL$ is a mixed agonist of mutant EAG and EAG/@GENE$ chimera channels that inactivate by a combination of slow and fast mechanisms.
8162	CPRFalse	With the exception of three residues, the specific @CHEMICAL$ that form the putative binding pocket for ICA in @GENE$ are conserved in EAG.
8163	CPRFalse	With the exception of three residues, the specific @CHEMICAL$ that form the putative binding pocket for ICA in ERG are conserved in @GENE$.
8164	CPRFalse	With the exception of three residues, the specific amino acids that form the putative binding pocket for @CHEMICAL$ in @GENE$ are conserved in EAG.
8165	CPRFalse	With the exception of three residues, the specific amino acids that form the putative binding pocket for @CHEMICAL$ in ERG are conserved in @GENE$.
8166	CPRFalse	Mutations introduced into @CHEMICAL$ to replicate the @GENE$ binding site in ERG did not alter the functional response to ICA.
8167	CPRFalse	Mutations introduced into EAG to replicate the @CHEMICAL$ binding site in @GENE$ did not alter the functional response to ICA.
8168	CPRFalse	Mutations introduced into @CHEMICAL$ to replicate the ICA binding site in ERG did not alter the functional response to @GENE$.
8169	CPRFalse	Mutations introduced into EAG to replicate the ICA binding site in @CHEMICAL$ did not alter the functional response to @GENE$.
8170	CPRFalse	Together these findings suggest that @CHEMICAL$ binds to the same site in @GENE$ and ERG channels to elicit opposite functional effects.
8171	CPRFalse	Together these findings suggest that @CHEMICAL$ binds to the same site in EAG and @GENE$ channels to elicit opposite functional effects.
8172	CPRFalse	Methylation of @CHEMICAL$ on @GENE$ 4 by the lysine methyltransferase SET1 protein is needed for normal clock gene expression.
8173	CPRFalse	Methylation of histone H3 on @CHEMICAL$ 4 by the @GENE$ SET1 protein is needed for normal clock gene expression.
8174	CPRFalse	Methylation of histone H3 on @CHEMICAL$ 4 by the lysine methyltransferase @GENE$ protein is needed for normal clock gene expression.
8175	CPRFalse	Methylation of @CHEMICAL$ on lysine 4 by the @GENE$ methyltransferase SET1 protein is needed for normal clock gene expression.
8176	CPRFalse	Methylation of histone H3 on lysine 4 by the @CHEM-GENE$ SET1 protein is needed for normal clock gene expression.
8177	CPRFalse	Methylation of histone H3 on lysine 4 by the @CHEMICAL$ methyltransferase @GENE$ protein is needed for normal clock gene expression.
8178	CPRFalse	The a7 nicotinic @CHEMICAL$ receptor (@GENE$) is highly expressed in different regions of the brain and is associated with cognitive function as well as anxiety.
8179	CPRFalse	The @CHEM-GENE$ (nAChR) is highly expressed in different regions of the brain and is associated with cognitive function as well as anxiety.
8180	CPRFalse	Previously @CHEMICAL$, which activates both @GENE$, has been shown to have an anxiogenic effect in behavioral tests.
8181	CPRFalse	@CHEMICAL$ on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the @GENE$ antagonist WAY-100135.
8182	CPR:6	PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the @CHEMICAL$ antagonist @GENE$.
8183	CPR:6	However the @CHEMICAL$ antagonist @GENE$ was unable to reverse these anxiety-like effects seen with PNU-282987.
8184	CPRFalse	However the @CHEMICAL$ antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with @GENE$.
8185	CPRFalse	@CHEM-GENE$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8186	CPRFalse	@CHEMICAL$ palmitoyltransferase 2 and @GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.
8187	CPR:9	@CHEMICAL$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.
8188	CPR:9	Carnitine palmitoyltransferase 2 and @CHEMICAL$ are involved in the mitochondrial synthesis and export of @GENE$.
8189	CPRFalse	@CHEMICAL$ and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8190	CPRFalse	Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.
8191	CPRFalse	@CHEMICAL$ and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8192	CPRFalse	Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.
8193	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.
8194	CPRFalse	We used lentiviral shRNA to knock down the expression of @CHEM-GENE$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8195	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (@GENE$) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8196	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and @GENE$ (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8197	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@GENE$)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8198	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8199	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8200	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain @CHEMICAL$ dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.
8201	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.
8202	CPRFalse	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and @GENE$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8203	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and @GENE$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8204	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEM-GENE$ (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8205	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (@GENE$)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8206	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, @GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8207	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8208	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.
8209	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.
8210	CPRFalse	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8211	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and carnitine palmitoyltransferase 2 (CPT2)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8212	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ (CPT2)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8213	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@CHEMICAL$)-, @GENE$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8214	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEM-GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8215	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$/acylcarnitine translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8216	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.
8217	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@CHEMICAL$ translocase (CACT)-, and plasmalemmal @GENE$ (OCTN2)-deficient human fibroblasts.
8218	CPRFalse	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8219	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8220	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ (CPT2)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8221	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@CHEMICAL$)-, carnitine/@GENE$ translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8222	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEM-GENE$ (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8223	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@CHEMICAL$ translocase (@GENE$)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.
8224	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/@CHEMICAL$ translocase (CACT)-, and plasmalemmal carnitine transporter (@GENE$)-deficient human fibroblasts.
8225	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @CHEM-GENE$ (OCTN2)-deficient human fibroblasts.
8226	CPRFalse	We used lentiviral shRNA to knock down the expression of @CHEMICAL$ (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.
8227	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (@CHEMICAL$) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.
8228	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and @CHEMICAL$ (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.
8229	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (@CHEMICAL$)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.
8230	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, @CHEMICAL$ (CACT)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.
8231	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (@CHEMICAL$)-, and plasmalemmal @GENE$ transporter (OCTN2)-deficient human fibroblasts.
8232	CPRFalse	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal @CHEMICAL$ transporter (@GENE$)-deficient human fibroblasts.
8233	CPRFalse	In control fibroblasts, @CHEMICAL$ knockdown markedly increased the production of @GENE$ (3-fold, P<0.01).
8234	CPRFalse	OCTN2-deficient cell lines also showed extracellular accumulation of @CHEMICAL$ (2.8-fold, P<0.01), suggesting that the cellular export of acylcarnitines does not depend on @GENE$.
8235	CPRFalse	@CHEMICAL$-deficient cell lines also showed extracellular accumulation of @GENE$ (2.8-fold, P<0.01), suggesting that the cellular export of acylcarnitines does not depend on OCTN2.
8236	CPRFalse	OCTN2-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P<0.01), suggesting that the cellular export of @CHEMICAL$ does not depend on @GENE$.
8237	CPRFalse	@CHEMICAL$-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P<0.01), suggesting that the cellular export of @GENE$ does not depend on OCTN2.
8238	CPRFalse	In contrast, in @CHEMICAL$- and CACT-deficient cells, the accumulation of @GENE$ in the medium did not significantly increase in the MCAD knockdown.
8239	CPRFalse	In contrast, in CPT2- and @CHEMICAL$-deficient cells, the accumulation of @GENE$ in the medium did not significantly increase in the MCAD knockdown.
8240	CPRFalse	In contrast, in CPT2- and CACT-deficient cells, the accumulation of @CHEMICAL$ in the medium did not significantly increase in the @GENE$ knockdown.
8241	CPRFalse	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.
8242	CPRFalse	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.
8243	CPR:9	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of @GENE$.
8244	CPR:9	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @CHEMICAL$ are involved in the mitochondrial synthesis and export of @GENE$.
8245	CPR:9	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial @GENE$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8246	CPR:9	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial @GENE$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8247	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial @CHEMICAL$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @GENE$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8248	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial @CHEMICAL$ formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.
8249	CPRFalse	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @GENE$ palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8250	CPRFalse	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @GENE$ palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8251	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEM-GENE$ and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8252	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ palmitoyltransferase 2 and @GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.
8253	CPRFalse	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8254	CPRFalse	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8255	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ and @GENE$/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8256	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.
8257	CPRFalse	This shows that @CHEMICAL$ and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8258	CPRFalse	This shows that CPT2 and @CHEMICAL$ are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8259	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. @CHEMICAL$ and carnitine/@GENE$ translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
8260	CPRFalse	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and @CHEM-GENE$ are involved in the mitochondrial synthesis and export of acylcarnitines.
8261	CPRFalse	When evaluated for their effects on @CHEM-GENE$ (nAChRs), several of these compounds were shown to be active as nAChR antagonists.
8262	CPRFalse	When evaluated for their effects on human a3b4 or a4b2 nicotinic @CHEMICAL$ receptors (@GENE$), several of these compounds were shown to be active as nAChR antagonists.
8263	CPRFalse	When evaluated for their effects on human a3b4 or a4b2 nicotinic @CHEMICAL$ receptors (nAChRs), several of these compounds were shown to be active as @GENE$ antagonists.
8264	CPRFalse	As a result of this study, @CHEMICAL$ (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit nicotinic receptor antagonistic activity for both the @GENE$ subtypes.
8265	CPR:6	As a result of this study, @CHEMICAL$ (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit @GENE$ antagonistic activity for both the ha3b4 and ha4b2 receptor subtypes.
8266	CPRFalse	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express calbindin-D28k, a @CHEM-GENE$ previously associated with resistance to injury in PD and in animal models.
8267	CPRFalse	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express @CHEMICAL$-D28k, a @GENE$-binding protein previously associated with resistance to injury in PD and in animal models.
8268	CPRFalse	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express calbindin-@CHEMICAL$, a @GENE$-binding protein previously associated with resistance to injury in PD and in animal models.
8269	CPRFalse	Cell-mapping studies in wild-type mice revealed that @CHEMICAL$ is primarily expressed in the ventral SN, a region particularly susceptible to @GENE$ and other dopaminergic neurotoxins.
8270	CPRFalse	Furthermore, @CHEMICAL$-expressing SN cells are preferentially lost following @GENE$ treatment.
8271	CPRFalse	Finally, SN mDA neurons in @CHEMICAL$ hemizygous mice show increased sensitivity when exposed to @GENE$.
8272	CPRFalse	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant Pitx3-autonomous, calbindin-positive neurons, and @GENE$-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.
8273	CPRFalse	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant Pitx3-autonomous, calbindin-positive neurons, and calbindin-negative @GENE$-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.
8274	CPRFalse	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant @GENE$-autonomous, calbindin-positive neurons, and calbindin-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.
8275	CPRFalse	Thus, SN mDA neurons are represented by at least two distinct subpopulations including @CHEMICAL$-resistant Pitx3-autonomous, @GENE$-positive neurons, and calbindin-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.
8276	CPRFalse	@CHEMICAL$ phosphorylates BAD at @GENE$-26 (Ser26) and primes it for inactivation.
8277	CPRFalse	IKK phosphorylates @CHEMICAL$ at @GENE$-26 (Ser26) and primes it for inactivation.
8278	CPRFalse	@CHEMICAL$ phosphorylates BAD at serine-26 (@GENE$26) and primes it for inactivation.
8279	CPRFalse	IKK phosphorylates @CHEMICAL$ at serine-26 (@GENE$26) and primes it for inactivation.
8280	CPRFalse	Elimination of @CHEMICAL$26 phosphorylation promotes @GENE$ proapoptotic activity, thereby accelerating TNFa-induced apoptosis in cultured cells and increasing mortality in animals.
8281	CPRFalse	Elimination of @CHEMICAL$26 phosphorylation promotes BAD proapoptotic activity, thereby accelerating @GENE$-induced apoptosis in cultured cells and increasing mortality in animals.
8282	CPRFalse	@CHEMICAL$ effects on @GENE$ activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
8283	CPRFalse	Almorexant effects on @CHEMICAL$ activity studied by its simultaneous and time-separated administration with @GENE$ and atorvastatin.
8284	CPRFalse	Almorexant effects on @CHEMICAL$ activity studied by its simultaneous and time-separated administration with simvastatin and @GENE$.
8285	CPR:6	PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual @CHEMICAL$ antagonist @GENE$.
8286	CPRFalse	PURPOSE: To characterise further the previously observed @CHEMICAL$ (CYP3A4) interaction of the dual orexin receptor antagonist @GENE$.
8287	CPRFalse	PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (@CHEMICAL$) interaction of the dual orexin receptor antagonist @GENE$.
8288	CPRFalse	This suggests that the observed interaction of almorexant with @CHEMICAL$ is mainly caused by intestinal @GENE$ inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition.
8289	CPRFalse	This suggests that the observed interaction of almorexant with @CHEMICAL$ is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic @GENE$ inhibition.
8290	CPRFalse	This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal @CHEMICAL$ inhibition, whereas the interaction with @GENE$ is more due to hepatic CYP3A4 inhibition.
8291	CPRFalse	This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with @CHEMICAL$ is more due to hepatic @GENE$ inhibition.
8292	CPRFalse	This suggests that the observed interaction of @CHEMICAL$ with simvastatin is mainly caused by intestinal @GENE$ inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition.
8293	CPRFalse	This suggests that the observed interaction of @CHEMICAL$ with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic @GENE$ inhibition.
8294	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.
8295	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.
8296	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.
8297	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.
8298	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: @GENE$, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.
8299	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.
8300	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.
8301	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.
8302	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.
8303	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, @GENE$, tolbutamide, metoprolol and midazolam, respectively.
8304	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.
8305	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.
8306	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.
8307	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.
8308	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, @GENE$, metoprolol and midazolam, respectively.
8309	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.
8310	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.
8311	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.
8312	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.
8313	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, @GENE$ and midazolam, respectively.
8314	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, @CHEMICAL$, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.
8315	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, @CHEMICAL$, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.
8316	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, @CHEMICAL$ and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.
8317	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and @CHEMICAL$, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.
8318	CPRFalse	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of @CHEMICAL$, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and @GENE$, respectively.
8319	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).
8320	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$ of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).
8321	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @CHEMICAL$ peptide (@GENE$(289)<Lys(290)).
8322	CPRFalse	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).
8323	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).
8324	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).
8325	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @CHEMICAL$, generating a truncated mature BMP-2 peptide (@GENE$(289)<Lys(290)).
8326	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).
8327	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).
8328	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @CHEMICAL$ peptide (Arg(289)<@GENE$(290)).
8329	CPRFalse	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).
8330	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).
8331	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).
8332	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @CHEMICAL$, generating a truncated mature BMP-2 peptide (Arg(289)<@GENE$(290)).
8333	CPRFalse	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @GENE$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8334	CPRFalse	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8335	CPRFalse	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).
8336	CPRFalse	@CHEMICAL$-terminal sequencing indicated that @GENE$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8337	CPRFalse	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by @GENE$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8338	CPRFalse	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @GENE$ (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8339	CPRFalse	@CHEMICAL$-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8340	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8341	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@CHEMICAL$(282)<Gln(283)), as well as in the @GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8342	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@CHEMICAL$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).
8343	CPRFalse	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8344	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8345	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (@GENE$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8346	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (@CHEMICAL$(282)<Gln(283)), as well as in the N-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8347	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8348	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@CHEMICAL$(283)), as well as in the @GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8349	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@CHEMICAL$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).
8350	CPRFalse	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8351	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8352	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<@GENE$(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8353	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<@CHEMICAL$(283)), as well as in the N-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8354	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical @CHEMICAL$, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8355	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEM-GENE$ of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8356	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$-terminal heparin binding region of mature BMP-2, generating a truncated mature @GENE$ peptide (Arg(289)<Lys(290)).
8357	CPRFalse	N-terminal sequencing indicated that @CHEMICAL$ was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8358	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by @CHEMICAL$ at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8359	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature @CHEMICAL$ (Arg(282)<Gln(283)), as well as in the @GENE$-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8360	CPRFalse	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)<Gln(283)), as well as in the @CHEMICAL$-terminal heparin binding region of mature @GENE$, generating a truncated mature BMP-2 peptide (Arg(289)<Lys(290)).
8361	CPRFalse	Similarly, mature @CHEMICAL$ was also cleaved to a truncated peptide within its @GENE$-terminal region (Arg(289)<Lys(290)).
8362	CPRFalse	Similarly, mature @CHEMICAL$ was also cleaved to a truncated peptide within its N-terminal region (@GENE$(289)<Lys(290)).
8363	CPRFalse	Similarly, mature @CHEMICAL$ was also cleaved to a truncated peptide within its N-terminal region (Arg(289)<@GENE$(290)).
8364	CPRFalse	A brief history of @CHEM-GENE$ and its role in modulating psychostimulant effects.
8365	CPRFalse	Over the past century, the polypeptide @CHEM-GENE$ has played an important role in medicine with major highlights including the identification of its involvement in parturition and the milk let-down reflex.
8366	CPRFalse	@CHEM-GENE$ is now implicated in an extensive range of psychological phenomena including reward and memory processes and has been investigated as a treatment for several psychiatric disorders including addiction, anxiety, autism, and schizophrenia.
8367	CPRFalse	In this review, we first provide an historical overview of @CHEM-GENE$ and describe key aspects of its physiological activity.
8368	CPRFalse	We then outline some pharmacological limitations in this field of research before highlighting the role of @CHEM-GENE$ in a wide range of behavioral and neuronal processes.
8369	CPRFalse	Finally, we review evidence for a modulatory role of @CHEM-GENE$ with regard to psychostimulant effects.
8370	CPRFalse	Key findings suggest that @CHEM-GENE$ attenuates a broad number of cocaine and methamphetamine induced behaviors and associated neuronal activity in rodents.
8371	CPRFalse	Key findings suggest that @CHEMICAL$ attenuates a broad number of @GENE$ and methamphetamine induced behaviors and associated neuronal activity in rodents.
8372	CPRFalse	Key findings suggest that @CHEMICAL$ attenuates a broad number of cocaine and @GENE$ induced behaviors and associated neuronal activity in rodents.
8373	CPRFalse	Evidence also outlines a role for @CHEM-GENE$ in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in both rodents and humans.
8374	CPRFalse	Evidence also outlines a role for @CHEMICAL$ in the prosocial effects of @GENE$ (MDMA, Ecstasy) in both rodents and humans.
8375	CPRFalse	Evidence also outlines a role for @CHEMICAL$ in the prosocial effects of 3,4-methylenedioxymethamphetamine (@GENE$, Ecstasy) in both rodents and humans.
8376	CPRFalse	Evidence also outlines a role for @CHEMICAL$ in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, @GENE$) in both rodents and humans.
8377	CPRFalse	Clinical trials should now investigate the effectiveness of @CHEM-GENE$ as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of MDMA that are currently being investigated.
8378	CPRFalse	Clinical trials should now investigate the effectiveness of @CHEMICAL$ as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of @GENE$ that are currently being investigated.
8379	CPRFalse	The @CHEMICAL$/IDE T2D locus is associated with decreased insulin secretion in response to oral @GENE$ stimulation in humans.
8380	CPRFalse	The HHEX/@CHEMICAL$ T2D locus is associated with decreased insulin secretion in response to oral @GENE$ stimulation in humans.
8381	CPRFalse	The HHEX/IDE T2D locus is associated with decreased @CHEMICAL$ secretion in response to oral @GENE$ stimulation in humans.
8382	CPRFalse	We find that @CHEMICAL$ stimulated @GENE$ secretion (GSIS) is decreased in Ide KO mice due to impaired replenishment of the releasable pool of granules and that the Ide gene is haploinsufficient.
8383	CPRFalse	We find that @CHEMICAL$ stimulated insulin secretion (GSIS) is decreased in @GENE$ KO mice due to impaired replenishment of the releasable pool of granules and that the Ide gene is haploinsufficient.
8384	CPRFalse	We find that @CHEMICAL$ stimulated insulin secretion (GSIS) is decreased in Ide KO mice due to impaired replenishment of the releasable pool of granules and that the @GENE$ gene is haploinsufficient.
8385	CPRFalse	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven @GENE$-lox, and low-frequency ubiquitous cre-lox reveal that PDL does not convert progenitors to the b-cell lineage.
8386	CPRFalse	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven cre-@GENE$, and low-frequency ubiquitous cre-lox reveal that PDL does not convert progenitors to the b-cell lineage.
8387	CPRFalse	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven cre-lox, and low-frequency ubiquitous @GENE$-lox reveal that PDL does not convert progenitors to the b-cell lineage.
8388	CPRFalse	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, rat insulin 2 promoter-driven cre-lox, and low-frequency ubiquitous cre-@GENE$ reveal that PDL does not convert progenitors to the b-cell lineage.
8389	CPRFalse	Lineage-tracing studies using sequential administration of @CHEMICAL$ analogs, @GENE$-driven cre-lox, and low-frequency ubiquitous cre-lox reveal that PDL does not convert progenitors to the b-cell lineage.
8390	CPRFalse	Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective @CHEMICAL$ receptor ligands and the @GENE$ elicited head-twitch response model.
8391	CPRFalse	Support for @CHEMICAL$ receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the @GENE$ elicited head-twitch response model.
8392	CPRFalse	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @CHEMICAL$ agonist 2,5-dimethoxy-4-iodoamphetamine (@GENE$).
8393	CPRFalse	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) @CHEMICAL$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (@GENE$).
8394	CPRFalse	There are seemingly conflicting data in the literature regarding the role of @CHEMICAL$ (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @GENE$ agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).
8395	CPRFalse	There are seemingly conflicting data in the literature regarding the role of @CHEMICAL$ (5-HT) @GENE$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).
8396	CPRFalse	There are seemingly conflicting data in the literature regarding the role of serotonin (@CHEMICAL$) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @GENE$ agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).
8397	CPRFalse	There are seemingly conflicting data in the literature regarding the role of serotonin (@CHEMICAL$) @GENE$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).
8398	CPRFalse	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic @CHEMICAL$ agonist @GENE$ (DOI).
8399	CPRFalse	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) @CHEMICAL$ receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist @GENE$ (DOI).
8400	CPRFalse	The present experiments tested the hypothesis that both classes of @CHEMICAL$ receptor compounds could attenuate the @GENE$-elicited-HTR in a single strain of mice, C57Bl/6J. The expected results were considered in accordance with ligand functional selectivity.
8401	CPRFalse	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8402	CPRFalse	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8403	CPR:5	Commercially-available @CHEMICAL$ agonists (@GENE$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8404	CPRFalse	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8405	CPRFalse	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8406	CPRFalse	Commercially-available 5-HT2C agonists (@CHEMICAL$, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8407	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8408	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8409	CPR:5	Commercially-available @CHEMICAL$ agonists (CP 809101, @GENE$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8410	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8411	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8412	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, @CHEMICAL$, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8413	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8414	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8415	CPR:5	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, @GENE$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8416	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8417	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8418	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, @CHEMICAL$, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8419	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8420	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8421	CPR:5	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, @GENE$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8422	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8423	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8424	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, @CHEMICAL$, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8425	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8426	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8427	CPR:5	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @GENE$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8428	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8429	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8430	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and @CHEMICAL$), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8431	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8432	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8433	CPRFalse	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @GENE$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8434	CPR:5	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8435	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8436	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel @CHEMICAL$ (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8437	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with @GENE$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8438	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8439	CPRFalse	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@GENE$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8440	CPR:5	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type @GENE$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8441	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @GENE$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8442	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (@CHEMICAL$)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8443	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.
8444	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @CHEMICAL$ (SB-206553) receptors attenuated the @GENE$-elicited-HTR.
8445	CPRFalse	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.
8446	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.
8447	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.
8448	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @CHEMICAL$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the @GENE$-elicited-HTR.
8449	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8450	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@CHEMICAL$), 5-HT2C (SB-242084), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8451	CPRFalse	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8452	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8453	CPR:6	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (@GENE$), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8454	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (@CHEMICAL$), @GENE$ (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8455	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8456	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@CHEMICAL$), and @GENE$ (SB-206553) receptors attenuated the DOI-elicited-HTR.
8457	CPRFalse	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8458	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8459	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (M100907), 5-HT2C (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8460	CPR:6	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @CHEMICAL$ (@GENE$), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.
8461	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with @CHEMICAL$ antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.
8462	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and @CHEMICAL$ (@GENE$) receptors attenuated the DOI-elicited-HTR.
8463	CPRFalse	Commercially-available @CHEMICAL$ agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.
8464	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type @CHEMICAL$ agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.
8465	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for @CHEMICAL$ (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.
8466	CPRFalse	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), @CHEMICAL$ (SB-242084), and 5-HT2B/2C (@GENE$) receptors attenuated the DOI-elicited-HTR.
8467	CPRFalse	The @CHEMICAL$ agonists and @GENE$ decreased locomotion, SB-242084 increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.
8468	CPRFalse	The @CHEMICAL$ agonists and M100907 decreased locomotion, @GENE$ increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.
8469	CPRFalse	The @CHEMICAL$ agonists and M100907 decreased locomotion, SB-242084 increased locomotion, @GENE$ resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.
8470	CPRFalse	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the @CHEMICAL$-elicited-HTR also reduced the efficacy of DOI to activate mouse 5-HT2C receptor-mediated @GENE$ signaling in HEK cells.
8471	CPRFalse	In vitro molecular pharmacology studies showed that @CHEMICAL$ agonists potent for attenuating the @GENE$-elicited-HTR also reduced the efficacy of DOI to activate mouse 5-HT2C receptor-mediated PLC signaling in HEK cells.
8472	CPRFalse	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the @CHEMICAL$-elicited-HTR also reduced the efficacy of DOI to activate @GENE$ receptor-mediated PLC signaling in HEK cells.
8473	CPRFalse	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of @CHEMICAL$ to activate mouse 5-HT2C receptor-mediated @GENE$ signaling in HEK cells.
8474	CPRFalse	In vitro molecular pharmacology studies showed that @CHEMICAL$ agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of @GENE$ to activate mouse 5-HT2C receptor-mediated PLC signaling in HEK cells.
8475	CPR:3	In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of @CHEMICAL$ to activate @GENE$ receptor-mediated PLC signaling in HEK cells.
8476	CPRFalse	Results indicate that @CHEMICAL$ receptor agonists and antagonists attenuate the @GENE$-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different 5-HT2C receptor signaling outcomes compared to DOI.
8477	CPRFalse	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the @CHEMICAL$-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse @GENE$ ligands result in different 5-HT2C receptor signaling outcomes compared to DOI.
8478	CPRFalse	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the @CHEMICAL$-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different @GENE$ receptor signaling outcomes compared to DOI.
8479	CPRFalse	Results indicate that @CHEMICAL$ receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different 5-HT2C receptor signaling outcomes compared to @GENE$.
8480	CPRFalse	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse @CHEMICAL$ ligands result in different 5-HT2C receptor signaling outcomes compared to @GENE$.
8481	CPRFalse	Results indicate that 5-HT2C receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different @CHEMICAL$ receptor signaling outcomes compared to @GENE$.
8482	CPRFalse	Role of @CHEMICAL$ in @GENE$ metabolism and clearance.
8483	CPR:9	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to @GENE$.
8484	CPR:9	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic @GENE$ (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.
8485	CPR:9	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (@GENE$) and CYP3A4, but clinical disposition is often attributed to CYP3A4.
8486	CPR:9	@CHEMICAL$ N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and @GENE$, but clinical disposition is often attributed to CYP3A4.
8487	CPR:9	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to @GENE$.
8488	CPR:9	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic @GENE$ (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.
8489	CPR:9	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (@GENE$) and CYP3A4, but clinical disposition is often attributed to CYP3A4.
8490	CPR:9	Methadone @CHEMICAL$-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and @GENE$, but clinical disposition is often attributed to CYP3A4.
8491	CPR:9	This investigation tested the hypothesis that CYP2B6 is a prominent @CHEMICAL$ isoform responsible for clinical @GENE$ N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.
8492	CPR:9	This investigation tested the hypothesis that @CHEMICAL$ is a prominent CYP isoform responsible for clinical @GENE$ N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.
8493	CPRFalse	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical @CHEMICAL$ N-demethylation and clearance, using the in vivo mechanism-based @GENE$ inhibitor ticlopidine, given orally for 4 days.
8494	CPR:9	This investigation tested the hypothesis that CYP2B6 is a prominent @CHEMICAL$ isoform responsible for clinical methadone @GENE$-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.
8495	CPR:9	This investigation tested the hypothesis that @CHEMICAL$ is a prominent CYP isoform responsible for clinical methadone @GENE$-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.
8496	CPRFalse	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone @CHEMICAL$-demethylation and clearance, using the in vivo mechanism-based @GENE$ inhibitor ticlopidine, given orally for 4 days.
8497	CPRFalse	This investigation tested the hypothesis that CYP2B6 is a prominent @CHEMICAL$ isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor @GENE$, given orally for 4 days.
8498	CPRFalse	This investigation tested the hypothesis that @CHEMICAL$ is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor @GENE$, given orally for 4 days.
8499	CPR:4	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based @CHEMICAL$ inhibitor @GENE$, given orally for 4 days.
8500	CPRFalse	A preliminary clinical investigation with the @CHEMICAL$ substrate probe @GENE$ established that ticlopidine did not inhibit intestinal or hepatic CYP3A4/5.
8501	CPRFalse	A preliminary clinical investigation with the CYP3A4/5 substrate probe @CHEMICAL$ established that ticlopidine did not inhibit intestinal or hepatic @GENE$.
8502	CPRFalse	A preliminary clinical investigation with the @CHEMICAL$ substrate probe alfentanil established that @GENE$ did not inhibit intestinal or hepatic CYP3A4/5.
8503	CPRFalse	A preliminary clinical investigation with the CYP3A4/5 substrate probe alfentanil established that @CHEMICAL$ did not inhibit intestinal or hepatic @GENE$.
8504	CPRFalse	@CHEMICAL$ inhibition reduces @GENE$ N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.
8505	CPRFalse	CYP2B6 inhibition reduces @CHEMICAL$ N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for @GENE$ in clinical methadone disposition.
8506	CPRFalse	@CHEMICAL$ inhibition reduces methadone @GENE$-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.
8507	CPRFalse	CYP2B6 inhibition reduces methadone @CHEMICAL$-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for @GENE$ in clinical methadone disposition.
8508	CPRFalse	@CHEMICAL$ inhibition reduces methadone N-demethylation and clearance, and alters @GENE$ concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.
8509	CPRFalse	CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters @CHEMICAL$ concentrations, demonstrating an important role for @GENE$ in clinical methadone disposition.
8510	CPRFalse	@CHEMICAL$ inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical @GENE$ disposition.
8511	CPR:9	CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for @CHEMICAL$ in clinical @GENE$ disposition.
8512	CPRFalse	@CHEMICAL$ D2 receptor activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gbg-@GENE$-dependent induction of Zif268.
8513	CPRFalse	@CHEM-GENE$ activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gbg-Erk1/2-dependent induction of Zif268.
8514	CPRFalse	@CHEMICAL$ D2 receptor activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gbg-Erk1/2-dependent induction of @GENE$.
8515	CPRFalse	@CHEMICAL$ D2 receptor activation leads to an up-regulation of @GENE$ via Gbg-Erk1/2-dependent induction of Zif268.
8516	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEM-GENE$ (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8517	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (@GENE$) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8518	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of @GENE$ that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8519	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$ (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8520	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (@GENE$), a DNA-binding transcription factor encoded by an immediate-early gene.
8521	CPR:5	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ (D2R) agonist, @GENE$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8522	CPR:5	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (@CHEMICAL$) agonist, @GENE$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8523	CPR:3	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, @CHEMICAL$, triggered an increase in the expression of @GENE$ that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8524	CPR:3	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, @CHEMICAL$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$ (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8525	CPR:3	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, @CHEMICAL$, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (@GENE$), a DNA-binding transcription factor encoded by an immediate-early gene.
8526	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the @CHEMICAL$ (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8527	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (@CHEMICAL$) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @GENE$-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8528	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of @CHEMICAL$ that was temporally preceded by an increase in the levels of @GENE$-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8529	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @CHEM-GENE$ (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.
8530	CPRFalse	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of @CHEMICAL$-finger protein 268 (@GENE$), a DNA-binding transcription factor encoded by an immediate-early gene.
8531	CPR:4	Moreover, the @CHEMICAL$ inhibitor @GENE$ blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.
8532	CPR:4	Moreover, the D2R inhibitor @CHEMICAL$ blocked the increase of both @GENE$ and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.
8533	CPR:4	Moreover, the D2R inhibitor @CHEMICAL$ blocked the increase of both GDNF and @GENE$ expression following potassium-evoked dopamine release in SH-SY5Y cells.
8534	CPRFalse	Moreover, the @CHEMICAL$ inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following @GENE$-evoked dopamine release in SH-SY5Y cells.
8535	CPRFalse	Moreover, the D2R inhibitor raclopride blocked the increase of both @CHEMICAL$ and Zif268 expression following @GENE$-evoked dopamine release in SH-SY5Y cells.
8536	CPRFalse	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and @CHEMICAL$ expression following @GENE$-evoked dopamine release in SH-SY5Y cells.
8537	CPRFalse	Moreover, the @CHEMICAL$ inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked @GENE$ release in SH-SY5Y cells.
8538	CPRFalse	Moreover, the D2R inhibitor raclopride blocked the increase of both @CHEMICAL$ and Zif268 expression following potassium-evoked @GENE$ release in SH-SY5Y cells.
8539	CPRFalse	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and @CHEMICAL$ expression following potassium-evoked @GENE$ release in SH-SY5Y cells.
8540	CPRFalse	Here, we have perturbed vibrational motions in @CHEMICAL$ reductase (@GENE$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and (2)H).
8541	CPRFalse	Here, we have perturbed vibrational motions in @CHEM-GENE$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and (2)H).
8542	CPRFalse	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (@CHEMICAL$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope (@GENE$, (15)N, and (2)H).
8543	CPRFalse	Here, we have perturbed vibrational motions in @CHEMICAL$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope (@GENE$, (15)N, and (2)H).
8544	CPRFalse	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (@CHEMICAL$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, @GENE$, and (2)H).
8545	CPRFalse	Here, we have perturbed vibrational motions in @CHEMICAL$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, @GENE$, and (2)H).
8546	CPRFalse	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (@CHEMICAL$) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and @GENE$).
8547	CPRFalse	Here, we have perturbed vibrational motions in @CHEMICAL$ (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and @GENE$).
8548	CPRFalse	Characterization of the mouse promoter region of the @CHEMICAL$ synthetase 4 gene: role of Sp1 and @GENE$.
8549	CPRFalse	Characterization of the mouse promoter region of the @CHEM-GENE$ gene: role of Sp1 and CREB.
8550	CPRFalse	Characterization of the mouse promoter region of the @CHEMICAL$ synthetase 4 gene: role of @GENE$ and CREB.
8551	CPRFalse	@CHEM-GENE$ (Acsl4) is involved in several cellular functions including steroidogenesis, synaptic development and cancer metastasis.
8552	CPRFalse	@CHEMICAL$ synthetase 4 (@GENE$) is involved in several cellular functions including steroidogenesis, synaptic development and cancer metastasis.
8553	CPRFalse	We demonstrated @CHEMICAL$ and @GENE$ regulation of Acsl4 mRNA in mouse steroidogenic MA-10 Leydig cells.
8554	CPRFalse	We demonstrated hCG and @CHEMICAL$ regulation of @GENE$ mRNA in mouse steroidogenic MA-10 Leydig cells.
8555	CPRFalse	Functional characterization revealed that the @CHEMICAL$/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @GENE$ stimulation of Acsl4 transcription.
8556	CPRFalse	Functional characterization revealed that the specificity protein/@CHEMICAL$ Sp1 binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @GENE$ stimulation of Acsl4 transcription.
8557	CPRFalse	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @CHEMICAL$-binding site is involved in @GENE$ stimulation of Acsl4 transcription.
8558	CPRFalse	Functional characterization revealed that the specificity protein/Kruppel-like factor @CHEMICAL$ binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @GENE$ stimulation of Acsl4 transcription.
8559	CPRFalse	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the cAMP response element-binding site is involved in @CHEMICAL$ stimulation of @GENE$ transcription.
8560	CPRFalse	Functional characterization revealed that the @CHEMICAL$/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @GENE$ response element-binding site is involved in cAMP stimulation of Acsl4 transcription.
8561	CPRFalse	Functional characterization revealed that the specificity protein/@CHEMICAL$ Sp1 binding site in the proximal promoter is involved in basal activity and that the @GENE$ response element-binding site is involved in cAMP stimulation of Acsl4 transcription.
8562	CPRFalse	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @CHEM-GENE$-binding site is involved in cAMP stimulation of Acsl4 transcription.
8563	CPRFalse	Functional characterization revealed that the specificity protein/Kruppel-like factor @CHEMICAL$ binding site in the proximal promoter is involved in basal activity and that the @GENE$ response element-binding site is involved in cAMP stimulation of Acsl4 transcription.
8564	CPRFalse	Functional characterization revealed that the specificity protein/Kruppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the @CHEMICAL$ response element-binding site is involved in cAMP stimulation of @GENE$ transcription.
8565	CPR:4	Synthesis and biological evaluation of @CHEMICAL$ analogues as novel @GENE$ and BuChE inhibitors.
8566	CPR:4	Synthesis and biological evaluation of @CHEMICAL$ analogues as novel AChE and @GENE$ inhibitors.
8567	CPRFalse	In this paper a series of new 1,3,4-thiadiazole derivatives has been designed, synthesized and evaluated as the @CHEM-GENE$ inhibitors.
8568	CPR:4	In this paper a series of new @CHEMICAL$ derivatives has been designed, synthesized and evaluated as the @GENE$ inhibitors.
8569	CPR:4	@CHEMICAL$, a specific @GENE$/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.
8570	CPR:4	@CHEMICAL$, a specific PI3K/@GENE$ inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.
8571	CPR:3	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the @GENE$ MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.
8572	CPR:3	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 @GENE$ kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.
8573	CPR:3	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK @GENE$ pathway and enhanced c-Jun phosphorylation, but did not activate JNK.
8574	CPRFalse	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate @GENE$.
8575	CPR:3	@CHEMICAL$, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced @GENE$ phosphorylation, but did not activate JNK.
8576	CPR:4	The pharmacological inhibitors @CHEMICAL$ (@GENE$ inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.
8577	CPRFalse	The pharmacological inhibitors @CHEMICAL$ (p38 inhibitor) and SP600125 (a @GENE$ inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.
8578	CPRFalse	The pharmacological inhibitors SB203580 (@CHEMICAL$ inhibitor) and @GENE$ (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.
8579	CPR:4	The pharmacological inhibitors SB203580 (p38 inhibitor) and @CHEMICAL$ (a @GENE$ inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.
8580	CPRFalse	The pharmacological inhibitors SB203580 (@CHEMICAL$ inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from @GENE$-induced apoptosis.
8581	CPRFalse	The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a @CHEMICAL$ inhibitor) protected primary cultures of rat CGCs from @GENE$-induced apoptosis.
8582	CPRFalse	We previously demonstrated that @CHEMICAL$ (P-gp) modulation at the blood-brain barrier (BBB) contributes highly to @GENE$-related respiratory toxicity, by limiting NBUP entrance into the brain.
8583	CPRFalse	We previously demonstrated that P-glycoprotein (@CHEMICAL$) modulation at the blood-brain barrier (BBB) contributes highly to @GENE$-related respiratory toxicity, by limiting NBUP entrance into the brain.
8584	CPRFalse	We previously demonstrated that @CHEMICAL$ (P-gp) modulation at the blood-brain barrier (BBB) contributes highly to BUP-related respiratory toxicity, by limiting @GENE$ entrance into the brain.
8585	CPRFalse	We previously demonstrated that P-glycoprotein (@CHEMICAL$) modulation at the blood-brain barrier (BBB) contributes highly to BUP-related respiratory toxicity, by limiting @GENE$ entrance into the brain.
8586	CPRFalse	In this work, we sought to investigate the role of @CHEMICAL$-mediated transport at the BBB in gender and strain-related variability of @GENE$ and NBUP-induced respiratory effects in mice.
8587	CPRFalse	In this work, we sought to investigate the role of @CHEMICAL$-mediated transport at the BBB in gender and strain-related variability of BUP and @GENE$-induced respiratory effects in mice.
8588	CPRFalse	No differences in @CHEMICAL$ expression or @GENE$ and NBUP transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.
8589	CPRFalse	No differences in @CHEMICAL$ expression or BUP and @GENE$ transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.
8590	CPRFalse	Our results suggest that @CHEMICAL$-mediated transport across the BBB does not play a key-role in gender and strain-related variability in @GENE$ and NBUP-induced respiratory toxicity in mice.
8591	CPRFalse	Our results suggest that @CHEMICAL$-mediated transport across the BBB does not play a key-role in gender and strain-related variability in BUP and @GENE$-induced respiratory toxicity in mice.
8592	CPRFalse	Autophagy takes place in mutated @CHEMICAL$ neuroblastoma cells in response to hypoxia mimetic @GENE$.
8593	CPR:3	Today, we used @CHEMICAL$, a hypoxia mimetic that inhibits proteasomal @GENE$ degradation and generates reactive oxygen species (ROS).
8594	CPRFalse	Today, we used cobalt chloride, a hypoxia mimetic that inhibits proteasomal @CHEMICAL$ degradation and generates reactive @GENE$ species (ROS).
8595	CPRFalse	We focused on @CHEMICAL$-induced cell death in a DNA-binding mutated @GENE$ neuroblastoma cell line (SKNBE(2c)).
8596	CPRFalse	An autophagic signaling was evidenced by an increase of Beclin-1, @CHEMICAL$, and LC3-II expression whereas the p53(mut) presence decreased with @GENE$ time exposure.
8597	CPRFalse	An autophagic signaling was evidenced by an increase of @CHEMICAL$, ATG 5-12, and LC3-II expression whereas the p53(mut) presence decreased with @GENE$ time exposure.
8598	CPRFalse	An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and @CHEMICAL$ expression whereas the p53(mut) presence decreased with @GENE$ time exposure.
8599	CPR:4	An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the @CHEMICAL$(mut) presence decreased with @GENE$ time exposure.
8600	CPRFalse	The myosin-18Aa isoform, additionally, has an @CHEMICAL$-terminal @GENE$.
8601	CPRFalse	The @CHEMICAL$ isoform, additionally, has an @GENE$-terminal PDZ domain.
8602	CPRFalse	@CHEMICAL$ binding was unchanged by presence of @GENE$.
8603	CPRFalse	Both myosin-18A isoforms bound @CHEMICAL$, but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by @GENE$.
8604	CPRFalse	Both @CHEMICAL$ isoforms bound @GENE$, but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.
8605	CPRFalse	Both myosin-18A isoforms bound N-methylanthraniloyl-nucleotides, but the rate of @CHEMICAL$ hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by @GENE$.
8606	CPRFalse	Both @CHEMICAL$ isoforms bound N-methylanthraniloyl-nucleotides, but the rate of @GENE$ hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.
8607	CPRFalse	Phosphorylation of the regulatory light chain had no effect on @CHEMICAL$ hydrolysis, and neither did the addition of tropomyosin or of GOLPH3, a @GENE$ binding partner.
8608	CPRFalse	Electron microscopy of @CHEMICAL$-S1 showed that the lever is strongly angled with respect to the long axis of the motor domain, suggesting a pre-power stroke conformation regardless of the presence of @GENE$.
8609	CPR:4	Cellular responses to DNA damage induced by @CHEMICAL$ or doxorubicin include down-regulation of endogenous @GENE$ coincident with increases in p53.
8610	CPR:3	Cellular responses to DNA damage induced by @CHEMICAL$ or doxorubicin include down-regulation of endogenous supervillin coincident with increases in @GENE$.
8611	CPR:4	Cellular responses to DNA damage induced by etoposide or @CHEMICAL$ include down-regulation of endogenous @GENE$ coincident with increases in p53.
8612	CPR:3	Cellular responses to DNA damage induced by etoposide or @CHEMICAL$ include down-regulation of endogenous supervillin coincident with increases in @GENE$.
8613	CPRFalse	@CHEMICAL$ binds directly to the supervillin @GENE$ terminus and can deubiquitinate and stabilize supervillin.
8614	CPRFalse	USP7 binds directly to the @CHEMICAL$ @GENE$ terminus and can deubiquitinate and stabilize supervillin.
8615	CPRFalse	USP7 binds directly to the supervillin @CHEMICAL$ terminus and can deubiquitinate and stabilize @GENE$.
8616	CPR:3	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (@GENE$) and/or decreased neuropeptide Y (NPY).
8617	CPR:4	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased @GENE$ (NPY).
8618	CPR:4	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (@GENE$).
8619	CPR:3	Novel @CHEMICAL$ derivatives that modulate body weight through enhancement of hypothalamic @GENE$ (POMC) and/or decreased neuropeptide Y (NPY).
8620	CPRFalse	Effects of @CHEMICAL$ on weight were dose-dependent, and it could be given orally. 1, 2, 4, 5 down-regulated @GENE$ mRNA expression.
8621	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and @CHEMICAL$ exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @GENE$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.
8622	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and @CHEMICAL$ exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @GENE$ (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.
8623	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @CHEMICAL$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and @GENE$ (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.
8624	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @CHEMICAL$ (1.0mg/ml) and @GENE$ (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.
8625	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @CHEMICAL$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% @GENE$.
8626	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @CHEMICAL$ (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% @GENE$.
8627	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and @CHEMICAL$ diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of @GENE$ (1.5mg/ml), very-low-density lipoprotein (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.
8628	CPRFalse	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and @CHEMICAL$ diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), @GENE$ (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.
8629	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and @CHEMICAL$ (PAI), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.
8630	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (@CHEMICAL$), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.
8631	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of @CHEMICAL$ (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.
8632	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (@CHEMICAL$) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial @GENE$ synthase (eNOS) protein expression and nitric oxide (NO) release.
8633	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in @CHEM-GENE$ (eNOS) protein expression and nitric oxide (NO) release.
8634	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial @CHEMICAL$ synthase (@GENE$) protein expression and nitric oxide (NO) release.
8635	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and @CHEMICAL$ (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.
8636	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (@CHEMICAL$), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.
8637	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of @CHEMICAL$ (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.
8638	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (@CHEMICAL$) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and @GENE$ (NO) release.
8639	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in @CHEMICAL$ (eNOS) protein expression and @GENE$ (NO) release.
8640	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (@CHEMICAL$) protein expression and @GENE$ (NO) release.
8641	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and @CHEMICAL$ (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.
8642	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (@CHEMICAL$), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.
8643	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of @CHEMICAL$ (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.
8644	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (@CHEMICAL$) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (eNOS) protein expression and nitric oxide (@GENE$) release.
8645	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in @CHEMICAL$ (eNOS) protein expression and nitric oxide (@GENE$) release.
8646	CPRFalse	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (@CHEMICAL$) protein expression and nitric oxide (@GENE$) release.
8647	CPRFalse	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and @CHEMICAL$ release and caused membrane damage, but caused no changes in the secretion of ET-1, prostacyclin and @GENE$.
8648	CPRFalse	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, @CHEMICAL$ protein expression, and @GENE$ release and caused membrane damage, but caused no changes in the secretion of ET-1, prostacyclin and PAI.
8649	CPRFalse	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and @CHEMICAL$ release and caused membrane damage, but caused no changes in the secretion of @GENE$, prostacyclin and PAI.
8650	CPRFalse	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of ET-1, @CHEMICAL$ and @GENE$.
8651	CPRFalse	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, @CHEMICAL$ protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of ET-1, @GENE$ and PAI.
8652	CPRFalse	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of @CHEMICAL$, @GENE$ and PAI.
8653	CPRFalse	We apply DFTB in a QM/MM framework to perform vibrational analysis of buried @CHEMICAL$ in @GENE$ and channelrhodopsin-2.
8654	CPRFalse	We apply DFTB in a QM/MM framework to perform vibrational analysis of buried @CHEMICAL$ in bacteriorhodopsin and @GENE$.
8655	CPRFalse	Refining the @CHEMICAL$ haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with @GENE$/irinotecan-based regimens.
8656	CPRFalse	Refining the @CHEMICAL$ haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/@GENE$-based regimens.
8657	CPRFalse	Refining the @CHEMICAL$ haplotype associated with @GENE$-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
8658	CPRFalse	Despite the importance of @CHEMICAL$*28 in @GENE$ pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited.
8659	CPRFalse	Despite the importance of @CHEM-GENE$*28 in irinotecan pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited.
8660	CPRFalse	Our results suggest that specific SNPs in @CHEMICAL$, other than UGT1A1*28, may influence @GENE$ toxicity and should be considered to refine pharmacogenetic testing.
8661	CPRFalse	Our results suggest that specific SNPs in UGT1A, other than @CHEMICAL$*28, may influence @GENE$ toxicity and should be considered to refine pharmacogenetic testing.
8662	CPRFalse	@CHEM-GENE$ mRNA Measured by Quantitative Real Time PCR is Decreased in the Urethral Mucosa of Patients with Middle Idiopathic Hypospadias.
8663	CPRFalse	@CHEMICAL$ action is exerted through the @GENE$.
8664	CPRFalse	Androgen action is exerted through the @CHEM-GENE$.
8665	CPRFalse	The normal 46,XY genital virilization depends on @CHEM-GENE$ gene expression, which is tissue specific, and requires normal androgen receptor mRNA levels in androgen sensitive tissues.
8666	CPRFalse	The normal 46,XY genital virilization depends on @CHEMICAL$ receptor gene expression, which is tissue specific, and requires normal @GENE$ mRNA levels in androgen sensitive tissues.
8667	CPRFalse	The normal 46,XY genital virilization depends on @CHEMICAL$ gene expression, which is tissue specific, and requires normal @GENE$ receptor mRNA levels in androgen sensitive tissues.
8668	CPRFalse	The normal 46,XY genital virilization depends on androgen receptor gene expression, which is tissue specific, and requires normal @CHEM-GENE$ mRNA levels in androgen sensitive tissues.
8669	CPRFalse	The normal 46,XY genital virilization depends on @CHEMICAL$ gene expression, which is tissue specific, and requires normal androgen receptor mRNA levels in @GENE$ sensitive tissues.
8670	CPRFalse	The normal 46,XY genital virilization depends on androgen receptor gene expression, which is tissue specific, and requires normal @CHEMICAL$ mRNA levels in @GENE$ sensitive tissues.
8671	CPRFalse	The aim of this study was to compare, by quantitative real time PCR, the amount of @CHEM-GENE$ mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the androgen receptor mRNA levels observed in control phimosis subjects with eutopic urethral opening.
8672	CPRFalse	The aim of this study was to compare, by quantitative real time PCR, the amount of @CHEMICAL$ receptor mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the @GENE$ mRNA levels observed in control phimosis subjects with eutopic urethral opening.
8673	CPRFalse	The aim of this study was to compare, by quantitative real time PCR, the amount of @CHEMICAL$ mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the @GENE$ receptor mRNA levels observed in control phimosis subjects with eutopic urethral opening.
8674	CPRFalse	The aim of this study was to compare, by quantitative real time PCR, the amount of androgen receptor mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the @CHEM-GENE$ mRNA levels observed in control phimosis subjects with eutopic urethral opening.
8675	CPRFalse	We observed significantly less @CHEM-GENE$ mRNA in the urethral mucosa of patients with hypospadias than in the controls (p=0.002).
8676	CPRFalse	The correlation between the level of @CHEM-GENE$ mRNA expression and the penile size was almost statistically significant only in hypospadias patients (r=0.47; p=0.053).
8677	CPRFalse	We also established the number of @CHEMICAL$ in exon 1 of the @GENE$ receptor gene by GeneScan analysis.
8678	CPRFalse	We also established the number of CAG repeats in exon 1 of the @CHEM-GENE$ gene by GeneScan analysis.
8679	CPRFalse	Our data suggest that a critical lower level of @CHEM-GENE$ mRNA expression could be a determining factor in the development of middle hypospadias.
8680	CPRFalse	The sCT released from NP stimulated @CHEMICAL$ production in human T47D breast cancer cells expressing @GENE$.
8681	CPRFalse	@CHEMICAL$ regulates transcription of the ion uptake @GENE$/Cl- cotransporter (ncc) gene in zebrafish gill.
8682	CPRFalse	Prolactin regulates transcription of the ion uptake @CHEM-GENE$ (ncc) gene in zebrafish gill.
8683	CPRFalse	Prolactin regulates transcription of the ion uptake @CHEMICAL$/Cl- cotransporter (@GENE$) gene in zebrafish gill.
8684	CPRFalse	@CHEMICAL$ regulates transcription of the ion uptake Na+/@GENE$ cotransporter (ncc) gene in zebrafish gill.
8685	CPRFalse	Prolactin regulates transcription of the ion uptake @CHEM-GENE$ (ncc) gene in zebrafish gill.
8686	CPRFalse	Prolactin regulates transcription of the ion uptake Na+/@CHEMICAL$ cotransporter (@GENE$) gene in zebrafish gill.
8687	CPRFalse	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), @GENE$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8688	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), @GENE$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8689	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEM-GENE$ (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8690	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (@GENE$; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8691	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; @GENE$), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8692	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), @GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8693	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8694	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8695	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.
8696	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.
8697	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.
8698	CPRFalse	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/@GENE$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8699	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/@GENE$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8700	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEM-GENE$ (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8701	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (@GENE$; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8702	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; @GENE$), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8703	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), @GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8704	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8705	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8706	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.
8707	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.
8708	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/@CHEMICAL$ cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.
8709	CPRFalse	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8710	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8711	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$ (ncc; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8712	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (@CHEMICAL$; slc12a10.2), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8713	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; @CHEMICAL$), @GENE$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8714	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEM-GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8715	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8716	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8717	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.
8718	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.
8719	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.
8720	CPRFalse	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8721	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8722	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$ (ncc; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8723	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (@CHEMICAL$; slc12a10.2), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8724	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; @CHEMICAL$), Na(+)/@GENE$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8725	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEM-GENE$ (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8726	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (@GENE$; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8727	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; @GENE$), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.
8728	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; slc9a3.2), and @GENE$ (ecac; trpv6) transcripts within the gill.
8729	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (@GENE$; trpv6) transcripts within the gill.
8730	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/@CHEMICAL$ exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; @GENE$) transcripts within the gill.
8731	CPRFalse	Ion-poor conditions led to increases in the expression of @CHEMICAL$ (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8732	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (@CHEMICAL$), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8733	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), @CHEMICAL$ (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8734	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (@CHEMICAL$; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8735	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; @CHEMICAL$), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8736	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), @CHEMICAL$ (nhe3b; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8737	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (@CHEMICAL$; slc9a3.2), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8738	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; @CHEMICAL$), and epithelial @GENE$ channel (ecac; trpv6) transcripts within the gill.
8739	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and @CHEM-GENE$ (ecac; trpv6) transcripts within the gill.
8740	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @CHEMICAL$ channel (@GENE$; trpv6) transcripts within the gill.
8741	CPRFalse	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial @CHEMICAL$ channel (ecac; @GENE$) transcripts within the gill.
8742	CPRFalse	These results suggest that PRL signaling through PRL receptors in the gill regulates the expression of ncc, thereby linking this @CHEMICAL$ with an effector of @GENE$ uptake in zebrafish for the first time.
8743	CPRFalse	These results suggest that PRL signaling through @CHEMICAL$ in the gill regulates the expression of ncc, thereby linking this pituitary hormone with an effector of @GENE$ uptake in zebrafish for the first time.
8744	CPRFalse	These results suggest that PRL signaling through PRL receptors in the gill regulates the expression of @CHEMICAL$, thereby linking this pituitary hormone with an effector of @GENE$ uptake in zebrafish for the first time.
8745	CPRFalse	These results suggest that @CHEMICAL$ signaling through PRL receptors in the gill regulates the expression of ncc, thereby linking this pituitary hormone with an effector of @GENE$ uptake in zebrafish for the first time.
8746	CPR:4	@CHEMICAL$ suppressed @GENE$ gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8747	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by @GENE$ without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8748	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting @GENE$ expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8749	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-@GENE$ complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8750	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to @GENE$, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8751	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with @GENE$. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8752	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of @GENE$ counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8753	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-@GENE$ antibody or IL-11 small interfering RNA.
8754	CPRFalse	@CHEMICAL$ suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or @GENE$ small interfering RNA.
8755	CPRFalse	Dexamethasone suppressed @CHEMICAL$ gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @GENE$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8756	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by @CHEMICAL$ without affecting DFosB expression or Smad1 phosphorylation, and @GENE$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8757	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting @CHEMICAL$ expression or Smad1 phosphorylation, and @GENE$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8758	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-@GENE$ complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8759	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to @GENE$, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8760	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with @GENE$. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8761	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of @GENE$ counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8762	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-@GENE$ antibody or IL-11 small interfering RNA.
8763	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and @CHEMICAL$-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of dexamethasone on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or @GENE$ small interfering RNA.
8764	CPRFalse	Dexamethasone suppressed @CHEMICAL$ gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8765	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by @CHEMICAL$ without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8766	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting @CHEMICAL$ expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8767	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-@CHEMICAL$ complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8768	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to @CHEMICAL$, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8769	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with @CHEMICAL$. High doses of PTH(1-34) counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8770	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of @CHEMICAL$ counteracted the effect of @GENE$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.
8771	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @CHEMICAL$ on apoptosis of mPOBs, which was blunted by neutralizing anti-@GENE$ antibody or IL-11 small interfering RNA.
8772	CPRFalse	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting DFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with DFosB. High doses of PTH(1-34) counteracted the effect of @CHEMICAL$ on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or @GENE$ small interfering RNA.
8773	CPRFalse	These results demonstrate that @CHEMICAL$ and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and @GENE$ may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.
8774	CPRFalse	These results demonstrate that PTH(1-34) and GCs interact to regulate @CHEMICAL$ expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and @GENE$ may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.
8775	CPRFalse	These results demonstrate that PTH(1-34) and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that @CHEMICAL$ and @GENE$ may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.
8776	CPRFalse	These results demonstrate that PTH(1-34) and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and @CHEMICAL$ may regulate osteoblast differentiation and apoptosis via their effect on @GENE$ expression.
8777	CPRFalse	Number and area of preneoplastic foci positive for @CHEM-GENE$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.
8778	CPRFalse	Number and area of preneoplastic foci positive for @CHEMICAL$ S-transferase placental form (@GENE$) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.
8779	CPRFalse	Number and area of preneoplastic foci positive for @CHEM-GENE$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.
8780	CPRFalse	Number and area of preneoplastic foci positive for glutathione @CHEMICAL$-transferase placental form (@GENE$) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.
8781	CPR:3	Number and area of preneoplastic foci positive for @CHEMICAL$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with @GENE$ or HCB alone.
8782	CPR:3	Number and area of preneoplastic foci positive for glutathione S-transferase placental form (@CHEMICAL$) were consistently higher in these groups than the sum of individual values in the groups treated with @GENE$ or HCB alone.
8783	CPR:3	Number and area of preneoplastic foci positive for @CHEMICAL$ (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or @GENE$ alone.
8784	CPR:3	Number and area of preneoplastic foci positive for glutathione S-transferase placental form (@CHEMICAL$) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or @GENE$ alone.
8785	CPRFalse	Consistent with these findings, HEP and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @CHEMICAL$ induction, which may lead to more efficient metabolic activation of @GENE$ and HCB.
8786	CPRFalse	Consistent with these findings, @CHEMICAL$ and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @GENE$ induction, which may lead to more efficient metabolic activation of HEP and HCB.
8787	CPRFalse	Consistent with these findings, HEP and @CHEMICAL$ had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @GENE$ induction, which may lead to more efficient metabolic activation of HEP and HCB.
8788	CPRFalse	Consistent with these findings, HEP and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and @CHEMICAL$ induction, which may lead to more efficient metabolic activation of HEP and @GENE$.
8789	CPR:3	On the basis of these findings, we conclude that @CHEMICAL$ and HCB have additive and synergistic effects on the development of @GENE$-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.
8790	CPR:3	On the basis of these findings, we conclude that HEP and @CHEMICAL$ have additive and synergistic effects on the development of @GENE$-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.
8791	CPRFalse	On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of @CHEMICAL$-positive foci and that higher risks are associated with a combination of residual @GENE$ pesticides in foods than with individual residual organochlorine pesticides.
8792	CPRFalse	On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of @CHEMICAL$-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual @GENE$ pesticides.
8793	CPR:3	The food contaminant @CHEMICAL$ activates the @GENE$ in the intestine: interest of ex vivo models as an alternative to in vivo experiments.
8794	CPRFalse	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the @GENE$ ERK 1/2, p38 and JNK.
8795	CPRFalse	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the MAPK @GENE$, p38 and JNK.
8796	CPRFalse	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the MAPK ERK 1/2, @GENE$ and JNK.
8797	CPRFalse	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of @CHEMICAL$ to induce histological changes in the intestine and to activate the MAPK ERK 1/2, p38 and @GENE$.
8798	CPR:3	Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to @CHEMICAL$ lead to similar intestinal lesions and activation of @GENE$.
8799	CPR:3	@CHEMICAL$ protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the @GENE$/heme oxygenase-1 pathway.
8800	CPR:3	@CHEMICAL$ protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/@GENE$ pathway.
8801	CPRFalse	Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the @CHEMICAL$/@GENE$ oxygenase-1 pathway.
8802	CPRFalse	Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/@CHEM-GENE$ pathway.
8803	CPR:4	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8804	CPR:4	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8805	CPR:3	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.
8806	CPR:3	In particular, we showed that @CHEMICAL$ significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.
8807	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8808	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8809	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.
8810	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive @CHEMICAL$ species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.
8811	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8812	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8813	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.
8814	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of @CHEMICAL$ (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.
8815	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and @GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8816	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and lactate dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8817	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.
8818	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (@CHEMICAL$) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.
8819	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEM-GENE$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8820	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ dehydrogenase (@GENE$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8821	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ (SOD) in EA.hy926 cells.
8822	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.
8823	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ (LDH) leakage, and enhanced production of the endogenous antioxidants, @GENE$ (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8824	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@CHEMICAL$) leakage, and enhanced production of the endogenous antioxidants, @GENE$ (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.
8825	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, @CHEMICAL$ (GSH) and @GENE$ (SOD) in EA.hy926 cells.
8826	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, @CHEMICAL$ (GSH) and superoxide dismutase (@GENE$) in EA.hy926 cells.
8827	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (@GENE$) and superoxide dismutase (SOD) in EA.hy926 cells.
8828	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@CHEMICAL$) leakage, and enhanced production of the endogenous antioxidants, glutathione (@GENE$) and superoxide dismutase (SOD) in EA.hy926 cells.
8829	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (@CHEMICAL$) and @GENE$ (SOD) in EA.hy926 cells.
8830	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (@CHEMICAL$) and superoxide dismutase (@GENE$) in EA.hy926 cells.
8831	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and @CHEMICAL$ (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ dismutase (SOD) in EA.hy926 cells.
8832	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (@CHEMICAL$) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @GENE$ dismutase (SOD) in EA.hy926 cells.
8833	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @CHEM-GENE$ (SOD) in EA.hy926 cells.
8834	CPRFalse	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and @CHEMICAL$ dismutase (@GENE$) in EA.hy926 cells.
8835	CPR:3	Treatment of these cells with @CHEMICAL$ significantly induced @GENE$ expression.
8836	CPRFalse	Moreover, @CHEMICAL$ promoted the nuclear translocation of @GENE$ (Nrf-2).
8837	CPRFalse	Moreover, @CHEMICAL$ promoted the nuclear translocation of nuclear factor erythroid 2 related factor-2 (@GENE$).
8838	CPR:3	The @CHEMICAL$-induced @GENE$ expression was abrogated by Nrf2 siRNA.
8839	CPRFalse	The @CHEMICAL$-induced HO-1 expression was abrogated by @GENE$ siRNA.
8840	CPR:4	Furthermore, inhibition of @CHEMICAL$ with @GENE$ (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.
8841	CPR:4	Furthermore, inhibition of @CHEMICAL$ with zinc protoporphyrin IX (@GENE$) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.
8842	CPR:3	Furthermore, inhibition of @CHEMICAL$ with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of @GENE$ against radiation-induced damage in EA.hy926 cells.
8843	CPR:3	Our findings confirmed that @CHEMICAL$ protected EA.hy926 cells against radiation-induced injury through the @GENE$/HO-1 pathway.
8844	CPR:3	Our findings confirmed that @CHEMICAL$ protected EA.hy926 cells against radiation-induced injury through the Nrf2/@GENE$ pathway.
8845	CPRFalse	The use of a combination of a @CHEMICAL$ @GENE$ receptor antagonist, dexamethasone and a neurokinin 1 (NK1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.
8846	CPRFalse	The use of a combination of a @CHEMICAL$ 5-HT3 receptor antagonist, dexamethasone and a @GENE$ antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.
8847	CPRFalse	The use of a combination of a serotonin @CHEMICAL$ receptor antagonist, @GENE$ and a neurokinin 1 (NK1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.
8848	CPRFalse	The use of a combination of a serotonin 5-HT3 receptor antagonist, @CHEMICAL$ and a @GENE$ antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.
8849	CPR:6	@CHEMICAL$, a second-generation @GENE$ receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.
8850	CPRFalse	@CHEMICAL$, a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation @GENE$ receptor antagonists appears to be the most effective agent in its class.
8851	CPR:6	@CHEMICAL$, the first and only agent clinically available in the @GENE$ antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.
8852	CPRFalse	@CHEMICAL$, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the @GENE$ receptor antagonists and dexamethasone to control CINV.
8853	CPRFalse	Aprepitant, the first and only agent clinically available in the @CHEMICAL$ antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and @GENE$ to control CINV.
8854	CPRFalse	Aprepitant, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the @CHEMICAL$ receptor antagonists and @GENE$ to control CINV.
8855	CPR:6	@CHEMICAL$ and netupitant are other @GENE$ antagonists that are currently in phase III clinical trials.
8856	CPR:6	Rolapitant and @CHEMICAL$ are other @GENE$ antagonists that are currently in phase III clinical trials.
8857	CPRFalse	The case study of @CHEMICAL$ synthase (@GENE$) illustrates how such an equilibrium holds lessons for disease mechanisms, drug discovery, understanding drug side effects, and identifying proteins wherein drug discovery efforts might focus on quaternary structure dynamics.
8858	CPRFalse	The case study of @CHEM-GENE$ (PBGS) illustrates how such an equilibrium holds lessons for disease mechanisms, drug discovery, understanding drug side effects, and identifying proteins wherein drug discovery efforts might focus on quaternary structure dynamics.
8859	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, HIV integrase, @GENE$, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8860	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEM-GENE$, HIV integrase, pyruvate kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8861	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, @GENE$, pyruvate kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8862	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, HIV integrase, pyruvate kinase, and @GENE$. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8863	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$ hydroxylase, HIV integrase, pyruvate kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of @GENE$ and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8864	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, @CHEM-GENE$, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8865	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins @CHEMICAL$, HIV integrase, @GENE$ kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8866	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, @CHEMICAL$, @GENE$ kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8867	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, @CHEMICAL$ kinase, and @GENE$. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8868	CPRFalse	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, @CHEMICAL$ kinase, and tumor necrosis factor a. Also highlighted is the quaternary structure equilibrium of @GENE$ and successful drug discovery efforts focused on controlling its quaternary structure dynamics.
8869	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of @CHEMICAL$, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and @GENE$ cholesterol (LDL-C) oxidation assay.
8870	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of @CHEMICAL$, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and low-density lipoprotein cholesterol (@GENE$-C) oxidation assay.
8871	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, @CHEMICAL$-linoleate model system and @GENE$ cholesterol (LDL-C) oxidation assay.
8872	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, @CHEMICAL$-linoleate model system and low-density lipoprotein cholesterol (@GENE$-C) oxidation assay.
8873	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-@CHEMICAL$ model system and @GENE$ cholesterol (LDL-C) oxidation assay.
8874	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-@CHEMICAL$ model system and low-density lipoprotein cholesterol (@GENE$-C) oxidation assay.
8875	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and @CHEMICAL$ @GENE$ (LDL-C) oxidation assay.
8876	CPRFalse	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, b-carotene-linoleate model system and low-density lipoprotein @CHEMICAL$ (@GENE$-C) oxidation assay.
8877	CPR:4	Moderate inhibitory effect of @CHEMICAL$-C oxidation by @GENE$ was observed.
8878	CPR:4	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the @GENE$ pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.
8879	CPR:4	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild @GENE$ inhibitory activity.
8880	CPR:4	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting @GENE$ (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.
8881	CPR:4	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate @GENE$ (IC(50), 66 mg/ml) and COX-2 (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.
8882	CPR:4	Aqueous @CHEMICAL$ (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 mg/ml), with moderate COX-1 (IC(50), 66 mg/ml) and @GENE$ (IC(50), 119 mg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.
8883	CPRFalse	Inhibitory activity of Filipendula ulmaria constituents on recombinant @CHEM-GENE$.
8884	CPR:9	@CHEMICAL$ (HDC) catalyses the formation of histamine, a bioactive @GENE$.
8885	CPR:9	Histidine decarboxylase (@CHEMICAL$) catalyses the formation of histamine, a bioactive @GENE$.
8886	CPRFalse	@CHEM-GENE$ (HDC) catalyses the formation of histamine, a bioactive amine.
8887	CPRFalse	@CHEMICAL$ decarboxylase (@GENE$) catalyses the formation of histamine, a bioactive amine.
8888	CPR:9	@CHEMICAL$ (HDC) catalyses the formation of @GENE$, a bioactive amine.
8889	CPR:9	Histidine decarboxylase (@CHEMICAL$) catalyses the formation of @GENE$, a bioactive amine.
8890	CPRFalse	Agents that control @CHEMICAL$ activity are beneficial for treating @GENE$-mediated symptoms, such as allergies and stomach ulceration.
8891	CPR:4	We searched for inhibitors of @CHEMICAL$ from the @GENE$ extract of the petal of Filipendula ulmaria, also called meadowsweet.
8892	CPR:5	Discovery of a novel series of @CHEMICAL$ @GENE$ agonists.
8893	CPRFalse	Discovery of a novel series of quinolone @CHEM-GENE$ agonists.
8894	CPR:5	High throughput screening led to the identification of a novel series of @CHEMICAL$ a7 nicotinic acetylcholine receptor (@GENE$) agonists.
8895	CPR:5	High throughput screening led to the identification of a novel series of @CHEMICAL$ @GENE$ (nAChR) agonists.
8896	CPRFalse	High throughput screening led to the identification of a novel series of quinolone a7 nicotinic @CHEMICAL$ receptor (@GENE$) agonists.
8897	CPRFalse	High throughput screening led to the identification of a novel series of quinolone @CHEM-GENE$ (nAChR) agonists.
8898	CPR:4	@CHEMICAL$ derived quinazolines as @GENE$/PKA inhibitors.
8899	CPR:4	@CHEMICAL$ derived quinazolines as Rock/@GENE$ inhibitors.
8900	CPR:4	Amino acid derived @CHEMICAL$ as @GENE$/PKA inhibitors.
8901	CPR:4	Amino acid derived @CHEMICAL$ as Rock/@GENE$ inhibitors.
8902	CPR:4	SAR and lead optimization studies for @CHEMICAL$ inhibitors based on @GENE$-derived quinazolines are described.
8903	CPR:4	SAR and lead optimization studies for @CHEMICAL$ inhibitors based on amino acid-derived @GENE$ are described.
8904	CPRFalse	Studies demonstrated that these @CHEMICAL$ derived quinazolinones were mainly pan-@GENE$ inhibitors.
8905	CPRFalse	Studies demonstrated that these amino acid derived @CHEMICAL$ were mainly pan-@GENE$ inhibitors.
8906	CPR:4	This is distinct from @CHEMICAL$ inhibitors based on non-@GENE$ derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.
8907	CPR:4	This is distinct from Rock inhibitors based on non-@CHEMICAL$ derived quinazolinones, where high selectivity against @GENE$ could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.
8908	CPRFalse	This is distinct from Rock inhibitors based on non-@CHEMICAL$ derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of @GENE$, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.
8909	CPRFalse	This is distinct from Rock inhibitors based on non-@CHEMICAL$ derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair @GENE$ inhibition, and good human microsomal stability.
8910	CPR:4	This is distinct from @CHEMICAL$ inhibitors based on non-amino acid derived @GENE$, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.
8911	CPR:4	This is distinct from Rock inhibitors based on non-amino acid derived @CHEMICAL$, where high selectivity against @GENE$ could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.
8912	CPRFalse	This is distinct from Rock inhibitors based on non-amino acid derived @CHEMICAL$, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of @GENE$, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.
8913	CPRFalse	This is distinct from Rock inhibitors based on non-amino acid derived @CHEMICAL$, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair @GENE$ inhibition, and good human microsomal stability.
8914	CPRFalse	@CHEMICAL$-based design of a @GENE$ prodrug.
8915	CPR:4	The @CHEMICAL$ inhibitor, @GENE$, is used in the clinic for its anti-inflammatory activity.
8916	CPRFalse	About 99% of a dose of @CHEMICAL$ is unavailable for reaction with the target enzyme, because diflunisal strongly binds to @GENE$ (HSA).
8917	CPRFalse	About 99% of a dose of @CHEMICAL$ is unavailable for reaction with the target enzyme, because diflunisal strongly binds to human serum albumin (@GENE$).
8918	CPRFalse	About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because @CHEMICAL$ strongly binds to @GENE$ (HSA).
8919	CPRFalse	About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because @CHEMICAL$ strongly binds to human serum albumin (@GENE$).
8920	CPRFalse	To reduce the binding affinity of @CHEMICAL$ to @GENE$, we designed and synthesized the prodrug acetyldiflunisal.
8921	CPRFalse	To reduce the binding affinity of diflunisal to @CHEMICAL$, we designed and synthesized the prodrug @GENE$.
8922	CPRFalse	The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the @CHEMICAL$ and that upon binding, it acetylates @GENE$ 199.
8923	CPRFalse	The crystal structure of @CHEMICAL$ complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates @GENE$ 199.
8924	CPRFalse	The crystal structure of HSA complexed with @CHEMICAL$ and acetyldiflunisal revealed that acetyldiflunisal binds to the @GENE$ and that upon binding, it acetylates lysine 199.
8925	CPRFalse	The crystal structure of @CHEMICAL$ complexed with @GENE$ and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.
8926	CPRFalse	The crystal structure of HSA complexed with fatty acid and @CHEMICAL$ revealed that acetyldiflunisal binds to the @GENE$ and that upon binding, it acetylates lysine 199.
8927	CPRFalse	The crystal structure of @CHEMICAL$ complexed with fatty acid and @GENE$ revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.
8928	CPRFalse	The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that @CHEMICAL$ binds to the @GENE$ and that upon binding, it acetylates lysine 199.
8929	CPRFalse	The crystal structure of @CHEMICAL$ complexed with fatty acid and acetyldiflunisal revealed that @GENE$ binds to the IIA subdomain and that upon binding, it acetylates lysine 199.
8930	CPRFalse	The @CHEMICAL$ had twofold weaker binding affinity for @GENE$ as demonstrated by fluorescence quenching.
8931	CPRFalse	Reduced binding affinity means that @CHEMICAL$ is more easily released from @GENE$ into the circulation.
8932	CPRFalse	Taken together, our results not only provide a template for design of @CHEMICAL$-based prodrugs, but also pave the way toward more effective use of @GENE$ in the clinic.
8933	CPRFalse	Effect of @CHEMICAL$ on @GENE$ signal transduction and glucose oxidation in skeletal muscle of adult male albino rat.
8934	CPRFalse	Effect of bisphenol-A on @CHEMICAL$ signal transduction and @GENE$ oxidation in skeletal muscle of adult male albino rat.
8935	CPRFalse	In the present study, we investigated the possible effects of @CHEMICAL$ on @GENE$-signaling molecules and glucose oxidation in skeletal muscle of male rat.
8936	CPRFalse	In the present study, we investigated the possible effects of BPA on @CHEMICAL$-signaling molecules and @GENE$ oxidation in skeletal muscle of male rat.
8937	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, @GENE$ and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8938	CPRFalse	Although there was no change in the levels of insulin receptor (IR), @CHEMICAL$ (protein kinase B) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8939	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (@CHEMICAL$) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8940	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and @GENE$ protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8941	CPRFalse	Although there was no change in the levels of @CHEMICAL$ (IR), Akt (protein kinase B) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8942	CPRFalse	Although there was no change in the levels of insulin receptor (@CHEMICAL$), Akt (protein kinase B) and @GENE$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8943	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEM-GENE$ (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8944	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (@GENE$) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8945	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the @GENE$, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8946	CPR:4	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @CHEMICAL$ significantly decreased the IR, @GENE$ and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8947	CPRFalse	Although there was no change in the levels of insulin receptor (IR), @CHEMICAL$ (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8948	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (@CHEMICAL$) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8949	CPR:4	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @CHEMICAL$ significantly decreased the IR, Akt and @GENE$ protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8950	CPRFalse	Although there was no change in the levels of @CHEMICAL$ (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8951	CPRFalse	Although there was no change in the levels of insulin receptor (@CHEMICAL$), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8952	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and @CHEMICAL$ (GLUT4) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8953	CPRFalse	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (@CHEMICAL$) messenger RNA, @GENE$ significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8954	CPR:4	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, @CHEMICAL$ significantly decreased the @GENE$, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.
8955	CPRFalse	There was an increase in serum @CHEMICAL$ and decrease in serum @GENE$ levels but fasting blood glucose level remained unaltered.
8956	CPRFalse	There was an increase in serum @CHEMICAL$ and decrease in serum testosterone levels but fasting blood @GENE$ level remained unaltered.
8957	CPR:4	In conclusion, @CHEMICAL$ has adverse effects on phosphorylation of @GENE$, GLUT4 translocation and (14)C-glucose oxidation.
8958	CPR:4	In conclusion, @CHEMICAL$ has adverse effects on phosphorylation of Akt, @GENE$ translocation and (14)C-glucose oxidation.
8959	CPRFalse	In conclusion, BPA has adverse effects on phosphorylation of @CHEMICAL$, GLUT4 translocation and @GENE$ oxidation.
8960	CPRFalse	In conclusion, BPA has adverse effects on phosphorylation of Akt, @CHEMICAL$ translocation and @GENE$ oxidation.
8961	CPR:4	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @GENE$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8962	CPR:4	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @GENE$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8963	CPR:4	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @GENE$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8964	CPR:4	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @GENE$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8965	CPR:4	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8966	CPR:4	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8967	CPR:4	The obtained results showed that @CHEMICAL$ increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8968	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, @GENE$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8969	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, @GENE$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8970	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, @GENE$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8971	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @GENE$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8972	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8973	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8974	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma @CHEMICAL$, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8975	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEM-GENE$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8976	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, @GENE$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8977	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, @GENE$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8978	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and @GENE$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8979	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8980	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8981	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$ dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8982	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8983	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @CHEMICAL$, alkaline phosphatase and testicular steroidogenic enzymes: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8984	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @CHEMICAL$ and testicular steroidogenic enzymes: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8985	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @CHEMICAL$: @GENE$ dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8986	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEM-GENE$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8987	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ dehydrogenase (@GENE$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8988	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ dehydrogenase (HSD), @GENE$ activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.
8989	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.
8990	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @CHEMICAL$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.
8991	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @CHEMICAL$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.
8992	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @CHEMICAL$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.
8993	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.
8994	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@CHEMICAL$), 17b-HSD activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.
8995	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @CHEMICAL$ activities as well as epididymal sperm counts and motility, while @GENE$ and Se treatment reversed this change to control values.
8996	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, @CHEMICAL$, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.
8997	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, @CHEMICAL$, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.
8998	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, @CHEMICAL$ and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.
8999	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and @CHEMICAL$: 3b-hydroxysteroid dehydrogenase (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.
9000	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: @CHEMICAL$ (HSD), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.
9001	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (@CHEMICAL$), 17b-HSD activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.
9002	CPRFalse	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (HSD), @CHEMICAL$ activities as well as epididymal sperm counts and motility, while RUT and @GENE$ treatment reversed this change to control values.
9003	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).
9004	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (@GENE$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9005	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@GENE$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9006	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @GENE$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9007	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9008	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).
9009	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @GENE$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9010	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@GENE$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9011	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9012	CPR:4	Acute intoxication with @CHEMICAL$ was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).
9013	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).
9014	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEM-GENE$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9015	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (@GENE$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9016	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), @GENE$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9017	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (@GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9018	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).
9019	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), @GENE$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9020	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (@GENE$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9021	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9022	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).
9023	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).
9024	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9025	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9026	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEM-GENE$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9027	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (@GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9028	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).
9029	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9030	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), @GENE$ peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9031	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9032	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ peroxidase (GSH-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).
9033	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).
9034	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9035	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9036	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9037	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEM-GENE$), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9038	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$ (GST)).
9039	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9040	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (@GENE$-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9041	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), @GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9042	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$-Px), glutathione reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).
9043	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (@GENE$)).
9044	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9045	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9046	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9047	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9048	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ reductase (GR), glutathione (GSH), and @GENE$ (GST)).
9049	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9050	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), @GENE$ reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9051	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEM-GENE$ (GR), glutathione (GSH), and glutathione-S-transferase (GST)).
9052	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ reductase (@GENE$), glutathione (GSH), and glutathione-S-transferase (GST)).
9053	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @CHEMICAL$ (GSH), and glutathione-S-transferase (@GENE$)).
9054	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9055	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9056	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9057	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9058	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @CHEMICAL$ (GSH), and @GENE$ (GST)).
9059	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9060	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9061	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9062	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), @GENE$ (GSH), and glutathione-S-transferase (GST)).
9063	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@CHEMICAL$), and glutathione-S-transferase (@GENE$)).
9064	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9065	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9066	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9067	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9068	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@CHEMICAL$), and @GENE$ (GST)).
9069	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9070	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9071	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9072	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), glutathione (@GENE$), and glutathione-S-transferase (GST)).
9073	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @CHEMICAL$-S-transferase (@GENE$)).
9074	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).
9075	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).
9076	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).
9077	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).
9078	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @CHEM-GENE$ (GST)).
9079	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).
9080	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).
9081	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), glutathione (GSH), and @GENE$-S-transferase (GST)).
9082	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), glutathione (GSH), and @GENE$-S-transferase (GST)).
9083	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@CHEMICAL$-transferase (@GENE$)).
9084	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (@CHEMICAL$ (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9085	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (@CHEMICAL$), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9086	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), @CHEMICAL$ (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9087	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (@CHEMICAL$), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9088	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and @CHEM-GENE$ (GST)).
9089	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), @CHEMICAL$ (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9090	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (@CHEMICAL$), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9091	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), @CHEMICAL$ (GR), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9092	CPRFalse	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (@CHEMICAL$), glutathione (GSH), and glutathione-@GENE$-transferase (GST)).
9093	CPRFalse	The @CHEM-GENE$ inhibitor a-methyltyrosine (300mM, 24h) completely abolished MeHg-induced DA release.
9094	CPR:4	The @CHEMICAL$ inhibitor @GENE$ (300mM, 24h) completely abolished MeHg-induced DA release.
9095	CPRFalse	The @CHEMICAL$ inhibitor a-methyltyrosine (300mM, 24h) completely abolished @GENE$-induced DA release.
9096	CPRFalse	@CHEMICAL$ significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10mM), revealing that MeHg increases @GENE$ activity.
9097	CPRFalse	MeHg significantly increased DA precursor accumulation in cells treated with @CHEMICAL$ (10mM), revealing that MeHg increases @GENE$ activity.
9098	CPR:3	MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10mM), revealing that @CHEMICAL$ increases @GENE$ activity.
9099	CPRFalse	MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10mM), revealing that MeHg increases @CHEM-GENE$ activity.
9100	CPR:4	The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of @CHEMICAL$ analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low @GENE$ inhibition.
9101	CPRFalse	The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against @CHEMICAL$-resistant strains and low @GENE$ inhibition.
9102	CPRFalse	The solubility-driven structural modification of @CHEMICAL$ is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low @GENE$ inhibition.
9103	CPRFalse	Activity of @CHEMICAL$ against clinically-relevant AC220-resistant @GENE$ mutants of FLT3-ITD.
9104	CPRFalse	Activity of @CHEMICAL$ against clinically-relevant AC220-resistant kinase domain mutants of @GENE$-ITD.
9105	CPRFalse	Activity of ponatinib against clinically-relevant @CHEMICAL$-resistant @GENE$ mutants of FLT3-ITD.
9106	CPRFalse	Activity of ponatinib against clinically-relevant @CHEMICAL$-resistant kinase domain mutants of @GENE$-ITD.
9107	CPRFalse	Secondary point mutations in the @CHEM-GENE$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.
9108	CPRFalse	Secondary point mutations in the Fms-like @CHEMICAL$ kinase 3 (FLT3) tyrosine kinase domain (@GENE$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.
9109	CPRFalse	Secondary point mutations in the Fms-like @CHEMICAL$ kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @GENE$ inhibitors AC220 (quizartinib) and sorafenib.
9110	CPRFalse	Secondary point mutations in the @CHEM-GENE$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.
9111	CPRFalse	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) @CHEMICAL$ kinase domain (@GENE$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.
9112	CPRFalse	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) @CHEMICAL$ kinase domain (KD) are common causes of acquired clinical resistance to the @GENE$ inhibitors AC220 (quizartinib) and sorafenib.
9113	CPRFalse	Secondary point mutations in the @CHEMICAL$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors @GENE$ (quizartinib) and sorafenib.
9114	CPRFalse	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (@CHEMICAL$) are common causes of acquired clinical resistance to the FLT3 inhibitors @GENE$ (quizartinib) and sorafenib.
9115	CPR:4	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @CHEMICAL$ inhibitors @GENE$ (quizartinib) and sorafenib.
9116	CPRFalse	Secondary point mutations in the @CHEMICAL$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (@GENE$) and sorafenib.
9117	CPRFalse	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (@CHEMICAL$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (@GENE$) and sorafenib.
9118	CPR:4	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @CHEMICAL$ inhibitors AC220 (@GENE$) and sorafenib.
9119	CPRFalse	Secondary point mutations in the @CHEMICAL$ (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and @GENE$.
9120	CPRFalse	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (@CHEMICAL$) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and @GENE$.
9121	CPR:4	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the @CHEMICAL$ inhibitors AC220 (quizartinib) and @GENE$.
9122	CPR:4	@CHEMICAL$ (AP24534) is a @GENE$ inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.
9123	CPRFalse	@CHEMICAL$ (AP24534) is a multikinase inhibitor with in vitro and clinical activity in @GENE$ inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.
9124	CPRFalse	@CHEMICAL$ (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of @GENE$ mutation.
9125	CPR:4	Ponatinib (@CHEMICAL$) is a @GENE$ inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.
9126	CPRFalse	Ponatinib (@CHEMICAL$) is a multikinase inhibitor with in vitro and clinical activity in @GENE$ inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.
9127	CPRFalse	Ponatinib (@CHEMICAL$) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of @GENE$ mutation.
9128	CPRFalse	Ponatinib (AP24534) is a @CHEMICAL$ inhibitor with in vitro and clinical activity in @GENE$ kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.
9129	CPRFalse	Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in @CHEM-GENE$ inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.
9130	CPRFalse	Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in @CHEMICAL$ kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of @GENE$ mutation.
9131	CPRFalse	@CHEMICAL$ has demonstrated early clinical efficacy in chemotherapy-resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in @GENE$.
9132	CPRFalse	We assessed the in vitro activity of @CHEMICAL$ against clinically relevant @GENE$-ITD mutant isoforms that confer resistance to AC220 or sorafenib.
9133	CPRFalse	We assessed the in vitro activity of ponatinib against clinically relevant @CHEMICAL$-ITD mutant isoforms that confer resistance to @GENE$ or sorafenib.
9134	CPRFalse	We assessed the in vitro activity of ponatinib against clinically relevant @CHEMICAL$-ITD mutant isoforms that confer resistance to AC220 or @GENE$.
9135	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" @CHEMICAL$ with leucine (@GENE$) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."
9136	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" @CHEMICAL$ with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the @GENE$ (AL) residue D835 conferred a high degree of resistance."
9137	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" @CHEMICAL$ with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (@GENE$) residue D835 conferred a high degree of resistance."
9138	CPRFalse	"Substitution of the @CHEMICAL$ ""gatekeeper"" @GENE$ with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."
9139	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with @CHEMICAL$ (@GENE$) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."
9140	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with @CHEMICAL$ (F691L) conferred mild resistance to ponatinib, but substitutions at the @GENE$ (AL) residue D835 conferred a high degree of resistance."
9141	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with @CHEMICAL$ (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (@GENE$) residue D835 conferred a high degree of resistance."
9142	CPRFalse	"Substitution of the @CHEMICAL$ ""gatekeeper"" phenylalanine with @GENE$ (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."
9143	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with leucine (@CHEMICAL$) conferred mild resistance to @GENE$, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."
9144	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with leucine (F691L) conferred mild resistance to @CHEMICAL$, but substitutions at the @GENE$ (AL) residue D835 conferred a high degree of resistance."
9145	CPRFalse	"Substitution of the FLT3 ""gatekeeper"" phenylalanine with leucine (F691L) conferred mild resistance to @CHEMICAL$, but substitutions at the FLT3 activation loop (@GENE$) residue D835 conferred a high degree of resistance."
9146	CPRFalse	"Substitution of the @CHEMICAL$ ""gatekeeper"" phenylalanine with leucine (F691L) conferred mild resistance to @GENE$, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance."
9147	CPRFalse	The switch control inhibitor @CHEMICAL$ was similarly inactive against @GENE$ AL mutations.
9148	CPRFalse	On the basis of its in vitro activity against @CHEMICAL$ TKI-resistant F691 substitutions, further clinical evaluation of @GENE$ in TKI-naive and select TKI-resistant FLT3-ITD+ AML patients is warranted.
9149	CPRFalse	On the basis of its in vitro activity against FLT3 TKI-resistant F691 substitutions, further clinical evaluation of @CHEMICAL$ in TKI-naive and select TKI-resistant @GENE$-ITD+ AML patients is warranted.
9150	CPRFalse	@CHEMICAL$ Cause G2/M Arrest Associated with the Modulation of @GENE$ and Chk2 in Human Breast Cancer MCF-7 Cells.
9151	CPRFalse	@CHEMICAL$ Cause G2/M Arrest Associated with the Modulation of CDK1 and @GENE$ in Human Breast Cancer MCF-7 Cells.
9152	CPRFalse	However, the involvement of the @CHEMICAL$-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor @GENE$.
9153	CPR:4	However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan@CHEMICAL$ inhibitor @GENE$.
9154	CPRFalse	However, the involvement of the @CHEMICAL$-dependent pathway in the process of cell death induced by either @GENE$ 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor z-VAD-fmk.
9155	CPRFalse	However, the involvement of the caspase-dependent pathway in the process of cell death induced by either @CHEMICAL$ 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan@GENE$ inhibitor z-VAD-fmk.
9156	CPRFalse	Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in @CHEMICAL$ levels could be detected in MCF-7 cells after @GENE$ 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.
9157	CPR:4	Moreover, since reduced levels of @CHEMICAL$ and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after @GENE$ 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.
9158	CPR:4	Moreover, since reduced levels of p21CIP1 and @CHEMICAL$ proteins but no change in p53 levels could be detected in MCF-7 cells after @GENE$ 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.
9159	CPRFalse	Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in @CHEMICAL$ levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that @GENE$ treated cells die from lethal mitosis.
9160	CPRFalse	Moreover, since reduced levels of @CHEMICAL$ and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that @GENE$ treated cells die from lethal mitosis.
9161	CPRFalse	Moreover, since reduced levels of p21CIP1 and @CHEMICAL$ proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that @GENE$ treated cells die from lethal mitosis.
9162	CPR:4	A one-pot domino synthesis and discovery of highly functionalized @CHEMICAL$ as @GENE$ inhibitors.
9163	CPR:4	These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and @CHEMICAL$ was found to be the most potent against @GENE$ with IC50 4.16 mmol/L.
9164	CPRFalse	These compounds were evaluated for their @CHEMICAL$ (AChE) inhibitory activity and @GENE$ was found to be the most potent against AChE with IC50 4.16 mmol/L.
9165	CPRFalse	These compounds were evaluated for their acetylcholinesterase (@CHEMICAL$) inhibitory activity and @GENE$ was found to be the most potent against AChE with IC50 4.16 mmol/L.
9166	CPRFalse	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEM-GENE$ for binding to integrin.
9167	CPRFalse	Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-@CHEMICAL$ (RGD) domain for binding to @GENE$.
9168	CPRFalse	@CHEMICAL$ (OPN), an extracellular matrix protein, has a functional arginine-glycine-@GENE$ (RGD) domain for binding to integrin.
9169	CPRFalse	Osteopontin (@CHEMICAL$), an extracellular matrix protein, has a functional arginine-glycine-@GENE$ (RGD) domain for binding to integrin.
9170	CPRFalse	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEM-GENE$ for binding to integrin.
9171	CPRFalse	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEMICAL$-glycine-aspartic acid (RGD) domain for binding to @GENE$.
9172	CPRFalse	@CHEMICAL$ (OPN), an extracellular matrix protein, has a functional @GENE$-glycine-aspartic acid (RGD) domain for binding to integrin.
9173	CPRFalse	Osteopontin (@CHEMICAL$), an extracellular matrix protein, has a functional @GENE$-glycine-aspartic acid (RGD) domain for binding to integrin.
9174	CPRFalse	Osteopontin (OPN), an extracellular matrix protein, has a functional @CHEM-GENE$ for binding to integrin.
9175	CPRFalse	Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-@CHEMICAL$-aspartic acid (RGD) domain for binding to @GENE$.
9176	CPRFalse	@CHEMICAL$ (OPN), an extracellular matrix protein, has a functional arginine-@GENE$-aspartic acid (RGD) domain for binding to integrin.
9177	CPRFalse	Osteopontin (@CHEMICAL$), an extracellular matrix protein, has a functional arginine-@GENE$-aspartic acid (RGD) domain for binding to integrin.
9178	CPRFalse	OPN increased the mRNA and protein expression of @CHEMICAL$ (P-gp), a subfamily of @GENE$-binding cassette transporter in a concentration- and time-dependent manner.
9179	CPRFalse	OPN increased the mRNA and protein expression of p-glycoprotein (@CHEMICAL$), a subfamily of @GENE$-binding cassette transporter in a concentration- and time-dependent manner.
9180	CPRFalse	OPN increased the mRNA and protein expression of p-glycoprotein (P-gp), a subfamily of @CHEM-GENE$ in a concentration- and time-dependent manner.
9181	CPRFalse	@CHEMICAL$ increased the mRNA and protein expression of p-glycoprotein (P-gp), a subfamily of @GENE$-binding cassette transporter in a concentration- and time-dependent manner.
9182	CPRFalse	@CHEMICAL$ (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and @GENE$ increased the drug pumping-out activity.
9183	CPRFalse	Daunomycin (@CHEMICAL$), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and @GENE$ increased the drug pumping-out activity.
9184	CPRFalse	OPN inhibited @CHEMICAL$-induced cell death, which was antagonized by @GENE$ monoclonal antibody.
9185	CPRFalse	@CHEMICAL$ inhibited @GENE$-induced cell death, which was antagonized by avb3 monoclonal antibody.
9186	CPRFalse	Long-term treatment with @CHEMICAL$ further enhanced the expression of @GENE$.
9187	CPRFalse	Knockdown of endogenous @CHEMICAL$ potentiated the @GENE$-induced apoptosis of PC-3 cells.
9188	CPR:9	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including @CHEMICAL$, doxorubicin, actinomycin-D, and rapamycin, which are also @GENE$ substrates.
9189	CPRFalse	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including @GENE$, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.
9190	CPR:9	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, @CHEMICAL$, actinomycin-D, and rapamycin, which are also @GENE$ substrates.
9191	CPRFalse	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including paclitaxel, @GENE$, actinomycin-D, and rapamycin, which are also P-gp substrates.
9192	CPR:9	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, @CHEMICAL$, and rapamycin, which are also @GENE$ substrates.
9193	CPRFalse	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, @GENE$, and rapamycin, which are also P-gp substrates.
9194	CPR:9	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and @CHEMICAL$, which are also @GENE$ substrates.
9195	CPRFalse	Furthermore, knockdown of @CHEMICAL$ enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and @GENE$, which are also P-gp substrates.
9196	CPRFalse	The animal studies also showed that @CHEMICAL$ knockdown enhanced the cytotoxic action of @GENE$.
9197	CPRFalse	A combination strategy to inhibit @CHEMICAL$: synergism between noncompetitive and @GENE$-competitive inhibitors.
9198	CPRFalse	Pim-1 is a @CHEM-GENE$ critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.
9199	CPRFalse	@CHEMICAL$ is a @GENE$/threonine kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.
9200	CPRFalse	Pim-1 is a @CHEM-GENE$ critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.
9201	CPRFalse	@CHEMICAL$ is a serine/@GENE$ kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.
9202	CPRFalse	In an effort to discover new potent @CHEMICAL$ inhibitors, a previously identified @GENE$-competitive indolyl-pyrrolone scaffold was expanded to derive structure-activity relationship data.
9203	CPRFalse	In an effort to discover new potent @CHEMICAL$ inhibitors, a previously identified ATP-competitive @GENE$ scaffold was expanded to derive structure-activity relationship data.
9204	CPRFalse	A synergistic effect in the inhibition of cell proliferation by @CHEMICAL$-competitive and ATP-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all @GENE$ inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.
9205	CPRFalse	A synergistic effect in the inhibition of cell proliferation by ATP-competitive and @CHEMICAL$-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all @GENE$ inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.
9206	CPRFalse	A synergistic effect in the inhibition of cell proliferation by ATP-competitive and ATP-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all @CHEMICAL$ inhibitors tested in showed synergism with the known anticancer agent, @GENE$.
9207	CPRFalse	PURPOSE: @CHEMICAL$ inhibitors and @GENE$ are the mainstay of pharmacological intervention for the cognitive symptoms of Alzheimer's disease (AD).
9208	CPRFalse	Introduction: The mGlu2 receptor, which belongs to the @CHEM-GENE$ (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology.
9209	CPRFalse	Introduction: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic @CHEMICAL$ receptors (mGlu) along with the @GENE$, has proven to be of particular importance in neuropharmacology.
9210	CPRFalse	Introduction: The @CHEMICAL$, which belongs to the group II subfamily of metabotropic @GENE$ receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology.
9211	CPRFalse	Preferentially expressed on presynaptic nerve terminals, the @CHEMICAL$ negatively modulates @GENE$ and GABA release and is widely distributed in the brain.
9212	CPRFalse	Preferentially expressed on presynaptic nerve terminals, the @CHEMICAL$ negatively modulates glutamate and @GENE$ release and is widely distributed in the brain.
9213	CPRFalse	High levels of @CHEMICAL$ are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where @GENE$ hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia.
9214	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEM-GENE$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9215	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9216	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.
9217	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, @GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9218	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and @GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9219	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9220	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9221	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9222	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$ S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.
9223	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEM-GENE$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9224	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9225	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.
9226	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, @GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9227	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and @GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9228	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9229	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9230	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9231	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione @CHEMICAL$-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.
9232	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase @GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9233	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9234	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.
9235	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEM-GENE$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9236	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and @GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9237	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9238	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9239	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9240	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.
9241	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and @GENE$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9242	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9243	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.
9244	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and @GENE$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9245	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEM-GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9246	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9247	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9248	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9249	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.
9250	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine @GENE$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9251	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9252	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.
9253	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine @GENE$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9254	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEM-GENE$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9255	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (@GENE$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9256	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower @GENE$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9257	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9258	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine @CHEMICAL$-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.
9259	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9260	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ dehydrogenase and @GENE$ activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9261	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ and depleted xanthine oxidase activities.
9262	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9263	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9264	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9265	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased @GENE$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9266	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEM-GENE$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.
9267	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ activities.
9268	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.
9269	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @CHEMICAL$ activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.
9270	CPR:3	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@CHEMICAL$ rats showed higher @GENE$ and depleted xanthine oxidase activities.
9271	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.
9272	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.
9273	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.
9274	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.
9275	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ and cytochrome P450 1A1/2 activities and PM-@GENE$ rats showed higher quinone reductase and depleted xanthine oxidase activities.
9276	CPR:4	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-@CHEMICAL$ rats showed higher quinone reductase and depleted @GENE$ activities.
9277	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.
9278	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @CHEMICAL$ activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.
9279	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @CHEM-GENE$ and depleted xanthine oxidase activities.
9280	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.
9281	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.
9282	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.
9283	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.
9284	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @GENE$ reductase and depleted xanthine oxidase activities.
9285	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @CHEMICAL$ reductase and depleted @GENE$ activities.
9286	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher @CHEMICAL$, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.
9287	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and @CHEMICAL$ activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.
9288	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher @CHEMICAL$ and depleted @GENE$ oxidase activities.
9289	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, @CHEMICAL$ and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.
9290	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and @CHEMICAL$ (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.
9291	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (@CHEMICAL$) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.
9292	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower @CHEMICAL$ activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.
9293	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased @CHEMICAL$ and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @GENE$ oxidase activities.
9294	CPRFalse	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted @CHEM-GENE$ activities.
9295	CPRFalse	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated @CHEMICAL$ production in PM-MMC rats. Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing @GENE$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.
9296	CPRFalse	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated prostaglandin E2 production in PM-@CHEMICAL$ rats. Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing @GENE$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.
9297	CPR:9	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated prostaglandin E2 production in PM-MMC rats. Conclusively, protein malnutrition alters CP, FU and @CHEMICAL$ metabolism in rat stomach by enhancing @GENE$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.
9298	CPRFalse	Protein-malnourished drug-treated groups exhibited exacerbated gastrotoxicity, relative to normally-fed counterparts, manifested by lower mucus levels, higher permeability and histopathological deterioration, along with increased oxidative stress in PM-CP rats and exaggerated prostaglandin E2 production in PM-MMC rats. Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing @CHEMICAL$ pathway for CP activation, delaying FU elimination and activating two-electron reduction of @GENE$, potentiating their gastrotoxicity.
9299	CPRFalse	@CHEMICAL$ (NAC, 33 mM) and the c-jun N-terminal kinase (@GENE$) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9300	CPRFalse	@CHEMICAL$ (NAC, 33 mM) and the @GENE$ (JNK) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9301	CPRFalse	N-acetylcysteine (@CHEMICAL$, 33 mM) and the c-jun N-terminal kinase (@GENE$) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9302	CPRFalse	N-acetylcysteine (@CHEMICAL$, 33 mM) and the @GENE$ (JNK) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9303	CPRFalse	N-acetylcysteine (NAC, 33 mM) and the c-jun @CHEMICAL$-terminal kinase (@GENE$) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9304	CPRFalse	N-acetylcysteine (NAC, 33 mM) and the @CHEM-GENE$ (JNK) inhibitor (SP600125, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9305	CPR:4	N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (@CHEMICAL$) inhibitor (@GENE$, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9306	CPR:4	N-acetylcysteine (NAC, 33 mM) and the @CHEMICAL$ (JNK) inhibitor (@GENE$, 33 mM) further decreased the viability in the presence of DEP (200 mg/ml) and 3.3% FCS.
9307	CPRFalse	Cerebrovascular Dilation via Selective Targeting of the @CHEMICAL$ Steroid-Recognition Site in the @GENE$ by a Novel Nonsteroidal Agent.
9308	CPRFalse	Cerebrovascular Dilation via Selective Targeting of the Cholane @CHEMICAL$-Recognition Site in the @GENE$ by a Novel Nonsteroidal Agent.
9309	CPRFalse	The @CHEM-GENE$ subunit is particularly abundant in vascular smooth muscle.
9310	CPRFalse	The @CHEM-GENE$ subunit is particularly abundant in vascular smooth muscle.
9311	CPRFalse	The endogenous steroid @CHEMICAL$ (LCA) dilates cerebral arteries via @GENE$ activation, which requires recognition by a BK b1 site that includes Thr169.
9312	CPRFalse	The endogenous steroid @CHEMICAL$ (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a @GENE$ site that includes Thr169.
9313	CPRFalse	The endogenous steroid lithocholic acid (@CHEMICAL$) dilates cerebral arteries via @GENE$ activation, which requires recognition by a BK b1 site that includes Thr169.
9314	CPRFalse	The endogenous steroid lithocholic acid (@CHEMICAL$) dilates cerebral arteries via BK channel activation, which requires recognition by a @GENE$ site that includes Thr169.
9315	CPRFalse	The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via @CHEMICAL$ activation, which requires recognition by a BK b1 site that includes @GENE$169.
9316	CPRFalse	The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a @CHEMICAL$ site that includes @GENE$169.
9317	CPRFalse	The endogenous @CHEMICAL$ lithocholic acid (LCA) dilates cerebral arteries via @GENE$ activation, which requires recognition by a BK b1 site that includes Thr169.
9318	CPRFalse	The endogenous @CHEMICAL$ lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a @GENE$ site that includes Thr169.
9319	CPR:3	@CHEMICAL$ activated the @GENE$ cloned from rat cerebral artery myocytes with a potency (EC50 = 53 mM) similar to and an efficacy (*2.5 potentiation) significantly greater than that of LCA.
9320	CPR:3	HENA activated the @CHEMICAL$ cloned from rat cerebral artery myocytes with a potency (EC50 = 53 mM) similar to and an efficacy (*2.5 potentiation) significantly greater than that of @GENE$.
9321	CPR:3	@CHEMICAL$ failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets @GENE$ via the BK b1 steroid-sensing site.
9322	CPRFalse	@CHEMICAL$ failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets b1-containing BK channels via the @GENE$ steroid-sensing site.
9323	CPRFalse	HENA failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets @CHEMICAL$ via the BK b1 @GENE$-sensing site.
9324	CPRFalse	HENA failed to activate the channels made of cbv1 + b2, b3, b4, or b1T169A, indicating that this drug selectively targets b1-containing BK channels via the @CHEMICAL$ @GENE$-sensing site.
9325	CPRFalse	@CHEMICAL$ failed to dilate the arteries from the @GENE$ knockout mouse, underscoring BK b1's role in HENA action.
9326	CPRFalse	@CHEMICAL$ failed to dilate the arteries from the KCNMB1 knockout mouse, underscoring @GENE$'s role in HENA action.
9327	CPRFalse	HENA failed to dilate the arteries from the @CHEMICAL$ knockout mouse, underscoring BK b1's role in @GENE$ action.
9328	CPRFalse	HENA failed to dilate the arteries from the KCNMB1 knockout mouse, underscoring @CHEMICAL$'s role in @GENE$ action.
9329	CPRFalse	Finally, carotid artery-infusion of @CHEMICAL$ (45 mM) dilated the pial cerebral arterioles via selective @GENE$ targeting.
9330	CPRFalse	In conclusion, we have identified for the first time a nonsteroidal agent that selectively activates @CHEMICAL$ by targeting the @GENE$-sensing site in BK b1, rendering vasodilation.
9331	CPRFalse	In conclusion, we have identified for the first time a nonsteroidal agent that selectively activates b1-containing BK channels by targeting the @CHEMICAL$-sensing site in @GENE$, rendering vasodilation.
9332	CPR:6	Assessment of the abuse liability of @CHEMICAL$, a novel @GENE$ antagonist.
9333	CPRFalse	Assessment of the abuse liability of ABT-288, a novel @CHEM-GENE$ antagonist.
9334	CPR:6	RATIONALE: @CHEMICAL$ antagonists, such as @GENE$, have been shown to possess cognitive-enhancing and wakefulness-promoting effects.
9335	CPRFalse	RATIONALE: @CHEM-GENE$ antagonists, such as ABT-288, have been shown to possess cognitive-enhancing and wakefulness-promoting effects.
9336	CPRFalse	CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to @CHEMICAL$ antagonists, indicates that @GENE$ is unlikely to possess a high potential for abuse in the human population and suggests that H3 antagonists, as a class, are similar in this regard.
9337	CPR:6	CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that @CHEMICAL$ is unlikely to possess a high potential for abuse in the human population and suggests that @GENE$ antagonists, as a class, are similar in this regard.
9338	CPRFalse	Additionally, a structural model of the @CHEM-GENE$ obtained by molecular dynamics simulation and energy minimization suggests that the phosphate moiety of phospho-S16 could compete with the phospho-substrate.
9339	CPRFalse	Additionally, a structural model of the @CHEMICAL$ obtained by molecular dynamics simulation and energy minimization suggests that the @GENE$ moiety of phospho-S16 could compete with the phospho-substrate.
9340	CPRFalse	Additionally, a structural model of the @CHEMICAL$ obtained by molecular dynamics simulation and energy minimization suggests that the phosphate moiety of @GENE$-S16 could compete with the phospho-substrate.
9341	CPRFalse	Additionally, a structural model of the @CHEMICAL$ obtained by molecular dynamics simulation and energy minimization suggests that the phosphate moiety of phospho-S16 could compete with the @GENE$-substrate.
9342	CPR:9	Uptake of @CHEMICAL$ (5 nM) by @GENE$ was reduced by 82%-95%.
9343	CPR:9	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), @GENE$ (84%-98%) and lopinavir (64%-89%).
9344	CPR:9	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and @GENE$ (64%-89%).
9345	CPR:9	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for @GENE$ (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).
9346	CPR:9	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), @GENE$ (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).
9347	CPR:9	This methodology was subsequently used to assess the relative contribution of @CHEMICAL$ uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), @GENE$ (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).
9348	CPRFalse	A @CHEMICAL$ tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @GENE$, glucose, FFA and aldosterone.
9349	CPRFalse	A glucose tolerance test with 75 g @CHEMICAL$ load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @GENE$, glucose, FFA and aldosterone.
9350	CPRFalse	A glucose tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @CHEMICAL$, @GENE$, FFA and aldosterone.
9351	CPRFalse	A glucose tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for @CHEMICAL$, glucose, FFA and @GENE$.
9352	CPRFalse	Since FFAs are known to be involved in the development of @CHEMICAL$ resistance, these results suggest that @GENE$ may be useful for lowering insulin resistance in PCOS patients.
9353	CPRFalse	Since FFAs are known to be involved in the development of insulin resistance, these results suggest that @CHEMICAL$ may be useful for lowering @GENE$ resistance in PCOS patients.
9354	CPRFalse	Oral l-glutamine increases active @CHEMICAL$ (7-36) amide secretion and improves glycemic control in stretpozotocin-@GENE$ induced diabetic rats.
9355	CPRFalse	Oral l-glutamine increases active @CHEMICAL$ (7-36) @GENE$ secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
9356	CPR:3	Oral @CHEMICAL$ increases active @GENE$ (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
9357	CPRFalse	Oral l-glutamine increases active @CHEMICAL$ (7-36) amide secretion and improves glycemic control in @GENE$-nicotinamide induced diabetic rats.
9358	CPRFalse	It decreased blood @CHEMICAL$, stimulated @GENE$ secretion in type 2 diabetic patients.
9359	CPR:3	The objective of the present investigation was to evaluate @CHEMICAL$ increases @GENE$ (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
9360	CPR:3	The objective of the present investigation was to evaluate @CHEMICAL$ increases glucagon like peptide-1 (@GENE$) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
9361	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) @GENE$ secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
9362	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) @GENE$ secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
9363	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in @GENE$-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
9364	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in @GENE$-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
9365	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in streptozotocin-@GENE$ (STZ-NTM) induced diabetic Sprague Dawley rats.
9366	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in streptozotocin-@GENE$ (STZ-NTM) induced diabetic Sprague Dawley rats.
9367	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (@GENE$-NTM) induced diabetic Sprague Dawley rats.
9368	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in streptozotocin-nicotinamide (@GENE$-NTM) induced diabetic Sprague Dawley rats.
9369	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases @CHEMICAL$ (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-@GENE$) induced diabetic Sprague Dawley rats.
9370	CPRFalse	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (@CHEMICAL$) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-@GENE$) induced diabetic Sprague Dawley rats.
9371	CPRFalse	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) @GENE$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9372	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic @GENE$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9373	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@GENE$, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9374	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$, glutathione S transferase) were measured after 8week.
9375	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$) were measured after 8week.
9376	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) @GENE$, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9377	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) @CHEMICAL$, mRNA expression of proglucagon @GENE$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9378	CPRFalse	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9379	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9380	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9381	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @CHEMICAL$, malondialdehyde, @GENE$, glutathione S transferase) were measured after 8week.
9382	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @CHEMICAL$, malondialdehyde, glutathione peroxidase, @GENE$) were measured after 8week.
9383	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9384	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced @GENE$, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9385	CPRFalse	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9386	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9387	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9388	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @CHEMICAL$, @GENE$, glutathione S transferase) were measured after 8week.
9389	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @CHEMICAL$, glutathione peroxidase, @GENE$) were measured after 8week.
9390	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9391	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, @GENE$, glutathione peroxidase, glutathione S transferase) were measured after 8week.
9392	CPRFalse	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.
9393	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.
9394	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.
9395	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @CHEM-GENE$, glutathione S transferase) were measured after 8week.
9396	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @CHEMICAL$ peroxidase, @GENE$) were measured after 8week.
9397	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.
9398	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @GENE$ peroxidase, glutathione S transferase) were measured after 8week.
9399	CPRFalse	Glycosylated @CHEMICAL$, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.
9400	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic @CHEMICAL$, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.
9401	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (@CHEMICAL$, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.
9402	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, @CHEMICAL$, @GENE$ S transferase) were measured after 8week.
9403	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @CHEM-GENE$) were measured after 8week.
9404	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (@CHEMICAL$) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.
9405	CPRFalse	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon @CHEMICAL$, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, @GENE$ S transferase) were measured after 8week.
9406	CPRFalse	Plasma @CHEMICAL$, active GLP-1 (7-36) amide concentration and @GENE$ levels were measured after glucose loading.
9407	CPRFalse	Plasma @CHEMICAL$, active @GENE$ (7-36) amide concentration and insulin levels were measured after glucose loading.
9408	CPRFalse	Plasma glucose, active GLP-1 (7-36) @CHEMICAL$ concentration and @GENE$ levels were measured after glucose loading.
9409	CPRFalse	Plasma glucose, active @CHEMICAL$ (7-36) @GENE$ concentration and insulin levels were measured after glucose loading.
9410	CPRFalse	Plasma glucose, active GLP-1 (7-36) amide concentration and @CHEMICAL$ levels were measured after @GENE$ loading.
9411	CPRFalse	Plasma glucose, active @CHEMICAL$ (7-36) amide concentration and insulin levels were measured after @GENE$ loading.
9412	CPRFalse	The docking data indicated that @CHEMICAL$ bind to the @GENE$.
9413	CPR:3	@CHEMICAL$ decreased plasma glucose, increased plasma and pancreatic @GENE$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.
9414	CPR:3	@CHEMICAL$ decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @GENE$ (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.
9415	CPRFalse	l-glutamine decreased plasma @CHEMICAL$, increased plasma and pancreatic @GENE$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.
9416	CPRFalse	l-glutamine decreased plasma @CHEMICAL$, increased plasma and pancreatic insulin, increased plasma and colonic active @GENE$ (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.
9417	CPRFalse	l-glutamine decreased plasma glucose, increased plasma and pancreatic @CHEMICAL$, increased plasma and colonic active GLP-1 (7-36) @GENE$ secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.
9418	CPRFalse	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @CHEMICAL$ (7-36) @GENE$ secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.
9419	CPRFalse	l-glutamine decreased plasma glucose, increased plasma and pancreatic @CHEMICAL$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in @GENE$-nicotinamide induced diabetic rats.
9420	CPRFalse	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @CHEMICAL$ (7-36) amide secretion as well as decreased oxidative stress in @GENE$-nicotinamide induced diabetic rats.
9421	CPRFalse	l-glutamine decreased plasma glucose, increased plasma and pancreatic @CHEMICAL$, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-@GENE$ induced diabetic rats.
9422	CPRFalse	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active @CHEMICAL$ (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-@GENE$ induced diabetic rats.
9423	CPRFalse	ZEB2 @CHEM-GENE$ missense mutations lead to hypomorphic alleles and a mild Mowat-Wilson syndrome.
9424	CPRFalse	@CHEMICAL$ @GENE$-finger missense mutations lead to hypomorphic alleles and a mild Mowat-Wilson syndrome.
9425	CPRFalse	His1045Arg, identified in the highly conserved @CHEM-GENE$ of ZEB2.
9426	CPRFalse	His1045Arg, identified in the highly conserved C-@CHEMICAL$-finger (C-ZF) domain of @GENE$.
9427	CPRFalse	@CHEMICAL$ and @GENE$ enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala.
9428	CPRFalse	While these behaviors can be modulated by @CHEMICAL$ (CRF) and @GENE$ signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.
9429	CPRFalse	While these behaviors can be modulated by corticotropin releasing factor (@CHEMICAL$) and @GENE$ signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.
9430	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEM-GENE$ agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.
9431	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, @GENE$ (DA) and the b-adrenergic receptor agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.
9432	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEMICAL$ agonist @GENE$ (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.
9433	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, dopamine (DA) and the b-adrenergic receptor agonist @GENE$ (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.
9434	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEMICAL$ agonist isoproterenol (@GENE$) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.
9435	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, dopamine (DA) and the b-adrenergic receptor agonist isoproterenol (@GENE$) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.
9436	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, @CHEMICAL$ agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic @GENE$ release.
9437	CPRFalse	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that @CHEMICAL$, dopamine (DA) and the b-adrenergic receptor agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic @GENE$ release.
9438	CPRFalse	While previous work from our lab suggests that CRFRs mediate the effect of @CHEMICAL$ on excitatory transmission in other subregions of the extended amygdala, blockade of @GENE$ in the CeAL failed to significantly alter effects of DA and ISO on glutamatergic transmission.
9439	CPRFalse	While previous work from our lab suggests that @CHEMICAL$ mediate the effect of @GENE$ on excitatory transmission in other subregions of the extended amygdala, blockade of CRFRs in the CeAL failed to significantly alter effects of DA and ISO on glutamatergic transmission.
9440	CPRFalse	While previous work from our lab suggests that CRFRs mediate the effect of catecholamines on excitatory transmission in other subregions of the extended amygdala, blockade of @CHEMICAL$ in the CeAL failed to significantly alter effects of DA and @GENE$ on glutamatergic transmission.
9441	CPRFalse	While previous work from our lab suggests that @CHEMICAL$ mediate the effect of catecholamines on excitatory transmission in other subregions of the extended amygdala, blockade of CRFRs in the CeAL failed to significantly alter effects of DA and @GENE$ on glutamatergic transmission.
9442	CPRFalse	These findings suggest that @CHEMICAL$ and @GENE$ enhancement of glutamatergic transmission onto CeAL neurons occurs via distinct mechanisms.
9443	CPRFalse	While @CHEMICAL$ increased spontaneous @GENE$ release in the CeAL, CRF caused no significant changes to optogenetically evoked glutamate release in this region.
9444	CPRFalse	While CRF increased spontaneous @CHEMICAL$ release in the CeAL, @GENE$ caused no significant changes to optogenetically evoked glutamate release in this region.
9445	CPRFalse	While @CHEMICAL$ increased spontaneous glutamate release in the CeAL, CRF caused no significant changes to optogenetically evoked @GENE$ release in this region.
9446	CPRFalse	While CRF increased spontaneous glutamate release in the CeAL, @CHEMICAL$ caused no significant changes to optogenetically evoked @GENE$ release in this region.
9447	CPRFalse	Environmental stress, @CHEM-GENE$ gene (OXTR) polymorphism, and mental health following collective stress.
9448	CPRFalse	Environmental stress, @CHEMICAL$ receptor gene (@GENE$) polymorphism, and mental health following collective stress.
9449	CPRFalse	We examined whether the @CHEM-GENE$ gene (OXTR) single nucleotide polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).
9450	CPRFalse	We examined whether the @CHEMICAL$ receptor gene (@GENE$) single nucleotide polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).
9451	CPRFalse	We examined whether the @CHEMICAL$ gene (OXTR) single @GENE$ polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).
9452	CPRFalse	We examined whether the oxytocin receptor gene (@CHEMICAL$) single @GENE$ polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).
9453	CPRFalse	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a @CHEM-GENE$.
9454	CPRFalse	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of @CHEMICAL$, corresponding to a @GENE$-to-proline mutation at residue 107.
9455	CPRFalse	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a @CHEM-GENE$.
9456	CPRFalse	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of @CHEMICAL$, corresponding to a leucine-to-@GENE$ mutation at residue 107.
9457	CPRFalse	Expression of SIRT1-@CHEMICAL$ in insulin-producing cells resulted in overproduction of @GENE$, cytokines, and chemokines.
9458	CPRFalse	Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of @CHEMICAL$, @GENE$, and chemokines.
9459	CPRFalse	Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of @CHEMICAL$, cytokines, and @GENE$.
9460	CPRFalse	Expression of @CHEMICAL$-L107P in insulin-producing cells resulted in overproduction of @GENE$, cytokines, and chemokines.
9461	CPRFalse	Expression of SIRT1-L107P in @CHEMICAL$-producing cells resulted in overproduction of @GENE$, cytokines, and chemokines.
9462	CPRFalse	Melanoma targeting property of a @CHEMICAL$-labeled lactam bridge-cyclized @GENE$ peptide.
9463	CPRFalse	Melanoma targeting property of a Lu-177-labeled @CHEMICAL$ bridge-cyclized @GENE$ peptide.
9464	CPRFalse	The purpose of this study was to determine the melanoma targeting property of @CHEM-GENE$ in B16/F1 melanoma-bearing C57 mice.
9465	CPR:4	In the present study, @CHEMICAL$ (1 and 2mM) inhibited the @GENE$-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.
9466	CPRFalse	In the present study, @CHEMICAL$ (1 and 2mM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including @GENE$, arachidonic acid, and ADP.
9467	CPRFalse	In the present study, hinokitiol (1 and 2mM) inhibited the @CHEMICAL$-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, @GENE$, and ADP.
9468	CPRFalse	In the present study, hinokitiol (1 and 2mM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including @CHEMICAL$, @GENE$, and ADP.
9469	CPRFalse	In the present study, hinokitiol (1 and 2mM) inhibited the @CHEMICAL$-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and @GENE$.
9470	CPRFalse	In the present study, hinokitiol (1 and 2mM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including @CHEMICAL$, arachidonic acid, and @GENE$.
9471	CPR:4	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, @GENE$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.
9472	CPR:4	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@GENE$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.
9473	CPR:4	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @GENE$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.
9474	CPR:4	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@GENE$), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.
9475	CPR:4	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @GENE$ in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.
9476	CPR:4	@CHEMICAL$ inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @GENE$-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.
9477	CPR:4	@CHEMICAL$ inhibited the phosphorylation of @GENE$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.
9478	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, @CHEMICAL$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.
9479	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@CHEMICAL$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.
9480	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @CHEMICAL$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.
9481	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@CHEMICAL$), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.
9482	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @CHEMICAL$ in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.
9483	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @CHEMICAL$-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.
9484	CPRFalse	Hinokitiol inhibited the phosphorylation of @CHEMICAL$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular @GENE$ mobilization and hydroxyl radical (OH) formation.
9485	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, @CHEMICAL$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.
9486	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@CHEMICAL$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.
9487	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @CHEMICAL$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.
9488	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@CHEMICAL$), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.
9489	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @CHEMICAL$ in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.
9490	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @CHEMICAL$-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.
9491	CPRFalse	Hinokitiol inhibited the phosphorylation of @CHEMICAL$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and @GENE$ radical (OH) formation.
9492	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, @CHEMICAL$ (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.
9493	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (@CHEMICAL$), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.
9494	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), @CHEMICAL$ (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.
9495	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (@CHEMICAL$), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.
9496	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and @CHEMICAL$ in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.
9497	CPRFalse	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)g2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in @CHEMICAL$-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.
9498	CPRFalse	Hinokitiol inhibited the phosphorylation of @CHEMICAL$, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (@GENE$) formation.
9499	CPR:4	@CHEMICAL$ also reduced the @GENE$ activation and platelet aggregation stimulated by PDBu.
9500	CPRFalse	@CHEMICAL$ did not influence the binding of a fluorescent triflavin probe to the @GENE$ on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.
9501	CPRFalse	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the @CHEMICAL$ on platelet membrane, and neither @GENE$ nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.
9502	CPRFalse	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the @CHEMICAL$ on platelet membrane, and neither ODQ nor @GENE$ significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.
9503	CPRFalse	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the @CHEMICAL$ on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the @GENE$-mediated inhibition of platelet aggregation.
9504	CPR:4	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the PLCg2-@GENE$ cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.
9505	CPR:4	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of @GENE$ and Akt.
9506	CPR:4	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and @GENE$.
9507	CPR:4	In conclusion, @CHEMICAL$ may inhibit platelet activation by inhibiting the @GENE$-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.
9508	CPRFalse	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCg2-@CHEMICAL$ cascade and @GENE$ radical formation, followed by suppressing the activation of MAPKs and Akt.
9509	CPRFalse	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and @CHEMICAL$ radical formation, followed by suppressing the activation of @GENE$ and Akt.
9510	CPRFalse	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLCg2-PKC cascade and @CHEMICAL$ radical formation, followed by suppressing the activation of MAPKs and @GENE$.
9511	CPRFalse	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the @CHEMICAL$-PKC cascade and @GENE$ radical formation, followed by suppressing the activation of MAPKs and Akt.
9512	CPR:4	Novel @CHEMICAL$ derivatives as potent @GENE$ inhibitors.
9513	CPRFalse	A series of novel @CHEMICAL$ were designed, synthesized and biologically evaluated for @GENE$ inhibition.
9514	CPR:5	Design, Synthesis, and Pharmacological Characterization of Novel @CHEMICAL$ Analogues as Extremely Potent @GENE$ Agonists.
9515	CPRFalse	Of the new compounds, Dmt(1)-(R)-bPro(2)-@CHEMICAL$(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).
9516	CPRFalse	Of the new compounds, Dmt(1)-(R)-bPro(2)-Trp(3)-@CHEMICAL$(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).
9517	CPRFalse	Of the new compounds, @CHEMICAL$(1)-(R)-bPro(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).
9518	CPRFalse	Of the new compounds, Dmt(1)-@CHEMICAL$(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward @GENE$, in the picomolar range (Ki(m) = 3.72 pM).
9519	CPRFalse	We report that two common variants of @CHEMICAL$ (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for @GENE$34 and Gly36 to less frequently used codons.
9520	CPRFalse	We report that two common variants of high-temperature requirement A1 (@CHEMICAL$) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for @GENE$34 and Gly36 to less frequently used codons.
9521	CPRFalse	We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of @CHEMICAL$ that convert common codons for @GENE$34 and Gly36 to less frequently used codons.
9522	CPRFalse	We report that two common variants of @CHEMICAL$ (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and @GENE$36 to less frequently used codons.
9523	CPRFalse	We report that two common variants of high-temperature requirement A1 (@CHEMICAL$) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and @GENE$36 to less frequently used codons.
9524	CPRFalse	We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of @CHEMICAL$ that convert common codons for Ala34 and @GENE$36 to less frequently used codons.
9525	CPRFalse	In search of a basis for the impressive potency of an @CHEMICAL$ that cleaves SNAP-25, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.
9526	CPRFalse	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @CHEMICAL$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM @GENE$ despite cleaving <20% of the SNAP-25.
9527	CPRFalse	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @CHEMICAL$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the @GENE$.
9528	CPRFalse	In search of a basis for the impressive potency of an endoprotease that cleaves @CHEMICAL$, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.
9529	CPRFalse	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, @CHEMICAL$ (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.
9530	CPRFalse	In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, botulinum neurotoxin type A (@CHEMICAL$), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmission were studied in rat sympathetic neurons. @GENE$-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BoNT/A despite cleaving <20% of the SNAP-25.
9531	CPRFalse	Moreover, limited cleavage of SNAP-25 was conferred onto the @CHEMICAL$ from BoNT/E when fused to the @GENE$-terminus of BoNT/A.
9532	CPRFalse	Moreover, limited cleavage of SNAP-25 was conferred onto the protease from BoNT/E when fused to the @CHEMICAL$-terminus of @GENE$.
9533	CPRFalse	Moreover, limited cleavage of @CHEMICAL$ was conferred onto the protease from BoNT/E when fused to the @GENE$-terminus of BoNT/A.
9534	CPRFalse	Moreover, limited cleavage of SNAP-25 was conferred onto the protease from @CHEMICAL$ when fused to the @GENE$-terminus of BoNT/A.
9535	CPRFalse	@CHEMICAL$-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional @GENE$.
9536	CPRFalse	Dexamethasone-mediated changes in adipose @CHEMICAL$ metabolism are exaggerated, not diminished, in the absence of a functional @GENE$.
9537	CPRFalse	To understand the role of @CHEMICAL$ dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and GR(dim/dim) mice administered the potent GC @GENE$ (DEX).
9538	CPRFalse	To understand the role of GR dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and @CHEMICAL$(dim/dim) mice administered the potent GC @GENE$ (DEX).
9539	CPRFalse	To understand the role of @CHEMICAL$ dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and GR(dim/dim) mice administered the potent GC dexamethasone (@GENE$).
9540	CPRFalse	To understand the role of GR dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and @CHEMICAL$(dim/dim) mice administered the potent GC dexamethasone (@GENE$).
9541	CPRFalse	Absolute @CHEMICAL$ synthesis was increased in both wild-type and @GENE$(dim/dim) mice by DEX in the inguinal and epididymal fat depots.
9542	CPRFalse	Absolute triglyceride synthesis was increased in both wild-type and @CHEMICAL$(dim/dim) mice by @GENE$ in the inguinal and epididymal fat depots.
9543	CPRFalse	@CHEMICAL$(dim/dim) mice showed an exaggerated response to @GENE$ in both depots.
9544	CPRFalse	De novo lipogenesis was also greatly increased in both depots in response to @CHEMICAL$ in @GENE$(dim/dim), but not wild-type mice.
9545	CPRFalse	In contrast, the inhibitory effect of @CHEMICAL$ on bone and skin collagen synthesis rates was greater in wild-type compared with @GENE$(dim/dim) mice.
9546	CPRFalse	Wild-type mice were more sensitive to @CHEMICAL$-dependent decreases in @GENE$ sensitivity than GR(dim/dim) mice.
9547	CPRFalse	Wild-type mice were more sensitive to @CHEMICAL$-dependent decreases in insulin sensitivity than @GENE$(dim/dim) mice.
9548	CPRFalse	Wild-type and @CHEMICAL$(dim/dim) mice were equally sensitive to @GENE$-dependent decreases in muscle protein synthesis.
9549	CPRFalse	X-box binding protein 1 (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in b-cells has been reported to impair @CHEMICAL$ secretion leading to @GENE$ intolerance.
9550	CPRFalse	@CHEMICAL$ (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in b-cells has been reported to impair insulin secretion leading to @GENE$ intolerance.
9551	CPRFalse	X-box binding protein 1 (@CHEMICAL$) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in b-cells has been reported to impair insulin secretion leading to @GENE$ intolerance.
9552	CPRFalse	aXBPKO mice exhibited @CHEMICAL$ intolerance, mild @GENE$ resistance and an inability to suppress glucagon secretion following glucose stimulation.
9553	CPRFalse	a@CHEMICAL$KO mice exhibited @GENE$ intolerance, mild insulin resistance and an inability to suppress glucagon secretion following glucose stimulation.
9554	CPRFalse	aXBPKO mice exhibited @CHEMICAL$ intolerance, mild insulin resistance and an inability to suppress @GENE$ secretion following glucose stimulation.
9555	CPRFalse	aXBPKO mice exhibited glucose intolerance, mild @CHEMICAL$ resistance and an inability to suppress glucagon secretion following @GENE$ stimulation.
9556	CPRFalse	a@CHEMICAL$KO mice exhibited glucose intolerance, mild insulin resistance and an inability to suppress glucagon secretion following @GENE$ stimulation.
9557	CPRFalse	aXBPKO mice exhibited glucose intolerance, mild insulin resistance and an inability to suppress @CHEMICAL$ secretion following @GENE$ stimulation.
9558	CPRFalse	Interestingly, insulin treatment of aXBPKD cells reduced @CHEMICAL$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of @GENE$, while enhancing serine phosphorylation (pS(307)) of IRS-1.
9559	CPRFalse	Interestingly, @CHEMICAL$ treatment of aXBPKD cells reduced @GENE$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.
9560	CPRFalse	Interestingly, insulin treatment of a@CHEMICAL$KD cells reduced @GENE$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.
9561	CPRFalse	Interestingly, insulin treatment of aXBPKD cells reduced @CHEMICAL$ phosphorylation of @GENE$ (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.
9562	CPRFalse	Interestingly, insulin treatment of aXBPKD cells reduced @CHEMICAL$ phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of @GENE$.
9563	CPRFalse	Interestingly, insulin treatment of aXBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of @CHEMICAL$, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.
9564	CPRFalse	Interestingly, @CHEMICAL$ treatment of aXBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.
9565	CPRFalse	Interestingly, insulin treatment of a@CHEMICAL$KD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.
9566	CPRFalse	Interestingly, insulin treatment of aXBPKD cells reduced tyrosine phosphorylation of @CHEMICAL$ (pY(896)), and phosphorylation of Akt, while enhancing @GENE$ phosphorylation (pS(307)) of IRS-1.
9567	CPRFalse	Interestingly, insulin treatment of aXBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing @CHEMICAL$ phosphorylation (pS(307)) of @GENE$.
9568	CPRFalse	Consequently the a@CHEMICAL$KD cells exhibited blunted suppression of glucagon secretion following insulin treatment in the presence of high @GENE$.
9569	CPRFalse	Consequently the aXBPKD cells exhibited blunted suppression of @CHEMICAL$ secretion following insulin treatment in the presence of high @GENE$.
9570	CPRFalse	Consequently the aXBPKD cells exhibited blunted suppression of glucagon secretion following @CHEMICAL$ treatment in the presence of high @GENE$.
9571	CPRFalse	Toxicological profiles of selected synthetic @CHEMICAL$ showing high binding affinities to the @GENE$.
9572	CPRFalse	Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the @CHEM-GENE$.
9573	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (@CHEMICAL$) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.
9574	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; @CHEMICAL$ was included as the classical non-endogenous @GENE$ ligand.
9575	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four @CHEMICAL$ compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.
9576	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (@CHEMICAL$, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.
9577	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, @CHEMICAL$, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.
9578	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, @CHEMICAL$ and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.
9579	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and @CHEMICAL$) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.
9580	CPRFalse	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one @CHEMICAL$ (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous @GENE$ ligand.
9581	CPRFalse	Furthermore, no impact on @CHEMICAL$ release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.
9582	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, @CHEMICAL$/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.
9583	CPR:4	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @CHEMICAL$ and JWH-122 which caused a decrease of TNFa and @GENE$/23p40.
9584	CPRFalse	Furthermore, no impact on cytokine release (i.e., on @CHEMICAL$, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.
9585	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, @CHEMICAL$, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.
9586	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/@CHEMICAL$ and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.
9587	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and @CHEMICAL$ levels) was seen in LPS-stimulated human PBMCs, except with @GENE$ and JWH-122 which caused a decrease of TNFa and IL-12/23p40.
9588	CPR:4	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @CHEMICAL$ and JWH-122 which caused a decrease of @GENE$ and IL-12/23p40.
9589	CPR:4	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with @CHEMICAL$ and JWH-122 which caused a decrease of TNFa and IL-12/@GENE$.
9590	CPRFalse	Furthermore, no impact on @CHEMICAL$ release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.
9591	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, @CHEMICAL$/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.
9592	CPR:4	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @CHEMICAL$ which caused a decrease of TNFa and @GENE$/23p40.
9593	CPRFalse	Furthermore, no impact on cytokine release (i.e., on @CHEMICAL$, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.
9594	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, @CHEMICAL$, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.
9595	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/@CHEMICAL$ and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.
9596	CPRFalse	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and @CHEMICAL$ levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @GENE$ which caused a decrease of TNFa and IL-12/23p40.
9597	CPR:4	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @CHEMICAL$ which caused a decrease of @GENE$ and IL-12/23p40.
9598	CPR:4	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFa levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and @CHEMICAL$ which caused a decrease of TNFa and IL-12/@GENE$.
9599	CPRFalse	@CHEMICAL$ Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and @GENE$ in Obese Individuals.
9600	CPRFalse	@CHEMICAL$ Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to @GENE$ and Oxidized LDL in Obese Individuals.
9601	CPRFalse	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-Hsp27) and oxLDL (anti-@GENE$) were investigated.
9602	CPRFalse	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-Hsp27) and @GENE$ (anti-oxLDL) were investigated.
9603	CPRFalse	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to @GENE$ (anti-Hsp27) and oxLDL (anti-oxLDL) were investigated.
9604	CPRFalse	In this randomized double-blind placebo-controlled cross-over trial, the effects of a @CHEMICAL$ supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-@GENE$) and oxLDL (anti-oxLDL) were investigated.
9605	CPR:4	@CHEMICAL$ markedly reduced AA performance and activities of @GENE$ (COX) and acetylcholinesterase (AChE) in all regions.
9606	CPR:4	@CHEMICAL$ markedly reduced AA performance and activities of cytochrome c oxidase (@GENE$) and acetylcholinesterase (AChE) in all regions.
9607	CPR:4	@CHEMICAL$ markedly reduced AA performance and activities of cytochrome c oxidase (COX) and @GENE$ (AChE) in all regions.
9608	CPR:4	@CHEMICAL$ markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (@GENE$) in all regions.
9609	CPR:4	GTLE pretreatment completely reversed the damaging effects of @CHEMICAL$ on AA and @GENE$ activity, markedly corrected COX and AChE activities, and moderately improved TGC.
9610	CPR:4	GTLE pretreatment completely reversed the damaging effects of @CHEMICAL$ on AA and superoxide dismutase activity, markedly corrected @GENE$ and AChE activities, and moderately improved TGC.
9611	CPR:4	GTLE pretreatment completely reversed the damaging effects of @CHEMICAL$ on AA and superoxide dismutase activity, markedly corrected COX and @GENE$ activities, and moderately improved TGC.
9612	CPRFalse	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and @CHEM-GENE$ activity, markedly corrected COX and AChE activities, and moderately improved TGC.
9613	CPRFalse	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and @CHEMICAL$ dismutase activity, markedly corrected @GENE$ and AChE activities, and moderately improved TGC.
9614	CPRFalse	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and @CHEMICAL$ dismutase activity, markedly corrected COX and @GENE$ activities, and moderately improved TGC.
9615	CPRFalse	By modulating expression levels of endogenous @CHEMICAL$ in primary cortical neurons, the frequency and amplitude of @GENE$ oscillations is modified, implying a key role for APP in maintaining neuronal calcium homeostasis essential for synaptic transmission.
9616	CPRFalse	By modulating expression levels of endogenous APP in primary cortical neurons, the frequency and amplitude of @CHEMICAL$ oscillations is modified, implying a key role for @GENE$ in maintaining neuronal calcium homeostasis essential for synaptic transmission.
9617	CPRFalse	By modulating expression levels of endogenous @CHEMICAL$ in primary cortical neurons, the frequency and amplitude of calcium oscillations is modified, implying a key role for APP in maintaining neuronal @GENE$ homeostasis essential for synaptic transmission.
9618	CPRFalse	By modulating expression levels of endogenous APP in primary cortical neurons, the frequency and amplitude of calcium oscillations is modified, implying a key role for @CHEMICAL$ in maintaining neuronal @GENE$ homeostasis essential for synaptic transmission.
9619	CPRFalse	Furthermore, the @CHEMICAL$ (11) selectively induced apoptosis in A549 cells without affecting the @GENE$ activity level.
9620	CPRFalse	Female C57BL/6 mice were exposed to dextran @CHEMICAL$ (DSS) and treated by intrarectal administration with either CD.siRNA @GENE$ or a control solution.
9621	CPRFalse	@CHEMICAL$ attenuates allergic airway inflammation by regulation of CD4(+)CD25(+) regulatory T cells (Tregs)/Th17 balance in @GENE$-sensitized mice.
9622	CPRFalse	The present study aimed to determine the protective effects and the underlying mechanisms of @CHEMICAL$ on @GENE$ (OVA)-induced allergic inflammation in a mouse model of allergic asthma.
9623	CPRFalse	The present study aimed to determine the protective effects and the underlying mechanisms of @CHEMICAL$ on ovalbumin (@GENE$)-induced allergic inflammation in a mouse model of allergic asthma.
9624	CPRFalse	A total of 60 mice were randomly assigned to six experimental groups: control, model, @CHEMICAL$ (2mg/kg), and curcumin (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and eosin (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).
9625	CPRFalse	A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg), and @CHEMICAL$ (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and eosin (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).
9626	CPRFalse	A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg), and curcumin (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by @CHEMICAL$ and eosin (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).
9627	CPRFalse	A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg), and curcumin (50mg/kg, 100mg/kg, 200mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and @CHEMICAL$ (HE) staining, BALF levels of Treg/Th17 @GENE$ were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).
9628	CPR:4	Our study demonstrated that @CHEMICAL$ inhibited @GENE$-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.
9629	CPR:4	Our study demonstrated that @CHEMICAL$ inhibited OVA-induced increases in eosinophil count; @GENE$ level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.
9630	CPR:3	Our study demonstrated that @CHEMICAL$ inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased @GENE$ level in bronchoalveolar lavage fluid.
9631	CPR:4	Histological studies demonstrated that @CHEMICAL$ substantially inhibited @GENE$-induced eosinophilia in lung tissue.
9632	CPR:4	The results in vivo show @CHEMICAL$-induced significantly broke Treg/Th17 balance; @GENE$ treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.
9633	CPRFalse	Structural Basis for the @CHEMICAL$-Induced Isomerization of @GENE$.
9634	CPRFalse	@CHEMICAL$ (KIFs) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of @GENE$.
9635	CPRFalse	Kinesin superfamily proteins (@CHEMICAL$) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of @GENE$.
9636	CPRFalse	Kinesin superfamily proteins (KIFs) are @CHEMICAL$ driven by the energy derived from the hydrolysis of @GENE$.
9637	CPRFalse	Previous studies have revealed that the @CHEMICAL$ binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of @GENE$ activity to guarantee the processive movement of dimeric KIFs.
9638	CPRFalse	Previous studies have revealed that the @CHEMICAL$ binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of ATPase activity to guarantee the processive movement of dimeric @GENE$.
9639	CPRFalse	Here, we report the first crystal structure of @CHEMICAL$ complexed with the non-hydrolyzable @GENE$ analog, AMPPNP (adenylyl imidodiphosphate), at 1.7A resolution.
9640	CPRFalse	Here, we report the first crystal structure of @CHEMICAL$ complexed with the non-hydrolyzable ATP analog, @GENE$ (adenylyl imidodiphosphate), at 1.7A resolution.
9641	CPRFalse	Here, we report the first crystal structure of @CHEMICAL$ complexed with the non-hydrolyzable ATP analog, AMPPNP (@GENE$), at 1.7A resolution.
9642	CPRFalse	By combining our structure with previously solved @CHEMICAL$ structures complexed with two @GENE$ analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.
9643	CPRFalse	By combining our structure with previously solved @CHEMICAL$ structures complexed with two ATP analogs, molecular snapshots during @GENE$ binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.
9644	CPRFalse	By combining our structure with previously solved @CHEMICAL$ structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the @GENE$-binding pocket during ATP binding is achieved by closure of the backdoor.
9645	CPRFalse	By combining our structure with previously solved @CHEMICAL$ structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during @GENE$ binding is achieved by closure of the backdoor.
9646	CPRFalse	Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that @CHEMICAL$-terminal @GENE$ peptides might be considered a promising bone anabolic therapy.
9647	CPRFalse	In addition, putative osteogenic actions of @CHEMICAL$ might be ascribed not only to its @GENE$-terminal domain but also to its PTH-unrelated C-terminal region.
9648	CPRFalse	In addition, putative osteogenic actions of PTHrP might be ascribed not only to its @CHEMICAL$-terminal domain but also to its @GENE$-unrelated C-terminal region.
9649	CPRFalse	In addition, putative osteogenic actions of @CHEMICAL$ might be ascribed not only to its N-terminal domain but also to its PTH-unrelated @GENE$-terminal region.
9650	CPRFalse	In addition, putative osteogenic actions of PTHrP might be ascribed not only to its N-terminal domain but also to its @CHEMICAL$-unrelated @GENE$-terminal region.
9651	CPRFalse	While studies of @CHEMICAL$, @GENE$, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics.
9652	CPRFalse	Newer lines of research, including cholinergic and glutamatergic agents and @CHEM-GENE$, will be of considerable interest in the future.
9653	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), @CHEMICAL$ (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9654	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (@CHEMICAL$) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9655	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for @CHEMICAL$, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9656	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, @CHEMICAL$, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9657	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, @CHEMICAL$ (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9658	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (@CHEMICAL$/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9659	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/@CHEMICAL$/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9660	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/@CHEMICAL$), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9661	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, @CHEMICAL$, pendrin, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9662	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, @CHEMICAL$, human @GENE$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9663	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, @CHEM-GENE$ (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9664	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (@GENE$), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9665	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), @GENE$ (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9666	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (@GENE$) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9667	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (PAX8) and @GENE$ (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9668	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (@GENE$), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.
9669	CPRFalse	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human @CHEMICAL$ symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the @GENE$ gene by in situ hybridization analysis.
9670	CPR:4	Synthesis of a @CHEMICAL$ (Gd(3+))-conjugate of @GENE$ inhibitor pantoprazole for gastric wall imaging studies.
9671	CPR:4	Synthesis of a DOTA (@CHEMICAL$)-conjugate of @GENE$ inhibitor pantoprazole for gastric wall imaging studies.
9672	CPR:4	Synthesis of a DOTA (Gd(3+))-conjugate of @CHEMICAL$ inhibitor @GENE$ for gastric wall imaging studies.
9673	CPRFalse	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a @CHEMICAL$-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to @GENE$ in the stomach and colon.
9674	CPR:4	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a @CHEMICAL$-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used @GENE$ inhibitor that binds to proton pumps in the stomach and colon.
9675	CPRFalse	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (@CHEMICAL$), with pantoprazole, which is a widely used proton pump inhibitor that binds to @GENE$ in the stomach and colon.
9676	CPR:4	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (@CHEMICAL$), with pantoprazole, which is a widely used @GENE$ inhibitor that binds to proton pumps in the stomach and colon.
9677	CPRFalse	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with @CHEMICAL$, which is a widely used proton pump inhibitor that binds to @GENE$ in the stomach and colon.
9678	CPR:4	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with @CHEMICAL$, which is a widely used @GENE$ inhibitor that binds to proton pumps in the stomach and colon.
9679	CPRFalse	@CHEMICAL$ inhibition reveals endogenous nicotinic modulation of @GENE$ inputs to CA1 stratum radiatum interneurons in hippocampal slices.
9680	CPRFalse	The involvement of brain @CHEM-GENE$ (nAChRs) in the neurotoxicological effects of soman, a potent acetylcholinesterase (AChE) inhibitor and a chemical warfare agent, is not clear.
9681	CPRFalse	The involvement of brain nicotinic @CHEMICAL$ receptors (@GENE$) in the neurotoxicological effects of soman, a potent acetylcholinesterase (AChE) inhibitor and a chemical warfare agent, is not clear.
9682	CPRFalse	The involvement of brain nicotinic @CHEMICAL$ receptors (nAChRs) in the neurotoxicological effects of soman, a potent @GENE$ (AChE) inhibitor and a chemical warfare agent, is not clear.
9683	CPRFalse	The involvement of brain nicotinic @CHEMICAL$ receptors (nAChRs) in the neurotoxicological effects of soman, a potent acetylcholinesterase (@GENE$) inhibitor and a chemical warfare agent, is not clear.
9684	CPRFalse	To test the hypothesis that AChE inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates @CHEMICAL$-dependent @GENE$ transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.
9685	CPRFalse	To test the hypothesis that @CHEMICAL$ inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates nAChR-dependent @GENE$ transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.
9686	CPRFalse	To test the hypothesis that AChE inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates @CHEMICAL$-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous @GENE$ excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.
9687	CPRFalse	To test the hypothesis that @CHEMICAL$ inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates nAChR-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous @GENE$ excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.
9688	CPRFalse	To test the hypothesis that AChE inhibition builds sufficient @CHEMICAL$ (ACh) in the brain and facilitates @GENE$-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.
9689	CPRFalse	To test the hypothesis that @CHEMICAL$ inhibition builds sufficient @GENE$ (ACh) in the brain and facilitates nAChR-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.
9690	CPR:4	Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible @CHEMICAL$ inhibitor @GENE$ (100nM).
9691	CPRFalse	These results support the concept that AChE inhibition is able to recruit @CHEMICAL$-dependent @GENE$ transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of soman.
9692	CPRFalse	These results support the concept that @CHEMICAL$ inhibition is able to recruit nAChR-dependent @GENE$ transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of soman.
9693	CPR:9	A Nanogram Dose of the @CHEMICAL$ Probe Substrate @GENE$ to Evaluate Drug Interactions.
9694	CPRFalse	The objective of the study was to establish an in vivo method for assessing @CHEMICAL$ (CYP3A) activity using therapeutically inert nanogram doses of @GENE$.
9695	CPRFalse	The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (@CHEMICAL$) activity using therapeutically inert nanogram doses of @GENE$.
9696	CPRFalse	We administered four escalating single doses of oral @CHEMICAL$ (0.0001-3 mg) to 12 healthy participants, stratified according to @GENE$ carrier status, to assess pharmacokinetics linearity.
9697	CPR:4	We then evaluated the interactions with the @CHEMICAL$ inhibitor @GENE$ (400 mg q.d.) after nanogram and regular doses of midazolam.
9698	CPRFalse	We then evaluated the interactions with the @CHEMICAL$ inhibitor ketoconazole (400 mg q.d.) after nanogram and regular doses of @GENE$.
9699	CPR:4	@CHEMICAL$ carrier status had no influence on midazolam oral clearance or its inhibition by @GENE$.
9700	CPR:9	@CHEMICAL$ carrier status had no influence on @GENE$ oral clearance or its inhibition by ketoconazole.
9701	CPRFalse	This is the first study showing that @CHEMICAL$ pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess @GENE$ activity even in the presence of strong CYP3A inhibitors.
9702	CPRFalse	This is the first study showing that @CHEMICAL$ pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong @GENE$ inhibitors.
9703	CPRFalse	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of @CHEMICAL$ can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess @GENE$ activity even in the presence of strong CYP3A inhibitors.
9704	CPRFalse	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of @CHEMICAL$ can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong @GENE$ inhibitors.
9705	CPRFalse	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of @CHEMICAL$ in therapeutic doses and can be used to assess @GENE$ activity even in the presence of strong CYP3A inhibitors.
9706	CPRFalse	This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of @CHEMICAL$ in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong @GENE$ inhibitors.
9707	CPRFalse	@CHEM-GENE$ Inducer Activity of Some Saudi Arabian Medicinal Plants.
9708	CPRFalse	@CHEM-GENE$ Inducer Activity of Some Saudi Arabian Medicinal Plants.
9709	CPRFalse	One such multifunctional cytoprotective enzyme is @CHEM-GENE$.
9710	CPRFalse	One such multifunctional cytoprotective enzyme is @CHEM-GENE$.
9711	CPRFalse	In this study, we prepared extracts of 27 Saudi Arabian medicinal plants which belong to 18 different plant families and tested their ability to induce @CHEM-GENE$ in murine hepatoma cells grown in microtiter plate wells.
9712	CPRFalse	In this study, we prepared extracts of 27 Saudi Arabian medicinal plants which belong to 18 different plant families and tested their ability to induce @CHEM-GENE$ in murine hepatoma cells grown in microtiter plate wells.
9713	CPRFalse	In addition to the Brassicaceae, a known source of @CHEM-GENE$, we found substantial inducer activity in extracts from the Apiaceae, Apocynaceae, and the Asteraceae families.
9714	CPRFalse	In addition to the Brassicaceae, a known source of @CHEM-GENE$, we found substantial inducer activity in extracts from the Apiaceae, Apocynaceae, and the Asteraceae families.
9715	CPRFalse	Thus, the @CHEM-GENE$ inducer activity of extracts of some Saudi Arabian medicinal plants indicates the presence of specific phytochemicals which have the potential to protect against chronic degenerative diseases.
9716	CPRFalse	Thus, the @CHEM-GENE$ inducer activity of extracts of some Saudi Arabian medicinal plants indicates the presence of specific phytochemicals which have the potential to protect against chronic degenerative diseases.
9717	CPR:9	Metabolism of @CHEMICAL$ by @GENE$ Enzymes.
9718	CPR:9	It is possible that variations in @CHEMICAL$ enzyme-mediated metabolism of @GENE$ may contribute to this phenomenon.
9719	CPRFalse	This hypothesis was explored by evaluating the contributions of @CHEMICAL$, and esterase enzymes in the metabolism of @GENE$ in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.
9720	CPR:9	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and @CHEMICAL$ enzymes in the metabolism of @GENE$ in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.
9721	CPRFalse	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of @CHEMICAL$ in vitro and relating metabolism to changes in @GENE$ enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.
9722	CPRFalse	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of @CHEMICAL$ in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the @GENE$ in lung and liver cells.
9723	CPR:9	@CHEMICAL$ and CYP3A5 metabolized @GENE$ via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.
9724	CPR:9	CYP3A4 and @CHEMICAL$ metabolized @GENE$ via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.
9725	CPRFalse	CYP3A4 and CYP3A5 metabolized @CHEMICAL$ via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; @GENE$ did not metabolize BDP.
9726	CPRFalse	@CHEMICAL$ and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize @GENE$.
9727	CPRFalse	CYP3A4 and @CHEMICAL$ metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize @GENE$.
9728	CPRFalse	CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; @CHEMICAL$ did not metabolize @GENE$.
9729	CPR:9	These studies show that @CHEMICAL$ and CYP3A5 metabolize @GENE$ to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.
9730	CPR:9	These studies show that CYP3A4 and @CHEMICAL$ metabolize @GENE$ to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.
9731	CPRFalse	These studies show that @CHEMICAL$ and CYP3A5 metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence @GENE$ disposition in humans.
9732	CPRFalse	These studies show that CYP3A4 and @CHEMICAL$ metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence @GENE$ disposition in humans.
9733	CPRFalse	Effect of the Potent Antiviral @CHEMICAL$ on @GENE$ Production by Murine Macrophages Stimulated with HSV-2.
9734	CPRFalse	The antiherpetic action of @CHEMICAL$ was measured by plaque reduction assay, and the immunomodulatory effect was determined by measuring the @GENE$ production using a bioassay and ELISA method.
9735	CPR:3	In macrophages, levels of @CHEMICAL$, IFN-g, NO, IL-6 and IL-10 were increased by @GENE$ used alone or in combination with HSV-2.
9736	CPR:3	In macrophages, levels of TNF-a, @CHEMICAL$, NO, IL-6 and IL-10 were increased by @GENE$ used alone or in combination with HSV-2.
9737	CPR:3	In macrophages, levels of TNF-a, IFN-g, NO, @CHEMICAL$ and IL-10 were increased by @GENE$ used alone or in combination with HSV-2.
9738	CPR:3	In macrophages, levels of TNF-a, IFN-g, NO, IL-6 and @CHEMICAL$ were increased by @GENE$ used alone or in combination with HSV-2.
9739	CPR:3	Besides, @CHEMICAL$ not only synergized @GENE$ production combined with IFN-g, but also prolonged its expression in time.
9740	CPR:3	Besides, @CHEMICAL$ not only synergized TNF-a production combined with @GENE$, but also prolonged its expression in time.
9741	CPR:3	Results indicate that @CHEMICAL$ inhibits HSV-2 multiplication in epithelial cells and also increases @GENE$ production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.
9742	CPR:4	Intestinal and hepatic first-pass extraction of the @CHEMICAL$ inhibitor @GENE$ in rats with chronic vascular catheters.
9743	CPR:4	A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an @CHEMICAL$ inhibitor, @GENE$.
9744	CPRFalse	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on @GENE$ (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.
9745	CPRFalse	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (@GENE$)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.
9746	CPRFalse	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced @GENE$ (TNF-a) production by these cells.
9747	CPRFalse	Sixty one compounds, grouped as the 6H, @CHEMICAL$, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (@GENE$) production by these cells.
9748	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on @GENE$ (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.
9749	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (@GENE$)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.
9750	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced @GENE$ (TNF-a) production by these cells.
9751	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, @CHEMICAL$ and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (@GENE$) production by these cells.
9752	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on @GENE$ (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.
9753	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (@GENE$)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-a) production by these cells.
9754	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced @GENE$ (TNF-a) production by these cells.
9755	CPRFalse	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and @CHEMICAL$ derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (@GENE$) production by these cells.
9756	CPRFalse	@CHEMICAL$ was shown to induce rapid oncosis in @GENE$-expressing cells.
9757	CPRFalse	We have shown that @CHEMICAL$ is more active in cells harboring epithelial phenotype with high @GENE$ and low vimentin expression.
9758	CPRFalse	We have shown that @CHEMICAL$ is more active in cells harboring epithelial phenotype with high E-cadherin and low @GENE$ expression.
9759	CPRFalse	In addition, high @CHEMICAL$ and Muc1 expression was correlated with sensitivity to @GENE$, whereas the presence of KRAS activating mutations was associated with resistance.
9760	CPRFalse	In addition, high ErbB3 and @CHEMICAL$ expression was correlated with sensitivity to @GENE$, whereas the presence of KRAS activating mutations was associated with resistance.
9761	CPRFalse	In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to @CHEMICAL$, whereas the presence of @GENE$ activating mutations was associated with resistance.
9762	CPR:4	In DU-PM cells with acquired resistance to @CHEMICAL$, @GENE$ expression was decreased, while Bcl2 was increased.
9763	CPR:3	In DU-PM cells with acquired resistance to @CHEMICAL$, ErbB3 expression was decreased, while @GENE$ was increased.
9764	CPRFalse	The use of peptide (@CHEM-GENE$) as ligands to stabilize and functionalize gold nanoparticles provides technical and operational convenience.
9765	CPRFalse	w-Agatoxin-IVA is a well known @CHEMICAL$ blocker and has been shown to affect presynaptic @GENE$ currents as well postsynaptic potentials.
9766	CPRFalse	@CHEMICAL$ is a well known P/Q-type Ca(2+) channel blocker and has been shown to affect presynaptic @GENE$ currents as well postsynaptic potentials.
9767	CPRFalse	w-Agatoxin-IVA is a well known @CHEM-GENE$ blocker and has been shown to affect presynaptic Ca(2+) currents as well postsynaptic potentials.
9768	CPRFalse	@CHEMICAL$ is a well known P/Q-type @GENE$ channel blocker and has been shown to affect presynaptic Ca(2+) currents as well postsynaptic potentials.
9769	CPRFalse	@CHEM-GENE$ play a vital role in presynaptic neurotransmitter release and thus play a role in action potential generation.
9770	CPR:4	Administration of @CHEMICAL$, a @GENE$ inhibitor, isolated a single response to w-agatoxin, which was characterized by a reduction in network activity.
9771	CPR:4	Administration of @CHEMICAL$, a GABAA inhibitor, isolated a single response to @GENE$, which was characterized by a reduction in network activity.
9772	CPRFalse	There was inconsistent stereological evidence of a loss of DA neurons, as identified by chromogenic or fluorescent-tagged antibodies to @CHEM-GENE$ in the substantia nigra pars compacta (SNpc).
9773	CPRFalse	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of @CHEMICAL$ stain or reduced immunolabeling of @GENE$-positive (TH(+)) neurons.
9774	CPRFalse	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of @CHEMICAL$ stain or reduced immunolabeling of tyrosine-hydroxylase-positive (@GENE$(+)) neurons.
9775	CPRFalse	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of silver stain or reduced immunolabeling of @CHEM-GENE$-positive (TH(+)) neurons.
9776	CPRFalse	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of silver stain or reduced immunolabeling of @CHEMICAL$-hydroxylase-positive (@GENE$(+)) neurons.
9777	CPRFalse	This study also suggests that even if the reduction in @CHEMICAL$(+) neurons reported by others occurs in PQ-treated mice, this apparent phenotypic change is unaccompanied by neuronal cell death or by modification of @GENE$ levels in the striatum.
9778	CPR:4	@CHEMICAL$-Containing @GENE$ Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.
9779	CPR:4	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9780	CPR:4	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9781	CPRFalse	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.
9782	CPRFalse	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the @CHEMICAL$ group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9783	CPR:4	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9784	CPR:4	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9785	CPRFalse	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.
9786	CPRFalse	Herein we report novel @CHEMICAL$- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9787	CPRFalse	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @CHEMICAL$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other @GENE$ effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9788	CPRFalse	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@CHEMICAL$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other @GENE$ effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9789	CPR:3	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other @CHEMICAL$ effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.
9790	CPRFalse	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @CHEMICAL$ at the nanomolar level, whereas the other @GENE$ effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9791	CPR:4	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9792	CPR:4	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9793	CPRFalse	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.
9794	CPRFalse	Herein we report novel pyrrole- and @CHEMICAL$-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9795	CPR:4	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9796	CPR:4	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9797	CPRFalse	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.
9798	CPRFalse	Herein we report novel pyrrole- and benzene-based @CHEMICAL$ (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9799	CPR:4	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as @GENE$ (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9800	CPR:4	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (@GENE$) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9801	CPRFalse	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in @GENE$ levels in human acute myeloid leukemia U937 cells.
9802	CPRFalse	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and @CHEMICAL$ (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited @GENE$ at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-a-tubulin levels in human acute myeloid leukemia U937 cells.
9803	CPR:4	Discovery of a synthetic @CHEMICAL$ inhibitor @GENE$ as a potential anticancer agent.
9804	CPR:4	@CHEMICAL$ is the first synthetic @GENE$ inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.
9805	CPR:4	As a potent synthetic @CHEMICAL$ inhibitor (IC50=850nM, versus @GENE$ of 8.1mM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.
9806	CPR:4	As a potent synthetic @CHEMICAL$ inhibitor (IC50=850nM, versus bestatin of 8.1mM), @GENE$ was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.
9807	CPR:4	As a potent synthetic @CHEMICAL$ inhibitor (IC50=850nM, versus bestatin of 8.1mM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than @GENE$.
9808	CPRFalse	Multipart Copolyelectrolyte Adhesive of the Sandcastle Worm, Phragmatopoma californica (Fewkes): @CHEMICAL$ Catalyzed Curing through Peptidyl-@GENE$.
9809	CPRFalse	Multipart Copolyelectrolyte Adhesive of the Sandcastle Worm, Phragmatopoma californica (Fewkes): @CHEM-GENE$ Catalyzed Curing through Peptidyl-DOPA.
9810	CPRFalse	Both types of granules contain @CHEM-GENE$ that catalyzes oxidative cross-linking of L-DOPA.
9811	CPR:9	Both types of granules contain @CHEMICAL$ that catalyzes oxidative cross-linking of @GENE$.
9812	CPRFalse	Co-secretion of @CHEM-GENE$ guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets.
9813	CPRFalse	@CHEM-GENE$ remains active long after the glue is fully cured, perhaps providing an active cue for conspecific larval settlement.
9814	CPRFalse	Disruption of AtWNK8 Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating @CHEMICAL$ Content and Activities of @GENE$ and Peroxidase.
9815	CPRFalse	Disruption of AtWNK8 Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating @CHEMICAL$ Content and Activities of Catalase and @GENE$.
9816	CPRFalse	Disruption of @CHEMICAL$ Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating @GENE$ Content and Activities of Catalase and Peroxidase.
9817	CPRFalse	@CHEM-GENE$ (WNKs) play important roles in plant growth and development.
9818	CPRFalse	With no @CHEMICAL$ kinases (@GENE$) play important roles in plant growth and development.
9819	CPRFalse	Here, we report that @CHEMICAL$ is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by @GENE$ and sorbitol treatment.
9820	CPRFalse	Here, we report that @CHEMICAL$ is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by NaCl and @GENE$ treatment.
9821	CPRFalse	Compared to the wild-type, the T-DNA knock-out @CHEMICAL$ mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the @GENE$ and sorbitol treatment, respectively.
9822	CPRFalse	Compared to the wild-type, the T-DNA knock-out @CHEMICAL$ mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the NaCl and @GENE$ treatment, respectively.
9823	CPRFalse	The @CHEMICAL$ mutant also accumulated 1.43-fold more @GENE$ than the wild-type in the sorbitol treatment.
9824	CPRFalse	The @CHEMICAL$ mutant also accumulated 1.43-fold more proline than the wild-type in the @GENE$ treatment.
9825	CPR:3	Under @CHEMICAL$ and sorbitol stresses, @GENE$ (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.
9826	CPR:3	Under @CHEMICAL$ and sorbitol stresses, catalase (@GENE$) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.
9827	CPRFalse	Under @CHEMICAL$ and sorbitol stresses, catalase (CAT) activity in @GENE$ mutant was 1.92- and 3.7-times of that in Col-0, respectively.
9828	CPR:3	Under NaCl and @CHEMICAL$ stresses, @GENE$ (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.
9829	CPR:3	Under NaCl and @CHEMICAL$ stresses, catalase (@GENE$) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.
9830	CPRFalse	Under NaCl and @CHEMICAL$ stresses, catalase (CAT) activity in @GENE$ mutant was 1.92- and 3.7-times of that in Col-0, respectively.
9831	CPRFalse	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @CHEMICAL$ and higher activities of @GENE$ and POD might result in the higher tolerance of WNK8 to osmotic stress.
9832	CPRFalse	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @CHEMICAL$ and higher activities of CAT and @GENE$ might result in the higher tolerance of WNK8 to osmotic stress.
9833	CPRFalse	Taken together, we revealed that maintaining higher @CHEMICAL$ and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @GENE$ and higher activities of CAT and POD might result in the higher tolerance of WNK8 to osmotic stress.
9834	CPRFalse	Taken together, we revealed that maintaining higher CAT and @CHEMICAL$ activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @GENE$ and higher activities of CAT and POD might result in the higher tolerance of WNK8 to osmotic stress.
9835	CPRFalse	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of @CHEMICAL$ enhances the tolerance to salt stress, and accumulating more @GENE$ and higher activities of CAT and POD might result in the higher tolerance of WNK8 to osmotic stress.
9836	CPRFalse	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more @CHEMICAL$ and higher activities of CAT and POD might result in the higher tolerance of @GENE$ to osmotic stress.
9837	CPR:4	Immunofluorescence staining and western blotting demonstrated that @CHEMICAL$ treatment reduced GFAP and @GENE$ expression in the retinas of OLETF rats.
9838	CPR:4	Immunofluorescence staining and western blotting demonstrated that @CHEMICAL$ treatment reduced @GENE$ and VEGF expression in the retinas of OLETF rats.
9839	CPR:5	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEMICAL$ (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and @GENE$) without or with 0.5M (0.5MAhR).
9840	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (@CHEMICAL$) agonists (non-ortho PCBs, PC-dibenzodioxins and @GENE$) without or with 0.5M (0.5MAhR).
9841	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and @CHEMICAL$) without or with 0.5M (0.5M@GENE$).
9842	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEM-GENE$ (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).
9843	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl @CHEMICAL$ receptor (@GENE$) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).
9844	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl @CHEMICAL$ receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5M@GENE$).
9845	CPR:5	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEMICAL$ (AhR) agonists (@GENE$s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).
9846	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (@CHEMICAL$) agonists (@GENE$s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).
9847	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (@CHEMICAL$s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5M@GENE$).
9848	CPR:5	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of @CHEMICAL$ (AhR) agonists (non-ortho PCBs, @GENE$ and PC-dibenzofurans) without or with 0.5M (0.5MAhR).
9849	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (@CHEMICAL$) agonists (non-ortho PCBs, @GENE$ and PC-dibenzofurans) without or with 0.5M (0.5MAhR).
9850	CPRFalse	At birth, some control (C) and M litters were cross-fostered to create four groups with the following in utero/postnatal exposure: C/C, M/C, C/M, M/M. Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, @CHEMICAL$ and PC-dibenzofurans) without or with 0.5M (0.5M@GENE$).
9851	CPRFalse	Phlebotomy and dietary @CHEMICAL$ restriction reduces @GENE$ in NAFLD/NASH patients.
9852	CPRFalse	Hepatic mRNA expression of @CHEMICAL$, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.
9853	CPRFalse	Hepatic mRNA expression of transferrin receptor 1 and 2, @CHEMICAL$, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.
9854	CPRFalse	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and @CHEMICAL$ were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.
9855	CPRFalse	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, @CHEMICAL$, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.
9856	CPRFalse	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, @CHEMICAL$, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.
9857	CPRFalse	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and @CHEMICAL$ mRNA levels were increased in CE compared to C. In Experiment 2, hepatic @GENE$ concentrations were higher in HIE than HI.
9858	CPRFalse	Although the @CHEMICAL$ deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (androgen receptor, @GENE$, Rab11A).
9859	CPRFalse	Although the @CHEMICAL$ deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@GENE$, calmodulin, Rab11A).
9860	CPRFalse	Although the @CHEMICAL$ deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (androgen receptor, calmodulin, @GENE$).
9861	CPRFalse	Although the androgen deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@CHEMICAL$ receptor, @GENE$, Rab11A).
9862	CPRFalse	Although the androgen deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@CHEM-GENE$, calmodulin, Rab11A).
9863	CPRFalse	Although the androgen deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (@CHEMICAL$ receptor, calmodulin, @GENE$).
9864	CPR:4	Discovery of a series of novel @CHEMICAL$, as potent JAK3 @GENE$ inhibitors.
9865	CPR:4	Discovery of a series of novel @CHEMICAL$, as potent @GENE$ kinase inhibitors.
9866	CPR:4	We report the discovery of a novel series of ATP-competitive @CHEMICAL$ (JAK3) inhibitors based on the @GENE$ scaffold.
9867	CPR:4	We report the discovery of a novel series of ATP-competitive Janus kinase 3 (@CHEMICAL$) inhibitors based on the @GENE$ scaffold.
9868	CPRFalse	We report the discovery of a novel series of @CHEMICAL$-competitive @GENE$ (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold.
9869	CPRFalse	We report the discovery of a novel series of @CHEMICAL$-competitive Janus kinase 3 (@GENE$) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold.
9870	CPR:4	@CHEMICAL$ depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of @GENE$ pathway.
9871	CPR:4	@CHEMICAL$ inhibited the phosphorylation and activation of AKT and STAT3 through @GENE$ signaling blockade.
9872	CPR:4	@CHEMICAL$ inhibited the phosphorylation and activation of @GENE$ and STAT3 through Notch signaling blockade.
9873	CPR:4	@CHEMICAL$ inhibited the phosphorylation and activation of AKT and @GENE$ through Notch signaling blockade.
9874	CPR:4	These data show that the @CHEMICAL$ is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of @GENE$ pathway.
9875	CPRFalse	Here, we quantified expression of @CHEMICAL$ and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.
9876	CPRFalse	Here, we quantified expression of INSL3 and its receptor @CHEMICAL$ in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.
9877	CPRFalse	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). @CHEMICAL$ and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.
9878	CPRFalse	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and @CHEMICAL$ mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.
9879	CPRFalse	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with @CHEMICAL$ peaking in large (11-18 mm) @GENE$-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.
9880	CPRFalse	Here, we quantified expression of INSL3 and its receptor RXFP2 in theca interna cell (TIC) and granulosa cell compartments of developing bovine antral follicles and in corpora lutea (CL). INSL3 and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) @CHEMICAL$-active follicles and @GENE$ peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.
9881	CPRFalse	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of @CHEMICAL$ greatly attenuated expression of both INSL3 and its receptor while increasing @GENE$ secretion and expression of STAR and CYP11A1.
9882	CPRFalse	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both @CHEMICAL$ and its receptor while increasing @GENE$ secretion and expression of STAR and CYP11A1.
9883	CPRFalse	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both INSL3 and its receptor while increasing @CHEMICAL$ secretion and expression of @GENE$ and CYP11A1.
9884	CPRFalse	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both INSL3 and its receptor while increasing @CHEMICAL$ secretion and expression of STAR and @GENE$.
9885	CPRFalse	Moreover, in vivo, a significant cyclic variation in plasma INSL3 was observed during synchronized estrous cycles. INSL3 and @CHEMICAL$ followed a similar pattern, both increasing after luteolysis, before falling sharply after the @GENE$ surge.
9886	CPRFalse	Moreover, in vivo, a significant cyclic variation in plasma INSL3 was observed during synchronized estrous cycles. @CHEMICAL$ and @GENE$ followed a similar pattern, both increasing after luteolysis, before falling sharply after the LH surge.
9887	CPRFalse	Moreover, in vivo, a significant cyclic variation in plasma @CHEMICAL$ was observed during synchronized estrous cycles. INSL3 and @GENE$ followed a similar pattern, both increasing after luteolysis, before falling sharply after the LH surge.
9888	CPRFalse	Genomic variation in the @CHEMICAL$ gene is associated with b-thalassemia disease severity and @GENE$ treatment efficacy.
9889	CPRFalse	Aim: In this study we explored the association between genetic variations in MAP3K5 and @CHEMICAL$ genes, residing on chromosome 6q23, and disease severity in b-hemoglobinopathy patients, as well as the association between these variants with response to @GENE$ (HU) treatment.
9890	CPRFalse	Aim: In this study we explored the association between genetic variations in @CHEMICAL$ and PDE7B genes, residing on chromosome 6q23, and disease severity in b-hemoglobinopathy patients, as well as the association between these variants with response to @GENE$ (HU) treatment.
9891	CPR:4	The high fat diet significantly increased hepatic mRNA expressions of @CHEMICAL$, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with @GENE$.
9892	CPR:4	The high fat diet significantly increased hepatic mRNA expressions of PPARg, @CHEMICAL$ and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with @GENE$.
9893	CPR:4	The high fat diet significantly increased hepatic mRNA expressions of PPARg, SREBP1C and @CHEMICAL$ genes in comparison to the control diet, which was subsequently reversed by supplementation with @GENE$.
9894	CPR:4	In addition, @CHEMICAL$ supplementation significantly reduced hepatic mRNA abundance of @GENE$, ATPCL and G6Pase compared to the control group.
9895	CPR:4	In addition, @CHEMICAL$ supplementation significantly reduced hepatic mRNA abundance of FAS, @GENE$ and G6Pase compared to the control group.
9896	CPR:4	In addition, @CHEMICAL$ supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and @GENE$ compared to the control group.
9897	CPR:3	Finally, epididymal mRNA abundance of @CHEMICAL$ was significantly increased by @GENE$ supplementation, compared to levels in the control and HF groups.
9898	CPR:3	Enhancement of @CHEMICAL$ expression by @GENE$ was further confirmed in differentiated 3T3-L1 adipocytes.
9899	CPRFalse	Discovery of @CHEMICAL$: The first sub-micromolar, selective @GENE$ PAM.
9900	CPRFalse	This Letter describes the further chemical optimization of the @CHEMICAL$ PAM MLPCN probes @GENE$ and ML172.
9901	CPRFalse	This Letter describes the further chemical optimization of the @CHEMICAL$ PAM MLPCN probes ML129 and @GENE$.
9902	CPRFalse	An HTS campaign identified several weak @CHEMICAL$ PAMs (M5 EC50 >10mM) with a structurally related @GENE$ core that possessed a southern phenethyl ether linkage.
9903	CPRFalse	An HTS campaign identified several weak M5 PAMs (@CHEMICAL$ EC50 >10mM) with a structurally related @GENE$ core that possessed a southern phenethyl ether linkage.
9904	CPRFalse	An HTS campaign identified several weak @CHEMICAL$ PAMs (M5 EC50 >10mM) with a structurally related isatin core that possessed a southern @GENE$ linkage.
9905	CPRFalse	An HTS campaign identified several weak M5 PAMs (@CHEMICAL$ EC50 >10mM) with a structurally related isatin core that possessed a southern @GENE$ linkage.
9906	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (@CHEMICAL$), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9907	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (@CHEMICAL$), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9908	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar @CHEMICAL$ PAM, ML326 (@GENE$), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9909	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @CHEMICAL$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the @GENE$ CRC.
9910	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @CHEMICAL$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the @GENE$ CRC.
9911	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar @CHEMICAL$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the @GENE$ CRC.
9912	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the @CHEMICAL$ linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9913	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the @CHEMICAL$ linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9914	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the @CHEMICAL$ linkage onto the ML129/ML172 cores led to the first sub-micromolar @GENE$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9915	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the @CHEMICAL$/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9916	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the @CHEMICAL$/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9917	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the @CHEMICAL$/ML172 cores led to the first sub-micromolar @GENE$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9918	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/@CHEMICAL$ cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9919	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/@CHEMICAL$ cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9920	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/@CHEMICAL$ cores led to the first sub-micromolar @GENE$ PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9921	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, @CHEMICAL$ (VU0467903), (human and rat @GENE$ EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9922	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, @CHEMICAL$ (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent @GENE$ selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9923	CPRFalse	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar @CHEMICAL$ PAM, @GENE$ (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30mM) and a robust 20-fold leftward shift of the ACh CRC.
9924	CPRFalse	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in @CHEMICAL$(-/-) mice also lacking adaptive immunity (T-bet(-/-)xRag2(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.
9925	CPRFalse	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (@CHEMICAL$(-/-)xRag2(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.
9926	CPRFalse	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (T-bet(-/-)x@CHEMICAL$(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.
9927	CPRFalse	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (T-bet(-/-)xRag2(-/-)), demonstrating that @CHEMICAL$ expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.
9928	CPRFalse	However, the favorable metabolic phenotype observed in @CHEMICAL$-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (T-bet(-/-)xRag2(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host @GENE$ homeostasis.
9929	CPR:4	Western blot assay demonstrated that @CHEMICAL$ decreased @GENE$ level and induced Bax translocation to cause cytochrome c release.
9930	CPR:3	Western blot assay demonstrated that @CHEMICAL$ decreased Bcl-2 level and induced @GENE$ translocation to cause cytochrome c release.
9931	CPR:3	Western blot assay demonstrated that @CHEMICAL$ decreased Bcl-2 level and induced Bax translocation to cause @GENE$ release.
9932	CPRFalse	Meanwhile, the alterations of @CHEMICAL$, p-CDK1 and p-cdc25c levels were also observed in response to @GENE$ treatment.
9933	CPRFalse	Meanwhile, the alterations of cyclin A and B1, @CHEMICAL$ and p-cdc25c levels were also observed in response to @GENE$ treatment.
9934	CPRFalse	Meanwhile, the alterations of cyclin A and B1, p-CDK1 and @CHEMICAL$ levels were also observed in response to @GENE$ treatment.
9935	CPR:3	@CHEMICAL$ and rutin also increased @GENE$ activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).
9936	CPR:3	Quercetin and @CHEMICAL$ also increased @GENE$ activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).
9937	CPR:3	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like @GENE$, osterix, RunX2, osteoprotegerin and osteocalcin.
9938	CPR:3	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, @GENE$, RunX2, osteoprotegerin and osteocalcin.
9939	CPR:3	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, @GENE$, osteoprotegerin and osteocalcin.
9940	CPR:3	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, @GENE$ and osteocalcin.
9941	CPR:3	Further, both the @CHEMICAL$ were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and @GENE$.
9942	CPRFalse	@CHEMICAL$-nitrosation of @GENE$ is controlled by the conformation of a dynamic active-site helix.
9943	CPRFalse	S-nitrosation of @CHEM-GENE$ is controlled by the conformation of a dynamic active-site helix.
9944	CPRFalse	We used transient kinetic methods to determine a minimal mechanism for spontaneous GSNO-mediated transnitrosation of @CHEM-GENE$, a major detoxification enzyme and key regulator of cell proliferation.
9945	CPRFalse	C47 of @CHEMICAL$ is @GENE$-nitrosated in two steps, with the chemical step limited by a pre-equilibrium between the open and closed conformations of helix a2 at the active site.
9946	CPRFalse	Despite the presence of a @CHEMICAL$ at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using @GENE$ demonstrate that GSNO binding does not precede S-nitrosation of GSTP1-1.
9947	CPRFalse	Despite the presence of a GSNO binding site at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using @CHEMICAL$ demonstrate that GSNO binding does not precede S-nitrosation of @GENE$.
9948	CPRFalse	Despite the presence of a GSNO binding site at the active site of @CHEMICAL$, isothermal titration calorimetry as well as nitrosation experiments using @GENE$ demonstrate that GSNO binding does not precede S-nitrosation of GSTP1-1.
9949	CPRFalse	Despite the presence of a @CHEMICAL$ at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede @GENE$-nitrosation of GSTP1-1.
9950	CPRFalse	Despite the presence of a GSNO binding site at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede @CHEMICAL$-nitrosation of @GENE$.
9951	CPRFalse	Despite the presence of a GSNO binding site at the active site of @CHEMICAL$, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede @GENE$-nitrosation of GSTP1-1.
9952	CPRFalse	@CHEM-GENE$ (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9953	CPRFalse	@CHEMICAL$ aminotransferase (@GENE$), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9954	CPRFalse	@CHEMICAL$ aminotransferase (ALT), @GENE$ (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9955	CPRFalse	@CHEMICAL$ aminotransferase (ALT), Aspartate aminotransferase (@GENE$), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9956	CPRFalse	@CHEMICAL$ aminotransferase (ALT), Aspartate aminotransferase (AST), @GENE$ (ALP), Bilirubin were measured in serum.
9957	CPRFalse	@CHEMICAL$ aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (@GENE$), Bilirubin were measured in serum.
9958	CPRFalse	@CHEMICAL$ (ALT), @GENE$ aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9959	CPRFalse	Alanine aminotransferase (@CHEMICAL$), @GENE$ aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9960	CPRFalse	Alanine aminotransferase (ALT), @CHEM-GENE$ (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9961	CPRFalse	Alanine aminotransferase (ALT), @CHEMICAL$ aminotransferase (@GENE$), Alkaline phosphatase (ALP), Bilirubin were measured in serum.
9962	CPRFalse	Alanine aminotransferase (ALT), @CHEMICAL$ aminotransferase (AST), @GENE$ (ALP), Bilirubin were measured in serum.
9963	CPRFalse	Alanine aminotransferase (ALT), @CHEMICAL$ aminotransferase (AST), Alkaline phosphatase (@GENE$), Bilirubin were measured in serum.
9964	CPRFalse	@CHEMICAL$ (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), @GENE$ were measured in serum.
9965	CPRFalse	Alanine aminotransferase (@CHEMICAL$), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), @GENE$ were measured in serum.
9966	CPRFalse	Alanine aminotransferase (ALT), @CHEMICAL$ (AST), Alkaline phosphatase (ALP), @GENE$ were measured in serum.
9967	CPRFalse	Alanine aminotransferase (ALT), Aspartate aminotransferase (@CHEMICAL$), Alkaline phosphatase (ALP), @GENE$ were measured in serum.
9968	CPRFalse	Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), @CHEMICAL$ (ALP), @GENE$ were measured in serum.
9969	CPRFalse	Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (@CHEMICAL$), @GENE$ were measured in serum.
9970	CPRFalse	@CHEMICAL$ (HP), lipid peroxidation (LPO), catalase (CAT), @GENE$ (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9971	CPRFalse	@CHEMICAL$ (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (@GENE$) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9972	CPRFalse	@CHEMICAL$ (HP), lipid peroxidation (LPO), @GENE$ (CAT), Glutathione peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9973	CPRFalse	@CHEMICAL$ (HP), lipid peroxidation (LPO), catalase (@GENE$), Glutathione peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9974	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEM-GENE$ (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9975	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEMICAL$ peroxidase (@GENE$) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9976	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), @CHEMICAL$ (CAT), @GENE$ peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9977	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (@CHEMICAL$), @GENE$ peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.
9978	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEMICAL$ (GPx) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.
9979	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (@CHEMICAL$) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.
9980	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), @CHEMICAL$ (CAT), Glutathione peroxidase (GPx) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.
9981	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (@CHEMICAL$), Glutathione peroxidase (GPx) and @GENE$ (GSH) were determined in liver samples by colorimetric methods.
9982	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), @CHEMICAL$ (GPx) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.
9983	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (@CHEMICAL$) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.
9984	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), @CHEMICAL$ (CAT), Glutathione peroxidase (GPx) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.
9985	CPRFalse	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (@CHEMICAL$), Glutathione peroxidase (GPx) and Glutathione (@GENE$) were determined in liver samples by colorimetric methods.
9986	CPR:9	@CHEMICAL$ (CYP 450 2E1), activity was determined as hydroxylation of @GENE$ in liver microsomes.
9987	CPR:9	Cytochrome P450 2E1 (@CHEMICAL$), activity was determined as hydroxylation of @GENE$ in liver microsomes.
9988	CPRFalse	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and @GENE$) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9989	CPRFalse	Serum markers of liver damage (AST, @CHEMICAL$, ALP and @GENE$) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9990	CPRFalse	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and @GENE$) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9991	CPR:3	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and Bilirubin) were increased by @GENE$ and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9992	CPR:3	Serum markers of liver damage (AST, @CHEMICAL$, ALP and Bilirubin) were increased by @GENE$ and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9993	CPR:3	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and Bilirubin) were increased by @GENE$ and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9994	CPR:3	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and Bilirubin) were increased by CCl4 and @GENE$ intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9995	CPR:3	Serum markers of liver damage (AST, @CHEMICAL$, ALP and Bilirubin) were increased by CCl4 and @GENE$ intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9996	CPR:3	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and Bilirubin) were increased by CCl4 and @GENE$ intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).
9997	CPR:4	Serum markers of liver damage (@CHEMICAL$, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with @GENE$ reversed such changes (p<0.001).
9998	CPR:4	Serum markers of liver damage (AST, @CHEMICAL$, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with @GENE$ reversed such changes (p<0.001).
9999	CPR:4	Serum markers of liver damage (AST, ALT, @CHEMICAL$ and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with @GENE$ reversed such changes (p<0.001).
10000	CPRFalse	LPO was increased while as @CHEMICAL$, CAT and @GENE$ decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001).
10001	CPRFalse	LPO was increased while as @CHEMICAL$, @GENE$ and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001).
10002	CPR:3	LPO was increased while as GSH, CAT and @CHEMICAL$ decreased by the administration of CCl4 and TAA (p<0.001); co-administration of @GENE$ restored these liver markers to normal levels (p<0.001).
10003	CPR:3	LPO was increased while as GSH, @CHEMICAL$ and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of @GENE$ restored these liver markers to normal levels (p<0.001).
10004	CPR:3	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory @CHEMICAL$, IL-6 and IL-8, caused by a mixture of @GENE$ representative of a high cholesterol diet.
10005	CPR:3	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, @CHEMICAL$ and IL-8, caused by a mixture of @GENE$ representative of a high cholesterol diet.
10006	CPR:3	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and @CHEMICAL$, caused by a mixture of @GENE$ representative of a high cholesterol diet.
10007	CPR:3	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory @CHEMICAL$, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high @GENE$ diet.
10008	CPR:3	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, @CHEMICAL$ and IL-8, caused by a mixture of oxysterols representative of a high @GENE$ diet.
10009	CPR:3	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and @CHEMICAL$, caused by a mixture of oxysterols representative of a high @GENE$ diet.
10010	CPRFalse	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive @CHEMICAL$ species through the colonic @GENE$ NOX1 activation.
10011	CPRFalse	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive @CHEMICAL$ species through the colonic NADPH-oxidase @GENE$ activation.
10012	CPRFalse	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive oxygen species through the colonic @CHEM-GENE$ NOX1 activation.
10013	CPRFalse	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive oxygen species through the colonic @CHEMICAL$-oxidase @GENE$ activation.
10014	CPR:3	@CHEMICAL$-dependent NOX1 activation, as well as @GENE$ synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.
10015	CPR:3	@CHEMICAL$-dependent @GENE$ activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.
10016	CPR:4	Oxysterol-dependent NOX1 activation, as well as @CHEMICAL$ synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular @GENE$ and flavonoids.
10017	CPR:4	Oxysterol-dependent @CHEMICAL$ activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular @GENE$ and flavonoids.
10018	CPR:4	Oxysterol-dependent NOX1 activation, as well as @CHEMICAL$ synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and @GENE$.
10019	CPR:4	Oxysterol-dependent @CHEMICAL$ activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and @GENE$.
10020	CPR:3	Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in @CHEMICAL$ synthesis induced by dietary @GENE$.
10021	CPR:3	Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial @CHEMICAL$ down-regulation and was ineffective in interleukin synthesis induced by dietary @GENE$.
10022	CPRFalse	Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related @CHEMICAL$ induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary @GENE$.
10023	CPR:4	Besides this direct activity, an excess of @CHEMICAL$ compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related @GENE$ induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.
10024	CPR:3	Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking @CHEMICAL$-related @GENE$ induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.
10025	CPRFalse	A physiologically-based pharmacokinetic model was used to quantitatively predict the impact of @CHEMICAL$ on sensitive CYP3A4 substrates. Elevated @GENE$ AUC in virtual rheumatoid arthritis patients, following 100 pg/mL of IL-6 was comparable to observed clinical data (59% versus 58%).
10026	CPRFalse	A physiologically-based pharmacokinetic model was used to quantitatively predict the impact of IL-6 on sensitive @CHEMICAL$ substrates. Elevated @GENE$ AUC in virtual rheumatoid arthritis patients, following 100 pg/mL of IL-6 was comparable to observed clinical data (59% versus 58%).
10027	CPRFalse	A physiologically-based pharmacokinetic model was used to quantitatively predict the impact of IL-6 on sensitive CYP3A4 substrates. Elevated @CHEMICAL$ AUC in virtual rheumatoid arthritis patients, following 100 pg/mL of @GENE$ was comparable to observed clinical data (59% versus 58%).
10028	CPRFalse	In virtual bone marrow transplant (BMT) patients, 500 pg/ml of @CHEMICAL$ resulted in increase in @GENE$ AUC that was in good agreement with the observed data (45% versus 39%).
10029	CPRFalse	In a different group of BMT patients treated with @CHEMICAL$, the magnitude of interaction with @GENE$ was under predicted ~3-fold.
10030	CPRFalse	A DPYD Variant (@CHEMICAL$) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. @GENE$ (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.
10031	CPRFalse	A @CHEMICAL$ Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. @GENE$ (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.
10032	CPRFalse	A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced @CHEMICAL$ Enzyme Activity. @GENE$ (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.
10033	CPRFalse	A DPYD Variant (@CHEMICAL$) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. 5-Fluorouracil (@GENE$) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.
10034	CPRFalse	A @CHEMICAL$ Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity. 5-Fluorouracil (@GENE$) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.
10035	CPRFalse	A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced @CHEMICAL$ Enzyme Activity. 5-Fluorouracil (@GENE$) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.
10036	CPRFalse	The responses to @CHEMICAL$, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @GENE$ (DPD, encoded by the DPYD gene).
10037	CPRFalse	The responses to @CHEMICAL$, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (@GENE$, encoded by the DPYD gene).
10038	CPRFalse	The responses to @CHEMICAL$, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the @GENE$ gene).
10039	CPRFalse	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @CHEM-GENE$ (DPD, encoded by the DPYD gene).
10040	CPRFalse	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @CHEMICAL$ dehydrogenase (@GENE$, encoded by the DPYD gene).
10041	CPRFalse	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme @CHEMICAL$ dehydrogenase (DPD, encoded by the @GENE$ gene).
10042	CPRFalse	The DPYD-@CHEMICAL$ variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 + 35 vs. 514 + 168 pmol @GENE$ min(-1) mg(-1); P = 0.00029).
10043	CPRFalse	The @CHEMICAL$-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 + 35 vs. 514 + 168 pmol @GENE$ min(-1) mg(-1); P = 0.00029).
10044	CPRFalse	The DPYD-Y186C variant was unique to individuals of African ancestry, and @CHEMICAL$ activity was 46% lower in carriers as compared with noncarriers (279 + 35 vs. 514 + 168 pmol @GENE$ min(-1) mg(-1); P = 0.00029).
10045	CPRFalse	In this study, 26% of the African Americans with reduced DPD activity were carriers of @CHEMICAL$. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.
10046	CPRFalse	In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding @CHEMICAL$ carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.
10047	CPRFalse	In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of @CHEMICAL$ showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.
10048	CPRFalse	In this study, 26% of the African Americans with reduced @CHEMICAL$ activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.
10049	CPRFalse	In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher @CHEMICAL$ activity as compared with noncarriers (609 + 152 and 480 + 152 pmol @GENE$ min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013.
10050	CPR:3	@CHEMICAL$ inhibits autophagic flux activating the @GENE$-Keap1 pathway in a p62-dependent manner.
10051	CPR:3	@CHEMICAL$ inhibits autophagic flux activating the Nrf2-@GENE$ pathway in a p62-dependent manner.
10052	CPRFalse	@CHEMICAL$ inhibits autophagic flux activating the Nrf2-Keap1 pathway in a @GENE$-dependent manner.
10053	CPR:4	@CHEMICAL$ deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and @GENE$.
10054	CPR:4	@CHEMICAL$ deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of @GENE$, Keap1, and LC3.
10055	CPR:4	@CHEMICAL$ deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, @GENE$, and LC3.
10056	CPR:3	Thus, @CHEMICAL$ activates @GENE$ through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2.
10057	CPRFalse	Thus, @CHEMICAL$ activates Nrf2 through a non-canonical mechanism (@GENE$-dependent), leading to a chronic, sustained activation of Nrf2.
10058	CPR:3	Thus, @CHEMICAL$ activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of @GENE$.
10059	CPR:3	In contrast, activation of @CHEMICAL$ by @GENE$ and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).
10060	CPRFalse	In contrast, activation of Nrf2 by @CHEMICAL$ and tert-butylhydroquinone depend upon @GENE$-C151 and not p62 (the canonical mechanism).
10061	CPRFalse	In contrast, activation of Nrf2 by @CHEMICAL$ and tert-butylhydroquinone depend upon Keap1-C151 and not @GENE$ (the canonical mechanism).
10062	CPR:3	In contrast, activation of @CHEMICAL$ by sulforaphane and @GENE$ depend upon Keap1-C151 and not p62 (the canonical mechanism).
10063	CPRFalse	In contrast, activation of Nrf2 by sulforaphane and @CHEMICAL$ depend upon @GENE$-C151 and not p62 (the canonical mechanism).
10064	CPRFalse	In contrast, activation of Nrf2 by sulforaphane and @CHEMICAL$ depend upon Keap1-C151 and not @GENE$ (the canonical mechanism).
10065	CPR:3	Collectively, these findings provide evidence that @CHEMICAL$ causes prolonged activation of @GENE$ through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers.
10066	CPR:3	Collectively, these findings provide evidence that @CHEMICAL$ causes prolonged activation of Nrf2 through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of @GENE$ found in certain human cancers.
10067	CPRFalse	@CHEMICAL$ and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.
10068	CPRFalse	Melatonin and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate @CHEM-GENE$ in the ovaries, oviducts, and uteri of adult rats.
10069	CPRFalse	Melatonin and @CHEMICAL$ intake exert opposite effects on circulating estradiol and progesterone and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.
10070	CPRFalse	Melatonin and ethanol intake exert opposite effects on circulating @CHEMICAL$ and progesterone and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.
10071	CPRFalse	Melatonin and ethanol intake exert opposite effects on circulating estradiol and @CHEMICAL$ and differentially regulate @GENE$ in the ovaries, oviducts, and uteri of adult rats.
10072	CPRFalse	We report the effects of ethanol intake and @CHEMICAL$ treatment (at doses of 100mg/100gBW/day) on sex hormones and @GENE$ in the ovaries, oviducts and uteri of ethanol-preferring rats.
10073	CPRFalse	We report the effects of ethanol intake and melatonin treatment (at doses of 100mg/100gBW/day) on sex hormones and @CHEM-GENE$ in the ovaries, oviducts and uteri of ethanol-preferring rats.
10074	CPRFalse	We report the effects of ethanol intake and melatonin treatment (at doses of 100mg/100gBW/day) on sex hormones and @CHEMICAL$ in the ovaries, oviducts and uteri of @GENE$-preferring rats.
10075	CPRFalse	We report the effects of @CHEMICAL$ intake and melatonin treatment (at doses of 100mg/100gBW/day) on sex hormones and @GENE$ in the ovaries, oviducts and uteri of ethanol-preferring rats.
10076	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10077	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10078	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).
10079	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).
10080	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).
10081	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).
10082	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEMICAL$, estrogen, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).
10083	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10084	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10085	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).
10086	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).
10087	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).
10088	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).
10089	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, @CHEMICAL$, progesterone and melatonin receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).
10090	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10091	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10092	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).
10093	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).
10094	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).
10095	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).
10096	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, @CHEMICAL$ and melatonin receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).
10097	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate @CHEM-GENE$ subunits (AR, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10098	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (@GENE$, ER-a and ER-b, PRA, PRB and MT1R, respectively).
10099	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, @GENE$ and ER-b, PRA, PRB and MT1R, respectively).
10100	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and @GENE$, PRA, PRB and MT1R, respectively).
10101	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and ER-b, @GENE$, PRB and MT1R, respectively).
10102	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and ER-b, PRA, @GENE$ and MT1R, respectively).
10103	CPRFalse	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and @CHEMICAL$ receptor subunits (AR, ER-a and ER-b, PRA, PRB and @GENE$, respectively).
10104	CPRFalse	Ovarian @CHEMICAL$ was not influenced by either treatment, and oviduct AR was reduced after @GENE$-melatonin combination.
10105	CPR:4	Ovarian AR was not influenced by either treatment, and oviduct @CHEMICAL$ was reduced after @GENE$-melatonin combination.
10106	CPRFalse	Ovarian @CHEMICAL$ was not influenced by either treatment, and oviduct AR was reduced after ethanol-@GENE$ combination.
10107	CPR:4	Ovarian AR was not influenced by either treatment, and oviduct @CHEMICAL$ was reduced after ethanol-@GENE$ combination.
10108	CPR:4	Oviduct @CHEMICAL$, ER-b and uterine ER-b were down-regulated by either @GENE$ or melatonin.
10109	CPR:4	Oviduct ER-a, @CHEMICAL$ and uterine ER-b were down-regulated by either @GENE$ or melatonin.
10110	CPR:4	Oviduct ER-a, ER-b and uterine @CHEMICAL$ were down-regulated by either @GENE$ or melatonin.
10111	CPR:4	Oviduct @CHEMICAL$, ER-b and uterine ER-b were down-regulated by either ethanol or @GENE$.
10112	CPR:4	Oviduct ER-a, @CHEMICAL$ and uterine ER-b were down-regulated by either ethanol or @GENE$.
10113	CPR:4	Oviduct ER-a, ER-b and uterine @CHEMICAL$ were down-regulated by either ethanol or @GENE$.
10114	CPRFalse	Conversely, ovarian PRA and PRB were positively regulated by @CHEMICAL$ and ethanol-melatonin combination, whereas @GENE$ was down-regulated in the uterus and oviduct after ethanol consumption.
10115	CPRFalse	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by @GENE$ and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.
10116	CPRFalse	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by @GENE$ and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.
10117	CPRFalse	Conversely, ovarian PRA and PRB were positively regulated by ethanol and @CHEMICAL$-melatonin combination, whereas @GENE$ was down-regulated in the uterus and oviduct after ethanol consumption.
10118	CPRFalse	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by ethanol and @GENE$-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.
10119	CPRFalse	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by ethanol and @GENE$-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.
10120	CPRFalse	Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-@CHEMICAL$ combination, whereas @GENE$ was down-regulated in the uterus and oviduct after ethanol consumption.
10121	CPRFalse	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by ethanol and ethanol-@GENE$ combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.
10122	CPRFalse	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by ethanol and ethanol-@GENE$ combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.
10123	CPR:4	Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas @CHEMICAL$ was down-regulated in the uterus and oviduct after @GENE$ consumption.
10124	CPRFalse	Conversely, ovarian @CHEMICAL$ and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after @GENE$ consumption.
10125	CPRFalse	Conversely, ovarian PRA and @CHEMICAL$ were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after @GENE$ consumption.
10126	CPR:3	@CHEMICAL$ was increased in ovaries and uteri of @GENE$-treated rats.
10127	CPRFalse	@CHEMICAL$ and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of @GENE$ in female reproductive tissues.
10128	CPRFalse	Ethanol and @CHEMICAL$ exert opposite effects on E2 and P4, and they differentially regulate the expression of @GENE$ in female reproductive tissues.
10129	CPRFalse	Ethanol and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of @CHEM-GENE$ in female reproductive tissues.
10130	CPRFalse	Pha1b toxin prevents @CHEMICAL$-induced nociceptive behavior and mechanical hypersensitivity without acting on @GENE$ channels.
10131	CPRFalse	We also investigated the effect of Pha1b on @CHEMICAL$ transients in cultured dorsal root ganglia (DRG) neurons and HEK293 cells expressing the @GENE$ receptor.
10132	CPRFalse	Intraplantar or intrathecal administered Pha1b reduced both nocifensive behavior and mechanical hypersensitivity induced by @CHEMICAL$ similarly to that observed with SB366791, a specific @GENE$ antagonist.
10133	CPR:6	Intraplantar or intrathecal administered Pha1b reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with @CHEMICAL$, a specific @GENE$ antagonist.
10134	CPRFalse	In contrast, w-conotoxin MVIIA (a selective @CHEM-GENE$ blocker) was effective only when administered intrathecally.
10135	CPRFalse	Moreover, Pha1b did not inhibit @CHEMICAL$-activated currents in patch-clamp recordings of HEK293 cells that expressed @GENE$ receptors.
10136	CPRFalse	Rescue of @CHEMICAL$-damaged oocytes from programmed cell death through inactivation of the @GENE$ family signaling network.
10137	CPR:4	Recently, the c-Abl @CHEMICAL$ inhibitor @GENE$ (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.
10138	CPR:4	Recently, the @CHEMICAL$ kinase inhibitor @GENE$ (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.
10139	CPR:4	Recently, the c-Abl @CHEMICAL$ inhibitor imatinib mesylate (@GENE$) has become the focus of research as a fertoprotective drug against cisplatin.
10140	CPR:4	Recently, the @CHEMICAL$ kinase inhibitor imatinib mesylate (@GENE$) has become the focus of research as a fertoprotective drug against cisplatin.
10141	CPRFalse	Recently, the c-Abl @CHEMICAL$ inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against @GENE$.
10142	CPRFalse	Recently, the @CHEMICAL$ kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against @GENE$.
10143	CPR:3	We found that, before apoptosis, @CHEMICAL$ induces @GENE$ and TAp73 expression in the oocyte.
10144	CPR:3	We found that, before apoptosis, @CHEMICAL$ induces c-Abl and @GENE$ expression in the oocyte.
10145	CPRFalse	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of @GENE$, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10146	CPRFalse	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10147	CPRFalse	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10148	CPRFalse	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.
10149	CPRFalse	While @CHEMICAL$ was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.
10150	CPR:3	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of @GENE$, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10151	CPRFalse	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10152	CPRFalse	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10153	CPRFalse	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.
10154	CPRFalse	While imatinib was unable to block @CHEMICAL$-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.
10155	CPRFalse	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of @CHEMICAL$, @GENE$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10156	CPR:4	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10157	CPR:4	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10158	CPR:3	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.
10159	CPR:4	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, @CHEMICAL$ inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.
10160	CPRFalse	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of @CHEMICAL$, imatinib inhibited the @GENE$-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10161	CPR:3	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of @GENE$/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10162	CPR:3	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of c-Abl/@GENE$ and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.
10163	CPR:4	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of @GENE$ and upregulation of Bax, thereby abrogating oocyte cell death.
10164	CPR:3	While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the @CHEMICAL$-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of @GENE$, thereby abrogating oocyte cell death.
10165	CPRFalse	Surprisingly, the conditional deletion of @CHEM-GENE$, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin.
10166	CPRFalse	Surprisingly, the conditional deletion of @CHEMICAL$63, but not @GENE$, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin.
10167	CPRFalse	Surprisingly, the conditional deletion of @CHEMICAL$63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of @GENE$ and TAp73 caused by cisplatin.
10168	CPRFalse	Surprisingly, the conditional deletion of @CHEMICAL$63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and @GENE$ caused by cisplatin.
10169	CPRFalse	Surprisingly, the conditional deletion of @CHEMICAL$, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by @GENE$.
10170	CPRFalse	Surprisingly, the conditional deletion of Trp63, but not @CHEMICAL$, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by @GENE$.
10171	CPR:3	Surprisingly, the conditional deletion of Trp63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of @CHEMICAL$ and TAp73 caused by @GENE$.
10172	CPR:3	Surprisingly, the conditional deletion of Trp63, but not DNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and @CHEMICAL$ caused by @GENE$.
10173	CPRFalse	These data suggest that @CHEMICAL$ is the master regulator of @GENE$-induced oocyte death.
10174	CPRFalse	The expression kinetics of @CHEMICAL$, c-Abl and TAp73 suggest that @GENE$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.
10175	CPRFalse	The expression kinetics of TAp63, @CHEMICAL$ and TAp73 suggest that @GENE$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.
10176	CPRFalse	The expression kinetics of TAp63, c-Abl and @CHEMICAL$ suggest that @GENE$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.
10177	CPR:3	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates @GENE$-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.
10178	CPR:3	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of @GENE$ and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.
10179	CPR:3	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and @GENE$ and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.
10180	CPR:3	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of @GENE$ by c-Abl-induced BAX expression.
10181	CPR:3	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by @GENE$-induced BAX expression.
10182	CPR:3	The expression kinetics of TAp63, c-Abl and TAp73 suggest that @CHEMICAL$ activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced @GENE$ expression.
10183	CPR:3	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting c-Abl @GENE$, which would otherwise activate TAp73-BAX-mediated apoptosis.
10184	CPR:4	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting @GENE$ kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.
10185	CPR:4	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate @GENE$-BAX-mediated apoptosis.
10186	CPR:4	Our findings indicate that @CHEMICAL$ protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-@GENE$-mediated apoptosis.
10187	CPR:3	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting c-Abl @GENE$, which would otherwise activate TAp73-BAX-mediated apoptosis.
10188	CPR:3	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting @GENE$ kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.
10189	CPR:3	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting c-Abl kinase, which would otherwise activate @GENE$-BAX-mediated apoptosis.
10190	CPR:3	Our findings indicate that imatinib protects oocytes from @CHEMICAL$-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-@GENE$-mediated apoptosis.
10191	CPRFalse	Thus, imatinib and other c-Abl @CHEMICAL$ inhibitors provide an intriguing new way to halt @GENE$-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.
10192	CPRFalse	Thus, imatinib and other @CHEMICAL$ kinase inhibitors provide an intriguing new way to halt @GENE$-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.
10193	CPR:4	Thus, @CHEMICAL$ and other c-Abl @GENE$ inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.
10194	CPR:4	Thus, @CHEMICAL$ and other @GENE$ kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.
10195	CPRFalse	Suppression of @CHEMICAL$ expression is a common feature of @GENE$-resistant and manganese-resistant RBL-2H3 cells.
10196	CPRFalse	Suppression of @CHEMICAL$ expression is a common feature of cadmium-resistant and @GENE$-resistant RBL-2H3 cells.
10197	CPRFalse	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and @GENE$, respectively.
10198	CPRFalse	To clarify the roles of @CHEMICAL$ in hyperaccumulation of @GENE$ and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.
10199	CPRFalse	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and @GENE$ in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.
10200	CPRFalse	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, @GENE$-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.
10201	CPRFalse	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and @GENE$-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.
10202	CPRFalse	To clarify the roles of @CHEMICAL$ in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to @GENE$ and MnCl2, respectively.
10203	CPRFalse	RBL-Cdr cells also showed cross-resistance to @CHEMICAL$ and AgNO3 probably due to enhanced expression of @GENE$.
10204	CPRFalse	RBL-Cdr cells also showed cross-resistance to HgCl2 and @CHEMICAL$ probably due to enhanced expression of @GENE$.
10205	CPR:9	Among the possible transporters involved in the uptake of @CHEMICAL$ and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by @GENE$, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.
10206	CPR:9	Among the possible transporters involved in the uptake of @CHEMICAL$ and Mn(2+), the expression of @GENE$ (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.
10207	CPR:9	Among the possible transporters involved in the uptake of @CHEMICAL$ and Mn(2+), the expression of ZIP8 (@GENE$), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.
10208	CPR:9	Among the possible transporters involved in the uptake of Cd(2+) and @CHEMICAL$, the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by @GENE$, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.
10209	CPR:9	Among the possible transporters involved in the uptake of Cd(2+) and @CHEMICAL$, the expression of @GENE$ (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.
10210	CPR:9	Among the possible transporters involved in the uptake of Cd(2+) and @CHEMICAL$, the expression of ZIP8 (@GENE$), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.
10211	CPR:9	These results suggest that @CHEMICAL$ plays a pivotal role in the transport and toxicity of @GENE$ and Mn(2+) in RBL-2H3 cells.
10212	CPR:9	These results suggest that @CHEMICAL$ plays a pivotal role in the transport and toxicity of Cd(2+) and @GENE$ in RBL-2H3 cells.
10213	CPRFalse	In the present work we show that reduction sensitive and @CHEMICAL$-stable heteromers can be reconstituted in vitro by mixing proMMP-9 with either serglycin, versican or @GENE$ isolated from various monocytic cell lines.
10214	CPRFalse	In the present work we show that reduction sensitive and @CHEMICAL$-stable heteromers can be reconstituted in vitro by mixing @GENE$ with either serglycin, versican or CSPGs isolated from various monocytic cell lines.
10215	CPRFalse	In addition, a strong but @CHEMICAL$-soluble proMMP-9*@GENE$ heteromer was formed.
10216	CPRFalse	In addition, a strong but @CHEMICAL$-soluble @GENE$*CSPG heteromer was formed.
10217	CPRFalse	As for the heteromer isolated from THP-1 cells, the in vitro reconstituted @CHEMICAL$-stable and SDS-soluble heteromers had a weaker binding to gelatin than the @GENE$ monomer.
10218	CPRFalse	As for the heteromer isolated from THP-1 cells, the in vitro reconstituted SDS-stable and @CHEMICAL$-soluble heteromers had a weaker binding to gelatin than the @GENE$ monomer.
10219	CPRFalse	However, the presence of @CHEMICAL$ inhibited the formation of the @GENE$-soluble heteromer, but not the SDS-stable reduction sensitive heteromer.
10220	CPRFalse	However, the presence of @CHEMICAL$ inhibited the formation of the SDS-soluble heteromer, but not the @GENE$-stable reduction sensitive heteromer.
10221	CPR:4	Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of @CHEMICAL$ assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-@GENE$ moiety.
10222	CPR:4	Optimization of a @CHEMICAL$ series of @GENE$ assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety.
10223	CPR:4	Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of @CHEMICAL$ inhibitors of @GENE$ (CA) assembly are described.
10224	CPR:4	Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of @CHEMICAL$ inhibitors of HIV capsid (@GENE$) assembly are described.
10225	CPRFalse	Detailed structure-activity relationships of the C3-@CHEMICAL$ moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of @GENE$ (CA) assembly are described.
10226	CPRFalse	Detailed structure-activity relationships of the C3-@CHEMICAL$ moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of HIV capsid (@GENE$) assembly are described.
10227	CPRFalse	The present work evaluated the effects of nicotine (@CHEMICAL$), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10228	CPRFalse	The present work evaluated the effects of nicotine (@CHEMICAL$), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10229	CPRFalse	The present work evaluated the effects of nicotine (NIC), @CHEMICAL$ (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10230	CPRFalse	The present work evaluated the effects of nicotine (NIC), @CHEMICAL$ (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10231	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (@CHEMICAL$), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10232	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (@CHEMICAL$), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10233	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), @CHEMICAL$ (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10234	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), @CHEMICAL$ (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10235	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (@CHEMICAL$), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10236	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (@CHEMICAL$), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10237	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), @CHEMICAL$ (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10238	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), @CHEMICAL$ (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10239	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (@CHEMICAL$) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10240	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (@CHEMICAL$) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10241	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and @CHEMICAL$ (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10242	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and @CHEMICAL$ (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10243	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (@CHEMICAL$) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10244	CPRFalse	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (@CHEMICAL$) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10245	CPRFalse	The present work evaluated the effects of @CHEMICAL$ (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of @GENE$ (ERK 1/2).
10246	CPRFalse	The present work evaluated the effects of @CHEMICAL$ (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHbE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (@GENE$).
10247	CPRFalse	Cotinine also increased the phosphorylation of @CHEMICAL$ in a similar fashion as @GENE$.
10248	CPRFalse	@CHEMICAL$ also increased the phosphorylation of @GENE$ in a similar fashion as nicotine.
10249	CPR:3	@CHEMICAL$ upregulates the expression of @GENE$ in mouse aortic endothelial cells.
10250	CPRFalse	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 @CHEMICAL$ (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.
10251	CPRFalse	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (@CHEMICAL$) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.
10252	CPR:3	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 @CHEMICAL$ subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.
10253	CPRFalse	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, @CHEMICAL$ and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.
10254	CPRFalse	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and @CHEMICAL$, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following @GENE$ (SA) treatment.
10255	CPR:3	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, @CHEMICAL$ and AT1BR following @GENE$ (SA) treatment.
10256	CPR:3	To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and @CHEMICAL$ following @GENE$ (SA) treatment.
10257	CPRFalse	In addition, western blot analysis revealed that SA enhances the phosphorylations of @CHEM-GENE$ (JNK) and activated protein 1 (AP-1).
10258	CPRFalse	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun @CHEMICAL$-terminal kinases (@GENE$) and activated protein 1 (AP-1).
10259	CPRFalse	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun @CHEMICAL$-terminal kinases (JNK) and @GENE$ (AP-1).
10260	CPRFalse	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun @CHEMICAL$-terminal kinases (JNK) and activated protein 1 (@GENE$).
10261	CPR:4	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific @CHEMICAL$ inhibitor, @GENE$, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.
10262	CPRFalse	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, @CHEMICAL$, strongly indicating that @GENE$ upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.
10263	CPRFalse	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, @CHEMICAL$, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the @GENE$ signaling pathway.
10264	CPR:4	Finally, SA-induced @CHEMICAL$ expression was found to be prevented both by NAC and specific JNK inhibitor, @GENE$, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.
10265	CPR:3	Taken together, our results indicate that @CHEMICAL$ indeed upregulates the @GENE$ expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.
10266	CPRFalse	Taken together, our results indicate that @CHEMICAL$ indeed upregulates the AT1R expression, thus highlighting a role of arsenic-induced aberrant @GENE$ signaling in the pathogenesis of hypertension.
10267	CPRFalse	Taken together, our results indicate that arsenic indeed upregulates the @CHEMICAL$ expression, thus highlighting a role of @GENE$-induced aberrant AT1R signaling in the pathogenesis of hypertension.
10268	CPR:3	Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of @CHEMICAL$-induced aberrant @GENE$ signaling in the pathogenesis of hypertension.
10269	CPR:4	The mRNA levels of SOD1, CAT, @CHEMICAL$ and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.
10270	CPR:4	The mRNA levels of @CHEMICAL$, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.
10271	CPR:4	The mRNA levels of SOD1, @CHEMICAL$, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.
10272	CPR:4	The mRNA levels of SOD1, CAT, GPx and @CHEMICAL$ were increased significantly (P<0.05) in the combined Na2SeO3+@GENE$ treatment group.
10273	CPR:3	The mRNA levels of SOD1, CAT, @CHEMICAL$ and Txnrd1 were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.
10274	CPR:3	The mRNA levels of @CHEMICAL$, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.
10275	CPR:3	The mRNA levels of SOD1, @CHEMICAL$, GPx and Txnrd1 were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.
10276	CPR:4	The mRNA levels of SOD1, CAT, GPx and @CHEMICAL$ were increased significantly (P<0.05) in the combined @GENE$+NaAsO2 treatment group.
10277	CPR:3	The expressions of @CHEMICAL$ and HO-1 were significantly (P<0.05) increased in the @GENE$ group and reduced in the combined treatment group.
10278	CPR:3	The expressions of HSP70 and @CHEMICAL$ were significantly (P<0.05) increased in the @GENE$ group and reduced in the combined treatment group.
10279	CPRFalse	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEM-GENE$ (AR) and galactitol formation in rat lenses with high levels of glucose.
10280	CPRFalse	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEMICAL$ reductase (@GENE$) and galactitol formation in rat lenses with high levels of glucose.
10281	CPRFalse	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEMICAL$ (AR) and @GENE$ formation in rat lenses with high levels of glucose.
10282	CPRFalse	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on aldose reductase (@CHEMICAL$) and @GENE$ formation in rat lenses with high levels of glucose.
10283	CPRFalse	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on @CHEMICAL$ (AR) and galactitol formation in rat lenses with high levels of @GENE$.
10284	CPRFalse	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on aldose reductase (@CHEMICAL$) and galactitol formation in rat lenses with high levels of @GENE$.
10285	CPR:4	From the 10 isolated compounds, @CHEMICAL$ showed the most potent inhibition, with IC50 values of 0.30 and 0.67 mM for @GENE$ and rhAR, respectively.
10286	CPR:4	From the 10 isolated compounds, @CHEMICAL$ showed the most potent inhibition, with IC50 values of 0.30 and 0.67 mM for rAR and @GENE$, respectively.
10287	CPR:4	In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, @CHEMICAL$ showed competitive inhibition of @GENE$.
10288	CPRFalse	Enzyme activities such as @CHEM-GENE$, glutathione, catalase and lipid peroxidation were also determined in the stomach tissues.
10289	CPRFalse	Enzyme activities such as @CHEMICAL$ dismutase, glutathione, @GENE$ and lipid peroxidation were also determined in the stomach tissues.
10290	CPRFalse	Enzyme activities such as @CHEMICAL$, @GENE$, catalase and lipid peroxidation were also determined in the stomach tissues.
10291	CPRFalse	Enzyme activities such as superoxide dismutase, @CHEMICAL$, @GENE$ and lipid peroxidation were also determined in the stomach tissues.
10292	CPRFalse	Consequently significant changes were observed in enzyme activities such as @CHEMICAL$, CAT, @GENE$ and LPO in the stomach tissues when compared with ethanol control group.
10293	CPRFalse	Consequently significant changes were observed in enzyme activities such as SOD, @CHEMICAL$, @GENE$ and LPO in the stomach tissues when compared with ethanol control group.
10294	CPRFalse	Consequently significant changes were observed in enzyme activities such as @CHEMICAL$, CAT, GSH and LPO in the stomach tissues when compared with @GENE$ control group.
10295	CPRFalse	Consequently significant changes were observed in enzyme activities such as SOD, @CHEMICAL$, GSH and LPO in the stomach tissues when compared with @GENE$ control group.
10296	CPRFalse	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that MK2 catalytic activity directly regulated the promoters of the fast fiber-specific @CHEMICAL$ and the slow fiber-specific sarco/endoplasmic reticulum @GENE$-ATPase (SERCA) 2 gene.
10297	CPRFalse	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that @CHEMICAL$ catalytic activity directly regulated the promoters of the fast fiber-specific myosin heavy chain IId/x and the slow fiber-specific sarco/endoplasmic reticulum @GENE$-ATPase (SERCA) 2 gene.
10298	CPRFalse	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that MK2 catalytic activity directly regulated the promoters of the fast fiber-specific myosin heavy chain IId/x and the slow fiber-specific @CHEM-GENE$ gene.
10299	CPRFalse	These results link @CHEMICAL$ to the regulation of @GENE$ dynamics and identify enzymatic activity of MK2/3 as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in MK2/3(-/-) mice.
10300	CPRFalse	These results link MK2/3 to the regulation of @CHEMICAL$ dynamics and identify enzymatic activity of @GENE$ as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in MK2/3(-/-) mice.
10301	CPRFalse	These results link MK2/3 to the regulation of @CHEMICAL$ dynamics and identify enzymatic activity of MK2/3 as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in @GENE$(-/-) mice.
10302	CPRFalse	Recent observations revealed that @CHEM-GENE$ catalyzes N-glucuronidation of amine-containing compounds.
10303	CPR:9	Recent observations revealed that @CHEMICAL$ catalyzes N-glucuronidation of @GENE$-containing compounds.
10304	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of @GENE$, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.
10305	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, @GENE$, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.
10306	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, @GENE$, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.
10307	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, @GENE$, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.
10308	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, @GENE$, diphenhydramine, tamoxifen, ketoconazole and midazolam.
10309	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, @GENE$, tamoxifen, ketoconazole and midazolam.
10310	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, @GENE$, ketoconazole and midazolam.
10311	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, @GENE$ and midazolam.
10312	CPR:9	Using recombinant @CHEMICAL$, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and @GENE$.
10313	CPRFalse	These are drugs that were previously reported to be substrates for @CHEMICAL$ or UGT1A3 and that contain in their structure either @GENE$, cyclic amines, or an imidazole group.
10314	CPRFalse	These are drugs that were previously reported to be substrates for UGT1A4 or @CHEMICAL$ and that contain in their structure either @GENE$, cyclic amines, or an imidazole group.
10315	CPRFalse	These are drugs that were previously reported to be substrates for @CHEMICAL$ or UGT1A3 and that contain in their structure either tertiary aliphatic amines, @GENE$, or an imidazole group.
10316	CPRFalse	These are drugs that were previously reported to be substrates for UGT1A4 or @CHEMICAL$ and that contain in their structure either tertiary aliphatic amines, @GENE$, or an imidazole group.
10317	CPRFalse	These are drugs that were previously reported to be substrates for @CHEMICAL$ or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an @GENE$ group.
10318	CPRFalse	These are drugs that were previously reported to be substrates for UGT1A4 or @CHEMICAL$ and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an @GENE$ group.
10319	CPRFalse	@CHEMICAL$ was inactive in the glucuronidation of @GENE$, nortriptyline, carbamazepine and afloqualone.
10320	CPRFalse	@CHEMICAL$ was inactive in the glucuronidation of desipramine, @GENE$, carbamazepine and afloqualone.
10321	CPRFalse	@CHEMICAL$ was inactive in the glucuronidation of desipramine, nortriptyline, @GENE$ and afloqualone.
10322	CPRFalse	@CHEMICAL$ was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine and @GENE$.
10323	CPRFalse	This group of drugs contains @CHEMICAL$, and these results suggest that @GENE$ preferably conjugates tertiary amines.
10324	CPR:9	This group of drugs contains secondary or primary amines, and these results suggest that @CHEMICAL$ preferably conjugates @GENE$.
10325	CPRFalse	This preference is partial because @CHEMICAL$ did not conjugate the @GENE$ in trifluoperazine.
10326	CPRFalse	This preference is partial because @CHEMICAL$ did not conjugate the tertiary cyclic amine in @GENE$.
10327	CPR:9	Kinetic analyses revealed that the affinity and clearance of @CHEMICAL$ for @GENE$, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10328	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for @CHEMICAL$, imipramine, and diphenhydramine are significantly higher than the corresponding values of @GENE$ and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10329	CPRFalse	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for @CHEMICAL$, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and @GENE$, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10330	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for @CHEMICAL$, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of @GENE$ toward these drugs are considerably higher.
10331	CPR:9	Kinetic analyses revealed that the affinity and clearance of @CHEMICAL$ for amitriptyline, @GENE$, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10332	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, @CHEMICAL$, and diphenhydramine are significantly higher than the corresponding values of @GENE$ and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10333	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, @CHEMICAL$, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and @GENE$, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10334	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, @CHEMICAL$, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of @GENE$ toward these drugs are considerably higher.
10335	CPR:9	Kinetic analyses revealed that the affinity and clearance of @CHEMICAL$ for amitriptyline, imipramine, and @GENE$ are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10336	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and @CHEMICAL$ are significantly higher than the corresponding values of @GENE$ and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10337	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and @CHEMICAL$ are significantly higher than the corresponding values of UGT1A4 and @GENE$, although the Vmax values of UGT1A4 toward these drugs are considerably higher.
10338	CPR:9	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and @CHEMICAL$ are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of @GENE$ toward these drugs are considerably higher.
10339	CPR:9	In conclusion, this study expands the understanding of the substrate specificity of @CHEMICAL$, highlighting its preference for @GENE$ with higher affinities and clearance values than those of UGT1A4 and UGT1A3.
10340	CPR:9	In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for @CHEMICAL$ with higher affinities and clearance values than those of @GENE$ and UGT1A3.
10341	CPR:9	In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for @CHEMICAL$ with higher affinities and clearance values than those of UGT1A4 and @GENE$.
10342	CPR:6	@CHEMICAL$ (SB) is an @GENE$ (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.
10343	CPR:6	@CHEMICAL$ (SB) is an IL-8 receptor B (@GENE$) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.
10344	CPR:4	@CHEMICAL$ (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit @GENE$-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.
10345	CPRFalse	Molecular docking studies suggested that SB has a good affinity towards @CHEMICAL$-binding site on @GENE$ subunit.
10346	CPR:6	Of note, @CHEMICAL$ which is a close structural analogue of SB225002 with a potent @GENE$ antagonistic activity did not exhibit a similar antimitotic activity.
10347	CPR:6	Of note, SB265610 which is a close structural analogue of @CHEMICAL$ with a potent @GENE$ antagonistic activity did not exhibit a similar antimitotic activity.
10348	CPRFalse	In this report, we utilized a library of @CHEMICAL$ that produce two and three GAG chains on the same scaffold, respectively, thus mimicking PGs, to examine the importance of GAG valency and chain type in regulating @GENE$/FGFR interactions in vivo in zebrafish.
10349	CPRFalse	In this report, we utilized a library of @CHEMICAL$ that produce two and three GAG chains on the same scaffold, respectively, thus mimicking PGs, to examine the importance of GAG valency and chain type in regulating FGF/@GENE$ interactions in vivo in zebrafish.
10350	CPRFalse	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor @CHEMICAL$, mRNA for the @GENE$ antagonist sprouty4, or FGF8 morpholino.
10351	CPR:4	In support of this observation, elongation can be reversed by the @CHEMICAL$ inhibitor @GENE$, mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.
10352	CPRFalse	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor @CHEMICAL$, mRNA for the FGFR antagonist @GENE$, or FGF8 morpholino.
10353	CPRFalse	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor @CHEMICAL$, mRNA for the FGFR antagonist sprouty4, or @GENE$ morpholino.
10354	CPRFalse	Furthermore, expression of a multivalent but not a monovalent GAG containing @CHEMICAL$ proteoglycan recapitulates the elongation phenotype observed with the bivalent @GENE$.
10355	CPR:4	@CHEMICAL$ Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of @GENE$ Signaling.
10356	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10357	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10358	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10359	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10360	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10361	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10362	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10363	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10364	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10365	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10366	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, @GENE$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10367	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEM-GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10368	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10369	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10370	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10371	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10372	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10373	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10374	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10375	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10376	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10377	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10378	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10379	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10380	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10381	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10382	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10383	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10384	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10385	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, @GENE$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10386	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEM-GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10387	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10388	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10389	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10390	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10391	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10392	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10393	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10394	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10395	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @CHEMICAL$, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10396	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEM-GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10397	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10398	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10399	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10400	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10401	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10402	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10403	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10404	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$ Thr32, NF-kB, @GENE$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10405	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10406	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10407	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10408	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10409	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10410	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10411	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10412	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10413	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @CHEMICAL$, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10414	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$ Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10415	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10416	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10417	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10418	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10419	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10420	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10421	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10422	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10423	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @CHEMICAL$, @GENE$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10424	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEM-GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10425	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10426	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10427	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10428	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10429	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10430	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10431	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @CHEMICAL$, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10432	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @CHEMICAL$ Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10433	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10434	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10435	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10436	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @CHEMICAL$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10437	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @CHEMICAL$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10438	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @CHEMICAL$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10439	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @CHEMICAL$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10440	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @CHEMICAL$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10441	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @CHEMICAL$, phospho-Rb @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10442	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @CHEMICAL$ @GENE$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10443	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @CHEMICAL$807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10444	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @CHEMICAL$807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10445	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb @CHEMICAL$807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10446	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of @GENE$, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10447	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, @GENE$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10448	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10449	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10450	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10451	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, @GENE$, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10452	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, @GENE$, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10453	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, @GENE$, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10454	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10455	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10456	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10457	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10458	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10459	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10460	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10461	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10462	CPR:4	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10463	CPR:3	Treatment with @CHEMICAL$ decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10464	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10465	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEM-GENE$ Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10466	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, @GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10467	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10468	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10469	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10470	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10471	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, @GENE$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10472	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10473	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10474	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10475	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10476	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10477	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10478	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10479	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10480	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10481	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$-Akt Ser473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10482	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10483	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10484	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, @GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10485	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10486	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10487	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10488	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10489	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt @GENE$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10490	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10491	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10492	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10493	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10494	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10495	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10496	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10497	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10498	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10499	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt @CHEMICAL$473, phospho-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10500	CPRFalse	Treatment with CAPE decreased protein abundance of @CHEMICAL$, Akt1, Akt2, Akt3, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10501	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, @CHEMICAL$ Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10502	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEM-GENE$ Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10503	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, @GENE$, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10504	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, @GENE$ Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10505	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, @CHEMICAL$, Akt2, Akt3, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10506	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, @CHEMICAL$, Akt3, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10507	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, @CHEMICAL$, phospho-Akt Ser473, @GENE$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10508	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, @GENE$, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10509	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, @GENE$, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10510	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, @GENE$, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10511	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, @GENE$ Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10512	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, @GENE$ Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10513	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, @GENE$, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10514	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, @GENE$ Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10515	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, @GENE$, and cyclin D1, but increased cell cycle inhibitor p27Kip.
10516	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and @GENE$, but increased cell cycle inhibitor p27Kip.
10517	CPRFalse	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, @CHEMICAL$-Akt Thr 308, GSK3b, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-kB, phospho-NF-kB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor @GENE$.
10518	CPRFalse	Overexpression of @CHEMICAL$ or Akt2 in TW2.6 cells rescued growth inhibition caused by @GENE$ treatment.
10519	CPRFalse	Overexpression of Akt1 or @CHEMICAL$ in TW2.6 cells rescued growth inhibition caused by @GENE$ treatment.
10520	CPRFalse	Concurrent Regulation of the Transcription Factors @CHEMICAL$ and ATF4 Mediates the Enhancement of Glutathione Levels by the @GENE$ Fisetin.
10521	CPRFalse	Concurrent Regulation of the Transcription Factors Nrf2 and @CHEMICAL$ Mediates the Enhancement of Glutathione Levels by the @GENE$ Fisetin.
10522	CPRFalse	Concurrent Regulation of the Transcription Factors @CHEMICAL$ and ATF4 Mediates the Enhancement of Glutathione Levels by the Flavonoid @GENE$.
10523	CPRFalse	Concurrent Regulation of the Transcription Factors Nrf2 and @CHEMICAL$ Mediates the Enhancement of Glutathione Levels by the Flavonoid @GENE$.
10524	CPRFalse	Concurrent Regulation of the Transcription Factors @CHEMICAL$ and ATF4 Mediates the Enhancement of @GENE$ Levels by the Flavonoid Fisetin.
10525	CPRFalse	Concurrent Regulation of the Transcription Factors Nrf2 and @CHEMICAL$ Mediates the Enhancement of @GENE$ Levels by the Flavonoid Fisetin.
10526	CPRFalse	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are @GENE$ (Nrf2) and activating transcription factor 4 (ATF4).
10527	CPRFalse	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are NF-E2-related factor 2 (@GENE$) and activating transcription factor 4 (ATF4).
10528	CPRFalse	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are NF-E2-related factor 2 (Nrf2) and @GENE$ (ATF4).
10529	CPRFalse	Among the transcription factors that play critical roles in @CHEMICAL$ metabolism are NF-E2-related factor 2 (Nrf2) and activating transcription factor 4 (@GENE$).
10530	CPR:3	Here we show that @CHEMICAL$ rapidly increases the levels of both @GENE$ and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.
10531	CPR:3	Here we show that @CHEMICAL$ rapidly increases the levels of both Nrf2 and @GENE$ as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.
10532	CPR:3	Here we show that @CHEMICAL$ rapidly increases the levels of both Nrf2 and ATF4 as well as @GENE$- and ATF4-dependent gene transcription via distinct mechanisms.
10533	CPR:3	Here we show that @CHEMICAL$ rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and @GENE$-dependent gene transcription via distinct mechanisms.
10534	CPRFalse	Although @CHEMICAL$ greatly increases the stability of both Nrf2 and ATF4, only the effect on ATF4 is dependent on @GENE$ activity.
10535	CPR:3	Although @CHEMICAL$ greatly increases the stability of both @GENE$ and ATF4, only the effect on ATF4 is dependent on protein kinase activity.
10536	CPR:3	Although @CHEMICAL$ greatly increases the stability of both Nrf2 and @GENE$, only the effect on ATF4 is dependent on protein kinase activity.
10537	CPRFalse	Although @CHEMICAL$ greatly increases the stability of both Nrf2 and ATF4, only the effect on @GENE$ is dependent on protein kinase activity.
10538	CPRFalse	Using siRNA we found that @CHEMICAL$, but not Nrf2, is important for @GENE$'s ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.
10539	CPRFalse	Using siRNA we found that ATF4, but not @CHEMICAL$, is important for @GENE$'s ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.
10540	CPRFalse	Using siRNA we found that ATF4, but not Nrf2, is important for @CHEMICAL$'s ability to increase GSH levels under basal conditions whereas both @GENE$ and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.
10541	CPRFalse	Using siRNA we found that ATF4, but not Nrf2, is important for @CHEMICAL$'s ability to increase GSH levels under basal conditions whereas both ATF4 and @GENE$ appear to cooperate to increase GSH levels under oxidative stress conditions.
10542	CPRFalse	Using siRNA we found that @CHEMICAL$, but not Nrf2, is important for fisetin's ability to increase @GENE$ levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.
10543	CPRFalse	Using siRNA we found that ATF4, but not @CHEMICAL$, is important for fisetin's ability to increase @GENE$ levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.
10544	CPRFalse	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase @CHEMICAL$ levels under basal conditions whereas both @GENE$ and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.
10545	CPRFalse	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase @CHEMICAL$ levels under basal conditions whereas both ATF4 and @GENE$ appear to cooperate to increase GSH levels under oxidative stress conditions.
10546	CPRFalse	Using siRNA we found that @CHEMICAL$, but not Nrf2, is important for fisetin's ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase @GENE$ levels under oxidative stress conditions.
10547	CPRFalse	Using siRNA we found that ATF4, but not @CHEMICAL$, is important for fisetin's ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase @GENE$ levels under oxidative stress conditions.
10548	CPRFalse	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase GSH levels under basal conditions whereas both @CHEMICAL$ and Nrf2 appear to cooperate to increase @GENE$ levels under oxidative stress conditions.
10549	CPRFalse	Using siRNA we found that ATF4, but not Nrf2, is important for fisetin's ability to increase GSH levels under basal conditions whereas both ATF4 and @CHEMICAL$ appear to cooperate to increase @GENE$ levels under oxidative stress conditions.
10550	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a @CHEMICAL$ (RBV) prodrug, exploiting the presence of @GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10551	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a @CHEMICAL$ (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10552	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (@CHEMICAL$) prodrug, exploiting the presence of @GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10553	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (@CHEMICAL$) prodrug, exploiting the presence of carbohydrate receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10554	CPRFalse	GALACTOSYLATED MICELLES FOR A @CHEMICAL$ PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10555	CPRFalse	GALACTOSYLATED MICELLES FOR A @CHEMICAL$ PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10556	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @CHEM-GENE$, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10557	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @CHEMICAL$ receptors, i.e., @GENE$, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.
10558	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of @CHEMICAL$, i.e., ASGPR, were prepared starting from a @GENE$ conjugate.
10559	CPRFalse	GALACTOSYLATED MICELLES FOR A RIBAVIRIN PRODRUG TARGETING TO HEPATOCYTES. Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., @CHEMICAL$, were prepared starting from a @GENE$ conjugate.
10560	CPRFalse	Molecular and functional characterization of @CHEM-GENE$ in cynomolgus macaque.
10561	CPRFalse	@CHEM-GENE$ (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and FMO6P), but remain to be investigated in cynomolgus macaque.
10562	CPRFalse	@CHEMICAL$-containing monooxygenases (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including @GENE$ and FMO6P), but remain to be investigated in cynomolgus macaque.
10563	CPRFalse	@CHEMICAL$-containing monooxygenases (@GENE$), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and FMO6P), but remain to be investigated in cynomolgus macaque.
10564	CPRFalse	@CHEMICAL$-containing monooxygenases (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and @GENE$), but remain to be investigated in cynomolgus macaque.
10565	CPRFalse	@CHEMICAL$ sequences of cynomolgus @GENE$, respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with human FMO1-5.
10566	CPRFalse	@CHEMICAL$ sequences of cynomolgus FMO1-5, respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with @GENE$.
10567	CPRFalse	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized @CHEMICAL$, and @GENE$/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.
10568	CPRFalse	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized @CHEMICAL$, and FMO1/@GENE$ and FMO3 also metabolized methimazole and trimethylamine, respectively.
10569	CPRFalse	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized @CHEMICAL$, and FMO1/FMO3 and @GENE$ also metabolized methimazole and trimethylamine, respectively.
10570	CPR:9	@CHEMICAL$, FMO2, FMO3, and FMO5 metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.
10571	CPR:9	Cynomolgus FMO1, @CHEMICAL$, FMO3, and FMO5 metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.
10572	CPR:9	Cynomolgus FMO1, FMO2, @CHEMICAL$, and FMO5 metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.
10573	CPR:9	Cynomolgus FMO1, FMO2, FMO3, and @CHEMICAL$ metabolized @GENE$, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.
10574	CPR:9	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and @CHEMICAL$/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.
10575	CPR:9	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/@CHEMICAL$ and FMO3 also metabolized @GENE$ and trimethylamine, respectively.
10576	CPR:9	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and @CHEMICAL$ also metabolized @GENE$ and trimethylamine, respectively.
10577	CPRFalse	@CHEMICAL$, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.
10578	CPRFalse	Cynomolgus FMO1, @CHEMICAL$, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.
10579	CPRFalse	Cynomolgus FMO1, FMO2, @CHEMICAL$, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.
10580	CPRFalse	Cynomolgus FMO1, FMO2, FMO3, and @CHEMICAL$ metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized @GENE$ and trimethylamine, respectively.
10581	CPR:9	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and @CHEMICAL$/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.
10582	CPR:9	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/@CHEMICAL$ and FMO3 also metabolized methimazole and @GENE$, respectively.
10583	CPR:9	Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and @CHEMICAL$ also metabolized methimazole and @GENE$, respectively.
10584	CPRFalse	@CHEMICAL$, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.
10585	CPRFalse	Cynomolgus FMO1, @CHEMICAL$, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.
10586	CPRFalse	Cynomolgus FMO1, FMO2, @CHEMICAL$, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.
10587	CPRFalse	Cynomolgus FMO1, FMO2, FMO3, and @CHEMICAL$ metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and @GENE$, respectively.
10588	CPR:9	Rates of @CHEMICAL$ N-oxygenation (catalyzed by @GENE$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.
10589	CPRFalse	Rates of @CHEMICAL$ N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @GENE$ protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.
10590	CPRFalse	Rates of @CHEMICAL$ N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable @GENE$ expression.
10591	CPR:9	Rates of benzydamine @CHEMICAL$-oxygenation (catalyzed by @GENE$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.
10592	CPRFalse	Rates of benzydamine @CHEMICAL$-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @GENE$ protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.
10593	CPRFalse	Rates of benzydamine @CHEMICAL$-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable @GENE$ expression.
10594	CPRFalse	Rates of benzydamine N-oxygenation (catalyzed by @CHEMICAL$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in @GENE$ N-oxygenation might be partly accounted for by the variable FMO3 expression.
10595	CPRFalse	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @CHEMICAL$ protein expression, indicating that the inter-animal variations in @GENE$ N-oxygenation might be partly accounted for by the variable FMO3 expression.
10596	CPR:9	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in @CHEMICAL$ N-oxygenation might be partly accounted for by the variable @GENE$ expression.
10597	CPRFalse	Rates of benzydamine N-oxygenation (catalyzed by @CHEMICAL$) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine @GENE$-oxygenation might be partly accounted for by the variable FMO3 expression.
10598	CPRFalse	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with @CHEMICAL$ protein expression, indicating that the inter-animal variations in benzydamine @GENE$-oxygenation might be partly accounted for by the variable FMO3 expression.
10599	CPR:9	Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine @CHEMICAL$-oxygenation might be partly accounted for by the variable @GENE$ expression.
10600	CPR:9	@CHEMICAL$ metabolized @GENE$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.
10601	CPRFalse	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of @GENE$ in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.
10602	CPRFalse	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of @GENE$ in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.
10603	CPR:9	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus @GENE$, FMO2, FMO3, and FMO5 which were all functional.
10604	CPR:9	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, @GENE$, FMO3, and FMO5 which were all functional.
10605	CPR:9	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, @GENE$, and FMO5 which were all functional.
10606	CPR:9	Cynomolgus FMO6 metabolized @CHEMICAL$ only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and @GENE$ which were all functional.
10607	CPRFalse	Effect of paraoxonase 1 @CHEMICAL$ polymorphism on paraoxonase and acetylcholinesterase enzyme activities in Turkish population exposed to @GENE$.
10608	CPRFalse	Effect of @CHEMICAL$ 192 Q/R polymorphism on paraoxonase and acetylcholinesterase enzyme activities in Turkish population exposed to @GENE$.
10609	CPRFalse	Effect of paraoxonase 1 192 Q/R polymorphism on @CHEMICAL$ and acetylcholinesterase enzyme activities in Turkish population exposed to @GENE$.
10610	CPRFalse	Effect of paraoxonase 1 192 Q/R polymorphism on paraoxonase and @CHEMICAL$ enzyme activities in Turkish population exposed to @GENE$.
10611	CPRFalse	The aim of this study was to determine the effects of @CHEMICAL$ gene polymorphism and its effects on PON and AChE enzyme activities in individuals who were exposed to @GENE$ insecticides due to occupational reasons, and to profile the probability of susceptibility to organophosphorus compounds.
10612	CPRFalse	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on @CHEMICAL$ and AChE enzyme activities in individuals who were exposed to @GENE$ insecticides due to occupational reasons, and to profile the probability of susceptibility to organophosphorus compounds.
10613	CPRFalse	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on PON and @CHEMICAL$ enzyme activities in individuals who were exposed to @GENE$ insecticides due to occupational reasons, and to profile the probability of susceptibility to organophosphorus compounds.
10614	CPRFalse	The aim of this study was to determine the effects of @CHEMICAL$ gene polymorphism and its effects on PON and AChE enzyme activities in individuals who were exposed to organophosphorus insecticides due to occupational reasons, and to profile the probability of susceptibility to @GENE$ compounds.
10615	CPRFalse	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on @CHEMICAL$ and AChE enzyme activities in individuals who were exposed to organophosphorus insecticides due to occupational reasons, and to profile the probability of susceptibility to @GENE$ compounds.
10616	CPRFalse	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on PON and @CHEMICAL$ enzyme activities in individuals who were exposed to organophosphorus insecticides due to occupational reasons, and to profile the probability of susceptibility to @GENE$ compounds.
10617	CPRFalse	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @CHEMICAL$-activated Protein Kinase and p38beta @GENE$.
10618	CPRFalse	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @CHEM-GENE$ and p38beta Mitogen-activated Protein Kinase.
10619	CPRFalse	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @CHEMICAL$-activated Protein Kinase and @GENE$ Mitogen-activated Protein Kinase.
10620	CPRFalse	Store-operated Ca2+ Entry (SOCE) Induced by @CHEMICAL$ mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @GENE$-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.
10621	CPRFalse	Store-operated Ca2+ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates @CHEMICAL$ Phosphorylation to inhibit SOCE in Endothelial Cells through @GENE$-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.
10622	CPRFalse	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and p38beta @GENE$.
10623	CPRFalse	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through @GENE$ and p38beta Mitogen-activated Protein Kinase.
10624	CPRFalse	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and @GENE$ Mitogen-activated Protein Kinase.
10625	CPRFalse	Store-operated @CHEMICAL$ Entry (SOCE) Induced by @GENE$ mediates STIM1 Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.
10626	CPRFalse	Store-operated @CHEMICAL$ Entry (SOCE) Induced by Protease-activated Receptor-1 mediates @GENE$ Phosphorylation to inhibit SOCE in Endothelial Cells through AMP-activated Protein Kinase and p38beta Mitogen-activated Protein Kinase.
10627	CPRFalse	The @CHEMICAL$ sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through TRPC and @GENE$.
10628	CPRFalse	The @CHEMICAL$ sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through @GENE$ and Orai channels.
10629	CPRFalse	The @CHEMICAL$ sensor @GENE$ is crucial for activation of store-operated Ca2+ entry (SOCE) through TRPC and Orai channels.
10630	CPRFalse	The Ca2+ sensor STIM1 is crucial for activation of store-operated @CHEMICAL$ entry (SOCE) through TRPC and @GENE$.
10631	CPRFalse	The Ca2+ sensor STIM1 is crucial for activation of store-operated @CHEMICAL$ entry (SOCE) through @GENE$ and Orai channels.
10632	CPRFalse	The Ca2+ sensor @CHEMICAL$ is crucial for activation of store-operated @GENE$ entry (SOCE) through TRPC and Orai channels.
10633	CPRFalse	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b @GENE$ (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).
10634	CPRFalse	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b mitogen-activated protein kinase (p38b @GENE$) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).
10635	CPRFalse	Here we show that SOCE activates @CHEM-GENE$ (AMPK); its effector p38b mitogen-activated protein kinase (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).
10636	CPRFalse	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (@GENE$); its effector p38b mitogen-activated protein kinase (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).
10637	CPRFalse	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector @GENE$ mitogen-activated protein kinase (p38b MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).
10638	CPRFalse	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b mitogen-activated protein kinase (@GENE$ MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).
10639	CPRFalse	Here we show that SOCE activates @CHEMICAL$-activated protein kinase (AMPK); its effector p38b mitogen-activated protein kinase (p38b MAPK) phosphorylates @GENE$, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).
10640	CPR:3	Activation of @CHEMICAL$ using @GENE$ resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.
10641	CPR:3	Activation of AMPK using @CHEMICAL$ resulted in @GENE$ phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.
10642	CPR:4	Activation of AMPK using @CHEMICAL$ resulted in STIM1 phosphorylation on serine residues and prevented @GENE$-induced Ca2+ entry.
10643	CPRFalse	Activation of @CHEMICAL$ using AICAR resulted in STIM1 phosphorylation on @GENE$ residues and prevented PAR-1-induced Ca2+ entry.
10644	CPRFalse	Activation of AMPK using AICAR resulted in @CHEMICAL$ phosphorylation on @GENE$ residues and prevented PAR-1-induced Ca2+ entry.
10645	CPRFalse	Activation of AMPK using AICAR resulted in STIM1 phosphorylation on @CHEMICAL$ residues and prevented @GENE$-induced Ca2+ entry.
10646	CPRFalse	Activation of @CHEMICAL$ using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced @GENE$ entry.
10647	CPRFalse	Activation of AMPK using AICAR resulted in @CHEMICAL$ phosphorylation on serine residues and prevented PAR-1-induced @GENE$ entry.
10648	CPRFalse	Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented @CHEMICAL$-induced @GENE$ entry.
10649	CPR:4	Further, @CHEMICAL$ pretreatment blocked @GENE$-induced increase in permeability of mouse-lung microvessels.
10650	CPRFalse	Interestingly, SB203580, a selective inhibitor of @CHEMICAL$ MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and @GENE$ entry.
10651	CPRFalse	Interestingly, SB203580, a selective inhibitor of p38 @CHEMICAL$, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and @GENE$ entry.
10652	CPRFalse	Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked @CHEMICAL$ phosphorylation and led to sustained STIM1-puncta formation and @GENE$ entry.
10653	CPRFalse	Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained @CHEMICAL$-puncta formation and @GENE$ entry.
10654	CPR:4	Interestingly, @CHEMICAL$, a selective inhibitor of @GENE$ MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.
10655	CPR:4	Interestingly, @CHEMICAL$, a selective inhibitor of p38 @GENE$, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.
10656	CPR:4	Interestingly, @CHEMICAL$, a selective inhibitor of p38 MAPK, blocked @GENE$ phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.
10657	CPRFalse	Interestingly, @CHEMICAL$, a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained @GENE$-puncta formation and Ca2+ entry.
10658	CPRFalse	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the @CHEMICAL$ side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, @GENE$ and ferredoxin.
10659	CPRFalse	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the @CHEMICAL$ side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, ferredoxin reductase and @GENE$.
10660	CPR:9	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the @CHEMICAL$ side-chain cleavage enzyme, @GENE$, and its two electron-transfer partners, ferredoxin reductase and ferredoxin.
10661	CPRFalse	Several other steroidogenic enzymes, including @CHEM-GENE$, 11b-hydroxylase and aldosterone synthase also reside in mitochondria.
10662	CPRFalse	Several other steroidogenic enzymes, including @CHEMICAL$ dehydrogenase, @GENE$ and aldosterone synthase also reside in mitochondria.
10663	CPRFalse	Several other steroidogenic enzymes, including @CHEMICAL$ dehydrogenase, 11b-hydroxylase and @GENE$ also reside in mitochondria.
10664	CPRFalse	Several other steroidogenic enzymes, including @CHEMICAL$, 11b-hydroxylase and @GENE$ synthase also reside in mitochondria.
10665	CPRFalse	Several other steroidogenic enzymes, including 3b-hydroxysteroid dehydrogenase, @CHEMICAL$ and @GENE$ synthase also reside in mitochondria.
10666	CPRFalse	Several other steroidogenic enzymes, including 3b-hydroxysteroid dehydrogenase, 11b-hydroxylase and @CHEM-GENE$ also reside in mitochondria.
10667	CPRFalse	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of @CHEMICAL$. The access of cholesterol to the mitochondria is regulated by the @GENE$, StAR, serving as the acute regulator of steroidogenesis.
10668	CPRFalse	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of @CHEMICAL$. The access of cholesterol to the mitochondria is regulated by the steroidogenic acute regulatory protein, @GENE$, serving as the acute regulator of steroidogenesis.
10669	CPRFalse	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of vitamin D. The access of @CHEMICAL$ to the mitochondria is regulated by the @GENE$, StAR, serving as the acute regulator of steroidogenesis.
10670	CPRFalse	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of vitamin D. The access of @CHEMICAL$ to the mitochondria is regulated by the steroidogenic acute regulatory protein, @GENE$, serving as the acute regulator of steroidogenesis.
10671	CPR:9	The precise fashion in which these proteins interact and move @CHEMICAL$ from the OMM to @GENE$, and the means by which cholesterol is loaded into the OMM, remain unclear.
10672	CPRFalse	The precise fashion in which these proteins interact and move cholesterol from the OMM to @CHEMICAL$, and the means by which @GENE$ is loaded into the OMM, remain unclear.
10673	CPRFalse	Human deficiency diseases have been described for @CHEMICAL$ and for all the mitochondrial steroidogenic enzymes, but not for the electron transfer proteins or for the components of the @GENE$ import machine.
10674	CPR:4	@CHEMICAL$ Inhibitors Based on the @GENE$ Core.
10675	CPR:4	New series of @CHEMICAL$, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine @GENE$ inhibitors (MMPIs) were designed, synthesized, and evaluated.
10676	CPR:4	New series of pyrrolidine mercaptosulfide, @CHEMICAL$, and 3-mercapto-4-arylsulfonamido pyrrolidine @GENE$ inhibitors (MMPIs) were designed, synthesized, and evaluated.
10677	CPR:4	New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and @CHEMICAL$ @GENE$ inhibitors (MMPIs) were designed, synthesized, and evaluated.
10678	CPR:4	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several @GENE$ in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).
10679	CPR:4	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including @GENE$ (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).
10680	CPR:4	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), @GENE$ (~2 to 50 nM), and MMP-14 (~4 to 60 nM).
10681	CPR:4	Exhibiting unique properties over other MMPIs (e.g., @CHEMICAL$), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and @GENE$ (~4 to 60 nM).
10682	CPRFalse	Our previous work with the @CHEMICAL$ functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the @GENE$ tested.
10683	CPRFalse	Our previous work with the mercaptosulfide functionality attached to both @CHEMICAL$ and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the @GENE$ tested.
10684	CPRFalse	Our previous work with the mercaptosulfide functionality attached to both cyclopentane and @CHEMICAL$ frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the @GENE$ tested.
10685	CPRFalse	A Structural Snapshot of @CHEMICAL$ in Complex with @GENE$ Provides Insights into Ligand Binding and Clusters of Conformational States.
10686	CPRFalse	An X-ray crystal structure of @CHEMICAL$ in complex with the drug @GENE$ was solved at 2.14 A resolution.
10687	CPRFalse	The @CHEMICAL$-@GENE$ structure is nearly superimposable on a previously solved closed structure in a ligand free state.
10688	CPRFalse	Protective Role of @CHEMICAL$ Bioactivated with @GENE$ in an Experimental Model of Multiple Sclerosis.
10689	CPR:9	Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in @CHEMICAL$, which upon @GENE$ hydrolysis release the corresponding isothiocyanates.
10690	CPR:9	Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon @CHEMICAL$ hydrolysis release the corresponding @GENE$.
10691	CPRFalse	acephala sabellica) bioactivated with @CHEMICAL$ (bioactive @GENE$) (10 mg/kg/day intraperitoneally), in an experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis.
10692	CPR:4	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased @GENE$ translocation, pro-inflammatory cytokine production such as interleukin-1b (IL-1b), and apoptosis (Bax and caspase 3 expression).
10693	CPR:4	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory @GENE$ production such as interleukin-1b (IL-1b), and apoptosis (Bax and caspase 3 expression).
10694	CPR:4	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as @GENE$ (IL-1b), and apoptosis (Bax and caspase 3 expression).
10695	CPR:4	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1b (@GENE$), and apoptosis (Bax and caspase 3 expression).
10696	CPR:4	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1b (IL-1b), and apoptosis (@GENE$ and caspase 3 expression).
10697	CPR:4	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive @CHEMICAL$ significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1b (IL-1b), and apoptosis (Bax and @GENE$ expression).
10698	CPRFalse	Involvement of @CHEMICAL$ and phase II detoxifying enzyme system in neuroprotection mediated by the flavonoid @GENE$ isolated from Dracocephalum kotschyi.
10699	CPRFalse	Involvement of p-CREB and @CHEMICAL$ system in neuroprotection mediated by the flavonoid @GENE$ isolated from Dracocephalum kotschyi.
10700	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, @CHEMICAL$, on H2O2-induced disruption of @GENE$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10701	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, @CHEMICAL$, on H2O2-induced disruption of phase II detoxifying enzyme system and @GENE$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10702	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, @CHEMICAL$, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@GENE$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10703	CPR:4	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on @CHEMICAL$-induced disruption of @GENE$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10704	CPR:4	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on @CHEMICAL$-induced disruption of phase II detoxifying enzyme system and @GENE$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10705	CPR:4	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on @CHEMICAL$-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@GENE$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10706	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of @CHEMICAL$ system and @GENE$ response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10707	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEM-GENE$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10708	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEMICAL$ response element binding protein (@GENE$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding H2O2 (150mM) for 24h.
10709	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of @CHEMICAL$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of @GENE$ for 3h, followed by adding H2O2 (150mM) for 24h.
10710	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEMICAL$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of @GENE$ for 3h, followed by adding H2O2 (150mM) for 24h.
10711	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@CHEMICAL$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of @GENE$ for 3h, followed by adding H2O2 (150mM) for 24h.
10712	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of @CHEMICAL$ system and cAMP response element binding protein (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding @GENE$ (150mM) for 24h.
10713	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and @CHEMICAL$ (CREB) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding @GENE$ (150mM) for 24h.
10714	CPRFalse	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (@CHEMICAL$) phosphorylation. METHODS: PC12 cells were treated with 25, 50 and 100mM of calycopterin for 3h, followed by adding @GENE$ (150mM) for 24h.
10715	CPRFalse	The level of @CHEMICAL$, nuclear factor erythroid 2-related factor 2 (Nrf2), @GENE$ synthetase (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.
10716	CPRFalse	The level of phosphorylated CREB, @CHEMICAL$ (Nrf2), @GENE$ synthetase (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.
10717	CPRFalse	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (@CHEMICAL$), @GENE$ synthetase (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.
10718	CPRFalse	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEM-GENE$ (g-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.
10719	CPRFalse	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEMICAL$ synthetase (@GENE$) and heme oxygenase 1 (HO-1) were measured by western blot method.
10720	CPRFalse	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEMICAL$ synthetase (g-GCS) and @GENE$ (HO-1) were measured by western blot method.
10721	CPRFalse	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), @CHEMICAL$ synthetase (g-GCS) and heme oxygenase 1 (@GENE$) were measured by western blot method.
10722	CPRFalse	In @CHEMICAL$-treated cells, calycopterin also suppressed @GENE$ release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.
10723	CPR:4	In H2O2-treated cells, @CHEMICAL$ also suppressed @GENE$ release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.
10724	CPR:3	Moreover, @CHEMICAL$, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, @GENE$ and Nrf2, which play an important role in antioxidant capacity of the cell.
10725	CPR:3	Moreover, @CHEMICAL$, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and @GENE$, which play an important role in antioxidant capacity of the cell.
10726	CPRFalse	Moreover, calycopterin, in presence of @CHEMICAL$ inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, @GENE$ and Nrf2, which play an important role in antioxidant capacity of the cell.
10727	CPRFalse	Moreover, calycopterin, in presence of @CHEMICAL$ inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and @GENE$, which play an important role in antioxidant capacity of the cell.
10728	CPR:3	There was also an increase in @CHEMICAL$ and HO-1 levels in @GENE$ pretreated cells.
10729	CPR:3	There was also an increase in g-GCS and @CHEMICAL$ levels in @GENE$ pretreated cells.
10730	CPRFalse	In the presence of @CHEMICAL$, calycopterin inhibited decrease in GSH level and @GENE$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.
10731	CPRFalse	In the presence of @CHEMICAL$, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.
10732	CPRFalse	In the presence of @CHEMICAL$, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.
10733	CPR:3	In the presence of H2O2, @CHEMICAL$ inhibited decrease in GSH level and @GENE$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.
10734	CPRFalse	In the presence of H2O2, @CHEMICAL$ inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.
10735	CPRFalse	In the presence of H2O2, @CHEMICAL$ inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.
10736	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in @CHEMICAL$ level and @GENE$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.
10737	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in @CHEMICAL$ level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.
10738	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in @CHEMICAL$ level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.
10739	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in GSH level and @CHEMICAL$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, @GENE$, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.
10740	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, @CHEMICAL$, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.
10741	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, @CHEMICAL$, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.
10742	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in GSH level and @CHEMICAL$ activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against @GENE$-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and Nrf2 pathway.
10743	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against @CHEMICAL$-induced oxidative stress in differentiated PC12 cells by modulating the level of @GENE$ phosphorylation and Nrf2 pathway.
10744	CPRFalse	In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity. CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against @CHEMICAL$-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and @GENE$ pathway.
10745	CPR:3	@CHEMICAL$ stimulates Th17 differentiation enhancing phosphorylation of @GENE$ and STAT3 to worsen experimental autoimmune encephalomyelitis.
10746	CPR:3	@CHEMICAL$ stimulates Th17 differentiation enhancing phosphorylation of c-Src and @GENE$ to worsen experimental autoimmune encephalomyelitis.
10747	CPR:3	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by @GENE$ (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.
10748	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by @CHEMICAL$ (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @GENE$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.
10749	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by @CHEMICAL$ (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical @GENE$ ligand.
10750	CPR:3	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (@GENE$), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.
10751	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (@CHEMICAL$), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @GENE$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.
10752	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (@CHEMICAL$), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical @GENE$ ligand.
10753	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. @GENE$ increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.
10754	CPR:3	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. @CHEMICAL$ increased expression of @GENE$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.
10755	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. @CHEMICAL$ increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical @GENE$ ligand.
10756	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as @GENE$ (TCDD), a prototypical AhR ligand.
10757	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @CHEMICAL$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as @GENE$ (TCDD), a prototypical AhR ligand.
10758	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as @CHEMICAL$ (TCDD), a prototypical @GENE$ ligand.
10759	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of @CHEMICAL$ activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (@GENE$), a prototypical AhR ligand.
10760	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of @CHEMICAL$, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (@GENE$), a prototypical AhR ligand.
10761	CPRFalse	In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORgt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (@CHEMICAL$), a prototypical @GENE$ ligand.
10762	CPR:3	Activation of @CHEMICAL$, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and @GENE$.
10763	CPR:3	Activation of STAT3, which is phosphorylated by the @CHEMICAL$ signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and @GENE$.
10764	CPR:3	Activation of @CHEMICAL$, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by @GENE$ and TCDD.
10765	CPR:3	Activation of STAT3, which is phosphorylated by the @CHEMICAL$ signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by @GENE$ and TCDD.
10766	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.
10767	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.
10768	CPR:3	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by @GENE$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10769	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by @GENE$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10770	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of @GENE$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10771	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @GENE$ and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10772	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by @CHEMICAL$ and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @GENE$, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10773	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.
10774	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.
10775	CPR:3	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and @GENE$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10776	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and @GENE$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10777	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of @GENE$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10778	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @GENE$ and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10779	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and @CHEMICAL$, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @GENE$, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10780	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.
10781	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.
10782	CPRFalse	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @GENE$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10783	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @GENE$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10784	CPR:4	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of @CHEMICAL$ activity by @GENE$ (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10785	CPR:4	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both @GENE$ and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10786	CPR:4	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by @CHEMICAL$ (PP2) inhibited phosphorylation of both c-Src and @GENE$, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10787	CPR:3	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @CHEMICAL$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.
10788	CPR:3	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @CHEMICAL$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.
10789	CPRFalse	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10790	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10791	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of @CHEMICAL$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10792	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @CHEMICAL$ and STAT3, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10793	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @CHEMICAL$, raising a possibility that stimulatory activities of @GENE$ and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10794	CPR:3	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @CHEMICAL$ on Th17 differentiation could be exerted via increased phosphorylation of @GENE$, which in turn stimulates STAT3 activation.
10795	CPR:3	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @CHEMICAL$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates @GENE$ activation.
10796	CPRFalse	Phosphorylation of @CHEMICAL$, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10797	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by @CHEMICAL$ ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10798	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of @CHEMICAL$ activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10799	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both @CHEMICAL$ and STAT3, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10800	CPRFalse	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and @CHEMICAL$, raising a possibility that stimulatory activities of I3S and @GENE$ on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.
10801	CPR:3	Finally, we found that @CHEMICAL$ worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of @GENE$-producing cells in draining lymph nodes.
10802	CPRFalse	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, @GENE$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10803	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, @CHEMICAL$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @GENE$ activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10804	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, @CHEMICAL$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10805	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, @CHEMICAL$ metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.
10806	CPRFalse	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum @GENE$, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10807	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum @GENE$, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10808	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum @CHEMICAL$, GSH/GSSG ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10809	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum @CHEMICAL$, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.
10810	CPRFalse	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, @GENE$/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10811	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, @GENE$/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10812	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, @CHEMICAL$/GSSG ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10813	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, @CHEMICAL$/GSSG ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.
10814	CPRFalse	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/@GENE$ ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10815	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, GSH/@GENE$ ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10816	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/@CHEMICAL$ ratio, @GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10817	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/@CHEMICAL$ ratio, glucose-6-phosphatase and @GENE$ activities, liver glycogen.
10818	CPRFalse	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @GENE$-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10819	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, GSH/GSSG ratio, @GENE$-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10820	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @CHEM-GENE$ and phosphoenolpyruvate carboxykinase activities, liver glycogen.
10821	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @CHEMICAL$-6-phosphatase and @GENE$ activities, liver glycogen.
10822	CPRFalse	Analyses of these genes identified over-represented functions associated with @CHEMICAL$ signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ carboxykinase activities, liver glycogen.
10823	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of @CHEMICAL$ activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @GENE$ carboxykinase activities, liver glycogen.
10824	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, @CHEMICAL$ and @GENE$ carboxykinase activities, liver glycogen.
10825	CPRFalse	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and @CHEM-GENE$ activities, liver glycogen.
10826	CPRFalse	These data suggest that TP treatment could alter the hepatic redox status, reduce serum @CHEMICAL$ and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in @GENE$ signaling pathway, glucose metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.
10827	CPRFalse	These data suggest that TP treatment could alter the hepatic redox status, reduce serum glucose and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in @CHEMICAL$ signaling pathway, @GENE$ metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.
10828	CPR:3	@CHEMICAL$ induces the expression of @GENE$ in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.
10829	CPRFalse	TCDD induces the expression of @CHEMICAL$ in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on @GENE$ toxicity.
10830	CPRFalse	TCDD treatment of the cells largely prevented the activation of @CHEMICAL$, a regulator of translation initiation and substrate of the mammalian target of @GENE$ (mTOR).
10831	CPRFalse	TCDD treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the @CHEM-GENE$ (mTOR).
10832	CPRFalse	TCDD treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of @CHEMICAL$ (@GENE$).
10833	CPRFalse	@CHEMICAL$ treatment of the cells largely prevented the activation of @GENE$, a regulator of translation initiation and substrate of the mammalian target of rapamycin (mTOR).
10834	CPRFalse	@CHEMICAL$ treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the @GENE$ (mTOR).
10835	CPRFalse	@CHEMICAL$ treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of rapamycin (@GENE$).
10836	CPR:4	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and IGF-I-induced @GENE$ and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."
10837	CPR:4	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and IGF-I-induced AKT and @GENE$ activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."
10838	CPRFalse	"By ""working upwards"" from @CHEMICAL$, we observed that @GENE$ inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."
10839	CPR:4	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and @GENE$-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."
10840	CPRFalse	"By ""working upwards"" from mTOR, we observed that @CHEMICAL$ inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of @GENE$."
10841	CPRFalse	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced @CHEMICAL$ and ERK activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."
10842	CPRFalse	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and @CHEMICAL$ activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."
10843	CPRFalse	"By ""working upwards"" from @CHEMICAL$, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."
10844	CPRFalse	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and @CHEMICAL$-induced AKT and ERK activation by interfering with @GENE$ phosphorylation of insulin receptor substrate 1."
10845	CPRFalse	"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with @CHEMICAL$ phosphorylation of @GENE$."
10846	CPR:3	This inhibition was mediated by a @CHEMICAL$-induced secreted factor which was identified as @GENE$ (IGFBP-4).
10847	CPR:3	This inhibition was mediated by a @CHEMICAL$-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (@GENE$).
10848	CPRFalse	The induction of @CHEMICAL$ protein was dependent on a functional @GENE$ receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.
10849	CPRFalse	The induction of IGFBP-4 protein was dependent on a functional @CHEM-GENE$ and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.
10850	CPRFalse	The induction of IGFBP-4 protein was dependent on a functional @CHEMICAL$ receptor and was preceded by a rapid increase in the level of @GENE$ mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.
10851	CPRFalse	The induction of IGFBP-4 protein was dependent on a functional @CHEMICAL$ receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that @GENE$ is a previously unknown transcriptional target of TCDD in 5L cells.
10852	CPRFalse	The induction of @CHEMICAL$ protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of @GENE$ in 5L cells.
10853	CPRFalse	The induction of IGFBP-4 protein was dependent on a functional @CHEMICAL$ and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of @GENE$ in 5L cells.
10854	CPR:4	The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of @CHEMICAL$ mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of @GENE$ in 5L cells.
10855	CPRFalse	The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that @CHEMICAL$ is a previously unknown transcriptional target of @GENE$ in 5L cells.
10856	CPRFalse	@CHEMICAL$ was not induced by @GENE$ in the parental cell line of 5L cells, Fao, and in various closely related rat hepatoma cell lines as well as in other unrelated cell types.
10857	CPRFalse	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing @CHEM-GENE$ leading to the induction of IGFBP-4 by TCDD.
10858	CPRFalse	The observations suggest that in 5L cells the @CHEMICAL$ gene may have got under the control of a promoter containing @GENE$ responsive element(s) leading to the induction of IGFBP-4 by TCDD.
10859	CPRFalse	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing @CHEMICAL$ responsive element(s) leading to the induction of @GENE$ by TCDD.
10860	CPRFalse	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing @CHEMICAL$ leading to the induction of IGFBP-4 by @GENE$.
10861	CPRFalse	The observations suggest that in 5L cells the @CHEMICAL$ gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of IGFBP-4 by @GENE$.
10862	CPR:3	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of @CHEMICAL$ by @GENE$.
10863	CPRFalse	Similar concentrations of these compounds blocked @CHEMICAL$-induced growth of MCF-7 cells, but @GENE$ (ER) interactions do not seem to be involved.
10864	CPRFalse	Similar concentrations of these compounds blocked @CHEMICAL$-induced growth of MCF-7 cells, but estrogen receptor (@GENE$) interactions do not seem to be involved.
10865	CPRFalse	Similar concentrations of these compounds blocked estradiol-induced growth of MCF-7 cells, but @CHEM-GENE$ (ER) interactions do not seem to be involved.
10866	CPRFalse	Similar concentrations of these compounds blocked estradiol-induced growth of MCF-7 cells, but @CHEMICAL$ receptor (@GENE$) interactions do not seem to be involved.
10867	CPRFalse	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 @CHEMICAL$, nor did pimozide interfere with the induction of progesterone receptors by @GENE$.
10868	CPRFalse	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @CHEMICAL$ by @GENE$.
10869	CPRFalse	@CHEMICAL$ and thioridazine had no effect on the estradiol binding properties of the MCF-7 @GENE$, nor did pimozide interfere with the induction of progesterone receptors by estradiol.
10870	CPRFalse	@CHEMICAL$ and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @GENE$ by estradiol.
10871	CPRFalse	Pimozide and @CHEMICAL$ had no effect on the estradiol binding properties of the MCF-7 @GENE$, nor did pimozide interfere with the induction of progesterone receptors by estradiol.
10872	CPRFalse	Pimozide and @CHEMICAL$ had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @GENE$ by estradiol.
10873	CPRFalse	Pimozide and thioridazine had no effect on the @CHEMICAL$ binding properties of the MCF-7 @GENE$, nor did pimozide interfere with the induction of progesterone receptors by estradiol.
10874	CPRFalse	Pimozide and thioridazine had no effect on the @CHEMICAL$ binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @GENE$ by estradiol.
10875	CPRFalse	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 @CHEMICAL$, nor did @GENE$ interfere with the induction of progesterone receptors by estradiol.
10876	CPRFalse	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did @CHEMICAL$ interfere with the induction of @GENE$ by estradiol.
10877	CPRFalse	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 @CHEMICAL$, nor did pimozide interfere with the induction of @GENE$ receptors by estradiol.
10878	CPRFalse	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of @CHEM-GENE$ by estradiol.
10879	CPRFalse	Furthermore, @CHEMICAL$ also inhibited incorporation of [3H]thymidine into MCF-7 cells stimulated by @GENE$ in serum-free medium.
10880	CPRFalse	Furthermore, pimozide also inhibited incorporation of @CHEMICAL$ into MCF-7 cells stimulated by @GENE$ in serum-free medium.
10881	CPRFalse	The Ki for @CHEMICAL$ in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of @GENE$ (0.42 microM), insulin-like growth factor I (0.54 microM), and epidermal growth factor (0.43 microM).
10882	CPRFalse	The Ki for @CHEMICAL$ in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of insulin (0.42 microM), @GENE$ (0.54 microM), and epidermal growth factor (0.43 microM).
10883	CPRFalse	The Ki for @CHEMICAL$ in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of insulin (0.42 microM), insulin-like growth factor I (0.54 microM), and @GENE$ (0.43 microM).
10884	CPRFalse	@CHEMICAL$ also blocked cell growth and [3H]thymidine incorporation into the @GENE$-positive T47D and ZR75-1B human breast cancer cell lines and the ER-negative human breast cancer cell line, MDA-MB-231.
10885	CPRFalse	@CHEMICAL$ also blocked cell growth and [3H]thymidine incorporation into the ER-positive T47D and ZR75-1B human breast cancer cell lines and the @GENE$-negative human breast cancer cell line, MDA-MB-231.
10886	CPRFalse	Pimozide also blocked cell growth and @CHEMICAL$ incorporation into the @GENE$-positive T47D and ZR75-1B human breast cancer cell lines and the ER-negative human breast cancer cell line, MDA-MB-231.
10887	CPRFalse	Pimozide also blocked cell growth and @CHEMICAL$ incorporation into the ER-positive T47D and ZR75-1B human breast cancer cell lines and the @GENE$-negative human breast cancer cell line, MDA-MB-231.
10888	CPR:6	Although numerous mechanisms of action of @CHEMICAL$ and thioridazine have been identified, both drugs are @GENE$ antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.
10889	CPR:6	Although numerous mechanisms of action of pimozide and @CHEMICAL$ have been identified, both drugs are @GENE$ antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.
10890	CPR:6	Inhibition of MCF-7 cell growth by the selective @CHEMICAL$ antagonists @GENE$ and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.
10891	CPRFalse	Inhibition of MCF-7 cell growth by the selective calmodulin antagonists @CHEMICAL$ and W-12 is consistent with a role for @GENE$ antagonism in the broad growth-inhibitory properties of pimozide.
10892	CPR:6	Inhibition of MCF-7 cell growth by the selective @CHEMICAL$ antagonists W-13 and @GENE$ is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.
10893	CPRFalse	Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and @CHEMICAL$ is consistent with a role for @GENE$ antagonism in the broad growth-inhibitory properties of pimozide.
10894	CPRFalse	Inhibition of MCF-7 cell growth by the selective @CHEMICAL$ antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of @GENE$.
10895	CPR:4	Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for @CHEMICAL$ antagonism in the broad growth-inhibitory properties of @GENE$.
10896	CPRFalse	We conclude that @CHEMICAL$ and thioridazine may be useful in the control of estradiol- and @GENE$-induced growth of ER-positive and ER-negative human breast tumors.
10897	CPRFalse	We conclude that @CHEMICAL$ and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of @GENE$-positive and ER-negative human breast tumors.
10898	CPRFalse	We conclude that @CHEMICAL$ and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and @GENE$-negative human breast tumors.
10899	CPRFalse	We conclude that pimozide and @CHEMICAL$ may be useful in the control of estradiol- and @GENE$-induced growth of ER-positive and ER-negative human breast tumors.
10900	CPRFalse	We conclude that pimozide and @CHEMICAL$ may be useful in the control of estradiol- and polypeptide hormone-induced growth of @GENE$-positive and ER-negative human breast tumors.
10901	CPRFalse	We conclude that pimozide and @CHEMICAL$ may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and @GENE$-negative human breast tumors.
10902	CPRFalse	We conclude that pimozide and thioridazine may be useful in the control of @CHEMICAL$- and @GENE$-induced growth of ER-positive and ER-negative human breast tumors.
10903	CPRFalse	We conclude that pimozide and thioridazine may be useful in the control of @CHEMICAL$- and polypeptide hormone-induced growth of @GENE$-positive and ER-negative human breast tumors.
10904	CPRFalse	We conclude that pimozide and thioridazine may be useful in the control of @CHEMICAL$- and polypeptide hormone-induced growth of ER-positive and @GENE$-negative human breast tumors.
10905	CPRFalse	Effects of @CHEM-GENE$ inhibitors on levels of catechols and homovanillic acid in striatum and plasma.
10906	CPRFalse	Effects of @CHEMICAL$ inhibitors on levels of @GENE$ and homovanillic acid in striatum and plasma.
10907	CPRFalse	Effects of @CHEMICAL$ inhibitors on levels of catechols and @GENE$ in striatum and plasma.
10908	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @CHEMICAL$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10909	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @GENE$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10910	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by clorgyline (4 mg/kg i.p.), MAO-B by @GENE$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10911	CPR:4	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @CHEMICAL$ by @GENE$ (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10912	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @CHEMICAL$ (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10913	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by @CHEMICAL$ (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10914	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @CHEMICAL$ (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10915	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10916	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10917	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @CHEMICAL$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10918	CPR:4	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @CHEMICAL$ and MAO-B by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10919	CPR:4	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @CHEMICAL$ by @GENE$ (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10920	CPRFalse	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10921	CPRFalse	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10922	CPRFalse	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10923	CPRFalse	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10924	CPRFalse	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10925	CPRFalse	Levels of homovanillic acid (@CHEMICAL$), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10926	CPR:4	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @CHEMICAL$ by @GENE$ (40 mg/kg i.p.).
10927	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).
10928	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).
10929	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @CHEMICAL$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).
10930	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @CHEMICAL$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).
10931	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @CHEMICAL$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by @GENE$ (40 mg/kg i.p.).
10932	CPRFalse	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10933	CPRFalse	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10934	CPRFalse	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10935	CPRFalse	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10936	CPRFalse	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10937	CPRFalse	Levels of homovanillic acid (HVA), @CHEMICAL$ (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10938	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10939	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10940	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10941	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10942	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10943	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (@CHEMICAL$) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10944	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10945	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10946	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10947	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10948	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10949	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and @CHEMICAL$ (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10950	CPRFalse	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10951	CPRFalse	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10952	CPRFalse	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10953	CPRFalse	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10954	CPRFalse	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10955	CPRFalse	Levels of @CHEMICAL$ (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10956	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10957	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of @GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10958	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10959	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10960	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10961	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (@CHEMICAL$) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10962	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10963	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEM-GENE$ (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10964	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (@GENE$) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10965	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10966	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10967	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10968	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal @GENE$ by debrisoquin (40 mg/kg i.p.).
10969	CPR:4	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of @CHEMICAL$ (MAO-A) by @GENE$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10970	CPR:4	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (@CHEMICAL$) by @GENE$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10971	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), @GENE$ by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10972	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both @GENE$ and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10973	CPRFalse	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by @CHEMICAL$ (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and @GENE$ by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).
10974	CPR:9	The results suggest that most of the HVA in plasma is derived from deamination of @CHEMICAL$ by @GENE$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.
10975	CPR:9	The results suggest that most of the @CHEMICAL$ in plasma is derived from deamination of DA by @GENE$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.
10976	CPRFalse	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that @GENE$ in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.
10977	CPRFalse	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that @GENE$ in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.
10978	CPRFalse	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of @GENE$ in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.
10979	CPRFalse	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of @GENE$ after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.
10980	CPRFalse	The results suggest that most of the HVA in plasma is derived from deamination of DA by @CHEMICAL$ in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with @GENE$ provide an improved but limited indication of central dopaminergic activity.
10981	CPRFalse	This lack of difference was unexpected since the genes for @CHEMICAL$ and esterase D, also called @GENE$ hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.
10982	CPRFalse	This lack of difference was unexpected since the genes for catalase and @CHEMICAL$, also called @GENE$ hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.
10983	CPRFalse	This lack of difference was unexpected since the genes for catalase and esterase D, also called @CHEM-GENE$, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.
10984	CPRFalse	Developmental changes in @CHEM-GENE$ activity in young jaundiced male rats.
10985	CPRFalse	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, @CHEM-GENE$ (LDH-X), and serum testosterone levels.
10986	CPRFalse	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, @CHEMICAL$ dehydrogenase-X (@GENE$), and serum testosterone levels.
10987	CPRFalse	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, @CHEMICAL$ (LDH-X), and serum @GENE$ levels.
10988	CPRFalse	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, lactate dehydrogenase-X (@CHEMICAL$), and serum @GENE$ levels.
10989	CPRFalse	Testicular cytosolic @CHEMICAL$ activity was determined by oxidation of reduced @GENE$ (NADH).
10990	CPRFalse	Testicular cytosolic @CHEMICAL$ activity was determined by oxidation of reduced nicotinamide adenine dinucleotide (@GENE$).
10991	CPRFalse	@CHEMICAL$ activity and serum @GENE$ levels were similar for both genotypes at 180 days of age.
10992	CPRFalse	The delay of testicular maturation in the jaundiced males seems to be due to lower @CHEMICAL$ activity and serum @GENE$ levels.
10993	CPRFalse	@CHEMICAL$ modifies but does not block the @GENE$-induced ACTH response in patients with Addison's disease.
10994	CPRFalse	@CHEMICAL$ modifies but does not block the corticotropin-releasing hormone-induced @GENE$ response in patients with Addison's disease.
10995	CPRFalse	The effect of @CHEMICAL$ - a peripheral opiate agonist - on plasma @GENE$ response to Corticotropin-releasing Hormone (CRH) has been investigated in 6 patients with Addison's disease.
10996	CPRFalse	The effect of @CHEMICAL$ - a peripheral opiate agonist - on plasma ACTH response to @GENE$ (CRH) has been investigated in 6 patients with Addison's disease.
10997	CPRFalse	The effect of @CHEMICAL$ - a peripheral opiate agonist - on plasma ACTH response to Corticotropin-releasing Hormone (@GENE$) has been investigated in 6 patients with Addison's disease.
10998	CPRFalse	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of @GENE$ response to CRH was slightly delayed.
10999	CPRFalse	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to @GENE$ was slightly delayed.
11000	CPR:4	After @CHEMICAL$ administration @GENE$ levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.
11001	CPRFalse	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then @GENE$ was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.
11002	CPR:3	After @CHEMICAL$ administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an @GENE$ increase; the pattern of ACTH response to CRH was slightly delayed.
11003	CPR:6	@CHEMICAL$ is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize @GENE$ as well.
11004	CPR:4	@CHEMICAL$ is known to be an inhibitor of @GENE$, and recent data have shown this drug to antagonize muscarinic receptors as well.
11005	CPRFalse	@CHEMICAL$ was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the @GENE$ inhibitor neostigmine.
11006	CPRFalse	Ambenonium was a less potent antagonist of tissue responses to @CHEMICAL$, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the @GENE$ inhibitor neostigmine.
11007	CPRFalse	Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with @CHEMICAL$) could be eliminated by prior treatment of tissues with the @GENE$ inhibitor neostigmine.
11008	CPR:4	Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the @CHEMICAL$ inhibitor @GENE$.
11009	CPR:6	These data suggested that @CHEMICAL$ had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of @GENE$.
11010	CPR:4	These data suggested that @CHEMICAL$ had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of @GENE$.
11011	CPR:4	These data suggested that @CHEMICAL$ had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of @GENE$ and concomitant antagonism by blockade of muscarinic receptors.
11012	CPRFalse	These data suggested that ambenonium had a dual effect on tissue responses to @CHEMICAL$-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of @GENE$.
11013	CPR:5	These data suggested that ambenonium had a dual effect on tissue responses to @CHEMICAL$-producing potentiation by blockade of @GENE$ and concomitant antagonism by blockade of muscarinic receptors.
11014	CPR:4	However, @CHEMICAL$ produces less systemic beta 2- and possibly @GENE$ blockade than either timolol or levobunolol.
11015	CPR:4	However, betaxolol produces less systemic beta 2- and possibly @CHEMICAL$ blockade than either @GENE$ or levobunolol.
11016	CPR:4	However, betaxolol produces less systemic beta 2- and possibly @CHEMICAL$ blockade than either timolol or @GENE$.
11017	CPRFalse	@CHEMICAL$ sequence of the gene for @GENE$ (antihemophilic factor B).
11018	CPRFalse	@CHEMICAL$ sequence of the gene for human factor IX (@GENE$).
11019	CPRFalse	Autoradiography of @CHEMICAL$ gels of cross-linked @GENE$ showed only three protein bands specifically binding salmon calcitonin.
11020	CPR:9	@CHEMICAL$ catalyzes an unusual oxidative decarboxylation of @GENE$.
11021	CPR:9	@CHEMICAL$ usually catalyzes the conversion of @GENE$ to o-diphenols and oxidation of diphenols to the corresponding quinones.
11022	CPR:9	@CHEMICAL$ usually catalyzes the conversion of monophenols to o-diphenols and oxidation of @GENE$ to the corresponding quinones.
11023	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEM-GENE$, ceruloplasmin, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.
11024	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, @GENE$, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.
11025	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, superoxide dismutase, @GENE$, dopamine beta-hydroxylase, and peroxidase.
11026	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and @GENE$.
11027	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, @GENE$, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.
11028	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$ oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @GENE$, and peroxidase.
11029	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$, ceruloplasmin, @GENE$ dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.
11030	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEM-GENE$, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.
11031	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$ dismutase, @GENE$, dopamine beta-hydroxylase, and peroxidase.
11032	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$ dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and @GENE$.
11033	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, @CHEMICAL$, @GENE$ dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.
11034	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$ dismutase, ascorbate oxidase, @GENE$, and peroxidase.
11035	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$, ceruloplasmin, superoxide dismutase, @GENE$ oxidase, dopamine beta-hydroxylase, and peroxidase.
11036	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$, @GENE$ oxidase, dopamine beta-hydroxylase, and peroxidase.
11037	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEM-GENE$, dopamine beta-hydroxylase, and peroxidase.
11038	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEMICAL$ oxidase, dopamine beta-hydroxylase, and @GENE$.
11039	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, @CHEMICAL$, superoxide dismutase, @GENE$ oxidase, dopamine beta-hydroxylase, and peroxidase.
11040	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEMICAL$ oxidase, @GENE$, and peroxidase.
11041	CPRFalse	None of the following enzymes tested catalyzed the new reaction: @CHEMICAL$, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @GENE$ beta-hydroxylase, and peroxidase.
11042	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, @CHEMICAL$, ascorbate oxidase, @GENE$ beta-hydroxylase, and peroxidase.
11043	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, @CHEMICAL$, @GENE$ beta-hydroxylase, and peroxidase.
11044	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @CHEMICAL$ beta-hydroxylase, and @GENE$.
11045	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, @CHEMICAL$, superoxide dismutase, ascorbate oxidase, @GENE$ beta-hydroxylase, and peroxidase.
11046	CPRFalse	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, @CHEM-GENE$, and peroxidase.
11047	CPRFalse	@CHEM-GENE$ inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.
11048	CPR:4	@CHEMICAL$ inhibitors such as @GENE$, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.
11049	CPR:4	@CHEMICAL$ inhibitors such as phenylthiourea, @GENE$, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.
11050	CPR:4	@CHEMICAL$ inhibitors such as phenylthiourea, potassium cyanide, and @GENE$ inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.
11051	CPRFalse	@CHEMICAL$ inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site @GENE$ of the enzyme in the catalysis.
11052	CPR:4	@CHEMICAL$, a well-known competitive inhibitor of @GENE$, competitively inhibited the new reaction also.
11053	CPR:9	Present studies demonstrate that @CHEMICAL$ will also catalyze quinone methide production with the same active site copper if a suitable substrate such as @GENE$ is provided.
11054	CPR:9	Present studies demonstrate that @CHEMICAL$ will also catalyze @GENE$ production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.
11055	CPR:4	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (@CHEMICAL$) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).
11056	CPR:4	The activation of @CHEMICAL$ [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).
11057	CPR:4	The activation of human [Glu1]plasminogen [@CHEMICAL$) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).
11058	CPR:4	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain @CHEMICAL$ (t-PA) is inhibited by @GENE$, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).
11059	CPR:3	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (@CHEMICAL$) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).
11060	CPR:3	The activation of @CHEMICAL$ [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).
11061	CPR:3	The activation of human [Glu1]plasminogen [@CHEMICAL$) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).
11062	CPR:3	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain @CHEMICAL$ (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by @GENE$ (EACA), as well as fibrin(ogen).
11063	CPR:3	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (@CHEMICAL$) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).
11064	CPR:3	The activation of @CHEMICAL$ [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).
11065	CPR:3	The activation of human [Glu1]plasminogen [@CHEMICAL$) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).
11066	CPR:3	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain @CHEMICAL$ (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (@GENE$), as well as fibrin(ogen).
11067	CPRFalse	@CHEMICAL$ functions as a result of its binding to @GENE$, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-t-PA.
11068	CPRFalse	@CHEMICAL$ functions as a result of its binding to [Glu1]Pg, with a Ki of approximately 9.0 mM, thereby rendering @GENE$ a less effective substrate for two-chain rec-t-PA.
11069	CPRFalse	@CHEMICAL$ functions as a result of its binding to [Glu1]Pg, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-@GENE$.
11070	CPRFalse	@CHEMICAL$ appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-t-PA, with a Ka of approximately 3.7 microM in activation systems containing physiological levels of @GENE$.
11071	CPRFalse	Fibrinogen appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-@CHEMICAL$, with a Ka of approximately 3.7 microM in activation systems containing physiological levels of @GENE$.
11072	CPRFalse	Analysis of the results of this paper reveals that normal plasma components, @CHEMICAL$ and @GENE$, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-t-PA, in in vitro systems.
11073	CPRFalse	Analysis of the results of this paper reveals that normal plasma components, @CHEMICAL$ and fibrinogen, exert major regulatory roles on the ability of @GENE$ to be activated by two-chain rec-t-PA, in in vitro systems.
11074	CPRFalse	Analysis of the results of this paper reveals that normal plasma components, @CHEMICAL$ and fibrinogen, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-@GENE$, in in vitro systems.
11075	CPRFalse	The presence of @CHEMICAL$ inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of @GENE$, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.
11076	CPR:4	The presence of @CHEMICAL$ inhibits the stimulation of @GENE$ activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.
11077	CPRFalse	The presence of @CHEMICAL$ inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of @GENE$.
11078	CPRFalse	@CHEM-GENE$ activity was decreased when the assay was performed under both optimal and suboptimal reducing conditions, suggesting heterogeneity in the cblE disease.
11079	CPRFalse	We also analyzed the formation of 125I-@CHEMICAL$ -inhibitor complexes by sodium dodecyl sulfate @GENE$ gel electrophoresis (SDS-PAGE).
11080	CPRFalse	We also analyzed the formation of @CHEMICAL$-@GENE$ -inhibitor complexes by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
11081	CPRFalse	We also analyzed the formation of 125I-@CHEMICAL$ -inhibitor complexes by @GENE$ polyacrylamide gel electrophoresis (SDS-PAGE).
11082	CPRFalse	In purified systems, the bimolecular rate constants for the reactions of @CHEMICAL$ with @GENE$-1-inhibitor, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.
11083	CPRFalse	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with @CHEM-GENE$, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.
11084	CPRFalse	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with @CHEMICAL$-1-inhibitor, @GENE$, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.
11085	CPRFalse	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with @CHEMICAL$-1-inhibitor, alpha 2-antiplasmin, and @GENE$ were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.
11086	CPRFalse	Furthermore, SDS-PAGE analysis revealed that 1:1 stoichiometric complexes were formed between @CHEMICAL$-@GENE$ and each of these three inhibitors.
11087	CPRFalse	This constant was reduced to 1.8 X 10(-2) min-1 when @CHEMICAL$ was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of @GENE$-1-inhibitor.
11088	CPRFalse	This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by @CHEMICAL$-deficient plasma that had been immunodepleted (less than 5%) of @GENE$-1-inhibitor.
11089	CPRFalse	This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of @CHEM-GENE$.
11090	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-@GENE$ was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.
11091	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-Factor XIIf was found to form a complex with @GENE$, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.
11092	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with @GENE$ and antithrombin III.
11093	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active @CHEMICAL$-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and @GENE$.
11094	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active 125I-@CHEMICAL$ was found to form a complex with @GENE$-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.
11095	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with @CHEM-GENE$, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.
11096	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with @CHEMICAL$-1-inhibitor, whereas 26% of the enzyme formed complexes with @GENE$ and antithrombin III.
11097	CPRFalse	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with @CHEMICAL$-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and @GENE$.
11098	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with @CHEM-GENE$ when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.
11099	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$-1-inhibitor when 125I-@GENE$ was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.
11100	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$-1-inhibitor when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$.
11101	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$ when @GENE$-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.
11102	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when @CHEMICAL$-@GENE$ was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.
11103	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when @CHEMICAL$-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$.
11104	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with @CHEMICAL$ when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$-1-inhibitor.
11105	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when 125I-@CHEMICAL$ was inactivated in hereditary angioedema plasma that contained 32% of functional @GENE$-1-inhibitor.
11106	CPRFalse	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional @CHEM-GENE$.
11107	CPRFalse	This study quantitatively demonstrates the dominant role of @CHEM-GENE$ in the inactivation of Factor XIIf in the plasma milieu.
11108	CPRFalse	This study quantitatively demonstrates the dominant role of @CHEMICAL$-1-inhibitor in the inactivation of @GENE$ in the plasma milieu.
11109	CPRFalse	@CHEMICAL$-dependent norepinephrine-induced currents in @GENE$-transfected HEK-293 cells blocked by cocaine and antidepressants.
11110	CPR:4	Sodium-dependent norepinephrine-induced currents in @CHEMICAL$-transfected HEK-293 cells blocked by @GENE$ and antidepressants.
11111	CPR:3	Sodium-dependent @CHEMICAL$-induced currents in @GENE$-transfected HEK-293 cells blocked by cocaine and antidepressants.
11112	CPRFalse	Sodium-dependent norepinephrine-induced currents in @CHEM-GENE$-transfected HEK-293 cells blocked by cocaine and antidepressants.
11113	CPRFalse	To explore the relationship between @CHEMICAL$ transport and ion permeation through the @GENE$, we established a human norepinephrine transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.
11114	CPRFalse	To explore the relationship between @CHEMICAL$ transport and ion permeation through the NE transporter, we established a @GENE$ (hNET) cell line suitable for biochemical analysis and patch-clamp recording.
11115	CPRFalse	To explore the relationship between @CHEMICAL$ transport and ion permeation through the NE transporter, we established a human norepinephrine transporter (@GENE$) cell line suitable for biochemical analysis and patch-clamp recording.
11116	CPRFalse	To explore the relationship between catecholamine transport and ion permeation through the @CHEM-GENE$, we established a human norepinephrine transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.
11117	CPRFalse	To explore the relationship between catecholamine transport and ion permeation through the @CHEMICAL$ transporter, we established a @GENE$ (hNET) cell line suitable for biochemical analysis and patch-clamp recording.
11118	CPRFalse	To explore the relationship between catecholamine transport and ion permeation through the @CHEMICAL$ transporter, we established a human norepinephrine transporter (@GENE$) cell line suitable for biochemical analysis and patch-clamp recording.
11119	CPRFalse	To explore the relationship between catecholamine transport and ion permeation through the @CHEMICAL$, we established a human @GENE$ transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.
11120	CPRFalse	To explore the relationship between catecholamine transport and ion permeation through the NE transporter, we established a @CHEM-GENE$ (hNET) cell line suitable for biochemical analysis and patch-clamp recording.
11121	CPRFalse	To explore the relationship between catecholamine transport and ion permeation through the NE transporter, we established a human @CHEMICAL$ transporter (@GENE$) cell line suitable for biochemical analysis and patch-clamp recording.
11122	CPRFalse	Stable transfection of @CHEMICAL$ cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and hNET-specific antibodies, (2) high-affinity, @GENE$-dependent transport of NE, and (3) inhibitor sensitivities similar to those of native membranes.
11123	CPRFalse	Stable transfection of hNET cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and @CHEMICAL$-specific antibodies, (2) high-affinity, @GENE$-dependent transport of NE, and (3) inhibitor sensitivities similar to those of native membranes.
11124	CPRFalse	Stable transfection of @CHEMICAL$ cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and hNET-specific antibodies, (2) high-affinity, Na(+)-dependent transport of @GENE$, and (3) inhibitor sensitivities similar to those of native membranes.
11125	CPRFalse	Stable transfection of hNET cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and @CHEMICAL$-specific antibodies, (2) high-affinity, Na(+)-dependent transport of @GENE$, and (3) inhibitor sensitivities similar to those of native membranes.
11126	CPR:3	Whole-cell voltage-clamp of @CHEMICAL$-293 cells reveals @GENE$-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.
11127	CPRFalse	Whole-cell voltage-clamp of @CHEMICAL$-293 cells reveals NE-induced, @GENE$-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.
11128	CPR:4	Whole-cell voltage-clamp of @CHEMICAL$-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and @GENE$ that are absent in parental cells.
11129	CPRFalse	In addition to NE-dependent currents, transfected cells posses an @CHEMICAL$-independent mode of charge movement mediated by @GENE$.
11130	CPRFalse	In addition to @CHEMICAL$-dependent currents, transfected cells posses an NE-independent mode of charge movement mediated by @GENE$.
11131	CPRFalse	@CHEMICAL$ antagonists without effect in non-transfected cells abolish both @GENE$-dependent and NE-independent modes of charge movement in transfected cells.
11132	CPRFalse	@CHEMICAL$ antagonists without effect in non-transfected cells abolish both NE-dependent and @GENE$-independent modes of charge movement in transfected cells.
11133	CPRFalse	To explain our observations, we propose that hNETs function as @CHEMICAL$ with an indefinite stoichiometry relating ion flux to @GENE$ transport.
11134	CPR:9	To explain our observations, we propose that @CHEMICAL$ function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to @GENE$ transport.
11135	CPRFalse	The @CHEMICAL$-terminal portion of TSG-6 shows sequence homology to members of the cartilage link protein family of @GENE$.
11136	CPRFalse	The @CHEMICAL$-terminal portion of @GENE$ shows sequence homology to members of the cartilage link protein family of hyaluronan binding proteins.
11137	CPRFalse	The @CHEMICAL$-terminal half of TSG-6 contains a so-called @GENE$, characteristic for developmentally regulated proteins.
11138	CPRFalse	The @CHEMICAL$-terminal half of @GENE$ contains a so-called CUB domain, characteristic for developmentally regulated proteins.
11139	CPRFalse	The protein that binds TSG-6 was purified from human serum and identified as @CHEMICAL$ (I alpha I) by @GENE$-terminal microsequencing.
11140	CPRFalse	The protein that binds TSG-6 was purified from human serum and identified as inter-alpha-inhibitor (@CHEMICAL$) by @GENE$-terminal microsequencing.
11141	CPRFalse	The protein that binds @CHEMICAL$ was purified from human serum and identified as inter-alpha-inhibitor (I alpha I) by @GENE$-terminal microsequencing.
11142	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/@CHEMICAL$ complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11143	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by @CHEM-GENE$, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11144	CPRFalse	Experiments with recombinant TSG-6 and @CHEMICAL$ purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11145	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/@CHEMICAL$ complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11146	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The @CHEMICAL$/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11147	CPRFalse	Experiments with recombinant @CHEMICAL$ and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11148	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the @CHEMICAL$/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin @GENE$ ABC lyase, suggesting that cross-linking by chondroitin sulfate is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11149	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/@CHEMICAL$ complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11150	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by @CHEMICAL$, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11151	CPRFalse	Experiments with recombinant TSG-6 and @CHEMICAL$ purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11152	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/@CHEMICAL$ complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11153	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The @CHEMICAL$/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11154	CPRFalse	Experiments with recombinant @CHEMICAL$ and I alpha I purified from human serum showed that the TSG-6/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11155	CPRFalse	Experiments with recombinant TSG-6 and I alpha I purified from human serum showed that the @CHEMICAL$/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/I alpha I complex was cleaved by chondroitin sulfate ABC lyase, suggesting that cross-linking by chondroitin @GENE$ is required for the stability of the complex.(ABSTRACT TRUNCATED AT 250 WORDS)
11156	CPR:4	BACKGROUND: The active metabolite of the anti-inflammatory drug @CHEMICAL$ has been characterized as a selective inhibitor of the inducible @GENE$ (PGHS).
11157	CPR:4	BACKGROUND: The active metabolite of the anti-inflammatory drug @CHEMICAL$ has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (@GENE$).
11158	CPRFalse	BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible @CHEM-GENE$ (PGHS).
11159	CPRFalse	BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible @CHEMICAL$ H synthase (@GENE$).
11160	CPRFalse	METHODS: We measured the urinary excretion of products of platelet (@CHEMICAL$ [TXB2]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.
11161	CPRFalse	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [@CHEMICAL$]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.
11162	CPRFalse	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (@CHEMICAL$ [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.
11163	CPRFalse	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (prostaglandin IF2 alpha [@CHEMICAL$]) arachidonate metabolism as in vivo indexes of the constitutive @GENE$ pathway.
11164	CPRFalse	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) @CHEMICAL$ metabolism as in vivo indexes of the constitutive @GENE$ pathway.
11165	CPR:9	Moreover, the production of @CHEMICAL$ during whole blood clotting was assessed as an index of the @GENE$ activity of platelet PGHS-1 ex vivo.
11166	CPR:9	Moreover, the production of @CHEMICAL$ during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet @GENE$ ex vivo.
11167	CPR:4	The daily administration of low-dose @CHEMICAL$ (40 mg), a selective inhibitor of platelet @GENE$, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.
11168	CPR:9	The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet @CHEMICAL$, caused a cumulative inhibition of urinary @GENE$ and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.
11169	CPR:9	The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet @CHEMICAL$, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood @GENE$ production that recovered with a timecourse consistent with platelet turnover.
11170	CPR:4	CONCLUSIONS: @CHEMICAL$ does dose-dependently inhibit the @GENE$ activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.
11171	CPR:4	CONCLUSIONS: @CHEMICAL$ does dose-dependently inhibit the cyclooxygenase activity of platelet @GENE$ of healthy subjects both in vivo and ex vivo.
11172	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ (CREB).
11173	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (@GENE$).
11174	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (@GENE$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11175	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), @GENE$ (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11176	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (@GENE$), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11177	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @GENE$ (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11178	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (@GENE$), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11179	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ (RAR gamma), and cAMP response element binding protein (CREB).
11180	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic @CHEMICAL$ receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (@GENE$), and cAMP response element binding protein (CREB).
11181	CPRFalse	This analysis revealed significant differences in the expression level of the @CHEM-GENE$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11182	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ (CREB).
11183	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (@GENE$).
11184	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (@CHEMICAL$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11185	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), @CHEMICAL$ (TGF beta 2), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11186	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (@CHEMICAL$), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11187	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @CHEM-GENE$ (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11188	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (@GENE$), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11189	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), @GENE$ (RAR gamma), and cAMP response element binding protein (CREB).
11190	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @CHEMICAL$ binding protein (CRBP-1), retinoic acid receptor gamma (@GENE$), and cAMP response element binding protein (CREB).
11191	CPRFalse	This analysis revealed significant differences in the expression level of the @CHEMICAL$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular @GENE$ binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11192	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ receptor gamma (RAR gamma), and @GENE$ (CREB).
11193	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ receptor gamma (RAR gamma), and cAMP response element binding protein (@GENE$).
11194	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (@CHEMICAL$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11195	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), @CHEMICAL$ (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11196	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (@CHEMICAL$), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11197	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @CHEMICAL$ (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11198	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (@CHEMICAL$), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11199	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEM-GENE$ (RAR gamma), and cAMP response element binding protein (CREB).
11200	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ receptor gamma (@GENE$), and cAMP response element binding protein (CREB).
11201	CPRFalse	This analysis revealed significant differences in the expression level of the @CHEMICAL$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @GENE$ receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).
11202	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @CHEM-GENE$ (CREB).
11203	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @CHEMICAL$ response element binding protein (@GENE$).
11204	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (@CHEMICAL$), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).
11205	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), @CHEMICAL$ (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).
11206	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (@CHEMICAL$), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).
11207	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), @CHEMICAL$ (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).
11208	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (@CHEMICAL$), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).
11209	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), @CHEMICAL$ (RAR gamma), and @GENE$ response element binding protein (CREB).
11210	CPRFalse	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (@CHEMICAL$), and @GENE$ response element binding protein (CREB).
11211	CPRFalse	This analysis revealed significant differences in the expression level of the @CHEMICAL$ (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and @GENE$ response element binding protein (CREB).
11212	CPRFalse	@CHEM-GENE$ in primary tumours and metastases of malignant melanoma.
11213	CPRFalse	The presence of @CHEMICAL$ (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the @GENE$ receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.
11214	CPRFalse	The presence of estramustine binding protein (@CHEMICAL$), a 54 kD cytosolic glycoprotein, which is distinct from the @GENE$ receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.
11215	CPRFalse	The presence of estramustine binding protein (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the @CHEM-GENE$, was investigated in a pilot study of primary malignant melanomas and their metastases.
11216	CPRFalse	The presence of @CHEM-GENE$ (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the estrogen receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.
11217	CPRFalse	The presence of @CHEMICAL$ binding protein (@GENE$), a 54 kD cytosolic glycoprotein, which is distinct from the estrogen receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.
11218	CPRFalse	The presence of @CHEMICAL$ binding protein (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the @GENE$, was investigated in a pilot study of primary malignant melanomas and their metastases.
11219	CPR:6	Preclinical efficacy of @CHEMICAL$, a potent, selective @GENE$ antagonist for topical ocular use.
11220	CPRFalse	Preclinical efficacy of emedastine, a potent, selective @CHEM-GENE$ antagonist for topical ocular use.
11221	CPRFalse	@CHEMICAL$ (0.1%) failed to significantly attenuate either serotonin or platelet-activating-factor induced vascular permeability changes indicating high selectivity for the @GENE$.
11222	CPRFalse	Emedastine (0.1%) failed to significantly attenuate either serotonin or platelet-activating-factor induced vascular permeability changes indicating high selectivity for the @CHEM-GENE$.
11223	CPR:4	(2) Exposure histories vary in secondary 11q23 leukemia, as the only @CHEMICAL$ inhibitor was @GENE$ in one case, and, in another case, no topoisomerase II inhibitor was administered.
11224	CPRFalse	(2) Exposure histories vary in secondary 11q23 leukemia, as the only topoisomerase II inhibitor was @CHEMICAL$ in one case, and, in another case, no @GENE$ inhibitor was administered.
11225	CPRFalse	There are two isozymes of @CHEMICAL$ endoperoxide (PGH) synthase (cyclooxygenase) called PGH synthase-1 and -2 or @GENE$.
11226	CPRFalse	There are two isozymes of @CHEM-GENE$ (cyclooxygenase) called PGH synthase-1 and -2 or COX I and II.
11227	CPRFalse	There are two isozymes of @CHEMICAL$ endoperoxide (PGH) synthase (@GENE$) called PGH synthase-1 and -2 or COX I and II.
11228	CPRFalse	There are two isozymes of @CHEMICAL$ endoperoxide (PGH) synthase (cyclooxygenase) called @GENE$ or COX I and II.
11229	CPR:4	@CHEMICAL$, piroxicam, and sulindac sulfide were found to preferentially inhibit @GENE$.
11230	CPR:4	Indomethacin, @CHEMICAL$, and sulindac sulfide were found to preferentially inhibit @GENE$.
11231	CPR:4	Indomethacin, piroxicam, and @CHEMICAL$ were found to preferentially inhibit @GENE$.
11232	CPR:4	@CHEMICAL$, the active metabolite of Relafen, inhibits murine @GENE$ preferentially.
11233	CPR:4	6-Methoxy-2-naphthylacetic acid, the active metabolite of @CHEMICAL$, inhibits murine @GENE$ preferentially.
11234	CPRFalse	Aspirin irreversibly inhibits @CHEMICAL$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (@GENE$) instead of PGH2.
11235	CPR:9	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of @CHEMICAL$ causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (@GENE$) instead of PGH2.
11236	CPR:4	@CHEMICAL$ irreversibly inhibits @GENE$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.
11237	CPRFalse	@CHEMICAL$ irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of @GENE$ causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.
11238	CPRFalse	Aspirin irreversibly inhibits @CHEMICAL$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, @GENE$ treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.
11239	CPRFalse	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, @CHEMICAL$ treatment of @GENE$ causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.
11240	CPRFalse	Aspirin irreversibly inhibits @CHEMICAL$, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form @GENE$ (15-HETE) instead of PGH2.
11241	CPR:9	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of @CHEMICAL$ causes this enzyme to form @GENE$ (15-HETE) instead of PGH2.
11242	CPRFalse	@CHEMICAL$ receptors mediate the satiating effect of @GENE$, whereas the mechanism by which 5-HT uptake inhibitors such as fluoxetine and sertraline cause anorexia is not clear.
11243	CPRFalse	@CHEMICAL$ receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which @GENE$ uptake inhibitors such as fluoxetine and sertraline cause anorexia is not clear.
11244	CPRFalse	@CHEMICAL$ receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which 5-HT uptake inhibitors such as @GENE$ and sertraline cause anorexia is not clear.
11245	CPRFalse	@CHEMICAL$ receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which 5-HT uptake inhibitors such as fluoxetine and @GENE$ cause anorexia is not clear.
11246	CPRFalse	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and @CHEMICAL$ seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.
11247	CPRFalse	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of @CHEMICAL$ and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.
11248	CPRFalse	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or @CHEMICAL$ from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.
11249	CPR:3	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of @CHEMICAL$, to stimulate directly @GENE$.
11250	CPRFalse	Anorexia induced by @CHEMICAL$, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.
11251	CPRFalse	Anorexia induced by (+)-amphetamine, @CHEMICAL$, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.
11252	CPRFalse	Anorexia induced by (+)-amphetamine, phentermine, @CHEMICAL$ and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly @GENE$.
11253	CPRFalse	It has been suggested that @CHEMICAL$ and D1 @GENE$ receptors are involved in their effect on food intake.
11254	CPRFalse	It has been suggested that beta- and alpha 1-adrenoceptors and @CHEM-GENE$ are involved in their effect on food intake.
11255	CPRFalse	Further characterization of @CHEM-GENE$ (putative 5-HT2B) in rat stomach fundus longitudinal muscle.
11256	CPRFalse	Further characterization of @CHEMICAL$ receptors (putative @GENE$) in rat stomach fundus longitudinal muscle.
11257	CPRFalse	1. The present study was undertaken to isolate and characterize pharmacologically homogeneous populations of @CHEM-GENE$ from a possible mixed receptor population mediating concentration of the longitudinal muscle of rat stomach fundus.
11258	CPRFalse	1. The present study was undertaken to isolate and characterize pharmacologically homogeneous populations of @CHEM-GENE$ from a possible mixed receptor population mediating concentration of the longitudinal muscle of rat stomach fundus.
11259	CPRFalse	Under these conditions, blockade of @CHEM-GENE$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.
11260	CPR:4	Under these conditions, blockade of @CHEMICAL$ with @GENE$ (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.
11261	CPRFalse	Under these conditions, blockade of @CHEMICAL$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both @GENE$ (5-MeO-T) and tryptamine.
11262	CPRFalse	Under these conditions, blockade of @CHEMICAL$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (@GENE$) and tryptamine.
11263	CPRFalse	Under these conditions, blockade of @CHEMICAL$ with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and @GENE$.
11264	CPR:5	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), @GENE$, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11265	CPR:5	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), @GENE$, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11266	CPR:5	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, @GENE$ and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11267	CPR:5	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, @GENE$ and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11268	CPR:5	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and @GENE$ were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11269	CPR:5	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and @GENE$ were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11270	CPRFalse	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst @GENE$, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11271	CPRFalse	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst @GENE$, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11272	CPRFalse	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, @GENE$ and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11273	CPRFalse	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, @GENE$ and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11274	CPRFalse	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and @GENE$ (8-OH-DPAT) were very weak or inactive.
11275	CPRFalse	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and @GENE$ (8-OH-DPAT) were very weak or inactive.
11276	CPRFalse	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (@GENE$) were very weak or inactive.
11277	CPRFalse	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (@GENE$) were very weak or inactive.
11278	CPR:5	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including @GENE$ (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11279	CPR:5	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including @GENE$ (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11280	CPR:5	In addition several ligands known to act as agonists at either @CHEMICAL$ or 5-HT2C receptors including 1-m-chlorophenylpiperazine (@GENE$), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11281	CPR:5	In addition several ligands known to act as agonists at either 5-HT2A or @CHEMICAL$ receptors including 1-m-chlorophenylpiperazine (@GENE$), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.
11282	CPRFalse	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of @CHEMICAL$ and yohimbine, the close pharmacological identity of @GENE$ in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.
11283	CPRFalse	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of @CHEMICAL$ and yohimbine, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned @GENE$ receptor is maintained.
11284	CPRFalse	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and @CHEMICAL$, the close pharmacological identity of @GENE$ in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.
11285	CPRFalse	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and @CHEMICAL$, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned @GENE$ receptor is maintained.
11286	CPRFalse	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and yohimbine, the close pharmacological identity of @CHEM-GENE$ in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.
11287	CPRFalse	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and yohimbine, the close pharmacological identity of @CHEMICAL$ receptors in rat stomach fundus and the recently cloned @GENE$ receptor is maintained.
11288	CPRFalse	@CHEMICAL$, which demonstrates some selectivity for @GENE$ in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of 5-HT2B function both in vitro and in vivo.
11289	CPRFalse	@CHEMICAL$, which demonstrates some selectivity for 5-HT receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of @GENE$ function both in vitro and in vivo.
11290	CPRFalse	SB 200646, which demonstrates some selectivity for @CHEM-GENE$ in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of 5-HT2B function both in vitro and in vivo.
11291	CPRFalse	SB 200646, which demonstrates some selectivity for @CHEMICAL$ receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of @GENE$ function both in vitro and in vivo.
11292	CPRFalse	Only strains of P. aeruginosa producing large amounts of @CHEMICAL$ may be resistant to both @GENE$ and cefepime.
11293	CPRFalse	Only strains of P. aeruginosa producing large amounts of @CHEMICAL$ may be resistant to both ceftazidime and @GENE$.
11294	CPR:4	Phorbol esters and @CHEMICAL$ destabilize @GENE$ mRNA in vascular smooth muscle cells.
11295	CPR:4	The mechanism by which @CHEMICAL$ (NE) down-regulates alpha 1B-adrenergic receptor (@GENE$) mRNA was studied in rabbit aortic smooth muscle cells.
11296	CPR:4	The mechanism by which @CHEMICAL$ (NE) down-regulates @GENE$ (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.
11297	CPR:4	The mechanism by which norepinephrine (@CHEMICAL$) down-regulates alpha 1B-adrenergic receptor (@GENE$) mRNA was studied in rabbit aortic smooth muscle cells.
11298	CPR:4	The mechanism by which norepinephrine (@CHEMICAL$) down-regulates @GENE$ (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.
11299	CPR:4	@CHEMICAL$, phorbol esters, and bradykinin each decreased @GENE$ mRNA levels by 70-80%.
11300	CPRFalse	@CHEMICAL$, phorbol esters, and @GENE$ each decreased alpha-AR mRNA levels by 70-80%.
11301	CPR:4	NE, @CHEMICAL$, and bradykinin each decreased @GENE$ mRNA levels by 70-80%.
11302	CPRFalse	NE, @CHEMICAL$, and @GENE$ each decreased alpha-AR mRNA levels by 70-80%.
11303	CPR:4	The @CHEMICAL$ inhibitor @GENE$ (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.
11304	CPR:4	The @CHEMICAL$ inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (@GENE$) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.
11305	CPRFalse	The @CHEMICAL$ inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of @GENE$ and NE and decreased basal mRNA levels by 52 +/- 3%.
11306	CPRFalse	The @CHEMICAL$ inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of phorbol esters and @GENE$ and decreased basal mRNA levels by 52 +/- 3%.
11307	CPR:3	Neither ryanodine nor @CHEMICAL$ inhibited down-regulation of @GENE$ mRNA by NE.
11308	CPR:4	Neither ryanodine nor EGTA inhibited down-regulation of @CHEMICAL$ mRNA by @GENE$.
11309	CPR:3	Neither @CHEMICAL$ nor EGTA inhibited down-regulation of @GENE$ mRNA by NE.
11310	CPR:4	@CHEMICAL$ caused @GENE$ mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.
11311	CPR:4	@CHEMICAL$ caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal @GENE$ mRNA level.
11312	CPRFalse	Actinomycin D caused @CHEMICAL$ mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of @GENE$ to decrease basal alpha-AR mRNA level.
11313	CPRFalse	Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of @CHEMICAL$ to decrease basal @GENE$ mRNA level.
11314	CPR:4	Both @CHEMICAL$ and phorbol esters increased the rate of @GENE$ mRNA degradation.
11315	CPR:4	Both NE and @CHEMICAL$ increased the rate of @GENE$ mRNA degradation.
11316	CPR:4	In @CHEMICAL$-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of @GENE$ mRNA.
11317	CPRFalse	In @CHEMICAL$-desensitized cells, phorbol esters and @GENE$ each caused the expected down-regulation of alpha-AR mRNA.
11318	CPR:4	In NE-desensitized cells, @CHEMICAL$ and bradykinin each caused the expected down-regulation of @GENE$ mRNA.
11319	CPRFalse	In NE-desensitized cells, @CHEMICAL$ and @GENE$ each caused the expected down-regulation of alpha-AR mRNA.
11320	CPRFalse	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on @GENE$ mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.
11321	CPRFalse	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a @GENE$ substrate and 2) a permissive effect on alpha-AR gene transcription.
11322	CPRFalse	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on @GENE$ gene transcription.
11323	CPR:4	The @CHEMICAL$ inhibitor @GENE$ prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.
11324	CPRFalse	The protein phosphatase inhibitor @CHEMICAL$ prolonged the normally transient effect of NE for at least 24 h. We conclude that @GENE$ exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.
11325	CPRFalse	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on @GENE$ mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.
11326	CPRFalse	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a @GENE$ substrate and 2) a permissive effect on alpha-AR gene transcription.
11327	CPRFalse	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on @GENE$ gene transcription.
11328	CPRFalse	The @CHEMICAL$ inhibitor okadaic acid prolonged the normally transient effect of @GENE$ for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.
11329	CPRFalse	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of @CHEMICAL$ for at least 24 h. We conclude that @GENE$ exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.
11330	CPRFalse	Molecular cloning and functional expression of @CHEMICAL$-like rat and human @GENE$ receptor genes.
11331	CPRFalse	Molecular cloning and functional expression of 5-HT1E-like @CHEM-GENE$ genes.
11332	CPRFalse	Sequential polymerase chain reaction experiments were performed to amplify a unique sequence representing a @CHEM-GENE$ from rat hypothalamic cDNA.
11333	CPRFalse	Degenerate @CHEMICAL$ corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@GENE$, 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11334	CPRFalse	Degenerate @CHEMICAL$ corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @GENE$, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11335	CPRFalse	Degenerate @CHEMICAL$ corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @GENE$; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11336	CPRFalse	Degenerate oligonucleotides corresponding to conserved @CHEMICAL$ from transmembrane domains III, V, and VI of known receptors [@GENE$, 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11337	CPRFalse	Degenerate oligonucleotides corresponding to conserved @CHEMICAL$ from transmembrane domains III, V, and VI of known receptors [5-HT1A, @GENE$, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11338	CPRFalse	Degenerate oligonucleotides corresponding to conserved @CHEMICAL$ from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @GENE$; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11339	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@CHEMICAL$, 5-HT1C, and 5-HT2; @GENE$ is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11340	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @CHEMICAL$, and 5-HT2; @GENE$ is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11341	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @CHEMICAL$; @GENE$ is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11342	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@CHEMICAL$, 5-HT1C, and 5-HT2; 5-HT is @GENE$ (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11343	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @CHEMICAL$, and 5-HT2; 5-HT is @GENE$ (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11344	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @CHEMICAL$; 5-HT is @GENE$ (5-hydroxytryptamine)] were used as primers for the sequential reactions.
11345	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [@CHEMICAL$, 5-HT1C, and 5-HT2; 5-HT is serotonin (@GENE$)] were used as primers for the sequential reactions.
11346	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, @CHEMICAL$, and 5-HT2; 5-HT is serotonin (@GENE$)] were used as primers for the sequential reactions.
11347	CPRFalse	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and @CHEMICAL$; 5-HT is serotonin (@GENE$)] were used as primers for the sequential reactions.
11348	CPRFalse	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (MR77) containing an @CHEMICAL$ encoding a 366-@GENE$ seven-transmembrane domain protein.
11349	CPRFalse	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (MR77) containing an intronless open reading frame encoding a @CHEM-GENE$.
11350	CPRFalse	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (@CHEMICAL$) containing an intronless open reading frame encoding a 366-@GENE$ seven-transmembrane domain protein.
11351	CPRFalse	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known @GENE$, rat 5-HT1B, rat 5-HT1D, and human 5-HT1E receptors, respectively.
11352	CPRFalse	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known rat 5-HT1A, @GENE$, rat 5-HT1D, and human 5-HT1E receptors, respectively.
11353	CPRFalse	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known rat 5-HT1A, rat 5-HT1B, @GENE$, and human 5-HT1E receptors, respectively.
11354	CPRFalse	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% @CHEMICAL$ identity with the known rat 5-HT1A, rat 5-HT1B, rat 5-HT1D, and @GENE$ receptors, respectively.
11355	CPRFalse	The specific binding is displaced by the selective 5-HT1D agonist @CHEMICAL$ but not by the mixed @GENE$ agonist 5-carboxyamidotryptamine.
11356	CPR:5	The specific binding is displaced by the selective @CHEMICAL$ agonist @GENE$ but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.
11357	CPRFalse	The specific binding is displaced by the selective 5-HT1D agonist sumatriptan but not by the mixed @CHEMICAL$ agonist @GENE$.
11358	CPRFalse	The specific binding is displaced by the selective @CHEMICAL$ agonist sumatriptan but not by the mixed 5-HT1A/1D agonist @GENE$.
11359	CPRFalse	HeLa cells transfected with the MR77 gene exhibited inhibition of @CHEM-GENE$ in response to serotonin.
11360	CPRFalse	HeLa cells transfected with the @CHEMICAL$ gene exhibited inhibition of @GENE$ cyclase in response to serotonin.
11361	CPR:4	HeLa cells transfected with the MR77 gene exhibited inhibition of @CHEMICAL$ in response to @GENE$.
11362	CPRFalse	HeLa cells transfected with the @CHEMICAL$ gene exhibited inhibition of adenylate cyclase in response to @GENE$.
11363	CPRFalse	MR77 thus represents a @CHEM-GENE$ of the 5-HT1 class, and we propose that, based on the pharmacological characterization, MR77 represents an additional 5-HT1E-like receptor.
11364	CPRFalse	MR77 thus represents a @CHEMICAL$ receptor of the @GENE$ class, and we propose that, based on the pharmacological characterization, MR77 represents an additional 5-HT1E-like receptor.
11365	CPRFalse	@CHEMICAL$ thus represents a @GENE$ receptor of the 5-HT1 class, and we propose that, based on the pharmacological characterization, MR77 represents an additional 5-HT1E-like receptor.
11366	CPRFalse	MR77 thus represents a @CHEMICAL$ receptor of the 5-HT1 class, and we propose that, based on the pharmacological characterization, @GENE$ represents an additional 5-HT1E-like receptor.
11367	CPRFalse	MR77 thus represents a @CHEMICAL$ receptor of the 5-HT1 class, and we propose that, based on the pharmacological characterization, MR77 represents an additional @GENE$-like receptor.
11368	CPRFalse	The antiarrhythmic effects of exogenous @CHEMICAL$ and Valsalva on this form of VT may be due to receptor-mediated inhibition of @GENE$ or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.
11369	CPRFalse	The antiarrhythmic effects of exogenous @CHEMICAL$ and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial @GENE$, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.
11370	CPRFalse	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of @CHEM-GENE$ or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.
11371	CPRFalse	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of @CHEMICAL$ cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial @GENE$, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.
11372	CPRFalse	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of @CHEMICAL$ or to noncardiac receptor-mediated effects, i.e., exogenous @GENE$ may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.
11373	CPR:3	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous @CHEMICAL$ may modulate VT through alterations in autonomic tone by activation of arterial @GENE$, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.
11374	CPRFalse	VT recurred with the addition of aminophylline, a @CHEMICAL$ @GENE$ antagonist.
11375	CPR:6	VT recurred with the addition of @CHEMICAL$, a competitive @GENE$ antagonist.
11376	CPRFalse	VT recurred with the addition of aminophylline, a competitive @CHEM-GENE$ antagonist.
11377	CPRFalse	@CHEMICAL$ (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the @GENE$, terminated VT in four of four patients, an effect that was reversed by atropine.
11378	CPR:4	@CHEMICAL$ (10 mg i.v.), a @GENE$ inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine.
11379	CPRFalse	Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of @CHEMICAL$ at the @GENE$, terminated VT in four of four patients, an effect that was reversed by atropine.
11380	CPRFalse	Edrophonium (10 mg i.v.), a @CHEMICAL$ inhibitor that potentiates the effects of @GENE$ at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine.
11381	CPR:4	Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the @CHEMICAL$, terminated VT in four of four patients, an effect that was reversed by @GENE$.
11382	CPRFalse	Edrophonium (10 mg i.v.), a @CHEMICAL$ inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by @GENE$.
11383	CPRFalse	It can be identified by termination of the tachycardia in response to activation of the @CHEMICAL$ A1 or @GENE$, which results in inhibition of adenylate cyclase.
11384	CPRFalse	It can be identified by termination of the tachycardia in response to activation of the @CHEMICAL$ A1 or muscarinic cholinergic receptor, which results in inhibition of @GENE$.
11385	CPRFalse	It can be identified by termination of the tachycardia in response to activation of the @CHEM-GENE$ or muscarinic cholinergic receptor, which results in inhibition of adenylate cyclase.
11386	CPRFalse	It can be identified by termination of the tachycardia in response to activation of the adenosine A1 or @CHEMICAL$, which results in inhibition of @GENE$ cyclase.
11387	CPRFalse	It can be identified by termination of the tachycardia in response to activation of the adenosine A1 or muscarinic cholinergic receptor, which results in inhibition of @CHEM-GENE$.
11388	CPRFalse	It can be identified by termination of the tachycardia in response to activation of the @CHEMICAL$ or muscarinic cholinergic receptor, which results in inhibition of @GENE$ cyclase.
11389	CPRFalse	@CHEMICAL$ induces c-fos in rat striatum: reversal with dopamine D1 and @GENE$ antagonists.
11390	CPR:3	@CHEMICAL$ induces @GENE$ in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.
11391	CPRFalse	@CHEMICAL$ induces c-fos in rat striatum: reversal with @GENE$ and NMDA receptor antagonists.
11392	CPRFalse	Amantadine induces c-fos in rat striatum: reversal with @CHEMICAL$ D1 and @GENE$ antagonists.
11393	CPRFalse	Amantadine induces @CHEMICAL$ in rat striatum: reversal with @GENE$ D1 and NMDA receptor antagonists.
11394	CPRFalse	Amantadine induces c-fos in rat striatum: reversal with @CHEM-GENE$ and NMDA receptor antagonists.
11395	CPRFalse	Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and @CHEM-GENE$ antagonists.
11396	CPRFalse	Amantadine induces @CHEMICAL$ in rat striatum: reversal with dopamine D1 and @GENE$ receptor antagonists.
11397	CPRFalse	Amantadine induces c-fos in rat striatum: reversal with @CHEMICAL$ and @GENE$ receptor antagonists.
11398	CPR:3	@CHEMICAL$ (1-aminoadamantane) induced @GENE$ expression in the central, dorsal-medial and ventral-medial part of the striatum.
11399	CPR:3	Amantadine (@CHEMICAL$) induced @GENE$ expression in the central, dorsal-medial and ventral-medial part of the striatum.
11400	CPRFalse	The distribution pattern of Fos induced by @CHEMICAL$ was more similar to those seen with dopaminomimetics than with @GENE$ antagonists.
11401	CPR:3	The distribution pattern of @CHEMICAL$ induced by @GENE$ was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.
11402	CPRFalse	The distribution pattern of Fos induced by amantadine was more similar to those seen with dopaminomimetics than with @CHEM-GENE$ antagonists.
11403	CPRFalse	The distribution pattern of @CHEMICAL$ induced by amantadine was more similar to those seen with dopaminomimetics than with @GENE$ (NMDA) receptor antagonists.
11404	CPRFalse	The distribution pattern of Fos induced by amantadine was more similar to those seen with dopaminomimetics than with @CHEM-GENE$ antagonists.
11405	CPRFalse	The distribution pattern of @CHEMICAL$ induced by amantadine was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (@GENE$) receptor antagonists.
11406	CPRFalse	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEMICAL$ antagonist, MK-801, blocked @GENE$ induction of Fos in the striatum.
11407	CPRFalse	Pretreatment with the @CHEMICAL$ antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked @GENE$ induction of Fos in the striatum.
11408	CPR:3	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked @CHEMICAL$ induction of @GENE$ in the striatum.
11409	CPRFalse	Pretreatment with the @CHEMICAL$ D1 receptor antagonist, SCH23390, and the @GENE$ antagonist, MK-801, blocked amantadine induction of Fos in the striatum.
11410	CPRFalse	Pretreatment with the @CHEM-GENE$ antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.
11411	CPRFalse	Pretreatment with the @CHEMICAL$ D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of @GENE$ in the striatum.
11412	CPRFalse	Pretreatment with the dopamine D1 receptor antagonist, @CHEMICAL$, and the @GENE$ antagonist, MK-801, blocked amantadine induction of Fos in the striatum.
11413	CPR:6	Pretreatment with the @CHEMICAL$ antagonist, @GENE$, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.
11414	CPR:4	Pretreatment with the dopamine D1 receptor antagonist, @CHEMICAL$, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of @GENE$ in the striatum.
11415	CPRFalse	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEM-GENE$ antagonist, MK-801, blocked amantadine induction of Fos in the striatum.
11416	CPRFalse	Pretreatment with the @CHEMICAL$ antagonist, SCH23390, and the @GENE$ receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.
11417	CPRFalse	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEMICAL$ receptor antagonist, MK-801, blocked amantadine induction of @GENE$ in the striatum.
11418	CPR:6	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the @CHEMICAL$ antagonist, @GENE$, blocked amantadine induction of Fos in the striatum.
11419	CPRFalse	Pretreatment with the @CHEMICAL$ antagonist, SCH23390, and the NMDA receptor antagonist, @GENE$, blocked amantadine induction of Fos in the striatum.
11420	CPR:4	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, @CHEMICAL$, blocked amantadine induction of @GENE$ in the striatum.
11421	CPR:3	However, @CHEMICAL$ induction of @GENE$ in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.
11422	CPRFalse	However, @CHEMICAL$ induction of Fos in the striatum was unaffected by the @GENE$ antagonist, sulpiride.
11423	CPRFalse	However, amantadine induction of @CHEMICAL$ in the striatum was unaffected by the @GENE$ D2 receptor antagonist, sulpiride.
11424	CPRFalse	However, amantadine induction of Fos in the striatum was unaffected by the @CHEM-GENE$ antagonist, sulpiride.
11425	CPRFalse	However, amantadine induction of @CHEMICAL$ in the striatum was unaffected by the dopamine D2 receptor antagonist, @GENE$.
11426	CPR:6	However, amantadine induction of Fos in the striatum was unaffected by the @CHEMICAL$ antagonist, @GENE$.
11427	CPRFalse	These results suggest that @CHEMICAL$ induction of Fos in the rat striatum is related to dopamine D1 and @GENE$.
11428	CPR:3	These results suggest that @CHEMICAL$ induction of @GENE$ in the rat striatum is related to dopamine D1 and NMDA receptors.
11429	CPRFalse	These results suggest that @CHEMICAL$ induction of Fos in the rat striatum is related to @GENE$ and NMDA receptors.
11430	CPRFalse	These results suggest that amantadine induction of Fos in the rat striatum is related to @CHEMICAL$ D1 and @GENE$.
11431	CPRFalse	These results suggest that amantadine induction of @CHEMICAL$ in the rat striatum is related to @GENE$ D1 and NMDA receptors.
11432	CPRFalse	These results suggest that amantadine induction of Fos in the rat striatum is related to @CHEM-GENE$ and NMDA receptors.
11433	CPRFalse	These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and @CHEM-GENE$.
11434	CPRFalse	These results suggest that amantadine induction of @CHEMICAL$ in the rat striatum is related to dopamine D1 and @GENE$ receptors.
11435	CPRFalse	These results suggest that amantadine induction of Fos in the rat striatum is related to @CHEMICAL$ and @GENE$ receptors.
11436	CPR:4	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @CHEMICAL$ (ATA), an inhibitor of platelet @GENE$/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11437	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual @CHEMICAL$ inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11438	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and @CHEMICAL$ antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11439	CPR:4	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @CHEMICAL$ (ATA), an inhibitor of platelet glycoprotein Ib/@GENE$ interaction (10 mg/kg i.v. bolus).
11440	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of @CHEMICAL$ (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11441	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against @CHEMICAL$ (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received @GENE$ (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11442	CPR:4	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@CHEMICAL$), an inhibitor of platelet @GENE$/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11443	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual @CHEMICAL$ inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11444	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and @CHEMICAL$ antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11445	CPR:4	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@CHEMICAL$), an inhibitor of platelet glycoprotein Ib/@GENE$ interaction (10 mg/kg i.v. bolus).
11446	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of @CHEMICAL$ (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11447	CPRFalse	After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against @CHEMICAL$ (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (@GENE$), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).
11448	CPRFalse	Infusion of @CHEMICAL$ failed to restore CFVs in ridogrel e @GENE$ treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by FVIIa was overcome by inhibition of platelet function.
11449	CPRFalse	Infusion of FVIIa failed to restore CFVs in ridogrel e @CHEMICAL$ treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by @GENE$ was overcome by inhibition of platelet function.
11450	CPRFalse	Activated partial thromboplastin time, and ex vivo platelet aggregation in response to @CHEMICAL$ and @GENE$, were not different after FVIIai infusion, while prothrombin time was slightly but significantly prolonged as compared to baseline values.
11451	CPRFalse	Activated partial thromboplastin time, and ex vivo platelet aggregation in response to @CHEMICAL$ and thrombin, were not different after @GENE$ infusion, while prothrombin time was slightly but significantly prolonged as compared to baseline values.
11452	CPRFalse	@CHEM-GENE$ have channel modes of conduction.
11453	CPRFalse	Members of the @CHEM-GENE$ gene family presumably function with fixed stoichiometry in which a set number of ions cotransport with one transmitter molecule.
11454	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [@CHEMICAL$ (NE)+, Na+, and Cl-], human NE (hNET) in the @GENE$ gene family.
11455	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [@CHEMICAL$ (NE)+, Na+, and Cl-], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.
11456	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (@CHEMICAL$)+, Na+, and Cl-], human NE (hNET) in the @GENE$ gene family.
11457	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (@CHEMICAL$)+, Na+, and Cl-], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.
11458	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, @CHEMICAL$, and Cl-], human NE (hNET) in the @GENE$ gene family.
11459	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, @CHEMICAL$, and Cl-], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.
11460	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and @CHEMICAL$], human NE (hNET) in the @GENE$ gene family.
11461	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and @CHEMICAL$], human NE (@GENE$) in the gamma-aminobutyric acid transporter gene family.
11462	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human @CHEMICAL$ (hNET) in the @GENE$ gene family.
11463	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human @CHEMICAL$ (@GENE$) in the gamma-aminobutyric acid transporter gene family.
11464	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human NE (hNET) in the @CHEM-GENE$ gene family.
11465	CPRFalse	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human NE (@CHEMICAL$) in the @GENE$ transporter gene family.
11466	CPR:4	These events are stimulated by NE and by guanethidine, an @CHEMICAL$ substrate, and they are blocked by @GENE$ and the antidepressant desipramine.
11467	CPR:4	These events are stimulated by NE and by guanethidine, an @CHEMICAL$ substrate, and they are blocked by cocaine and the antidepressant @GENE$.
11468	CPR:9	These events are stimulated by @CHEMICAL$ and by guanethidine, an @GENE$ substrate, and they are blocked by cocaine and the antidepressant desipramine.
11469	CPR:9	These events are stimulated by NE and by @CHEMICAL$, an @GENE$ substrate, and they are blocked by cocaine and the antidepressant desipramine.
11470	CPR:9	Voltage-clamp data combined with @CHEMICAL$ uptake data from these same cells indicate that @GENE$ have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).
11471	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.
11472	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11473	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11474	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @GENE$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11475	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @GENE$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11476	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11477	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of @CHEMICAL$; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11478	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.
11479	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11480	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11481	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @GENE$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11482	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @GENE$ and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11483	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11484	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with @CHEMICAL$ and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11485	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @CHEMICAL$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.
11486	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @CHEMICAL$; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11487	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @CHEMICAL$; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11488	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11489	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11490	CPR:6	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @CHEMICAL$ (MR) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11491	CPR:6	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@CHEMICAL$) antagonist @GENE$; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11492	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @CHEMICAL$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.
11493	CPR:6	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @CHEMICAL$, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11494	CPR:6	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @CHEMICAL$ antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11495	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11496	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11497	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @CHEMICAL$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11498	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@CHEMICAL$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist @GENE$; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11499	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.
11500	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11501	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11502	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-@GENE$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11503	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEM-GENE$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11504	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11505	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11506	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.
11507	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11508	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11509	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @GENE$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11510	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of @GENE$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11511	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11512	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of @CHEMICAL$ or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11513	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on @GENE$ formation by cardiac fibroblasts are conflicting.
11514	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical @GENE$, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11515	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the @GENE$ antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11516	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue @CHEMICAL$-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @GENE$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11517	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-@CHEMICAL$ systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @GENE$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11518	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the @GENE$ (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11519	CPRFalse	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or @CHEMICAL$; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (@GENE$) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.
11520	CPRFalse	Although there is a high probability that the action of @CHEMICAL$ to cause cardiac fibrosis in this experimental model is an effect via non-epithelial @GENE$, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking MR occupancy by aldosterone and collagen deposition.
11521	CPRFalse	Although there is a high probability that the action of @CHEMICAL$ to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking @GENE$ occupancy by aldosterone and collagen deposition.
11522	CPRFalse	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial @CHEMICAL$, the locus of @GENE$ action remains to be established, as do the molecular mechanisms linking MR occupancy by aldosterone and collagen deposition.
11523	CPRFalse	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of @CHEMICAL$ action remains to be established, as do the molecular mechanisms linking @GENE$ occupancy by aldosterone and collagen deposition.
11524	CPRFalse	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial @CHEMICAL$, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking MR occupancy by @GENE$ and collagen deposition.
11525	CPRFalse	Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking @CHEMICAL$ occupancy by @GENE$ and collagen deposition.
11526	CPR:9	@CHEMICAL$ and debrisoquine are substrates of @GENE$ and potent inhibitors of monoamine oxidase in perfused lungs of rats.
11527	CPR:4	@CHEMICAL$ and debrisoquine are substrates of uptake1 and potent inhibitors of @GENE$ in perfused lungs of rats.
11528	CPR:9	Amezinium and @CHEMICAL$ are substrates of @GENE$ and potent inhibitors of monoamine oxidase in perfused lungs of rats.
11529	CPR:4	Amezinium and @CHEMICAL$ are substrates of uptake1 and potent inhibitors of @GENE$ in perfused lungs of rats.
11530	CPRFalse	Amezinium and debrisoquine are substrates of @CHEMICAL$ and potent inhibitors of @GENE$ oxidase in perfused lungs of rats.
11531	CPRFalse	Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of @CHEM-GENE$ in perfused lungs of rats.
11532	CPRFalse	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal @CHEM-GENE$ (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.
11533	CPRFalse	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal @CHEMICAL$ oxidase (@GENE$), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.
11534	CPRFalse	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal @CHEMICAL$ oxidase (MAO), because it is a much more potent @GENE$ inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.
11535	CPR:4	Previous studies have resulted in the classification of @CHEMICAL$ as a selective inhibitor of neuronal @GENE$ (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.
11536	CPR:4	Previous studies have resulted in the classification of @CHEMICAL$ as a selective inhibitor of neuronal monoamine oxidase (@GENE$), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.
11537	CPR:4	Previous studies have resulted in the classification of @CHEMICAL$ as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent @GENE$ inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.
11538	CPRFalse	In the present study, the effects of @CHEMICAL$ on the deamination of noradrenaline were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the catecholamine transporter is non-neuronal @GENE$.
11539	CPRFalse	In the present study, the effects of amezinium on the deamination of @CHEMICAL$ were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the catecholamine transporter is non-neuronal @GENE$.
11540	CPRFalse	In the present study, the effects of amezinium on the deamination of noradrenaline were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the @CHEMICAL$ transporter is non-neuronal @GENE$.
11541	CPR:9	In addition, another drug that is both a substrate of @CHEMICAL$ and a MAO inhibitor, @GENE$, was investigated in the study.
11542	CPR:4	In addition, another drug that is both a substrate of uptake1 and a @CHEMICAL$ inhibitor, @GENE$, was investigated in the study.
11543	CPRFalse	The first aim of the study was to show whether @CHEMICAL$ and debrisoquine are substrates of @GENE$ in rat lungs.
11544	CPRFalse	The first aim of the study was to show whether amezinium and @CHEMICAL$ are substrates of @GENE$ in rat lungs.
11545	CPRFalse	After loading of isolated perfused lungs with @CHEMICAL$ (@GENE$ and catechol-O-methyltransferase (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11546	CPRFalse	After loading of isolated perfused lungs with @CHEMICAL$ (MAO and @GENE$ (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11547	CPRFalse	After loading of isolated perfused lungs with @CHEMICAL$ (MAO and catechol-O-methyltransferase (@GENE$) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11548	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (@CHEMICAL$ and @GENE$-O-methyltransferase (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11549	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEM-GENE$ (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11550	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEMICAL$-O-methyltransferase (@GENE$) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11551	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (@CHEMICAL$ and catechol-@GENE$-methyltransferase (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11552	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEM-GENE$ (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11553	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and catechol-@CHEMICAL$-methyltransferase (@GENE$) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.
11554	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (@CHEMICAL$ and catechol-O-methyltransferase (COMT) inhibited), the efflux of @GENE$ was measured for 30 min.
11555	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and @CHEMICAL$ (COMT) inhibited), the efflux of @GENE$ was measured for 30 min.
11556	CPRFalse	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and catechol-O-methyltransferase (@CHEMICAL$) inhibited), the efflux of @GENE$ was measured for 30 min.
11557	CPRFalse	In lungs perfused with 1 nmol/l @CHEMICAL$ (@GENE$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.
11558	CPRFalse	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l @GENE$ caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.
11559	CPRFalse	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of @GENE$ deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.
11560	CPRFalse	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l @GENE$ caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.
11561	CPRFalse	In lungs perfused with 1 nmol/l 3H-noradrenaline (@CHEMICAL$ inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of @GENE$ deamination, respectively.
11562	CPRFalse	When @CHEMICAL$ was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of @GENE$ by MAO-A in the lungs.
11563	CPRFalse	When MAO-B was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of @CHEMICAL$ by @GENE$ in the lungs.
11564	CPRFalse	When @CHEMICAL$ was also inhibited, 10 nmol/l @GENE$ caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs.
11565	CPR:4	When MAO-B was also inhibited, 10 nmol/l @CHEMICAL$ caused 84% inhibition of the deamination of noradrenaline by @GENE$ in the lungs.
11566	CPRFalse	In contrast, in hearts perfused with 10 nmol/l @CHEMICAL$ under conditions where the amine was accumulated by @GENE$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.
11567	CPRFalse	In contrast, in hearts perfused with 10 nmol/l @CHEMICAL$ under conditions where the amine was accumulated by uptake2 (COMT, @GENE$ and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.
11568	CPRFalse	In contrast, in hearts perfused with 10 nmol/l @CHEMICAL$ under conditions where the amine was accumulated by uptake2 (@GENE$, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.
11569	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by @CHEMICAL$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l @GENE$ had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.
11570	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, @CHEMICAL$ and vesicular transport inhibited), 10 nmol/l @GENE$ had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.
11571	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (@CHEMICAL$, uptake1 and vesicular transport inhibited), 10 nmol/l @GENE$ had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.
11572	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by @CHEMICAL$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l @GENE$ caused only 36% inhibition of deamination of noradrenaline.
11573	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, @CHEMICAL$ and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l @GENE$ caused only 36% inhibition of deamination of noradrenaline.
11574	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (@CHEMICAL$, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l @GENE$ caused only 36% inhibition of deamination of noradrenaline.
11575	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by @CHEMICAL$ (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of @GENE$.
11576	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, @CHEMICAL$ and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of @GENE$.
11577	CPRFalse	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (@CHEMICAL$, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of @GENE$.
11578	CPR:4	The results when considered with previous reports in the literature show that @CHEMICAL$ is about 1000 times more potent and debrisoquine is about 20 times more potent for @GENE$ inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.
11579	CPR:9	The results when considered with previous reports in the literature show that @CHEMICAL$ is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by @GENE$.
11580	CPR:4	The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and @CHEMICAL$ is about 20 times more potent for @GENE$ inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.
11581	CPR:9	The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and @CHEMICAL$ is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by @GENE$.
11582	CPR:4	@CHEMICAL$ is much less potent as a @GENE$ inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.
11583	CPR:9	@CHEMICAL$ is much less potent as a MAO inhibitor in cells with the @GENE$, such as the myocardial cells of the heart.
11584	CPR:4	The results also confirmed previous reports that @CHEMICAL$ is highly selective for @GENE$.
11585	CPRFalse	Role of @CHEM-GENE$ and mast cells in gaseous formaldehyde-induced airway microvascular leakage in rats.
11586	CPRFalse	Role of @CHEMICAL$ and mast cells in gaseous @GENE$-induced airway microvascular leakage in rats.
11587	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11588	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11589	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @CHEM-GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11590	CPR:6	We have investigated the effects of @CHEMICAL$ [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @GENE$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11591	CPRFalse	We have investigated the effects of @CHEMICAL$ [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11592	CPRFalse	We have investigated the effects of @CHEMICAL$ [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11593	CPR:6	We have investigated the effects of CP-99,994 @CHEMICAL$, a @GENE$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11594	CPRFalse	We have investigated the effects of CP-99,994 @CHEMICAL$, a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11595	CPRFalse	We have investigated the effects of CP-99,994 @CHEMICAL$, a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11596	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous @GENE$.
11597	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous @GENE$.
11598	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @CHEMICAL$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous @GENE$.
11599	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, @GENE$ (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11600	CPR:6	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, @CHEMICAL$ (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11601	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, @CHEMICAL$ (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11602	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 @GENE$, a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11603	CPR:6	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 @CHEMICAL$, a @GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11604	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 @CHEMICAL$, a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11605	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @GENE$ B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11606	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEM-GENE$ antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11607	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11608	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and @GENE$ (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11609	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and @GENE$ (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11610	CPR:6	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and @CHEMICAL$ (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11611	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a @CHEMICAL$ antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen @GENE$, a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11612	CPRFalse	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a @CHEMICAL$ antagonist, and ketotifen @GENE$, a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11613	CPR:6	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen @CHEMICAL$, a @GENE$ antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.
11614	CPRFalse	The increase in vascular permeability induced by @CHEMICAL$ in the rat airway was mediated predominantly by @GENE$ stimulation.
11615	CPRFalse	Activation of @CHEM-GENE$ and mast cells did not appear to play an important role in this airway response.
11616	CPR:4	Molecular determinants of @CHEMICAL$ block of HERG @GENE$.
11617	CPR:4	Molecular determinants of @CHEMICAL$ block of @GENE$ K+ channels.
11618	CPRFalse	Molecular determinants of dofetilide block of HERG @CHEM-GENE$.
11619	CPRFalse	Molecular determinants of dofetilide block of @CHEMICAL$ @GENE$ channels.
11620	CPRFalse	The human ether-a-go-go-related gene (HERG) encodes a @CHEMICAL$ channel with biophysical properties nearly identical to the @GENE$ (IKr).
11621	CPRFalse	The human ether-a-go-go-related gene (HERG) encodes a @CHEMICAL$ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (@GENE$).
11622	CPRFalse	The human ether-a-go-go-related gene (HERG) encodes a @CHEM-GENE$ with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr).
11623	CPRFalse	The human ether-a-go-go-related gene (@CHEMICAL$) encodes a @GENE$ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr).
11624	CPRFalse	The @CHEMICAL$ (HERG) encodes a @GENE$ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr).
11625	CPRFalse	The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the @CHEM-GENE$ (IKr).
11626	CPRFalse	The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @CHEMICAL$ current (@GENE$).
11627	CPRFalse	The human ether-a-go-go-related gene (HERG) encodes a @CHEMICAL$ with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @GENE$ current (IKr).
11628	CPRFalse	The human ether-a-go-go-related gene (@CHEMICAL$) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @GENE$ current (IKr).
11629	CPRFalse	The @CHEMICAL$ (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier @GENE$ current (IKr).
11630	CPR:4	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, @GENE$, and MK-499, at submicromolar concentrations.
11631	CPR:4	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, @GENE$, and MK-499, at submicromolar concentrations.
11632	CPR:4	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and @GENE$, at submicromolar concentrations.
11633	CPR:4	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and @GENE$, at submicromolar concentrations.
11634	CPR:4	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic @GENE$ drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.
11635	CPR:4	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic @GENE$ drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.
11636	CPR:4	HERG/@CHEMICAL$ channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as @GENE$, E4031, and MK-499, at submicromolar concentrations.
11637	CPR:4	@CHEMICAL$/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as @GENE$, E4031, and MK-499, at submicromolar concentrations.
11638	CPRFalse	By contrast, the closely related @CHEMICAL$ (BEAG) is 100-fold less sensitive to @GENE$.
11639	CPRFalse	By contrast, the closely related bovine ether-a-go-go channel (@CHEMICAL$) is 100-fold less sensitive to @GENE$.
11640	CPRFalse	To identify the molecular determinants for @CHEMICAL$ block, we first engineered chimeras between @GENE$ and BEAG and then used site-directed mutagenesis to localize single amino acid residues responsible for block.
11641	CPRFalse	To identify the molecular determinants for @CHEMICAL$ block, we first engineered chimeras between HERG and @GENE$ and then used site-directed mutagenesis to localize single amino acid residues responsible for block.
11642	CPRFalse	To identify the molecular determinants for dofetilide block, we first engineered chimeras between @CHEMICAL$ and BEAG and then used site-directed mutagenesis to localize single @GENE$ residues responsible for block.
11643	CPRFalse	To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and @CHEMICAL$ and then used site-directed mutagenesis to localize single @GENE$ residues responsible for block.
11644	CPRFalse	Thus, our results indicate that important determinants of @CHEMICAL$ binding are localized to the pore region of @GENE$.
11645	CPRFalse	Moreover, the reverse mutation BEAG @CHEMICAL$ increased the affinity of BEAG @GENE$ channels for dofetilide, whereas C-type inactivation could not be recovered.
11646	CPRFalse	Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG @CHEM-GENE$ for dofetilide, whereas C-type inactivation could not be recovered.
11647	CPRFalse	Moreover, the reverse mutation @CHEMICAL$ T432S increased the affinity of BEAG @GENE$ channels for dofetilide, whereas C-type inactivation could not be recovered.
11648	CPRFalse	Moreover, the reverse mutation BEAG T432S increased the affinity of @CHEMICAL$ @GENE$ channels for dofetilide, whereas C-type inactivation could not be recovered.
11649	CPRFalse	Moreover, the reverse mutation BEAG @CHEMICAL$ increased the affinity of BEAG K+ channels for @GENE$, whereas C-type inactivation could not be recovered.
11650	CPRFalse	Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG @CHEMICAL$ for @GENE$, whereas C-type inactivation could not be recovered.
11651	CPRFalse	Moreover, the reverse mutation @CHEMICAL$ T432S increased the affinity of BEAG K+ channels for @GENE$, whereas C-type inactivation could not be recovered.
11652	CPRFalse	Moreover, the reverse mutation BEAG T432S increased the affinity of @CHEMICAL$ K+ channels for @GENE$, whereas C-type inactivation could not be recovered.
11653	CPRFalse	Thus, the @CHEMICAL$ in position @GENE$ 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.
11654	CPRFalse	Thus, the serine in position @CHEMICAL$ 620 may participate directly in @GENE$ binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.
11655	CPRFalse	Treatment using a combination of @CHEMICAL$ and the @GENE$ inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than testosterone alone.
11656	CPR:4	Treatment using a combination of testosterone and the @CHEMICAL$ inhibitor @GENE$ may have significantly better effects on sexual function and also seizure frequency than testosterone alone.
11657	CPRFalse	Treatment using a combination of testosterone and the @CHEMICAL$ inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than @GENE$ alone.
11658	CPRFalse	Identification of binding sites for @CHEMICAL$ and trifluoperazine on cardiac troponin C. The solution structure of @GENE$ (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.
11659	CPRFalse	Identification of binding sites for @CHEMICAL$ and trifluoperazine on cardiac troponin C. The solution structure of cardiac troponin C (@GENE$) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.
11660	CPRFalse	Identification of binding sites for @CHEMICAL$ and trifluoperazine on @GENE$. The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.
11661	CPRFalse	Identification of binding sites for bepridil and @CHEMICAL$ on cardiac troponin C. The solution structure of @GENE$ (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.
11662	CPRFalse	Identification of binding sites for bepridil and @CHEMICAL$ on cardiac troponin C. The solution structure of cardiac troponin C (@GENE$) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.
11663	CPRFalse	Identification of binding sites for bepridil and @CHEMICAL$ on @GENE$. The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A. & Sykes, B. D. (1997) J. Biol.
11664	CPRFalse	For example, it is clear that the closed conformation of the regulatory @CHEMICAL$-terminal domain in Ca2+-bound @GENE$ (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.
11665	CPRFalse	For example, it is clear that the closed conformation of the regulatory @CHEMICAL$-terminal domain in Ca2+-bound cardiac troponin C (@GENE$) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.
11666	CPRFalse	For example, it is clear that the closed conformation of the regulatory N-terminal domain in @CHEMICAL$-bound @GENE$ (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.
11667	CPRFalse	For example, it is clear that the closed conformation of the regulatory N-terminal domain in @CHEMICAL$-bound cardiac troponin C (@GENE$) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.
11668	CPRFalse	For example, it is clear that the closed conformation of the regulatory N-terminal domain in Ca2+-bound @CHEMICAL$ (cTnC) presents a much different binding surface for @GENE$-sensitizing compounds than previously thought.
11669	CPRFalse	For example, it is clear that the closed conformation of the regulatory N-terminal domain in Ca2+-bound cardiac troponin C (@CHEMICAL$) presents a much different binding surface for @GENE$-sensitizing compounds than previously thought.
11670	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [@GENE$]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11671	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [@CHEMICAL$]Met-labeled @GENE$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11672	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that @GENE$ and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11673	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @CHEMICAL$ indicate that @GENE$ and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11674	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and @GENE$ bind to similar sites but only in the presence of Ca2+.
11675	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @CHEMICAL$ indicate that bepridil and @GENE$ bind to similar sites but only in the presence of Ca2+.
11676	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on @CHEMICAL$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of @GENE$.
11677	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @CHEMICAL$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of @GENE$.
11678	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for @CHEMICAL$ and bepridil on @GENE$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11679	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for @CHEMICAL$ and bepridil on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @GENE$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11680	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and @CHEMICAL$ on @GENE$. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11681	CPRFalse	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and @CHEMICAL$ on cTnC. Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled @GENE$ indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.
11682	CPRFalse	There are 3-4 drug binding sites in the @CHEMICAL$- and C-terminal domains of intact @GENE$ that exhibit fast exchange on the NMR time scale.
11683	CPRFalse	There are 3-4 drug binding sites in the N- and @CHEMICAL$-terminal domains of intact @GENE$ that exhibit fast exchange on the NMR time scale.
11684	CPRFalse	This subregion in @CHEMICAL$ makes a likely target against which to design new and selective @GENE$-sensitizing compounds.
11685	CPRFalse	Peripheral blood mononuclear cells express mutated @CHEMICAL$ mRNA in Gitelman's syndrome: evidence for abnormal @GENE$-sensitive NaCl cotransport.
11686	CPRFalse	Peripheral blood mononuclear cells express mutated @CHEMICAL$ mRNA in Gitelman's syndrome: evidence for abnormal thiazide-sensitive @GENE$ cotransport.
11687	CPRFalse	Genetic analysis has demonstrated complete linkage between the human @CHEMICAL$-sensitive sodium chloride cotransporter gene (@GENE$ or TSC) and Gitelman's syndrome (GS).
11688	CPRFalse	Genetic analysis has demonstrated complete linkage between the human @CHEMICAL$-sensitive sodium chloride cotransporter gene (NCCT or @GENE$) and Gitelman's syndrome (GS).
11689	CPRFalse	Genetic analysis has demonstrated complete linkage between the @CHEM-GENE$ gene (NCCT or TSC) and Gitelman's syndrome (GS).
11690	CPRFalse	Genetic analysis has demonstrated complete linkage between the human thiazide-sensitive @CHEMICAL$ cotransporter gene (@GENE$ or TSC) and Gitelman's syndrome (GS).
11691	CPRFalse	Genetic analysis has demonstrated complete linkage between the human thiazide-sensitive @CHEMICAL$ cotransporter gene (NCCT or @GENE$) and Gitelman's syndrome (GS).
11692	CPRFalse	Genetic analysis has demonstrated complete linkage between the @CHEM-GENE$ gene (NCCT or TSC) and Gitelman's syndrome (GS).
11693	CPRFalse	This study was performed to determine whether peripheral blood mononuclear cells (PBMC) express @CHEMICAL$ mRNA and whether defective PBMC @GENE$ cotransport could be demonstrated in GS.
11694	CPRFalse	Furthermore, functional evidence is provided that the underlying cause of GS is defective @CHEMICAL$ @GENE$ cotransport.
11695	CPR:4	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with @CHEMICAL$ inhibitors, @GENE$ and mitoxantrone, and the alkylating agent, cyclophosphamide.
11696	CPR:4	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with @CHEMICAL$ inhibitors, etoposide and @GENE$, and the alkylating agent, cyclophosphamide.
11697	CPRFalse	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with @CHEMICAL$ inhibitors, etoposide and mitoxantrone, and the alkylating agent, @GENE$.
11698	CPR:4	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with @CHEMICAL$ inhibitors, @GENE$ and mitoxantrone, and an alkylating agent, cyclophosphamide.
11699	CPR:4	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with @CHEMICAL$ inhibitors, etoposide and @GENE$, and an alkylating agent, cyclophosphamide.
11700	CPRFalse	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with @CHEMICAL$ inhibitors, etoposide and mitoxantrone, and an alkylating agent, @GENE$.
11701	CPR:4	@CHEMICAL$ (deprenyl), a selective, irreversible inhibitor of @GENE$ (MAO-B) is widely used in the treatment of Parkinson's disease.
11702	CPR:4	@CHEMICAL$ (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (@GENE$) is widely used in the treatment of Parkinson's disease.
11703	CPRFalse	Selegiline (deprenyl), a selective, irreversible inhibitor of @CHEM-GENE$ (MAO-B) is widely used in the treatment of Parkinson's disease.
11704	CPRFalse	Selegiline (deprenyl), a selective, irreversible inhibitor of @CHEMICAL$ oxidase type B (@GENE$) is widely used in the treatment of Parkinson's disease.
11705	CPR:4	Selegiline (@CHEMICAL$), a selective, irreversible inhibitor of @GENE$ (MAO-B) is widely used in the treatment of Parkinson's disease.
11706	CPR:4	Selegiline (@CHEMICAL$), a selective, irreversible inhibitor of monoamine oxidase type B (@GENE$) is widely used in the treatment of Parkinson's disease.
11707	CPR:4	Unlike the nonselective @CHEMICAL$ inhibitors, @GENE$ does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.
11708	CPRFalse	Unlike the nonselective @CHEMICAL$ inhibitors, selegiline does not significantly potentiate @GENE$-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.
11709	CPRFalse	A low @CHEMICAL$ diet is recommended if selegiline is used together with nonselective @GENE$ inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.
11710	CPRFalse	A low @CHEMICAL$ diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible @GENE$ inhibitor, moclobemide.
11711	CPR:4	A low tyramine diet is recommended if @CHEMICAL$ is used together with nonselective @GENE$ inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.
11712	CPRFalse	A low tyramine diet is recommended if @CHEMICAL$ is used together with nonselective MAO inhibitors or the selective, reversible @GENE$ inhibitor, moclobemide.
11713	CPRFalse	A low tyramine diet is recommended if selegiline is used together with nonselective @CHEMICAL$ inhibitors or the selective, reversible MAO-A inhibitor, @GENE$.
11714	CPR:4	A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible @CHEMICAL$ inhibitor, @GENE$.
11715	CPR:4	@CHEMICAL$ inhibits @GENE$-mediated Cl- secretion.
11716	CPRFalse	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of @CHEMICAL$ and salicylic acid on CFTR @GENE$ in excised, inside-out patches from L-cells were evaluated.
11717	CPRFalse	To determine whether this inhibition of ICl was due to the inhibition of @CHEMICAL$, the effects of @GENE$ and salicylic acid on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated.
11718	CPRFalse	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of @CHEMICAL$ and salicylic acid on @GENE$ Cl- channels in excised, inside-out patches from L-cells were evaluated.
11719	CPRFalse	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and @CHEMICAL$ on CFTR @GENE$ in excised, inside-out patches from L-cells were evaluated.
11720	CPRFalse	To determine whether this inhibition of ICl was due to the inhibition of @CHEMICAL$, the effects of ibuprofen and @GENE$ on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated.
11721	CPRFalse	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and @CHEMICAL$ on @GENE$ Cl- channels in excised, inside-out patches from L-cells were evaluated.
11722	CPR:4	@CHEMICAL$ (300 microM) reduced @GENE$ Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).
11723	CPR:4	Similarly, @CHEMICAL$ (3 mM) reduced @GENE$ Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4).
11724	CPRFalse	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @CHEMICAL$ as well as basolateral membrane @GENE$ channels.
11725	CPRFalse	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @CHEM-GENE$.
11726	CPRFalse	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @CHEMICAL$ Cl- channels as well as basolateral membrane @GENE$ channels.
11727	CPR:4	Based on these results, we conclude that the NSAIDs @CHEMICAL$ and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @GENE$ as well as basolateral membrane K+ channels.
11728	CPR:4	Based on these results, we conclude that the NSAIDs @CHEMICAL$ and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @GENE$.
11729	CPR:4	Based on these results, we conclude that the NSAIDs @CHEMICAL$ and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @GENE$ Cl- channels as well as basolateral membrane K+ channels.
11730	CPR:4	Based on these results, we conclude that the NSAIDs ibuprofen and @CHEMICAL$ inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @GENE$ as well as basolateral membrane K+ channels.
11731	CPR:4	Based on these results, we conclude that the NSAIDs ibuprofen and @CHEMICAL$ inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @GENE$.
11732	CPR:4	Based on these results, we conclude that the NSAIDs ibuprofen and @CHEMICAL$ inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @GENE$ Cl- channels as well as basolateral membrane K+ channels.
11733	CPRFalse	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit @CHEMICAL$-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR @GENE$ as well as basolateral membrane K+ channels.
11734	CPRFalse	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit @CHEMICAL$-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane @GENE$.
11735	CPRFalse	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit @CHEMICAL$-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of @GENE$ Cl- channels as well as basolateral membrane K+ channels.
11736	CPR:3	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in @CHEMICAL$ and ACTH levels after i.v. @GENE$, pointing to a general state of arousal in these mCPP-treated animals.
11737	CPR:3	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and @CHEMICAL$ levels after i.v. @GENE$, pointing to a general state of arousal in these mCPP-treated animals.
11738	CPRFalse	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in @CHEMICAL$ and ACTH levels after i.v. mCPP, pointing to a general state of arousal in these @GENE$-treated animals.
11739	CPRFalse	Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and @CHEMICAL$ levels after i.v. mCPP, pointing to a general state of arousal in these @GENE$-treated animals.
11740	CPRFalse	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @GENE$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11741	CPRFalse	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @GENE$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11742	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @CHEMICAL$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.
11743	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and @CHEMICAL$ antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.
11744	CPRFalse	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @GENE$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11745	CPRFalse	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @GENE$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11746	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @CHEMICAL$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.
11747	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as @CHEMICAL$ and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.
11748	CPRFalse	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @GENE$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11749	CPRFalse	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @GENE$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11750	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @CHEMICAL$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.
11751	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and @CHEMICAL$ are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.
11752	CPRFalse	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @GENE$-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11753	CPRFalse	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @GENE$-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11754	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @CHEMICAL$-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.
11755	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of @CHEMICAL$-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.
11756	CPRFalse	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist @GENE$.
11757	CPRFalse	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist @GENE$.
11758	CPR:6	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @CHEMICAL$/5-HT2C antagonist @GENE$.
11759	CPR:6	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@CHEMICAL$ antagonist @GENE$.
11760	CPR:6	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as @GENE$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11761	CPR:6	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as @GENE$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11762	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as @CHEMICAL$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.
11763	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as @CHEMICAL$ and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.
11764	CPR:6	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and @GENE$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11765	CPR:6	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and @GENE$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11766	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and @CHEMICAL$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.
11767	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and @CHEMICAL$, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.
11768	CPRFalse	These data indicate that mixed @CHEMICAL$/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed @GENE$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11769	CPRFalse	These data indicate that mixed 5-HT1/@CHEMICAL$ receptor antagonists such as pizotifen and methysergide, and mixed @GENE$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.
11770	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed @CHEMICAL$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective @GENE$/5-HT2C antagonist ritanserin.
11771	CPRFalse	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed @CHEMICAL$ and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/@GENE$ antagonist ritanserin.
11772	CPRFalse	Pressor and bradycardic effects of @CHEMICAL$ and other @GENE$ inhibitors in the rat.
11773	CPR:4	The cardiovascular effects of three different @CHEMICAL$ inhibitors: @GENE$, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.
11774	CPR:4	The cardiovascular effects of three different @CHEMICAL$ inhibitors: physostigmine, @GENE$ and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.
11775	CPR:4	The cardiovascular effects of three different @CHEMICAL$ inhibitors: physostigmine, tacrine and @GENE$ injected by intravenous (i.v.) route were compared in freely moving Wistar rats.
11776	CPR:4	@CHEMICAL$ was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. @GENE$ inhibitors.
11777	CPR:6	The @CHEMICAL$ antagonist @GENE$ or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11778	CPRFalse	The alpha1-adrenoceptor antagonist @CHEMICAL$ or the @GENE$ antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11779	CPRFalse	The alpha1-adrenoceptor antagonist @CHEMICAL$ or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11780	CPRFalse	The @CHEMICAL$ antagonist prazosin or the @GENE$ V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11781	CPRFalse	The alpha1-adrenoceptor antagonist prazosin or the @CHEM-GENE$ antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11782	CPRFalse	The alpha1-adrenoceptor antagonist prazosin or the @CHEMICAL$ V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11783	CPRFalse	The @CHEMICAL$ antagonist prazosin or the vasopressin V1 receptor antagonist, @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11784	CPR:6	The alpha1-adrenoceptor antagonist prazosin or the @CHEMICAL$ antagonist, @GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11785	CPRFalse	The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, @CHEM-GENE$ partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.
11786	CPRFalse	The @CHEMICAL$ antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced @GENE$ pressor effect and mostly abolished it when administered concomitantly.
11787	CPRFalse	The alpha1-adrenoceptor antagonist prazosin or the @CHEMICAL$ antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced @GENE$ pressor effect and mostly abolished it when administered concomitantly.
11788	CPRFalse	The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] @CHEMICAL$ partially but significantly reduced @GENE$ pressor effect and mostly abolished it when administered concomitantly.
11789	CPR:6	administration of the non-selective @CHEMICAL$ antagonist @GENE$ (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11790	CPRFalse	administration of the non-selective muscarinic receptor antagonist @CHEMICAL$ (ID50 = 1.45 microg), the @GENE$ antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11791	CPRFalse	administration of the non-selective muscarinic receptor antagonist @CHEMICAL$ (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the @GENE$ antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11792	CPRFalse	administration of the non-selective muscarinic receptor antagonist @CHEMICAL$ (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the @GENE$ antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11793	CPRFalse	administration of the non-selective @CHEMICAL$ antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist @GENE$ (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11794	CPR:6	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the @CHEMICAL$ antagonist @GENE$ (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11795	CPRFalse	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist @CHEMICAL$ (ID50 = 4.33 microg), the @GENE$ antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11796	CPRFalse	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist @CHEMICAL$ (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the @GENE$ antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11797	CPRFalse	administration of the non-selective @CHEMICAL$ antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist @GENE$ (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11798	CPRFalse	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the @CHEMICAL$ antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist @GENE$ (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11799	CPR:6	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the @CHEMICAL$ antagonist @GENE$ (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11800	CPRFalse	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist @CHEMICAL$ (ID50 = 1.39 microg) and the @GENE$ antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).
11801	CPRFalse	administration of the non-selective @CHEMICAL$ antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist @GENE$ (ID50 = 31.19 microg).
11802	CPRFalse	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the @CHEMICAL$ antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist @GENE$ (ID50 = 31.19 microg).
11803	CPRFalse	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the @CHEMICAL$ antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist @GENE$ (ID50 = 31.19 microg).
11804	CPR:6	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the @CHEMICAL$ antagonist @GENE$ (ID50 = 31.19 microg).
11805	CPRFalse	Central injection of such @CHEMICAL$ antagonists did not affect @GENE$-induced bradycardia.
11806	CPRFalse	Our results show that @CHEMICAL$ inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central muscarinic M2 receptors inducing a secondary increase in sympathetic outflow and @GENE$ release.
11807	CPRFalse	Our results show that acetylcholinesterase inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central @CHEMICAL$ inducing a secondary increase in sympathetic outflow and @GENE$ release.
11808	CPR:4	State-dependent @CHEMICAL$ block of @GENE$ isoforms, chimeras, and channels coexpressed with the beta1 subunit.
11809	CPRFalse	State-dependent cocaine block of @CHEM-GENE$ isoforms, chimeras, and channels coexpressed with the beta1 subunit.
11810	CPR:4	@CHEMICAL$ block of @GENE$ and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.
11811	CPR:4	@CHEMICAL$ block of human cardiac (hH1) and @GENE$ was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.
11812	CPRFalse	Cocaine block of @CHEMICAL$ and rat skeletal (mu1) muscle @GENE$ channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.
11813	CPRFalse	Cocaine block of human cardiac (hH1) and @CHEM-GENE$ was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.
11814	CPR:4	@CHEMICAL$ block of @GENE$ was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.
11815	CPR:4	@CHEMICAL$ block of hH1 channels was greater than block of @GENE$ at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.
11816	CPR:4	@CHEMICAL$ block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of @GENE$ in this voltage range makes them more susceptible to cocaine block.
11817	CPRFalse	Cocaine block of @CHEMICAL$ was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to @GENE$ block.
11818	CPRFalse	Cocaine block of hH1 channels was greater than block of @CHEMICAL$ at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to @GENE$ block.
11819	CPR:4	Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of @CHEMICAL$ in this voltage range makes them more susceptible to @GENE$ block.
